WO2018228920A1 - Substituted pyrrolopyridine-derivatives - Google Patents

Substituted pyrrolopyridine-derivatives Download PDF

Info

Publication number
WO2018228920A1
WO2018228920A1 PCT/EP2018/065036 EP2018065036W WO2018228920A1 WO 2018228920 A1 WO2018228920 A1 WO 2018228920A1 EP 2018065036 W EP2018065036 W EP 2018065036W WO 2018228920 A1 WO2018228920 A1 WO 2018228920A1
Authority
WO
WIPO (PCT)
Prior art keywords
pyridin
pyrrolo
alkyl
oxy
urea
Prior art date
Application number
PCT/EP2018/065036
Other languages
French (fr)
Inventor
Bernd Buchmann
Norbert Schmees
Jeffrey Stuart MOWAT
Gabriele Leder
Olaf Panknin
Rafael CARRETERO
Nuria AIGUABELLA FONT
Hans Briem
Anders Roland FRIBERG
Manfred Husemann
Ulf Bömer
Detlef STÖCKIGT
Roland Neuhaus
Sandra Berndt
Kirstin Petersen
Rienk Offringa
Original Assignee
Bayer Pharma Aktiengesellschaft
Deutsches Krebsforschungszentrum Heidelberg
Bayer Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma Aktiengesellschaft, Deutsches Krebsforschungszentrum Heidelberg, Bayer Aktiengesellschaft filed Critical Bayer Pharma Aktiengesellschaft
Priority to CA3066859A priority Critical patent/CA3066859A1/en
Priority to EP18728901.2A priority patent/EP3638669A1/en
Publication of WO2018228920A1 publication Critical patent/WO2018228920A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the present invention relates to protein-inhibitory substituted pyrrolopyridine derivatives, to pharmaceutical compositions and combinations comprising the compounds according to the invention, and to the prophylactic and therapeutic use of the inventive compounds, respectively to the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular for neoplastic disorders, repectively cancer or conditions with dysregulated immune responses or other disorders associated with aberrant MAP4K1 signaling, as a sole agent or in combination with other active ingredients.
  • the present invention further relates to the use, respectively to the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of protein inhibitors in benign hyperplasias, atherosclerotic disorders, sepsis, autoimmune disorders, vascular disorders, viral infections, in neurodegenerative disorders, in inflammatory disorders, in atherosclerotic disorders and in male fertility control.
  • T-cell immune checkpoint such as CTLA-4, PD-1 or PD-L1 were recently shown to result in a remarkable clinical efficacy in subsets of cancer patients.
  • cell surface receptors that act as negative immune regulators, several mediators of intracellular signaling have been identified that also represent potential immunoevasive mechanisms utilized by the tumor.
  • MAP4K1 also known as hematopoietic progenitor kinase 1 (HPK1 ).
  • HPK1 hematopoietic progenitor kinase 1
  • MAP4K1 GenelD1 1 184
  • MAP4K1 expression is restricted to hematopoietic cell types.
  • the MAP4K1 protein consist of a N-terminal kinase domain, followed by a proline-rich domain that can interact with adaptor molecules through SH2 and SH3 domains, and a C-terminal citron homology domain of which the exact function remains to be identified.
  • MAP4K1 is capable of binding to a diversity of adaptors in hematopoietic cells, including those involved in T-cell receptor (TCR), B-cell receptor (BCR) and cytokine signaling (Hu et al., Genes Dev. 1996 Sep 15;10(18):2251 -64, 2.; Ling et al.,. J Biol Chem. 2001 Jun 1 ;276(22), Sauer et al., J Biol Chem. 2001 Nov 30;276(48):45207-16., Tsuji et al., J Exp Med. 2001 Aug 20;194(4):529-39, Boomer et al., J Cell Biochem.
  • TCR T-cell receptor
  • BCR B-cell receptor
  • cytokine signaling Hu et al., Genes Dev. 1996 Sep 15;10(18):2251 -64, 2.; Ling et al.,. J Biol Chem. 2001 Jun 1 ;2
  • MAP4K1 MAP4K1 phosphorylates the SLP-76 adaptor protein at Serine-376, resulting in downregulation of AP-1 and Erk2 pathways.
  • MAPK1 acts as a negative feedback on TCR-signaling (Liou et al., Immunity. 2000
  • MAP4K1 can be triggered to suppress T cell function by prostaglandin E2 (PGE2), and possibly also by transforming growth factor beta (TGF-beta), factors that are commonly found in the tumor microenvironment.
  • PGE2 prostaglandin E2
  • TGF-beta transforming growth factor beta
  • MAP4K1 activation by these mediators involves protein kinase A (PKA)-dependent phosphorylation of Serine 171 (S-171 ; also in mouse) (Alzabin et al., Cancer Immunol Immunother. 2010 Mar;59(3):419-29; Sawasdikosol et al., J Biol Chem. 2007 Nov 30;282(48):34693-9.).
  • PKA protein kinase A
  • MAP4K1 -deficient mice show an apparent normal phenotype, are fertile and exhibit normal lymphocyte development. These animals are prone to develop T-cell dependent autoimmune reactivity as indicated by development of a more severe disease score in the EAE
  • cytokines like IL-2 or IFNg
  • MAP4K1 -/- T-cells are resistant to PGE2-mediated suppression of T cell proliferation, suppression of IL-2 production and induction of apoptosis (Alzabin et al., Cancer Immunol Immunother. 2010 Mar;59(3):419-29).
  • MAP4K1 -/- mice are much more resistant to tumorigenesis by PGE2-producing Lewis lung carcinoma than wild type mice, which correlated with increased T-lymphocyte infiltration in the tumor areas.
  • the crucial role of T-cells in tumor rejection was supported by experiments in which MAP4K1 -/- T-cells adoptively transferred into T-cell-deficient mice were able to eradicate tumors more efficiently than wild-type T-cells (Alzabin et al., Cancer Immunol Immunother. 2010 Mar;59(3):419-29).
  • MAP4K1 also regulates the stimulation and activation of dendritic cells.
  • MAP4K1 deficient Bone marrow derived cells express after maturation and stimulation higher level of costimulatory molecules and produce more proinflammatory cytokines. Also elimination of tumors was observed to be more efficient by MAP4K1 -/- BMDC compared to their wildtype counterparts (Alzabin et al., J Immunol. 2009 May 15;182(10):6187-94).
  • Rho kinase inhibitors and their use in cardiovascular and cancer treatment are described. These compounds differ from the instant compounds in their chemical structure.
  • HPK1 kinase inhibitors and their use in cancer treatment are described. These compounds differ from the instant compounds in their chemical structure.
  • HPK1 kinase inhibitors and their use in cancer treatment are described. These compounds differ from the instant compounds in their chemical structure.
  • HPK1 kinase inhibitors and their use in cancer treatment are described. These compounds differ from the instant compounds in their chemical structure.
  • HPK1 kinase inhibitors and their use in cancer treatment are described. These compounds differ from the instant compounds in their chemical structure.
  • a further object of the present invention is to provide compounds and pharmaceutical compositions comprising these compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of protein inhibitors in benign hyperplasias, atherosclerotic disorders, sepsis, autoimmune disorders, vascular disorders, viral infections, in
  • neurodegenerative disorders in inflammatory disorders, in atherosclerotic disorders and in male fertility control.
  • the compounds according to the invention inhibit the MAP4K1 protein and inhibit the growth of cancer cells. Accordingly, they provide novel structures for the therapy of human and animal disorders, in particular of cancers.
  • X represents a nitrogen, a sulphur or an oxygene atom
  • Y represents a sulphur or an oxygene atom
  • R 1 represents hydrogen, halogen, Ci-C6-alkyl, halo-Ci-C6-alkyl or cyano,
  • R 2 represents fluorine or chlorine
  • R 3 represents hydrogen or Ci-C6-alkyl
  • C3-Cio-cycloalkyl- which itself may optionally be mono- or polysubstituted by dentical or different substituents from the group consisting of of halogen, cyano, nitro, hydroxy, amino, oxo, carboxy, Ci-C6-alkyl-, Ci-C6-alkoxy-, Ci-C6-alkoxy- Ci-C6-alkyl-, hydroxy-Ci-C6-alkyl-, Ci-C6-alkylamino-, Ci-C6-alkylcarbonylamino- , amino-Ci-C6-alkyl-, Ci-C6-alkylamino-Ci-C6-alkyl-, halo-Ci-C6-alkyl-, halo-Ci-C6-alkoxy-, C3-Cio-cycloalkyl-, phenyl-, halophenyl-, phenyl-Ci-C6-al
  • each of which mentioned supra may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of halogen, cyano, nitro, hydroxy, amino, oxo, carboxy, Ci-C6-alkyl-, Ci-C6-alkoxy-, Ci-C6-alkoxy- Ci-C6-alkyl-, hydroxy-Ci-C6-alkyl-, Ci-C6-alkylamino-, Ci-C6-alkylcarbonylamino- , amino-Ci-C6-alkyl-, Ci-C6-alkylamino-Ci-C6-alkyl-, halo-Ci-C6-alkyl-, halo-Ci-C6-alkoxy-, C3-Cio-cycloalkyl-, phenyl-, halophenyl-, phenyl-Ci-C6-alkyl-, phenoxy-, pyridin
  • C3-Cio-cycloalkyl- which may optionally be mono- or polysubstituted by dentical or different substituents from the group consisting of of of halogen, cyano, nitro, hydroxy, amino, oxo, carboxy, Ci-C6-alkyl-, Ci-C6-alkoxy-,
  • phenyl- which may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of of halogen, cyano, nitro, hydroxy, amino, carboxy, Ci-C6-alkyl-, Ci-C6-alkoxy-, Ci-C6-alkoxy-Ci-C6- alkyl-, hydroxy-Ci-C6-alkyl-, Ci-C6-alkylamino-, Ci-C6-alkylcarbonylamino-, amino-Ci-C6-alkyl-, Ci-C6-alkylamino-Ci-C6-alkyl-, halo-Ci-C6-alkyl-, halo-Ci-C6- alkoxy-, C3-Cio-cycloalkyl-, phenyl-, halophenyl-, phenyl-Ci-C6-alkyl-, phenoxy-, pyridinyl-
  • radicals mentioned may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of of halogen, cyano, nitro, hydroxy, amino, oxo, carboxy, Ci-C6-alkyl-, Ci-C6-alkoxy-, Ci-C6-alkoxy-Ci-C6- alkyl-, hydroxy-Ci-C6-alkyl-, Ci-C6-alkylamino-, Ci-C6-alkylcarbonylamino-, amino-Ci
  • R 3 and R 4 together with the nitrogen atom form a 4 to 10 membered heterocycloalkyi or a 5 to 12 membered heterospirocycloalkyl, which may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of of halogen, cyano, nitro, hydroxy, amino, oxo, carboxy, Ci-C6-alkyl-, Ci-C6-alkoxy-, Ci-C6-alkoxy-Ci-C6-alkyl-, hydroxy-Ci-C6-alkyl-,
  • R 5 and R 6 independently of one another represent hydrogen, Ci-C3-alkyl-, cyclopropyl- or di-Ci-C3-alkylamino-Ci-C3-alkyl-, or
  • R 5 and R 6 together with the nitrogen atom form a monocyclic heterocyclyl- having 3 to 8 ring atoms which itself may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of halogen, amino, hydroxy, cyano, oxo, Ci-C6-alkyl-, Ci-C6-alkoxy-, Ci-C6-alkylamino-, halo-Ci-C6-alkyl-, halo-Ci-C6-alkoxy-,
  • R 7 represents hydroxy, Ci-C6-alkyl-, Ci-C6-alkoxy-, halo-Ci-C3-alkyl-, hydroxy-Ci- C3-alkyl-, Ci-C3-alkoxy-Ci-C3-alkyl-, Cs-Cs-cycloalkyl-, phenyl-, monocyclic heterocyclyl- having 3 to 8 ring atoms or monocyclic heteroaryl- having 5 or 6 ring atoms where phenyl-, heteroaryl- and heterocyclyl- may optionally be mono- or disubstituted by halogen, Ci-C3-alkoxy- or Ci-C3-alkyl-, R 8 represents Ci-C6-alkyl-,
  • R 9 represents Ci-C 6 -alkyl-, -NH 2 , -NH-Ci-C 6 -alkyl, -N(Ci-C 6 -alkyl) 2 , or Ci-C 6 -alkoxy- d-Ce-alkyl-,
  • R x represents Ci-C6-alkyl- or Ci-C6-alkoxy-Ci-C6-alkyl-,
  • R y represents hydrogen, halo-Ci-C6-alkyl, Ci-C6-alkyl, Ci-C6-alkyl substituted with
  • substituted means that one or more hydrogen atoms on the designated atom or group are replaced with a selection from the indicated group, provided that the designated atom's normal valency under the existing circumstances is not exceeded. Combinations of substituents and/or variables are permissible.
  • optionally substituted means that the number of substituents can be equal to or different from zero. Unless otherwise indicated, it is possible that optionally substituted groups are substituted with as many optional substituents as can be accommodated by replacing a hydrogen atom with a non-hydrogen substituent on any available carbon atom. Commonly, it is possible for the number of optional substituents, when present, to be 1 , 2 or 3.
  • halogen means a fluorine, chlorine, bromine or iodine, particularly a fluorine, chlorine or bromine atom.
  • Ci-C6-alkyl means a linear or branched, saturated, monovalent hydrocarbon group having 1 , 2, 3, 4, 5 or 6 carbon atoms, e.g. a methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, isobutyl, ie f-butyl, pentyl, isopentyl, 2-methylbutyl, 1 -methylbutyl, 1 -ethylpropyl,
  • said group has 1 , 2, 3 or 4 carbon atoms ("Ci-C4-alkyl”), e.g. a methyl, ethyl, propyl, isopropyl, butyl, sec-butyl isobutyl, or ie f-butyl group, more particularly 1 , 2 or 3 carbon atoms (“Ci-C3-alkyl”), e.g. a methyl, ethyl, n-propyl or isopropyl group.
  • hydroxy-Ci-C6-alkyl means a linear or branched, saturated, monovalent hydrocarbon group in which the term "Ci-C6-alkyl” is defined supra, and in which 1 or 2 hydrogen atoms are replaced with a hydroxy group, e.g. a hydroxy methyl, 1 -hydroxyethyl, 2-hydroxyethyl, 1 ,2-dihydroxyethyl, 3-hydroxypropyl, 2-hydroxypropyl, 1 -hydroxypropyl,
  • Ci-C6-alkoxy means a linear or branched, saturated, monovalent group of formula (Ci-C6-alkyl)-0-, which means methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, sec-butoxy, isobutoxy or ie f-butoxy.
  • Ci-C6-alkoxy-Ci-C6-alkyl- means a linear or branched, saturated, monovalent group of formula (Ci-C6-alkyl)-0-(Ci-C6-alkyl)-, in which the term "Ci-C6-alkyl” is defined supra, and in which 1 to 3 hydrogen atoms of the Ci-C6-alkyl group are replace by Ci-C6-alkoxy.
  • Ci-C6-alkylamino- means an amino radical having one or two alkyl substituents (selected independently of one another) having generally 1 to 6 (Ci-C6-alkylamino) and preferably 1 to 3 (Ci-C3-alkylamino) carbon atoms.
  • (Ci-C3)-Alkylamino represents, for example, a monoalkylamino radical having 1 to 3 carbon atoms or a dialkylamino radical having 1 to 3 carbon atoms each per alkyl substituent.
  • amino-Ci-C6-alkyl- means a linear or branched, saturated, monovalent hydrocarbon group in which the term “Ci-C6-alkyl” is defined supra, and in which 1 or 2 hydrogen atoms are replaced with an amino group, e.g. a aminomethyl, 1 -aminoethyl, 2-aminoethyl,
  • Ci-C6-alkylamino-Ci-C6-alkyl means that the alkylaminoalkyl group is attached via the alkyl moiety to the remainder of the molecule, e.g. ⁇ /,/V-dimethylaminoethyl-, N,N- dimethylaminomethyh ⁇ /,/V-diethylaminoethyl-, ⁇ /,/V-dimethylaminopropyl-, N- methylaminoethyl-, /V-methylaminomethyl-.
  • halo-Ci-C6-alkyl- means an alkyl radical having at least one halogen substituent.
  • Ci-C6-alkyl- is as defined supra.
  • a halo-Ci-C6-alkyl radical is an alkyl radical having 1 -6 carbon atoms and at least one halogen substituent. If a plurality of halogen substituents is present, these may also be different from one another. Preference is given to fluoro-Ci-C6-alkyl, fluoro-Ci-C4-alkyl, fluoro-Ci-C3-alkyl, chloro-Ci-C6-alkyl, chloro-Ci-C4-alkyl, chloro-Ci-C3-alkyl, bromo-Ci-C6-alkyl, bromo-Ci-C4-alkyl and bromo-Ci-C3-alkyl radicals.
  • perfluorinated alkyl radicals such as trifluoromethyl or 2,2,2- trifluoroethyl.
  • haloalkoxy means an alkoxy radical having at least one halogen substituent.
  • a halo-Ci-C6-alkoxy radical is an alkoxy radical having 1 -6 carbon atoms and at least one halogen substituent. If a plurality of halogen substituents is present, these may also be different from one another. Preference is given to fluoro-Ci-C6-alkoxy, fluoro-Ci-C4-alkoxy, fluoro-Ci-C3-alkoxy, chloro-Ci-C6-alkoxy, chloro-Ci-C4-alkoxy, chloro-Ci-C3-alkoxy, bromo-Ci- C6-alkoxy, bromo-Ci-C4-alkoxy and bromo-Ci-C3-alkoxy radicals.
  • trifluoromethoxy and 2,2,2-trifluoroethoxy radicals are preferred.
  • halophenyl means a phenyl radical which is mono- or polysubstituted by identical or different substituents from the group consisting of fluorine, chlorine and bromine.
  • C3-Cio-cycloalkyl means a saturated, monovalent, monocyclic hydrocarbon ring which contains 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms (“C3-Cio-cycloalkyl”).
  • Said C3-C10- cycloalkyl group is a monocyclic hydrocarbon ring, e.g. a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl or cyclodecanyl.
  • C3-C8- cycloalkyl and particularly preferably 3 to 7 (C3-C7-cycloalkyl) carbon atoms.
  • phenyl-Ci-C6-alkyl- is understood to mean a group composed of an optionally substituted phenyl radical and a Ci-C6-alkyl group, and bonded to the rest of the molecule via the Ci-C6-alkyl group.
  • the Ci-C6-alkyl is as defined supra.
  • Examples which may be mentioned include benzyl, phenethyl, phenylpropyl, phenylpentyl, with benzyl being preferred.
  • monocyclic heterocyclyl- means a non-aromatic monocyclic ring system having one, two or three heteroatoms which may be identical or different.
  • the heteroatoms may be nitrogen atoms, oxygen atoms or sulphur atoms.
  • a monocyclic heterocyclyl ring according to the present invention may have 3 to 8, preferably 4 to 7, particularly preferably 5 or 6 ring atoms.
  • monocyclic heterocyclyl radicals having 3 ring atoms may be mentioned:
  • azepanyl-, oxepanyl-, 1 ,3-diazepanyl-, 1 ,4-diazepanyk By way of example and with preference, the following may be mentioned for monocyclic heterocyclyl radicals having 8 ring atoms:
  • oxocanyl-, azocanyk From among the monocyclic heterocyclyl radicals, preference is given to 4- to 7-membered saturated heterocyclyl radicals having up to two heteroatoms from the group consisting of O, N and S.
  • heterocycloalkyl means a monocyclic, saturated heterocycle with 4, 5, 6, 7, 8, 9 or 10 ring atoms in total, which contains one or two identical or different ring heteroatoms from the series N and O, it being possible for said heterocycloalkyl group to be attached to the rest of the molecule via any one of the carbon atoms or, if present, a nitrogen atom.
  • heterocycloalkyl is as defined supra.
  • Said heterocycloalkyl group can be a 4-membered ring, such as azetidinyl or oxetanyl, for example; or a 5-membered ring, such as tetrahydrofuranyl, 1 ,3- dioxolanyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, 1 ,2-oxazolidinyl or 1 ,3-oxazolidinyl, for example; or a 6-membered ring, such as tetrahydropyranyl, piperidinyl, morpholinyl, piperazinyl, 1 ,3-dioxanyl, 1 ,4-dioxanyl or 1 ,2-oxazinanyl, for example.
  • 4-membered ring such as azetidinyl or oxetanyl, for example
  • a 5-membered ring such as tetrahydro
  • 4- to 6-membered heterocycloalkyl means a 4- to 6-membered heterocycloalkyl as defined supra containing one ring oxygen atom and optionally one further ring heteroatom from the series: N, O.
  • 5- or 6-membered heterocycloalkyl means a monocyclic, saturated heterocycle with 5 or 6 ring atoms in total, containing one ring oxygen atom.
  • heteroaryl means a monovalent, monocyclic aromatic ring or bicyclic aromatic ring system having 5 to 10 ring atoms (a "5- or 10-membered heteroaryl” group), which contains at least one ring heteroatom and optionally one or two further ring heteroatoms from the series: N, O and/or S, and which is bound via a ring carbon atom or optionally via a ring nitrogen atom (if allowed by valency).
  • monocyclic heteroaryl means a monovalent, aromatic ring having 5 or 6 ring atoms (a “5- or 6-membered heteroaryl” group), which contains at least one ring heteroatom and optionally one or two further ring heteroatoms from the series: N, O and/or S, and which is bound via a ring carbon atom or optionally via a ring nitrogen atom (if allowed by valency).
  • Said heteroaryl group can be a 5-membered heteroaryl group, such as, for example, thienyl, furanyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl or tetrazolyl; or a 6-membered heteroaryl group, such as, for example, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl or triazinyl.
  • a 5-membered heteroaryl group such as, for example, thienyl, furanyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl
  • heteroaryl or heteroarylene groups include all possible isomeric forms thereof, e.g.: tautomers and positional isomers with respect to the point of linkage to the rest of the molecule.
  • pyridinyl includes pyridin-2-yl, pyridin-3-yl and pyridin-4-yl; or the term thienyl includes thien-2-yl and thien-3-yl.
  • the heteroaryl group is a isothiazolyl, pyrazolyl, pyridinyl, pyridazinyl or pyrimidinyl group.
  • spirocycloalkyl means a Cs- to Ci2-membered bicyclic, saturated ring system with 5, 6, 7, 8, 9, 10, 1 1 or 12 carbon atoms in total which rings are fused in a way that they share one common ring carbon atom, it being possible for said spirocycloalkyl group to be attached to the rest of the molecule via any one of the carbon atoms, except the spiro carbon atom.
  • heterospirocycloalkyi means a 5 to 12 -membered bicyclic, saturated ring system with 5, 6, 7, 8, 9, 10, 1 1 or 12 ring atoms in total whereas one, two, three or four ring atoms are heteroatoms as defined above, the remaining ring atoms are carbon atoms and which rings are fused in a way that they share one common ring carbon atom, it being possible for said heterospirocycloalkyi group to be attached to the rest of the molecule via any one of the carbon atoms, except the spiro carbon atom, or, if present, a nitrogen atom.
  • C6-Cio-heterospirocycloalkyl- Preference is given to C6-Cio-heterospirocycloalkyl-, by way of example and with particular preference 2-azaspiro[3.3]heptyl-, 2,2-dioxido-2-thia-6-azaspiro[3.3]heptyl.
  • Examples are radicals derived from bicyclo[2.2.0]hexyl-, bicyclo[3.3.0]octyl-,
  • azabicyclo[4.4.0]decyl- and the further possible combinations as per the definition.
  • C6-Ci2-bicycloalkyl- are perhydronaphthalenyl- (decalinyl-),
  • bridged cycloalkyi and “bridged heterocycloalkyi” mean a bridged C6-C12 ring system such as bridged C6-Ci2-cycloalkyl- or bridged C6-Ci2-heterocycloalkyl- is understood to mean a fusion of at least two saturated rings which share two atoms that are not directly adjacent to one another.
  • bridged carbocycle bridged cycloalkyi-
  • bridged heterocycle bridged heterocycloalkyi-
  • Examples are bicyclo[2.2.1]heptyl-, azabicyclo[2.2.1 ]heptyl-, oxazabicyclo[2.2.1 ]heptyl-, thiazabicyclo[2.2.1 ]heptyl-, diazabicyclo[2.2.1]heptyl-, bicyclo[2.2.2]octyl-,
  • stable compound' or “stable structure” is meant a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent.
  • the compounds of the present invention optionally contain one or more asymmetric centres, depending upon the location and nature of the various substituents desired. It is possible that one or more asymmetric carbon atoms are present in the (R) or (S) configuration, which can result in racemic mixtures in the case of a single asymmetric centre, and in diastereomeric mixtures in the case of multiple asymmetric centres. In certain instances, it is possible that asymmetry also be present due to restricted rotation about a given bond, for example, the central bond adjoining two substituted aromatic rings of the specified compounds.
  • Preferred compounds are those which produce the more desirable biological activity.
  • Preferred isomers are those which produce the more desirable biological activity.
  • These separated, pure or partially purified isomers or racemic mixtures of the compounds of this invention are also included within the scope of the present invention.
  • the purification and the separation of such materials can be accomplished by standard techniques known in the art.
  • the optical isomers can be obtained by resolution of the racemic mixtures according to conventional processes, for example, by the formation of diastereoisomeric salts using an optically active acid or base or formation of covalent diastereomers.
  • appropriate acids are tartaric, diacetyltartaric, ditoluoyltartaric and camphorsulfonic acid.
  • Mixtures of diastereoisomers can be separated into their individual diastereomers on the basis of their physical and/or chemical differences by methods known in the art, for example, by chromatography or fractional crystallisation.
  • the optically active bases or acids are then liberated from the separated diastereomeric salts.
  • a different process for separation of optical isomers involves the use of chiral chromatography (e.g., HPLC columns using a chiral phase), with or without conventional derivatisation, optimally chosen to maximise the separation of the enantiomers.
  • Suitable HPLC columns using a chiral phase are commercially available, such as those manufactured by Daicel, e.g., Chiracel OD and Chiracel OJ, for example, among many others, which are all routinely selectable.
  • Enzymatic separations, with or without derivatisation are also useful.
  • the optically active compounds of the present invention can likewise be obtained by chiral syntheses utilizing optically active starting materials.
  • the present invention includes all possible stereoisomers of the compounds of the present invention as single stereoisomers, or as any mixture of said stereoisomers, e.g. (R)- or (S)- isomers, in any ratio.
  • Isolation of a single stereoisomer, e.g. a single enantiomer or a single diastereomer, of a compound of the present invention is achieved by any suitable state of the art method, such as chromatography, especially chiral chromatography, for example.
  • the compounds of the present invention can exist as N-oxides, which are defined in that at least one nitrogen of the compounds of the present invention is oxidised.
  • the present invention includes all such possible N-oxides.
  • the present invention also covers useful forms of the compounds of the present invention, such as metabolites, hydrates, solvates, prodrugs, salts, in particular pharmaceutically acceptable salts, and/or co-precipitates.
  • the compounds of the present invention can exist as a hydrate, or as a solvate, wherein the compounds of the present invention contain polar solvents, in particular water, methanol or ethanol for example, as structural element of the crystal lattice of the compounds. It is possible for the amount of polar solvents, in particular water, to exist in a stoichiometric or non- stoichiometric ratio.
  • polar solvents in particular water
  • stoichiometric solvates e.g. a hydrate, hemi-, (semi-), mono-, sesqui-, di-, tri-, tetra-, penta- etc. solvates or hydrates, respectively, are possible.
  • the present invention includes all such hydrates or solvates.
  • the compounds of the present invention may exist in free form, e.g. as a free base, or as a free acid, or as a zwitterion, or to exist in the form of a salt.
  • Said salt may be any salt, either an organic or inorganic addition salt, particularly any pharmaceutically acceptable organic or inorganic addition salt, which is customarily used in pharmacy, or which is used, for example, for isolating or purifying the compounds of the present invention.
  • pharmaceutically acceptable salt refers to an inorganic or organic acid addition salt of a compound of the present invention.
  • pharmaceutically acceptable salt refers to an inorganic or organic acid addition salt of a compound of the present invention.
  • S. M. Berge, et al. “Pharmaceutical Salts,” J. Pharm. Sci. 1977, 66, 1 -19.
  • a suitable pharmaceutically acceptable salt of the compounds of the present invention may be, for example, an acid-addition salt of a compound of the present invention bearing a nitrogen atom, in a chain or in a ring, for example, which is sufficiently basic, such as an acid-addition salt with an inorganic acid, or "mineral acid", such as hydrochloric, hydrobromic, hydroiodic, sulfuric, sulfamic, bisulfuric, phosphoric, or nitric acid, for example, or with an organic acid, such as formic, acetic, acetoacetic, pyruvic, trifluoroacetic, propionic, butyric, hexanoic, heptanoic, undecanoic, lauric, benzoic, salicylic, 2-(4-hydroxybenzoyl)-benzoic, camphoric, cinnamic, cyclopentanepropionic, digluconic, 3-hydroxy-2-naphthoic, nico
  • D-gluconic, mandelic, ascorbic, glucoheptanoic, glycerophosphoric, aspartic, sulfosalicylic, or thiocyanic acid for example.
  • an alkali metal salt for example a sodium or potassium salt
  • an alkaline earth metal salt for example a calcium, magnesium or strontium salt, or an aluminium or a zinc salt
  • acid addition salts of the claimed compounds to be prepared by reaction of the compounds with the appropriate inorganic or organic acid via any of a number of known methods.
  • alkali and alkaline earth metal salts of acidic compounds of the present invention are prepared by reacting the compounds of the present invention with the appropriate base via a variety of known methods.
  • the present invention includes all possible salts of the compounds of the present invention as single salts, or as any mixture of said salts, in any ratio.
  • the present invention includes all possible crystalline forms, or polymorphs, of the compounds of the present invention, either as single polymorph, or as a mixture of more than one polymorph, in any ratio.
  • the present invention also includes prodrugs of the compounds according to the invention.
  • prodrugs here designates compounds which themselves can be biologically active or inactive, but are converted (for example metabolically or hydrolytically) into compounds according to the invention during their residence time in the body.
  • the invention further includes all possible crystallized and polymorphic forms of the inventive compounds, whereby the polymorphs are existing either as a single polymorph form or are existing as a mixture of several polymorphs in all concentrations.
  • the invention further includes all possible cyclodextrin clathrates, i.e alpha-, beta-, or gamma- cyclodextrins, hydroxypropyl-beta-cyclodextrins, methylbetacyclodextrins.
  • the present invention covers compounds of general formula (I), in which X represents an oxygene atom.
  • the present invention covers compounds of general formula (I), in which Y represents a sulphur or an oxygene atom. In accordance with a further embodiment, the present invention covers compounds of general formula (I), in which X represents a sulphur or an oxygene atom.
  • the present invention covers compounds of general formula (I), in which Y represents a sulphur or an oxygene atom.
  • the present invention covers compounds of general formula (I), in which X represents a sulphur and Y an oxygene atom.
  • the present invention covers compounds of general formula (I), in which Y represents a sulphur and X an oxygene atom.
  • the present invention covers compounds of general formula (I), in which R 1 represents hydrogen, halogen, Ci-C6-alkyl, halo-Ci-C6-alkyl and cyano. In accordance with a further embodiment, the present invention covers compounds of general formula (I), in which R 2 represents fluorine.
  • the present invention covers compounds of general formula (I), in which R 3 represents hydrogen or Ci-C6-alkyl.
  • the present invention covers compounds of general formula (I), in which R 3 represents hydrogen or Ci-C3-alkyl.
  • the present invention covers compounds of general formula (I), in which R 3 represents hydrogen or methyl. In accordance with a further embodiment, the present invention covers compounds of general formula (I), in which R 4
  • Ci-C6-alkyl- represents hydrogen or represents Ci-C6-alkyl-, which may optionally be mono- or
  • a monocyclic heterocyclyl- having 3 to 8 ring atoms which may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of halogen, oxo, Ci-C6-alkylamino-Ci-C6-alkyl or monocyclic heterocyclyl radical having 3 to 8 ring atoms or
  • phenyl- which may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of halogen, Ci-C6-alkoxy- or halo-Ci-C6-alkyl-, or
  • the present invention covers compounds of general formula (I), in which R 4
  • Ci-C6-alkyl- represents hydrogen or represents Ci-C6-alkyl-, which may optionally be mono- or
  • phenyl- which may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of halogen, Ci-C3-alkoxy- or halo-Ci-C3-alkyl-, or
  • heterospirocycloalkyl which may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of halogen, Ci-C3-alkyl-,
  • the present invention covers compounds of general formula (I), in which R 4 represents
  • the present invention covers compounds of general formula (I), in which X and Y represent an oxygene atom.
  • the present invention covers compounds of general formula (I), in which R 1 represents chlorine, bromine, cyano and trifluoromethyl.
  • the present invention covers compounds of general formula (I), in which R 2 represents fluorine and R 3 represents hydrogen. In accordance with a further embodiment, the present invention covers compounds of general formula (I), in which R 4 represents
  • R x represents methyl or -CH 2 -CH 2 -0-CH3.
  • R 4 represents Ci-C6-alkyl-, which may optionally be mono- or disubstituted by identical or different substituents from the group consisting of
  • R 4 represents Ci-C6-alkyl-, which may optionally be mono- or disubstituted by identical or different substituents from the group consisting of
  • the present invention covers compounds of general formula (I), in which X represents an oxygene atom, Y represents a sulphur atom, R 1 represents trifluoromethyl and R 2 represents fluorine.
  • the present invention covers compounds of general formula (I), in which
  • R 5 and R 6 independently of one another represent hydrogen or Ci-C3-alkyl-
  • R 5 and R 6 together with the nitrogen atom form a monocyclic heterocyclyl- having 3 to 8 ring atoms which itself may optionally be substituted by Ci-C6-alkyk
  • the present invention covers compounds of general formula (I), in which
  • R 5 and R 6 independently of one another represent hydrogen or Ci-C3-alkyl-
  • R 5 and R 6 together with the nitrogen atom form a monocyclic heterocyclyl- having 4 to 6 ring atoms which itself may optionally be substituted by Ci-C3-alkyk
  • the present invention covers compounds of general formula (I), in which R 8 represents Ci-C6-alkyk
  • the present invention covers compounds of general formula (I), in which R 8 represents Ci-C3-alkyk
  • the present invention covers compounds of general formula (I), in which R 9 represents Ci-C6-alkyl- or -Nh .
  • the present invention covers compounds of general formula (I), in which R 9 represents Ci-C3-alkyl- or -Nh . In accordance with a further embodiment, the present invention covers compounds of general formula (I), in which R x represents Ci-C6-alkoxy-Ci-C6-alkyk
  • the present invention covers compounds of general formula (I), in which R x represents Ci-C3-alkoxy-Ci-C3-alkyk
  • X represents a nitrogen, a sulphur or an oxygene atom
  • Y represents a sulphur or an oxygene atom
  • R 1 represents hydrogen, halogen, Ci-C6-alkyl, halo-Ci-C6-alkyl and cyano,
  • R 2 represents fluorine or chlorine
  • R 3 represents hydrogen or Ci-C6-alkyl
  • R 4 represents hydrogen or represents Ci-C6-alkyl-, which may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of halogen, cyano, hydroxy, Ci-C3-alkoxy-, -IM H2, -N H-(Ci-C6-alkyl),
  • C3-Cio-cycloalkyl- which itself may optionally be mono- or polysubstituted by dentical or different substituents from the group consisting of of halogen, cyano, nitro, hydroxy, amino, oxo, carboxy, Ci-C6-alkyl-, Ci-C6-alkoxy-, Ci-C6-alkoxy- Ci-C6-alkyl-, hydroxy-Ci-C6-alkyl-, Ci-C6-alkylamino-, Ci-C6-alkylcarbonylamino- , amino-Ci-C6-alkyl-, Ci-C6-alkylamino-Ci-C6-alkyl-, halo-Ci-C6-alkyl-, halo-Ci- C6-alkoxy-, C3-Cio-cycloalkyl-, phenyl-, halophenyl-, phenyl-Ci-C6-al
  • each of which mentioned supra may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of halogen, cyano, nitro, hydroxy, amino, oxo, carboxy, Ci-C6-alkyl-, Ci-C6-alkoxy-, Ci-C6-alkoxy- Ci-C6-alkyl-, hydroxy-Ci-C6-alkyl-, Ci-C6-alkylamino-, Ci-C6-alkylcarbonylamino- , amino-Ci-C6-alkyl-, Ci-C6-alkylamino-Ci-C6-alkyl-, halo-Ci-C6-alkyl-, halo-Ci- C6-alkoxy-, C3-Cio-cycloalkyl-, phenyl-, halophenyl-, phenyl-Ci-C6-alkyl-, phenoxy-, pyridin
  • C3-Cio-cycloalkyl- which may optionally be mono- or polysubstituted by dentical or different substituents from the group consisting of of of of halogen, cyano, nitro, hydroxy, amino, oxo, carboxy, Ci-C6-alkyl-, Ci-C6-alkoxy-, C1-C6- alkoxy-Ci-C6-alkyl-, hydroxy-Ci-C6-alkyl-, Ci-C6-alkylamino-, C1-C6- alkylcarbonylamino-, amino-Ci-C6-alkyl-, Ci-C6-alkylamino-Ci-C6-alkyl-, halo-Ci- C6-alkyl-, halo-Ci-C6-alkoxy-, C3-Cio-cycloalkyl-, phenyl-, halophenyl-, phenyl- d-C
  • phenyl- which may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of of halogen, cyano, nitro, hydroxy, amino, carboxy, Ci-C6-alkyl-, Ci-C6-alkoxy-, Ci-C6-alkoxy-Ci-C6- alkyl-, hydroxy-Ci-C6-alkyl-, Ci-C6-alkylamino-, Ci-C6-alkylcarbonylamino-, amino-Ci-C6-alkyl-, Ci-C6-alkylamino-Ci-C6-alkyl-, halo-Ci-C6-alkyl-, halo-Ci-C6- alkoxy-, C3-Cio-cycloalkyl-, phenyl-, halophenyl-, phenyl-Ci-C6-alkyl-, phenoxy-, pyridinyl-
  • bicycloalkyl a heterobicycloalkyl radical, a bridged cycloalkyl radical or a bridged heterocycloalkyl radical, a naphthyl radical or a bicyclic heteroaryl radical, or a partially saturated bicyclic aryl- or heteroaryl radical, where the radicals mentioned may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of of halogen, cyano, nitro, hydroxy, amino, oxo, carboxy, Ci-C6-alkyl-, Ci-C6-alkoxy-, Ci-C6-alkoxy-Ci-C6- alkyl-, hydroxy-Ci-C6-alkyl-, Ci-C6-alkylamino-, Ci-C6-alkylcarbonylamino-, amino-Ci-C6-alkyl-, Ci-C6-alkylamino-Ci-C6-alkyl-, halo-
  • R 3 and R 4 together with the nitrogen atom form a 4 to 10 membered heterocycloalkyi ring, which may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of of halogen, cyano, nitro, hydroxy, amino, oxo, carboxy, Ci-C6-alkyl-, Ci-C6-alkoxy-, Ci-C6-alkoxy-Ci-C6-alkyl-, hydroxy-Ci-C6-alkyl-, Ci-C6-alkylamino-, Ci-C6-alkylcarbonylamino-, amino-Ci-
  • R 5 and R 6 independently of one another represent hydrogen, Ci-C3-alkyl-, cyclopropyl- or di-Ci-C3-alkylamino-Ci-C3-alkyl-,
  • R 7 represents hydroxy, Ci-C6-alkyl-, Ci-C6-alkoxy-, halo-Ci-C3-alkyl-, hydroxy-Ci-
  • R 8 represents Ci-C6-alkyl-
  • R 9 represents Ci-C 6 -alkyl-, -NH 2 , -NH-Ci-C 6 -alkyl, -N(Ci-C 6 -alkyl) 2 , or Ci-C 6 -alkoxy- d-Ce-alkyl-,
  • R x represents Ci-C6-alkyl- or Ci-C6-alkoxy-Ci-C6-alkyl-,
  • R y represents hydrogen, halo-Ci-C6-alkyl, Ci-C6-alkyl, Ci-C6-alkyl substituted with
  • X represents an oxygene atom
  • Y represents a sulphur or an oxygene atom
  • R 1 represents hydrogen, halogen, Ci-C6-alkyl, halo-Ci-C6-alkyl and cyano
  • R 2 represents fluorine
  • R 3 represents hydrogen or Ci-C6-alkyl
  • R 4 represents hydrogen or represents Ci-C6-alkyl-, which may optionally be mono- or disubstituted by identical or different substituents from the group consisting of halogen, cyano, hydroxy, Ci-C3-alkoxy-, -NH 2 , -NH-(Ci-C6-alkyl), -N(Ci-C 6 -alkyl) 2 , -NH-(Ci-C 6 -alkyl)-Ci-C 6 -alkoxy, Ci-C 6 -alkyl-, Ci-C 6 -alkoxy-,
  • monocyclic heteroaryl- having 5 or 6 ring atoms which itself may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of halogen, cyano, nitro, hydroxy, amino, carboxy, Ci-C6-alkyl-,
  • phenyl- which itself may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of halogen, cyano, nitro, hydroxy, amino, carboxy, Ci-C6-alkyl-, Ci-C6-alkoxy-, Ci- C6-alkoxy-Ci-C6-alkyl-, hydroxy-Ci-C6-alkyl-, Ci-C6-alkylamino-, C1-C6- alkylcarbonylamino-, amino-Ci-C6-alkyl-, Ci-C6-alkylamino-Ci-C6-alkyl-, halo-Ci C6-alkyl-, halo-Ci-C6-alkoxy-, C3-Cio-cycloalkyl-, phenyl-
  • phenyl- which may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of halogen, cyano, nitro, hydroxy, amino, carboxy, Ci-C6-alkyl-, Ci-C6-alkoxy-, Ci- C6-alkoxy-Ci-C6-alkyl-, hydroxy-Ci-C6-alkyl-, Ci-C6-alkylamino-, C1-C6- alkylcarbonylamino-, amino-Ci-C6-alkyl-, Ci-C6-alkylamino-Ci-C6-alkyl-, halo-Ci- C6-alkyl-, halo-Ci-C6-alkoxy-, C3-Cio-cycloalkyl-, phenyl-, halophenyl-, phenyl- d-Ce-alkyl-, phenoxy-, pyridinyl-
  • R 3 and R 4 together with the nitrogen atom form a 4 to 10 membered heterocycloalkyl ring, which may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of halogen, cyano, nitro, hydroxy, amino, oxo, carboxy, Ci-C6-alkyl-, Ci-C6-alkoxy-, Ci-C6-alkoxy-Ci-C6-alkyl-, hydroxy-Ci- C6-alkyl-, Ci-C6-alkylamino-, Ci-C6-alkylcarbonylamino-, amino-Ci-C6-alkyl-, Ci- C6-alkylamino-Ci-C6-alkyl-, halo-Ci-C6-alkyl-, halo-Ci-C6-alkoxy-, C3-C10- cycloalkyl-, phenyl-, halophenyl-,
  • heterobicycloalkyi group each of which mentioned may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of halogen, cyano, nitro, hydroxy, amino, oxo, carboxy, Ci-C6-alkyl-, Ci-C6-alkoxy-, Ci-C6-alkoxy-Ci-C6-alkyl-, hydroxy-Ci-C6-alkyl-, Ci-C6-alkylamino-, C1-C6- alkylcarbonylamino-, amino-Ci-C6-alkyl-, Ci-C6-alkylamino-Ci-C6-alkyl-, halo-Ci- C6-alkyl-, halo-Ci-C6-alkoxy-, C3-Cio-cycloalkyl-, phenyl-, halophenyl-, phenyl- d-Ce-alkyl-,
  • R 5 and R 6 independently of one another represent hydrogen, Ci-C3-alkyl-, cyclopropyl- or di-Ci-C3-alkylamino-Ci-C3-alkyl-,
  • R 7 represents hydroxy, Ci-C6-alkyl-, Ci-C6-alkoxy-, halo-Ci-C3-alkyl-, hydroxy-Ci-
  • R 9 represents Ci-C 6 -alkyl-, -NH 2 , -NH-Ci-C 6 -alkyl, -N(Ci-C 6 -alkyl) 2 , Ci-C 6 -alkoxy- d-Ce-alkyl-,
  • R y represents hydrogen, halo-Ci-C6-alkyl, Ci-C6-alkyl, Ci-C6-alkyl substituted with
  • X represents a sulphur or an oxygene atom
  • Y represents a sulphur or an oxygene atom
  • R 1 represents hydrogen, halogen, Ci-C6-alkyl, halo-Ci-C6-alkyl or cyano,
  • R 2 represents fluorine
  • R 3 represents hydrogen or Ci-C6-alkyl
  • R 4 represents hydrogen or represents Ci-C6-alkyl-, which may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of
  • R 4 represents a C3-Cio-cycloalkyl- which may optionally substituted by
  • R 3 and R 4 together with the nitrogen atom form a 4 to 10 membered heterocycloalkyl or a
  • heterospirocycloalkyl which may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of halogen, Ci-C6-alkyl-, Ci-C6-alkoxy- or hydroxy-Ci-C6-alkyl-, R 5 and R 6 independently of one another represent hydrogen or Ci-C3-alkyl-,
  • R 5 and R 6 together with the nitrogen atom form a monocyclic heterocyclyl- having 3 to 8 ring atoms which itself may optionally be substituted by Ci-C6-alkyl-,
  • R 8 represents Ci-C6-alkyl-
  • R 9 represents d-Ce-alkyl- or -NH 2 .
  • R x represents Ci-C6-alkoxy-Ci-C6-alkyl-
  • X represents a sulphur or an oxygene atom
  • Y represents a sulphur or an oxygene atom
  • R 1 represents hydrogen, halogen, Ci-C6-alkyl, halo-Ci-C6-alkyl or cyano,
  • R 2 represents fluorine
  • R 3 represents hydrogen or Ci-C3-alkyl
  • R 4 represents hydrogen or represents Ci-C6-alkyl-, which may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of
  • R 3 and R 4 together with the nitrogen atom form a 4 to 6 membered heterocycloalkyl or a
  • heterospirocycloalkyl which may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of halogen, Ci-C3-alkyl-, Ci-C3-alkoxy-, hydroxy-Ci-C3-alkyl-,
  • R 5 and R 6 independently of one another represent hydrogen or Ci-C3-alkyl-
  • R 5 and R 6 together with the nitrogen atom form a monocyclic heterocyclyl- having 4 to 6 ring atoms which itself may optionally be substituted by Ci-C3-alkyl-,
  • R 8 represents Ci-C3-alkyl-
  • R 9 represents d-Cs-alkyl- or -NH 2 .
  • R x represents Ci-C3-alkoxy-Ci-C3-alkyl-
  • X represents an oxygene atom
  • Y represents a sulphur or an oxygene atom
  • R 1 represents hydrogen, chlorine, bromine, methyl-, trifluoromethyl and cyano
  • R 2 represents fluorine
  • R 3 represents hydrogen or methyl
  • R 4 represents hydrogen, Ci-C6-alkyl-, which may optionally be mono- or
  • R 9 represents methyl, -NH 2 or -CH2-CH2-O-CH3 or
  • R x represents methyl or -CH 2 -CH 2 -0-CH 3 ,
  • R 10 represents hydrogen, methyl, methoxy and cyano
  • R 11 represents hydrogen and trifluoromethyl
  • R 12 represents hydrogen, fluorine and methoxy
  • R 13 represents hydrogen and methyl
  • R 14 represents hydrogen and -CH 2 -0-CH3,
  • X represents an oxygene atom
  • Y represents an oxygene atom
  • R 1 represents hydrogen, chlorine, bromine, methyl-, trifluoromethyl and cyano
  • R 2 represents fluorine
  • R 3 represents hydrogen or methyl
  • R 4 represents hydrogen, Ci-C6-alkyl-, which may optionally be mono- or
  • R 1 1 0 0 represents hydrogen, methyl, methoxy and cyano
  • X represents an oxygene atom
  • Y represents an oxygene atom
  • R 1 represents chlorine, bromine, cyano and trifluoromethyl
  • R 2 represents fluorine
  • R 3 represents hydrogen
  • R 4 represents hydrogen, Ci-C6-alkyl-, which may optionally be mono- or
  • R 9 represents methyl, -NH 2 or -CH2-CH2-O-CH3 or
  • R x represents methyl or -CH2-CH2-O-CH3,
  • R 10 represents hydrogen
  • R 13 represents hydrogen
  • X represents an oxygene atom
  • Y represents a sulphur atom
  • R 1 represents trifluoromethyl
  • R 2 represents fluorine
  • R 3 represents hydrogen
  • R 4 represents Ci-C3-alkyl-, which may optionally be mono-substituted by
  • the compounds of general formula (I) of the present invention can be converted to any salt, preferably pharmaceutically acceptable salts, as described herein, by any method which is known to the person skilled in the art.
  • any salt of a compound of general formula (I) of the present invention can be converted into the free compound, by any method which is known to the person skilled in the art.
  • MAP4K1 MAP4K1
  • disorders and conditions particularly suitable for treatment with an MAP4K1 inhibitor of the present invention are liquid and solid tumours, such as cancers of the breast, respiratory tract, brain, reproductive organs, digestive tract, urinary tract, eye, liver, skin, head and neck, thyroid, parathyroid and their distant metastases. Those disorders also include lymphomas, sarcomas, and leukaemias.
  • breast cancers include, but are not limited to, triple negative breast cancer, invasive ductal carcinoma, invasive lobular carcinoma, ductal carcinoma in situ, and lobular carcinoma in situ.
  • cancers of the respiratory tract include, but are not limited to, small-cell and non- small-cell lung carcinoma, as well as bronchial adenoma and pleuropulmonary blastoma.
  • brain cancers include, but are not limited to, brain stem and hypophtalmic glioma, cerebellar and cerebral astrocytoma, glioblastoma, medulloblastoma, ependymoma, as well as neuroectodermal and pineal tumour.
  • Tumours of the male reproductive organs include, but are not limited to, prostate and testicular cancer.
  • Tumours of the female reproductive organs include, but are not limited to, endometrial, cervical, ovarian, vaginal, and vulvar cancer, as well as sarcoma of the uterus.
  • ovarian cancer examples include, but are not limited to serous tumour, endometrioid tumour, mucinous cystadenocarcinoma, granulosa cell tumour, Sertoli-Leydig cell tumour and arrhenoblastoma.
  • cervical cancer examples include, but are not limited to squamous cell carcinoma, adenocarcinoma, adenosquamous carcinoma, small cell carcinoma, neuroendocrine tumour, glassy cell carcinoma and villoglandular adenocarcinoma.
  • Tumours of the digestive tract include, but are not limited to, anal, colon, colorectal, esophageal, gallbladder, gastric, pancreatic, rectal, small-intestine, and salivary gland cancers.
  • esophageal cancer include, but are not limited to esophageal cell carcinomas and adenocarcinomas, as well as squamous cell carcinomas, leiomyosarcoma, malignant melanoma, rhabdomyosarcoma and lymphoma.
  • gastric cancer examples include, but are not limited to intestinal type and diffuse type gastric adenocarcinoma.
  • pancreatic cancer examples include, but are not limited to ductal adenocarcinoma, adenosquamous carcinomas and pancreatic endocrine tumours.
  • Tumours of the urinary tract include, but are not limited to, bladder, penile, kidney, renal pelvis, ureter, urethral and human papillary renal cancers.
  • kidney cancer examples include, but are not limited to renal cell carcinoma, urothelial cell carcinoma, juxtaglomerular cell tumour (reninoma), angiomyolipoma, renal oncocytoma, Bellini duct carcinoma, clear-cell sarcoma of the kidney, mesoblastic nephroma and Wilms' tumour.
  • bladder cancer examples include, but are not limited to transitional cell carcinoma, squamous cell carcinoma, adenocarcinoma, sarcoma and small cell carcinoma.
  • Eye cancers include, but are not limited to, intraocular melanoma and retinoblastoma.
  • liver cancers include, but are not limited to, hepatocellular carcinoma (liver cell carcinomas with or without fibrolamellar variant), cholangiocarcinoma (intrahepatic bile duct carcinoma), and mixed hepatocellular cholangiocarcinoma.
  • Skin cancers include, but are not limited to, squamous cell carcinoma, Kaposi's sarcoma, malignant melanoma, Merkel cell skin cancer, and non-melanoma skin cancer.
  • Head-and-neck cancers include, but are not limited to, squamous cell cancer of the head and neck, laryngeal, hypopharyngeal, nasopharyngeal, oropharyngeal cancer, salivary gland cancer, lip and oral cavity cancer and squamous cell.
  • Lymphomas include, but are not limited to, AIDS-related lymphoma, non-Hodgkin's lymphoma, cutaneous T-cell lymphoma, Burkitt lymphoma, Hodgkin's disease, and lymphoma of the central nervous system.
  • Sarcomas include, but are not limited to, sarcoma of the soft tissue, osteosarcoma, malignant fibrous histiocytoma, lymphosarcoma, and rhabdomyosarcoma.
  • Leukemias include, but are not limited to, acute myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, and hairy cell leukemia.
  • treating or “treatment” as stated throughout this document is used conventionally, for example the management or care of a subject for the purpose of combating, alleviating, reducing, relieving, improving the condition of a disease or disorder, such as a carcinoma.
  • the compounds of the present invention can be used in particular in therapy and prevention, i.e. prophylaxis, of tumour growth and metastases, especially in solid tumours of all indications and stages with or without pre-treatment of the tumour growth.
  • chemotherapeutic agents and/or anti-cancer agents in combination with a compound or pharmaceutical composition of the present invention will serve to:
  • chemotherapies and certain other combined therapies 4. provide for treating a broader spectrum of different cancer types in mammals, especially humans,
  • the compounds of general formula (I) of the present invention can also be used in combination with radiotherapy and/or surgical intervention.
  • the compounds of general formula (I) of the present invention may be used to sensitize a cell to radiation, i.e. treatment of a cell with a compound of the present invention prior to radiation treatment of the cell renders the cell more susceptible to DNA damage and cell death than the cell would be in the absence of any treatment with a compound of the present invention.
  • the cell is treated with at least one compound of general formula (I) of the present invention.
  • the present invention also provides a method of killing a cell, wherein a cell is
  • the present invention also provides a method of rendering a cell more susceptible to cell death, wherein the cell is treated with one or more compounds of general formula (I) of the present invention prior to the treatment of the cell to cause or induce cell death.
  • the cell is treated with at least one compound, or at least one method, or a combination thereof, in order to cause DNA damage for the purpose of inhibiting the function of the normal cell or killing the cell.
  • a cell is killed by treating the cell with at least one DNA damaging agent, i.e. after treating a cell with one or more compounds of general formula (I) of the present invention to sensitize the cell to cell death, the cell is treated with at least one DNA damaging agent to kill the cell.
  • DNA damaging agents useful in the present invention include, but are not limited to, chemotherapeutic agents (e.g. cis platin), ionizing radiation (X-rays, ultraviolet radiation), carcinogenic agents, and mutagenic agents.
  • a cell is killed by treating the cell with at least one method to cause or induce DNA damage.
  • Such methods include, but are not limited to, activation of a cell signalling pathway that results in DNA damage when the pathway is activated, inhibiting of a cell signalling pathway that results in DNA damage when the pathway is inhibited, and inducing a biochemical change in a cell, wherein the change results in DNA damage.
  • a DNA repair pathway in a cell can be inhibited, thereby preventing the repair of DNA damage and resulting in an abnormal accumulation of DNA damage in a cell.
  • a compound of general formula (I) of the present invention is administered to a cell prior to the radiation or other induction of DNA damage in the cell.
  • a compound of general formula (I) of the present invention is administered to a cell concomitantly with the radiation or other induction of DNA damage in the cell.
  • a compound of general formula (I) of the present invention is administered to a cell immediately after radiation or other induction of DNA damage in the cell has begun.
  • the cell is in vitro. In another embodiment, the cell is in vivo.
  • the compounds of the present invention can be administered as the sole pharmaceutical agent or in combination with one or more other pharmaceutically active ingredients where the combination causes no unacceptable adverse effects.
  • the present invention also covers such pharmaceutical combinations.
  • the compounds of the present invention can be combined with: 131 1-chTNT, abarelix, abiraterone, aclarubicin, adalimumab, ado-trastuzumab emtansine, afatinib, aflibercept, aldesleukin, alectinib, alemtuzumab, alendronic acid, alitretinoin, altretamine, amifostine, aminoglutethimide, hexyl aminolevulinate, amrubicin, amsacrine, anastrozole, ancestim, anethole dithiolethione, anetumab ravtansine, angiotensin II, antithrombin III, aprepitant, arcitumomab, arglabin, arsenic trioxide, asparaginase, atezolizumab, axitinib, azacitidine, basilixim
  • pentazocine pentostatin, peplomycin, Perflubutane, perfosfamide, Pertuzumab, picibanil, pilocarpine, pirarubicin, pixantrone, plerixafor, plicamycin, poliglusam, polyestradiol phosphate, polyvinylpyrrolidone + sodium hyaluronate, polysaccharide-K, pomalidomide, ponatinib, porfimer sodium, pralatrexate, prednimustine, prednisone, procarbazine, procodazole, propranolol, quinagolide, rabeprazole, racotumomab, radium-223 chloride, radotinib, raloxifene, raltitrexed, ramosetron, ramucirumab, ranimustine, rasburicase, razoxane,
  • nofetumomab merpentan 99mTc-HYNIC-[Tyr3]-octreotide, tegafur, tegafur + gimeracil + oteracil, temoporfin, temozolomide, temsirolimus, teniposide, testosterone, tetrofosmin, thalidomide, thiotepa, thymalfasin, thyrotropin alfa, tioguanine, tocilizumab, topotecan, toremifene, tositumomab, trabectedin, trametinib, tramadol, trastuzumab, trastuzumab emtansine, treosulfan, tretinoin, trifluridine + tipiracil, trilostane, triptorelin, trametinib, trofosfamide, thrombo
  • the compounds of the invention can further be combined with other reagents targeting the immune system, such as immune checkpoint inhibitors, e.g. aPD-1/-L1 axis antagonists.
  • immune checkpoint inhibitors e.g. aPD-1/-L1 axis antagonists.
  • PD-1 along with its ligands PD-L1 and PD-L2, function as negative regulators of T cell activation.
  • MAP4K1 suppresses immune cell function.
  • PD-L1 is overexpressed in many cancers and overexpression of PD-1 often occurs concomitantly in tumor infiltrating T cells. Thus results in attenuation of T cell activation and evasion of immune surveillance, which contributes to impaired antitumor immune responses.
  • inventive compounds can also be used as a therapeutic in a variety of other disorders wherein MAP4K1 is involved such as, cardiovascular and lung diseases.
  • the compounds according to the invention are suitable for the treatment and/or prophylaxis in particular of cardiovascular, inflammatory and fibrotic disorders and of renal disorders, in particular of acute and chronic renal insufficiency, and also of acute and chronic renal failure.
  • the compounds according to the invention can be used in medicaments for the treatment and/or prophylaxis of cardiovascular, inflammatory and fibrotic disorders, renal disorders, in particular of acute and chronic renal insufficiency, and also of acute and chronic renal failure.
  • renal insufficiency comprises both acute and chronic manifestations of renal insufficiency, and also underlying or related renal disorders such as diabetic and non-diabetic nephropathies, hypertensive nephropathies, ischaemic renal disorders, renal hypoperfusion, intradialytic hypotension, obstructive uropathy, renal stenoses, glomerulopathies, glomerulonephritis (such as, for example, primary glomerulonephritides; minimal change glomerulonephritis (lipoidnephrosis); membranous glomerulonephritis; focal segmental glomerulosclerosis (FSGS); membrane-proliferative glomerulonephritis; crescentic glomerulonephritis; mesangioproliferative glomerulonephritis (IgA nephritis, Berger's disease); post-infectious glomerulonephritis; secondary
  • the present invention also comprises the use of the compounds according to the invention for the treatment and/or prophylaxis of sequelae of renal insufficiency, for example pulmonary oedema, heart failure, uremia, anemia, electrolyte disturbances (for example hypercalemia, hyponatremia) and disturbances in bone and carbohydrate metabolism.
  • sequelae of renal insufficiency for example pulmonary oedema, heart failure, uremia, anemia, electrolyte disturbances (for example hypercalemia, hyponatremia) and disturbances in bone and carbohydrate metabolism.
  • the present invention also comprises the use of the compounds according to the invention for the treatment and/or prevention of sequelae of renal insufficiency, for example pulmonary oedema, heart failure, uraemia, anaemia, electrolyte disturbances (for example hyperkalaemia, hyponatraemia) and disturbances in bone and carbohydrate metabolism.
  • sequelae of renal insufficiency for example pulmonary oedema, heart failure, uraemia, anaemia, electrolyte disturbances (for example hyperkalaemia, hyponatraemia) and disturbances in bone and carbohydrate metabolism.
  • the compounds according to the invention are further suitable for the treatment and/or prevention of polycystic kidney disease (PCKD) and of the syndrome of inappropriate ADH secretion (SIADH). Furthermore, the compounds according to the invention are also suitable for the treatment and/or prophylaxis of metabolic syndrome, hypertension, resistant hypertension, acute and chronic heart failure, coronary heart disease, stable and unstable angina pectoris, peripheral and cardiac vascular disorders, arrhythmias, atrial and ventricular arrhythmias and impaired conduction, for example atrioventricular blocks degrees l-lll (AB block l-lll), supraventricular tachyarrhythmia, atrial fibrillation, atrial flutter, ventricular fibrillation, ventricular flutter, ventricular tachyarrhythmia, Torsade de pointes tachycardia, atrial and ventricular
  • extrasystoles AV-junctional extrasystoles, sick sinus syndrome, syncopes, AV-nodal re-entry tachycardia, Wolff-Parkinson-White syndrome, of acute coronary syndrome (ACS),
  • ACS acute coronary syndrome
  • autoimmune cardiac disorders peripheral cardiac disorders (pericarditis, endocarditis, valvolitis, aortitis, cardiomyopathies), shock such as cardiogenic shock, septic shock and anaphylactic shock, aneurysms, boxer cardiomyopathy (premature ventricular contraction (PVC)), for treatment and/or prophylaxis of thromboembolic disorders and ischaemias such as myocardial ischaemia, myocardial infarction, stroke, cardiac hypertrophy, transient and ischaemic attacks, preeclampsia, inflammatory cardiovascular disorders, spasms of the coronary arteries and peripheral arteries, oedema formation, for example pulmonary oedema, cerebral oedema, renal oedema or oedema caused by heart failure, peripheral circulatory disturbances, reperfusion damage, arterial and venous thromboses, myocardial insufficiency, endothelial dysfunction, to prevent restenoses, for example after thrombolysis
  • the compounds according to the invention are also suitable for treatment and/or prophylaxis of asthmatic disorders, pulmonary arterial hypertension (PAH) and other forms of pulmonary hypertension (PH) including left-heart disease, HIV, sickle cell anaemia,
  • PAH pulmonary arterial hypertension
  • PH pulmonary hypertension
  • CTEPH chronic-obstructive pulmonary disease
  • COPD chronic-obstructive pulmonary disease
  • ARDS acute respiratory distress syndrome
  • ALI acute lung injury
  • AATD alpha-1 -antitrypsin deficiency
  • CF cystic fibrosis
  • the compounds described in the present invention are also active compounds for control of central nervous system disorders characterized by disturbances of the NO/cGMP system. They are suitable in particular for improving perception, concentration, learning or memory after cognitive impairments like those occurring in particular in association with
  • situations/diseases/syndromes such as mild cognitive impairment, age-associated learning and memory impairments, age-associated memory losses, vascular dementia, craniocerebral trauma, stroke, dementia occurring after strokes (post stroke dementia), post-traumatic craniocerebral trauma, general concentration impairments, concentration impairments in children with learning and memory problems, Alzheimer's disease, Lewy body dementia, dementia with degeneration of the frontal lobes including Pick ' s syndrome, Parkinson's disease, progressive dementia with corticobasal degeneration, amyolateral sclerosis (ALS), Huntington's disease, demyelinization, multiple sclerosis, thalamic degeneration, Creutzfeld- Jacob dementia, HIV dementia, schizophrenia with dementia or Korsakoff's psychosis. They are also suitable for treatment and/or prophylaxis of central nervous system disorders such as states of anxiety, tension and depression, CNS-related sexual dysfunctions and sleep disturbances, and for controlling pathological disturbances of the intake of food, stimulants and addictive substances.
  • the compounds according to the invention are furthermore also suitable for controlling cerebral blood flow and thus represent effective agents for controlling migraines. They are also suitable for the prophylaxis and control of sequelae of cerebral infarction (cerebral apoplexy) such as stroke, cerebral ischaemia and craniocerebral trauma.
  • the compounds according to the invention can likewise be used for controlling states of pain and tinnitus.
  • the compounds according to the invention have anti-inflammatory action and can therefore be used as anti-inflammatory agents for treatment and/or prophylaxis of sepsis (SIRS), multiple organ failure (MODS, MOF), inflammatory disorders of the kidney, chronic intestinal inflammations (IBD, Crohn's disease, UC), pancreatitis, peritonitis, rheumatoid disorders, inflammatory skin disorders and inflammatory eye disorders.
  • SIRS sepsis
  • MODS multiple organ failure
  • IBD chronic intestinal inflammations
  • Crohn's disease UC
  • pancreatitis peritonitis
  • rheumatoid disorders inflammatory skin disorders and inflammatory eye disorders.
  • the compounds according to the invention can also be used for treatment and/or prophylaxis of autoimmune diseases.
  • the compounds according to the invention are also suitable for treatment and/or prophylaxis of fibrotic disorders of the internal organs, for example the lung, the heart, the kidney, the bone marrow and in particular the liver, and also dermatological fibroses and fibrotic eye disorders.
  • fibrotic disorders includes in particular the following terms: hepatic fibrosis, cirrhosis of the liver, pulmonary fibrosis, endomyocardial fibrosis, nephropathy, glomerulonephritis, interstitial renal fibrosis, fibrotic damage resulting from diabetes, bone marrow fibrosis and similar fibrotic disorders, scleroderma, morphea, keloids, hypertrophic scarring (also following surgical procedures), naevi, diabetic retinopathy, proliferative vitroretinopathy and disorders of the connective tissue (for example sarcoidosis).
  • the compounds according to the invention are also suitable for controlling postoperative scarring, for example as a result of glaucoma operations.
  • the compounds according to the invention can also be used cosmetically for ageing and keratinized skin.
  • the compounds according to the invention are suitable for treatment and/or prophylaxis of hepatitis, neoplasms, osteoporosis, glaucoma and gastroparesis.
  • the present invention further provides for the use of the compounds according to the invention for treatment and/or prophylaxis of disorders, especially the disorders mentioned above.
  • the present invention further provides for the use of the compounds according to the invention for the treatment and/or prophylaxis of chronic renal disorders, acute and chronic renal insufficiency, diabetic, inflammatory or hypertensive nephropaties, fibrotic disorders, cardiac insufficiency, angina pectoris, hypertension, pulmonary hypertension, ischemias, vascular disorders, thromboembolic disorders, arteriosclerosis, sickle cell anemia, erectile dysfunction, benign prostate hyperplasia, dysuria associated with benign prostate hyperplasia, Huntington, dementia, Alzheimer and Creutzfeld-Jakob.
  • the present invention further provides a method for treatment and/or prophylaxis of disorders, in particular the disorders mentioned above, using an effective amount of at least one of the compounds according to the invention.
  • the present invention further provides a method for the treatment and/or prophylaxis of chronic renal disorders, acute and chronic renal insufficiency, diabetic, inflammatory or hypertensive nephropathies, fibrotic disorders, cardiac insufficiency, angina pectoris, hypertension, pulmonary hypertension, ischemias, vascular disorders, thromboembolic disorders, arteriosclerosis, sickle cell anemia, erectile dysfunction, benign prostate hyperplasia, dysuria associated with benign prostate hyperplasia, Huntington, dementia, Alzheimer and Creutzfeld- Jakob.
  • the inventive compounds can also be used to treat or to prevent uterine fibroids (uterine leiomyoma or uterine myoma) in women.
  • Uterine fibroids are benign tumors of the myometrium, the smooth muscle layer of the uterus. Uterine fibroids grow slowly during a women ' s life, and their growth is dependent on the female sexual hormones estradiol and progesterone [Kawaguchi K et al. Immunohistochemical analysis of oestrogen receptors, progesterone receptors and Ki-67 in leiomyoma and myometrium during the menstrual cycle and pregnancy Virchows Arch A Pathol Anat
  • Compounds of the present invention can be utilized to inhibit, block, reduce or decrease MAP4K1 activation by exogenous and/or endogenous ligands for the reduction of tumour growth and the modulation of dysregulated immune responses e.g. to block
  • This method comprises administering to a mammal in need thereof, including a human, an amount of a compound of this invention, or a
  • MAP4K1 is involved in various disorders wherein MAP4K1 is involved such as, but not limited to, disorders with dysregulated immune responses, inflammation, vaccination for infection & cancer, viral infections, obesity and diet- induced obesity, adiposity, metabolic disorders, hepatic steatosis and uterine fibroids.
  • treating or “treatment” as used in the present text is used conventionally, e.g., the management or care of a subject for the purpose of combating, alleviating, reducing, relieving, improving the condition of a disease or disorder, such as liquid and solid tumours.
  • the present invention covers compounds of general formula (I), as described supra, or stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, particularly pharmaceutically acceptable salts thereof, or mixtures of same, for use in the treatment or prophylaxis of diseases, in particular cancer or conditions with dysregulated immune responses or other disorders associated with aberrant MAP4K1 signaling.
  • the pharmaceutical activity of the compounds according to the invention can be explained by their activity as MAP4K1 inhibitors.
  • the present invention covers the use of compounds of general formula (I), as described supra, or stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, particularly pharmaceutically acceptable salts thereof, or mixtures of same, for the treatment or prophylaxis of diseases, in particular cancer or conditions with dysregulated immune responses or other disorders associated with aberrant MAP4K1 signaling, particularly liquid and solid tumours.
  • the present invention covers the use of compounds of general formula (I), as described supra, or stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, particularly pharmaceutically acceptable salts thereof, or mixtures of same, in a method of treatment or prophylaxis of diseases, in particular cancer or conditions with dysregulated immune responses or other disorders associated with aberrant MAP4K1 signaling, particularly liquid and solid tumours.
  • the present invention covers use of a compound of general formula (I), as described supra, or stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, particularly pharmaceutically acceptable salts thereof, or mixtures of same, for the preparation of a pharmaceutical composition, preferably a medicament, for the prophylaxis or treatment of diseases, in particular cancer or conditions with dysregulated immune responses or other disorders associated with aberrant MAP4K1 signaling, particularly liquid and solid tumours.
  • a pharmaceutical composition preferably a medicament
  • the present invention covers a method of treatment or prophylaxis of diseases, in particular cancer or conditions with dysregulated immune responses or other disorders associated with aberrant MAP4K1 signaling, particularly liquid and solid tumours, using an effective amount of a compound of general formula (I), as described supra, or stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, particularly pharmaceutically acceptable salts thereof, or mixtures of same.
  • a compound of general formula (I) as described supra, or stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, particularly pharmaceutically acceptable salts thereof, or mixtures of same.
  • the present invention covers pharmaceutical compositions, in particular a medicament, comprising a compound of general formula (I), as described supra, or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, a salt thereof, particularly a pharmaceutically acceptable salt, or a mixture of same, and one or more excipients), in particular one or more pharmaceutically acceptable excipient(s).
  • a medicament comprising a compound of general formula (I), as described supra, or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, a salt thereof, particularly a pharmaceutically acceptable salt, or a mixture of same, and one or more excipients), in particular one or more pharmaceutically acceptable excipient(s).
  • excipients in particular one or more pharmaceutically acceptable excipient(s).
  • the present invention furthermore covers pharmaceutical compositions, in particular medicaments, which comprise at least one compound according to the invention,
  • the compounds according to the invention can be administered in a suitable manner, such as, for example, via the oral, parenteral, pulmonary, nasal, sublingual, lingual, buccal, rectal, vaginal, dermal, transdermal, conjunctival, otic route or as an implant or stent.
  • the compounds according to the invention for oral administration, it is possible to formulate the compounds according to the invention to dosage forms known in the art that deliver the compounds of the invention rapidly and/or in a modified manner, such as, for example, tablets (uncoated or coated tablets, for example with enteric or controlled release coatings that dissolve with a delay or are insoluble), orally- disintegrating tablets, films/wafers, films/lyophylisates, capsules (for example hard or soft gelatine capsules), sugar-coated tablets, granules, pellets, powders, emulsions, suspensions, aerosols or solutions. It is possible to incorporate the compounds according to the invention in crystalline and/or amorphised and/or dissolved form into said dosage forms.
  • Parenteral administration can be effected with avoidance of an absorption step (for example intravenous, intraarterial, intracardial, intraspinal or intralumbal) or with inclusion of absorption (for example intramuscular, subcutaneous, intracutaneous, percutaneous or intraperitoneal).
  • absorption step for example intravenous, intraarterial, intracardial, intraspinal or intralumbal
  • absorption for example intramuscular, subcutaneous, intracutaneous, percutaneous or intraperitoneal.
  • Administration forms which are suitable for parenteral administration are, inter alia,
  • preparations for injection and infusion in the form of solutions, suspensions, emulsions, lyophylisates or sterile powders are pharmaceutical forms for inhalation [inter alia powder inhalers, nebulizers], nasal drops, nasal solutions, nasal sprays; tablets/films/wafers/capsules for lingual, sublingual or buccal administration; suppositories; eye drops, eye ointments, eye baths, ocular inserts, ear drops, ear sprays, ear powders, ear- rinses, ear tampons; vaginal capsules, aqueous suspensions (lotions, mixturae agitandae), lipophilic suspensions, emulsions, ointments, creams, transdermal therapeutic systems (such as, for example, patches), milk, pastes, foams, dusting powders, implants or stents.
  • inhalation inter alia powder inhalers, nebulizers
  • nasal drops nasal solutions, nasal
  • the compounds according to the invention can be incorporated into the stated administration forms. This can be effected in a manner known per se by mixing with pharmaceutically suitable excipients.
  • Pharmaceutically suitable excipients include, inter alia,
  • fillers and carriers for example cellulose, microcrystalline cellulose (such as, for example, Avicel®), lactose, mannitol, starch, calcium phosphate (such as, for example, Di-Cafos®)),
  • ⁇ ointment bases for example petroleum jelly, paraffins, triglycerides, waxes, wool wax, wool wax alcohols, lanolin, hydrophilic ointment, polyethylene glycols
  • ointment bases for example petroleum jelly, paraffins, triglycerides, waxes, wool wax, wool wax alcohols, lanolin, hydrophilic ointment, polyethylene glycols
  • bases for suppositories for example polyethylene glycols, cacao butter, hard fat
  • solvents for example water, ethanol, isopropanol, glycerol, propylene glycol, medium chain-length triglycerides fatty oils, liquid polyethylene glycols, paraffins
  • surfactants for example sodium dodecyl sulfate), lecithin, phospholipids, fatty alcohols (such as, for example, Lanette®), sorbitan fatty acid esters (such as, for example, Span®), polyoxyethylene sorbitan fatty acid esters (such as, for example, Tween®), polyoxyethylene fatty acid glycerides (such as, for example, Cremophor®), polyoxethylene fatty acid esters, polyoxyethylene fatty alcohol ethers, glycerol fatty acid esters, poloxamers (such as, for example, Pluronic®),
  • buffers for example phosphates, carbonates, citric acid, acetic acid, hydrochloric acid, sodium hydroxide solution, ammonium carbonate, trometamol, triethanolamine
  • acids and bases for example phosphates, carbonates, citric acid, acetic acid, hydrochloric acid, sodium hydroxide solution, ammonium carbonate, trometamol, triethanolamine
  • isotonicity agents for example glucose, sodium chloride
  • ⁇ adsorbents for example highly-disperse silicas
  • viscosity-increasing agents for example polyvinylpyrrolidone, methylcellulose, hydroxypropylmethylcellulose, hydroxypropyl- cellulose, carboxymethylcellulose-sodium, starch, carbomers, polyacrylic acids (such as, for example, Carbopol®); alginates, gelatine), • disintegrants (for example modified starch, carboxymethylcellulose-sodium, sodium starch glycolate (such as, for example, Explotab®), cross- linked polyvinylpyrrolidone, croscarmellose-sodium (such as, for example, AcDiSol®)),
  • binders for example polyvinylpyrrolidone, methylcellulose, hydroxypropylmethylcellulose, hydroxypropyl- cellulose, carboxymethylcellulose-sodium, starch, carbomers, polyacrylic acids (such as, for example, Carbopol®); alginates, gelatine), • disintegrants (for example modified starch, carboxymethylcellulose-
  • lubricants for example magnesium stearate, stearic acid, talc, highly-disperse silicas (such as, for example, Aerosil®)
  • mould release agents for example magnesium stearate, stearic acid, talc, highly-disperse silicas (such as, for example, Aerosil®)
  • coating materials for example sugar, shellac
  • film formers for films or diffusion membranes which dissolve rapidly or in a modified manner
  • polyvinylpyrrolidones such as, for example, Kollidon®
  • polyvinyl alcohol such as, for example, polyvinyl alcohol
  • hydroxypropylmethylcellulose hydroxypropylcellulose, ethylcellulose, hydroxypropyl- methylcellulose phthalate, cellulose acetate, cellulose acetate phthalate, polyacrylates, polymethacrylates such as, for example, Eudragit®)),
  • capsule materials for example gelatine, hydroxypropylmethylcellulose
  • polymethacrylates such as, for example, Eudragit®
  • polyvinylpyrrolidones such as, for example, Kollidon®
  • polyvinyl alcohols such as, for example, polyvinyl acetates, polyethylene oxides, polyethylene glycols and their copolymers and blockcopolymers
  • plasticizers for example polyethylene glycols, propylene glycol, glycerol, triacetine, triacetyl citrate, dibutyl phthalate
  • antioxidants for example antioxidants such as, for example, ascorbic acid, ascorbyl palmitate, sodium ascorbate, butylhydroxyanisole, butylhydroxytoluene, propyl gallate
  • antioxidants such as, for example, ascorbic acid, ascorbyl palmitate, sodium ascorbate, butylhydroxyanisole, butylhydroxytoluene, propyl gallate
  • preservatives for example parabens, sorbic acid, thiomersal, benzalkonium chloride, chlorhexidine acetate, sodium benzoate
  • colourants for example inorganic pigments such as, for example, iron oxides, titanium dioxide
  • flavourings • flavourings, sweeteners, flavour- and/or odour-masking agents.
  • the present invention furthermore relates to a pharmaceutical composition which comprise at least one compound according to the invention, conventionally together with one or more pharmaceutically suitable excipient(s), and to their use according to the present invention.
  • the present invention covers pharmaceutical combinations, in particular medicaments, comprising at least one compound of general formula (I) of the present invention and at least one or more further active ingredients, in particular for the treatment and/or prophylaxis of cancer or conditions with dysregulated immune responses or other disorders associated with aberrant MAP4K1 signalinggeneric name disorders, particularly liquid and solid tumours.
  • the term "combination" in the present invention is used as known to persons skilled in the art, it being possible for said combination to be a fixed combination, a non-fixed combination or a kit-of-parts.
  • a "fixed combination” in the present invention is used as known to persons skilled in the art and is defined as a combination wherein, for example, a first active ingredient, such as one or more compounds of general formula (I) of the present invention, and a further active ingredient are present together in one unit dosage or in one single entity.
  • a “fixed combination” is a pharmaceutical composition wherein a first active ingredient and a further active ingredient are present in admixture for simultaneous administration, such as in a formulation.
  • Another example of a "fixed combination” is a pharmaceutical combination wherein a first active ingredient and a further active ingredient are present in one unit without being in admixture.
  • a non-fixed combination or "kit-of-parts" in the present invention is used as known to persons skilled in the art and is defined as a combination wherein a first active ingredient and a further active ingredient are present in more than one unit.
  • a non-fixed combination or kit-of-parts is a combination wherein the first active ingredient and the further active ingredient are present separately. It is possible for the components of the non-fixed combination or kit-of- parts to be administered separately, sequentially, simultaneously, concurrently or
  • the effective dosage of the compounds of the present invention can readily be determined for treatment of each desired indication.
  • the amount of the active ingredient to be administered in the treatment of one of these conditions can vary widely according to such considerations as the particular compound and dosage unit employed, the mode of administration, the period of treatment, the age and sex of the patient treated, and the nature and extent of the condition treated.
  • the total amount of the active ingredient to be administered will generally range from about 0.001 mg/kg to about 200 mg/kg body weight per day, and preferably from about 0.01 mg/kg to about 20 mg/kg body weight per day.
  • Clinically useful dosing schedules will range from one to three times a day dosing to once every four weeks dosing.
  • drug holidays in which a patient is not dosed with a drug for a certain period of time, to be beneficial to the overall balance between pharmacological effect and tolerability. It is possible for a unit dosage to contain from about 0.5 mg to about 1500 mg of active ingredient, and can be administered one or more times per day or less than once a day.
  • the average daily dosage for administration by injection will preferably be from 0.01 to 200 mg/kg of total body weight.
  • the average daily rectal dosage regimen will preferably be from 0.01 to 200 mg/kg of total body weight.
  • the average daily vaginal dosage regimen will preferably be from 0.01 to 200 mg/kg of total body weight.
  • the average daily topical dosage regimen will preferably be from 0.1 to 200 mg administered between one to four times daily.
  • transdermal concentration will preferably be that required to maintain a daily dose of from 0.01 to 200 mg/kg.
  • the average daily inhalation dosage regimen will preferably be from 0.01 to 100 mg/kg of total body weight.
  • the specific initial and continuing dosage regimen for each patient will vary according to the nature and severity of the condition as determined by the attending diagnostician, the activity of the specific compound employed, the age and general condition of the patient, time of administration, route of administration, rate of excretion of the drug, drug combinations, and the like.
  • the desired mode of treatment and number of doses of a compound of the present invention or a pharmaceutically acceptable salt or ester or composition thereof can be ascertained by those skilled in the art using conventional treatment tests.
  • NMR peak forms are stated as they appear in the spectra, possible higher order effects have not been considered.
  • the multiplicities are stated according to the signal form which appears in the spectrum, NMR-spectroscopic effects of a higher order were not taken into
  • the compounds and intermediates produced according to the methods of the invention may require purification. Purification of organic compounds is well known to the person skilled in the art and there may be several ways of purifying the same compound. In some cases, no purification may be necessary. In some cases, the compounds may be purified by
  • the compounds may be purified by chromatography, particularly flash column chromatography, using for example prepacked silica gel cartridges, e.g. Biotage SNAP cartidges KP-Sil ® or KP-NH ® in combination with a Biotage autopurifier system (SP4 ® or Isolera Four ® ) and eluents such as gradients of hexane/ethyl acetate or DCM/methanol.
  • chromatography particularly flash column chromatography
  • silica gel cartridges e.g. Biotage SNAP cartidges KP-Sil ® or KP-NH ® in combination with a Biotage autopurifier system (SP4 ® or Isolera Four ® ) and eluents such as gradients of hexane/ethyl acetate or DCM/methanol.
  • SP4 ® or Isolera Four ® Biotage autopurifier system
  • eluents such as gradients of hexane
  • the compounds may be purified by preparative HPLC using for example a Waters autopurifier equipped with a diode array detector and/or on-line electrospray ionization mass spectrometer in combination with a suitable prepacked reverse phase column and eluents such as gradients of water and acetonitrile which may contain additives such as trifluoroacetic acid, formic acid or aqueous ammonia.
  • a Waters autopurifier equipped with a diode array detector and/or on-line electrospray ionization mass spectrometer in combination with a suitable prepacked reverse phase column and eluents such as gradients of water and acetonitrile which may contain additives such as trifluoroacetic acid, formic acid or aqueous ammonia.
  • purification methods as described above can provide those compounds of the present invention which possess a sufficiently basic or acidic functionality in the form of a salt, such as, in the case of a compound of the present invention which is sufficiently basic, a trifluoroacetate or formate salt for example, or, in the case of a compound of the present invention which is sufficiently acidic, an ammonium salt for example.
  • a salt of this type can either be transformed into its free base or free acid form, respectively, by various methods known to the person skilled in the art, or be used as salts in subsequent biological assays. It is to be understood that the specific form (e.g. salt, free base etc.) of a compound of the present invention as isolated and as described herein is not necessarily the only form in which said compound can be applied to a biological assay in order to quantify the specific biological activity.
  • modifications can be, for example, the introduction of protective groups, cleavage of protective groups, reduction or oxidation of functional groups, halogenation, metallation, metal catalysed coupling reactions, exemplified by but not limited to e.g. Buchwald, Suzuki, Sonogashira and Ullmann coupling, ester saponifications, amide coupling reactions, and/or substitution or other reactions known to a person skilled in the art.
  • These transformations include those which introduce a functionality allowing for further interconversion of substituents.
  • Appropriate protective groups and their introduction and cleavage are well-known to a person skilled in the art (see for example T.W. Greene and P.G.M.
  • Compounds of general formula (I) can also be assembled by conversion of amine derivatives of formula (II) to an intermediately formed and possibly isolated carbamate or thiocarbamate (IVb) using a suitable reagent such as phenyl chloroformate or O-phenyl chlorothionoformate in which Z is H, NO2, or perfluoro in an appropriate solvent such as tetrahydrofuran, dichloromethane, or ethylacetate in the presence of an appropriate base such as pyridine, sodium hydrogencarbonate, or
  • a suitable reagent such as phenyl chloroformate or O-phenyl chlorothionoformate in which Z is H, NO2, or perfluoro and R 3 , R 4 and Y are as defined for the compounds of general formula (I) with the second amine (II).
  • the deprotection can be performed using trifluoroacetic acid in the case of trimethylsilylethyloxymethyl, in an inert solvent such as dichloromethane, within a temperature range from 0°C to the boiling point of the used solvent.
  • the deprotection in the case of trimethylsilylethyloxymethyl can be also performed using tetra-butylammonium fluoride in the presence of ethylenediamine in an inert solvent such as tetrahydrofuran within a temperature range from 0°C to the boiling point of the used solvent.
  • an inert solvent such as tetrahydrofuran
  • the deprotection can be performed by using for example sodium hydroxide in methanol within a temperature range from 0°C to the boiling point of the used solvent.
  • Preferred herein is the performance of said urea formation using the amine (II) and the intermediately formed and maybe isolated carbamate (IVb) or cyanate (Vb) and the subsequent reaction with the second amine (II) in DMF or pyridine as a solvent, within a temperature range from 0°C to 100°C.
  • the amine intermediates of formula (II) are known to the person skilled in the art and can, if not commercially available, be prepared according to Schemes 3 and 4 shown below.
  • the second amine derivatives of formula (III) are either commercially available in some structural variety, or they can be prepared using synthetic methods described in many textbooks such as March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, 7th Edition.
  • the amine derivatives of formula (II) are known, commercially available, or can be prepared from the commercially available heterocyle of the formula (VI), in which R 1a represents a hydrogen or a trifluoromethyl group.
  • heterocycles of formula (VII) can be transformed to the protected intermediates of the formula
  • trimetylsilylethoxymethyl chloride triisopropylsilyl chloride, trityl chloride or tosylchloride or other reagents known to a person skilled in the art.
  • trimetylsilylethoxymethyl chloride is used, in the presence of a base such as sodium hydride, triethyl amine, or ethyl diisopropyl amine in an inert solvent such as THF, DMSO or DMF.
  • an inert solvent such as dichloro methane or tetrachloro methane.
  • dimethylsulfoxide in the presence of a base, for example potassium carbonate or cesium carbonate, in a temperature range from room temperature to the boiling point of the respective solvent.
  • a base for example potassium carbonate or cesium carbonate
  • the reaction is carried out at room temperature to furnish intermediates of general formula (XIV).
  • Intemediates of general formula (XIV), are then protected with an appropriate protecting group, for example using an appropriate reagent such as trimetylsilylethoxymethyl chloride, triisopropylsilyl chloride or trityl chloride or other reagents known to a person skilled in the art.
  • trimetylsilylethoxymethyl chloride is used, in the presence of a base such as sodium hydride, triethylamine, or ethyldiisopropylamine in an inert solvent such as
  • an inert solvent such as dichloromethane, dimethylformamide, or tetrachloromethane
  • reaction is carried out at room temperature to furnish intermediates of general formula (XVI).
  • diphenyl(trifluoromethyl)sulfonium trifluoromethanesulfonate is used, in the presence of additives, such as copper(O), in a solvent such as dimethylformamide, in a temperature range from room temperature to the boiling point of the respective solvent.
  • additives such as copper(O)
  • a solvent such as dimethylformamide
  • Reduction of the nitro functionalitiy contained within compounds of formula (XVI) affords amines of formula (II).
  • the reduction of a nitro functionality can be performed for example under hydrogene atmosphere and a Pd or Pt/V catalyst in an inert solvent such as
  • the reaction is performed with the addition of a reducing agent, for example lron(0), with additives such as ammonium chloride, in an appropriate mixture of solvents, for example a mixture of water, tetrahydrofuran, and methanol, in a temperature range from room temperature to the boiling point of the respective solvent.
  • a reducing agent for example lron(0)
  • additives such as ammonium chloride
  • solvents for example a mixture of water, tetrahydrofuran, and methanol
  • the reaction is performed at 80 °C to furnish amine intermediates of general formula (II).
  • reaction can be carried out using alternative reducing agents to those skilled in the art, for example tin(ll)chloride, in an appropriate solvent, such as methanol, in a temperature range from room temperature to the boiling point of the respective solvent. Ideally the reaction is performed at room temperature to furnish amine intermediates of general formula (II).
  • Method 3 Waters Acquity UPLCMS SingleQuad; Column: Acquity UPLC BEH C18 1 .7 50x2.1 mm; eluent A: water + 0.1 vol % formic acid (99%), eluent B: acetonitrile; gradient: 0-1 .6 min 1 -99% B, 1.6-2.0 min 99% B; flow 0.8 mL/min; temperature: 60 °C; DAD scan: 210-400 nm Method 4: (prep.
  • HPLC Waters Autopurificationsystem; column: Waters XBrigde C18 5 ⁇ 100x30mm; eluent A: water + 0.1 Vol-% formic acid (99%), eluent B: acetonitrile; gradient: 0.00-0.50 min 8% B (40->70mL/min), 0.51-5.50 min 16-36% B (70mL/min), DAD scan: 210- 400 nm
  • the resulting residue was purified 3 times via a Biotage chromatography system (55g and 2 times 28g snap KP-NH column, hexane / 0 - 100% ethyl acetate, then ethyl acetate / 0 - 100% methanol) to obtain 970 mg (95 % purity, 71 % yield) of the desired title compound.

Abstract

The present invention relates to protein-inhibitory substituted pyrrolopyridine derivatives of formula (I) in which X, Y, R1, R2, R3 and R4 are as defined herein, to pharmaceutical compositions and combinations comprising the compounds according to the invention, and to the prophylactic and therapeutic use of the inventive compounds, respectively to the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular for neoplastic disorders, repectively cancer or conditions with dysregulated immune responses or other disorders associated with aberrant MAP4K1 signaling, as a sole agent or in combination with other active ingredients. The present invention further relates to the use, respectively to the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of protein inhibitors in benign hyperplasias, atherosclerotic disorders, sepsis, autoimmune disorders, vascular disorders, viral infections, in neurodegenerative disorders, in inflammatory disorders, in atherosclerotic disorders and in male fertility control.

Description

Substituted Pyrrolopyridine-Derivatives
The present invention relates to protein-inhibitory substituted pyrrolopyridine derivatives, to pharmaceutical compositions and combinations comprising the compounds according to the invention, and to the prophylactic and therapeutic use of the inventive compounds, respectively to the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular for neoplastic disorders, repectively cancer or conditions with dysregulated immune responses or other disorders associated with aberrant MAP4K1 signaling, as a sole agent or in combination with other active ingredients.
The present invention further relates to the use, respectively to the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of protein inhibitors in benign hyperplasias, atherosclerotic disorders, sepsis, autoimmune disorders, vascular disorders, viral infections, in neurodegenerative disorders, in inflammatory disorders, in atherosclerotic disorders and in male fertility control.
Background
Although cancer cell commonly can be recognize by the adaptive immune system, the response generated is evidently not capable of eliminating the tumor. A major reason for this is the presence of immunosuppressive mechanisms in the tumor microenvironment. In this respect, inhibitors of T-cell immune checkpoint such as CTLA-4, PD-1 or PD-L1 were recently shown to result in a remarkable clinical efficacy in subsets of cancer patients. Besides cell surface receptors that act as negative immune regulators, several mediators of intracellular signaling have been identified that also represent potential immunoevasive mechanisms utilized by the tumor.
One of these is MAP4K1 , also known as hematopoietic progenitor kinase 1 (HPK1 ). MAP4K1 (GenelD1 1 184) is a serine/threonine kinase and member of the Germinal Center Kinase family. In the adult organism MAP4K1 expression is restricted to hematopoietic cell types. The MAP4K1 protein consist of a N-terminal kinase domain, followed by a proline-rich domain that can interact with adaptor molecules through SH2 and SH3 domains, and a C-terminal citron homology domain of which the exact function remains to be identified. Through its proline-rich domain, MAP4K1 is capable of binding to a diversity of adaptors in hematopoietic cells, including those involved in T-cell receptor (TCR), B-cell receptor (BCR) and cytokine signaling (Hu et al., Genes Dev. 1996 Sep 15;10(18):2251 -64, 2.; Ling et al.,. J Biol Chem. 2001 Jun 1 ;276(22), Sauer et al., J Biol Chem. 2001 Nov 30;276(48):45207-16., Tsuji et al., J Exp Med. 2001 Aug 20;194(4):529-39, Boomer et al., J Cell Biochem. 2005 May 1 ;95(1 ):34-44). The function of MAP4K1 has been studied in greatest detail in the context of TCR signaling. Upon TCR stimulation, MAP4K1 is phosphorylated on tyrosine 381 (Y-381 ; Y-379 in mouse) (Di Bartolo et al., J Exp Med. 2007 Mar 19;204(3):681 -91 ). Consequently, MAP4K1 is recruited to the TCR-signaling complex where it induces dissociation of this complex through its serine/threonine kinase function. In particular MAP4K1 phosphorylates the SLP-76 adaptor protein at Serine-376, resulting in downregulation of AP-1 and Erk2 pathways. As, such, MAPK1 acts as a negative feedback on TCR-signaling (Liou et al., Immunity. 2000
Apr;12(4):399-408; Lasserre et al., J Cell Biol. 201 1 Nov 28;195(5):839-53.). Alternatively, MAP4K1 can be triggered to suppress T cell function by prostaglandin E2 (PGE2), and possibly also by transforming growth factor beta (TGF-beta), factors that are commonly found in the tumor microenvironment. Notably, MAP4K1 activation by these mediators involves protein kinase A (PKA)-dependent phosphorylation of Serine 171 (S-171 ; also in mouse) (Alzabin et al., Cancer Immunol Immunother. 2010 Mar;59(3):419-29; Sawasdikosol et al., J Biol Chem. 2007 Nov 30;282(48):34693-9.).
Further important insights into the function of MAP4K1 in the regulation of T cell immunity stem from in vivo and in vitro experiments respectively with MAP4K1 deficient mice produced by two laboratories and with immune cells isolated from these mice (Shui et al., Nat Immunol. 2007 Jan;8(1 ):84-91 ; Alzabin et al., Cancer Immunol Immunother. 2010 Mar;59(3):419-29).
MAP4K1 -deficient mice show an apparent normal phenotype, are fertile and exhibit normal lymphocyte development. These animals are prone to develop T-cell dependent autoimmune reactivity as indicated by development of a more severe disease score in the EAE
(experimental autoimmune encephalomyelitis) model of multiple sclerosis (Shui et al., Nat Immunol. 2007 Jan;8(1 ):84-91 ). In case of the second strain, a dysregulation of immune function was observed when, at the age of approximately 6 months, MAP4K1 -deficient mice develop a spontaneous autoimmune phenotype (Alzabin et al., Cancer Immunol Immunother. 2010 Mar;59(3):419-29). In vitro studies showed that MAP4K1 -/- T-cells display hyper- responsiveness upon TCR-stimulation. These cells proliferate and secrete pro-inflammatory cytokines like IL-2 or IFNg to a significantly greater extent than their wild-type counterparts (Shui et al., Nat Immunol. 2007 Jan;8(1 ):84-91 ). Furthermore, MAP4K1 -/- T-cells are resistant to PGE2-mediated suppression of T cell proliferation, suppression of IL-2 production and induction of apoptosis (Alzabin et al., Cancer Immunol Immunother. 2010 Mar;59(3):419-29). In the context of tumor immunology, in vivo experiments revealed that MAP4K1 -/- mice are much more resistant to tumorigenesis by PGE2-producing Lewis lung carcinoma than wild type mice, which correlated with increased T-lymphocyte infiltration in the tumor areas. The crucial role of T-cells in tumor rejection was supported by experiments in which MAP4K1 -/- T-cells adoptively transferred into T-cell-deficient mice were able to eradicate tumors more efficiently than wild-type T-cells (Alzabin et al., Cancer Immunol Immunother. 2010 Mar;59(3):419-29). The important role of the kinase enzymatic activity was demonstrated by studies were only wild type MAP4K1 , but not the MAP4K1 kinase-dead mutant, could mediate serine-phosphorylation of the TCR-signaling complex component SLP-76 and subsequent binding of SLP-76 to the negative regulator of TCR-signaling 14-3-3-t (Shui et al., Nat Immunol. 2007 Jan;8(1 ):84-91 ). MAP4K1 also regulates the stimulation and activation of dendritic cells. MAP4K1 deficient Bone marrow derived cells (BMDC) express after maturation and stimulation higher level of costimulatory molecules and produce more proinflammatory cytokines. Also elimination of tumors was observed to be more efficient by MAP4K1 -/- BMDC compared to their wildtype counterparts (Alzabin et al., J Immunol. 2009 May 15;182(10):6187-94).
Prior art
In WO 2016/205942 HPK1 , respectively inhibitors and methods of their use in cancer treatment are described. Especially, the application concerns thieno-pyridinones that can be used in anti-cancer therapy. These compounds differ from the instant compounds in their chemical structure.
In WO 2016/195776 inhibitors and methods for leukemia, cancer and diabetes treatment dependent on inhibition the interaction of menin with of MLL1 , MLL2 and MLL-fusion oncoproteins are described. These compounds differ from the instant compounds in their chemical structure.
In WO 2006/014325 C-MET modulators and their use in cancer treatment are described.
These compounds differ from the instant compounds in their chemical structur. In WO 2005/058891 Rho kinase inhibitors and their use in cardiovascular and cancer treatment are described. These compounds differ from the instant compounds in their chemical structure.
In WO 2015/089479 several inhibitors are described that show inhibition of several kinases (e.g., BTK, HCK, TAK1 and HPK1 ). These compounds differ from the instant compounds in their chemical structure.
In WO 2018/049200 HPK1 kinase inhibitors and their use in cancer treatment are described. These compounds differ from the instant compounds in their chemical structure.
In WO 2018/049152 HPK1 kinase inhibitors and their use in cancer treatment are described. These compounds differ from the instant compounds in their chemical structure. In WO 2018/049214 HPK1 kinase inhibitors and their use in cancer treatment are described. These compounds differ from the instant compounds in their chemical structure.
In WO 2018/049191 HPK1 kinase inhibitors and their use in cancer treatment are described. These compounds differ from the instant compounds in their chemical structure.
It would therefore be desirable to provide novel compounds having prophylactic and therapeutic properties. Accordingly, it is an object of the present invention to provide compounds and pharmaceutical compositions comprising these compounds used for prophylactic and therapeutic applications for hyperproliferative disorders, in particular for cancer, respectively tumour disorders, and conditions with dysregulated immune responses, as a sole agent or in combination with other active ingredients.
A further object of the present invention is to provide compounds and pharmaceutical compositions comprising these compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of protein inhibitors in benign hyperplasias, atherosclerotic disorders, sepsis, autoimmune disorders, vascular disorders, viral infections, in
neurodegenerative disorders, in inflammatory disorders, in atherosclerotic disorders and in male fertility control.
Surprisingly, the compounds according to the invention inhibit the MAP4K1 protein and inhibit the growth of cancer cells. Accordingly, they provide novel structures for the therapy of human and animal disorders, in particular of cancers.
It has now been found that compounds of formula (I)
Figure imgf000006_0001
in which X represents a nitrogen, a sulphur or an oxygene atom,
Y represents a sulphur or an oxygene atom,
R1 represents hydrogen, halogen, Ci-C6-alkyl, halo-Ci-C6-alkyl or cyano,
R2 represents fluorine or chlorine,
R3 represents hydrogen or Ci-C6-alkyl,
R4 represents hydrogen or represents Ci-C6-alkyl-, which may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of halogen, cyano, hydroxy, Ci-C3-alkoxy-, -IMH2, -NH-(Ci-C6-alkyl), -N(Ci-C6-alkyl)2, -NH-(Ci-C6-alkyl)-Ci-C6-alkoxy, Ci-C6-alkyl-, Ci-C6-alkoxy-, -S(=0)2NH2, -C(=0)-R9, -C(=0)-NH-Rx, -C(=0)-NR5R6, -NH-C(=0)-R9,
-NH-S(=0)2-R9, -S(=0)2-R9, -S(=0)(=NRy)-Rx, -S(=0)-Rx,
C3-Cio-cycloalkyl- which itself may optionally be mono- or polysubstituted by dentical or different substituents from the group consisting of of halogen, cyano, nitro, hydroxy, amino, oxo, carboxy, Ci-C6-alkyl-, Ci-C6-alkoxy-, Ci-C6-alkoxy- Ci-C6-alkyl-, hydroxy-Ci-C6-alkyl-, Ci-C6-alkylamino-, Ci-C6-alkylcarbonylamino- , amino-Ci-C6-alkyl-, Ci-C6-alkylamino-Ci-C6-alkyl-, halo-Ci-C6-alkyl-, halo-Ci-C6-alkoxy-, C3-Cio-cycloalkyl-, phenyl-, halophenyl-, phenyl-Ci-C6-alkyl-, phenoxy-, pyridinyl-, -C(=0)-NR5R6, -NH-C(=0)-R8, -C(=0)-R7, -S(=0)2-NR5R6, -S(=0)-R8, -S(=0)(=NR5)-R6, -S(=0)2-R8, -NH-S(=0)2-R8, or a monocyclic heterocyclyl radical having 3 to 8 ring atoms, monocyclic heteroaryl- having 5 or 6 ring atoms which itself may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of halogen, amino, hydroxy, cyano, nitro, carboxy, Ci-C6-alkyl-, Ci-C6-alkoxy-, C1-C6- alkoxy-Ci-C6-alkyl-, hydroxy-Ci-C6-alkyl-, Ci-C6-alkylamino-, amino-Ci-C6-alkyl-, Ci-C6-alkylamino-Ci-C6-alkyl, halo-Ci-C6- alkyl-, halo-Ci-C6-alkoxy-, C3-Cio-cycloalkyl and a monocyclic heterocyclyl radical having 3 to 8 ring atoms, monocyclic heterocyclyl- having 3 to 8 ring atoms which itself may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of halogen, amino, hydroxy, cyano, oxo, carboxy, Ci-C6-alkyl-, -carboxy-Ci-C6-alkyl-, Ci-C6-alkoxy-, Ci-C6-alkoxy-Ci-C6-alkyl-,
Ci-C6-alkylamino-, amino-Ci-C6-alkyl-, Ci-C6-alkylamino-Ci-C6-alkyl-, hydroxy-Ci-C6-alkyl-, halo-Ci-C6-alkyl-, halo-Ci-C6-alkoxy-, C3-Cio-cycloalkyl- and a monocyclic heterocyclyl radical having 3 to 8 ring atoms, phenyl- which itself may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of halogen, amino, hydroxy, cyano, nitro, carboxy, Ci-C6-alkyl-, Ci-C6-alkoxy-, Ci-C6-alkoxy-Ci-C6-alkyl-, Ci-C6-alkyl-amino-, amino-Ci-C6-alkyl-, Ci-C6-alkylaminocarbonyl-, Ci-C6-alkyl- aminosulphonyl-, Ci-C6-alkylamino-Ci-C6-alkyl-, hydroxy-Ci-C6-alkyl-, halo-Ci-C6-alkyl-, halo-Ci-C6-alkoxy-, C3-Cio-cycloalkyl- and a monocyclic heterocyclyl radical having 3 to 8 ring atoms, spirocycloalkyl, 5 to 12 membered heterospirocycloalkyl, bicycloalkyl-, heterobicycloalkyl-, bridged cycloalkyl or a bridged heterocycloalkyl, naphthyl or bicyclic heteroaryl, or partially saturated bicyclic aryl- or heteroaryl,
each of which mentioned supra may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of halogen, cyano, nitro, hydroxy, amino, oxo, carboxy, Ci-C6-alkyl-, Ci-C6-alkoxy-, Ci-C6-alkoxy- Ci-C6-alkyl-, hydroxy-Ci-C6-alkyl-, Ci-C6-alkylamino-, Ci-C6-alkylcarbonylamino- , amino-Ci-C6-alkyl-, Ci-C6-alkylamino-Ci-C6-alkyl-, halo-Ci-C6-alkyl-, halo-Ci-C6-alkoxy-, C3-Cio-cycloalkyl-, phenyl-, halophenyl-, phenyl-Ci-C6-alkyl-, phenoxy-, pyridinyl-, -C(=0)-NR5R6, -NH-C(=0)-R8, -C(=0)-R7, -S(=0)2-NR5R6, -S(=0)-R8, -S(=0)(=NR5)-R6, -S(=0)2-R8, -NH-S(=0)2-R8, or a monocyclic heterocyclyl radical having 3 to 8 ring atoms,
or
represents C3-Cio-cycloalkyl- which may optionally be mono- or polysubstituted by dentical or different substituents from the group consisting of of of halogen, cyano, nitro, hydroxy, amino, oxo, carboxy, Ci-C6-alkyl-, Ci-C6-alkoxy-,
Ci-C6-alkoxy-Ci-C6-alkyl-, hydroxy-Ci-C6-alkyl-, Ci-C6-alkylamino-,
Ci-C6-alkylcarbonylamino-, amino-Ci-C6-alkyl-, Ci-C6-alkylamino-Ci-C6-alkyl-, halo-Ci-C6-alkyl-, halo-Ci-C6-alkoxy-, C3-Cio-cycloalkyl-, phenyl-, halophenyl-, phenyl-d-Ce-alkyl-, phenoxy-, pyridinyl-, -C(=0)-NR5R6, -NH-C(=0)-R8, -C(=0)-R7, -S(=0)2-NR5R6, -S(=0)-R8, -S(=0)(=NR5)-R6, -S(=0)2-R8,
-NH-S(=0)2-R8, or a monocyclic heterocyclyl radical having 3 to 8 ring atoms, or
represents monocyclic heteroaryl- having 5 or 6 ring atoms which may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of of halogen, cyano, nitro, hydroxy, amino, carboxy, Ci-C6-alkyl-, Ci-C6-alkoxy-, Ci-C6-alkoxy-Ci-C6-alkyl-, hydroxy-Ci-C6-alkyl-,
Ci-C6-alkylamino-, Ci-C6-alkylcarbonylamino-, amino-Ci-C6-alkyl-, C1-C6- alkylamino-Ci-C6-alkyl-, halo-Ci-C6-alkyl-, halo-Ci-C6-alkoxy-, C3-Cio-cycloalkyl-, phenyl-, halophenyl-, phenyl-Ci-C6-alkyl-, phenoxy-, pyridinyl-, -C(=0)-NR5R6, -NH-C(=0)-R8, -C(=0)-R7, -S(=0)2-NR5R6, -S(=0)-R8, -S(=0)(=NR5)-R6, -S(=0)2-R8, -NH-S(=0)2-R8, or a monocyclic heterocyclyl radical having 3 to 8 ring atoms,
or
represents monocyclic heterocyclyl- having 3 to 8 ring atoms which may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of of halogen, cyano, nitro, hydroxy, amino, oxo, carboxy, Ci-C6-alkyl-, Ci-C6-alkoxy-, Ci-C6-alkoxy-Ci-C6-alkyl-, hydroxy-Ci-C6-alkyl-, Ci-C6-alkylamino-, Ci-C6-alkylcarbonylamino-, amino-Ci-C6-alkyl-,
Ci-C6-alkylamino-Ci-C6-alkyl-, halo-Ci-C6-alkyl-, halo-Ci-C6-alkoxy-, C3-C10- cycloalkyl-, phenyl-, halophenyl-, phenyl-Ci-C6-alkyl-, phenoxy-, pyridinyl-,
-C(=0)-NR5R6, -NH-C(=0)-R8, -C(=0)-R7, -S(=0)2-NR5R6, -S(=0)-R8,
-S(=0)(=NR5)-R6, -S(=0)2-R8, -NH-S(=0)2-R8, or a monocyclic heterocyclyl radical having 3 to 8 ring atoms,
or
represents phenyl- which may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of of halogen, cyano, nitro, hydroxy, amino, carboxy, Ci-C6-alkyl-, Ci-C6-alkoxy-, Ci-C6-alkoxy-Ci-C6- alkyl-, hydroxy-Ci-C6-alkyl-, Ci-C6-alkylamino-, Ci-C6-alkylcarbonylamino-, amino-Ci-C6-alkyl-, Ci-C6-alkylamino-Ci-C6-alkyl-, halo-Ci-C6-alkyl-, halo-Ci-C6- alkoxy-, C3-Cio-cycloalkyl-, phenyl-, halophenyl-, phenyl-Ci-C6-alkyl-, phenoxy-, pyridinyl-, -C(=0)-NR5R6, -NH-C(=0)-R8, -C(=0)-R7, -S(=0)2-NR5R6,
-S(=0)-R8, -S(=0)(=NR5)-R6, -S(=0)2-R8, -NH-S(=0)2-R8, or a monocyclic heterocyclyl radical having 3 to 8 ring atoms,
or
represents a spirocycloalkyl radical, a 5 to 12 membered heterospirocycloalkyl radical, a bicycloalkyl, a heterobicycloalkyl radical, a bridged cycloalkyl radical or a bridged heterocycloalkyi radical, a naphthyl radical or a bicyclic heteroaryl radical, or a partially saturated bicyclic aryl- or heteroaryl radical, where the radicals mentioned may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of of halogen, cyano, nitro, hydroxy, amino, oxo, carboxy, Ci-C6-alkyl-, Ci-C6-alkoxy-, Ci-C6-alkoxy-Ci-C6- alkyl-, hydroxy-Ci-C6-alkyl-, Ci-C6-alkylamino-, Ci-C6-alkylcarbonylamino-, amino-Ci-C6-alkyl-, Ci-C6-alkylamino-Ci-C6-alkyl-, halo-Ci-C6-alkyl-, halo-Ci-C6- alkoxy-, C3-Cio-cycloalkyl-, phenyl-, halophenyl-, phenyl-Ci-C6-alkyl-, phenoxy-, pyridinyl-, -C(=0)-NR5R6, -NH-C(=0)-R8, -C(=0)-R7, -S(=0)2-NR5R6,
-S(=0)-R8, -S(=0)(=NR5)-R6, -S(=0)2-R8, -NH-S(=0)2-R8, or a monocyclic heterocyclyl radical having 3 to 8 ring atoms,
or R3 and R4 together with the nitrogen atom form a 4 to 10 membered heterocycloalkyi or a 5 to 12 membered heterospirocycloalkyl, which may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of of halogen, cyano, nitro, hydroxy, amino, oxo, carboxy, Ci-C6-alkyl-, Ci-C6-alkoxy-, Ci-C6-alkoxy-Ci-C6-alkyl-, hydroxy-Ci-C6-alkyl-,
Ci-C6-alkylamino-, Ci-C6-alkylcarbonylamino-, amino-Ci-C6-alkyl-, C1-C6- alkylamino-Ci-C6-alkyl-, halo-Ci-C6-alkyl-, halo-Ci-C6-alkoxy-, C3-Cio-cycloalkyl-, phenyl-, halophenyl-, phenyl-Ci-C6-alkyl-, phenoxy-, pyridinyl-, -C(=0)-NR5R6, -NH-C(=0)-R8, -C(=0)-R7, -S(=0)2-NR5R6, -S(=0)-R8,
-S(=0)(=NR5)-R6, -S(=0)2-R8, -NH-S(=0)2-R8, or a monocyclic heterocyclyl radical having 3 to 8 ring atoms,
R5 and R6 independently of one another represent hydrogen, Ci-C3-alkyl-, cyclopropyl- or di-Ci-C3-alkylamino-Ci-C3-alkyl-, or
R5 and R6 together with the nitrogen atom form a monocyclic heterocyclyl- having 3 to 8 ring atoms which itself may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of halogen, amino, hydroxy, cyano, oxo, Ci-C6-alkyl-, Ci-C6-alkoxy-, Ci-C6-alkylamino-, halo-Ci-C6-alkyl-, halo-Ci-C6-alkoxy-,
R7 represents hydroxy, Ci-C6-alkyl-, Ci-C6-alkoxy-, halo-Ci-C3-alkyl-, hydroxy-Ci- C3-alkyl-, Ci-C3-alkoxy-Ci-C3-alkyl-, Cs-Cs-cycloalkyl-, phenyl-, monocyclic heterocyclyl- having 3 to 8 ring atoms or monocyclic heteroaryl- having 5 or 6 ring atoms where phenyl-, heteroaryl- and heterocyclyl- may optionally be mono- or disubstituted by halogen, Ci-C3-alkoxy- or Ci-C3-alkyl-, R8 represents Ci-C6-alkyl-,
R9 represents Ci-C6-alkyl-, -NH2, -NH-Ci-C6-alkyl, -N(Ci-C6-alkyl)2, or Ci-C6-alkoxy- d-Ce-alkyl-,
or
represents monocyclic heterocyclyl- having 3 to 8 ring atoms which itself may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of of halogen, cyano, nitro, hydroxy, amino, oxo, carboxy,
Ci-C6-alkyl-, Ci-C6-alkoxy-, Ci-C6-alkoxy-Ci-C6-alkyl-, hydroxy-Ci-C6-alkyl-, Ci-C6-alkylamino-, Ci-C6-alkylcarbonylamino-, amino-Ci-C6-alkyl-, C1-C6- alkylamino-Ci-C6-alkyl-, halo-Ci-C6-alkyl-, halo-Ci-C6-alkoxy-, C3-Cio-cycloalkyl-, phenyl-, halophenyl-, phenyl-Ci-C6-alkyl-, phenoxy-, pyridinyl-, -C(=0)-NR5R6, -NH-C(=0)-R8, -C(=0)-R7, -S(=0)2-NR5R6, -S(=0)-R8,
-S(=0)(=NR5)-R6, -S(=0)2-R8, -NH-S(=0)2-R8, or a monocyclic heterocyclyl radical having 3 to 8 ring atoms, Rx represents Ci-C6-alkyl- or Ci-C6-alkoxy-Ci-C6-alkyl-,
Ry represents hydrogen, halo-Ci-C6-alkyl, Ci-C6-alkyl, Ci-C6-alkyl substituted with
C3-C6-cycloalkyl,
and their polymorphs, enantiomers, diastereomers, racemates, tautomers, solvates, physiologically acceptable salts and solvates of these salts are particularly suitable for a large number of prophylactic and therapeutic applications, in particular for hyperproliferative disorders, for tumour disorders and as proteine inhibitors and further for viral infections, for neurodegenerative disorders, for inflammatory disorders, for atherosclerotic disorders and for male fertility control.
Further, it covers their use in combination with other anti cancer medications such as immunotherapeutics, targeted anti cancer agents, radiation or chemotherapy.
DEFINITIONS
The term "substituted" means that one or more hydrogen atoms on the designated atom or group are replaced with a selection from the indicated group, provided that the designated atom's normal valency under the existing circumstances is not exceeded. Combinations of substituents and/or variables are permissible. The term "optionally substituted" means that the number of substituents can be equal to or different from zero. Unless otherwise indicated, it is possible that optionally substituted groups are substituted with as many optional substituents as can be accommodated by replacing a hydrogen atom with a non-hydrogen substituent on any available carbon atom. Commonly, it is possible for the number of optional substituents, when present, to be 1 , 2 or 3.
The term "comprising" when used in the specification includes "consisting of".
If within the present text any item is referred to as "as mentioned herein", it means that it may be mentioned anywhere in the present text.
The terms as mentioned in the present text have the following meanings:
The term "halogen" means a fluorine, chlorine, bromine or iodine, particularly a fluorine, chlorine or bromine atom.
The term "Ci-C6-alkyl" means a linear or branched, saturated, monovalent hydrocarbon group having 1 , 2, 3, 4, 5 or 6 carbon atoms, e.g. a methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, isobutyl, ie f-butyl, pentyl, isopentyl, 2-methylbutyl, 1 -methylbutyl, 1 -ethylpropyl,
1 .2- dimethylpropyl, neo-pentyl, 1 ,1 -dimethylpropyl, hexyl, 1 -methylpentyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 1 -ethylbutyl, 2-ethylbutyl, 1 ,1 -dimethylbutyl, 2,2-dimethylbutyl,
3.3- dimethylbutyl, 2,3-dimethylbutyl, 1 ,2-dimethylbutyl or 1 ,3-dimethylbutyl group, or an isomer thereof. Particularly, said group has 1 , 2, 3 or 4 carbon atoms ("Ci-C4-alkyl"), e.g. a methyl, ethyl, propyl, isopropyl, butyl, sec-butyl isobutyl, or ie f-butyl group, more particularly 1 , 2 or 3 carbon atoms ("Ci-C3-alkyl"), e.g. a methyl, ethyl, n-propyl or isopropyl group. The term "hydroxy-Ci-C6-alkyl" means a linear or branched, saturated, monovalent hydrocarbon group in which the term "Ci-C6-alkyl" is defined supra, and in which 1 or 2 hydrogen atoms are replaced with a hydroxy group, e.g. a hydroxy methyl, 1 -hydroxyethyl, 2-hydroxyethyl, 1 ,2-dihydroxyethyl, 3-hydroxypropyl, 2-hydroxypropyl, 1 -hydroxypropyl,
1 - hydroxypropan-2-yl, 2-hydroxypropan-2-yl, 2,3-dihydroxypropyl, 1 ,3-dihydroxypropan-2-yl, 3-hydroxy-2-methyl-propyl, 2-hydroxy-2-methyl-propyl, 1 -hydroxy-2-methyl-propyl group.
The term "Ci-C6-alkoxy" means a linear or branched, saturated, monovalent group of formula (Ci-C6-alkyl)-0-, which means methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, sec-butoxy, isobutoxy or ie f-butoxy.
The term "Ci-C6-alkoxy-Ci-C6-alkyl-" means a linear or branched, saturated, monovalent group of formula (Ci-C6-alkyl)-0-(Ci-C6-alkyl)-, in which the term "Ci-C6-alkyl" is defined supra, and in which 1 to 3 hydrogen atoms of the Ci-C6-alkyl group are replace by Ci-C6-alkoxy. The term "Ci-C6-alkylamino-" means an amino radical having one or two alkyl substituents (selected independently of one another) having generally 1 to 6 (Ci-C6-alkylamino) and preferably 1 to 3 (Ci-C3-alkylamino) carbon atoms. (Ci-C3)-Alkylamino represents, for example, a monoalkylamino radical having 1 to 3 carbon atoms or a dialkylamino radical having 1 to 3 carbon atoms each per alkyl substituent.
The following may be mentioned by way of example:
methylamino, ethylamino, n-propylamino, isopropylamino, ie f-butylamino, n-pentylamino, n-hexylamino, Λ/,/V-dimethylamino, Λ/,/V-diethylamino, /V-ethyl-/V-methylamino, /V-methyl-N-n- propylamino, /V-isopropyl-/V-n-propylamino, /V-ie f-butyl-/V-methylamino, /V-ethyl-/V-n-pentylamino and /V-n-hexyl-/V-methylamino.
The term "amino-Ci-C6-alkyl-" means a linear or branched, saturated, monovalent hydrocarbon group in which the term "Ci-C6-alkyl" is defined supra, and in which 1 or 2 hydrogen atoms are replaced with an amino group, e.g. a aminomethyl, 1 -aminoethyl, 2-aminoethyl,
1 ,2-diaminoethyl, 3-aminopropyl, 2-aminopropyl, 1-aminopropyl, 1 -aminopropan-2-yl,
2-aminopropan-2-yl, 2,3-diaminopropyl, 1 ,3-diaminopropan-2-yl, 3-amino-2-methyl-propyl,
2- amino-2-methyl-propyl, 1 -amino-2-methyl-propyl group. The term "Ci-C6-alkylamino-Ci-C6-alkyl means that the alkylaminoalkyl group is attached via the alkyl moiety to the remainder of the molecule, e.g. Λ/,/V-dimethylaminoethyl-, N,N- dimethylaminomethyh Λ/,/V-diethylaminoethyl-, Λ/,/V-dimethylaminopropyl-, N- methylaminoethyl-, /V-methylaminomethyl-.
The term "halo-Ci-C6-alkyl-" means an alkyl radical having at least one halogen substituent. The term "Ci-C6-alkyl-" is as defined supra.
A halo-Ci-C6-alkyl radical is an alkyl radical having 1 -6 carbon atoms and at least one halogen substituent. If a plurality of halogen substituents is present, these may also be different from one another. Preference is given to fluoro-Ci-C6-alkyl, fluoro-Ci-C4-alkyl, fluoro-Ci-C3-alkyl, chloro-Ci-C6-alkyl, chloro-Ci-C4-alkyl, chloro-Ci-C3-alkyl, bromo-Ci-C6-alkyl, bromo-Ci-C4-alkyl and bromo-Ci-C3-alkyl radicals.
In this regard preferred are difluoromethyl, trifluoromethyl, 2,2,2-trifluoroethyl, pentafluoroethyl, 4,4,5,5,5-pentafluoropentyl or 3,3,4,4,5,5,5-heptafluoropentyl.
Preference is given to perfluorinated alkyl radicals such as trifluoromethyl or 2,2,2- trifluoroethyl.
The term "haloalkoxy" means an alkoxy radical having at least one halogen substituent.
A halo-Ci-C6-alkoxy radical is an alkoxy radical having 1 -6 carbon atoms and at least one halogen substituent. If a plurality of halogen substituents is present, these may also be different from one another. Preference is given to fluoro-Ci-C6-alkoxy, fluoro-Ci-C4-alkoxy, fluoro-Ci-C3-alkoxy, chloro-Ci-C6-alkoxy, chloro-Ci-C4-alkoxy, chloro-Ci-C3-alkoxy, bromo-Ci- C6-alkoxy, bromo-Ci-C4-alkoxy and bromo-Ci-C3-alkoxy radicals.
In this regard preferred are trifluoromethoxy and 2,2,2-trifluoroethoxy radicals.
The term "halophenyl" means a phenyl radical which is mono- or polysubstituted by identical or different substituents from the group consisting of fluorine, chlorine and bromine.
The term "C3-Cio-cycloalkyl" means a saturated, monovalent, monocyclic hydrocarbon ring which contains 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms ("C3-Cio-cycloalkyl"). Said C3-C10- cycloalkyl group is a monocyclic hydrocarbon ring, e.g. a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl or cyclodecanyl. Preferred are 3 to 8 (C3-C8- cycloalkyl) and particularly preferably 3 to 7 (C3-C7-cycloalkyl) carbon atoms. The term "Ci-C6-alkylcarbonylamino" means the group alkyl-C(=0)-NH- having generally 1 to 6 (Ci-C6-alkylcarbonylamino), preferably 1 to 4 and particularly preferably 1 to 3 carbon atoms in the alkyl moiety. The term "phenyl-Ci-C6-alkyl-" is understood to mean a group composed of an optionally substituted phenyl radical and a Ci-C6-alkyl group, and bonded to the rest of the molecule via the Ci-C6-alkyl group. Here, the Ci-C6-alkyl is as defined supra.
Examples which may be mentioned include benzyl, phenethyl, phenylpropyl, phenylpentyl, with benzyl being preferred.
The term "monocyclic heterocyclyl-" means a non-aromatic monocyclic ring system having one, two or three heteroatoms which may be identical or different. The heteroatoms may be nitrogen atoms, oxygen atoms or sulphur atoms. The sulphur atom may be substituted with oxygene to form a -S(=0)- or -S(=0)2- group in the ring.
A monocyclic heterocyclyl ring according to the present invention may have 3 to 8, preferably 4 to 7, particularly preferably 5 or 6 ring atoms. By way of example and with preference, the following may be mentioned for monocyclic heterocyclyl radicals having 3 ring atoms:
aziridinyk
By way of example and with preference, the following may be mentioned for monocyclic heterocyclyl radicals having 4 ring atoms:
azetidinyl-, oxetanyl- and 1 ,1 -dioxidothietanyk
By way of example and with preference, the following may be mentioned for monocyclic heterocyclyl radicals having 5 ring atoms:
pyrrolidinyl-, imidazolidinyl-, pyrazolidinyl-, pyrrolinyl-, dioxolanyl-, 1 ,1 -dioxidotetrahydro- thiophen-yl-, oxopyrrolidinyl- and tetrahydrofuranyk
By way of example and with preference, the following may be mentioned for monocyclic heterocyclyl radicals having 6 ring atoms:
piperidinyl-, piperazinyl-, morpholinyl-, dioxanyl-, tetrahydropyranyl-, 1 ,1 -dioxidotetrahydro-2H- thiopyranyl-, oxopiperidinyl- and thiomorpholinyk
By way of example and with preference, the following may be mentioned for monocyclic heterocyclyl radicals having 7 ring atoms:
azepanyl-, oxepanyl-, 1 ,3-diazepanyl-, 1 ,4-diazepanyk By way of example and with preference, the following may be mentioned for monocyclic heterocyclyl radicals having 8 ring atoms:
oxocanyl-, azocanyk From among the monocyclic heterocyclyl radicals, preference is given to 4- to 7-membered saturated heterocyclyl radicals having up to two heteroatoms from the group consisting of O, N and S.
Particular preference is given to morpholinyl-, piperidinyl- and pyrrolidinyl-. The term "4- to 10-membered heterocycloalkyl" means a monocyclic, saturated heterocycle with 4, 5, 6, 7, 8, 9 or 10 ring atoms in total, which contains one or two identical or different ring heteroatoms from the series N and O, it being possible for said heterocycloalkyl group to be attached to the rest of the molecule via any one of the carbon atoms or, if present, a nitrogen atom. The term "heterocycloalkyl" is as defined supra.
Said heterocycloalkyl group, without being limited thereto, can be a 4-membered ring, such as azetidinyl or oxetanyl, for example; or a 5-membered ring, such as tetrahydrofuranyl, 1 ,3- dioxolanyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, 1 ,2-oxazolidinyl or 1 ,3-oxazolidinyl, for example; or a 6-membered ring, such as tetrahydropyranyl, piperidinyl, morpholinyl, piperazinyl, 1 ,3-dioxanyl, 1 ,4-dioxanyl or 1 ,2-oxazinanyl, for example.
Particularly, "4- to 6-membered heterocycloalkyl" means a 4- to 6-membered heterocycloalkyl as defined supra containing one ring oxygen atom and optionally one further ring heteroatom from the series: N, O. More particularly, "5- or 6-membered heterocycloalkyl" means a monocyclic, saturated heterocycle with 5 or 6 ring atoms in total, containing one ring oxygen atom.
The term "heteroaryl" means a monovalent, monocyclic aromatic ring or bicyclic aromatic ring system having 5 to 10 ring atoms (a "5- or 10-membered heteroaryl" group), which contains at least one ring heteroatom and optionally one or two further ring heteroatoms from the series: N, O and/or S, and which is bound via a ring carbon atom or optionally via a ring nitrogen atom (if allowed by valency).
The term "monocyclic heteroaryl" means a monovalent, aromatic ring having 5 or 6 ring atoms (a "5- or 6-membered heteroaryl" group), which contains at least one ring heteroatom and optionally one or two further ring heteroatoms from the series: N, O and/or S, and which is bound via a ring carbon atom or optionally via a ring nitrogen atom (if allowed by valency). Said heteroaryl group can be a 5-membered heteroaryl group, such as, for example, thienyl, furanyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl or tetrazolyl; or a 6-membered heteroaryl group, such as, for example, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl or triazinyl.
In general, and unless otherwise mentioned, the heteroaryl or heteroarylene groups include all possible isomeric forms thereof, e.g.: tautomers and positional isomers with respect to the point of linkage to the rest of the molecule. Thus, for some illustrative non-restricting examples, the term pyridinyl includes pyridin-2-yl, pyridin-3-yl and pyridin-4-yl; or the term thienyl includes thien-2-yl and thien-3-yl.
Particularly, the heteroaryl group is a isothiazolyl, pyrazolyl, pyridinyl, pyridazinyl or pyrimidinyl group. The term "spirocycloalkyl" means a Cs- to Ci2-membered bicyclic, saturated ring system with 5, 6, 7, 8, 9, 10, 1 1 or 12 carbon atoms in total which rings are fused in a way that they share one common ring carbon atom, it being possible for said spirocycloalkyl group to be attached to the rest of the molecule via any one of the carbon atoms, except the spiro carbon atom. The term "heterospirocycloalkyi" means a 5 to 12 -membered bicyclic, saturated ring system with 5, 6, 7, 8, 9, 10, 1 1 or 12 ring atoms in total whereas one, two, three or four ring atoms are heteroatoms as defined above, the remaining ring atoms are carbon atoms and which rings are fused in a way that they share one common ring carbon atom, it being possible for said heterospirocycloalkyi group to be attached to the rest of the molecule via any one of the carbon atoms, except the spiro carbon atom, or, if present, a nitrogen atom.
Examples are spiro[2.2]pentyl, spiro[2.3]hexyl, azaspiro[2.3]hexyl, spiro[3.3]heptyl,
azaspiro[3.3]heptyl, oxaazaspiro[3.3]heptyl, thiaazaspiro[3.3]heptyl, oxaspiro[3.3]heptyl, oxazaspiro[3.5]nonyl, oxazaspiro[3.4]octyl, oxazaspiro[5.5]undecyl, diazaspiro[3.3]heptyl, thiazaspiro[3.3]heptyl, thiazaspiro[3.4]octyl, azaspiro[5.5]decyl, and the further homologous spiro[3.4], spiro[4.4], spiro[5.5], spiro[6.6], spiro[2.4], spiro[2.5], spiro[2.6], spiro[3.5], spiro[3.6], spiro[4.5], spiro[4.6] and spiro[5.6] systems including the variants modified by heteroatoms as per the definition. Preference is given to C6-Cio-heterospirocycloalkyl-, by way of example and with particular preference 2-azaspiro[3.3]heptyl-, 2,2-dioxido-2-thia-6-azaspiro[3.3]heptyl.
1 ,1 -dioxido-1 -thia-6-azaspiro[3.3]heptyl, 1 -thia-6-azaspiro[3.3]heptyl-, 2-thia-6- azaspiro[3.3]heptyl-, 2-oxa-6-azaspiro[3.3]heptyl-,2,6-diazaspiro[3.3]heptyl-, 2-oxa-6- azaspiro[3.4]octyl-, 2-oxa-6-azaspiro[3.5]nonyl-,2-oxa-7-azaspiro[3.5]nonyl-, 8- azaspiro[4.5]decyl-, 2,8-diazaspiro[4.5]decyl- or 3-oxa-1 ,8-diazaspiro[4.5]decyk The terms "bicycloalkyl" and "heterobicycloalkyi" mean C6-Ci2-bicycloalkyl or C6-C12- heterobicycloalkyl where one, two, three or four carbon atoms are replaced by heteroatoms as defined above in any combination is understood to mean a fusion of two saturated ring systems which share two directly adjacent atoms.
Examples are radicals derived from bicyclo[2.2.0]hexyl-, bicyclo[3.3.0]octyl-,
bicyclo[4.4.0]decyl-, bicyclo[5.4.0]undecyl-, bicyclo[3.2.0]heptyl-, bicyclo[4.2.0]octyl-, bicyclo[5.2.0]nonyl-, bicyclo[6.2.0]decyl-, bicyclo[4.3.0]nonyl-, bicyclo[5.3.0]decyl-,
bicyclo[6.3.0]undecyl- and bicyclo[5.4.0]undecyl-, including the variants modified by heteroatoms, for example azabicyclo[3.3.0]octyl-, azabicyclo[4.3.0]nonyl-,
diazabicyclo[4.3.0]nonyl-, oxazabicyclo[4.3.0]nonyl-, thiazabicyclo[4.3.0]nonyl- or
azabicyclo[4.4.0]decyl-, and the further possible combinations as per the definition. Preference is given to C6-Cio-heterobicycloalkyl-, by way of example and with particular preference perhydrocyclopenta[c]pyrrolyl-, perhydrofuro[3,2-c]pyridinyl-, perhydropyrrolo[1 ,2-a]pyrazinyl-, perhydropyrrolo[3,4-c]pyrrolyl-.
Preferred examples of C6-Ci2-bicycloalkyl- are perhydronaphthalenyl- (decalinyl-),
perhydrobenzoannulenyl-, perhydroazulenyl-, perhydroindanyl-, perhydropentalenyl-. The terms "bridged cycloalkyi" and "bridged heterocycloalkyi" mean a bridged C6-C12 ring system such as bridged C6-Ci2-cycloalkyl- or bridged C6-Ci2-heterocycloalkyl- is understood to mean a fusion of at least two saturated rings which share two atoms that are not directly adjacent to one another. This may give rise either to a bridged carbocycle (bridged cycloalkyi-) or to a bridged heterocycle (bridged heterocycloalkyi-) where one, two, three or four carbon atoms are replaced by heteroatoms as defined above in any combination.
Examples are bicyclo[2.2.1]heptyl-, azabicyclo[2.2.1 ]heptyl-, oxazabicyclo[2.2.1 ]heptyl-, thiazabicyclo[2.2.1 ]heptyl-, diazabicyclo[2.2.1]heptyl-, bicyclo[2.2.2]octyl-,
azabicyclo[2.2.2]octyl-, diazabicyclo[2.2.2]octyl-, oxazabicyclo[2.2.2]octyl-,
thiazabicyclo[2.2.2]octyl-, bicyclo[3.2.1]octyl-, azabicyclo[3.2.1 ]octyl-, diazabicyclo[3.2.1]octyl-, oxazabicyclo[3.2.1 ]octyl-, thiazabicyclo[3.2.1]octyl-, bicyclo[3.3.1]nonyl-,
azabicyclo[3.3.1 ]nonyl-, diazabicyclo[3.3.1 ]nonyl- oxazabicyclo[3.3.1 ]nonyl-,
thiazabicyclo[3.3.1 jnonyl-, bicyclo[4.2.1 jnonyl-, azabicyclo[4.2.1 jnonyl-,
diazabicyclo[4.2.1 ]nonyl-, oxazabicyclo[4.2.1 jnonyl-, thiazabicyclo[4.2.1 jnonyl-,
bicyclo[3.3.2]decyl-, azabicyclo[3.3.2]decyl-, diazabicyclo[3.3.2]decyl-,
oxazabicyclo[3.3.2]decyl-, thiazabicyclo[3.3.2]decyl- or azabicyclo[4.2.2]decyl- and the further possible combinations according to the definition. Preference is given to bridged C6-Cio-heterocycloalkyl-, by way of example and with particular preference
2-azabicyclo[2.2.1]heptyl-, 2,5-diazabicyclo[2.2.1]heptyl-, 2-oxa-5-azabicyclo[2.2.1]heptyl-, 8-azabicyclo[3.2.1]octyl-, 8-oxa-3-azabicyclo[3.2.1]octyl-, 3,9-diazabicyclo[4.2.1 ]nonyl-.
Where the plural form of the word compounds, salts, polymorphs, hydrates, solvates and the like, is used herein, this is taken to mean also a single compound, salt, polymorph, isomer, hydrate, solvate or the like. By "stable compound' or "stable structure" is meant a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent.
The compounds of the present invention optionally contain one or more asymmetric centres, depending upon the location and nature of the various substituents desired. It is possible that one or more asymmetric carbon atoms are present in the (R) or (S) configuration, which can result in racemic mixtures in the case of a single asymmetric centre, and in diastereomeric mixtures in the case of multiple asymmetric centres. In certain instances, it is possible that asymmetry also be present due to restricted rotation about a given bond, for example, the central bond adjoining two substituted aromatic rings of the specified compounds.
Preferred compounds are those which produce the more desirable biological activity.
Separated, pure or partially purified isomers and stereoisomers or racemic or diastereomeric mixtures of the compounds of the present invention are also included within the scope of the present invention. The purification and the separation of such materials can be accomplished by standard techniques known in the art.
Preferred isomers are those which produce the more desirable biological activity. These separated, pure or partially purified isomers or racemic mixtures of the compounds of this invention are also included within the scope of the present invention. The purification and the separation of such materials can be accomplished by standard techniques known in the art.
The optical isomers can be obtained by resolution of the racemic mixtures according to conventional processes, for example, by the formation of diastereoisomeric salts using an optically active acid or base or formation of covalent diastereomers. Examples of appropriate acids are tartaric, diacetyltartaric, ditoluoyltartaric and camphorsulfonic acid. Mixtures of diastereoisomers can be separated into their individual diastereomers on the basis of their physical and/or chemical differences by methods known in the art, for example, by chromatography or fractional crystallisation. The optically active bases or acids are then liberated from the separated diastereomeric salts. A different process for separation of optical isomers involves the use of chiral chromatography (e.g., HPLC columns using a chiral phase), with or without conventional derivatisation, optimally chosen to maximise the separation of the enantiomers. Suitable HPLC columns using a chiral phase are commercially available, such as those manufactured by Daicel, e.g., Chiracel OD and Chiracel OJ, for example, among many others, which are all routinely selectable. Enzymatic separations, with or without derivatisation, are also useful. The optically active compounds of the present invention can likewise be obtained by chiral syntheses utilizing optically active starting materials.
In order to distinguish different types of isomers from each other reference is made to lUPAC Rules Section E (Pure Appl Chem 45, 1 1 -30, 1976).
The present invention includes all possible stereoisomers of the compounds of the present invention as single stereoisomers, or as any mixture of said stereoisomers, e.g. (R)- or (S)- isomers, in any ratio. Isolation of a single stereoisomer, e.g. a single enantiomer or a single diastereomer, of a compound of the present invention is achieved by any suitable state of the art method, such as chromatography, especially chiral chromatography, for example.
Further, the compounds of the present invention can exist as N-oxides, which are defined in that at least one nitrogen of the compounds of the present invention is oxidised. The present invention includes all such possible N-oxides.
The present invention also covers useful forms of the compounds of the present invention, such as metabolites, hydrates, solvates, prodrugs, salts, in particular pharmaceutically acceptable salts, and/or co-precipitates.
The compounds of the present invention can exist as a hydrate, or as a solvate, wherein the compounds of the present invention contain polar solvents, in particular water, methanol or ethanol for example, as structural element of the crystal lattice of the compounds. It is possible for the amount of polar solvents, in particular water, to exist in a stoichiometric or non- stoichiometric ratio. In the case of stoichiometric solvates, e.g. a hydrate, hemi-, (semi-), mono-, sesqui-, di-, tri-, tetra-, penta- etc. solvates or hydrates, respectively, are possible. The present invention includes all such hydrates or solvates. Further, it is possible for the compounds of the present invention to exist in free form, e.g. as a free base, or as a free acid, or as a zwitterion, or to exist in the form of a salt. Said salt may be any salt, either an organic or inorganic addition salt, particularly any pharmaceutically acceptable organic or inorganic addition salt, which is customarily used in pharmacy, or which is used, for example, for isolating or purifying the compounds of the present invention.
The term "pharmaceutically acceptable salt" refers to an inorganic or organic acid addition salt of a compound of the present invention. For example, see S. M. Berge, et al. "Pharmaceutical Salts," J. Pharm. Sci. 1977, 66, 1 -19.
A suitable pharmaceutically acceptable salt of the compounds of the present invention may be, for example, an acid-addition salt of a compound of the present invention bearing a nitrogen atom, in a chain or in a ring, for example, which is sufficiently basic, such as an acid-addition salt with an inorganic acid, or "mineral acid", such as hydrochloric, hydrobromic, hydroiodic, sulfuric, sulfamic, bisulfuric, phosphoric, or nitric acid, for example, or with an organic acid, such as formic, acetic, acetoacetic, pyruvic, trifluoroacetic, propionic, butyric, hexanoic, heptanoic, undecanoic, lauric, benzoic, salicylic, 2-(4-hydroxybenzoyl)-benzoic, camphoric, cinnamic, cyclopentanepropionic, digluconic, 3-hydroxy-2-naphthoic, nicotinic, pamoic, pectinic, 3-phenylpropionic, pivalic, 2-hydroxyethanesulfonic, itaconic, trifluoromethanesulfonic, dodecylsulfuric, ethanesulfonic, benzenesulfonic, para-toluenesulfonic, methanesulfonic, 2-naphthalenesulfonic, naphthalinedisulfonic, camphorsulfonic acid, citric, tartaric, stearic, lactic, oxalic, malonic, succinic, malic, adipic, alginic, maleic, fumaric,
D-gluconic, mandelic, ascorbic, glucoheptanoic, glycerophosphoric, aspartic, sulfosalicylic, or thiocyanic acid, for example.
Further, another suitably pharmaceutically acceptable salt of a compound of the present invention which is sufficiently acidic, is an alkali metal salt, for example a sodium or potassium salt, an alkaline earth metal salt, for example a calcium, magnesium or strontium salt, or an aluminium or a zinc salt, or an ammonium salt derived from ammonia or from an organic primary, secondary or tertiary amine having 1 to 20 carbon atoms, such as ethylamine, diethylamine, triethylamine, ethyldiisopropylamine, monoethanolamine, diethanolamine, triethanolamine, dicyclohexylamine, dimethylaminoethanol, diethylaminoethanol,
tris(hydroxymethyl)aminomethane, procaine, dibenzylamine, /V-methylmorpholine, arginine, lysine, 1 ,2-ethylenediamine, /V-methylpiperidine, /V-methyl-glucamine, /V,/V-dimethyl-glucamine, /V-ethyl-glucamine, 1 ,6-hexanediamine, glucosamine, sarcosine, serinol, 2-amino-1 ,3- propanediol, 3-amino-1 ,2-propanediol, 4-amino-1 ,2,3-butanetriol, or a salt with a quarternary ammonium ion having 1 to 20 carbon atoms, such as tetramethylammonium, tetraethylammonium, tetra(n-propyl)ammonium, tetra(n-butyl)ammonium, /V-benzyl-/V,/V,/V- trimethylammonium, choline or benzalkonium.
Those skilled in the art will further recognise that it is possible for acid addition salts of the claimed compounds to be prepared by reaction of the compounds with the appropriate inorganic or organic acid via any of a number of known methods. Alternatively, alkali and alkaline earth metal salts of acidic compounds of the present invention are prepared by reacting the compounds of the present invention with the appropriate base via a variety of known methods.
The present invention includes all possible salts of the compounds of the present invention as single salts, or as any mixture of said salts, in any ratio.
In the present text, in particular in the Experimental Section, for the synthesis of intermediates and of examples of the present invention, when a compound is mentioned as a salt form with the corresponding base or acid, the exact stoichiometric composition of said salt form, as obtained by the respective preparation and/or purification process, is, in most cases, unknown.
Unless specified otherwise, suffixes to chemical names or structural formulae relating to salts, such as "hydrochloride", "trifluoroacetate", "sodium salt", or "x HCI", "x CF3COOH", "x Na+", for example, mean a salt form, the stoichiometry of which salt form not being specified.
This applies analogously to cases in which synthesis intermediates or example compounds or salts thereof have been obtained, by the preparation and/or purification processes described, as solvates, such as hydrates, with (if defined) unknown stoichiometric composition.
Furthermore, the present invention includes all possible crystalline forms, or polymorphs, of the compounds of the present invention, either as single polymorph, or as a mixture of more than one polymorph, in any ratio.
Moreover, the present invention also includes prodrugs of the compounds according to the invention. The term "prodrugs" here designates compounds which themselves can be biologically active or inactive, but are converted (for example metabolically or hydrolytically) into compounds according to the invention during their residence time in the body.
The invention further includes all possible crystallized and polymorphic forms of the inventive compounds, whereby the polymorphs are existing either as a single polymorph form or are existing as a mixture of several polymorphs in all concentrations. The invention further includes all possible cyclodextrin clathrates, i.e alpha-, beta-, or gamma- cyclodextrins, hydroxypropyl-beta-cyclodextrins, methylbetacyclodextrins.
In accordance with a further embodiment, the present invention covers compounds of general formula (I), in which X represents an oxygene atom.
In accordance with a further embodiment, the present invention covers compounds of general formula (I), in which Y represents a sulphur or an oxygene atom. In accordance with a further embodiment, the present invention covers compounds of general formula (I), in which X represents a sulphur or an oxygene atom.
In accordance with a further embodiment, the present invention covers compounds of general formula (I), in which Y represents a sulphur or an oxygene atom.
In accordance with a further embodiment, the present invention covers compounds of general formula (I), in which X represents a sulphur and Y an oxygene atom.
In accordance with a further embodiment, the present invention covers compounds of general formula (I), in which Y represents a sulphur and X an oxygene atom.
In accordance with a further embodiment, the present invention covers compounds of general formula (I), in which R1 represents hydrogen, halogen, Ci-C6-alkyl, halo-Ci-C6-alkyl and cyano. In accordance with a further embodiment, the present invention covers compounds of general formula (I), in which R2 represents fluorine.
In accordance with a further embodiment, the present invention covers compounds of general formula (I), in which R3 represents hydrogen or Ci-C6-alkyl.
In accordance with a further embodiment, the present invention covers compounds of general formula (I), in which R3 represents hydrogen or Ci-C3-alkyl.
In accordance with a further embodiment, the present invention covers compounds of general formula (I), in which R3 represents hydrogen or methyl. In accordance with a further embodiment, the present invention covers compounds of general formula (I), in which R4
represents hydrogen or represents Ci-C6-alkyl-, which may optionally be mono- or
polysubstituted by identical or different substituents from the group consisting of halogen, cyano, hydroxy, Ci-C3-alkoxy-, -N(Ci-C6-alkyl)2, -C(=0)-R9, -C(=0)-NH-Rx,
-C(=0)-NR5R6, -NH-C(=0)-R9, -NH-S(=0)2-R9 or -S(=0)2-R9,
or a C3-Cio-cycloalkyl- which itself may optionally substituted by hydroxyl, or a monocyclic heteroaryl- having 5 or 6 ring atoms which itself may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of cyano, Ci-C6-alkyl-, Ci-C6-alkoxy- or Ci-C6-alkoxy-Ci-C6-alkyl-, or a monocyclic heterocyclyl- having 3 to 8 ring atoms which itself may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of halogen, hydroxyl, carboxy, Ci-C6-alkyl- or hydroxy-Ci-C6-alkyl-, or a phenyl, 5 to 12 membered heterospirocycloalkyl or partially saturated bicyclic heteroaryl, each of which mentioned supra may optionally be substituted by -C(=0)-NR5R6, or R4
represents a C3-Cio-cycloalkyl- which may optionally substituted by -C(=0)-NR5R6 or
Ci -Ce-a I koxy-Ci -C6-a I ky I- or
represents a monocyclic heteroaryl- having 5 or 6 ring atoms which may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of halogen, d-Ce-alkyl-, halo-Ci-C6-alkyl-, C3-Cio-cycloalkyl-,-C(=0)-NR5R6, -S(=0)2-R8 or a monocyclic heterocyclyl radical having 3 to 8 ring atoms,
or
represents a monocyclic heterocyclyl- having 3 to 8 ring atoms which may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of halogen, oxo, Ci-C6-alkylamino-Ci-C6-alkyl or monocyclic heterocyclyl radical having 3 to 8 ring atoms or
represents a phenyl- which may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of halogen, Ci-C6-alkoxy- or halo-Ci-C6-alkyl-, or
represents a 5 to 12 membered heterospirocycloalkyl radical, or a bridged heterocycloalkyl radical, or R3 and R4
together with the nitrogen atom form a 4 to 10 membered heterocycloalkyl or a 5 to 12 membered heterospirocycloalkyl, which may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of halogen, Ci-C6-alkyl-,
Ci-C6-alkoxy- or hydroxy-Ci-C6-alkyk
In accordance with a further embodiment, the present invention covers compounds of general formula (I), in which R4
represents hydrogen or represents Ci-C6-alkyl-, which may optionally be mono- or
polysubstituted by identical or different substituents from the group consisting of halogen, cyano, hydroxy, Ci-C3-alkoxy-, -N(Ci-C3-alkyl)2, -C(=0)-R9, -C(=0)-NH-Rx, -C(=0)-NR5R6, -NH-C(=0)-R9, -NH-S(=0)2-R9, -S(=0)2-R9, or a C3-C7-cycloalkyl- which itself may optionally substituted by hydroxy, or a monocyclic heteroaryl- having 5 or 6 ring atoms which itself may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of cyano, Ci-C6-alkyl-, Ci-C6-alkoxy- or Ci-C6-alkoxy-Ci-C6-alkyl-, or a monocyclic heterocyclyl- having 4 to 6 ring atoms which itself may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of halogen, hydroxyl, carboxy, Ci-C6-alkyl- or hydroxy-Ci-C6-alkyl-, or a phenyl, 7 to 9 membered heterospirocycloalkyl or partially saturated bicyclic heteroaryl, each of which mentioned supra may optionally be substituted by -C(=0)-NR5R6, or R4
represents a C3-C7-cycloalkyl- which may optionally substituted by -C(=0)-NR5R6 or
Ci -Ce-a I koxy-Ci -C6-a I ky I- or
represents a monocyclic heteroaryl- having 5 or 6 ring atoms which may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of halogen, d-Cs-alkyl-, halo-Ci-C3-alkyl-, C3-C7-cycloalkyl-, -C(=0)-NR5R6, -S(=0)2-R8 or a monocyclic heterocyclyl radical having 4 to 6 ring atoms,
or represents a monocyclic heterocyclyl- having 4 to 6 ring atoms which may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of halogen, oxo, Ci-C3-alkylamino-Ci-C3-alkyl or monocyclic heterocyclyl radical having 4 to 6 ring atoms, or
represents a phenyl- which may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of halogen, Ci-C3-alkoxy- or halo-Ci-C3-alkyl-, or
represents a 7 to 9 membered heterospirocycloalkyl radical, or a bridged heterocycloalkyl radical, or R3 and R4
together with the nitrogen atom form a 4 to 6 membered heterocycloalkyl or a
7 to 9 membered heterospirocycloalkyl, which may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of halogen, Ci-C3-alkyl-,
Ci-C3-alkoxy-, hydroxy-Ci-C3-alkyk
In accordance with a further embodiment, the present invention covers compounds of general formula (I), in which R4 represents
Figure imgf000025_0001
C H3 and where "*" denotes the point of attachment to the remainder of the molecule. In accordance with a further embodiment, the present invention covers compounds of general formula (I), in which R3 and R4 together with the nitrogen atom form the group
Figure imgf000026_0001
and where "*" denotes the point of attachment to the remainder of the molecule.
In accordance with a further embodiment, the present invention covers compounds of general formula (I), in which X and Y represent an oxygene atom.
In accordance with a further embodiment, the present invention covers compounds of general formula (I), in which R1 represents chlorine, bromine, cyano and trifluoromethyl.
In accordance with a further embodiment, the present invention covers compounds of general formula (I), in which R2 represents fluorine and R3 represents hydrogen. In accordance with a further embodiment, the present invention covers compounds of general formula (I), in which R4 represents
Figure imgf000026_0002
where "*" denotes the point of attachment to the remainder of the molecule. In accordance with a further embodiment, the present invention covers compounds of general formula (I), in which R4 represents hydrogen, Ci-C6-alkyl-, which may optionally be mono- or disubstituted by identical or different substituents from the group consisting of halogen, cyano, hydroxy, Ci-C3-alkoxy-, -NH2, -NH-(Ci-C6-alkyl), -N(Ci-C6-alkyl)2, -NH-(Ci-C6-alkyl)-Ci-C6- alkoxy, Ci-C6-alkyl-, Ci-C6-alkoxy-, -S(=0)2NH2, -C(=0)-R9, -C(=0)-NH-Rx, -NH-C(=0)-R9, -NH-S(=0)2-R9, -S(=0)2-R9, in which R9 represents methyl, -NH2 or -CH2-CH2-0-CH3 or
Figure imgf000026_0003
where "*" denotes the point of attachment to the remainder of the molecule,
and Rx represents methyl or -CH2-CH2-0-CH3. In accordance with a further embodiment, the present invention covers compounds of general formula (I), in which R4 represents Ci-C6-alkyl-, which may optionally be mono- or disubstituted by identical or different substituents from the group consisting of
Figure imgf000027_0001
where "*" denotes the point of attachment to the remainder of the molecule. In accordance with a further embodiment, the present invention covers compounds of general formula (I), in which R4 represents Ci-C6-alkyl-, which may optionally be mono- or disubstituted by identical or different substituents from the group consisting of
Figure imgf000028_0001
where "*" denotes the point of attachment to the remainder of the molecule.
In accordance with a further embodiment, the present invention covers compounds of general formula (I), in which X represents an oxygene atom, Y represents a sulphur atom, R1 represents trifluoromethyl and R2 represents fluorine.
In accordance with a further embodiment, the present invention covers compounds of general formula (I), in which
R5 and R6 independently of one another represent hydrogen or Ci-C3-alkyl-,
or
R5 and R6 together with the nitrogen atom form a monocyclic heterocyclyl- having 3 to 8 ring atoms which itself may optionally be substituted by Ci-C6-alkyk In accordance with a further embodiment, the present invention covers compounds of general formula (I), in which
R5 and R6 independently of one another represent hydrogen or Ci-C3-alkyl-,
or
R5 and R6 together with the nitrogen atom form a monocyclic heterocyclyl- having 4 to 6 ring atoms which itself may optionally be substituted by Ci-C3-alkyk
In accordance with a further embodiment, the present invention covers compounds of general formula (I), in which R8 represents Ci-C6-alkyk
In accordance with a further embodiment, the present invention covers compounds of general formula (I), in which R8 represents Ci-C3-alkyk
In accordance with a further embodiment, the present invention covers compounds of general formula (I), in which R9 represents Ci-C6-alkyl- or -Nh .
In accordance with a further embodiment, the present invention covers compounds of general formula (I), in which R9 represents Ci-C3-alkyl- or -Nh . In accordance with a further embodiment, the present invention covers compounds of general formula (I), in which Rx represents Ci-C6-alkoxy-Ci-C6-alkyk
In accordance with a further embodiment, the present invention covers compounds of general formula (I), in which Rx represents Ci-C3-alkoxy-Ci-C3-alkyk
Of selected interest are those compounds of formula (I), in which
X represents a nitrogen, a sulphur or an oxygene atom,
Y represents a sulphur or an oxygene atom,
R1 represents hydrogen, halogen, Ci-C6-alkyl, halo-Ci-C6-alkyl and cyano,
R2 represents fluorine or chlorine,
R3 represents hydrogen or Ci-C6-alkyl,
R4 represents hydrogen or represents Ci-C6-alkyl-, which may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of halogen, cyano, hydroxy, Ci-C3-alkoxy-, -IM H2, -N H-(Ci-C6-alkyl),
-N(Ci-C6-alkyl)2, -N H-(Ci-C6-alkyl)-Ci-C6-alkoxy, Ci-C6-alkyl-, Ci-C6-alkoxy-, -S(=0)2N H2, -C(=0)-R9, -C(=0)-N H-Rx, -N H-C(=0)-R9, -N H-S(=0)2-R9,
-S(=0)2-R9, -S(=0)(=N Ry)-Rx, -S(=0)-Rx,
C3-Cio-cycloalkyl- which itself may optionally be mono- or polysubstituted by dentical or different substituents from the group consisting of of halogen, cyano, nitro, hydroxy, amino, oxo, carboxy, Ci-C6-alkyl-, Ci-C6-alkoxy-, Ci-C6-alkoxy- Ci-C6-alkyl-, hydroxy-Ci-C6-alkyl-, Ci-C6-alkylamino-, Ci-C6-alkylcarbonylamino- , amino-Ci-C6-alkyl-, Ci-C6-alkylamino-Ci-C6-alkyl-, halo-Ci-C6-alkyl-, halo-Ci- C6-alkoxy-, C3-Cio-cycloalkyl-, phenyl-, halophenyl-, phenyl-Ci-C6-alkyl-, phenoxy-, pyridinyl-, -C(=0)-N R5R6, -N H-C(=0)-R8, -C(=0)-R7, -S(=0)2-N R5R6, -S(=0)-R8, -S(=0)(=N R5)-R6, -S(=0)2-R8, -N H-S(=0)2-R8, or a monocyclic heterocyclyl radical having 3 to 8 ring atoms, monocyclic heteroaryl- having 5 or 6 ring atoms which itself may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of halogen, amino, hydroxy, cyano, nitro, carboxy, Ci-C6-alkyl-, Ci-C6-alkoxy-, C1-C6- alkoxy-Ci-C6-alkyl-, hydroxy-Ci-C6-alkyl-, C1-C6- alkylamino-, amino-Ci-C6-alkyl-, Ci-C6-alkylamino-Ci-C6-alkyl, halo-Ci-C6-alkyl-, halo-Ci-C6-alkoxy-, C3-Cio-cycloalkyl and a monocyclic heterocyclyl radical having 3 to 8 ring atoms, monocyclic heterocyclyl- having 3 to 8 ring atoms which itself may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of halogen, amino, hydroxy, cyano, oxo, carboxy, Ci-C6-alkyl-,
-carboxy-Ci-C6-alkyl-, Ci-C6-alkoxy-, Ci-C6-alkoxy-Ci-C6-alkyl-, C1-C6- alkylamino-, amino-Ci-C6-alkyl-, Ci-C6-alkylamino-Ci-C6-alkyl-, hydroxy-Ci-C6- alkyl-, halo-Ci-C6-alkyl-, halo-Ci-C6-alkoxy-, C3-Cio-cycloalkyl- and a monocyclic heterocyclyl radical having 3 to 8 ring atoms, phenyl- which itself may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of halogen, amino, hydroxy, cyano, nitro, carboxy, Ci-C6-alkyl-, Ci-C6-alkoxy-, Ci-C6-alkoxy-Ci-C6-alkyl-, Ci- C6-alkyl-amino-, amino-Ci-C6-alkyl-, Ci-C6-alkylaminocarbonyl-, Ci-C6-alkyl- aminosulphonyl-, Ci-C6-alkylamino-Ci-C6-alkyl-, hydroxy-Ci-C6-alkyl-, halo-Ci-
C6-alkyl-, halo-Ci-C6-alkoxy-, C3-Cio-cycloalkyl- and a monocyclic heterocyclyl radical having 3 to 8 ring atoms, spirocycloalkyl-, heterospirocycloalkyl-, bicycloalkyl-, heterobicycloalkyl-, bridged cycloalkyi or a bridged heterocycloalkyi, naphthyl or bicyclic heteroaryl, or partially saturated bicyclic aryl- or heteroaryl,
each of which mentioned supra may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of halogen, cyano, nitro, hydroxy, amino, oxo, carboxy, Ci-C6-alkyl-, Ci-C6-alkoxy-, Ci-C6-alkoxy- Ci-C6-alkyl-, hydroxy-Ci-C6-alkyl-, Ci-C6-alkylamino-, Ci-C6-alkylcarbonylamino- , amino-Ci-C6-alkyl-, Ci-C6-alkylamino-Ci-C6-alkyl-, halo-Ci-C6-alkyl-, halo-Ci- C6-alkoxy-, C3-Cio-cycloalkyl-, phenyl-, halophenyl-, phenyl-Ci-C6-alkyl-, phenoxy-, pyridinyl-, -C(=0)-NR5R6, -NH-C(=0)-R8, -C(=0)-R7, -S(=0)2-NR5R6, -S(=0)-R8, -S(=0)(=NR5)-R6, -S(=0)2-R8, -NH-S(=0)2-R8, or a monocyclic heterocyclyl radical having 3 to 8 ring atoms,
or
represents C3-Cio-cycloalkyl- which may optionally be mono- or polysubstituted by dentical or different substituents from the group consisting of of of halogen, cyano, nitro, hydroxy, amino, oxo, carboxy, Ci-C6-alkyl-, Ci-C6-alkoxy-, C1-C6- alkoxy-Ci-C6-alkyl-, hydroxy-Ci-C6-alkyl-, Ci-C6-alkylamino-, C1-C6- alkylcarbonylamino-, amino-Ci-C6-alkyl-, Ci-C6-alkylamino-Ci-C6-alkyl-, halo-Ci- C6-alkyl-, halo-Ci-C6-alkoxy-, C3-Cio-cycloalkyl-, phenyl-, halophenyl-, phenyl- d-Ce-alkyl-, phenoxy-, pyridinyl-, -C(=0)-NR5R6, -NH-C(=0)-R8, -C(=0)-R7, - S(=0)2-NR5R6, -S(=0)-R8, -S(=0)(=NR5)-R6, -S(=0)2-R8, -NH-S(=0)2-R8, or a monocyclic heterocyclyl radical having 3 to 8 ring atoms,
or
represents monocyclic heteroaryl- having 5 or 6 ring atoms which may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of of halogen, cyano, nitro, hydroxy, amino, carboxy, Ci-C6-alkyl-, Ci-C6-alkoxy-, Ci-C6-alkoxy-Ci-C6-alkyl-, hydroxy-Ci-C6-alkyl-, C1-C6- alkylamino-, Ci-C6-alkylcarbonylamino-, amino-Ci-C6-alkyl-, Ci-C6-alkylamino- Ci-C6-alkyl-, halo-Ci-C6-alkyl-, halo-Ci-C6-alkoxy-, C3-Cio-cycloalkyl-, phenyl-, halophenyl-, phenyl-d-Ce-alkyl-, phenoxy-, pyridinyl-, -C(=0)-NR5R6, -NH- C(=0)-R8, -C(=0)-R7, -S(=0)2-NR5R6, -S(=0)-R8, -S(=0)(=NR5)-R6, -S(=0)2-R8, -NH-S(=0)2-R8, or a monocyclic heterocyclyl radical having 3 to 8 ring atoms, or represents monocyclic heterocyclyl- having 3 to 8 ring atoms which may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of of halogen, cyano, nitro, hydroxy, amino, oxo, carboxy, Ci-C6-alkyl-, Ci-C6-alkoxy-, Ci-C6-alkoxy-Ci-C6-alkyl-, hydroxy-Ci-C6-alkyl-, Ci- C6-alkylamino-, Ci-C6-alkylcarbonylamino-, amino-Ci-C6-alkyl-, C1-C6- alkylamino-Ci-C6-alkyl-, halo-Ci-C6-alkyl-, halo-Ci-C6-alkoxy-, C3-Cio-cycloalkyl-, phenyl-, halophenyl-, phenyl-Ci-C6-alkyl-, phenoxy-, pyridinyl-, -C(=0)-NR5R6, - NH-C(=0)-R8, -C(=0)-R7, -S(=0)2-NR5R6, -S(=0)-R8,
-S(=0)(=NR5)-R6, -S(=0)2-R8, -NH-S(=0)2-R8, or a monocyclic heterocyclyl radical having 3 to 8 ring atoms,
or
represents phenyl- which may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of of halogen, cyano, nitro, hydroxy, amino, carboxy, Ci-C6-alkyl-, Ci-C6-alkoxy-, Ci-C6-alkoxy-Ci-C6- alkyl-, hydroxy-Ci-C6-alkyl-, Ci-C6-alkylamino-, Ci-C6-alkylcarbonylamino-, amino-Ci-C6-alkyl-, Ci-C6-alkylamino-Ci-C6-alkyl-, halo-Ci-C6-alkyl-, halo-Ci-C6- alkoxy-, C3-Cio-cycloalkyl-, phenyl-, halophenyl-, phenyl-Ci-C6-alkyl-, phenoxy-, pyridinyl-, -C(=0)-NR5R6, -NH-C(=0)-R8, -C(=0)-R7, -S(=0)2-NR5R6, -S(=0)- R8, -S(=0)(=NR5)-R6, -S(=0)2-R8, -NH-S(=0)2-R8, or a monocyclic heterocyclyl radical having 3 to 8 ring atoms,
or
represents a spirocycloalkyl radical, a heterospirocycloalkyl radical, a
bicycloalkyl, a heterobicycloalkyl radical, a bridged cycloalkyl radical or a bridged heterocycloalkyl radical, a naphthyl radical or a bicyclic heteroaryl radical, or a partially saturated bicyclic aryl- or heteroaryl radical, where the radicals mentioned may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of of halogen, cyano, nitro, hydroxy, amino, oxo, carboxy, Ci-C6-alkyl-, Ci-C6-alkoxy-, Ci-C6-alkoxy-Ci-C6- alkyl-, hydroxy-Ci-C6-alkyl-, Ci-C6-alkylamino-, Ci-C6-alkylcarbonylamino-, amino-Ci-C6-alkyl-, Ci-C6-alkylamino-Ci-C6-alkyl-, halo-Ci-C6-alkyl-, halo-Ci-C6- alkoxy-, C3-Cio-cycloalkyl-, phenyl-, halophenyl-, phenyl-Ci-C6-alkyl-, phenoxy-, pyridinyl-, -C(=0)-NR5R6, -NH-C(=0)-R8, -C(=0)-R7, -S(=0)2-NR5R6, -S(=0)- R8, -S(=0)(=NR5)-R6, -S(=0)2-R8, -NH-S(=0)2-R8, or a monocyclic heterocyclyl radical having 3 to 8 ring atoms,
or R3 and R4 together with the nitrogen atom form a 4 to 10 membered heterocycloalkyi ring, which may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of of halogen, cyano, nitro, hydroxy, amino, oxo, carboxy, Ci-C6-alkyl-, Ci-C6-alkoxy-, Ci-C6-alkoxy-Ci-C6-alkyl-, hydroxy-Ci-C6-alkyl-, Ci-C6-alkylamino-, Ci-C6-alkylcarbonylamino-, amino-Ci-
C6-alkyl-, Ci-C6-alkylamino-Ci-C6-alkyl-, halo-Ci-C6-alkyl-, halo-Ci-C6-alkoxy-, C3-Cio-cycloalkyl-, phenyl-, halophenyl-, phenyl-Ci-C6-alkyl-, phenoxy-, pyridinyl- , -C(=0)-NR5R6, -NH-C(=0)-R8, -C(=0)-R7, -S(=0)2-NR5R6, -S(=0)-R8, - S(=0)(=NR5)-R6, -S(=0)2-R8, -NH-S(=0)2-R8, or a monocyclic heterocyclyl radical having 3 to 8 ring atoms,
R5 and R6 independently of one another represent hydrogen, Ci-C3-alkyl-, cyclopropyl- or di-Ci-C3-alkylamino-Ci-C3-alkyl-,
R7 represents hydroxy, Ci-C6-alkyl-, Ci-C6-alkoxy-, halo-Ci-C3-alkyl-, hydroxy-Ci-
C3-alkyl-, Ci-C3-alkoxy-Ci-C3-alkyl-, Cs-Cs-cycloalkyl-, phenyl-, monocyclic heterocyclyl- having 3 to 8 ring atoms or monocyclic heteroaryl- having 5 or 6 ring atoms where phenyl-, heteroaryl- and heterocyclyl- may optionally be mono- or disubstituted by halogen, Ci-C3-alkoxy- or Ci-C3-alkyl-,
R8 represents Ci-C6-alkyl-,
R9 represents Ci-C6-alkyl-, -NH2, -NH-Ci-C6-alkyl, -N(Ci-C6-alkyl)2, or Ci-C6-alkoxy- d-Ce-alkyl-,
or
represents monocyclic heterocyclyl- having 3 to 8 ring atoms which itself may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of of halogen, cyano, nitro, hydroxy, amino, oxo, carboxy, Ci-C6-alkyl-, Ci-C6-alkoxy-, Ci-C6-alkoxy-Ci-C6-alkyl-, hydroxy-Ci-C6-alkyl-, Ci-
C6-alkylamino-, Ci-C6-alkylcarbonylamino-, amino-Ci-C6-alkyl-, C1-C6- alkylamino-Ci-C6-alkyl-, halo-Ci-C6-alkyl-, halo-Ci-C6-alkoxy-, C3-Cio-cycloalkyl-, phenyl-, halophenyl-, phenyl-Ci-C6-alkyl-, phenoxy-, pyridinyl-, -C(=0)-NR5R6, - NH-C(=0)-R8, -C(=0)-R7, -S(=0)2-NR5R6, -S(=0)-R8, -S(=0)(=NR5)- R6, -S(=0)2-R8, -NH-S(=0)2-R8, or a monocyclic heterocyclyl radical having 3 to
8 ring atoms,
Rx represents Ci-C6-alkyl- or Ci-C6-alkoxy-Ci-C6-alkyl-,
Ry represents hydrogen, halo-Ci-C6-alkyl, Ci-C6-alkyl, Ci-C6-alkyl substituted with
C3-C6-cycloalkyl,
and their polymorphs, enantiomers, diastereomers, racemates, tautomers, solvates, physiologically acceptable salts and solvates of these salts Of selected interest are those compounds of formula (I), in which
X represents an oxygene atom,
Y represents a sulphur or an oxygene atom,
R1 represents hydrogen, halogen, Ci-C6-alkyl, halo-Ci-C6-alkyl and cyano, R2 represents fluorine,
R3 represents hydrogen or Ci-C6-alkyl,
R4 represents hydrogen or represents Ci-C6-alkyl-, which may optionally be mono- or disubstituted by identical or different substituents from the group consisting of halogen, cyano, hydroxy, Ci-C3-alkoxy-, -NH2, -NH-(Ci-C6-alkyl), -N(Ci-C6-alkyl)2, -NH-(Ci-C6-alkyl)-Ci-C6-alkoxy, Ci-C6-alkyl-, Ci-C6-alkoxy-,
-S(=0)2N H2, -C(=0)-R9, -C(=0)-N H-Rx, -N H-C(=0)-R9, -N H-S(=0)2-R9,
-S(=0)2-R9, -S(=0)(=N Ry)-Rx, -S(=0)-Rx, C3-Cio-cycloalkyl-,
monocyclic heteroaryl- having 5 or 6 ring atoms which itself may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of halogen, cyano, nitro, hydroxy, amino, carboxy, Ci-C6-alkyl-,
Ci-C6-alkoxy-, Ci-C6-alkoxy-Ci-C6-alkyl-, hydroxy-Ci-C6-alkyl-, C1-C6- alkylamino-, Ci-C6-alkylcarbonylamino-, amino-Ci-C6-alkyl-, Ci-C6-alkylamino- Ci-C6-alkyl-, halo-Ci-C6-alkyl-, halo-Ci-C6-alkoxy-, C3-Cio-cycloalkyl-, phenyl-, halophenyl-, phenyl-d-Ce-alkyl-, phenoxy-, pyridinyl-, -C(=0)-N R5R6, -N H- C(=0)-R8, -C(=0)-R7, -S(=0)2-N R5R6, -S(=0)-R8, -S(=0)(=N R5)-R6, -S(=0)2-R8,
-N H-S(=0)2-R8, or a monocyclic heterocyclyl radical having 3 to 8 ring atoms, monocyclic heterocyclyl- having 4 to 8 ring atoms which itself may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of halogen, cyano, nitro, hydroxy, amino, oxo, carboxy, Ci-C6-alkyl-,
Ci-C6-alkoxy-, Ci-C6-alkoxy-Ci-C6-alkyl-, hydroxy-Ci-C6-alkyl-, C1-C6- alkylamino-, Ci-C6-alkylcarbonylamino-, amino-Ci-C6-alkyl-, Ci-C6-alkylamino- Ci-C6-alkyl-, halo-Ci-C6-alkyl-, halo-Ci-C6-alkoxy-, C3-Cio-cycloalkyl-, phenyl-, halophenyl-, phenyl-d-Ce-alkyl-, phenoxy-, pyridinyl-, -C(=0)-N R5R6, -N H- C(=0)-R8, -C(=0)-R7, -S(=0)2-N R5R6, -S(=0)-R8, -S(=0)(=N R5)-R6, -S(=0)2-R8,
-N H-S(=0)2-R8, or a monocyclic heterocyclyl radical having 3 to 8 ring atoms, phenyl- which itself may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of halogen, cyano, nitro, hydroxy, amino, carboxy, Ci-C6-alkyl-, Ci-C6-alkoxy-, Ci- C6-alkoxy-Ci-C6-alkyl-, hydroxy-Ci-C6-alkyl-, Ci-C6-alkylamino-, C1-C6- alkylcarbonylamino-, amino-Ci-C6-alkyl-, Ci-C6-alkylamino-Ci-C6-alkyl-, halo-Ci C6-alkyl-, halo-Ci-C6-alkoxy-, C3-Cio-cycloalkyl-, phenyl-, halophenyl-, phenyl- d-Ce-alkyl-, phenoxy-, pyridinyl-, -C(=0)-NR5R6, -NH-C(=0)-R8, -C(=0)-R7, - S(=0)2-NR5R6, -S(=0)-R8, -S(=0)(=NR5)-R6, -S(=0)2-R8, -NH-S(=0)2-R8, or a monocyclic heterocyclyl radical having 3 to 8 ring atoms, spirocycloalkyl-, heterospirocycloalkyl-, bicycloalkyl-, heterobicycloalkyl-, bridged cycloalkyi or a bridged heterocycloalkyi, naphthyl or bicyclic heteroaryl, or partially saturated bicyclic aryl- or heteroaryl, each of which mentioned may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of halogen, cyano, nitro, hydroxy, amino, oxo, carboxy, Ci- C6-alkyl-, Ci-C6-alkoxy-, Ci-C6-alkoxy-Ci-C6-alkyl-, hydroxy-Ci-C6-alkyl-, C1-C6- alkylamino-, Ci-C6-alkylcarbonylamino-, amino-Ci-C6-alkyl-, Ci-C6-alkylamino- Ci-C6-alkyl-, halo-Ci-C6-alkyl-, halo-Ci-C6-alkoxy-, C3-Cio-cycloalkyl-, phenyl-, halophenyl-, phenyl-d-Ce-alkyl-, phenoxy-, pyridinyl-, -C(=0)-NR5R6, -NH- C(=0)-R8, -C(=0)-R7, -S(=0)2-NR5R6, -S(=0)-R8, -S(=0)(=NR5)-R6, -S(=0)2-R8 -NH-S(=0)2-R8, or a monocyclic heterocyclyl radical having 3 to 8 ring atoms, or
represents monocyclic heterocyclyl- having 3 to 8 ring atoms which may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of halogen, cyano, nitro, hydroxy, amino, oxo, carboxy, Ci- C6-alkyl-, Ci-C6-alkoxy-, Ci-C6-alkoxy-Ci-C6-alkyl-, hydroxy-Ci-C6-alkyl-, C1-C6- alkylamino-, Ci-C6-alkylcarbonylamino-, amino-Ci-C6-alkyl-, Ci-C6-alkylamino- Ci-C6-alkyl-, halo-Ci-C6-alkyl-, halo-Ci-C6-alkoxy-, C3-Cio-cycloalkyl-, phenyl-, halophenyl-, phenyl-d-Ce-alkyl-, phenoxy-, pyridinyl-, -C(=0)-NR5R6, -NH- C(=0)-R8, -C(=0)-R7, -S(=0)2-NR5R6, -S(=0)-R8, -S(=0)(=NR5)-R6, -S(=0)2-R8 -NH-S(=0)2-R8, or a monocyclic heterocyclyl radical having 3 to 8 ring atoms, or
represents phenyl- which may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of halogen, cyano, nitro, hydroxy, amino, carboxy, Ci-C6-alkyl-, Ci-C6-alkoxy-, Ci- C6-alkoxy-Ci-C6-alkyl-, hydroxy-Ci-C6-alkyl-, Ci-C6-alkylamino-, C1-C6- alkylcarbonylamino-, amino-Ci-C6-alkyl-, Ci-C6-alkylamino-Ci-C6-alkyl-, halo-Ci- C6-alkyl-, halo-Ci-C6-alkoxy-, C3-Cio-cycloalkyl-, phenyl-, halophenyl-, phenyl- d-Ce-alkyl-, phenoxy-, pyridinyl-, -C(=0)-NR5R6, -NH-C(=0)-R8, -C(=0)-R7, - S(=0)2-NR5R6, -S(=0)-R8, -S(=0)(=NR5)-R6, -S(=0)2-R8, -NH-S(=0)2-R8, or a monocyclic heterocyclyl radical having 3 to 8 ring atoms,
or
R3 and R4 together with the nitrogen atom form a 4 to 10 membered heterocycloalkyl ring, which may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of halogen, cyano, nitro, hydroxy, amino, oxo, carboxy, Ci-C6-alkyl-, Ci-C6-alkoxy-, Ci-C6-alkoxy-Ci-C6-alkyl-, hydroxy-Ci- C6-alkyl-, Ci-C6-alkylamino-, Ci-C6-alkylcarbonylamino-, amino-Ci-C6-alkyl-, Ci- C6-alkylamino-Ci-C6-alkyl-, halo-Ci-C6-alkyl-, halo-Ci-C6-alkoxy-, C3-C10- cycloalkyl-, phenyl-, halophenyl-, phenyl-Ci-C6-alkyl-, phenoxy-, pyridinyl-, - C(=0)-NR5R6, -NH-C(=0)-R8, -C(=0)-R7, -S(=0)2-NR5R6, -S(=0)-R8, - S(=0)(=NR5)-R6, -S(=0)2-R8, -NH-S(=0)2-R8, or a monocyclic heterocyclyl radical having 3 to 8 ring atoms,
or
together with the nitrogen atom form a heterospirocycloalkyl or
heterobicycloalkyi group, each of which mentioned may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of halogen, cyano, nitro, hydroxy, amino, oxo, carboxy, Ci-C6-alkyl-, Ci-C6-alkoxy-, Ci-C6-alkoxy-Ci-C6-alkyl-, hydroxy-Ci-C6-alkyl-, Ci-C6-alkylamino-, C1-C6- alkylcarbonylamino-, amino-Ci-C6-alkyl-, Ci-C6-alkylamino-Ci-C6-alkyl-, halo-Ci- C6-alkyl-, halo-Ci-C6-alkoxy-, C3-Cio-cycloalkyl-, phenyl-, halophenyl-, phenyl- d-Ce-alkyl-, phenoxy-, pyridinyl-, -C(=0)-NR5R6, -NH-C(=0)-R8, -C(=0)-R7, - S(=0)2-NR5R6, -S(=0)-R8, -S(=0)(=NR5)-R6, -S(=0)2-R8, -NH-S(=0)2-R8, or a monocyclic heterocyclyl radical having 3 to 8 ring atoms,
R5 and R6 independently of one another represent hydrogen, Ci-C3-alkyl-, cyclopropyl- or di-Ci-C3-alkylamino-Ci-C3-alkyl-,
R7 represents hydroxy, Ci-C6-alkyl-, Ci-C6-alkoxy-, halo-Ci-C3-alkyl-, hydroxy-Ci-
C3-alkyl-, Ci-C3-alkoxy-Ci-C3-alkyl-, Cs-Cs-cycloalkyl-, phenyl-, monocyclic heterocyclyl- having 3 to 8 ring atoms or monocyclic heteroaryl- having 5 or 6 ring atoms where phenyl-, heteroaryl- and heterocyclyl- may optionally be mono- or disubstituted by halogen, Ci-C3-alkoxy- or Ci-C3-alkyl-, R8 represents Ci-C6-alkyl-,
R9 represents Ci-C6-alkyl-, -NH2, -NH-Ci-C6-alkyl, -N(Ci-C6-alkyl)2, Ci-C6-alkoxy- d-Ce-alkyl-,
or
represents monocyclic heterocyclyl- having 3 to 8 ring atoms which itself may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of halogen, cyano, nitro, hydroxy, amino, oxo, carboxy, Ci- C6-alkyl-, Ci-C6-alkoxy-, Ci-C6-alkoxy-Ci-C6-alkyl-, hydroxy-Ci-C6-alkyl-, C1-C6- alkylamino-, Ci-C6-alkylcarbonylamino-, amino-Ci-C6-alkyl-, Ci-C6-alkylamino- Ci-C6-alkyl-, halo-Ci-C6-alkyl-, halo-Ci-C6-alkoxy-, C3-Cio-cycloalkyl-, phenyl-, halophenyl-, phenyl-d-Ce-alkyl-, phenoxy-, pyridinyl-, -C(=0)-NR5R6, -NH- C(=0)-R8, -C(=0)-R7, -S(=0)2-NR5R6, -S(=0)-R8, -S(=0)(=NR5)-R6, -S(=0)2-R8, -NH-S(=0)2-R8, or a monocyclic heterocyclyl radical having 3 to 8 ring atoms, Rx represents Ci-C6-alkyl- or Ci-C6-alkoxy-Ci-C6-alkyl-,
Ry represents hydrogen, halo-Ci-C6-alkyl, Ci-C6-alkyl, Ci-C6-alkyl substituted with
C3-C6-cycloalkyl,
and their polymorphs, enantiomers, diastereomers, racemates, tautomers, solvates, physiologically acceptable salts and solvates of these salts.
Of selected interest are those compounds of formula (I), in which
X represents a sulphur or an oxygene atom,
Y represents a sulphur or an oxygene atom,
R1 represents hydrogen, halogen, Ci-C6-alkyl, halo-Ci-C6-alkyl or cyano,
R2 represents fluorine,
R3 represents hydrogen or Ci-C6-alkyl,
R4 represents hydrogen or represents Ci-C6-alkyl-, which may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of
halogen, cyano, hydroxy, Ci-C3-alkoxy-, -N(Ci-C6-alkyl)2, -C(=0)-R9,
-C(=0)-NH-Rx, -C(=0)-NR5R6, -NH-C(=0)-R9, -NH-S(=0)2-R9 or -S(=0)2-R9, or a C3-Cio-cycloalkyl- which itself may optionally substituted by hydroxy, or a monocyclic heteroaryl- having 5 or 6 ring atoms which itself may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of cyano, Ci-C6-alkyl-, Ci-C6-alkoxy- or Ci-C6-alkoxy-Ci-C6-alkyl-, or a monocyclic heterocyclyl- having 3 to 8 ring atoms which itself may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of halogen, hydroxyl, carboxy, Ci-C6-alkyl- or hydroxy-Ci-C6-alkyl-, or a phenyl, 5 to 12 membered heterospirocycloalkyl or partially saturated bicyclic heteroaryl, each of which mentioned supra may optionally be substituted by -C(=0)-NR5R6, or
R4 represents a C3-Cio-cycloalkyl- which may optionally substituted by
-C(=0)-NR5R6 or Ci-C6-alkoxy-Ci-C6-alkyl- or
represents a monocyclic heteroaryl- having 5 or 6 ring atoms which may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of halogen, Ci-C6-alkyl-, halo-Ci-C6-alkyl-,
C3-Cio-cycloalkyl-,-C(=0)-NR5R6, -S(=0)2-R8 or a monocyclic heterocyclyl radical having 3 to 8 ring atoms,
or
represents a monocyclic heterocyclyl- having 3 to 8 ring atoms which may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of halogen, oxo, Ci-C6-alkylamino-Ci-C6-alkyl or monocyclic heterocyclyl radical having 3 to 8 ring atoms
or
represents a phenyl- which may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of halogen,
Ci-C6-alkoxy- or halo-Ci-C6-alkyl-,
or
represents a 5 to 12 membered heterospirocycloalkyl radical, or a bridged heterocycloalkyl radical,
or
R3 and R4 together with the nitrogen atom form a 4 to 10 membered heterocycloalkyl or a
5 to 12 membered heterospirocycloalkyl, which may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of halogen, Ci-C6-alkyl-, Ci-C6-alkoxy- or hydroxy-Ci-C6-alkyl-, R5 and R6 independently of one another represent hydrogen or Ci-C3-alkyl-,
R5 and R6 together with the nitrogen atom form a monocyclic heterocyclyl- having 3 to 8 ring atoms which itself may optionally be substituted by Ci-C6-alkyl-,
R8 represents Ci-C6-alkyl-,
R9 represents d-Ce-alkyl- or -NH2,
Rx represents Ci-C6-alkoxy-Ci-C6-alkyl-,
and their polymorphs, enantiomers, diastereomers, racemates, tautomers, solvates, physiologically acceptable salts and solvates of these salts.
Of selected interest are those compounds of formula (I), in which
X represents a sulphur or an oxygene atom,
Y represents a sulphur or an oxygene atom,
R1 represents hydrogen, halogen, Ci-C6-alkyl, halo-Ci-C6-alkyl or cyano,
R2 represents fluorine,
R3 represents hydrogen or Ci-C3-alkyl,
R4 represents hydrogen or represents Ci-C6-alkyl-, which may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of
halogen, cyano, hydroxy, Ci-C3-alkoxy-, -N(Ci-C3-alkyl)2,
-C(=0)-R9, -C(=0)-NH-Rx, -C(=0)-NR5R6, -NH-C(=0)-R9, -NH-S(=0)2-R9, -S(=0)2-R9, or a C3-C7-cycloalkyl- which itself may optionally substituted by hydroxy, or a monocyclic heteroaryl- having 5 or 6 ring atoms which itself may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of cyano, Ci-C6-alkyl-, Ci-C6-alkoxy- or Ci-C6-alkoxy-Ci-C6-alkyl-, or a monocyclic heterocyclyl- having 4 to 6 ring atoms which itself may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of halogen, hydroxyl, carboxy, Ci-C6-alkyl- or hydroxy-Ci- Ce-alkyl-, or a phenyl, 7 to 9 membered heterospirocycloalkyi or partially saturated bicyclic heteroaryl, each of which mentioned supra may optionally be substituted by -C(=0)-NR5R6, or R4 represents a C3-C7-cycloalkyl- which may optionally substituted by
-C(=0)-NR5R6 or Ci-C6-alkoxy-Ci-C6-alkyl- or
represents a monocyclic heteroaryl- having 5 or 6 ring atoms which may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of halogen, Ci-C3-alkyl-, halo-Ci-C3-alkyl-, C3-C7-cycloalkyl-, -C(=0)-NR5R6, -S(=0)2-R8 or a monocyclic heterocyclyl radical having 4 to 6 ring atoms,
or
represents a monocyclic heterocyclyl- having 4 to 6 ring atoms which may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of halogen, oxo, Ci-C3-alkylamino-Ci-C3-alkyl or monocyclic heterocyclyl radical having 4 to 6 ring atoms
or
represents a phenyl- which may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of halogen,
Ci-C3-alkoxy- or halo-Ci-C3-alkyl-,
or
represents a 7 to 9 membered heterospirocycloalkyl radical, or a bridged heterocycloalkyl radical,
or
R3 and R4 together with the nitrogen atom form a 4 to 6 membered heterocycloalkyl or a
7 to 9 membered heterospirocycloalkyl, which may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of halogen, Ci-C3-alkyl-, Ci-C3-alkoxy-, hydroxy-Ci-C3-alkyl-,
R5 and R6 independently of one another represent hydrogen or Ci-C3-alkyl-,
R5 and R6 together with the nitrogen atom form a monocyclic heterocyclyl- having 4 to 6 ring atoms which itself may optionally be substituted by Ci-C3-alkyl-,
R8 represents Ci-C3-alkyl-,
R9 represents d-Cs-alkyl- or -NH2,
Rx represents Ci-C3-alkoxy-Ci-C3-alkyl-,
and their polymorphs, enantiomers, diastereomers, racemates, tautomers, solvates, physiologically acceptable salts and solvates of these salts. Of special interest are those compounds of formula (I) in which
X represents an oxygene atom,
Y represents a sulphur or an oxygene atom,
R1 represents hydrogen, chlorine, bromine, methyl-, trifluoromethyl and cyano, R2 represents fluorine,
R3 represents hydrogen or methyl,
R4 represents hydrogen, Ci-C6-alkyl-, which may optionally be mono- or
disubstituted by identical or different substituents from the group consisting of halogen, cyano, hydroxy, Ci-C3-alkoxy-, -NH2, -NH-(Ci-C6-alkyl),
-N(Ci-C6-alkyl)2, -NH-(Ci-C6-alkyl)-Ci-C6-alkoxy, Ci-C6-alkyl-, Ci-C6-alkoxy-,
-S(=0)2NH2, -C(=0)-R9, -C(=0)-NH-R9, -NH-C(=0)-Rx, -NH-S(=0)2-R9, -S(=0)2-R9,
Figure imgf000041_0001
C H ,
Figure imgf000041_0002
Figure imgf000041_0003
Figure imgf000041_0004
Figure imgf000042_0001
R9 represents methyl, -NH2 or -CH2-CH2-O-CH3 or
Figure imgf000043_0001
Rx represents methyl or -CH2-CH2-0-CH3,
R10 represents hydrogen, methyl, methoxy and cyano
R11 represents hydrogen and trifluoromethyl,
R12 represents hydrogen, fluorine and methoxy,
R13 represents hydrogen and methyl,
R14 represents hydrogen and -CH2-0-CH3,
where "*" denotes the point of attachment to the remainder of the molecule,
and their polymorphs, enantiomers, diastereomers, racemates, tautomers, solvates, physiologically acceptable salts and solvates of these salts.
Further of selected interest are those compounds of formula (I) in which
X represents an oxygene atom,
Y represents an oxygene atom,
R1 represents hydrogen, chlorine, bromine, methyl-, trifluoromethyl and cyano,
R2 represents fluorine,
R3 represents hydrogen or methyl,
R4 represents hydrogen, Ci-C6-alkyl-, which may optionally be mono- or
disubstituted by identical or different substituents from the group consisting of halogen, cyano, hydroxy, Ci-C3-alkoxy-, -IMH2, -NH-(Ci-C6-alkyl),
-N(Ci-C6-alkyl)2, -NH-(Ci-C6-alkyl)-Ci-C6-alkoxy, Ci-C6-alkyl-, Ci-C6-alkoxy-, -S(=0)2NH2, -C(=0)-R9, -C(=0)-NH-Rx, -NH-C(=0)-R9, -NH-S(=0)2-R9, -S(=0)2-R9,
Figure imgf000044_0001
 R4 represents
Figure imgf000045_0001
or
R3 and R4 together with the nitrogen atom form the group
Figure imgf000045_0002
represents methyl, -IMH2 or -CH2-CH2-0-CH3 or
Figure imgf000045_0003
represents methyl or -Ch -Ch -O-CHs,
R 1100 represents hydrogen, methyl, methoxy and cyano
11 represents hydrogen and trifluoromethyl,
12 represents hydrogen, fluorine and methoxy,
13 represents hydrogen and methyl,
14 represents hydrogen and -CH2-O-CH3,
where "*" denotes the point of attachment to the remainder of the molecule, and their polymorphs, enantiomers, diastereomers, racemates, tautomers, solvates, physiologically acceptable salts and solvates of these salts. Thereof of special interest are those compounds of formula (I), in which
X represents an oxygene atom,
Y represents an oxygene atom,
R1 represents chlorine, bromine, cyano and trifluoromethyl,
R2 represents fluorine,
R3 represents hydrogen,
R4 represents hydrogen, Ci-C6-alkyl-, which may optionally be mono- or
disubstituted by identical or different substituents from the group consisting of halogen, cyano, hydroxy, Ci-C3-alkoxy-, -NH2, -NH-(Ci-C6-alkyl),
-N(Ci-C6-alkyl)2, -NH-(Ci-C6-alkyl)-Ci-C6-alkoxy, Ci-C6-alkyl-, Ci-C6-alkoxy-, -S(=0)2NH2, -C(=0)-R9, -C(=0)-NH-Rx, -NH-C(=0)-R9, -NH-S(=0)2-R9, -S(=0)2-R9, or
Figure imgf000046_0001
Figure imgf000046_0002
or R4 represents
Figure imgf000047_0001
R9 represents methyl, -NH2 or -CH2-CH2-O-CH3 or
Figure imgf000047_0002
Rx represents methyl or -CH2-CH2-O-CH3,
R10 represents hydrogen,
R13 represents hydrogen,
where "*" denotes the point of attachment to the remainder of the molecule, and their polymorphs, enantiomers, diastereomers, racemates, tautomers, solvates, physiologically acceptable salts and solvates of these salts.
Further of selected interest are those compounds of formula (I) in which
X represents an oxygene atom,
Y represents a sulphur atom,
R1 represents trifluoromethyl,
R2 represents fluorine,
R3 represents hydrogen,
R4 represents Ci-C3-alkyl-, which may optionally be mono-substituted by
-N(Ci-C3-alkyl)2, Ci-C6-alkoxy-, or
Figure imgf000047_0003
where "*" denotes the point of attachment to the remainder of the molecule, and their polymorphs, enantiomers, diastereomers, racemates, tautomers, solvates, physiologically acceptable salts and solvates of these salts. Compounds of most interest are those as follows:
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[3- (morpholin-4-yl)propyl]urea;
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(2- methoxyethyl)urea;
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[3- (methylsulfonyl)propyl]urea;
1 -(2,2-difluoroethyl)-3-(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4- yl]oxy}phenyl)urea;
- N3-[(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4- yl]oxy}phenyl)carbamoyl]-beta-alaninamide;
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3- (pyridin-4-ylmethyl)urea;
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[(1 - hydroxycyclopropyl)methyl]urea;
4-{[(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4- yl]oxy}phenyl)carbamoyl]amino}butanamide;
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(3- methoxypropyl)urea;
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[2- (morpholin-4-yl)-2-oxoethyl]urea;
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3- (pyridin-3-ylmethyl)urea;
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3- (pyridin-2-ylmethyl)urea;
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[2- (pyridin-4-yl)ethyl]urea;
(+/-)-1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[2- hydroxy-3-(morpholin-4-yl)propyl]urea;
- (+/-)-1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3- (tetrahydrofuran-2-ylmethyl)urea;
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3- (tetrahydro-2H-pyran-4-ylmethyl)urea;
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(1 H- 1 ,2,3-triazol-5-ylmethyl)urea; N2-[(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrTolo[2,3-b]pyridin-4- yl]oxy}phenyl)carbamoyl]glycinamide;
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[2- (morpholin-4-yl)ethyl]urea;
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[2- (piperidin-1 -yl)ethyl]urea;
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[3- (piperidin-1 -yl)propyl]urea;
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[3- (dimethylamino)propyl]urea;
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[2- (dimethylamino)ethyl]urea;
l -iS.S-difluoro^-i^-itrifluoromethy -I H-pyrrolop.S-^pyridin^-y oxyJpheny -S-til .l - dioxidothietan-3-yl)methyl]urea;
N-(2-{[(3!5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4- yl]oxy}phenyl)carbamoyl]amino}ethyl)acetamide;
(+/-)-1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[1 (morpholin-4-yl)propan-2-yl]urea;
(+/-)-1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[2 (morpholin-4-yl)propyl]urea;
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[2- (methylsulfonyl)ethyl]urea;
3-{[(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4- yl]oxy}phenyl)carbamoyl]amino}propane-1 -sulfonamide;
3-(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-1 -methyl 1 -[2-(morpholin-4-yl)ethyl]urea;
N-(2-{[(3!5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4- yl]oxy}phenyl)carbamoyl]amino}ethyl)methanesulfonamide;
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-pyridin 3-ylurea;
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[3- (trifluoromethyl)phenyl]urea;
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(1 ,3,4- thiadiazol-2-yl)urea; 1 -(3,5 lifluoro^^[3-(trifluoromethyl)-1 H-pyrTolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[2- fluoro-5-(trifluoromethyl)phenyl]urea;
l -iS.S-difluoro^-i^-itrifluoromethy -I H-pyrroloP.S-blpyridin^-y oxyJpheny -S- pyridazin-3-ylurea;
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(2- methoxyphenyl)urea;
1 -(2,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[3- (morpholin-4-yl)propyl]urea;
1 -(2,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[2- (morpholin-4-yl)ethyl]urea;
1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[3-(piperidin-' yl)propyl]urea;
1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[2- (dimethylamino)ethyl]urea;
1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[2-(piperidin-' yl)ethyl]urea;
1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[3-(morpholin yl)propyl]urea;
1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(2- methoxyethyl)urea;
1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-ethylurea;
1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[2-(morpholin yl)ethyl]urea;
1 -benzyl-3-{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}urea
1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(pyrimidin-5- ylmethyl)urea;
1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(pyridin-4- ylmethyl)urea;
1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(2- cyanoethyl)urea;
1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(3- methylbutyl)urea;
1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(1 ,2-oxazol-3 yl)urea; 1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-pyridazin-3- ylurea;
1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}urea;
N-{2-[({4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}carbamoyl)- amino]ethyl}acetamide;
1 -{4-[(3-bromo-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[2- (dimethylamino)ethyl]urea;
1 -{4-[(3-bromo-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[3- (dimethylamino)propyl]urea;
1 -{4-[(3-bromo-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-butylurea;
1 -benzyl-3-{4-[(3-bromo-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}urea;
1 -(2,3-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[3- (morpholin-4-yl)propyl]urea;
1 -(2,3-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[2- (morpholin-4-yl)ethyl]urea;
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[2- (dimethylamino)ethyl]thiourea;
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[2- (morpholin-4-yl)ethyl]thiourea;
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(2- methoxyethyl)thiourea;
l -iS.S-difluoro^-i^-itrifluoromethy -I H-pyrroloP.S-blpyridin^-y oxyJpheny -S- ethylthiourea
and
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[3- (morpholin-4-yl)propyl]thiourea,
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3- (oxetan-3-ylmethyl)urea
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)urea
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3- methylurea
- 3-(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-1 ,1 - dimethylurea
- N-(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4- yl]oxy}phenyl)morpholine-4-carboxamide - N-iS.S-difluoro^-i^-itrifluoromethy -I H-pyrroloP.S-blpyridin^-y oxyJphenylH- methylpiperazine-1 -carboxamide
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[2-(4- methylpiperazin-1 -yl)-2-oxoethyl]urea
- N-iS.S-difluoro^-i^-itrifluoromethy -I H-pyrroloP.S-blpyridin^-y oxyJphenyl^-oxa-e- azaspiro[3.3]heptane-6-carboxamide
- N2-[(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4- yl]oxy}phenyl)carbamoyl]-N-methylglycinamide
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(1 ,2- thiazol-4-yl)urea
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(1 - methyl-1 H-pyrazol-4-yl)urea
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(6- methylpyridin-3-yl)urea
- 1 -[(1 -acetylazetidin-3-yl)methyl]-3-(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3- b]pyridin-4-yl]oxy}phenyl)urea
- N2-[(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4- yl]oxy}phenyl)carbamoyl]-N-(2-methoxyethyl)glycinamide
- (+/-)-1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3- [(1 ,1 -dioxidothietan-2-yl)methyl]urea
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(2- methylpyrimidin-5-yl)urea
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(1 H- pyrazol-4-yl)urea
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[2-(1 - oxa-6-azaspiro[3.3]hept-6-yl)ethyl]urea
- l -iS.S-difluoro^-i^-itrifluoromethy -I H-pyrrolop.S-^pyridin^-y oxyJpheny -S-p-il .l - dioxido-1 -thia-6-azaspiro[3.3]hept-6-yl)ethyl]urea
- (+/-)-1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3- (2-oxopyrrolidin-3-yl)urea
- (+/-)-1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3- (1 ,1 -dioxidotetrahydrothiophen-3-yl)urea
- (+/-)-1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3- (5-oxopyrrolidin-3-yl)urea - 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(1 ,1 - dioxidotetrahydro-2H-thiopyran-4-yl)urea
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(1 H- pyrazol-3-ylmethyl)urea
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(1 H- imidazol-2-ylmethyl)urea
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[(1 - methyl-1 H-pyrazol-3-yl)methyl]urea
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(1 ,3- thiazol-2-ylmethyl)urea
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3- (pyrimidin-4-ylmethyl)urea
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[(2- methylpyridin-4-yl)methyl]urea
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3- (pyridazin-3-ylmethyl)urea
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[(5- methyl-1 H-imidazol-2-yl)methyl]urea
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-{[3- (methoxymethyl)-l ,2,4-oxadiazol-5-yl]methyl}urea
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[(5- methyl-4H-1 ,2,4-triazol-3-yl)methyl]urea
- (+/-)-1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3- (tetrahydrofuran-3-yl)urea
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[(3R)- tetrahydrofuran-3-yl]urea
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[(3S)- tetrahydrofuran-3-yl]urea
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-{3- [(2R!6R)-2,6-dimethylmorpholin-4-yl]propyl}urea
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[(1 - methyl-1 H-imidazol-2-yl)methyl]urea
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[(4- methyl-1 ,2,5-oxadiazol-3-yl)methyl]urea - 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[(2- methoxypyridin-4-yl)methyl]urea
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[(1 - methyl-1 H-imidazol-4-yl)methyl]urea
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-{2- [(2RS!6RS)-2,6-dimethylmorpholin-4-yl]ethyl}urea
- 1 -[(2-cyanopyridin-4-yl)methyl]-3-(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3- b]pyridin-4-yl]oxy}phenyl)urea
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3- (pyridazin-4-ylmethyl)urea
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(1 ,2,4- oxadiazol-3-ylmethyl)urea
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(1 ,3- oxazol-2-ylmethyl)urea
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(1 ,3- thiazol-5-ylmethyl)urea
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[2-(2- oxa-6-azaspiro[3.3]hept-6-yl)ethyl]urea
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[(5- methyl-1 ,3,4-oxadiazol-2-yl)methyl]urea
- N-(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-N'-[(3- methyloxetan-3-yl)methyl]urea
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(5- methylpyridazin-3-yl)urea
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[(2R)- tetrahydrofuran-2-ylmethyl]urea
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[(2S)- tetrahydrofuran-2-ylmethyl]urea
- (+/-)-1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3- [(5,5-dimethyltetrahydrofuran-2-yl)methyl]urea
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3- (tetrahydro-2H-pyran-4-yl)urea
- (+/-)-1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3- (tetrahydro-2H-pyran-2-ylmethyl)urea - (+/-)-1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3- (tetrahydro-2H-pyran-3-yl)urea
- (+/-)-1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3- [(2-methyltetrahydrofuran-2-yl)methyl]urea
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(2- methoxy-2-methylpropyl)urea
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[2- methyl-2-(morpholin-4-yl)propyl]urea
- (+/-)-1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3- (tetrahydro-2H-pyran-3-ylmethyl)urea
- (+/-)-1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3- (tetrahydrofuran-3-ylmethyl)urea
- 1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-pyridazin-4- ylurea
- 1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(6- methylpyridazin-3-yl)urea
- 1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-pyridin-3-ylurea
- 1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-pyridin-2-ylurea
- 1 -[3,5-difluoro-4-(1 H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-3-[2-(piperidin-1 -yl)ethyl]urea - N3-{[3,5-difluoro-4-(1 H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]carbamoyl}-beta- alaninamide
- 1 -[3,5-difluoro-4-(1 H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-3-(1 H-1 ,2,3-triazol-5- ylmethyl)urea
- 1 -[3,5-difluoro-4-(1 H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-3-[3- (dimethylamino)propyl]urea
- 4-({[3,5-difluoro-4-(1 H-pyrrolo[2,3-b]pyridin-4- yloxy)phenyl]carbamoyl}amino)butanamide
- 1 -[3,5-difluoro-4-(1 H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-3-(2-methoxyethyl)urea
- 1 -[3,5-difluoro-4-(1 H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-3-(pyridin-2-ylmethyl)urea - 1 -[3,5-difluoro-4-(1 H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-3-[3- (methylsulfonyl)propyl]urea
- 1 -[3,5-difluoro-4-(1 H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-3-[2- (dimethylamino)ethyl]urea
- 1 -[3,5-difluoro-4-(1 H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-3-[3-(piperidin-1 - yl)propyl]urea - 1 -{4-[(3-bromo-1 H-pyrrolo[2!3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(3- methoxypropyl)urea
- 1 -{4-[(3-bromo-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[(1 -methyl-1 H- pyrazol-3-yl)methyl]urea
- 1 -{4-[(3-bromo-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(1 ,3-thiazol-2- ylmethyl)urea
- 1 -{4-[(3-bromo-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(1 H-pyrazol-3- ylmethyl)urea
- N3-({4-[(3-bromo-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}carbamoyl)-beta- alaninamide
- 1 -{4-[(3-bromo-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[2-(piperidin-1 - yl)ethyl]urea
- N-{2-[({4-[(3-bromo-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}carbamoyl)amino]ethyl}methanesulfonamide
- 1 -{4-[(3-bromo-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[3-(morpholin-4- yl)propyl]urea
- N-{2-[({4-[(3-bromo-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}carbamoyl)amino]ethyl}acetamide
- 1 -{4-[(3-bromo-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[2-(morpholin-4- yl)-2-oxoethyl]urea
- 1 -{4-[(3-bromo-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(pyridin-2- ylmethyl)urea
- 1 -{4-[(3-bromo-1 H-pyrrolo[2!3-b]pyridin-4-yl)oxy]-3!5-difluorophenyl}-3-[(1 ,1 - dioxidothietan-3-yl)methyl]urea
- 1 -{4-[(3-bromo-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(2- methoxyethyl)urea
- 1 -{4-[(3-bromo-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(pyridin-4- ylmethyl)urea
- N2-({4-[(3-bromo-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}carbamoyl)glycinamide
- 1 -{4-[(3-bromo-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[3-(piperidin-1 - yl)propyl]urea
- 1 -{4-[(3-bromo-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(1 H-1 ,2,3-triazol- 4-ylmethyl)urea - 1 -{4-[(3-bromo-1 H-pyrrolo[2!3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[3- (methylsulfonyl)propyl]urea
- 4-[({4-[(3-bromo-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}carbamoyl)amino]butanamide
- 1 -{4-[(3-bromo-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[2-(4- methylpiperazin-1 -yl)-2-oxoethyl]urea
- 1 -{3,5-difluoro-4-[(3-methyl-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl}-3-[2- (dimethylamino)ethyl]urea
- (+/-)- 1 -{4-[(3-cyano-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3- (tetrahydrofuran-3-yl)urea
- 1 -{4-[(3-cyano-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[2- (dimethylamino)ethyl]urea
- (+/-)- 1 -{4-[(3-cyano-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3- (tetrahydrofuran-2-ylmethyl)urea
- 1 -{4-[(3-cyano-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(3- methoxypropyl)urea
- 1 -{4-[(3-cyano-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[3-(morpholin-4- yl)propyl]urea
- 1 -{4-[(3-cyano-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[(1 -methyl-1 H- pyrazol-3-yl)methyl]urea
- 1 -{4-[(3-cyano-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(1 ,3-thiazol-2- ylmethyl)urea
- 1 -{4-[(3-cyano-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(pyridin-4- ylmethyl)urea
- 1 -{4-[(3-cyano-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(2- methoxyethyl)urea
- 1 -{4-[(3-cyano-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(1 H-pyrazol-3- ylmethyl)urea
- (+/-)-1 -{4-[(3-bromo-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3- (tetrahydrofuran-3-yl)urea
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(6- methoxypyridazin-3-yl)urea
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(6,7- dihydro-5H-cyclopenta[c]pyridazin-3-yl)urea - 1 -(6-bromopyridazin-3-yl)-3-{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}urea
- (+/-)-1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3- (tetrahydrofuran-2-ylmethyl)urea
- 1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[(3S)- tetrahydrofuran-3-yl]urea
- 1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[(1 -methyl-1 H- pyrazol-3-yl)methyl]urea
- 1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(2- oxaspiro[3.3]hept-6-yl)urea
- 1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[6- (difluoromethyl)pyridazin-3-yl]urea
- (+/-)-1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3- (tetrahydrofuran-3-yl)urea
- 1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(3- methoxypropyl)urea
- 1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[(3R)- tetrahydrofuran-3-yl]urea
- 1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(1 H-pyrazol-3- ylmethyl)urea
- 1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3!5-difluorophenyl}-3-(2!2,2- trifluoroethyl)urea
- (+/-)-N-{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3- [(dimethylamino)methyl]pyrrolidine-1 -carboxamide
- 1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[(4-methyl-1 ,2,5- oxadiazol-3-yl)methyl]urea
- 1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(2- fluoroethyl)urea
- N-{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-2-oxa-7- azaspiro[3.5]nonane-7-carboxamide
- 1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(2,2- difluoroethyl)urea
- 1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[(4-methyl-1 H- imidazol-2-yl)methyl]urea - 1 -{4-[(3-chloro-1 H-pyrrolo[2!3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(6- methoxypyridazin-3-yl)urea
- 1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(1 ,3,4-thiadiazol-
2- yl)urea
- 1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(1 ,3-thiazol-2- ylmethyl)urea
- 1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(6-iodopyridazin-
3- yl)urea
- 1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[6-(morpholin-4- yl)pyridazin-3-yl]urea
- 1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(5- methylpyridazin-3-yl)urea
- 1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(6- cyclopropylpyridazin-3-yl)urea
- (+/-)-1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3- (1 -methyl-5-oxopyrrolidin-3-yl)urea
- N-iS.S-difluoro^-i^-itrifluoromethy -I H-pyrroloP.S-blpyridin^-y oxyJphenylH^- difluoropiperidine-1 -carboxamide
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[3- (propan-2-yloxy)propyl]urea
- N-(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3- methoxyazetidine-1 -carboxamide
- N-(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-1 -oxa-6- azaspiro[3.3]heptane-6-carboxamide
- N-(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-2-oxa-6- azaspiro[3.5]nonane-6-carboxamide
- N-iS.S-difluoro^-i^-itrifluoromethy -I H-pyrrolop.S-^pyridin^-y oxyJpheny -N'-i^- (propan-2-yl)oxetan-3-yl]methyl}urea
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[3- methyl-3-(morpholin-4-yl)butyl]urea
- 1 -{4-[(3-bromo-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[(4-methyl-1 ,2,5- oxadiazol-3-yl)methyl]urea
- (+/-) 1 -{4-[(3-bromo-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3- (tetrahydrofuran-2-ylmethyl)urea - 1 -{4-[(3-bromo-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-pyridazin-3- ylurea
- 1 -{4-[(3-bromo-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(6- methylpyridazin-3-yl)urea
- 1 -{4-[(3-bromo-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(1 ,3,4-thiadiazol- 2-yl)urea
- 1 -{4-[(3-bromo-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[(4-methyl-1 H- imidazol-2-yl)methyl]urea
- 1 -{4-[(3-cyano-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(6- methylpyridazin-3-yl)urea
- 1 -{4-[(3-cyano-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-pyridazin-3- ylurea
- 1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-{1 -[(4- methylpiperazin-1 -yl)carbonyl]cyclopropyl}urea
- 1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[1 -(morpholin-4- ylcarbonyl)cyclopropyl]urea
- 1 -[({4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}carbamoyl)amino]-N,N-dimethylcyclopropanecarboxamide
- 1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[1 -(piperidin-1 - ylcarbonyl)cyclopropyl]urea
- (+/-)1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(1 - methoxypropan-2-yl)urea
- 1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[1 - (methoxymethyl)cyclopropyl]urea
- (+/-) 1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3!5-difluorophenyl}-3-(2,2- dimethyltetrahydrofuran-3-yl)urea
- (+/-) 1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(5- oxaspiro[3.4]oct-7-yl)urea
- (+/-) 1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[(trans)-4- (pyrrolidin-1 -yl)tetrahydrofuran-3-yl]urea
- N2-({4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}carbamoyl)-N,N- dimethylalaninamide
- N2-({4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}carbamoyl)-N,N- dimethylvalinamide - (+/-)1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(3- methyltetrahydrofuran-3-yl)urea
- (+/-)1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[7- oxabicyclo[2.2.1 ]hept-2-yl]urea - mixture of isomers
- (+/-)-1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(1 -methyl- 2-oxopyrrolidin-3-yl)urea
- N-(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)azetidine- 1 -carboxamide
- N-(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4- yl]oxy}phenyl)pyrrolidine-1 -carboxamide
- N-(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-N'-[(3- fluorooxetan-3-yl)methyl]urea
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(2- hydroxy-2-methylpropyl)urea
- (+/-)-1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3- [2-hydroxy-2-methyl-3-(morpholin-4-yl)propyl]urea
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(3- hydroxy-3-methylbutyl)urea
- 6-[({4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}carbamoyl)amino]-N-methylpyridazine-3-carboxamide
- 1 -(6-tert-butylpyridazin-3-yl)-3-{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}urea
- 6-[({4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}carbamoyl)amino]-N,N-dimethylpyridazine-3-carboxamide
- 1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[6- (trifluoromethyl)pyridazin-3-yl]urea
- 1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[6- (methylsulfonyl)pyridazin-3-yl]urea
- (+/-)-N-(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-N'- (2-fluoro-3-methoxypropyl)urea
- (+/-)-N-(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-N'- [(4,4-dimethyloxetan-2-yl)methyl]urea
- (+/-)-N-(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-N'- (2-fluoro-3-methoxy-2-methylpropyl)urea - N-iS.S-difluoro^^p-itrifluoromethylJ-I H-pyrTolop.S-blpyridin^-ylloxylphenylJ-N'-tP- (hydroxymethyl)oxetan-3-yl]methyl}urea
- N-iS.S-difluoro^^p-itrifluoromethylJ-I H-pyrTolop.S-blpyridin^-ylloxylphenylJ-N'-IiS- hydroxyoxetan-3-yl)methyl]urea
- N-(2,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-N'-[(3- methyloxetan-3-yl)methyl]urea
- N^-KS-bromo-I H-pyrrolop.S-blpyridin^-y sulfanyll-S.S-difluorophenylJ-N'-p- (morpholin-4-yl)-2-oxoethyl]urea
- N-{4-[(3-bromo-1 H-pyrrolo[2!3-b]pyridin-4-yl)sulfanyl]-3,5-difluorophenyl}-N'-(2- methoxyethyl)urea
- N-{4-[(3-bromo-1 H-pyrrolo[2,3-b]pyridin-4-yl)sulfanyl]-3,5-difluorophenyl}-N'-ethylurea
- N-{4-[(3-bromo-1 H-pyrrolo[2,3-b]pyridin-4-yl)sulfanyl]-3,5-difluorophenyl}morpholine-4- carboxamide
- N-(3,5-difluoro-4-{[3-(propan-2-yl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-N'-[(3- fluorooxetan-3-yl)methyl]urea
- N-iS^-difluoro^p-iS^^-trifluoropropylJ-I H^yrrolop^-blpyridin^-ylloxylphenylJ-N'- [(3-fluorooxetan-3-yl)methyl]urea
- (+/-)-N-[3,5-difluoro-4-({3-[1 ,1 ,1 -trifluoropropan-2-yl]-1 H-pyrrolo[2,3-b]pyridin-4- yl}oxy)phenyl]-N'-[(3-fluorooxetan-3-yl)methyl]urea
- N-(3,5-difluoro-4-{[3-(propan-2-yl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-N'-(2- methoxyethyl)urea
- N-(3,5-difluoro-4-{[3-(propan-2-yl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-N'-[(3- methyloxetan-3-yl)methyl]urea
- N-(3,5-difluoro-4-{[3-(propan-2-yl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-N'-{[3- (propan-2-yl)oxetan-3-yl]methyl}urea
- N-(3,5-difluoro-4-{[3-(propan-2-yl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)morpholine- 4-carboxamide
- N-(3,5-difluoro-4-{[3-(propan-2-yl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-N'-[2- (morpholin-4-yl)-2-oxoethyl]urea
- (+/-)-N-[3,5-difluoro-4-({3-[1 ,1 ,1 -trifluoropropan-2-yl]-1 H-pyrrolo[2,3-b]pyridin-4- yl}oxy)phenyl]-N'-(2-methoxyethyl)urea
- (+/-)-N-[4-({3-(butan-2-yl)-1 H-pyrrolo[2!3-b]pyridin-4-yl}oxy)-3,5-difluorophenyl]-N'-(2- methoxyethyl)urea
- (+/-)-N-[3!5-difluoro-4-({3-(3-methylbutan-2-yl)-1 H-pyrrolo[2,3-b]pyridin-4- yl}oxy)phenyl]-N'-(2-methoxyethyl)urea - N-(3!5-difluoro-4-{[3-(pentan-3-yl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-N'-(2- methoxyethyl)urea
- N-(3,5-difluoro-4-{[3-(2-methylpropyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-N'-(2- methoxyethyl)urea
- (+/-)-N-[3!5-difluoro-4-({3-[4!4,4-trifluorobutan-2-yl]-1 H-pyrrolo[2,3-b]pyridin-4- yl}oxy)phenyl]-N'-(2-methoxyethyl)urea
- N-{4-[(3-bromo-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-2-methylazetidine- 1 -carboxamide
- N-{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}azetidine-1 - carboxamide
- N'-{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-N,N-dimethylurea
- (+/-)-N-{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3!5-difluorophenyl}-4,4-difluoro- 3-(hydroxymethyl)piperidine-1 -carboxamide
- N-{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-N'-(1 -methoxy-2- methylpropan-2-yl)urea
- (+/-)-N-{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-N'-1 - oxaspiro[4.4]nonan-6-ylurea - mixture of isomers
- (+/-)-N-{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-N'-[1 - (morpholin-4-yl)-1 -oxopropan-2-yl]urea
and their polymorphs, enantiomers, diastereomers, racemates, tautomers, solvates, physiologically acceptable salts and solvates of these salts.
The compounds of general formula (I) of the present invention can be converted to any salt, preferably pharmaceutically acceptable salts, as described herein, by any method which is known to the person skilled in the art. Similarly, any salt of a compound of general formula (I) of the present invention can be converted into the free compound, by any method which is known to the person skilled in the art.
Compounds of general formula (I) of the present invention demonstrate a valuable
pharmacological spectrum of action, which could not have been predicted. Compounds of the present invention have surprisingly been found to effectively inhibit MAP4K1 and it is possible therefore that said compounds be used for the treatment or prophylaxis of diseases, preferably cancer or conditions with dysregulated immune responses or other disorders associated with aberrant MAP4K1 signaling, in humans and animals. Disorders and conditions particularly suitable for treatment with an MAP4K1 inhibitor of the present invention are liquid and solid tumours, such as cancers of the breast, respiratory tract, brain, reproductive organs, digestive tract, urinary tract, eye, liver, skin, head and neck, thyroid, parathyroid and their distant metastases. Those disorders also include lymphomas, sarcomas, and leukaemias.
Examples of breast cancers include, but are not limited to, triple negative breast cancer, invasive ductal carcinoma, invasive lobular carcinoma, ductal carcinoma in situ, and lobular carcinoma in situ.
Examples of cancers of the respiratory tract include, but are not limited to, small-cell and non- small-cell lung carcinoma, as well as bronchial adenoma and pleuropulmonary blastoma.
Examples of brain cancers include, but are not limited to, brain stem and hypophtalmic glioma, cerebellar and cerebral astrocytoma, glioblastoma, medulloblastoma, ependymoma, as well as neuroectodermal and pineal tumour.
Tumours of the male reproductive organs include, but are not limited to, prostate and testicular cancer.
Tumours of the female reproductive organs include, but are not limited to, endometrial, cervical, ovarian, vaginal, and vulvar cancer, as well as sarcoma of the uterus.
Examples of ovarian cancer include, but are not limited to serous tumour, endometrioid tumour, mucinous cystadenocarcinoma, granulosa cell tumour, Sertoli-Leydig cell tumour and arrhenoblastoma.
Examples of cervical cancer include, but are not limited to squamous cell carcinoma, adenocarcinoma, adenosquamous carcinoma, small cell carcinoma, neuroendocrine tumour, glassy cell carcinoma and villoglandular adenocarcinoma.
Tumours of the digestive tract include, but are not limited to, anal, colon, colorectal, esophageal, gallbladder, gastric, pancreatic, rectal, small-intestine, and salivary gland cancers. Examples of esophageal cancer include, but are not limited to esophageal cell carcinomas and adenocarcinomas, as well as squamous cell carcinomas, leiomyosarcoma, malignant melanoma, rhabdomyosarcoma and lymphoma.
Examples of gastric cancer include, but are not limited to intestinal type and diffuse type gastric adenocarcinoma.
Examples of pancreatic cancer include, but are not limited to ductal adenocarcinoma, adenosquamous carcinomas and pancreatic endocrine tumours.
Tumours of the urinary tract include, but are not limited to, bladder, penile, kidney, renal pelvis, ureter, urethral and human papillary renal cancers.
Examples of kidney cancer include, but are not limited to renal cell carcinoma, urothelial cell carcinoma, juxtaglomerular cell tumour (reninoma), angiomyolipoma, renal oncocytoma, Bellini duct carcinoma, clear-cell sarcoma of the kidney, mesoblastic nephroma and Wilms' tumour. Examples of bladder cancer include, but are not limited to transitional cell carcinoma, squamous cell carcinoma, adenocarcinoma, sarcoma and small cell carcinoma.
Eye cancers include, but are not limited to, intraocular melanoma and retinoblastoma.
Examples of liver cancers include, but are not limited to, hepatocellular carcinoma (liver cell carcinomas with or without fibrolamellar variant), cholangiocarcinoma (intrahepatic bile duct carcinoma), and mixed hepatocellular cholangiocarcinoma.
Skin cancers include, but are not limited to, squamous cell carcinoma, Kaposi's sarcoma, malignant melanoma, Merkel cell skin cancer, and non-melanoma skin cancer.
Head-and-neck cancers include, but are not limited to, squamous cell cancer of the head and neck, laryngeal, hypopharyngeal, nasopharyngeal, oropharyngeal cancer, salivary gland cancer, lip and oral cavity cancer and squamous cell.
Lymphomas include, but are not limited to, AIDS-related lymphoma, non-Hodgkin's lymphoma, cutaneous T-cell lymphoma, Burkitt lymphoma, Hodgkin's disease, and lymphoma of the central nervous system.
Sarcomas include, but are not limited to, sarcoma of the soft tissue, osteosarcoma, malignant fibrous histiocytoma, lymphosarcoma, and rhabdomyosarcoma.
Leukemias include, but are not limited to, acute myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, and hairy cell leukemia.
The term "treating" or "treatment" as stated throughout this document is used conventionally, for example the management or care of a subject for the purpose of combating, alleviating, reducing, relieving, improving the condition of a disease or disorder, such as a carcinoma. The compounds of the present invention can be used in particular in therapy and prevention, i.e. prophylaxis, of tumour growth and metastases, especially in solid tumours of all indications and stages with or without pre-treatment of the tumour growth.
Generally, the use of chemotherapeutic agents and/or anti-cancer agents in combination with a compound or pharmaceutical composition of the present invention will serve to:
1 . yield better efficacy in reducing the growth of a tumour or even eliminate the tumour as compared to administration of either agent alone,
2. provide for the administration of lesser amounts of the administered chemotherapeutic agents,
3. provide for a chemotherapeutic treatment that is well tolerated in the patient with fewer deleterious pharmacological complications than observed with single agent
chemotherapies and certain other combined therapies, 4. provide for treating a broader spectrum of different cancer types in mammals, especially humans,
5. provide for a higher response rate among treated patients,
6. provide for a longer survival time among treated patients compared to standard
chemotherapy treatments,
7. provide a longer time for tumour progression, and/or
8. yield efficacy and tolerability results at least as good as those of the agents used alone, compared to known instances where other cancer agent combinations produce antagonistic effects.
In addition, the compounds of general formula (I) of the present invention can also be used in combination with radiotherapy and/or surgical intervention.
In a further embodiment of the present invention, the compounds of general formula (I) of the present invention may be used to sensitize a cell to radiation, i.e. treatment of a cell with a compound of the present invention prior to radiation treatment of the cell renders the cell more susceptible to DNA damage and cell death than the cell would be in the absence of any treatment with a compound of the present invention. In one aspect, the cell is treated with at least one compound of general formula (I) of the present invention.
Thus, the present invention also provides a method of killing a cell, wherein a cell is
administered one or more compounds of the present invention in combination with
conventional radiation therapy. The present invention also provides a method of rendering a cell more susceptible to cell death, wherein the cell is treated with one or more compounds of general formula (I) of the present invention prior to the treatment of the cell to cause or induce cell death. In one aspect, after the cell is treated with one or more compounds of general formula (I) of the present invention, the cell is treated with at least one compound, or at least one method, or a combination thereof, in order to cause DNA damage for the purpose of inhibiting the function of the normal cell or killing the cell.
In other embodiments of the present invention, a cell is killed by treating the cell with at least one DNA damaging agent, i.e. after treating a cell with one or more compounds of general formula (I) of the present invention to sensitize the cell to cell death, the cell is treated with at least one DNA damaging agent to kill the cell. DNA damaging agents useful in the present invention include, but are not limited to, chemotherapeutic agents (e.g. cis platin), ionizing radiation (X-rays, ultraviolet radiation), carcinogenic agents, and mutagenic agents. In other embodiments, a cell is killed by treating the cell with at least one method to cause or induce DNA damage. Such methods include, but are not limited to, activation of a cell signalling pathway that results in DNA damage when the pathway is activated, inhibiting of a cell signalling pathway that results in DNA damage when the pathway is inhibited, and inducing a biochemical change in a cell, wherein the change results in DNA damage. By way of a non-limiting example, a DNA repair pathway in a cell can be inhibited, thereby preventing the repair of DNA damage and resulting in an abnormal accumulation of DNA damage in a cell. In one aspect of the invention, a compound of general formula (I) of the present invention is administered to a cell prior to the radiation or other induction of DNA damage in the cell. In another aspect of the invention, a compound of general formula (I) of the present invention is administered to a cell concomitantly with the radiation or other induction of DNA damage in the cell. In yet another aspect of the invention, a compound of general formula (I) of the present invention is administered to a cell immediately after radiation or other induction of DNA damage in the cell has begun.
In another aspect, the cell is in vitro. In another embodiment, the cell is in vivo. The compounds of the present invention can be administered as the sole pharmaceutical agent or in combination with one or more other pharmaceutically active ingredients where the combination causes no unacceptable adverse effects. The present invention also covers such pharmaceutical combinations. For example, the compounds of the present invention can be combined with: 131 1-chTNT, abarelix, abiraterone, aclarubicin, adalimumab, ado-trastuzumab emtansine, afatinib, aflibercept, aldesleukin, alectinib, alemtuzumab, alendronic acid, alitretinoin, altretamine, amifostine, aminoglutethimide, hexyl aminolevulinate, amrubicin, amsacrine, anastrozole, ancestim, anethole dithiolethione, anetumab ravtansine, angiotensin II, antithrombin III, aprepitant, arcitumomab, arglabin, arsenic trioxide, asparaginase, atezolizumab, axitinib, azacitidine, basiliximab, belotecan, bendamustine, besilesomab, belinostat, bevacizumab, bexarotene, bicalutamide, bisantrene, bleomycin, blinatumomab, bortezomib, buserelin, bosutinib, brentuximab vedotin, busulfan, cabazitaxel, cabozantinib, calcitonine, calcium folinate, calcium levofolinate, capecitabine, capromab, carbamazepine carboplatin, carboquone, carfilzomib, carmofur, carmustine, catumaxomab, celecoxib, celmoleukin, ceritinib, cetuximab, chlorambucil, chlormadinone, chlormethine, cidofovir, cinacalcet, cisplatin, cladribine, clodronic acid, clofarabine, cobimetinib, copanlisib , crisantaspase, crizotinib, cyclophosphamide, cyproterone, cytarabine, dacarbazine, dactinomycin, daratumumab, darbepoetin alfa, dabrafenib, dasatinib, daunorubicin, decitabine, degarelix, denileukin diftitox, denosumab, depreotide, deslorelin, dianhydrogalactitol, dexrazoxane, dibrospidium chloride, dianhydrogalactitol, diclofenac, dinutuximab, docetaxel, dolasetron, doxifluridine, doxorubicin, doxorubicin + estrone, dronabinol, eculizumab, edrecolomab, elliptinium acetate, elotuzumab, eltrombopag, endostatin, enocitabine, enzalutamide, epirubicin, epitiostanol, epoetin alfa, epoetin beta, epoetin zeta, eptaplatin, eribulin, erlotinib, esomeprazole, estradiol, estramustine, ethinylestradiol, etoposide, everolimus, exemestane, fadrozole, fentanyl, filgrastim, fluoxymesterone, floxuridine, fludarabine, fluorouracil, flutamide, folinic acid, formestane, fosaprepitant, fotemustine, fulvestrant, gadobutrol, gadoteridol, gadoteric acid meglumine, gadoversetamide, gadoxetic acid, gallium nitrate, ganirelix, gefitinib, gemcitabine, gemtuzumab, Glucarpidase, glutoxim, GM-CSF, goserelin, granisetron, granulocyte colony stimulating factor, histamine
dihydrochloride, histrelin, hydroxycarbamide, 1-125 seeds, lansoprazole, ibandronic acid, ibritumomab tiuxetan, ibrutinib, idarubicin, ifosfamide, imatinib, imiquimod, improsulfan, indisetron, incadronic acid, ingenol mebutate, interferon alfa, interferon beta, interferon gamma, iobitridol, iobenguane (1231), iomeprol, ipilimumab, irinotecan, Itraconazole, ixabepilone, ixazomib, lanreotide, lansoprazole, lapatinib, lasocholine, lenalidomide, lenvatinib, lenograstim, lentinan, letrozole, leuprorelin, levamisole, levonorgestrel, levothyroxine sodium, lisuride, lobaplatin, lomustine, lonidamine, masoprocol, medroxyprogesterone, megestrol, melarsoprol, melphalan, mepitiostane, mercaptopurine, mesna, methadone, methotrexate, methoxsalen, methylaminolevulinate, methylprednisolone, methyltestosterone, metirosine, mifamurtide, miltefosine, miriplatin, mitobronitol, mitoguazone, mitolactol, mitomycin, mitotane, mitoxantrone, mogamulizumab, molgramostim, mopidamol, morphine hydrochloride, morphine sulfate, nabilone, nabiximols, nafarelin, naloxone + pentazocine, naltrexone, nartograstim, necitumumab, nedaplatin, nelarabine, neridronic acid, netupitant/palonosetron, nivolumab, pentetreotide, nilotinib, nilutamide, nimorazole, nimotuzumab, nimustine, nintedanib, nitracrine, nivolumab, obinutuzumab, octreotide, ofatumumab, olaparib, olaratumab, omacetaxine mepesuccinate, omeprazole, ondansetron, oprelvekin, orgotein, orilotimod, osimertinib, oxaliplatin, oxycodone, oxymetholone, ozogamicine, p53 gene therapy, paclitaxel, palbociclib, palifermin, palladium-103 seed, palonosetron, pamidronic acid, panitumumab, panobinostat, pantoprazole, pazopanib, pegaspargase, PEG-epoetin beta (methoxy PEG-epoetin beta), pembrolizumab, pegfilgrastim, peginterferon alfa-2b, pembrolizumab, pemetrexed,
pentazocine, pentostatin, peplomycin, Perflubutane, perfosfamide, Pertuzumab, picibanil, pilocarpine, pirarubicin, pixantrone, plerixafor, plicamycin, poliglusam, polyestradiol phosphate, polyvinylpyrrolidone + sodium hyaluronate, polysaccharide-K, pomalidomide, ponatinib, porfimer sodium, pralatrexate, prednimustine, prednisone, procarbazine, procodazole, propranolol, quinagolide, rabeprazole, racotumomab, radium-223 chloride, radotinib, raloxifene, raltitrexed, ramosetron, ramucirumab, ranimustine, rasburicase, razoxane, refametinib , regorafenib, risedronic acid, rhenium-186 etidronate, rituximab, rolapitant, romidepsin, romiplostim, romurtide, roniciclib , samarium (153Sm) lexidronam, sargramostim, satumomab, secretin, siltuximab, sipuleucel-T, sizofiran, sobuzoxane, sodium glycididazole, sonidegib, sorafenib, stanozolol, streptozocin, sunitinib, talaporfin, talimogene laherparepvec, tamibarotene, tamoxifen, tapentadol, tasonermin, teceleukin, technetium (99mTc)
nofetumomab merpentan, 99mTc-HYNIC-[Tyr3]-octreotide, tegafur, tegafur + gimeracil + oteracil, temoporfin, temozolomide, temsirolimus, teniposide, testosterone, tetrofosmin, thalidomide, thiotepa, thymalfasin, thyrotropin alfa, tioguanine, tocilizumab, topotecan, toremifene, tositumomab, trabectedin, trametinib, tramadol, trastuzumab, trastuzumab emtansine, treosulfan, tretinoin, trifluridine + tipiracil, trilostane, triptorelin, trametinib, trofosfamide, thrombopoietin, tryptophan, ubenimex, valatinib , valrubicin, vandetanib, vapreotide, vemurafenib, vinblastine, vincristine, vindesine, vinflunine, vinorelbine, vismodegib, vorinostat, vorozole, yttrium-90 glass microspheres, zinostatin, zinostatin stimalamer, zoledronic acid, zorubicin.
The compounds of the invention can further be combined with other reagents targeting the immune system, such as immune checkpoint inhibitors, e.g. aPD-1/-L1 axis antagonists.
PD-1 , along with its ligands PD-L1 and PD-L2, function as negative regulators of T cell activation. MAP4K1 suppresses immune cell function. PD-L1 is overexpressed in many cancers and overexpression of PD-1 often occurs concomitantly in tumor infiltrating T cells. Thus results in attenuation of T cell activation and evasion of immune surveillance, which contributes to impaired antitumor immune responses. (Keir M E et al. (2008) Annu. Rev.
Immunol. 26:677).
In addition, the inventive compounds can also be used as a therapeutic in a variety of other disorders wherein MAP4K1 is involved such as, cardiovascular and lung diseases.
Accordingly, the compounds according to the invention are suitable for the treatment and/or prophylaxis in particular of cardiovascular, inflammatory and fibrotic disorders and of renal disorders, in particular of acute and chronic renal insufficiency, and also of acute and chronic renal failure.
Accordingly, the compounds according to the invention can be used in medicaments for the treatment and/or prophylaxis of cardiovascular, inflammatory and fibrotic disorders, renal disorders, in particular of acute and chronic renal insufficiency, and also of acute and chronic renal failure.
For the purpose of the present invention the term renal insufficiency comprises both acute and chronic manifestations of renal insufficiency, and also underlying or related renal disorders such as diabetic and non-diabetic nephropathies, hypertensive nephropathies, ischaemic renal disorders, renal hypoperfusion, intradialytic hypotension, obstructive uropathy, renal stenoses, glomerulopathies, glomerulonephritis (such as, for example, primary glomerulonephritides; minimal change glomerulonephritis (lipoidnephrosis); membranous glomerulonephritis; focal segmental glomerulosclerosis (FSGS); membrane-proliferative glomerulonephritis; crescentic glomerulonephritis; mesangioproliferative glomerulonephritis (IgA nephritis, Berger's disease); post-infectious glomerulonephritis; secondary glomerulonephritides: diabetes mellitus, lupus erythematosus, amyloidosis, Goodpasture syndrome, Wegener granulomatosis, Henoch- Schonlein purpura, microscopic polyangiitis, acute glomerulonephritis, pyelonephritis (for example as a result of: urolithiasis, benign prostate hyperplasia, diabetes, malformations, abuse of analgesics, Crohn's disease), glomerulosclerosis, arteriolonecrose of the kidney, tubulointerstitial diseases, nephropathic disorders such as primary and congenital or aquired renal disorder, Alport syndrome, nephritis, immunological kidney disorders such as kidney transplant rejection and immunocomplex-induced renal disorders, nephropathy induced by toxic substances, nephropathy induced by contrast agents, diabetic and non-diabetic nephropathy, renal cysts, nephrosclerosis, hypertensive nephrosclerosis and nephrotic syndrome which can be characterized diagnostically, for example by abnormally reduced creatinine and/or water excretion, abnormally elevated blood concentrations of urea, nitrogen, potassium and/or creatinine, altered activity of renal enzymes, for example glutamyl synthetase, altered urine osmolarity or urine volume, elevated microalbuminuria,
macroalbuminuria, lesions on glomerulae and arterioles, tubular dilatation,
hyperphosphataemia and/or the need for dialysis. The present invention also comprises the use of the compounds according to the invention for the treatment and/or prophylaxis of sequelae of renal insufficiency, for example pulmonary oedema, heart failure, uremia, anemia, electrolyte disturbances (for example hypercalemia, hyponatremia) and disturbances in bone and carbohydrate metabolism.
The present invention also comprises the use of the compounds according to the invention for the treatment and/or prevention of sequelae of renal insufficiency, for example pulmonary oedema, heart failure, uraemia, anaemia, electrolyte disturbances (for example hyperkalaemia, hyponatraemia) and disturbances in bone and carbohydrate metabolism.
The compounds according to the invention are further suitable for the treatment and/or prevention of polycystic kidney disease (PCKD) and of the syndrome of inappropriate ADH secretion (SIADH). Furthermore, the compounds according to the invention are also suitable for the treatment and/or prophylaxis of metabolic syndrome, hypertension, resistant hypertension, acute and chronic heart failure, coronary heart disease, stable and unstable angina pectoris, peripheral and cardiac vascular disorders, arrhythmias, atrial and ventricular arrhythmias and impaired conduction, for example atrioventricular blocks degrees l-lll (AB block l-lll), supraventricular tachyarrhythmia, atrial fibrillation, atrial flutter, ventricular fibrillation, ventricular flutter, ventricular tachyarrhythmia, Torsade de pointes tachycardia, atrial and ventricular
extrasystoles, AV-junctional extrasystoles, sick sinus syndrome, syncopes, AV-nodal re-entry tachycardia, Wolff-Parkinson-White syndrome, of acute coronary syndrome (ACS),
autoimmune cardiac disorders (pericarditis, endocarditis, valvolitis, aortitis, cardiomyopathies), shock such as cardiogenic shock, septic shock and anaphylactic shock, aneurysms, boxer cardiomyopathy (premature ventricular contraction (PVC)), for treatment and/or prophylaxis of thromboembolic disorders and ischaemias such as myocardial ischaemia, myocardial infarction, stroke, cardiac hypertrophy, transient and ischaemic attacks, preeclampsia, inflammatory cardiovascular disorders, spasms of the coronary arteries and peripheral arteries, oedema formation, for example pulmonary oedema, cerebral oedema, renal oedema or oedema caused by heart failure, peripheral circulatory disturbances, reperfusion damage, arterial and venous thromboses, myocardial insufficiency, endothelial dysfunction, to prevent restenoses, for example after thrombolysis therapies, percutaneous transluminal angioplasties (PTA), transluminal coronary angioplasties (PTCA), heart transplants and bypass operations, and also micro- and macrovascular damage (vasculitis), increased levels of fibrinogen and of low-density lipoprotein (LDL) and increased concentrations of plasminogen activator inhibitor 1 (PAI-1 ), and also for treatment and/or prophylaxis of erectile dysfunction and female sexual dysfunction.
In addition, the compounds according to the invention are also suitable for treatment and/or prophylaxis of asthmatic disorders, pulmonary arterial hypertension (PAH) and other forms of pulmonary hypertension (PH) including left-heart disease, HIV, sickle cell anaemia,
thromboembolisms (CTEPH), sarcoidosis, COPD or pulmonary fibrosis-associated pulmonary hypertension, chronic-obstructive pulmonary disease (COPD), acute respiratory distress syndrome (ARDS), acute lung injury (ALI), alpha-1 -antitrypsin deficiency (AATD), pulmonary fibrosis, pulmonary emphysema (for example pulmonary emphysema induced by cigarette smoke) and cystic fibrosis (CF).
The compounds described in the present invention are also active compounds for control of central nervous system disorders characterized by disturbances of the NO/cGMP system. They are suitable in particular for improving perception, concentration, learning or memory after cognitive impairments like those occurring in particular in association with
situations/diseases/syndromes such as mild cognitive impairment, age-associated learning and memory impairments, age-associated memory losses, vascular dementia, craniocerebral trauma, stroke, dementia occurring after strokes (post stroke dementia), post-traumatic craniocerebral trauma, general concentration impairments, concentration impairments in children with learning and memory problems, Alzheimer's disease, Lewy body dementia, dementia with degeneration of the frontal lobes including Pick's syndrome, Parkinson's disease, progressive dementia with corticobasal degeneration, amyolateral sclerosis (ALS), Huntington's disease, demyelinization, multiple sclerosis, thalamic degeneration, Creutzfeld- Jacob dementia, HIV dementia, schizophrenia with dementia or Korsakoff's psychosis. They are also suitable for treatment and/or prophylaxis of central nervous system disorders such as states of anxiety, tension and depression, CNS-related sexual dysfunctions and sleep disturbances, and for controlling pathological disturbances of the intake of food, stimulants and addictive substances.
The compounds according to the invention are furthermore also suitable for controlling cerebral blood flow and thus represent effective agents for controlling migraines. They are also suitable for the prophylaxis and control of sequelae of cerebral infarction (cerebral apoplexy) such as stroke, cerebral ischaemia and craniocerebral trauma. The compounds according to the invention can likewise be used for controlling states of pain and tinnitus.
In addition, the compounds according to the invention have anti-inflammatory action and can therefore be used as anti-inflammatory agents for treatment and/or prophylaxis of sepsis (SIRS), multiple organ failure (MODS, MOF), inflammatory disorders of the kidney, chronic intestinal inflammations (IBD, Crohn's disease, UC), pancreatitis, peritonitis, rheumatoid disorders, inflammatory skin disorders and inflammatory eye disorders.
Furthermore, the compounds according to the invention can also be used for treatment and/or prophylaxis of autoimmune diseases.
The compounds according to the invention are also suitable for treatment and/or prophylaxis of fibrotic disorders of the internal organs, for example the lung, the heart, the kidney, the bone marrow and in particular the liver, and also dermatological fibroses and fibrotic eye disorders. In the context of the present invention, the term fibrotic disorders includes in particular the following terms: hepatic fibrosis, cirrhosis of the liver, pulmonary fibrosis, endomyocardial fibrosis, nephropathy, glomerulonephritis, interstitial renal fibrosis, fibrotic damage resulting from diabetes, bone marrow fibrosis and similar fibrotic disorders, scleroderma, morphea, keloids, hypertrophic scarring (also following surgical procedures), naevi, diabetic retinopathy, proliferative vitroretinopathy and disorders of the connective tissue (for example sarcoidosis). The compounds according to the invention are also suitable for controlling postoperative scarring, for example as a result of glaucoma operations. The compounds according to the invention can also be used cosmetically for ageing and keratinized skin.
Moreover, the compounds according to the invention are suitable for treatment and/or prophylaxis of hepatitis, neoplasms, osteoporosis, glaucoma and gastroparesis.
The present invention further provides for the use of the compounds according to the invention for treatment and/or prophylaxis of disorders, especially the disorders mentioned above.
The present invention further provides for the use of the compounds according to the invention for the treatment and/or prophylaxis of chronic renal disorders, acute and chronic renal insufficiency, diabetic, inflammatory or hypertensive nephropaties, fibrotic disorders, cardiac insufficiency, angina pectoris, hypertension, pulmonary hypertension, ischemias, vascular disorders, thromboembolic disorders, arteriosclerosis, sickle cell anemia, erectile dysfunction, benign prostate hyperplasia, dysuria associated with benign prostate hyperplasia, Huntington, dementia, Alzheimer and Creutzfeld-Jakob.
The present invention further provides a method for treatment and/or prophylaxis of disorders, in particular the disorders mentioned above, using an effective amount of at least one of the compounds according to the invention.
The present invention further provides a method for the treatment and/or prophylaxis of chronic renal disorders, acute and chronic renal insufficiency, diabetic, inflammatory or hypertensive nephropathies, fibrotic disorders, cardiac insufficiency, angina pectoris, hypertension, pulmonary hypertension, ischemias, vascular disorders, thromboembolic disorders, arteriosclerosis, sickle cell anemia, erectile dysfunction, benign prostate hyperplasia, dysuria associated with benign prostate hyperplasia, Huntington, dementia, Alzheimer and Creutzfeld- Jakob.
In another embodiment, the inventive compounds can also be used to treat or to prevent uterine fibroids (uterine leiomyoma or uterine myoma) in women.
Uterine fibroids are benign tumors of the myometrium, the smooth muscle layer of the uterus. Uterine fibroids grow slowly during a women's life, and their growth is dependent on the female sexual hormones estradiol and progesterone [Kawaguchi K et al. Immunohistochemical analysis of oestrogen receptors, progesterone receptors and Ki-67 in leiomyoma and myometrium during the menstrual cycle and pregnancy Virchows Arch A Pathol Anat
Histopathol. 1991 ;419(4):309-15.], therefore the highest prevalence of uterine fibroids with approx. 70% and >80% in white and afro-american women, respectively, is found from 35 years of age onwards to menopause, when they shrink due to reduced hormone levels [Baird DD et al. High cumulative incidence of uterine leiomyoma in black and white women:
Ultrasound evidence Am J Obstet Gynecol. 2003 Jan;188(1 ):100-7.]. Approx 30% and 45% of white and afro-american women, respectively, do show clinically relevant symptoms due to their fibroids, which are heavy menstrual bleeding and pain, which is related to the menstrual cycle [David M et al. Myoma-associated pain frequency and intensity: a retrospective evaluation of 1548 myoma patients. Eur J Obstet Gynecol Reprod Biol. 2016 Apr; 199: 137-40]. Heavy menstrual bleeding in this respect is defined by a blood loss of more than 80 mL in a menstrual bleeding period [Fraser IS et al. The FIGO Recommendations on Terminologies and Definitions for Normal and Abnormal Uterine Bleeding, Semin Reprod Med 201 1 ; 29(5): 383- 390]. Submucosal position of the uterine fibroids, e.g. those located directly below the endometrium, seems to have an even more severe effect on uterine bleeding, which may result in anemia in affected women [Yang JH et al. Impact of submucous myoma on the severity of anemia. Fertil Steril. 201 1 Apr;95(5):1 69-72]. Furthermore, uterine fibroids, due to their symptoms, do severly affect the quality of life of affected women [Downes E et al. The burden of uterine fibroids in five European countries. Eur J Obstet Gynecol Reprod Biol. 2010 Sep;152(1 ):96-102].
Compounds of the present invention can be utilized to inhibit, block, reduce or decrease MAP4K1 activation by exogenous and/or endogenous ligands for the reduction of tumour growth and the modulation of dysregulated immune responses e.g. to block
immunosuppression and increase immune cell activation and infiltration in the context of cancer and cancer immunotherapy; This method comprises administering to a mammal in need thereof, including a human, an amount of a compound of this invention, or a
pharmaceutically acceptable salt, isomer, polymorph, metabolite, hydrate, solvate or ester thereof; which is effective to treat the disorder. The present invention also provides methods of treating a variety of other disorders wherein MAP4K1 is involved such as, but not limited to, disorders with dysregulated immune responses, inflammation, vaccination for infection & cancer, viral infections, obesity and diet- induced obesity, adiposity, metabolic disorders, hepatic steatosis and uterine fibroids.
These disorders have been well characterized in humans, but also exist with a similar etiology in other mammals, and can be treated by administering pharmaceutical compositions of the present invention.
The term "treating" or "treatment" as used in the present text is used conventionally, e.g., the management or care of a subject for the purpose of combating, alleviating, reducing, relieving, improving the condition of a disease or disorder, such as liquid and solid tumours.
In accordance with a further aspect, the present invention covers compounds of general formula (I), as described supra, or stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, particularly pharmaceutically acceptable salts thereof, or mixtures of same, for use in the treatment or prophylaxis of diseases, in particular cancer or conditions with dysregulated immune responses or other disorders associated with aberrant MAP4K1 signaling.
The pharmaceutical activity of the compounds according to the invention can be explained by their activity as MAP4K1 inhibitors.
In accordance with a further aspect, the present invention covers the use of compounds of general formula (I), as described supra, or stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, particularly pharmaceutically acceptable salts thereof, or mixtures of same, for the treatment or prophylaxis of diseases, in particular cancer or conditions with dysregulated immune responses or other disorders associated with aberrant MAP4K1 signaling, particularly liquid and solid tumours.
In accordance with a further aspect, the present invention covers the use of compounds of general formula (I), as described supra, or stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, particularly pharmaceutically acceptable salts thereof, or mixtures of same, in a method of treatment or prophylaxis of diseases, in particular cancer or conditions with dysregulated immune responses or other disorders associated with aberrant MAP4K1 signaling, particularly liquid and solid tumours.
In accordance with a further aspect, the present invention covers use of a compound of general formula (I), as described supra, or stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, particularly pharmaceutically acceptable salts thereof, or mixtures of same, for the preparation of a pharmaceutical composition, preferably a medicament, for the prophylaxis or treatment of diseases, in particular cancer or conditions with dysregulated immune responses or other disorders associated with aberrant MAP4K1 signaling, particularly liquid and solid tumours. In accordance with a further aspect, the present invention covers a method of treatment or prophylaxis of diseases, in particular cancer or conditions with dysregulated immune responses or other disorders associated with aberrant MAP4K1 signaling, particularly liquid and solid tumours, using an effective amount of a compound of general formula (I), as described supra, or stereoisomers, tautomers, N-oxides, hydrates, solvates, and salts thereof, particularly pharmaceutically acceptable salts thereof, or mixtures of same. In accordance with a further aspect, the present invention covers pharmaceutical compositions, in particular a medicament, comprising a compound of general formula (I), as described supra, or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, a salt thereof, particularly a pharmaceutically acceptable salt, or a mixture of same, and one or more excipients), in particular one or more pharmaceutically acceptable excipient(s). Conventional procedures for preparing such pharmaceutical compositions in appropriate dosage forms can be utilized.
The present invention furthermore covers pharmaceutical compositions, in particular medicaments, which comprise at least one compound according to the invention,
conventionally together with one or more pharmaceutically suitable excipients, and to their use for the above mentioned purposes.
It is possible for the compounds according to the invention to have systemic and/or local activity. For this purpose, they can be administered in a suitable manner, such as, for example, via the oral, parenteral, pulmonary, nasal, sublingual, lingual, buccal, rectal, vaginal, dermal, transdermal, conjunctival, otic route or as an implant or stent.
For these administration routes, it is possible for the compounds according to the invention to be administered in suitable administration forms.
For oral administration, it is possible to formulate the compounds according to the invention to dosage forms known in the art that deliver the compounds of the invention rapidly and/or in a modified manner, such as, for example, tablets (uncoated or coated tablets, for example with enteric or controlled release coatings that dissolve with a delay or are insoluble), orally- disintegrating tablets, films/wafers, films/lyophylisates, capsules (for example hard or soft gelatine capsules), sugar-coated tablets, granules, pellets, powders, emulsions, suspensions, aerosols or solutions. It is possible to incorporate the compounds according to the invention in crystalline and/or amorphised and/or dissolved form into said dosage forms.
Parenteral administration can be effected with avoidance of an absorption step (for example intravenous, intraarterial, intracardial, intraspinal or intralumbal) or with inclusion of absorption (for example intramuscular, subcutaneous, intracutaneous, percutaneous or intraperitoneal). Administration forms which are suitable for parenteral administration are, inter alia,
preparations for injection and infusion in the form of solutions, suspensions, emulsions, lyophylisates or sterile powders. Examples which are suitable for other administration routes are pharmaceutical forms for inhalation [inter alia powder inhalers, nebulizers], nasal drops, nasal solutions, nasal sprays; tablets/films/wafers/capsules for lingual, sublingual or buccal administration; suppositories; eye drops, eye ointments, eye baths, ocular inserts, ear drops, ear sprays, ear powders, ear- rinses, ear tampons; vaginal capsules, aqueous suspensions (lotions, mixturae agitandae), lipophilic suspensions, emulsions, ointments, creams, transdermal therapeutic systems (such as, for example, patches), milk, pastes, foams, dusting powders, implants or stents.
The compounds according to the invention can be incorporated into the stated administration forms. This can be effected in a manner known per se by mixing with pharmaceutically suitable excipients. Pharmaceutically suitable excipients include, inter alia,
• fillers and carriers (for example cellulose, microcrystalline cellulose (such as, for example, Avicel®), lactose, mannitol, starch, calcium phosphate (such as, for example, Di-Cafos®)),
· ointment bases (for example petroleum jelly, paraffins, triglycerides, waxes, wool wax, wool wax alcohols, lanolin, hydrophilic ointment, polyethylene glycols),
• bases for suppositories (for example polyethylene glycols, cacao butter, hard fat),
• solvents (for example water, ethanol, isopropanol, glycerol, propylene glycol, medium chain-length triglycerides fatty oils, liquid polyethylene glycols, paraffins),
· surfactants, emulsifiers, dispersants or wetters (for example sodium dodecyl sulfate), lecithin, phospholipids, fatty alcohols (such as, for example, Lanette®), sorbitan fatty acid esters (such as, for example, Span®), polyoxyethylene sorbitan fatty acid esters (such as, for example, Tween®), polyoxyethylene fatty acid glycerides (such as, for example, Cremophor®), polyoxethylene fatty acid esters, polyoxyethylene fatty alcohol ethers, glycerol fatty acid esters, poloxamers (such as, for example, Pluronic®),
• buffers, acids and bases (for example phosphates, carbonates, citric acid, acetic acid, hydrochloric acid, sodium hydroxide solution, ammonium carbonate, trometamol, triethanolamine),
• isotonicity agents (for example glucose, sodium chloride),
· adsorbents (for example highly-disperse silicas),
• viscosity-increasing agents, gel formers, thickeners and/or binders (for example polyvinylpyrrolidone, methylcellulose, hydroxypropylmethylcellulose, hydroxypropyl- cellulose, carboxymethylcellulose-sodium, starch, carbomers, polyacrylic acids (such as, for example, Carbopol®); alginates, gelatine), • disintegrants (for example modified starch, carboxymethylcellulose-sodium, sodium starch glycolate (such as, for example, Explotab®), cross- linked polyvinylpyrrolidone, croscarmellose-sodium (such as, for example, AcDiSol®)),
• flow regulators, lubricants, glidants and mould release agents (for example magnesium stearate, stearic acid, talc, highly-disperse silicas (such as, for example, Aerosil®)),
• coating materials (for example sugar, shellac) and film formers for films or diffusion membranes which dissolve rapidly or in a modified manner (for example
polyvinylpyrrolidones (such as, for example, Kollidon®), polyvinyl alcohol,
hydroxypropylmethylcellulose, hydroxypropylcellulose, ethylcellulose, hydroxypropyl- methylcellulose phthalate, cellulose acetate, cellulose acetate phthalate, polyacrylates, polymethacrylates such as, for example, Eudragit®)),
• capsule materials (for example gelatine, hydroxypropylmethylcellulose),
• synthetic polymers (for example polylactides, polyglycolides, polyacrylates,
polymethacrylates (such as, for example, Eudragit®), polyvinylpyrrolidones (such as, for example, Kollidon®), polyvinyl alcohols, polyvinyl acetates, polyethylene oxides, polyethylene glycols and their copolymers and blockcopolymers),
• plasticizers (for example polyethylene glycols, propylene glycol, glycerol, triacetine, triacetyl citrate, dibutyl phthalate),
• penetration enhancers,
· stabilisers (for example antioxidants such as, for example, ascorbic acid, ascorbyl palmitate, sodium ascorbate, butylhydroxyanisole, butylhydroxytoluene, propyl gallate),
• preservatives (for example parabens, sorbic acid, thiomersal, benzalkonium chloride, chlorhexidine acetate, sodium benzoate),
• colourants (for example inorganic pigments such as, for example, iron oxides, titanium dioxide),
• flavourings, sweeteners, flavour- and/or odour-masking agents.
The present invention furthermore relates to a pharmaceutical composition which comprise at least one compound according to the invention, conventionally together with one or more pharmaceutically suitable excipient(s), and to their use according to the present invention.
In accordance with another aspect, the present invention covers pharmaceutical combinations, in particular medicaments, comprising at least one compound of general formula (I) of the present invention and at least one or more further active ingredients, in particular for the treatment and/or prophylaxis of cancer or conditions with dysregulated immune responses or other disorders associated with aberrant MAP4K1 signalinggeneric name disorders, particularly liquid and solid tumours. The term "combination" in the present invention is used as known to persons skilled in the art, it being possible for said combination to be a fixed combination, a non-fixed combination or a kit-of-parts.
A "fixed combination" in the present invention is used as known to persons skilled in the art and is defined as a combination wherein, for example, a first active ingredient, such as one or more compounds of general formula (I) of the present invention, and a further active ingredient are present together in one unit dosage or in one single entity. One example of a "fixed combination" is a pharmaceutical composition wherein a first active ingredient and a further active ingredient are present in admixture for simultaneous administration, such as in a formulation. Another example of a "fixed combination" is a pharmaceutical combination wherein a first active ingredient and a further active ingredient are present in one unit without being in admixture.
A non-fixed combination or "kit-of-parts" in the present invention is used as known to persons skilled in the art and is defined as a combination wherein a first active ingredient and a further active ingredient are present in more than one unit. One example of a non-fixed combination or kit-of-parts is a combination wherein the first active ingredient and the further active ingredient are present separately. It is possible for the components of the non-fixed combination or kit-of- parts to be administered separately, sequentially, simultaneously, concurrently or
chronologically staggered.
Based upon standard laboratory techniques known to evaluate compounds useful for the treatment of cancer or conditions with dysregulated immune responses or other disorders associated with aberrant MAP4K1 signaling, by standard toxicity tests and by standard pharmacological assays for the determination of treatment of the conditions identified above in mammals, and by comparison of these results with the results of known active ingredients or medicaments that are used to treat these conditions, the effective dosage of the compounds of the present invention can readily be determined for treatment of each desired indication. The amount of the active ingredient to be administered in the treatment of one of these conditions can vary widely according to such considerations as the particular compound and dosage unit employed, the mode of administration, the period of treatment, the age and sex of the patient treated, and the nature and extent of the condition treated.
The total amount of the active ingredient to be administered will generally range from about 0.001 mg/kg to about 200 mg/kg body weight per day, and preferably from about 0.01 mg/kg to about 20 mg/kg body weight per day. Clinically useful dosing schedules will range from one to three times a day dosing to once every four weeks dosing. In addition, it is possible for "drug holidays", in which a patient is not dosed with a drug for a certain period of time, to be beneficial to the overall balance between pharmacological effect and tolerability. It is possible for a unit dosage to contain from about 0.5 mg to about 1500 mg of active ingredient, and can be administered one or more times per day or less than once a day. The average daily dosage for administration by injection, including intravenous, intramuscular, subcutaneous and parenteral injections, and use of infusion techniques will preferably be from 0.01 to 200 mg/kg of total body weight. The average daily rectal dosage regimen will preferably be from 0.01 to 200 mg/kg of total body weight. The average daily vaginal dosage regimen will preferably be from 0.01 to 200 mg/kg of total body weight. The average daily topical dosage regimen will preferably be from 0.1 to 200 mg administered between one to four times daily. The
transdermal concentration will preferably be that required to maintain a daily dose of from 0.01 to 200 mg/kg. The average daily inhalation dosage regimen will preferably be from 0.01 to 100 mg/kg of total body weight.
Of course the specific initial and continuing dosage regimen for each patient will vary according to the nature and severity of the condition as determined by the attending diagnostician, the activity of the specific compound employed, the age and general condition of the patient, time of administration, route of administration, rate of excretion of the drug, drug combinations, and the like. The desired mode of treatment and number of doses of a compound of the present invention or a pharmaceutically acceptable salt or ester or composition thereof can be ascertained by those skilled in the art using conventional treatment tests. Experimental section
NMR peak forms are stated as they appear in the spectra, possible higher order effects have not been considered. The multiplicities are stated according to the signal form which appears in the spectrum, NMR-spectroscopic effects of a higher order were not taken into
consideration. Multiplicity of the NMR signals: s = singlet, d = doublet, t = triplet, q = quartet, quin = quintet, br = broad signal, m = multiplet. NMR signals: shift in [ppm]. Combinations of multiplicity could be e.g. dd = doublet from doublet.
In some cases not all H atoms are found as a signal in the NMR because the signal could overlays with a solvent signal or it is a very broad signal dependent on the NMR solvent used.
Chemical names were generated using the ACD/Name software from ACD/Labs. In some cases generally accepted names of commercially available reagents were used in place of ACD/Name generated names. Table 1 lists the abbreviations used in this paragraph and in the Examples section as far as they are not explained within the text body. Other abbreviations have their meanings customary per se to the skilled person. Table 1 : Abbreviations
PBMCs Peripheral blood mononuclear cells
AUC Area Under Curve
DMF N,N-dimethylformamide
DMSO dimethyl sulphoxide
EAE experimental autoimmune encephalomyelitis
EDTA Ethylenediaminetetraacetic acid
Expl. Example
FCS fetal calf serum
h hour
LPS lipopolysaccharide
mL milliliter
min. minute(s)
MW microwave
PBMC peripheral blood mononuclear cells
RT or rt room temperature
sat. saturated
SDS Sodium dodecyl sulfate
TNFa tumour necrosis factor alpha
L microliter
uM micromolar
IFNg Interferon gamma
The various aspects of the invention described in this application are illustrated by the following examples which are not meant to limit the invention in any way.
The example testing experiments described herein serve to illustrate the present invention and the invention is not limited to the examples given.
Experimental section - general part
All reagents, for which the synthesis is not described in the experimental part, are either commercially available, or are known compounds or may be formed from known compounds by known methods by a person skilled in the art.
The compounds and intermediates produced according to the methods of the invention may require purification. Purification of organic compounds is well known to the person skilled in the art and there may be several ways of purifying the same compound. In some cases, no purification may be necessary. In some cases, the compounds may be purified by
crystallization. In some cases, impurities may be stirred out using a suitable solvent. In some cases, the compounds may be purified by chromatography, particularly flash column chromatography, using for example prepacked silica gel cartridges, e.g. Biotage SNAP cartidges KP-Sil® or KP-NH® in combination with a Biotage autopurifier system (SP4® or Isolera Four®) and eluents such as gradients of hexane/ethyl acetate or DCM/methanol. In some cases, the compounds may be purified by preparative HPLC using for example a Waters autopurifier equipped with a diode array detector and/or on-line electrospray ionization mass spectrometer in combination with a suitable prepacked reverse phase column and eluents such as gradients of water and acetonitrile which may contain additives such as trifluoroacetic acid, formic acid or aqueous ammonia.
In some cases, purification methods as described above can provide those compounds of the present invention which possess a sufficiently basic or acidic functionality in the form of a salt, such as, in the case of a compound of the present invention which is sufficiently basic, a trifluoroacetate or formate salt for example, or, in the case of a compound of the present invention which is sufficiently acidic, an ammonium salt for example. A salt of this type can either be transformed into its free base or free acid form, respectively, by various methods known to the person skilled in the art, or be used as salts in subsequent biological assays. It is to be understood that the specific form (e.g. salt, free base etc.) of a compound of the present invention as isolated and as described herein is not necessarily the only form in which said compound can be applied to a biological assay in order to quantify the specific biological activity.
General synthesis of compounds of general formula (I) of the present invention
The following paragraphs outline a variety of synthetic approaches suitable to prepare compounds of the general formula (I), and intermediates useful for their synthesis.
In addition to the routes described below, also other routes may be used to synthesise the target compounds, in accordance with common general knowledge of a person skilled in the art of organic synthesis. The order of transformations exemplified in the following schemes is therefore not intended to be limiting, and suitable synthesis steps from various schemes can be combined to form additional synthesis sequences. In addition, interconversion of any of the substituents, in particular R1, R2, R3 and R4, which are as defined in formula (I) supra, can be achieved before and/or after the exemplified transformations. These modifications can be, for example, the introduction of protective groups, cleavage of protective groups, reduction or oxidation of functional groups, halogenation, metallation, metal catalysed coupling reactions, exemplified by but not limited to e.g. Buchwald, Suzuki, Sonogashira and Ullmann coupling, ester saponifications, amide coupling reactions, and/or substitution or other reactions known to a person skilled in the art. These transformations include those which introduce a functionality allowing for further interconversion of substituents. Appropriate protective groups and their introduction and cleavage are well-known to a person skilled in the art (see for example T.W. Greene and P.G.M. Wuts in Protective Groups in Organic Synthesis, 4th edition, Wiley 2006). Further, it is possible that two or more successive steps may be performed without work-up being performed between said steps, e.g. a "one-pot" reaction, as it is well-known to a person skilled in the art.
Figure imgf000083_0001
Figure imgf000083_0002
(Va for R4 = H) (Vb)
Scheme 1 : Preparation of compounds of general formula (I) from
the two amines (II) and (III) via an intermediately formed isocyanate (IVa) or (Va) with the corresponding second amine or via an intermediately formed activated carbamate (IVb) or (Vb) with the corresponding second amine. Compounds of general formula (I) can be assembled according to Scheme 1 , by reaction of amine derivatives of formula (II), in which R1, R2, and X are as defined for the compounds of general formula (I), and a second amine derivative (III), in which R3, and R4 are as defined for the compounds of general formula (I), by means of urea formation well known to the person skilled in the art. Said urea formation can be performed by reaction of compounds of the formula (II) with the intermediacy of a formed and possibly isolated isocyanate or
isothiocyantate (IVa) using a suitable reagent such as 1 ,1 '-carbonylbis-1 H-imidazole, di- or triphosgene for Y=0, or as thiophosgene or 1 ,1 '-thiocarbonylbis-1 H-imidazole for Y=S.
Compounds of general formula (I) can be assembled according to Scheme 1 , by reaction of amine derivatives of formula (II), in which R1, R2, X, and Y are as defined for the compounds of general formula (I), and a second amine derivative (III), in which R3, and R4 are as defined for the compounds of general formula (I), by means of urea formation well known to the person skilled in the art. Said urea formation can be performed by reaction of compounds of the formula (II) with the intermediacy of a formed and possibly isolated isocyanate (IVa) using a suitable reagent such as 1 ,1 '-carbonylbis-1 H-imidazole, di- or triphosgene for Y=0, or as thiophosgene or 1 ,1 '-thiocarbonylbis-1 H-imidazole for Y=S. Compounds of general formula (I) can also be assembled by conversion of amine derivatives of formula (II) to an intermediately formed and possibly isolated carbamate or thiocarbamate (IVb) using a suitable reagent such as phenyl chloroformate or O-phenyl chlorothionoformate in which Z is H, NO2, or perfluoro in an appropriate solvent such as tetrahydrofuran, dichloromethane, or ethylacetate in the presence of an appropriate base such as pyridine, sodium hydrogencarbonate, or
triethylamine. This intermediate IV(b) is then reacted with the second amine derivative (III) in an appropriate solvent such as pyridine, or dimethylformamide. In a similar way the
compounds of general formula (I) can be assembled using the amine (III) as starting material. With the former described reaction the amine (III) can react to the intermediately formed isocyanate (Va for R3 = H), if it is not commercially available, in which R4 and Y are as defined for the compounds of general formula (I) or the carbamate (Vb) using a suitable reagent such as phenyl chloroformate or O-phenyl chlorothionoformate in which Z is H, NO2, or perfluoro and R3, R4 and Y are as defined for the compounds of general formula (I) with the second amine (II).
Depending on the choice of protecting group PG in formula (II), (IVa), and (IVb), which is preferentially trimethylsilylethyloxymethyl (SEM), but can be any other protecting group well known to the person skilled in the art, the deprotection can be performed using trifluoroacetic acid in the case of trimethylsilylethyloxymethyl, in an inert solvent such as dichloromethane, within a temperature range from 0°C to the boiling point of the used solvent. The deprotection in the case of trimethylsilylethyloxymethyl can be also performed using tetra-butylammonium fluoride in the presence of ethylenediamine in an inert solvent such as tetrahydrofuran within a temperature range from 0°C to the boiling point of the used solvent. In the case of a toluenesulfonyl-group (Tos) the deprotection can be performed by using for example sodium hydroxide in methanol within a temperature range from 0°C to the boiling point of the used solvent.
Preferred herein is the performance of said urea formation using the amine (II) and the intermediately formed and maybe isolated carbamate (IVb) or cyanate (Vb) and the subsequent reaction with the second amine (II) in DMF or pyridine as a solvent, within a temperature range from 0°C to 100°C.
The amine intermediates of formula (II) are known to the person skilled in the art and can, if not commercially available, be prepared according to Schemes 3 and 4 shown below. The second amine derivatives of formula (III) are either commercially available in some structural variety, or they can be prepared using synthetic methods described in many textbooks such as March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, 7th Edition.
As illustrated in Scheme 2, the amine derivatives of formula (II) are known, commercially available, or can be prepared from the commercially available heterocyle of the formula (VI), in which R1a represents a hydrogen or a trifluoromethyl group. Said heterocycle of the formula (VI) can be reacted with nitric acid, in the case of leaving group (LG) = N02, or in a two step sequence for LG = CI using MCPBA to form a 7-N-oxide, which then reacts in a subsequent step with methanesulfonyl chloride to give intermediate heterocycles of formula (VII).
Compounds of the formula (VII) are converted to chlorides of formula (VIII) using a two step sequence, which begins with production of a 7-N-oxide which then reacts in a subsequent step with trichloroacetyl chloride in the presence of hexamethyldisilazane (HMDS). Said
heterocycles of formula (VII) can be transformed to the protected intermediates of the formula
(IX) using an apprioate reagent such as trimetylsilylethoxymethyl chloride, triisopropylsilyl chloride, trityl chloride or tosylchloride or other reagents known to a person skilled in the art. Preferably, trimetylsilylethoxymethyl chloride is used, in the presence of a base such as sodium hydride, triethyl amine, or ethyl diisopropyl amine in an inert solvent such as THF, DMSO or DMF.
Protected heterocycles of the formula (IX) are then reacted with a compound of the formula
(X) in the presence of sodium hydride or an alkali carbonate, such as sodium carbonate, potassiumcarbonate, or cesium carbonate, in a suitable solvent such as DMSO or DMF, as well known to the person skilled in the art, to give compounds of formula (XI). For compounds of (X) with X=NH it may be necessary to protect the other amino function in an intermediate fashion. Dechlorination is preferentially performed using a hydrogen atmosphere and palladium on carbon as catalyst in an inert solvent such as ethanol, ethyl acetate or dichloromethane at 20 50°C as described in Org. Process Res. Dev. 2010, page 168-173, to give a subset of the amines of the formula (II) named (lla) in which R1a are as defined for compounds of gerenal formula VI).
Figure imgf000086_0001
(IX)
CI, NO
Figure imgf000086_0002
Scheme 2: Preparation of compounds of formula (lla) from compounds of formula (VI). All other amines of the subset (lib) from the general formula (II) can be assembled from the amine (lla) with R1a=H according to Scheme 3. Protection of the free amine in (lla) with R1a=H using trifluoroacetic anhydride in an inert solvent such as dichloromethane in the presence of an tertiary amine such as triethyl amine or ethyl diisopropyl amine, yields the amides of the general formula (XII) in which R2, and X are as defined for the compounds of general formula (I). Said amides of formula (XII) can be converted into halogen substituted compounds of the general formula (XIII) with R1b = CI, Br, or I using the corresponding N-halo-succinimide in an inert solvent such as dichloro methane or tetrachloro methane. In the case of compounds of the general formula (XIII) with R1b = CN, and Ci-C6-alkyl, a subsequent reaction of a said halogen compound of the general formula (XII) with R1b = Br or I is used as starting material. For formation of the corresponding nitrile, a reaction using cuprous cyanide in an inert solvent such as dimethyl formamide or dimethyl acetamide at elevated temperatures, for example between 90 - 120°C is required. Furthermore, a palladium-catalyzed method known to the person skilled in the art, for example, with zinc cyanide or potassium ferrocyanide as described in Chem. Soc. Rev., 201 1 , 40, 5049-5067 can be utilized. For the preparation of compounds of the general formula (XIII) with R1b = Ci-C6-alkyl a Suzuki reaction known to the person skilled in the art is used as described, for example in Metal-Catalyzed Cross-Coupling
Reactions, Second Edition (Editors: Armin de Meijere, Frangois Diederich, Wiley-VCH) or in Catal. Lett. (2016) page 820-840. After saponification of compounds of the general formula (XII) using lithium, sodium or potassium hydroxide, the compounds of the general formula (lib) are obtained. Taken to ether, formulae (I la) and (lib) constitute formula (II).
Figure imgf000087_0001
(XIII) (lib with R1 b = CI, Br, I, CrC6-alykl, CN)
Scheme 3: Preparation of compounds of formula (lib) from compounds of formula (I la). A complementary approach to compounds of formula (II) is described in Scheme 4. The respective polyfluoro-nitrobenzene derivatives of formula (XIII) are reacted with 4-hydroxy-7- azaindole (XII) (e.g. US2007/238726) , in a suitable solvent system, for example
dimethylsulfoxide, in the presence of a base, for example potassium carbonate or cesium carbonate, in a temperature range from room temperature to the boiling point of the respective solvent. Preferable the reaction is carried out at room temperature to furnish intermediates of general formula (XIV).
Intemediates of general formula (XIV), are then protected with an appropriate protecting group, for example using an appropriate reagent such as trimetylsilylethoxymethyl chloride, triisopropylsilyl chloride or trityl chloride or other reagents known to a person skilled in the art. Preferably, trimetylsilylethoxymethyl chloride is used, in the presence of a base such as sodium hydride, triethylamine, or ethyldiisopropylamine in an inert solvent such as
tetrahydrofuran, dimethylsulfoxide or dimethylformamide to afford compounds of formula (XV).
Compounds of formula (XV) can be converted into halogen substituted compounds of the general formula (XVI) with R1 = CI, Br, or I using the corresponding N-halo-succinimide in an inert solvent such as dichloromethane, dimethylformamide, or tetrachloromethane, in a temperature range from room temperature to the boiling point of the respective solvent.
Preferable the reaction is carried out at room temperature to furnish intermediates of general formula (XVI).
Compounds of general formula (XVI), where R1 = I, can be reacted with trifluoromethylation reagents, for example diphenyl(trifluoromethyl)sulfonium trifluoromethanesulfonate as described in Angew. Chem. Int. Ed. 2011 , 50, pg. 1896-1900, or any other reagent know to one skilled in the art, to afford compounds of general formula (XVI) where R1 = CF3.
Preferably, diphenyl(trifluoromethyl)sulfonium trifluoromethanesulfonate is used, in the presence of additives, such as copper(O), in a solvent such as dimethylformamide, in a temperature range from room temperature to the boiling point of the respective solvent. Ideally, the reaction is carried out at 60°C to furnish intermediates of general formula (XVI) where R1 = CF3.
In the case of compounds of the general formula (XVI) with R1 = CN, and Ci-C6-alkyl, a subsequent reaction of a said halogen compounds of the general formula (XVI) with R1 = Br or I is required. For formation of the corresponding nitrile, a reaction using cuprous cyanide in an inert solvent such as dimethyl formamide or dimethyl acetamide at elevated temperatures, for example between 90 - 120°C is required. Furthermore, a palladium-catalyzed method known to the person skilled in the art, for example, with zinc cyanide or potassium ferrocyanide as described in Chem. Soc. Rev., 2011 , 40, 5049-5067 can be utilized. For the preparation of compounds of the general formula (XVI) with R1 = Ci-C6-alkyl a Suzuki reaction known to the person skilled in the art is used as described, for example in Metal-Catalyzed Cross-Coupling Reactions, Second Edition (Editors: Armin de Meijere, Frangois Diederich, Wiley-VCH) or in Catal. Lett. (2016) page 820-840.
Additionally, compounds of the general formula (XVI) with R1 = Ci-C6-alkyl and halo-Ci-C6- alkyl can be formed from compounds of the general formula (XVI) with R1 = Br by a light promoted, nickel catalysed reaction as described in J. Am. Chem. Soc. 2016, 138, 8084-8087 and Org. Lett. 2016, 18, 4012, and known to one skilled in the art. Preferentially, compounds of general formula (XVI) with R1 = Br are reacted with alkylbromides or haloaklybromides in the presence of a photoredox catalyst such as lr(4',6'-dF-5-CF3-ppy)2(4,4'-dtbbpy)PF6, a nickel precatalyst such as nickel II chloride dimethoxyethane adduct, and a ligand such as 4,4'-Di- tert-butyl-2,2'-bipyridine, with a base such as sodium carbonate, 2,6-dimethoxypyridine, or lithium carbonate, with additives such as tris(trimehylsilyl)silane, in a solvent or solvent mixture such as dimethoxyethane, Ν,Ν-dimethylacetamide/trifluorotoluene or 1 ,3-dimethyl-2- imidazolidinone/trifluorotoluene, irradiated with light generated by two 40W Kessil LED aquarium lights, at a temperature between 0°C and the boiling point of the respective solvent. Ideally the reaction is performed between room temperature and 35°C to afford compounds of general formula (XVI) with R1 = Ci-C6-alkyl and halo-Ci-C6-alkyl.
Reduction of the nitro functionalitiy contained within compounds of formula (XVI) affords amines of formula (II). The reduction of a nitro functionality can be performed for example under hydrogene atmosphere and a Pd or Pt/V catalyst in an inert solvent such as
dichloromethane, methanol, ethanol or ethyl acetate from room temperature to the boiling point of the respective solvent.. Preferentially, the reaction is performed with the addition of a reducing agent, for example lron(0), with additives such as ammonium chloride, in an appropriate mixture of solvents, for example a mixture of water, tetrahydrofuran, and methanol, in a temperature range from room temperature to the boiling point of the respective solvent. Ideally the reaction is performed at 80 °C to furnish amine intermediates of general formula (II). The reaction can be carried out using alternative reducing agents to those skilled in the art, for example tin(ll)chloride, in an appropriate solvent, such as methanol, in a temperature range from room temperature to the boiling point of the respective solvent. Ideally the reaction is performed at room temperature to furnish amine intermediates of general formula (II).
Figure imgf000090_0001
Figure imgf000090_0002
Scheme 4: Preparation of compounds of formula (II for X=0) from compounds of formula (XII).
Method 1 : (prep. HPLC) System: Labomatic, Pump: HD-5000, Fraction Collector: LABOCOL Vario-4000, UV-Detector: Knauer UVD 2.1 S; Column: Chromatorex RP C18 10μηι 125x30 mm; Solvent: A = water + 0.1 % Vol. ammonia (99%), B = Acetonitril; Flow: 150 mL/min;
temperature: room temperature
Method 2: Waters Acquity UPLCMS SingleQuad; Colum: Acquity UPLC BEH C18 1 .7
50x2.1 mm; eluent A: water + 0.2 vol % aqueous ammonia (32%), eluent B: acetonitrile;
gradient: 0-1 .6 min 1 -99% B, 1.6-2.0 min 99% B; flow 0.8 mL/min; temperature: 60 °C; DAD scan: 210-400 nm
Method 3: Waters Acquity UPLCMS SingleQuad; Column: Acquity UPLC BEH C18 1 .7 50x2.1 mm; eluent A: water + 0.1 vol % formic acid (99%), eluent B: acetonitrile; gradient: 0-1 .6 min 1 -99% B, 1.6-2.0 min 99% B; flow 0.8 mL/min; temperature: 60 °C; DAD scan: 210-400 nm Method 4: (prep. HPLC) System: Waters Autopurificationsystem; column: Waters XBrigde C18 5μ 100x30mm; eluent A: water + 0.1 Vol-% formic acid (99%), eluent B: acetonitrile; gradient: 0.00-0.50 min 8% B (40->70mL/min), 0.51-5.50 min 16-36% B (70mL/min), DAD scan: 210- 400 nm
EXPERIMENTAL SECTION - INTERMEDIATES
Intermediate 1
phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate
Figure imgf000091_0001
To solution of 3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl]oxy}aniline (4.00 g, 8.71 mmol, see Synthesis 2007, page 251-258, Org. Process Res. Dev. 2010, page 168-173) in pyridine (4.0 mL) and THF (60 mL) was slowly added at 0°C phenyl carbonochloridate (1 .2 mL, 9.6 mmol). After stirring this mixture 5 minutes at 0°C and then 30 minutes at room temperature ethyl acetate was added. This organic phase was washed with 1 N hydrochloric acid (75mL), water, concentrated aqueous sodium hydrogencarbonate, brine, dried over sodium sulfate, filtered and concentrated to dryness. The resulting residue was purified via a Biotage chromatography system (100g snap KP-Sil column, hexane / 0 - 100% ethyl acetate, then ethyl acetate / 0 - 75% methanol) to obtain 4.53 g (92 % purity, 83 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.10 (s, 9H), 0.79 - 0.86 (m, 2H), 3.54 - 3.61 (m, 2H), 5.69 (s, 2H), 6.61 (d, 1 H), 7.24 - 7.32 (m, 3H), 7.42 - 7.50 (m, 4H), 8.27 - 8.33 (m, 1 H), 8.35 - 8.40 (m, 1 H), 10.81 (s, 1 H). Intermediate 2
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]m
b]pyridin-4-yl]oxy}phenyl)-3-[3-(morpholin-4-yl)propyl]urea
Figure imgf000092_0001
To solution of phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (1 .20 g, 2.07 mmol, intermediate 1 ) in DMF (10 mL) was added 3-(morpholin-4-yl)propan-1 -amine (300 μΙ_, 2.1 mmol) and this mixture was stirred at 60°C for 2 hours. After cooling to room temperature ethyl acetate and water was added. After separation of the organic phase the aqueous phase was extracted two times with ethyl acetate. The combined organic phases were washed 3 times with halfconcentrated aqueous sodium chloride solution, dried over sodium sulfate, filtered and concentrated to dryness.
The resulting residue was purified 3 times via a Biotage chromatography system (55g and 2 times 28g snap KP-NH column, hexane / 0 - 100% ethyl acetate, then ethyl acetate / 0 - 100% methanol) to obtain 970 mg (95 % purity, 71 % yield) of the desired title compound. 1H-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.12 - -0.08 (m, 9H), 0.83 (t, 2H), 1 .60 (quin, 2H), 2.27 - 2.36 (m, 6H), 3.13 (q, 2H), 3.53 - 3.62 (m, 6H), 5.68 (s, 2H), 6.42 (t, 1 H), 6.57 (d, 1 H), 7.34 - 7.41 (m, 2H), 8.28 (d, 1 H), 8.36 (s, 1 H), 8.99 (s, 1 H). Intermediate 3
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]m
b]pyridin-4-yl]oxy}phen l)-3-(2-methoxyethyl)urea
Figure imgf000093_0001
In analogy to intermediate 2), using 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(2-methoxyethyl)urea (150 mg, 259 μηηοΙ, intermediate 1 ) and 2-methoxyethanamine (19.4 mg, 259 μηηοΙ) in DMF (1 .5 mL), we obtained after one single purification using a Biotage chromatography system 99.8 mg (93 % purity, 64 % yield) of the desired title compound.
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.1 1 - -0.08 (m, 9H), 0.79 - 0.86 (m, 2H), 3.24 - 3.29 (m, 5H), 3.39 (t, 2H), 3.54 - 3.60 (m, 2H), 5.68 (s, 2H), 6.49 (t, 1 H), 6.57 (d, 1 H), 7.33 - 7.40 (m, 2H), 8.29 (d, 1 H), 8.36 (s, 1 H), 9.1 1 (s, 1 H).
Intermediate 4
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl]oxy}phen l)-3-[3-(methylsulfonyl)propyl]urea
Figure imgf000093_0002
In analogy to intermediate 2), using phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (150 mg, 259 μηηοΙ, intermediate 1 ) and 3-(methylsulfonyl)propan-1 -amine hydrochloride (1 :1 ) (44.9 mg, 259 μηηοΙ) together with N,N-diisopropylethylamine (45 μΙ_, 260 μηηοΙ) in DMF (1 .5 ml_), we obtained after one single purification using a Biotage chromatography system 106 mg (94 % purity, 62 % yield) of the desired title compound.
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.1 1 - -0.08 (m, 9H), 0.80 - 0.86 (m, 2H), 1.83 - 1 .91 (m, 2H), 2.99 (s, 3H), 3.10 - 3.16 (m, 2H), 3.22 (q, 2H), 3.55 - 3.60 (m, 2H), 5.68 (s, 2H), 6.55 - 6.60 (m, 2H), 7.36 - 7.43 (m, 2H), 8.29 (d, 1 H), 8.36 (s, 1 H), 9.09 (s, 1 H).
Intermediate 5
1 -(2,2-difluoroethyl)-3-(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)urea
Figure imgf000094_0001
In analogy to intermediate 2), using phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (150 mg, 259 μηηοΙ, intermediate 1 ) and 2,2-difluoroethanamine (21 .0 mg, 259 μηηοΙ) in DMF (1 .5 ml_), we obtained after one single purification using a Biotage chromatography system 88.5 mg (94 % purity, 57 % yield) of the desired title compound.
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.1 1 - -0.08 (m, 9H), 0.79 - 0.87 (m, 2H), 3.48 - 3.61 (m, 4H), 5.68 (s, 2H), 6.07 (tt, 1 H), 6.58 (d, 1 H), 6.78 (t, 1 H), 7.36 - 7.44 (m, 2H), 8.29 (d, 1 H), 8.36 (s, 1 H), 9.24 (s, 1 H). Intermediate 6
N3-[(3,5-difluoro-4-{[3-(trifluoro
pyrrolo[2,3-b]pyridin-4-yl oxy}phenyl)carbamoyl]-beta-alaninamide
Figure imgf000095_0001
In analogy to intermediate 2), using phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (150 mg, 259 μηηοΙ, intermediate 1 ) and beta-alaninamide (22.8 mg, 259 μηηοΙ) together with N,N- diisopropylethylamine (45 μΙ_, 260 μηηοΙ) in DMF (1 .5 mL), we obtained after one single purification using a Biotage chromatography system 100 mg (94 % purity, 64 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.1 1 - -0.08 (m, 9H), 0.80 - 0.86 (m, 2H), 2.28 (t, 2H), 3.26 - 3.32 (m, 2H), 3.54 - 3.60 (m, 2H), 5.68 (s, 2H), 6.44 (t, 1 H), 6.57 (d, 1 H), 6.92 (br s, 1 H), 7.30 - 7.44 (m, 3H), 8.28 (d, 1 H), 8.36 (s, 1 H), 9.15 (s, 1 H). Intermediate 7
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl]oxy}phenyl)-3-(pyridin-4-ylmethyl)urea
Figure imgf000095_0002
In analogy to intermediate 2), using phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (150 mg, 259 μηηοΙ, intermediate 1 ) and 1 -(pyridin-4-yl)methanamine (28.0 mg, 259 μηηοΙ) in DMF (1 .5 mL), we obtained after one single purification using a Biotage chromatography system 145 mg (92 % purity, 87 % yield) of the desired title compound.
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.1 1 - -0.08 (m, 9H), 0.79 - 0.86 (m, 2H), 3.54 - 3.61 (m, 2H), 4.35 (d, 2H), 5.68 (s, 2H), 6.58 (d, 1 H), 7.04 (t, 1 H), 7.30 (d, 2H), 7.38 - 7.45 (m, 2H), 8.28 (d, 1 H), 8.36 (s, 1 H), 8.52 (d, 2H), 9.30 (s, 1 H). Intermediate 8
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]m
b]pyridin-4-yl]oxy}phenyl)-3-[(1 -hydroxycyclopropyl)methyl]urea
Figure imgf000096_0001
In analogy to intermediate 2), using phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (200 mg, 345 μηηοΙ, intermediate 1 ) and 1 -(aminomethyl)cyclopropanol (30.1 mg, 345 μηηοΙ) in DMF (2.0 mL, 26 mmol), we obtained after one single purification using a Biotage chromatography system 151 mg (92 % purity, 70 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.1 1 - -0.08 (m, 9H), 0.48 - 0.53 (m, 2H), 0.54 - 0.60 (m, 2H), 0.79 - 0.87 (m, 2H), 3.22 (d, 2H), 3.54 - 3.61 (m, 2H), 5.42 (s, 1 H), 5.68 (s, 2H), 6.47 (t, 1 H), 6.58 (d, 1 H), 7.33 - 7.40 (m, 2H), 8.28 (d, 1 H), 8.36 (s, 1 H), 9.09 (s, 1 H). Intermediate 9
4-{[(3,5-difluoro-4-{[3-(trifluoro
pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamoyl]amino}butanamide
Figure imgf000097_0001
In analogy to intermediate 2), using phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (175 mg, 302 μηηοΙ, intermediate 1 ) and 4-aminobutanamide hydrochloride (1 :1 ) (41 .8 mg, 302 μηηοΙ) together with N,N-diisopropylethylamine (53 μΙ_, 300 μηηοΙ) in DMF (1 .8 mL), we obtained after one single purification using a Biotage chromatography system 1 10 mg (85 % purity, 53 % yield) of the desired title compound.
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: 1H-NMR (400MHz, DMSO-d6): δ [ppm]= -0.1 1 - -0.08 (m, 9H), 0.80 - 0.86 (m, 2H), 1 .65 (quin, 2H), 2.08 (t, 2H), 3.09 (q, 2H), 3.55 - 3.60 (m, 2H), 5.68 (s, 2H), 6.45 (t, 1 H), 6.57 (d, 1 H), 6.77 (br s, 1 H), 7.30 (br s, 1 H), 7.36 - 7.43 (m, 2H), 8.28 (d, 1 H), 8.36 (s, 1 H), 9.02 (s, 1 H).
Intermediate 10
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl]oxy}phenyl)-3-(3-methoxypropyl)urea
Figure imgf000097_0002
In analogy to intermediate 2), using phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (150 mg, 259 μηηοΙ, intermediate 1 ) and 3-methoxypropan-1 -amine (23.1 mg, 259 μηηοΙ) in DMF (1 .5 mL), we obtained after one single purification using a Biotage chromatography system 88.0 mg (94 % purity, 56 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.1 1 - -0.08 (m, 9H), 0.80 - 0.86 (m, 2H), 1 .67 (tt, 2H), 3.1 1 - 3.18 (m, 2H), 3.24 (s, 3H), 3.34 - 3.39 (m, 2H), 3.54 - 3.60 (m, 2H), 5.68 (s, 2H), 6.42 (t, 1 H), 6.57 (d, 1 H), 7.35 - 7.42 (m, 2H), 8.28 (d, 1 H), 8.36 (s, 1 H), 9.01 (s, 1 H). Intermediate 11
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]m
b]pyridin-4-yl]oxy}phenyl)-3-[2-(morpholin-4-yl)-2-oxoethyl]urea
Figure imgf000098_0001
In analogy to intermediate 2), using phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (150 mg, 259 μηηοΙ, intermediate 1 ) and 2-amino-1 -(morpholin-4-yl)ethanone (37.3 mg, 259 μηηοΙ) in DMF (1 .5 mL), we obtained after one single purification using a Biotage chromatography system 124 mg (94 % purity, 72 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.1 1 - -0.08 (m, 9H), 0.80 - 0.86 (m, 2H), 3.39 - 3.49 (m, 4H), 3.54 - 3.62 (m, 6H), 4.01 (d, 2H), 5.68 (s, 2H), 6.54 - 6.62 (m, 2H), 7.33 - 7.40 (m, 2H), 8.28 (d, 1 H), 8.36 (s, 1 H), 9.46 (s, 1 H). Intermediate 12
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]m
b]pyridin-4-yl]oxy}phenyl)-3- ridin-3-ylmethyl)urea
Figure imgf000099_0001
In analogy to intermediate 2), using phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (150 mg, 259 μηηοΙ, intermediate 1 ) and 1 -(pyridin-3-yl)methanamine (28.0 mg, 259 μηηοΙ) in DMF (1 .5 mL), we obtained after one single purification using a Biotage chromatography system 99.8 mg (93 % purity, 61 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.1 1 - -0.08 (m, 9H), 0.79 - 0.86 (m, 2H), 3.54 - 3.60 (m, 2H), 4.34 (d, 2H), 5.68 (s, 2H), 6.58 (d, 1 H), 7.02 (t, 1 H), 7.35 - 7.44 (m, 3H), 7.72 (dt, 1 H), 8.28 (d, 1 H), 8.36 (s, 1 H), 8.47 (dd, 1 H), 8.53 (d, 1 H), 9.21 (s, 1 H).
Intermediate 13
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl]oxy}phenyl)-3-(pyridin-2-ylmethyl)urea
Figure imgf000099_0002
In analogy to intermediate 2), suing phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (150 mg, 259 μηηοΙ, intermediate 1 ) and 1 -(pyridin-2-yl)methanamine (28.0 mg, 259 μηηοΙ) in DMF (1 .5 mL), we obtained after one single purification using a Biotage chromatography system 90.0 mg (80 % purity, 47 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.1 1 - -0.08 (m, 9H), 0.79 - 0.86 (m, 2H), 3.53 - 3.62 (m, 2H), 4.43 (d, 2H), 5.68 (s, 2H), 6.58 (d, 1 H), 7.03 (t, 1 H), 7.26 - 7.32 (m, 1 H), 7.34 - 7.43 (m, 3H), 7.79 (td, 1 H), 8.28 (d, 1 H), 8.36 (s, 1 H), 8.53 (ddd, 1 H), 9.36 (s, 1 H). Intermediate 14
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]m
b]pyridin-4-yl]oxy}phenyl)-3-[2-(pyridin-4-yl)ethyl]urea
Figure imgf000100_0001
In analogy to intermediate 2), using phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (150 mg, 259 μηηοΙ, intermediate 1 ) and 2-(pyridin-4-yl)ethanamine (31 .6 mg, 259 μηηοΙ) in DMF (1 .5 mL), we obtained after one single purification using a Biotage chromatography system 123 mg (92 % purity, 72 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.1 1 - -0.08 (m, 9H), 0.80 - 0.86 (m, 2H), 2.80 (t, 2H), 3.40 (q, 2H), 3.54 - 3.61 (m, 2H), 5.68 (s, 2H), 6.44 (t, 1 H), 6.57 (d, 1 H), 7.25 - 7.30 (m, 2H), 7.34 - 7.41 (m, 2H), 8.28 (d, 1 H), 8.36 (s, 1 H), 8.47 - 8.51 (m, 2H), 9.03 (s, 1 H). Intermediate 15
(+/-)-1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl]ox phenyl)-3-[(2S)-2 -hydroxy -3 -(morpholin-4-yl)propyl]urea
Figure imgf000101_0001
In analogy to intermediate 2), using phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (150 mg, 259 μηηοΙ, intermediate 1 ) and (+/-)-1 -amino-3-(morpholin-4-yl)propan-2-ol ethanedioate (1 :1 ) (64.8 mg, 259 μηηοΙ) together with N,N-diisopropylethylamine (45 μΙ_, 260 μmol) in DMF (1 .5 mL), we obtained after one single purification using a Biotage chromatography system 75.5 mg (93 % purity, 42 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.1 1 - -0.08 (m, 9H), 0.79 - 0.86 (m, 2H), 2.28 (d, 2H), 2.36 - 2.45 (m, 4H), 2.93 - 3.01 (m, 1 H), 3.29 - 3.36 (m, 1 H), 3.53 - 3.62 (m, 6H), 3.64 - 3.75 (m, 1 H), 4.82 (d, 1 H), 5.68 (s, 2H), 6.37 (t, 1 H), 6.57 (d, 1 H), 7.32 - 7.40 (m, 2H), 8.29 (d, 1 H), 8.36 (s, 1 H), 9.13 (s, 1 H).
Intermediate 16
(+/-)-1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[(2R)-tetrahydrofuran-2-ylmethyl]urea
Figure imgf000101_0002
In analogy to intermediate 2), using phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (150 mg, 259 μηηοΙ, intermediate 1 ) and (+/-)-1 -[tetrahydrofuran-2-yl]methanamine (26.2 mg, 259 μηηοΙ) in DMF (1 .5 ml_), we obtained after one single purification using a Biotage chromatography system 162 mg (80 % purity, 85 % yield) of the desired title compound.
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.1 1 - -0.08 (m, 9H), 0.80 - 0.86 (m, 2H), 1.47 - 1 .56 (m, 1 H), 1.78 - 1.95 (m, 3H), 3.07 - 3.15 (m, 1 H), 3.21 - 3.28 (m, 1 H), 3.57 (t, 2H), 3.61 - 3.67 (m, 1 H), 3.75 - 3.82 (m, 1 H), 3.84 - 3.91 (m, 1 H), 5.68 (s, 2H), 6.45 (t, 1 H), 6.58 (d, 1 H), 7.33 - 7.40 (m, 2H), 8.28 (d, 1 H), 8.36 (s, 1 H), 9.07 (s, 1 H).
Intermediate 17
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]m
b]pyridin-4-yl]oxy}phenyl)-3-(tetrahydro-2H-pyran-4-ylmethyl)urea
Figure imgf000102_0001
In analogy to intermediate 2), using phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (150 mg, 259 μηηοΙ, intermediate 1 ) and 1 -(tetrahydro-2H-pyran-4-yl)methanamine (29.8 mg, 259 μηηοΙ) in DMF (1 .5 ml_), we obtained after one single purification using a Biotage chromatography system 205 mg (80 % purity, 105 % yield) of the desired title compound.
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.1 1 - -0.08 (m, 9H), 0.80 - 0.86 (m, 2H), 1.12 - 1 .25 (m, 2H), 1 .56 (br d, 2H), 1.61 - 1 .72 (m, 1 H), 3.01 (t, 2H), 3.22 - 3.31 (m, 2H), 3.55 - 3.60 (m, 2H), 3.85 (br dd, 2H), 5.68 (s, 2H), 6.53 (t, 1 H), 6.57 (d, 1 H), 7.35 - 7.42 (m, 2H), 8.28 (d, 1 H), 8.36 (s, 1 H), 8.99 (s, 1 H). Intermediate 18
1 -(3,5-difluoro-4-{[3-(trifluoromet^
b]pyridin-4-yl]oxy}phenyl)-3- 1 H-1 ,2,3-triazol-5-ylmethyl)urea
Figure imgf000103_0001
In analogy to intermediate 2), using phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (150 mg, 259 μηηοΙ, intermediate 1 ) and 1 -(1 H-1 ,2,3-triazol-5-yl)methanamine hydrochloride (1 :1 ) (69.6 mg, 518 μηιοΙ) together with N,N-diisopropylethylamine (90 μΙ_, 520 μηιοΙ) in DMF (1 .5 ml_), we obtained after one single purification using a Biotage chromatography system 95.6 mg (95 % purity, 60 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.1 1 - -0.08 (m, 9H), 0.80 - 0.86 (m, 2H), 3.53 - 3.61 (m, 2H), 4.38 (d, 2H), 5.68 (s, 2H), 6.58 (d, 1 H), 6.94 (t, 1 H), 7.37 - 7.44 (m, 2H), 7.69 (s, 1 H), 8.28 (d, 1 H), 8.36 (s, 1 H), 9.25 (s, 1 H).
Intermediate 19
N2-[(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl]ox henyl)carbamoyl]glycinamide
Figure imgf000103_0002
In analogy to intermediate 2), using phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (150 mg, 259 μηηοΙ, intermediate 1 ) and glycinamide hydrochloride (1 :1 ) (28.6 mg, 259 μηηοΙ) together with N,N-diisopropylethylamine (45 μΙ_, 260 μηηοΙ) in DMF (1 .5 ml_), we obtained after one single purification using a Biotage chromatography system 90.7 mg (93 % purity, 58 % yield) of the desired title compound.
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.1 1 - -0.08 (m, 9H), 0.79 - 0.87 (m, 2H), 3.54 - 3.61 (m, 2H), 3.70 (d, 2H), 5.68 (s, 2H), 6.53 (t, 1 H), 6.58 (d, 1 H), 7.10 (s, 1 H), 7.37 (d, 2H), 7.45 (s, 1 H), 8.28 (d, 1 H), 8.36 (s, 1 H), 9.34 (s, 1 H).
Intermediate 20
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]m
b]pyridin-4-yl]oxy}phenyl)-3-[2-(morpholin-4-yl)ethyl]urea
Figure imgf000104_0001
To a solution of 3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl]oxy}aniline (50.0 mg, 109 μηηοΙ, intermediate 1 ) in dichloromethane (10 mL) was added at 0°C N,N-diisopropylethylamine (42.2 mg, 326 μηιοΙ) and
bis(trichloromethyl) carbonate (32.3 mg, 109 μηηοΙ). After stirring at 0°C for 0.5 hour a solution of 2-(morpholin-4-yl)ethanamine (21 .3 mg, 163 μηηοΙ) in dichloromethane (2 mL) was added slowly. The reaction mixture was allowed to stir at 0°C for another 1 hour. A similar experiment using 3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl]oxy}aniline (100.0 mg, 218 μηηοΙ) was done. Both reaction mixture were quenched by water and extracted with dichloromethane. The combined organic phases were washed with aqueous sodium bicarbonate solution, dried over sodium sulfate and after filtration evaporated to dryness. The residue was subjected to column chromatography with methanol / dichloromethane (1 :10/v:v) to afford 55 mg (41 % yiled) of the desired title compound. Intermediate 21
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]m
b]pyridin-4-yl]oxy}phenyl)-3-[2-(piperidin-1 -yl)ethyl]urea
Figure imgf000105_0001
In analogy to intermediate 20), in a single experiment using 3,5-difluoro-4-{[3-(trifluoromethyl)- 1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}aniline (100 mg, 218 μηιοΙ, intermediate 1 ), 2-(piperidin-1 -yl)ethanamine (41 .9 mg, 326 μηηοΙ), N,N-diisopropylethylamine (84.4 mg, 653 μηηοΙ) and bis(trichloromethyl) carbonate (64.6 mg, 218 μηηοΙ) in
dichloromethane (15 ml_), we obtained 45 mg (34% yield) of the desired title compound.
Intermediate 22
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl]oxy}phenyl)-3-[3-(piperidin-1 -yl)propyl]urea
Figure imgf000105_0002
In analogy to intermediate 20), in a single experiment using 3,5-difluoro-4-{[3-(trifluoromethyl)- 1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}aniline (100 mg, 218 μηιοΙ, intermediate 1 ), 3-(piperidin-1 -yl)propan-1 -amine (46.4 mg, 326 μηηοΙ), Ν,Ν- diisopropylethylamine (84.4 mg, 653 μηηοΙ) and bis(trichloromethyl) carbonate (64.6 mg, 218 μηηοΙ) in dichloromethane (15 ml_), we obtained 43 mg (31 % yield) of the desired title compound. Intermediate 23
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]m
b]pyridin-4-yl]oxy}phenyl -3-[3-(dimethylamino)propyl]urea
Figure imgf000106_0001
In analogy to intermediate 20), in two experiments using 3,5-difluoro-4-{[3-(trifluoromethyl)-1 - {[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}aniline (20 + 100 mg, 44 μηηοΙ + 218 μηηοΙ, intermediate 1 ), N,N-dimethylpropane-1 ,3-diamine (6.67 + 33.4 mg, 65.3 + 326 μηηοΙ), triethylamine (18 + 91 μΙ_, 130 + 653 μηηοΙ) and bis(trichloromethyl) carbonate (12.9 + 64.6 mg, 43.5 + 218 μηηοΙ) in dichloromethane (3 + 15 ml_), we obtained 65 mg (51 % yield) of the desired title compound.
Intermediate 24
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl]oxy}phenyl)-3-[2-(dimethylamino)ethyl]urea
Figure imgf000106_0002
In analogy to intermediate 20), in a single experiment using 3,5-difluoro-4-{[3-(trifluoromethyl)- 1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}aniline (100 mg, 218 μηιοΙ, intermediate 1 ), N,N-dimethylethane-1 ,2-diamine (28.8 mg, 326 μηιοΙ), Ν,Ν- diisopropylethylamine (28.8 mg, 326 μmol) and bis(trichloromethyl) carbonate (64.6 mg, 218 μηηοΙ) in dichloromethane (15 ml_), we obtained 54 mg (43% yield) of the desired title compound. Intermediate 25
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]m
b]pyridin-4-yl]oxy}phenyl -3-[(1 ,1 -dioxidothietan-3-yl)methyl]urea
Figure imgf000107_0001
In analogy to intermediate 2), using phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (100 mg, 173 μηηοΙ), intermediate 1 ) and 1 -(1 ,1 -dioxidothietan-3-yl)methanamine (23.3 mg, 173 μηηοΙ) in DMF (1 .0 ml_, 13 mmol), we obtained after one single purification using a Biotage
chromatography system 83.9 mg (91 % purity, 71 % yield) of the desired title compound. Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.1 1 - -0.08 (m, 9H), 0.80 - 0.86 (m, 2H), 2.68 - 2.72 (m, 1 H), 3.34 - 3.39 (m, 2H), 3.54 - 3.60 (m, 2H), 3.89 - 3.96 (m, 2H), 4.19 - 4.27 (m, 2H), 5.68 (s, 2H), 6.58 (d, 1 H), 6.77 (t, 1 H), 7.36 - 7.44 (m, 2H), 8.28 (d, 1 H), 8.36 (s, 1 H), 9.22 (s, 1 H).
Intermediate 26
N-(2-{[(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamoyl]amino}ethyl)acetamide
Figure imgf000107_0002
In analogy to intermediate 2), using phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (100 mg, 173 μηηοΙ), intermediate 1 ) and N-(2-aminoethyl)acetamide (17.6 mg, 173 μηηοΙ) in DMF (1 .0 ml_, 13 mmol), we obtained after one single purification using a Biotage chromatography system 69.0 mg (90 % purity, 61 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.12 - -0.08 (m, 9H), 0.79 - 0.87 (m, 2H), 1.82 (s, 3H), 3.1 1 - 3.19 (m, 4H), 3.54 - 3.61 (m, 2H), 5.68 (s, 2H), 6.43 (t, 1 H), 6.57 (d, 1 H), 7.35 - 7.44 (m, 2H), 7.96 (br s, 1 H), 8.29 (d, 1 H), 8.36 (s, 1 H), 9.1 1 (s, 1 H). Intermediate 27
(+/-)-1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4- l]oxy}phenyl)-3-[1 -(morpholin-4-yl)propan-2-yl]urea
Figure imgf000108_0001
In analogy to intermediate 2), using phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (100 mg, 173 μηηοΙ), intermediate 1 ) and (+/-)-1 -(morpholin-4-yl)propan-2-amine (24.9 mg, 173 μηηοΙ) in DMF (1 .0 ml_, 13 mmol), we obtained after one single purification using a Biotage chromatography system 82.0 mg (100 % purity, 75 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.10 - -0.08 (m, 9H), 0.79 - 0.87 (m, 2H), 1 .1 1 (d, 3H), 2.18 - 2.25 (m, 1 H), 2.35 - 2.46 (m, 4H), 3.53 - 3.61 (m, 6H), 3.84 (spt, 1 H), 5.68 (s, 2H), 6.23 (d, 1 H), 6.57 (d, 1 H), 7.34 - 7.41 (m, 2H), 8.29 (d, 1 H), 8.36 (s, 1 H), 9.00 (s, 1 H), 9.32 (s, 1 H). Intermediate 28
(+/-)-1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4- l]oxy}phenyl)-3-[2-(morpholin-4-yl)propyl]urea
Figure imgf000109_0001
In analogy to intermediate 2), using phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (100 mg, 173 μηηοΙ), intermediate 1 ) and (+/-)-2-(morpholin-4-yl)propan-1 -amine (24.9 mg, 173 μηηοΙ) in DMF (1 .0 mL, 13 mmol), we obtained after one single purification using a Biotage chromatography system 84.8 mg (100 % purity, 78 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.1 1 - -0.08 (m, 9H), 0.79 - 0.87 (m, 2H), 0.93 (d, 3H), 2.36 - 2.44 (m, 2H), 2.62 (sxt, 1 H), 3.04 - 3.20 (m, 2H), 3.55 - 3.65 (m, 6H), 5.68 (s, 2H), 6.28 (t, 1 H), 6.58 (d, 1 H), 7.34 - 7.41 (m, 2H), 8.29 (d, 1 H), 8.36 (s, 1 H), 9.22 (s, 1 H).
Intermediate 29
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl]oxy}phenyl)-3-[2-(methylsulfonyl)ethyl]urea
Figure imgf000109_0002
In analogy to intermediate 2), using phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (100 mg, 173 μηηοΙ), intermediate 1 ) and 2-(methylsulfonyl)ethanamine hydrochloride (1 :1 ) (27.5 mg, 173 μηιοΙ) together with N,N-diisopropylethylamine (30 μΙ_, 170 μηιοΙ) in DMF (1 .0 ml_, 13 mmol), we obtained after one single purification using a Biotage chromatography system 72.0 mg (100 % purity, 69 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.1 1 - -0.07 (m, 9H), 0.83 (t, 2H), 3.04 (s, 3H), 3.32 (t, 2H), 3.52 - 3.60 (m, 4H), 5.68 (s, 2H), 6.58 (d, 1 H), 6.61 (t, 1 H), 7.39 (d, 2H), 8.28 (d, 1 H), 8.36 (s, 1 H), 9.33 (s, 1 H).
Intermediate 30
3-{[(3,5-difluoro-4-{[3-(trifluoro
pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamoyl]amino}propane-1 -sulfonamide
Figure imgf000110_0001
In analogy to intermediate 2), using phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (100 mg, 173 μηηοΙ), intermediate 1 ) and 3-aminopropane-1 -sulfonamide hydrochloride (1 :1 ) (30.1 mg, 173 μηιοΙ) together with N,N-diisopropylethylamine (30 μΙ_, 170 μηιοΙ) in DMF (1 .0 ml_, 13 mmol), we obtained after one single purification using a Biotage chromatography system 66.1 mg (85 % purity, 52 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.1 1 - -0.08 (m, 9H), 0.79 - 0.86 (m, 2H), 1 .86 (quin, 2H), 2.95 - 3.02 (m, 2H), 3.21 (q, 2H), 5.68 (s, 3H), 6.51 - 6.60 (m, 2H), 6.82 (s, 2H), 7.39 (d, 2H), 8.26 - 8.32 (m, 2H), 8.36 (s, 1 H), 9.06 (s, 1 H). Intermediate 31
3-(3,5-difluoro-4-{[3-(trifluoromet^
b]pyridin-4-yl]oxy}phenyl)-1 -methyl-1 -[2-(morpholin-4-yl)ethyl]urea
Figure imgf000111_0001
In analogy to intermediate 2), using phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (100 mg, 173 μηηοΙ), intermediate 1 ) and N-methyl-2-(morpholin-4-yl)ethanamine (24.9 mg, 173 μηηοΙ) in DMF (1 .0 ml_, 13 mmol), we obtained after one single purification using a Biotage
chromatography system 68.3 mg (91 % purity, 57 % yield) of the desired title compound. Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.12 - -0.08 (m, 9H), 0.79 - 0.87 (m, 2H), 2.37 - 2.47 (m, 6H), 2.99 (s, 3H), 3.35 - 3.49 (m, 2H), 3.52 - 3.62 (m, 6H), 5.68 (s, 2H), 6.57 (d, 1 H), 7.49 - 7.58 (m, 2H), 8.27 - 8.31 (m, 1 H), 8.36 (s, 1 H), 8.84 (s, 1 H).
Intermediate 32
N-(2-{[(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4- l]oxy}phenyl)carbamoyl]amino}ethyl)methanesulfonamide
Figure imgf000111_0002
In analogy to intermediate 2), using phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (100 mg, 173 μηηοΙ), intermediate 1 ) and N-(2-aminoethyl)methanesulfonamide (24.8 mg, 96 % purity, 173 μηηοΙ) in DMF (1 .0 mL, 13 mmol), we obtained after one single purification using a Biotage chromatography system 104 mg (93 % purity, 90 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.1 1 - -0.08 (m, 9H), 0.79 - 0.86 (m, 2H), 2.92 (s, 3H), 3.01 - 3.07 (m, 2H), 3.22 (q, 2H), 3.54 - 3.60 (m, 2H), 5.68 (s, 2H), 6.54 (br t, 1 H), 6.58 (d, 1 H), 7.12 (br s, 1 H), 7.35 - 7.43 (m, 2H), 8.28 (d, 1 H), 8.36 (s, 1 H), 9.23 (s, 1 H). Intermediate 33
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]m
b]pyridin-4-yl]oxy}phenyl)-3-pyridin-3-ylurea
Figure imgf000112_0001
In analogy to intermediate 2), using phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (100 mg, 173 μηηοΙ), intermediate 1 ) and pyridin-3-amine (16.2 mg, 173 μηηοΙ) in DMF (1 .0 mL, 13 mmol), we obtained after one single purification using a Biotage chromatography system 68.2 mg (93 % purity, 64 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.10 - -0.08 (m, 9H), 0.79 - 0.87 (m, 2H), 3.55 - 3.61 (m, 2H), 5.69 (s, 2H), 6.61 (d, 1 H), 7.35 (ddd, 1 H), 7.45 - 7.51 (m, 2H), 7.95 (ddd, 1 H), 8.23 (dd, 1 H), 8.30 (d, 1 H), 8.38 (s, 1 H), 8.63 (d, 1 H), 9.13 (s, 1 H), 9.36 (br s, 1 H). Intermediate 34
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]m
b]pyridin-4-yl]oxy}phenyl)-3-[3-(trifluoromethyl)phenyl]urea
Figure imgf000113_0001
In analogy to intermediate 2), using phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (100 mg, 173 μηιοΙ), intermediate 1 ) and 3-(trifluoromethyl)aniline (27.8 mg, 173 μηιοΙ) in DMF (1 .0 mL, 13 mmol), we obtained after one single purification using a Biotage chromatography system 40.0 mg (85 % purity, 30 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.1 1 - -0.08 (m, 9H), 0.80 - 0.86 (m, 2H), 3.55 - 3.61 (m, 2H), 5.69 (s, 2H), 6.60 - 6.63 (m, 1 H), 7.36 (d, 1 H), 7.46 - 7.57 (m, 3H), 7.59 - 7.65 (m, 1 H), 8.01 (s, 1 H), 8.28 - 8.32 (m, 1 H), 8.38 (s, 1 H), 9.33 (br s, 2H).
Intermediate 35
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl]oxy}phenyl)-3-(1 ,3,4-thiadiazol-2-yl)urea
Figure imgf000113_0002
To a solution of 1 ,3,4-thiadiazol-2-amine (66.0 mg, 653 μηηοΙ) in dichloromethane (9.0 mL) and pyridine (2.0 mL) was added di-1 H-imidazol-1 -ylmethanone (1 16 mg, 718 μηηοΙ) and the mixture was stirred at reflux for 30 minutes. Then this mixture was cooled to room tempetature and added to a solution of 3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}aniline (300 mg, 653 μηηοΙ, see Synthesis 2007, page 251-258, Org. Process Res. Dev. 2010, page 168-173) in
dichloromethane (3.0 mL) and pyridine (3.0 mL) and stirred at 60°C for 16 hours. After cooling to room temperature ethyl acetate and water was added. The aqueous phase was separated and washed twice with ethyl acetate. The combined organic phases were washed with brine, dried over sodium sulfate, filtered and concentrated to dryness. The resulting residue was purified via a Biotage chromatography system (28g snap KP-NH column, hexane / 0 - 100% ethyl acetate, then ethyl acetate / 0 - 100% methanol) to obtain 127 mg (86 % purity, 29 % yield) of the desired title compound.
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.1 1 - -0.07 (m, 9H), 0.80 - 0.87 (m, 2H), 3.54 - 3.61 (m, 2H), 5.69 (s, 2H), 6.61 (d, 1 H), 7.71 - 7.80 (m, 2H), 8.29 (d, 1 H), 8.35 (s, 1 H), 8.75 (s, 1 H), 10.41 (br s, 1 H), 10.74 (br s, 1 H).
Intermediate 36
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]m
b]pyridin-4-yl]oxy}phenyl)-3-[2-fluoro-5-(trifluoromethyl)phenyl]urea
Figure imgf000114_0001
To a solution of 3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl]oxy}aniline (100 mg, 218 μηηοΙ, see Synthesis 2007, page 251-258, Org. Process Res. Dev. 2010, page 168-173) and 1 -fluoro-2-isocyanato-4- (trifluoromethyl)benzene (49.1 mg, 239 μηηοΙ) in dichloromethane (1 .5 mL) and pyridine (1 .5 mL) was stirred at 60°C for 3 hours. After cooling to room temperature ethyl acetate and water was added. The aqueous phase was separated and washed twice with ethyl acetate. The combined organic phases were washed with brine, dried over sodium sulfate, filtered and concentrated to dryness. The resulting residue was purified via a Biotage chromatography system (1 1 g snap KP-NH column, hexane / 0 - 100% ethyl acetate, then ethyl acetate / 0 - 100% methanol) to obtain 240 mg (80 % purity, 133 % yield) of the desired title compound. Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.1 1 - -0.08 (m, 9H), 0.77 - 0.89 (m, 2H), 3.55 - 3.61 (m, 2H), 5.69 (s, 2H), 6.61 (d, 1 H), 7.41 - 7.55 (m, 2H), 8.30 (d, 1 H), 8.38 (s, 1 H), 8.59 (ddd, 2H), 9.09 (br s, 1 H), 9.48 (d, 1 H), 9.61 (s, 1 H).
Intermediate 37
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl]oxy}phenyl)-3-pyridazin-3-ylurea
Figure imgf000115_0001
In analogy to intermediate 36), using pyridazin-3-amine (103 mg, 1.09 mmol), di-1 H-imidazol- 1 -ylmethanone (194 mg, 1.20 mmol) and 3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}aniline (500 mg, 1.09 mmol), we obtained after one single purification using a Biotage chromatography system 222 mg (92 % purity, 32 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.1 1 - -0.07 (m, 9H), 0.80 - 0.86 (m, 2H), 3.53 - 3.62 (m, 2H), 5.69 (s, 2H), 6.62 (d, 1 H), 7.49 - 7.56 (m, 2H), 7.68 (dd, 1 H), 8.05 (dd, 1 H), 8.30 (d, 1 H), 8.38 (s, 1 H), 8.92 (dd, 1 H), 10.02 (br s, 1 H), 10.16 (br s, 1 H). Intermediate 38
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]m
b]pyridin-4-yl]oxy} henyl)-3-(2-methoxyphenyl)urea
Figure imgf000116_0001
In analogy to intermediate 36), using 1 -isocyanato-2-methoxybenzene (56 μΙ_, 420 μηηοΙ), Ν,Ν- diisopropylethylamine (1 10 μί, 650 μηιοΙ) and 3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}aniline (150 mg, 326 μηηοΙ, see Synthesis 2007, page 251-258, Org. Process Res. Dev. 2010, page 168-173), we obtained after one single purification using a Biotage chromatography system 175 mg (30 % purity, 88 % yield) of the desired title compound.
Intermediate 39
4-{[6-chloro-3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl]oxy}-2,5-difluoroaniline
Figure imgf000116_0002
A solution of 6-chloro-4-nitro-3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridine (460 mg, 1 .16 mmol, see Synthesis 2007 , page 251-258, Org. Process Res. Dev. 2010, page 168-173), 4-amino-2,5-difluorophenol (185 mg, 1 .28 mmol) and potassium carbonate (482 mg, 3.49 mmol) in DMSO (4.6 mL) was stirred at 120°C for 3 hours. After cooling to room temperature the reaction mixture was diluted with ethyl actate (200 mL). This organic phase was washed twotimes with water (30 mL) and once with brine (20 mL), then dried over sodium sulfate and after filtration dried to dryness. The resulting residue was purified via a Biotage chromatography system (28g snap KP-NH column, hexane / 0 - 70% ethyl acetate) to obtain 301 mg (92 % purity, 48 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.10 - -0.07 (m, 9H), 0.81 - 0.89 (m, 2H), 3.53 - 3.61 (m, 2H), 5.57 - 5.65 (m, 4H), 6.48 (d, 1 H), 6.76 (dd, 1 H), 7.30 (dd, 1 H), 8.37 (s, 1 H). Intermediate 40
2,5-difluoro-4-{[3-(trifluoromethy ^
b]pyridin-4-yl]oxy}aniline
Figure imgf000117_0001
To a solution of 4-{[6-chloro-3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl]oxy}-2,5-difluoroaniline (298 mg, 603 μηιοΙ) and triethylamine (100 μΙ_, 720 μmol) in ethanol (21 mL) was given 10% Pd on carbon (29.8 mg). This mixture was stirred in an hydrogen atmosphere for 7 hours at room temperature. Then the mixture was filtered through Celite and the Celite was washed with ethyl acetate. The organic phase was evaporated to dryness and the resulting residue was purified via a Biotage chromatography system (28g snap KP-NH column, hexane / 10 - 70% ethyl acetate) to obtain 174 mg (90 % purity, 61 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.10 - -0.07 (m, 9H), 0.80 - 0.87 (m, 2H), 3.53 - 3.60 (m, 2H), 5.54 (s, 2H), 5.67 (s, 2H), 6.50 (dd, 1 H), 6.75 (dd, 1 H), 7.23 (dd, 1 H), 8.25 (d, 1 H), 8.31 (d, 1 H).
Intermediate 41
phenyl (2,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate
Figure imgf000117_0002
In analogy to intermediate 1 ), using 2,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}aniline (170 mg, 370 μηηοΙ), intermediate 40) and phenyl carbonochloridate (51 μΙ_, 407 μηηοΙ) in pyridine (170 μΙ_, 2.1 mmol), we obtained after one single purification using a Biotage chromatography system 195 mg (95 % purity, 91 % yield) of the desired title compound. Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.10 - -0.07 (m, 9H), 0.79 - 0.87 (m, 2H), 3.54 - 3.61 (m, 2H), 5.69 (s, 2H), 6.64 (dd, 1 H), 6.72 - 6.78 (m, 2H), 7.13 - 7.31 (m, 2H), 7.42 - 7.48 (m, 1 H), 7.61 (dd, 1 H), 7.88 (dd, 1 H), 8.30 (d, 1 H), 8.37 (d, 1 H), 9.32 (s, 1 H). Intermediate 42
1 -(2,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]m
b]pyridin-4-yl]oxy}phenyl)-3-[3-(morpholin-4-yl)propyl]urea
Figure imgf000118_0001
In analogy to intermediate 2), phenyl (2,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (90.0 mg, 155 μηηοΙ, intermediate 41 ) and 3-(morpholin-4-yl)propan-1 -amine (45 μΙ_, 31 1 μηηοΙ) in DMF (750 μΙ_), we obtained after one single purification using a Biotage chromatography system 93.9 mg (89 % purity, 94 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.1 1 - -0.07 (m, 9H), 0.80 - 0.88 (m, 2H), 1 .60 (quin, 2H), 2.27 - 2.38 (m, 6H), 3.14 (q, 2H), 3.54 - 3.61 (m, 6H), 5.68 (s, 2H), 6.56 (dd, 1 H), 6.69 - 6.78 (m, 1 H), 7.51 (dd, 1 H), 8.21 - 8.29 (m, 2H), 8.34 (d, 1 H), 8.59 (s, 1 H).
Intermediate 43
1 -(2,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl]oxy}phenyl)-3-[2-(morpholin-4-yl)ethyl]urea
Figure imgf000118_0002
In analogy to intermediate 2), using phenyl (2,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (90.0 mg, 155 μηιοΙ, intermediate 41 ) and 2-(morpholin-4-yl)ethanamine (41 μΙ_, 310 μηιοΙ) in DMF (750 μΙ_), we obtained after one single purification using a Biotage chromatography system 72.5 mg (95 % purity, 76 % yield) of the desired title compound.
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.10 - -0.07 (m, 9H), 0.79 - 0.88 (m, 2H), 2.36 - 2.43 (m, 6H), 3.24 (q, 2H), 3.54 - 3.63 (m, 6H), 5.68 (s, 2H), 6.54 - 6.58 (m, 1 H), 6.72 - 6.78 (m, 1 H), 7.51 (dd, 1 H), 8.22 - 8.30 (m, 2H), 8.34 (s, 1 H), 8.80 (s, 1 H).
Intermediate 44
phenyl {4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4- yl)oxy]-3,5-difluorophenyl}carbamate
Figure imgf000119_0001
To solution of 4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]- 3,5-difluoroaniline (1.20 g, 2.82 mmol, synthesis see ChemMedChem 3, (2008), p. 1893 ff., cpd 63) in ethyl acetate (20 mL) and saturated sodium bicarbonate solution (10 mL) was slowly added at RT phenyl carbonochloridate (441 mg, 2.82 mmol). After stirring this mixture 5 hours, the mixture was diluted with water. The organic phase was washed with brine, dried over sodium sulfate, filtered and concentrated to dryness. The resulting residue was purified via a Biotage chromatography system (KP-Sil snap column; hexane / ethyl acetate gradient eith up to 35% ethyl acetate) to obtain 1 .37 g (89 % yield) of the desired title compound.
1H-NMR (400 MHz, CDCI3) δ [ppm]: -0.05 (s, 9H), 0.89 - 0.95 (m, 2H), 3.52 - 3.58 (m, 2H), 5.63 (s, 2H), 6.31 (d, 1 H), 7.12 (bs, 1 H); 7.17-7.22 (m, 2H); 7.23-7.31 (m, 4H + CHC ); 7.40- 7.45 (m, 2H); 8.14 (d, 1 H). Intermediate 45
1 -{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}-3-[3-(piperidin-1 -yl)propyl]urea
Figure imgf000120_0001
To solution of phenyl {4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin- 4-yl)oxy]-3,5-difluorophenyl}carbamate (120 mg, 0.22 mmol, intermediate 44) in DMF (2.4 mL) was added 3-(piperidin-1 -yl)propan-1 -amine (31 .3 mg, 0.22 mmol) and this mixture was stirred at 60°C for 3 hours. The mixture was diluted with water and extracted two times with ethyl acetate. The combined organic phases were washed 3 times with halfconcentrated aqueous sodium chloride solution, dried over sodium sulfate, filtered and concentrated to dryness. The resulting residue was purified via a Biotage chromatography system (KP-Sil snap column; dichloromethane / methanol gradient with up to 10% methanol) to obtain 122 mg (88 % yield) of the desired title compound.
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.12 - -0.08 (m, 9H), 0.82 (t, 2H), 1 .33-1.45 (m, 2H); 1 .45-1 .57 (m, 4H); 1 .47-1.68 (m, 2H); 2.30-2.46 (m, 4H); 3.1 1 (q, 2H); 3.53 (dd, 2H); 5.60 (s, 2H); 6.41 -6.50 (d+m, 2H); 7.36-7.41 (m, 2H); 7.84 (s, 1 H); 8.17 (d, 1 H); 9.08 (bs, 1 H). Intermediate 46
1 -{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}-3-[2-(dimethylamino ethyl]urea
Figure imgf000121_0001
According to the synthesis of intermediate 45, 175 mg (0.32 mmol) phenyl {4-[(3-chloro-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}carbamate (intermediate 44) and 28 mg (0.32 mmol) N,N-dimethylethane-1 ,2-diamine in 3.5 mL DMF were heated at 60°C for 3 hours. After workup, the resulting residue was purified via a Biotage chromatography system (KP-Sil snap column; dichloromethane / methanol gradient with up to 3% methanol) to yield to 122 mg (67%)of the title compound.
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.12- -0.07 (m, 9H); 0.79-0.85 (m, 2H); 2.21 (s, 6H); 2.34-2.42 (m, 2H); 3.20 (q, 2H); 3.50-3.56 (m, 2H); 5.60 (s, 2H); 6.32 (t, 1 H); 6.42 (d, 1 H); 7.33-7.39 (m, 2H); 7.84 (s, 1 H); 8.17 (d, 1 H); 9.21 (s, 1 H). Intermediate 47
1 -{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}-3-[2-(piperidin-1 - l)ethyl]urea
Figure imgf000121_0002
According to the synthesis of intermediate 45, 85 mg (0.156 mmol) phenyl {4-[(3-chloro-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}carbamate (intermediate 44) and 20 mg (0.156 mmol) 2-(piperidin-1 -yl)ethanamine in 1 .7 mL DMF were heated at 60°C for 2 hours. After workup, the resulting residue was purified via a Biotage chromatography system (KP-Sil snap column dichloromethane / methanol gradient with up to 10% methanol) to yield to 51 mg (54%)of the title compound.
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.12- -0.07 (m, 9H); 0.79-0.85 (m, 2H); 1 .33-1 .76 (m, 6H); 3.50-3.56 (m, 2H); 5.60 (s, 2H); 6.42 (d, 1 H); 7.35-7.43 (m, 2H); 7.84 (s, 1 H); 8.17 (d, 1 H); 9.38 (bs, 1 H).
Intermediate 48
1 -{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}-3-[3-(morpholin-4-yl)propyl]urea
Figure imgf000122_0001
According to the synthesis of intermediate 45, 120 mg (0.22 mmol) phenyl {4-[(3-chloro-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}carbamate (intermediate 44) and 31 .7 mg (0.22 mmol) 3-(morpholin-4-yl)propan-1 -amine in 2.4 mL DMF were heated at 60°C for 2 hours. After workup, the resulting residue was purified via a Biotage chromatography system (KP-Sil snap column dichloromethane / methanol gradient with up to 3% methanol) to yield to 102 mg (74%)of the title compound.
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.12- -0.06 (m, 9H); 0.79-0.85 (m, 2H); 1 .55-1 .64 (m, 2H); 2.25-2.38 (m, 6H); 3.12 (q, 2H); 3.50-3.61 (m, 6H); 5.60 (s, 2H); 6.41 -6.48 (m, 2H); 7.36- 7.41 (m, 2H); 7.84 (s, 1 H); 8.17 (d, 1 H); 9.02 (bs, 1 H). Intermediate 49
1 -{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}-3-(2-methoxyeth l)urea
Figure imgf000123_0001
According to the synthesis of intermediate 45, 150 mg (0.275 mmol) phenyl {4-[(3-chloro-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}carbamate (intermediate 44) and 20.6 mg (0.275 mmol) 2-methoxyethanamine in 3 mL DMF were heated at 60°C for 2 hours. After workup, the resulting residue was purified via a Biotage
chromatography system (KP-Sil snap column dichloromethane / methanol gradient with up to 3% methanol) to yield to 138 mg (91 %) of the title compound.
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.12- -0.06 (m, 9H); 0.79-0.85 (m, 2H); 3.24-3.31 (m+s, 5H); 3.39 (t, 2H); 3.50-3.56 (m, 2H); 5.60 (s, 2H); 6.43 (d, 1 H); 6.50 (t, 1 H); 7.35-7.40 (m, 2H); 7.84 (s, 1 H); 8.17 (d„ 1 H); 9.12 (s, 1 H). Intermediate 50
1 -{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}-3-ethylurea
Figure imgf000123_0002
According to the synthesis of intermediate 45, 175 mg (0.32 mmol) phenyl {4-[(3-chloro-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}carbamate (intermediate 44) and 0.16 mL (0.32 mmol) ethanamine in 3.5 mL DMF were heated at 60°C for 2 hours. After workup, the resulting residue was purified via a Biotage chromatography system (KP-Sil snap column dichloromethane / methanol gradient with up to 3% methanol) to yield to 140 mg (83%) of the title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.12- -0.06 (m, 9H); 0.79-0.85 (m, 2H); 1 .06 (t, 3H); 3.07-3.16 (m, 2H); 3.50-3.56 (m, 2H); 5.60 (s, 2H); 6.40-6.46 (m, 2H); 7.36-7.41 (m, 2H); 7.83 (s, 1 H); 8.17 (d, 1 H); 9.02 (s, 1 H).
Intermediate 51
1 -{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}-3-[2-(morpholin-4-yl)ethyl]urea
Figure imgf000124_0001
According to the synthesis of intermediate 45, 50 mg (0.092 mmol) phenyl {4-[(3-chloro-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}carbamate (intermediate 44) and 12 mg (0.092 mmol) 2-(morpholin-4-yl)ethanamine in 1 mL DMF were heated at 60°C for 2 hours. After workup, the resulting residue was purified via a Biotage chromatography system (KP-Sil snap column dichloromethane / methanol gradient with up to 3% methanol) to yield to 45 mg (80%) of the title compound.
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.12- -0.06 (m, 9H); 0.79-0.85 (m, 2H); 2.34-2.45 (m, 6H); 3.22 (q, 2H); 3.50-3.56 (m, 2H); 3.59 (t, 4H); 5.60 (2, 1 H); 6.32 (t, 1 H); 6.43 (d, 1 H); 7.34- 7.40 (m, 2H); 7.84 (s, 1 H); 8.17 (d, 1 H); 9.19 (s, 1 H). Intermediate 52
1 -benzyl-3-{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4- yl)oxy]-3,5-difluorophenyl}urea
Figure imgf000125_0001
According to the synthesis of intermediate 45, 150 mg (0.275 mmol) phenyl {4-[(3-chloro-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}carbamate (intermediate 44) and 29 mg (0.275 mmol) 1 -phenylmethanamine in 3 mL DMF were heated at 60°C for 2 hours. After workup, the resulting residue was purified via a Biotage
chromatography system (KP-Sil snap column dichloromethane / methanol gradient with up to 3% methanol) to yield to 150 mg (93%) of the title compound.
1H-NMR (400 MHz, CDCI3) δ [ppm]: -0.07- -0.03 (m, 9H); 0.88-0.94 (m, 2H); 3.51 -3.57 (m, 2H); 4.44 (d, 2H); 5.57 (t, 1 H); 5.62 (s, 2H); 6.29 (d, 1 H); 7.14-7.19 (m, 2H); 7.24 (s, 1 H); 7.27-7.37 (m, 5H); 7.44 (bs, 1 H); 8.1 1 (d, 1 H). Intermediate 53
1 -{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}-3-(pyrimidin-5-ylmeth l)urea
C
Figure imgf000125_0002
According to the synthesis of intermediate 45, 150 mg (0.275 mmol) phenyl {4-[(3-chloro-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}carbamate (intermediate 44) and 30 mg (0.275 mmol) 1 -(pyrimidin-5-yl)methanamine in 3 mL DMF were heated at 60°C for 4 hours. After workup, the resulting residue was purified via a Biotage chromatography system (KP-Sil snap column dichloromethane / methanol gradient with up to 3% methanol) to yield to 125 mg (77%) of the title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.12- -0.07 (m, 9H); 0.79-0.85 (m, 2H); 3.50-3.56 (m, 2H); 4.35 (d, 2H); 5.60 (s, 2H); 6.42 (d, 1 H); 7.09 (t, 1 H); 7.37-7.43 (m, 2H); 7.83 (s, 1 H); 8.16 (s, 1 H); 8.76 (s, 2H); 9.09 (s, 1 H); 9.31 (s, 1 H).
Intermediate 54
1 -{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}-3-(pyridin-4-ylmethyl)urea
Figure imgf000126_0001
According to the synthesis of intermediate 45, 150 mg (0.275 mmol) phenyl {4-[(3-chloro-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}carbamate (intermediate 44) and 30 mg (0.275 mmol) 1 -(pyridin-4-yl)methanamine in 3 mL DMF were heated at 60°C for 6 hours. After workup, the resulting residue was purified via a Biotage chromatography system (KP-Sil snap column dichloromethane / methanol gradient with up to 3% methanol) to yield to 85 mg (50%) of the title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.12- -0.07 (m, 9H); 0.79-0.85 (m, 2H); 3.50-3.56 (m, 2H); 4.34 (d, 2H); 5.60 (s, 2H); 6.43 (d, 1 H); 7.07 (t, 1 H); 7.29 (d, 2H); 7.38-7.44 (m, 2H); 7.84 (s, 1 H); 8.17 (d, 1 H); 8.51 (d, 2H); 9.33 (s, 1 H). Intermediate 55
1 -{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}-3-(2-cyanoethyl)urea
Figure imgf000127_0001
According to the synthesis of intermediate 45, 150 mg (0.275 mmol) phenyl {4-[(3-chloro-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}carbamate (intermediate 44) and 19 mg (0.275 mmol) 3-aminopropanenitrile in 3 mL DMF were heated at 60°C for 3 hours. After workup, the resulting residue was purified via a Biotage
chromatography system (KP-Sil snap column dichloromethane / methanol gradient with up to 3% methanol) to yield to 105 mg (70%) of the title compound.
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.12- -0.07 (m, 9H); 0.79-0.85 (m, 2H); 2.70 (t, 2H); 3.33-3.39 (m, signal covered by water signal); 3.50-3.56 (m, 2H); 5.60 (s, 2H); 6.44 (d, 1 H); 6.80 (t, 1 H); 7.39-7.44 (m, 2H); 7.84 (s, 1 H); 8.17 (d, 1 H); 9.29 (s, 1 H). Intermediate 56
1 -{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}-3-(3-methylbut l urea
C
Figure imgf000127_0002
According to the synthesis of intermediate 45, 150 mg (0.275 mmol) phenyl {4-[(3-chloro-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}carbamate (intermediate 44) and 24 mg (0.275 mmol) 3-methylbutan-1 -amine in 3 mL DMF were heated at 60°C for 2 hours. After workup, the resulting residue was purified via a Biotage
chromatography system (KP-Sil snap column dichloromethane / methanol gradient with up to 3% methanol) to yield to 130 mg (83%) of the title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.12- -0.07 (m, 9H); 0.79-0.85 (m, 2H); 0.89 (d, 6H); 1 .33 (q. 2H); 1 .55-1 .65 (m, 1 H); 3.1 1 (q, 2H); 3.50-3.56 (m, 2H); 5.60 (s, 2H); 6.39 (t, 1 H); 6.43 (d, 1 H); 7.36-7.41 (m, 2H); 7.83 (s, 1 H); 8.17 (d, 1 H); 8.96 (s, 1 H).
Intermediate 57
1 -{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}-3-(1 ,2-oxazol-3-yl urea
Figure imgf000128_0001
According to the synthesis of intermediate 45, 150 mg (0.275 mmol) phenyl {4-[(3-chloro-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}carbamate (intermediate 44) and 23 mg (0.275 mmol) 1 ,2-oxazol-3-amine in 3 mL DMF were heated at 60°C for 2 hours. The reaction was further continued for 3 hours at 80°C and 7 hours at 100°C. After workup, the resulting residue was purified via a Biotage chromatography system (KP-Sil snap column dichloromethane / methanol gradient with up to 3% methanol) to yield to 12 mg (8%) of the title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.12- -0.07 (m, 9H); 0.79-0.85 (m, 2H); 3.50-3.56 (m, 2H); 5.60 (s, 2H); 6.46 (d, 1 H); 6.86 (d, 1 H); 7.46-7.53 (m, 2H); 7.85 (s, 1 H); 8.18 (d, 1 H); 8.78 (d, 1 H); 9.31 (s, 1 H); 9.92 (s, 1 H). Intermediate 58
1 -{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}-3-pyridazin-3-ylurea
Figure imgf000129_0001
According to the synthesis of intermediate 45, 580 mg (1.06 mmol) phenyl {4-[(3-chloro-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}carbamate (intermediate 44) and 202 mg (1.06 mmol) pyridazin-3-amine in 10 mL DMF were heated at 60°C for 5 hours. After workup, the resulting residue was purified via a Biotage
chromatography system (KP-Sil snap column dichloromethane / methanol gradient with up to 3% methanol) to yield to 450 mg (74%) of the title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.12- -0.07 (m, 9H); 0.80-0.86 (m, 2H); 3.50-3.56 (m, 2H); 5.61 (d, 1 H); 6.48 (d, 1 H);7.50-7.55 (m, 2H); 7.68 (dd, 1 H); 7.86 (s, 1 H); 8.05 (dd, 1 H); 8.19 (d, 1 H); 8.92 (dd, 1 H); 9.99 (bs, 1 H); 10.12 (bs, 1 H). Intermediate 59
1 -{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}urea
C
Figure imgf000129_0002
To solution of phenyl {4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin- 4-yl)oxy]-3,5-difluorophenyl}carbamate (100 mg, 0.18 mmol, intermediate 44) in DMF (2.0 mL) was added an ammonium hydroxyd solution (25% in water, 0.03 mL) and this mixture was stirred at 60°C for 2 hours. The mixture was diluted with water and extracted two times with ethyl acetate. The combined organic phases were dried over sodium sulfate, filtered and concentrated to dryness. The resulting residue was purified via a Biotage chromatography system (KP-Sil snap column; dichloromethane / methanol gradient with up to 10% methanol) to obtain crude 194 mg of the desired title compound that was used without further purification in the next step.
1H-NMR (400 MHz, CDCI3) δ [ppm]: -0.09 - -0.02 (s, 9H); 0.88-0.94 (m, 2H); 4.52-3.58 (m, 2H); 5.09 (bs, 2H); 5.63 (s, 2H); 6.31 (d, 1 H); 7.16-7.26 (m, 3H); 7.96 (s, 1 H); 8.12 (d, 1 H);
Intermediate 60
Phenyl {4-[(3-chloro-1 H-pyrrolo[2,3-fe]pyridin-4-yl)oxy]-3,5-difluorophenyl}carbamate
Figure imgf000130_0001
4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluoroaniline (4.00 g, 13.5 mmol, synthesis see ChemMedChem 3, (2008), p. 1893 ff., cpd 63) was dissolved in ethyl acetate (160 mL) and saturated aqueous sodium bicarbonate solution (80 mL) was added. Under vigorous stirring phenyl carbonochloridate (2.0 mL, 17 mmol) was added dropwise. The mixture was stirred for 6 h at room temperature. The organic layer was separated, extracted with brine and dried over sodium sulfate. The solvent was evaporated and purified by column
chromatography on silica gel (eluent ethyl acetate : petroleum ether = 2:1 ) to yield 2.60 g (42%) of the title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 12.15 (s, 1 H), 10.79 (s, 1 H), 8.12 (d, 1 H), 7.63 (d, 1 H), 7.50-7.42 (m, 4H), 7.33-7.24 (m, 3H), 6.36 (d, 1 H) Intermediate 61
4-[(3-bromo-1 -{[2-(trimethylsilyl)eta
difluoroaniline
Figure imgf000131_0001
To a solution of N-(4-(3-bromo-1 -((2-(trimethylsilyl)ethoxy)methyl)-1 H- pyrrolo[2,3-b]pyridin-4- yloxy)-3,5-difluorophenyl)acetamide (6.5 g, 12.7 mmol, synthesis see ChemMedChem 3,
(2008), p. 1893 ff., cpd 53b) in 150 mL of ethanol and 15 mL of water. Then sodium hydroxide (2.5 g, 63.4 mmol) was added. The mixture was stirred for overnight at 60 °C. Then down to room temperature and the mixture was evaporated, and the residue was purified by column chromatography with petroleum ether/ ethyl acetate (2:3/v:v) to yield 4.8 g (80 %) of the product.
1H-NMR (300 MHz, DMSO-d6): δ [ppm] 0.01 -0.08 (s, 9H), 0.80-0.86 (t, 2H), 3.50-3.56 (t, 2H), 5.60 (s, 2H), 5.83 (s, 2H), 6.38-6.42 (m, 3H), 7.84 (s, 1 H), 8.15-8.18 (d, 1 H).
Intermediate 62
3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridine 7-oxide
Figure imgf000131_0002
To a solution of 3-chlorobenzenecarboperoxoic acid (46.5 g, 269 mmol) in 660 mL
dichlomethane was added portionwise at 4°C 3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridine (25.1 g, 135 mmol). Stirring was continued at 0-4°C for 1 h and at 25°C for 2 hours. The precipitate was collected by suction, washed with dichloro methane, and dried in airstream. filtration. The solid was then suspended in 300 mL acetone and stirred for 3 hours. The solid was the collected by filtration to obtain 13.1 g (99 % purity, 48 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 7.25 (dd, 1 H), 7.67 (d, 1 H), 8.16 (s, 1 H), 8.31 (d, 1 H), 13.43 (br s, 1 H). Intermediate 63
4-chloro-3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]p ridine
Figure imgf000132_0001
To a suspension of 3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridine 7-oxide (13.1 g, 65.0 mmol, intermediate 62) in 66 mL DMF was added at ambient temperature methanesulfonyl chloride (13 mL, 170 mmol). After stirring for 1 hour the mixture was warmed to 75°C for 2 hours. After cooling to 0°C 15 mL water was added dropwise and then aqueous sodium hydroxide (w=30%) waas added until pH=1 1 . After stirring for additional 20 minutes at 0°C the solid was collected by suction and the solid was dried using an airstream to obtain 1 1 .3 g (94 % purity, 1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 7.40 (d, 1 H), 8.29 (s, 1 H), 8.34 (d, 1 H), 12.89 (br s, 1 H).
Intermediate 64
4-chloro-3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridine 7-oxide
Figure imgf000132_0002
To a solution of 3-chlorobenzenecarboperoxoic acid (12.0 g, 69.6 mmol) in 98 mL
dichlomethane was added portionwise at 0°C 4-chloro-3-(trifluoromethyl)-1 H-pyrrolo[2,3- b]pyridine (1 1 .8 g, 53.5 mmol, intermediate 63). Stirring was continued at 0°C for 1 h and at 25°C for 2 hours. The precipitate was collected by filtration. The solid was then suspended in 40 mL acetone and stirred for 3 hours. The solid was the collected by filtration to obtain 8.54 g (99 % purity, 67 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 7.38 (d, 1 H), 8.24 (s, 1 H), 8.30 (d, 1 H). Intermediate 65
4,6-dichloro-3-(trifluoromethyl)-1 H-p rrolo[2,3-b]pyridine
Figure imgf000133_0001
To a suspension of 4-chloro-3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridine 7-oxide (8.54 g, 36.1 mmol, intermediate 64) 200 mL THF was added at 0°C 1 ,1 ,1 -trimethyl-N-
(trimethylsilyl)silanamine (7.5 mL, 36 mmol) followed by dropwise addition of trichloroacetyl chloride (14 mL, 130 mmol). The mixture was stirred for 15 minutes at 0°C and then for 2 hours at 25°C. The reaction was poured into 150 mL ice water and then was sodium bicarbonate added until pH=8. This mixture was extracted threetimes with 100 mL ethyl acetate. The combined organic layers were washed with brine, dried over sodium sulfate and after filtration evaporated to dryness. The residue was solved in a minimum of methanol and precipitated by the addition of water. The mixture was cooled at 0°C for 1 hour. The precipitate was collected by filtration, solved again in ethyl acetate, dried over sodium sulfate and after filtration evaporated to dryness to obtain 7.65 g (83 % yield) of the desired title compound. 1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 7.58 (s, 1 H), 8.33 (s, 1 H), 13.10 (br s, 1 H).
Intermediate 66
4,6-dichloro-3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b] pyridine
Figure imgf000133_0002
To a mixture of 4,6-dichloro-3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridine (7.65 g, 30.0 mmol, intermediate 65) and [2-(chloromethoxy)ethyl](trimethyl)silane (5.8 mL, 33 mmol) in 77 mL DMF was added portionwise sodium hydride (3.60 g, 60 % purity, 90.0 mmol) at 0°C. After stirring for 3.5 hours this mixture was poured carefully into 100 mL ice water. This was then extracted threetimes with 50 mL ethyl acetate. The combined organic layers were washed with brine, dried over sodium sulfate and after filtration evaporated to dryness. The residue was purified using a Biotage chromatography system to obtain 175 mg (30 % purity, 88 % yield) of the desired title compound.
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.12 - -0.08 (m, 9H), 0.79 - 0.87 (m, 2H), 3.51 - 3.60
(m, 2H), 5.64 (s, 2H), 7.70 (s, 1 H), 8.58 (s, 1 H). Intermediate 67
4-{[6-chloro-3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl^
b]pyridin-4-yl]oxy}-2,3-difluoroaniline
Figure imgf000134_0001
A mixture of 4,6-dichloro-3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridine (500 mg, 1 .30 mmol, intermediate 66), commercially available 4-amino-2,3- difluorophenol (207 mg, 1 .43 mmol) and potasium carbonate (538 mg, 3.89 mmol) in 5.0 mL DMSO was stirred at 120°C for 3h. After cooling to room temperature this mixture was diluted with 200 mL ethyl acetate. The resulting organic phase was then extracted twotimes with 30 mL of water, 20 mL brime, dried over sodium sulfate, filtered and evaporated to dryness. The residue was purified using a Biotage chromatography system to obtain 170 mg (93 % purity, 25% yield) of the desired title compound.
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.1 1 - -0.07 (m, 9H), 0.81 - 0.88 (m, 2H), 3.54 - 3.61 (m, 2H), 5.62 (s, 2H), 5.65 (s, 2H), 6.51 (s, 1 H), 6.65 (td, 1 H), 6.99 (td, 1 H), 8.38 (s, 1 H).
Intermediate 68
2,3-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H^yrrolo[2,3 b]pyridin-4-yl]oxy}aniline
Figure imgf000134_0002
A suspension of 4-{[6-chloro-3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl]oxy}-2,3-difluoroaniline (166 mg, 336 μηιοΙ, intermediate 67), triethylamine (56 μί, 400 μηηοΙ) and Palladium on carboni (16.6 mg, 10 % purity, 15.6 μηηοΙ) in 1 1 mL ethanol was stirred for 7 hours in an hydrogen atmosphere under normal pressure. The reaction mixture was filtered over Celite, the filter cake washed with ethyl acetate and the combine organic layers were evaporated to dryness. The residue was purified using a Biotage chromatography system to obtain 142 mg (93 % purity, 92% yield) of the desired title compound.
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.12 - -0.07 (m, 9H), 0.79 - 0.88 (m, 2H), 3.54 - 3.60 (m, 2H), 5.59 (s, 2H), 5.67 (s, 2H), 6.51 (dd, 1 H), 6.65 (td, 1 H), 6.95 (td, 1 H), 8.25 (d, 1 H), 8.32 (s, 1 H).
Intermediate 69
phenyl (2,3-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate
Figure imgf000135_0001
In analogy to intermediate 1 ), using 2,3-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}aniline (137 mg, 298 μηηοΙ, intermediate 68) and phenyl carbonochloridate (41 μΙ_, 330 μηηοΙ) in pyridine (140 μΙ_), we obtained after one single purification using a Biotage chromatography system 146 mg (96 % purity, 81 % yield) of the desired title compound.
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.12 - -0.07 (m, 9H), 0.80 - 0.88 (m, 2H), 3.54 - 3.62 (m, 2H), 5.69 (s, 2H), 6.67 (d, 1 H), 6.72 - 6.78 (m, 1 H), 7.1 1 - 7.19 (m, 1 H), 7.22 - 7.31 (m, 2H), 7.40 - 7.48 (m, 1 H), 7.62 (br t, 1 H), 8.29 - 8.35 (m, 1 H), 8.38 (s, 1 H), 9.32 (s, 1 H), 10.34 (br s, 1 H).
Intermediate 70
1 -(2,3-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl]oxy}phenyl)-3-[3-(morpholin-4-yl)propyl]urea
Figure imgf000135_0002
In analogy to intermediate 2), using phenyl (2,3-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (70.0 mg, 121 μηηοΙ, intermediate 69) and 3-(morpholin-4-yl)propan-1 -amine (18 μΙ_, 120 μηηοΙ) in DMF (600 μΙ_), we obtained after one single purification using a Biotage chromatography system 73.1 mg (93 % purity, 89 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.1 1 - -0.06 (m, 9H), 0.80 - 0.87 (m, 2H), 1 .60 (quin, 2H), 2.27 - 2.38 (m, 6H), 3.14 (q, 2H), 3.53 - 3.61 (m, 6H), 5.68 (s, 2H), 6.59 (d, 1 H), 6.66 (t, 1 H), 7.12 - 7.18 (m, 1 H), 8.02 (br t, 1 H), 8.28 (d, 1 H), 8.36 (s, 1 H), 8.56 (s, 1 H). Intermediate 71
1 -(2,3-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]m
b]pyridin-4-yl]oxy}phenyl)-3-[2-(morpholin-4-yl)ethyl]urea
Figure imgf000136_0001
In analogy to intermediate 2), using phenyl (2,3-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (70.0 mg, 121 μηηοΙ, intermediate 69) and 2-(morpholin-4-yl)ethanamine (16 μΙ_, 120 μηηοΙ) in DMF (600 μΙ_), we obtained after one single purification using a Biotage chromatography system 65.7 mg (93 % purity, 82 % yield) of the desired title compound.
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.1 1 - -0.07 (m, 9H), 0.79 - 0.88 (m, 2H), 2.36 - 2.43 (m, 6H), 3.24 (q, 2H), 3.55 - 3.64 (m, 6H), 5.68 (s, 2H), 6.59 (d, 1 H), 6.69 (t, 1 H), 7.13 - 7.20 (m, 1 H), 8.04 (t, 1 H), 8.28 (d, 1 H), 8.36 (s, 1 H), 8.76 (s, 1 H).
Intermediate 72
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl]oxy}phenyl)-3-[2-(dimethylamino)ethyl]thiourea
Figure imgf000137_0001
To solution of 3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl]oxy}aniline (100 mg, 218 μηηοΙ, see Synthesis 2007, page 251-258, Org. Process Res. Dev. 2010, page 168-173) in pyridine (1 .5 mL) and dichloromethana (1.5 mL) was added 2-isothiocyanato-N,N-dimethylethanamine (31 .2 mg, 239 μηηοΙ). After stirring this mixture 2 hours at 75°C and at 60°C over night an additional amount of 2-isothiocyanato- N,N-dimethylethanamine (31.2 mg, 239 μηηοΙ) was added. After heating this mixture for 2 hours at 75°C and at 60°C over three days. After cooling ethyl acetate and water was added to the reaction mixture and stirred. After separation of the organic pahe the aqueous phase was extracted two times with ethyl acetate. The combined organic phases were washed with brine, dried over sodium sulfate, filtered and concentrated to dryness. The resulting residue was purified via a Biotage chromatography system (1 1 g snap KP-NH column, hexane / 0 - 100% ethylacetate, then ethyl acetate / 0 - 100% methanol) to obtain 70.0 mg (95 % purity, 52 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.1 1 - -0.08 (m, 9H), 0.80 - 0.86 (m, 2H), 2.20 (s, 6H), 2.45 (t, 2H), 3.52 - 3.62 (m, 4H), 5.69 (s, 2H), 6.60 (d, 1 H), 7.58 - 7.66 (m, 2H), 8.02 (br s, 1 H), 8.31 (d, 1 H), 8.38 (s, 1 H), 10.1 1 (br s, 1 H). Intermediate 73
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]m
b]pyridin-4-yl]oxy}phen l)-3-[2-(morpholin-4-yl)ethyl]thiourea
Figure imgf000138_0001
In analogy to intermediate 72), using 3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}aniline (100 mg, 218 μηηοΙ, see Synthesis 2007, page 251-258, Org. Process Res. Dev. 2010, page 168-173) and 4-(2- isothiocyanatoethyl)morpholine (twice 41.2 mg, 239 μηηοΙ) in pyridine (1 .5 mL) and
dichloromethane (1.5 mL) we obtained 80.9 mg (95 % purity, 56 % yield) of the desired title compound.
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.12 - -0.07 (m, 9H), 0.79 - 0.86 (m, 2H), 2.39 - 2.46 (m, 4H), 2.51 - 2.54 (m, 2H), 3.54 - 3.65 (m, 8H), 5.69 (s, 2H), 6.61 (d, 1 H), 7.52 - 7.60 (m, 2H), 8.09 (br s, 1 H), 8.31 (d, 1 H), 8.38 (s, 1 H), 10.07 (s, 1 H). Intermediate 74
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl]oxy}phen l -3-(2-methoxyethyl)thiourea
Figure imgf000138_0002
In analogy to intermediate 72), using 3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}aniline (100 mg, 218 μηηοΙ, see Synthesis 2007, page 251-258, Org. Process Res. Dev. 2010, page 168-173) and only one portion of 2-isothiocyanatoethyl methyl ether (31 .9 mg, 272 μηηοΙ) in pyridine (1.5 mL) and dichloromethane (1 .5 mL) and 2 hours at 75°C and 60°C for three days reaction time we obtained 45.0 mg (92 % purity, 33 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.12 - -0.08 (m, 9H), 0.80 - 0.86 (m, 2H), 3.30 (s, 3H), 3.51 (t, 2H), 3.55 - 3.61 (m, 2H), 3.67 (br s, 2H), 5.69 (s, 2H), 6.60 (d, 1 H), 7.55 - 7.64 (m, 2H), 8.19 (br s, 1 H), 8.31 (d, 1 H), 8.38 (s, 1 H), 10.02 (br s, 1 H).
Intermediate 75
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]m
b]pyridin-4-yl]oxy}phenyl)-3-eth lthiourea
Figure imgf000139_0001
In analogy to intermediate 72), using 3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}aniline (100 mg, 218 μηηοΙ, see Synthesis 2007, page 251-258, Org. Process Res. Dev. 2010, page 168-173) and
isothiocyanatoethane (twice 20.9 mg, 239 μηηοΙ) in pyridine (1.5 mL) and dichloromethane (1 .5 mL) we obtained 58.0 mg (98 % purity, 48 % yield) of the desired title compound.
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.1 1 - -0.07 (m, 9H), 0.79 - 0.87 (m, 2H), 1.14 (t, 3H), 3.47 - 3.60 (m, 4H), 5.69 (s, 2H), 6.60 (d, 1 H), 7.49 - 7.58 (m, 2H), 8.15 (br s, 1 H), 8.31 (d, 1 H), 8.38 (s, 1 H), 9.88 (br s, 1 H). Intermediate 76
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]m
b]pyridin-4-yl]oxy}phenyl)-3-[3-(morpholin-4-yl)propyl]thiourea
Figure imgf000140_0001
In analogy to intermediate 72), using 3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}aniline (100 mg, 218 μηηοΙ, see Synthesis 2007, page 251-258, Org. Process Res. Dev. 2010, page 168-173) and 4-(3- isothiocyanatopropyl)morpholine (twice 44.6 mg, 239 μηηοΙ) in pyridine (1.5 mL) and dichloromethane (1.5 mL) and an additional stirring at 100°C for 5 hours and overnight at 60°C we obtained 71.0 mg (92 % purity, 46 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.1 1 - -0.08 (m, 9H), 0.80 - 0.86 (m, 2H), 1 .73 (quin, 2H), 2.28 - 2.39 (m, 6H), 3.49 - 3.60 (m, 8H), 5.69 (s, 2H), 6.60 (d, 1 H), 7.53 (m, 2H), 8.16 (br s, 1 H), 8.31 (d, 1 H), 8.38 (s, 1 H), 9.90 (br s, 1 H). Intermediate 77
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl]oxy}phenyl)-3-(oxetan-3- lmethyl)urea
Figure imgf000140_0002
In analogy to intermediate 2, using phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (150 mg, 259 μηηοΙ, intermediate 1 ) and 1 -(oxetan-3-yl)methanamine (22.5 mg, 259 μηηοΙ) in DMF (1 .5 ml_), we obtained after one single purification using a Biotage chromatography system 151 mg (94 % purity, 96 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.1 1 - -0.08 (m, 9H), 0.80 - 0.86 (m, 2H), 3.09 (spt, 1 H), 3.34 - 3.40 (m, 2H), 3.54 - 3.60 (m, 2H), 4.31 (t, 2H), 4.62 (dd, 2H), 5.68 (s, 2H), 6.57 (d, 1 H), 6.67 (t, 1 H), 7.36 - 7.42 (m, 2H), 8.28 (d, 1 H), 8.36 (s, 1 H), 9.08 (s, 1 H). Intermediate 78
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl]oxy}phenyl)urea
Figure imgf000141_0001
To a solution of phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}- 1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (150 mg, 259 μηηοΙ, intermediate 1 ) in DMF (1 .5 mL) was added ammonia in methanol (37 μΙ_, 7.0 M, 260 μηηοΙ) and this mixture was stirred at 60°C for 1 hour. After cooling to room temperature ethyl acetate and water was added. After separation of the organic phase the aqueous phase was extracted two times with ethyl acetate. The combined organic phases were washed with brine, dried over sodium sulfate, filtered and concentrated to dryness. The resulting residue was purified via a Biotage chromatography system (1 1 g snap KP-NH column, hexane / 0 - 100% ethyl acetate, then ethyl acetate / 0 - 100% methanol) to obtain 1 14 mg (94 % purity, 82 % yield) of the desired title compound.
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.1 1 - -0.05 (m, 9H), 0.79 - 0.87 (m, 2H), 3.54 - 3.60 (m, 2H), 5.68 (s, 2H), 6.15 (s, 2H), 6.58 (d, 1 H), 7.36 - 7.42 (m, 2H), 8.28 (d, 1 H), 8.36 (s, 1 H), 9.07 (s, 1 H). Intermediate 79
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl]oxy}phenyl)-3-meth lurea
Figure imgf000142_0001
In analogy to intermediate 78, using phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (150 mg, 259 μηηοΙ, intermediate 1 ) and methanamine in THF (130 μΙ_, 2.0 M, 260 μηηοΙ) together in DMF (1 .5 mL), we obtained after one single purification using a Biotage chromatography system 127 mg (93 % purity, 88 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.1 1 - -0.05 (m, 9H), 0.80 - 0.86 (m, 2H), 2.65 (d, 3H), 3.55 - 3.60 (m, 2H), 5.68 (s, 2H), 6.33 (q, 1 H), 6.57 (d, 1 H), 7.35 - 7.43 (m, 2H), 8.28 (d, 1 H), 8.36 (d, 1 H), 9.1 1 (s, 1 H).
Intermediate 80
3-(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl]oxy}phenyl)-1 ,1 -dimeth lurea
Figure imgf000142_0002
In analogy to intermediate 78, using phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (150 mg, 259 μηιοΙ, intermediate 1 ) and N-methylmethanamine in THF (130 μΙ_, 2.0 M, 260 μηιοΙ) in DMF (1 .5 mL), we obtained after one single purification using a Biotage chromatography system 176 mg (89 % purity, 1 14 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.1 1 - -0.05 (m, 9H), 0.80 - 0.86 (m, 2H), 2.95 (s, 6H), 3.55 - 3.60 (m, 2H), 5.68 (s, 2H), 6.57 (d, 1 H), 7.51 - 7.57 (m, 2H), 8.29 (d, 1 H), 8.36 (d, 1 H), 8.78 (s, 1 H). Intermediate 81
N-(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl]oxy}phenyl)morpholine-4-carboxamide
Figure imgf000143_0001
In analogy to intermediate 2, using phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (150 mg, 259 μηηοΙ, intermediate 1 ) and morpholine (23 μΙ_, 260 μηηοΙ) together in DMF (1.5 mL), we obtained after one single purification using a Biotage chromatography system 171 mg (92 % purity, 107 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.1 1 - -0.05 (m, 9H), 0.80 - 0.86 (m, 2H), 3.43 - 3.49 (m, 4H), 3.54 - 3.60 (m, 2H), 3.60 - 3.65 (m, 4H), 5.68 (s, 2H), 6.57 (d, 1 H), 7.48 - 7.54 (m, 2H), 8.29 (d, 1 H), 8.37 (s, 1 H), 9.02 (s, 1 H). Intermediate 82
N-(3,5-difluoro-4-{[3-(trifluorom
b]pyridin-4-yl]oxy}phenyl)-4-methylpiperazine-1 -carboxamide
Figure imgf000144_0001
In analogy to intermediate 2, phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (150 mg, 259 μηηοΙ, intermediate 1 ) and 1 -methylpiperazine (29 μΙ_, 260 μηηοΙ) together in DMF (1.5 mL), we obtained after one single purification using a Biotage chromatography system 248 mg (92 % purity, 150 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.1 1 - -0.05 (m, 9H), 0.80 - 0.86 (m, 2H), 2.20 (s, 3H), 2.33 (t, 4H), 3.42 - 3.50 (m, 4H), 3.55 - 3.60 (m, 2H), 5.68 (s, 2H), 6.57 (d, 1 H), 7.47 - 7.54 (m, 2H), 8.29 (d, 1 H), 8.36 (s, 1 H), 8.99 (s, 1 H).
Intermediate 83
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl]oxy}phenyl)-3-[2-(4-methylpiperazin-1 -yl)-2-oxoethyl]urea
Figure imgf000144_0002
In analogy to intermediate 2, phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (150 mg, 259 μηηοΙ, intermediate 1 ) and 2-amino-1 -(4-methylpiperazin-1 -yl)ethanone (40.7 mg,
259 μηηοΙ) together in DMF (1.5 mL), we obtained after one single purification using a Biotage chromatography system 83.5 mg (93 % purity, 47 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.1 1 - -0.05 (m, 9H), 0.80 - 0.86 (m, 2H), 2.19 (s, 3H), 2.27 (br t, 2H), 2.29 - 2.34 (m, 2H), 3.37 - 3.43 (m, 2H), 3.43 - 3.50 (m, 2H), 3.54 - 3.60 (m, 2H), 3.99 (d, 2H), 5.68 (s, 2H), 6.55 - 6.61 (m, 2H), 7.34 - 7.40 (m, 2H), 8.28 (d, 1 H), 8.36 (s, 1 H), 9.50 (s, 1 H).
Intermediate 84
N-(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl]oxy}phenyl)-2-oxa-6-azas iro[3.3]heptane-6-carboxamide
Figure imgf000145_0001
To a solution of phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}- 1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (150 mg, 259 μηηοΙ, intermediate 1 ) in DMF (1 .3 mL) was added 2-oxa-6-azaspiro[3.3]heptane ethanedioate (2:1 ) (74.6 mg, 259 μηιοΙ) and N,N-diisopropylethylamine (45 μί, 260 μηηοΙ) and this mixture was stirred at 50°C for 12 hours. After cooling to room temperature ethyl acetate and water was added. After separation of the organic phase the aqueous phase was extracted two times with ethyl acetate. The combined organic phases were washed with brine, dried over sodium sulfate, filtered and concentrated to dryness. The resulting residue was purified via a Biotage chromatography system (1 Og snap KP-Sil column, hexane / 0 - 100% ethyl acetate, then ethyl acetate / 0 - 100% methanol) to obtain 71 .0 mg (93 % purity, 44 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.1 1 - -0.05 (m, 9H), 0.79 - 0.86 (m, 2H), 3.54 - 3.60 (m, 2H), 4.15 (s, 4H), 4.69 (s, 4H), 5.68 (s, 2H), 6.57 (d, 1 H), 7.48 - 7.54 (m, 2H), 8.28 (d, 1 H), 8.36 (s, 1 H), 8.97 (s, 1 H). Intermediate 85
N2-[(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3^ b]pyridin-4-yl]oxy}phenyl)carbamoyl]-N-methylglycinamide
-
Figure imgf000146_0001
To a solution of phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}- 1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (150 mg, 259 μηηοΙ, intermediate 1 ) in DMF (1 .3 mL) was added N-methylglycinamide hydrochloride (1 :1 ) (32.2 mg, 259 μηιοΙ) and N,N- diisopropylethylamine (45 μΙ_, 260 μηηοΙ) and this mixture was stirred at 50°C for 12 hours. After cooling to room temperature ethyl acetate and water was added. After separation of the organic phase the aqueous phase was extracted two times with ethyl acetate. The combined organic phases were washed with brine, dried over sodium sulfate, filtered and concentrated to dryness. The resulting residue was purified via a Biotage chromatography system (1 Og snap KP-Sil column, hexane / 0 - 100% ethyl acetate, then ethyl acetate / 0 - 100% methanol) to obtain 146 mg (95 % purity, 93 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.10 - -0.05 (m, 9H), 0.80 - 0.86 (m, 2H), 2.61 (d, 3H), 3.55 - 3.60 (m, 2H), 3.71 (d, 2H), 5.68 (s, 2H), 6.56 - 6.61 (m, 2H), 7.34 - 7.41 (m, 2H), 7.91 (q, 1 H), 8.29 (d, 1 H), 8.36 (s, 1 H), 9.34 (s, 1 H).
Intermediate 86
1 -(3,5-difluoro-4-{[3-(trifluorom
b]pyridin-4-yl]oxy}phenyl)-3- 1 ,2-thiazol-4-yl)urea
Figure imgf000147_0001
To a solution of phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}- 1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (150 mg, 259 μηηοΙ, intermediate 1 ) in DMF (1 .3 mL) was added 1 ,2-thiazol-4-amine hydrochloride (1 :1 ) (35.4 mg, 259 μηιοΙ) and N,N- diisopropylethylamine (45 μΙ_, 260 μmol) and this mixture was stirred at 50°C for 12 hours. Then additional 1 ,2-thiazol-4-amine hydrochloride (1 :1 ) (35.4 mg, 259 μηιοΙ) and N,N- diisopropylethylamine (45 μΙ_, 260 μmol) was added and stirred at 50°C for 12 hours. After cooling to room temperature ethyl acetate and water was added. After separation of the organic phase the aqueous phase was extracted two times with ethyl acetate. The combined organic phases were washed with brine, dried over sodium sulfate, filtered and concentrated to dryness. The resulting residue was purified via a Biotage chromatography system (1 Og snap KP-Sil column, hexane / 0 - 100% ethyl acetate, then ethyl acetate / 0 - 100% methanol) to obtain 155 mg (75 % purity, 77 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.10 - -0.05 (m, 9H), 0.80 - 0.87 (m, 2H), 3.54 - 3.61 (m, 2H), 5.69 (s, 2H), 6.61 (d, 1 H), 7.45 - 7.52 (m, 2H), 8.27 - 8.33 (m, 1 H), 8.36 - 8.40 (m, 1 H), 8.60 (s, 1 H), 8.73 (s, 1 H), 9.46 (br s, 1 H), 9.57 (br s, 1 H). Intermediate 87
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl]oxy}phenyl)-3- 1 -methyl-1 H-pyrazol-4-yl)urea
Figure imgf000148_0001
In analogy to intermediate 2, using phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (150 mg, 259 μηιοΙ, intermediate 1 ) and 1 -methyl-1 H-pyrazol-4-amine (25.1 mg, 259 μηιοΙ) in DMF (1 .3 mL), we obtained after one single purification using a Biotage chromatography system (10g snap KP-Sil column, hexane / 0 - 100% ethyl acetate, then ethyl acetate / 0 - 100% methanol) 158 mg (85 % purity, 89 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.1 1 - -0.05 (m, 9H), 0.80 - 0.86 (m, 2H), 3.54 - 3.61 (m, 2H), 3.79 (s, 3H), 5.69 (s, 2H), 6.60 (d, 1 H), 7.39 (d, 1 H), 7.41 - 7.48 (m, 2H), 7.77 (s, 1 H), 8.29 (d, 1 H), 8.37 (s, 1 H), 8.66 (s, 1 H), 9.14 (s, 1 H). Intermediate 88
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl]oxy}phenyl)-3- 6-methylpyridin-3-yl)urea
Figure imgf000148_0002
In analogy to intermediate 2, using phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (150 mg, 259 μηηοΙ, intermediate 1 ) and 6-methylpyridin-3-amine (28.0 mg, 259 μηηοΙ) together in DMF (1 .3 mL), we obtained after one single purification using a Biotage chromatography system 146 mg (98 % purity, 93 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.13 - -0.05 (m, 9H), 0.79 - 0.87 (m, 2H), 2.41 (s, 3H), 3.55 - 3.61 (m, 2H), 5.69 (s, 2H), 6.61 (d, 1 H), 7.19 (d, 1 H), 7.43 - 7.50 (m, 2H), 7.82 (dd, 1 H), 8.30 (d, 1 H), 8.37 (s, 1 H), 8.50 (d, 1 H), 9.00 (s, 1 H), 9.30 (s, 1 H). Intermediate 89
1 -[(1 -acetylazetidin-3-yl)methyl]-3-(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]meth l}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)urea
Figure imgf000149_0001
In analogy to intermediate 85, using phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (150 mg, 259 μηηοΙ, intermediate 1 ), 1 -[3-(aminomethyl)azetidin-1 -yl]ethanone hydrochloride (1 :1 ) (42.6 mg, 259 μηηοΙ) and N,N-diisopropylethylamine (45 μΙ_, 260 μηηοΙ) together in DMF (1 .3 mL), we obtained after one single purification using a Biotage chromatography system 1 18 mg (100 % purity, 74 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.15 - -0.06 (m, 9H), 0.79 - 0.87 (m, 2H), 1 .73 (s, 3H), 2.68 - 2.72 (m, 1 H), 3.26 - 3.32 (m, 2H), 3.52 - 3.61 (m, 3H), 3.76 - 3.87 (m, 2H), 4.13 (t, 1 H), 5.68 (s, 2H), 6.58 (d, 1 H), 6.73 (br s, 1 H), 7.40 (d, 2H), 8.28 (d, 1 H), 8.36 (s, 1 H), 9.15 (br s, 1 H). Intermediate 90
N2-[(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyTO
b]pyridin-4-yl]oxy}phenyl)carbamo l]-N-(2-methoxyethyl)glycinamide
Figure imgf000150_0001
In analogy to intermediate 85, phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (150 mg, 259 μηηοΙ, intermediate 1 ), N-(2-methoxyethyl)glycinamide hydrochloride (1 :1 ) (43.6 mg, 259 μηιοΙ) and N,N-diisopropylethylamine (45 μΙ_, 260 μηιοΙ) together in DMF (1.3 mL), we obtained after one single purification using a Biotage chromatography system 160 mg (100 % purity, 100 % yield) of the desired title compound.
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.12 - -0.07 (m, 9H), 0.80 - 0.86 (m, 2H), 3.23 - 3.28 (m, 5H), 3.34 - 3.37 (m, 2H), 3.54 - 3.60 (m, 2H), 3.74 (d, 2H), 5.68 (s, 2H), 6.55 - 6.61 (m, 2H), 7.34 - 7.41 (m, 2H), 8.06 (t, 1 H), 8.28 (d, 1 H), 8.36 (s, 1 H), 9.35 (s, 1 H).
Intermediate 91
(+/-)-1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]me
b]pyridin-4-yl]oxy}phenyl)-3-[(1 ,1 -dioxidothietan-2-yl)methyl]urea
Figure imgf000151_0001
In analogy to intermediate 85, phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (150 mg, 259 μηηοΙ, intermediate 1 ), (+/-)-1 -[1 ,1 -dioxidothietan-2-yl]methanamine hydrochloride (1 :1 ) (44.4 mg, 259 μηηοΙ) and N,N-diisopropylethylamine (45 μΙ_, 260 μηηοΙ) together in DMF (1 .3 mL), we obtained after one single purification using a Biotage chromatography system 148 mg (100 % purity, 92 % yield) of the desired title compound.
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.15 - -0.06 (m, 9H), 0.79 - 0.87 (m, 2H), 1.72 - 1.82 (m, 1 H), 2.19 - 2.31 (m, 1 H), 3.52 - 3.60 (m, 4H), 3.96 - 4.13 (m, 2H), 4.56 (quin, 1 H), 5.68 (s, 2H), 6.58 (d, 1 H), 6.71 (t, 1 H), 7.39 (d, 2H), 8.28 (d, 1 H), 8.36 (s, 1 H), 9.23 (s, 1 H). Intermediate 92
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl]oxy}phenyl)-3- 2-methylpyrimidin-5-yl)urea
Figure imgf000151_0002
In analogy to intermediate 2, using phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (150 mg, 259 μηηοΙ, intermediate 1 ) and 2-methylpyrimidin-5-amine (28.2 mg, 259 μηηοΙ) together in DMF (1 .3 mL), we obtained after one single purification using a Biotage chromatography system (10g snap KP-Sil column, hexane / 0 - 100% ethyl acetate, then ethyl acetate / 0 - 100% methanol) 103 mg (97 % purity, 65 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.16 - -0.06 (m, 9H), 0.80 - 0.86 (m, 2H), 2.57 (s, 3H), 3.55 - 3.61 (m, 2H), 5.69 (s, 2H), 6.61 (d, 1 H), 7.45 - 7.52 (m, 2H), 8.30 (d, 1 H), 8.38 (s, 1 H), 8.80 (s, 2H), 9.18 (br s, 1 H), 9.52 (br s, 1 H).
Intermediate 93
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl]oxy}phenyl)-3- 1 H-pyrazol-4-yl)urea
Figure imgf000152_0001
In analogy to intermediate 2, using phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (150 mg, 259 μηηοΙ, intermediate 1 ) and 1 H-pyrazol-4-amine (21.5 mg, 259 μηηοΙ) together in DMF (1 .3 mL), we obtained after one single purification using a Biotage chromatography system 150 mg (92 % purity, 94 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.10 - -0.05 (m, 9H), 0.80 - 0.86 (m, 2H), 3.55 - 3.60 (m, 2H), 5.69 (s, 2H), 6.60 (d, 1 H), 7.42 - 7.51 (m, 3H), 7.76 (s, 1 H), 8.29 (d, 1 H), 8.37 (s, 1 H), 8.65 (s, 1 H), 9.15 (s, 1 H), 12.56 (br s, 1 H). Intermediate 94
1 -(3,5-difluoro-4-{[3-(trifluorom
b]pyridin-4-yl]oxy}phenyl)-3- 2-(1 -oxa-6-azaspiro[3.3]hept-6-yl)ethyl]urea
Figure imgf000153_0001
In analogy to intermediate 85, phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (150 mg, 259 μηηοΙ, intermediate 1 ), 2-(1 -oxa-6-azaspiro[3.3]hept-6-yl)ethanamine trifluoroacetate (1 :1 ) (66.3 mg, 259 μηηοΙ) and N,N-diisopropylethylamine (45 μΙ_, 260 μηηοΙ) together in DMF (1 .3 mL), we obtained after one single purification using a Biotage chromatography system (1 Og snap KP-Sil column, hexane / 0 - 100% ethyl acetate, then ethyl acetate / 0 - 100% methanol) 1 19 mg (85 % purity, 62 % yield) of the desired title compound.
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.12 - -0.05 (m, 9H), 0.79 - 0.86 (m, 2H), 2.44 (t, 2H), 2.73 - 2.77 (m, 2H), 3.02 - 3.09 (m, 4H), 3.50 - 3.60 (m, 4H), 4.37 (t, 2H), 5.68 (s, 2H), 6.31 (t, 1 H), 6.57 (d, 1 H), 7.35 (d, 2H), 8.28 (d, 1 H), 8.36 (s, 1 H), 9.15 (s, 1 H).
Intermediate 95
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl]oxy}phenyl)-3-[2-(1 ,1 -dioxido-1 -thia-6-azaspiro[3.3]hept-6-yl)ethyl]urea
Figure imgf000153_0002
In analogy to intermediate 85, phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (150 mg, 259 μηηοΙ, intermediate 1 ), 2-(1 ,1 -dioxido-1 -thia-6-azaspiro[3.3]hept-6-yl)ethanamine trifluoroacetate (1 :1 ) (78.7 mg, 259 μηηοΙ) and N,N-diisopropylethylamine (45 μΙ_, 260 μηηοΙ) together in DMF (1.3 ml_), we obtained after one single purification using a Biotage
chromatography system (1 Og snap KP-Sil column, hexane / 0 - 100% ethyl acetate, then ethyl acetate / 0 - 100% methanol) 174 mg (85 % purity, 85 % yield) of the desired title compound. Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.17 - -0.06 (m, 9H), 0.80 - 0.86 (m, 2H), 2.19 - 2.26 (m, 2H), 3.04 - 3.1 1 (m, 2H), 3.23 - 3.28 (m, 2H), 3.54 - 3.60 (m, 2H), 3.78 - 3.83 (m, 2H), 3.98 - 4.04 (m, 2H), 5.68 (s, 2H), 6.34 (t, 1 H), 6.57 (d, 1 H), 7.33 - 7.41 (m, 2H), 8.28 (d, 1 H), 8.36 (s, 1 H), 9.17 (s, 1 H).
Intermediate 96
(+/-)-1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl]oxy}phenyl)-3-(2-oxopyrrolidin-3-yl)urea
Figure imgf000154_0001
In analogy to intermediate 2, using phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (150 mg, 259 μηηοΙ, intermediate 1 ) and (+/-)-3-aminopyrrolidin-2-one (25.9 mg, 259 μηηοΙ) together in DMF (1 .3 ml_), we obtained after one single purification using a Biotage chromatography system (10g snap KP-Sil column, hexane / 0 - 100% ethyl acetate, then ethyl acetate / 0 - 100% methanol) 168 mg (85 % purity, 94 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.15 - -0.06 (m, 9H), 0.80 - 0.86 (m, 2H), 1 .80 - 1.91 (m, 1 H), 2.38 - 2.46 (m, 1 H), 3.17 - 3.23 (m, 2H), 3.54 - 3.61 (m, 2H), 4.14 - 4.22 (m, 1 H), 5.68
(s, 2H), 6.58 (d, 1 H), 6.68 (d, 1 H), 7.35 - 7.42 (m, 2H), 7.91 (s, 1 H), 8.29 (d, 1 H), 8.36 (s, 1 H), 9.22 (s, 1 H). Intermediate 97
(+/-)-1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]met^
b]pyridin-4-yl]oxy}phenyl)-3- 1 ,1 -dioxidotetrahydrothiophen-3-yl)urea
Figure imgf000155_0001
In analogy to intermediate 2, using phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (150 mg, 259 μηηοΙ, intermediate 1 ) and (+/-)-tetrahydrothiophen-3-amine 1 ,1 -dioxide (35.0 mg,
259 μηηοΙ) together in DMF (1.3 mL), we obtained after one single purification using a Biotage chromatography system 160 mg (89 % purity, 88 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.16 - -0.06 (m, 9H), 0.79 - 0.86 (m, 2H), 2.1 1 (dq, 1 H), 2.37 - 2.47 (m, 1 H), 2.98 - 3.06 (m, 1 H), 3.14 - 3.31 (m, 2H), 3.40 - 3.47 (m, 1 H), 3.54 - 3.61 (m, 2H), 4.46 (sxt, 1 H), 5.68 (s, 2H), 6.57 (d, 1 H), 6.92 (d, 1 H), 7.36 - 7.43 (m, 2H), 8.29 (d, 1 H), 8.37 (s, 1 H), 9.16 (s, 1 H). Intermediate 98
(+/-)-1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl]oxy}phenyl)-3-(5-oxopyrrolidin-3-yl)urea
Figure imgf000155_0002
In analogy to intermediate 85, phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (150 mg, 259 μηηοΙ, intermediate 1 ), (+/-)-4-aminopyrrolidin-2-one hydrochloride (1 :1 ) (35.3 mg,
259 μηιοΙ) and N,N-diisopropylethylamine (45 μί, 260 μηιοΙ) together in DMF (1.2 mL), we obtained after one single purification using a Biotage chromatography system (1 Og snap KP-Sil column, hexane / 0 - 100% ethyl acetate, then ethyl acetate / 0 - 100% methanol) 125 mg (97 % purity, 80 % yield) of the desired title compound.
LC-MS (method 3): Rt = 1 .38 min; MS (ESIpos): m/z = 586 [M+H]+
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.15 - -0.06 (m, 9H), 0.80 - 0.86 (m, 2H), 2.07 (dd, 1 H), 3.07 (dd, 1 H), 3.49 - 3.60 (m, 3H), 4.28 - 4.36 (m, 1 H), 5.68 (s, 2H), 6.57 (d, 1 H), 6.95 (d, 1 H), 7.35 - 7.43 (m, 2H), 7.68 (s, 1 H), 8.29 (d, 1 H), 8.36 (s, 1 H), 8.99 (s, 1 H).
Intermediate 99
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl]oxy}phenyl)-3- 1 ,1 -dioxidotetrah dro-2H-thiopyran-4-yl)urea
Figure imgf000156_0001
In analogy to intermediate 2, using phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (150 mg, 259 μηηοΙ, intermediate 1 ) and tetrahydro-2H-thiopyran-4-amine 1 ,1 -dioxide (38.6 mg,
259 μηηοΙ) together in DMF (1.3 mL), we obtained after one single purification using a Biotage chromatography system (1 Og snap KP-Sil column, hexane / 0 - 100% ethyl acetate, then ethyl acetate / 0 - 100% methanol) 152 mg (98 % purity, 90 % yield) of the desired title compound. Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.16 - -0.06 (m, 9H), 0.79 - 0.86 (m, 2H), 1.89 - 2.01 (m, 2H), 2.08 - 2.18 (m, 2H), 3.02 - 3.10 (m, 2H), 3.24 - 3.32 (m, 2H), 3.54 - 3.60 (m, 2H), 3.84 - 3.93 (m, 1 H), 5.68 (s, 2H), 6.57 (d, 1 H), 6.72 (d, 1 H), 7.36 - 7.43 (m, 2H), 8.29 (d, 1 H), 8.36 (s, 1 H), 8.90 (s, 1 H). Intermediate 100
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl]oxy}phenyl)-3-(1 H-pyrazol-3-ylmethyl)urea
Figure imgf000157_0001
In analogy to intermediate 2, using phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (150 mg, 259 μηηοΙ, intermediate 1 ) and 1 -(1 H-pyrazol-3-yl)methanamine (25.1 mg, 259 μηηοΙ) together in DMF (1.3 mL), we obtained after one single purification using a Biotage chromatography system 148 mg (100 % purity, 98 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.15 - -0.06 (m, 9H), 0.80 - 0.86 (m, 2H), 3.55 - 3.60 (m, 2H), 4.26 - 4.35 (m, 2H), 5.68 (s, 2H), 6.12 - 6.19 (m, 1 H), 6.58 (d, 1 H), 6.74 (t, 1 H), 7.39 (br d, 2H), 7.67 (s, 1 H), 8.28 (d, 1 H), 8.36 (s, 1 H), 9.14 (br s, 1 H), 12.60 - 12.72 (m, 1 H).
Intermediate 101
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl]oxy}phenyl)-3-(1 H-imidazol-2-ylmethyl)urea
Figure imgf000157_0002
In analogy to intermediate 85, using phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (150 mg, 259 μηηοΙ, intermediate 1 ) and 1 -(1 H-imidazol-2-yl)methanamine hydrochloride (1 :1 ) (34.6 mg, 259 μηιοΙ) together in DMF (1.3 mL) and N,N-diisopropylethylamine (45 μΙ_, 260 μηιοΙ), we obtained after one single purification using a Biotage chromatography system 1 17 mg (85 % purity, 66 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.16 - -0.07 (m, 9H), 0.79 - 0.86 (m, 2H), 3.55 - 3.60 (m, 2H), 4.32 (d, 2H), 5.68 (s, 2H), 6.57 (d, 1 H), 6.84 (br t, 2H), 7.04 (br s, 1 H), 7.37 - 7.43 (m, 2H), 8.29 (d, 1 H), 8.36 (s, 1 H), 9.24 (s, 1 H), 1 1.85 (br s, 1 H).
Intermediate 102
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl]oxy}phenyl)-3-[(1 -methyl-1 H-pyrazol-3-yl)methyl]urea
Figure imgf000158_0001
In analogy to intermediate 2, using phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (150 mg, 259 μηηοΙ, intermediate 1 ) and 1 -(1 -methyl-1 H-pyrazol-3-yl)methanamine (28.8 mg, 259 μηηοΙ) together in DMF (1 .3 mL, 16 mmol), we obtained after one single purification using a Biotage chromatography system 207 mg (98 % purity, 132 % yield) of the desired title compound. 1H-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.16 - -0.09 (m, 9H), 0.80 - 0.86 (m, 2H), 3.55 - 3.60 (m, 2H), 3.79 (s, 3H), 4.24 (d, 2H), 5.68 (s, 2H), 6.13 (d, 1 H), 6.58 (d, 1 H), 6.73 (t, 1 H), 7.36 - 7.42 (m, 2H), 7.61 (d, 1 H), 8.28 (d, 1 H), 8.36 (s, 1 H), 9.1 1 (s, 1 H). Intermediate 103
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl]oxy}phenyl)-3-(1 ,3-thiazol-2-ylmethyl)urea
Figure imgf000159_0001
In analogy to intermediate 2, using phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (150 mg, 259 μηηοΙ, intermediate 1 ), 1 -(1 ,3-thiazol-2-yl)methanamine (29.5 mg, 259 μηηοΙ) together in DMF (1 .3 mL), we obtained after one single purification using a Biotage chromatography system 216 mg (80 % purity, 1 1 1 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.13 - -0.05 (m, 9H), 0.80 - 0.86 (m, 2H), 3.55 - 3.60 (m, 2H), 4.61 (d, 2H), 5.68 (s, 2H), 6.59 (d, 1 H), 7.26 (t, 1 H), 7.39 - 7.46 (m, 2H), 7.63 (d, 1 H), 7.74 (d, 1 H), 8.28 (d, 1 H), 8.36 (s, 1 H), 9.39 (s, 1 H).
Intermediate 104
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl]oxy}phenyl)-3-(pyrimidin-4-ylmethyl)urea
Figure imgf000159_0002
In analogy to intermediate 2, using phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (150 mg, 259 μηηοΙ, intermediate 1 ) and 1 -(pyrimidin-4-yl)methanamine (28.2 mg, 259 μηηοΙ) together in DMF (1 .3 ml_), we obtained after one single purification using a Biotage chromatography system 175 mg (99 % purity, 1 13 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.17 - -0.06 (m, 9H), 0.79 - 0.86 (m, 2H), 3.55 - 3.60 (m, 2H), 4.42 (d, 2H), 5.68 (s, 2H), 6.58 (d, 1 H), 7.12 (t, 1 H), 7.38 - 7.44 (m, 2H), 7.46 (dd, 1 H), 8.29 (d, 1 H), 8.36 (s, 1 H), 8.76 (d, 1 H), 9.13 (d, 1 H), 9.49 (s, 1 H). Intermediate 105
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl]oxy}phenyl)-3-[(2-methylpyridin-4-yl)methyl]urea
Figure imgf000160_0001
In analogy to intermediate 2, using phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (150 mg, 259 μηηοΙ, intermediate 1 ) and 1 -(2-methylpyridin-4-yl)methanamine (31.6 mg, 259 μηηοΙ) together in DMF (1.3 ml_), we obtained after one single purification using a Biotage
chromatography system 178 mg (86 % purity, 98 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.1 1 - -0.06 (m, 9H), 0.80 - 0.86 (m, 2H), 2.45 (s, 3H), 3.55 - 3.60 (m, 2H), 4.30 (d, 2H), 5.68 (s, 2H), 6.58 (d, 1 H), 7.05 (t, 1 H), 7.09 (br d, 1 H), 7.15 (s, 1 H), 7.38 - 7.45 (m, 2H), 8.29 (d, 1 H), 8.36 - 8.39 (m, 2H), 9.31 (s, 1 H). Intermediate 106
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl]oxy}phenyl)-3-(pyridazin-3-ylmethyl)urea
Figure imgf000161_0001
To a solution of phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}- 1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (150 mg, 259 μηηοΙ, intermediate 1 ) in DMF (1 .3 mL) was added 1 -(pyridazin-3-yl)methanamine (28.2 mg, 259 μηηοΙ) and this mixture was stirred at 55 °C over night. Additional 1 -(pyridazin-3-yl)methanamine (14.1 mg, 129 μηηοΙ) was added and stirred over night at 60°C. After cooling to room temperature ethyl acetate and water was added. After separation of the organic phase the aqueous phase was extracted two times with ethyl acetate. The combined organic phases were washed with brine, dried over sodium sulfate, filtered and concentrated to dryness. The resulting residue was purified via a Biotage chromatography system (1 Og snap KP-Sil column, hexane / 0 - 100% ethyl acetate, then ethyl acetate / 0 - 100% methanol) to obtain 190 mg (84 % purity, 103 % yield) of the desired title compound.
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.1 1 - -0.06 (m, 9H), 0.79 - 0.86 (m, 2H), 3.54 - 3.61 (m, 2H), 4.62 (d, 2H), 5.68 (s, 2H), 6.58 (d, 1 H), 7.23 (t, 1 H), 7.37 - 7.45 (m, 2H), 7.64 (dd, 1 H), 7.70 (dd, 1 H), 8.28 (d, 1 H), 8.36 (s, 1 H), 9.15 (dd, 1 H), 9.43 (s, 1 H). Intermediate 107
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl]oxy}phenyl)-3- 5-methyl-1 H-imidazol-2-yl)methyl]urea
Figure imgf000162_0001
In analogy to intermediate 85, using phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (150 mg, 259 μηηοΙ, intermediate 1 ) and 1 -(5-methyl-1 H-imidazol-2-yl)methanamine dihydrochloride (47.6 mg, 259 μηηοΙ) together in DMF (1.3 mL) and N,N-diisopropylethylamine (90 μΙ_,
520 μηηοΙ), we obtained after one single purification using a Biotage chromatography system 145 mg (87 % purity, 82 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.16 - -0.06 (m, 9H), 0.80 - 0.87 (m, 2H), 2.10 (s, 3H), 3.54 - 3.61 (m, 2H), 4.25 (d, 2H), 5.68 (s, 2H), 6.54 - 6.72 (m, 2H), 6.79 (t, 1 H), 7.36 - 7.43 (m, 2H), 8.29 (d, 1 H), 8.36 (s, 1 H), 9.23 (s, 1 H), 1 1.58 (br s, 1 H). Intermediate 108
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl]oxy}phenyl)-3-{[3- methoxymethyl)-1 ,2,4-oxadiazol-5-yl]methyl}urea
Figure imgf000162_0002
In analogy to intermediate 85, using phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (150 mg, 259 μηηοΙ, intermediate 1 ) and 1 -[3-(methoxymethyl)-1 ,2,4-oxadiazol-5-yl]methanamine hydrochloride (1 : 1 ) (46.5 mg, 259 mol) together in DMF (1 .3 mL) and N,N- diisopropylethylamine (45 μΙ_, 260 mol), we obtained after one single purification using a Biotage chromatography system 184 mg (84 % purity, 95 % yield) of the desired title compound.
1H-N MR (400 MHz, DMSO-d6) δ [ppm]: -0.1 1 - -0.06 (m, 9H), 0.79 - 0.86 (m, 2H), 3.33 (s, 3H), 3.54 - 3.60 (m, 2H), 4.53 (s, 2H), 4.62 (d, 2H), 5.68 (s, 2H), 6.59 (d, 1 H), 7.20 (br t, 1 H), 7.37 - 7.44 (m, 2H), 8.28 (d, 1 H), 8.36 (s, 1 H), 9.52 (s, 1 H).
Intermediate 109
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl]oxy}phen l)-3-[(5-methyl-4H-1 ,2,4-triazol-3-yl)methyl]urea
Figure imgf000163_0001
In analogy to intermediate 85, using phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (150 mg, 259 mol, intermediate 1 ) and 1 -(5-methyl-4H-1 , 2, 4-triazol-3-yl)methanamine dihydrochloride (47.9 mg, 259 Mmol) together in DMF (1 .3 mL, 16 mmol) and N,N-diisopropylethylamine (90 M 520 Mmol), we obtained after one single purification using a Biotage chromatography system 134 mg (100 % purity, 87 % yield) of the desired title compound.
LC-MS (method 3): Rt = 1 .37 min; MS (ESIpos): m/z = 598 [M+H]+
1H-N MR (400 MHz, DMSO-d6) δ [ppm]: -0.1 1 - -0.06 (m, 9H), 0.80 - 0.86 (m, 2H), 3.54 - 3.60 (m, 2H), 4.29 (br s, 2H), 5.68 (s, 2H), 6.58 (d, 1 H), 6.77 (br s, 1 H), 7.35 - 7.43 (m, 2H), 8.28 (d, 1 H), 8.36 (s, 1 H), 9.24 (br s, 1 H), 13.43 (br s, 1 H). Intermediate 110
(+/-)- 1 -(3 , 5-d if I uoro-4-{[3-(trif I ^ ^
b]pyridin-4-yl]oxy}phenyl)-3-(tetrah drofuran-3-yl)urea
Figure imgf000164_0001
In analogy to intermediate 2, using phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (150 mg, 259 μηηοΙ, intermediate 1 ) and (+/-)-tetrahydrofuran-3-amine (22.5 mg, 259 μηηοΙ) together in DMF (1 .3 ml_), we obtained after one single purification using a Biotage chromatography system 101 mg (85 % purity, 58 % yield) of the desired title compound.
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.13 - -0.06 (m, 9H), 0.79 - 0.87 (m, 2H), 1.71 - 1.79 (m, 1 H), 2.08 - 2.18 (m, 1 H), 3.50 (dd, 1 H), 3.54 - 3.61 (m, 2H), 3.67 - 3.83 (m, 3H), 4.18 - 4.25 (m, 1 H), 5.68 (s, 2H), 6.57 (d, 1 H), 6.71 - 6.79 (m, 1 H), 7.35 - 7.42 (m, 2H), 8.29 (d, 1 H), 8.36 (s, 1 H), 8.89 (s, 1 H). Intermediate 111
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl]oxy}phenyl)-3-[ 3R)-tetrahydrofuran-3-yl]urea
Figure imgf000164_0002
In analogy to intermediate 2, phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (150 mg, 259 μηηοΙ, intermediate 1 ) and (3R)-tetrahydrofuran-3-amine (22.5 mg, 259 μηηοΙ) together in DMF (1 .3 mL), we obtained after one single purification using a Biotage chromatography system (10g snap KP-Sil column, hexane / 0 - 100% ethyl acetate, then ethyl acetate / 0 - 100% ethanol) 104 mg (86 % purity, 60 % yield) of the desired title compound.
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.13 - -0.06 (m, 9H), 0.79 - 0.87 (m, 2H), 1.71 - 1.79 (m, 1 H), 2.08 - 2.18 (m, 1 H), 3.50 (dd, 1 H), 3.54 - 3.61 (m, 2H), 3.67 - 3.83 (m, 3H), 4.18 - 4.25 (m, 1 H), 5.68 (s, 2H), 6.57 (d, 1 H), 6.71 - 6.79 (m, 1 H), 7.35 - 7.42 (m, 2H), 8.29 (d, 1 H), 8.36 (s, 1 H), 8.89 (s, 1 H).
Intermediate 112
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl]oxy}phenyl)-3-[ 3S)-tetrahydrofuran-3-yl]urea
Figure imgf000165_0001
In analogy to intermediate 85, using phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (150 mg, 259 μηηοΙ, intermediate 1 ), (3S)-tetrahydrofuran-3-amine 4-methylbenzenesulfonate (1 :1 ) (67.1 mg, 259 μηηοΙ) and N,N-diisopropylethylamine (45 μΙ_, 260 μηηοΙ) together in DMF (1 .3 mL) we obtained after one single purification using a Biotage chromatography system (10g snap KP-Sil column, hexane / 0 - 100% ethyl acetate, then ethyl acetate / 0 - 100% ethanol) 159 mg (100 % purity, 107 % yield) of the desired title compound.
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.13 - -0.06 (m, 9H), 0.79 - 0.87 (m, 2H), 1.71 - 1.79 (m, 1 H), 2.08 - 2.18 (m, 1 H), 3.50 (dd, 1 H), 3.54 - 3.61 (m, 2H), 3.67 - 3.83 (m, 3H), 4.18 - 4.25 (m, 1 H), 5.68 (s, 2H), 6.57 (d, 1 H), 6.71 - 6.78 (m, 1 H), 7.35 - 7.42 (m, 2H), 8.29 (d, 1 H), 8.36 (s, 1 H), 8.89 (s, 1 H). Intermediate 113
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl]oxy}phenyl)-3-{3-[(2R,6R)-2,6-dimethylmorpholin-4-yl]propyl}urea
Figure imgf000166_0001
In analogy to intermediate 2, using phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (150 mg, 259 μηηοΙ, intermediate 1 ) and 3-[(2R,6R)-2,6-dimethylmorpholin-4-yl]propan-1 -amine (44.6 mg, 259 μηηοΙ) together in DMF (1 .3 mL) we obtained after one single purification using a Biotage chromatography system (1 Og snap KP-Sil column, hexane / 0 - 100% ethyl acetate, then ethyl acetate / 0 - 100% ethanol) 139 mg (90 % purity, 73 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.15 - -0.06 (m, 9H), 0.80 - 0.86 (m, 2H), 1 .04 (d, 6H), 1 .50 - 1 .64 (m, 4H), 2.27 (t, 2H), 2.70 - 2.75 (m, 2H), 3.12 (q, 2H), 3.51 - 3.60 (m, 4H), 5.68 (s, 2H), 6.42 (br t, 1 H), 6.57 (d, 1 H), 7.35 - 7.42 (m, 2H), 8.29 (d, 1 H), 8.36 (s, 1 H), 8.99 (s, 1 H).
Intermediate 114
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl]oxy}phenyl)-3-[(1 -meth l-1 H-imidazol-2-yl)methyl]urea
Figure imgf000166_0002
In analogy to intermediate 2, using phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (150 mg, 259 μηηοΙ, intermediate 1 ) and 1 -(1 -methyl-1 H-imidazol-2-yl)methanamine (28.8 mg, 259 μηηοΙ) together in DMF (1 .3 mL) we obtained after one single purification using a Biotage chromatography system (1 Og snap KP-Sil column, hexane / 0 - 100% ethyl acetate, then ethyl acetate / 0 - 100% ethanol) 163 mg (100 % purity, 106 % yield) of the desired title compound. Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.1 1 - -0.08 (m, 9H), 0.79 - 0.87 (m, 2H), 3.54 - 3.60 (m, 2H), 3.63 (s, 3H), 4.35 (d, 2H), 5.68 (s, 2H), 6.58 (d, 1 H), 6.81 (d, 1 H), 6.89 (t, 1 H), 7.10 (d, 1 H), 7.35 - 7.42 (m, 2H), 8.28 (d, 1 H), 8.36 (s, 1 H), 9.25 (s, 1 H).
Intermediate 115
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl]oxy}phenyl)-3-[ 4-methyl-1 ,2,5-oxadiazol-3-yl)methyl]urea
Figure imgf000167_0001
In analogy to intermediate 2, using phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (150 mg, 259 μηηοΙ, intermediate 1 ) and 1 -(4-methyl-1 ,2,5-oxadiazol-3-yl)methanamine (29.3 mg, 259 μηηοΙ) together in DMF (1.3 mL, 16 mmol) we obtained after one single purification using a Biotage chromatography system (1 Og snap KP-Sil column, hexane / 0 - 100% ethyl acetate, then ethyl acetate / 0 - 100% ethanol) 144 mg (86 % purity, 80 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.14 - -0.05 (m, 9H), 0.79 - 0.87 (m, 2H), 2.39 (s, 3H), 3.54 - 3.61 (m, 2H), 4.51 (d, 2H), 5.68 (s, 2H), 6.58 (d, 1 H), 7.10 (t, 1 H), 7.36 - 7.44 (m, 2H), 8.28 (d, 1 H), 8.36 (s, 1 H), 9.31 (s, 1 H). Intermediate 116
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl]oxy}phenyl)-3- 2-methoxypyridin-4-yl)methyl]urea
Figure imgf000168_0001
In analogy to intermediate 2, using phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (150 mg, 259 μηηοΙ, intermediate 1 ) and 1 -(2-methoxypyridin-4-yl)methanamine (35.8 mg, 259 μηηοΙ) together in DMF (1 .3 mL) we obtained after one single purification using a Biotage chromatography system (1 Og snap KP-Sil column, hexane / 0 - 100% ethyl acetate, then ethyl acetate / 0 - 100% ethanol) 136 mg (85 % purity, 72 % yield) of the desired title compound.
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.1 1 - -0.06 (m, 9H), 0.79 - 0.87 (m, 2H), 3.57 (t, 2H), 3.83 (s, 3H), 4.30 (d, 2H), 5.68 (s, 2H), 6.58 (d, 1 H), 6.69 (s, 1 H), 6.91 (dd, 1 H), 7.01 (t, 1 H), 7.37 - 7.44 (m, 2H), 8.10 (d, 1 H), 8.28 (d, 1 H), 8.36 (s, 1 H), 9.27 (s, 1 H). Intermediate 117
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl]oxy}phenyl)-3-[(1 -methyl-1 H-imidazol-4-yl)methyl]urea
Figure imgf000168_0002
In analogy to intermediate 2, using phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (150 mg, 259 μηηοΙ, intermediate 1 ) and 1 -(1 -methyl-1 H-imidazol-4-yl)methanamine (28.8 mg, 259 μηηοΙ) together in DMF (1 .3 mL) we obtained after one single purification using a Biotage chromatography system (1 Og snap KP-Sil column, hexane / 0 - 100% ethyl acetate, then ethyl acetate / 0 - 100% ethanol) 172 mg (87 % purity, 96 % yield) of the desired title compound. 1H-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.1 1 - -0.06 (m, 9H), 0.79 - 0.86 (m, 2H), 3.53 - 3.60 (m, 2H), 3.61 (s, 3H), 4.14 (d, 2H), 5.68 (s, 2H), 6.57 (d, 1 H), 6.61 - 6.65 (m, 1 H), 6.98 (s, 1 H), 7.34 - 7.41 (m, 2H), 7.52 (s, 1 H), 8.28 (d, 1 H), 8.36 (s, 1 H), 9.1 1 (s, 1 H).
Intermediate 118
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl]oxy}phen l)-3-{2-[(2RS,6RS)-2,6-dimethylmorpholin-4-yl]ethyl}urea
Figure imgf000169_0001
In analogy to intermediate 2, using phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (150 mg, 259 μηηοΙ, intermediate 1 ) and cis/trans-2-[2,6-dimethylmorpholin-4-yl]ethanamine (41.0 mg, 259 μηηοΙ) together in DMF (1 .2 mL) we obtained after one single purification using a Biotage chromatography system (10g snap KP-Sil column, hexane / 0 - 100% ethyl acetate, then ethyl acetate / 0 - 100% ethanol) to obtain 166 mg (90 % purity, 89 % yield) of the desired title compound.
NMR of main isomer:
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.09 (s, 9H), 0.80 - 0.87 (m, 2H), 1.05 (d, 6H), 1 .62 (t, 2H), 2.20 (t, 2H), 2.77 (br d, 2H), 3.19 - 3.26 (m, 2H), 3.53 - 3.61 (m, 4H), 5.68 (s, 2H), 6.30 (br t, 1 H), 6.57 (d, 1 H), 7.32 - 7.41 (m, 2H), 8.29 (d, 1 H), 8.36 (s, 1 H), 9.17 (s, 1 H). Intermediate 119
1 -[(2-cyanopyridin-4-yl)methyl]-3-(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]meth l}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)urea
Figure imgf000170_0001
In analogy to intermediate 85, phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (150 mg, 259 μηηοΙ, intermediate 1 ), 4-(aminomethyl)pyridine-2-carbonitrile hydrochloride (1 :1 ) (43.9 mg, 259 μηιοΙ) and N,N-diisopropylethylamine (45 μΙ_, 260 μηιοΙ) together in DMF (1.3 mL), we obtained after one single purification using a Biotage chromatography system (1 Og snap KP-Sil column, hexane / 0 - 100% ethyl acetate, then ethyl acetate / 0 - 100% methanol) 1 1 1 mg (86 % purity, 59 % yield) of the desired title compound.
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.17 - -0.05 (m, 9H), 0.79 - 0.87 (m, 2H), 3.54 - 3.60 (m, 2H), 4.41 (d, 2H), 5.68 (s, 2H), 6.57 (d, 1 H), 7.12 (t, 1 H), 7.37 - 7.45 (m, 2H), 7.65 (dd, 1 H), 7.93 - 7.96 (m, 1 H), 8.29 (d, 1 H), 8.36 (s, 1 H), 8.71 (dd, 1 H), 9.40 (s, 1 H).
Intermediate 120
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl]oxy}phenyl)-3-(p ridazin-4- lmethyl)urea
Figure imgf000170_0002
In analogy to intermediate 85, phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (150 mg, 259 μηηοΙ, intermediate 1 ), 1 -(pyridazin-4-yl)methanamine hydrochloride (1 :1 ) (37.7 mg, 259 μηιοΙ) and N,N-diisopropylethylamine (45 μί, 260 μηιοΙ) together in DMF (1.3 mL), we obtained after one single purification using a Biotage chromatography system (1 Og snap KP-Sil column, hexane / 0 - 100% ethyl acetate, then ethyl acetate / 0 - 100% methanol) 49.8 mg (89 % purity, 29 % yield) of the desired title compound.
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.1 1 - -0.07 (m, 9H), 0.79 - 0.87 (m, 2H), 3.54 - 3.61 (m, 2H), 4.38 (d, 2H), 5.68 (s, 2H), 6.57 (d, 1 H), 7.12 (t, 1 H), 7.36 - 7.46 (m, 2H), 7.56 (dd, 1 H), 8.28 (d, 1 H), 8.36 (s, 1 H), 9.17 (dd, 1 H), 9.18 - 9.20 (m, 1 H), 9.46 (s, 1 H).
Intermediate 121
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl]oxy}phenyl)-3-(1 ,2,4-oxadiazol-3-ylmethyl)urea
Figure imgf000171_0001
In analogy to intermediate 85, using phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (150 mg, 259 μηηοΙ, intermediate 1 ) and 1 -(1 ,2,4-oxadiazol-3-yl)methanamine hydrochloride (1 :1 ) (35.1 mg, 259 μηιοΙ) together in DMF (1.3 mL) and N,N-diisopropylethylamine (45 μί,
260 μηηοΙ), we obtained after one single purification using a Biotage chromatography system (10g snap KP-Sil column, hexane / 0 - 100% ethyl acetate, then ethyl acetate / 0 - 100% ethanol) 1 12 mg (80 % purity, 59 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.13 - -0.05 (m, 9H), 0.80 - 0.86 (m, 2H), 3.54 - 3.61 (m, 2H), 4.50 (d, 2H), 5.68 (s, 2H), 6.58 (d, 1 H), 7.06 (t, 1 H), 7.37 - 7.44 (m, 2H), 8.28 (d, 1 H), 8.36 (s, 1 H), 9.35 (s, 1 H), 9.57 (s, 1 H). Intermediate 122
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl]oxy}phenyl)-3-(1 ,3-oxazol-2- lmethyl)urea
Figure imgf000172_0001
In analogy to intermediate 85, using phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (150 mg, 259 μηηοΙ, intermediate 1 ) and 1 -(1 ,3-oxazol-2-yl)methanamine hydrochloride (1 :1 ) (34.8 mg, 259 μηιοΙ) together in DMF (1.3 mL) and N,N-diisopropylethylamine (45 μΙ_, 260 μmol), we obtained after one single purification using a Biotage chromatography system (1 Og snap KP-Sil column, hexane / 0 - 100% ethyl acetate, then ethyl acetate / 0 - 100% ethanol) 175 mg (70 % purity, 81 % yield) of the desired title compound.
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.1 1 - -0.06 (m, 9H), 0.79 - 0.87 (m, 2H), 3.54 - 3.60 (m, 2H), 4.43 (d, 2H), 5.68 (s, 2H), 6.58 (d, 1 H), 7.08 (br t, 1 H), 7.17 (d, 1 H), 7.36 - 7.44 (m, 2H), 8.06 (d, 1 H), 8.28 (d, 1 H), 8.36 (s, 1 H), 9.38 (s, 1 H).
Intermediate 123
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl]oxy}phenyl)-3-(1 ,3-thiazol-5- lmethyl)urea
Figure imgf000172_0002
In analogy to intermediate 2, using phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (150 mg, 259 μηηοΙ, intermediate 1 ) and 1 -(1 ,3-thiazol-5-yl)methanamine (29.5 mg, 259 μηηοΙ) together in DMF (1 .3 mL), we obtained after one single purification using a Biotage chromatography system (10g snap KP-Sil column, hexane / 0 - 100% ethyl acetate, then ethyl acetate / 0 - 100% ethanol) 136 mg (89 % purity, 78 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.12 - -0.06 (m, 9H), 0.80 - 0.88 (m, 2H), 3.54 - 3.61 (m, 2H), 4.53 (d, 2H), 5.68 (s, 2H), 6.59 (d, 1 H), 7.06 (t, 1 H), 7.37 - 7.44 (m, 2H), 7.79 (s, 1 H), 8.28 (d, 1 H), 8.36 (s, 1 H), 8.98 (s, 1 H), 9.20 (s, 1 H).
Intermediate 124
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl]oxy}phenyl)-3-[2-(2-oxa-6-azaspiro[3.3]hept-6-yl)ethyl]urea
Figure imgf000173_0001
In analogy to intermediate 2, using phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (150 mg, 259 μηηοΙ, intermediate 1 ) and 2-(2-oxa-6-azaspiro[3.3]hept-6-yl)ethanamine (36.8 mg, 259 μηηοΙ) together in DMF (1 .3 mL), we obtained after one single purification using a Biotage chromatography system (1 Og snap KP-Sil column, hexane / 0 - 100% ethyl acetate, then ethyl acetate / 0 - 100% ethanol) 1 16 mg (95 % purity, 68 % yield) of the desired title compound.
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.15 - -0.06 (m, 9H), 0.79 - 0.86 (m, 2H), 2.35 - 2.44 (m, 2H), 3.02 (q, 2H), 3.29 (s, 4H), 3.54 - 3.60 (m, 2H), 4.60 (s, 4H), 5.68 (s, 2H), 6.40 (br t, 1 H), 6.57 (d, 1 H), 7.30 - 7.41 (m, 2H), 8.28 (d, 1 H), 8.36 (s, 1 H), 9.22 (s, 1 H). Intermediate 125
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl]oxy}phenyl)-3- 5-methyl-1 ,3,4-oxadiazol-2-yl)methyl]urea
Figure imgf000174_0001
In analogy to intermediate 85, using phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (150 mg,
259 μηηοΙ, intermediate 1 ) and 1 -(5-methyl-1 ,3,4-oxadiazol-2-yl)methanamine hydrochloride (1 :1 ) (38.7 mg, 259 μηηοΙ) together in DMF (1.3 mL) and N,N-diisopropylethylamine (45 μΙ_,
260 μηηοΙ), we obtained after one single purification using a Biotage chromatography system (1 Og snap KP-Sil column, hexane / 0 - 100% ethyl acetate, then ethyl acetate / 0 - 100% methanol) 1 18 mg (95 % purity, 72 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.16 - -0.06 (m, 9H), 0.79 - 0.87 (m, 2H), 2.48 (s, 3H), 3.54 - 3.61 (m, 2H), 4.52 (d, 2H), 5.68 (s, 2H), 6.58 (d, 1 H), 7.1 1 (t, 1 H), 7.37 - 7.44 (m, 2H), 8.28 (d, 1 H), 8.36 (s, 1 H), 9.40 (s, 1 H).
Intermediate 126
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl]oxy}phenyl)-3- 3-methyloxetan-3-yl)methyl]urea
Figure imgf000174_0002
In analogy to intermediate 2, 250 mg phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (250 mg, 431 μηηοΙ intermediate 1 ) and 1 -(3-methyloxetan-3-yl)methanamine (43.6 mg, 431 μηηοΙ) in DMF (2.1 mL) were reacted to give after purification of the crude product via a Biotage chromatography system (25g snap KP-Sil column, hexane / 0 - 100% ethyl acetate, then ethyl acetate / 0 - 100% ethanol) 178 mg (80 % purity, 56 % yield) of the desired title compound. 1H-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.15 - -0.06 (m, 9H), 0.79 - 0.87 (m, 2H), 1.23 (s, 3H), 3.25 - 3.31 (m, 2H), 3.54 - 3.62 (m, 2H), 4.20 (d, 2H), 4.39 (d, 2H), 5.68 (s, 2H), 6.58 (d, 1 H), 6.93 (t, 1 H), 7.36 - 7.44 (m, 2H), 8.28 (d, 1 H), 8.36 (s, 1 H), 9.26 (br s, 1 H).
Intermediate 127
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl]oxy}phenyl)-3-(5-methylpyridazin-3-yl)urea
Figure imgf000175_0001
To a solution of 5-methylpyridazin-3-amine (71 .3 mg, 653 μηηοΙ) in dichloromethane (9.0 mL, 140 mmol) and pyridine (3.0 mL, 37 mmol) was added di-1 H-imidazol-1 -ylmethanone (1 16 mg, 718 μηηοΙ) and refluxed 30 minutes. After cooling down 3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}aniline (300 mg, 653 μηηοΙ, see Synthesis 2007, page 251-258, Org. Process Res. Dev. 2010, page 168-173) in
dichloromethane (3.0 mL) and pyridine (2.0 mL, 25 mmol), was given to the mixture and stirred 2 nights at 55 °C. After cooling to room temperature ethyl acetate and water was added. After separation of the organic phase the aqueous phase was extracted two times with ethyl acetate. The combined organic phases were washed with brine, dried over sodium sulfate, filtered and concentrated to dryness.The resulting residue was purified via a Biotage chromatography system (25g snap KP-Sil column, hexane / 0 - 100% ethyl acetate, then ethyl acetate / 0 - 100% ethanol) to obtain 39.5 mg (92 % purity, 9 % yield) of the desired title compound. LC-MS (method 3): Rt = 1 .53 min; MS (ESIpos): m/z = 593 [M+H]+
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.12 - -0.04 (m, 9H), 0.79 - 0.88 (m, 2H), 2.33 (s, 3H), 3.54 - 3.62 (m, 2H), 5.69 (s, 2H), 6.62 (d, 1 H), 7.48 - 7.56 (m, 2H), 7.86 (s, 1 H), 8.30 (d, 1 H), 8.38 (s, 1 H), 8.80 (d, 1 H), 9.90 (s, 1 H), 10.20 (s, 1 H).
Intermediate 128
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl]oxy}phenyl)-3-[(2R)-tetrahydrofuran-2-ylmethyl]urea
Figure imgf000176_0001
In analogy to intermediate 2, using phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (150 mg, 259 μηηοΙ, intermediate 1 ), 1 -[(2R)-tetrahydrofuran-2-yl]methanamine (26.2 mg, 259 μηηοΙ) together in DMF (1.5 ml_), we obtained after one single purification using a Biotage
chromatography system (1 Og snap KP-Sil column, hexane / 0 - 100% ethyl acetate, then ethyl acetate / 0 - 100% ethanol) 171 mg (88 % purity, 100 % yield) of the desired title compound. LC-MS (method 3): Rt = 1 .53 min; MS (ESIpos): m/z = 587 [M+H]+
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.12 - -0.06 (m, 9H), 0.79 - 0.86 (m, 2H), 1.47 - 1.56 (m, 1 H), 1 .77 - 1 .95 (m, 3H), 3.05 - 3.15 (m, 1 H), 3.21 - 3.28 (m, 1 H), 3.54 - 3.68 (m, 3H), 3.75 - 3.82 (m, 1 H), 3.83 - 3.91 (m, 1 H), 5.68 (s, 2H), 6.44 (t, 1 H), 6.58 (d, 1 H), 7.33 - 7.40 (m, 2H), 8.28 (d, 1 H), 8.36 (s, 1 H), 9.05 (s, 1 H). Intermediate 129
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl]oxy}phenyl)-3-[(2S)-tetrahydrofuran-2-ylmethyl]urea
Figure imgf000177_0001
In analogy to intermediate 2, using phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (150 mg, 259 μmol, intermediate 1 ), 1 -[(2S)-tetrahydrofuran-2-yl]methanamine (26.2 mg, 259 μηηοΙ) together in DMF (1.5 ml_), we obtained after one single purification using a Biotage
chromatography system (1 Og snap KP-Sil column, hexane / 0 - 100% ethyl acetate, then ethyl acetate / 0 - 100% ethanol) 136 mg (86 % purity, 77 % yield) of the desired title compound. LC-MS (method 3): Rt = 1 .53 min; MS (ESIpos): m/z = 587 [M+H]+
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.12 - -0.06 (m, 9H), 0.79 - 0.86 (m, 2H), 1.47 - 1.57 (m, 1 H), 1 .77 - 1 .95 (m, 3H), 3.05 - 3.15 (m, 1 H), 3.21 - 3.28 (m, 1 H), 3.54 - 3.68 (m, 3H), 3.75 - 3.82 (m, 2H), 5.68 (s, 2H), 6.58 (d, 1 H), 7.33 - 7.40 (m, 2H), 8.28 (d, 1 H), 8.36 (s, 1 H), 9.07 (s, 1 H).
Intermediate 130
(+/-)-1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]me
b]pyridin-4-yl]oxy}phen l)-3-[(5,5-dimethyltetrahydrofuran-2-yl)methyl]urea
Figure imgf000178_0001
In analogy to intermediate 85, phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (150 mg,
259 μηηοΙ, intermediate 1 , (+/-)-1 -(5,5-dimethyltetrahydrofuran-2-yl)methanamine hydrochloride (1 :1 ) (42.9 mg, 259 μηηοΙ) together in DMF (1.3 mL) and N,N-diisopropylethylamine (45 μΙ_,
260 μmol), we obtained after one single purification using a Biotage chromatography system (1 Og snap KP-Sil column, hexane / 0 - 100% ethyl acetate, then ethyl acetate / 0 - 100% ethanol) 177 mg (87 % purity, 97 % yield) of the desired title compound.
LC-MS (method 3): Rt = 1 .61 min; MS (ESIpos): m/z = 615 [M+H]+
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.12 - -0.07 (m, 9H), 0.80 - 0.86 (m, 2H), 1 .16 (s, 3H), 1 .22 (s, 3H), 1 .59 - 1 .72 (m, 3H), 1.94 - 2.01 (m, 1 H), 3.03 - 3.1 1 (m, 1 H), 3.21 - 3.28 (m, 1 H), 3.55 - 3.60 (m, 2H), 3.93 - 4.00 (m, 1 H), 5.68 (s, 2H), 6.41 (t, 1 H), 6.58 (d, 1 H), 7.33 - 7.40 (m, 2H), 8.28 (d, 1 H), 8.36 (s, 1 H), 9.14 (s, 1 H).
Intermediate 131
1 -(3 , 5-d if I uoro-4-{[3-(trif I u oro
b]pyridin-4-yl]oxy}phenyl)-3- tetrahydro-2H-pyran-4-yl)urea
Figure imgf000179_0001
In analogy to intermediate 2, using phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (150 mg, 259 μηηοΙ, intermediate 1 ), tetrahydro-2H-pyran-4-amine (26.2 mg, 259 μηηοΙ) together in DMF (1 .3 mL), we obtained after one single purification using a Biotage chromatography system (10g snap KP-Sil column, hexane / 0 - 100% ethyl acetate, then ethyl acetate / 0 - 100% ethanol) 132 mg (100 % purity, 87 % yield) of the desired title compound.
LC-MS (method 3): Rt = 1 .51 min; MS (ESIpos): m/z = 587 [M+H]+
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.13 - -0.07 (m, 9H), 0.79 - 0.87 (m, 2H), 1.36 - 1.47 (m, 2H), 1 .74 - 1 .83 (m, 2H), 3.34 - 3.42 (m, 2H), 3.54 - 3.60 (m, 2H), 3.63 - 3.74 (m, 1 H), 3.83 (dt, 2H), 5.68 (s, 2H), 6.52 - 6.60 (m, 2H), 7.35 - 7.41 (m, 2H), 8.28 (d, 1 H), 8.36 (s, 1 H), 8.95 (s, 1 H).
Intermediate 132
(+/-)-1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]me
b]pyridin-4-yl]oxy}phenyl)-3-(tetrahydro-2H-pyran-2-ylmethyl)urea
Figure imgf000180_0001
In analogy to intermediate 85, using phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (150 mg,
259 μηηοΙ, intermediate 1 ), (+/-)-1 -(tetrahydro-2H-pyran-2-yl)methanamine hydrochloride (1 :1 ) (39.2 mg, 259 μηηοΙ) together in DMF (1.3 mL) and N,N-diisopropylethylamine (45 μΙ_,
260 μmol), we obtained after one single purification using a Biotage chromatography system (1 Og snap KP-Sil column, hexane / 0 - 100% ethyl acetate, then ethyl acetate / 0 - 100% ethanol) 171 mg (88 % purity, 100 % yield) of the desired title compound.
LC-MS (method 3): Rt = 1 .58 min; MS (ESIpos): m/z = 601 [M+H]+
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.13 - -0.07 (m, 9H), 0.79 - 0.87 (m, 2H), 1.12 - 1.27 (m, 1 H), 1 .39 - 1 .59 (m, 4H), 1 .73 - 1 .82 (m, 1 H), 2.98 - 3.06 (m, 1 H), 3.23 (ddd, 1 H), 3.28 - 3.39 (m, 2H), 3.54 - 3.61 (m, 2H), 3.86 - 3.93 (m, 1 H), 5.68 (s, 2H), 6.50 (br t, 1 H), 6.57 (d, 1 H), 7.33 - 7.39 (m, 2H), 8.28 (d, 1 H), 8.36 (s, 1 H), 9.15 (s, 1 H).
Intermediate 133
(+/-)-1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]meth
b]pyridin-4-yl]oxy}phenyl)-3- tetrahydro-2H-pyran-3-yl)urea
Figure imgf000181_0001
In analogy to intermediate 85, phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (150 mg, 259 μηηοΙ, intermediate 1 ), (+/-)-tetrahydro-2H-pyran-3-amine hydrochloride (1 :1 ) (35.6 mg, 259 μηιοΙ) together in DMF (1.3 mL) and N,N-diisopropylethylamine (45 μΙ_, 260 μηιοΙ), we obtained after one single purification using a Biotage chromatography system (1 Og snap KP-Sil column, hexane / 0 - 100% ethyl acetate, then ethyl acetate / 0 - 100% ethanol) 148 mg (100 % purity, 97 % yield) of the desired title compound.
LC-MS (method 3): Rt = 1 .52 min; MS (ESIpos): m/z = 587 [M+H]+
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.12 - -0.07 (m, 9H), 0.80 - 0.86 (m, 2H), 1.47 - 1.57 (m, 2H), 1 .63 - 1 .73 (m, 1 H), 1 .80 - 1 .89 (m, 1 H), 3.24 (dd, 1 H), 3.43 - 3.50 (m, 1 H), 3.55 - 3.66 (m, 4H), 3.72 (dd, 1 H), 5.68 (s, 2H), 6.57 (d, 1 H), 6.61 (br d, 1 H), 7.33 - 7.41 (m, 2H), 8.29 (d, 1 H), 8.36 (s, 1 H), 9.02 (s, 1 H).
Intermediate 134
(+/-)-1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]me
b]pyridin-4-yl]oxy}phenyl)-3-[(2-methyltetrahydrofuran-2-yl)methyl]urea
Figure imgf000182_0001
In analogy to intermediate 2, phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (150 mg, 259 μηηοΙ, intermediate 1 ), (+/-)-1 -(2-methyltetrahydrofuran-2-yl)methanamine (29.8 mg, 259 μηηοΙ) together in DMF (1.2 mL), we obtained after one single purification using a Biotage chromatography system (1 Og snap KP-Sil column, hexane / 0 - 100% ethyl acetate, then ethyl acetate / 0 - 100% ethanol) 154 mg (95 % purity, 94 % yield) of the desired title compound. LC-MS (method 3): Rt = 1 .57 min; MS (ESIpos): m/z = 601 [M+H]+
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.13 - -0.07 (m, 9H), 0.79 - 0.87 (m, 2H), 1 .12 (s, 3H), 1 .55 - 1 .63 (m, 1 H), 1 .71 - 1 .80 (m, 1 H), 1.82 - 1.93 (m, 2H), 3.1 1 - 3.20 (m, 2H), 3.54 - 3.61 (m, 2H), 3.71 - 3.79 (m, 2H), 5.68 (s, 2H), 6.42 (t, 1 H), 6.58 (d, 1 H), 7.33 - 7.40 (m, 2H), 8.28 (d, 1 H), 8.36 (s, 1 H), 9.10 (s, 1 H).
Intermediate 135
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl]oxy}phenyl)-3-(2-methoxy-2-methylpropyl)urea
Figure imgf000182_0002
In analogy to intermediate 2, phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (150 mg, 259 μηηοΙ, intermediate 1 ), 2-methoxy-2-methylpropan-1 -amine (26.7 mg, 259 μηηοΙ) together in DMF (1.5 mL), we obtained after one single purification using a Biotage chromatography system (1 1 g snap KP-NH column, hexane / 50 - 100% ethyl acetate, then ethyl acetate / 0 - 40% ethanol) 141 mg (100 % purity, 92 % yield) of the desired title compound.
LC-MS (method 2): Rt = 1 .56 min; MS (ESIpos): m/z = 589 [M+H]+
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.12 - -0.07 (m, 9H), 0.79 - 0.87 (m, 2H), 1 .10 (s, 6H), 3.13 (s, 3H), 3.15 (d, 2H), 3.55 - 3.60 (m, 2H), 5.68 (s, 2H), 6.32 (t, 1 H), 6.58 (d, 1 H), 7.32 - 7.39 (m, 2H), 8.28 (d, 1 H), 8.36 (s, 1 H), 9.09 (s, 1 H).
Intermediate 136
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl]oxy henyl)-3-[2-methyl-2-(morpholin-4-yl)propyl]urea
Figure imgf000183_0001
In analogy to intermediate 2, phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (150 mg, 259 μηηοΙ, intermediate 1 ), 2-methyl-2-(morpholin-4-yl)propan-1 -amine (41 .0 mg, 259 μηηοΙ) together in DMF (1.5 mL), we obtained after one single purification using a Biotage
chromatography system (1 1 g snap KP-NH column, hexane / 50 - 100% ethyl acetate, then ethyl acetate / 0 - 40% ethanol) 149 mg (100 % purity, 89 % yield) of the desired title compound.
LC-MS (method 2): Rt = 1 .58 min; MS (ESIpos): m/z = 645 [M+H]+
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.16 - -0.06 (m, 9H), 0.79 - 0.87 (m, 2H), 0.97 (s, 6H), 2.44 - 2.48 (m, 4H), 3.10 (d, 2H), 3.54 - 3.64 (m, 6H), 5.68 (s, 2H), 6.16 (t, 1 H), 6.58 (d, 1 H), 7.33 - 7.40 (m, 2H), 8.29 (d, 1 H), 8.36 (s, 1 H), 9.29 (s, 1 H). Intermediate 137
(+/-)-1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]me
b]pyridin-4-yl]oxy}phenyl)-3-(tetrahydro-2H-pyran-3-ylmethyl)urea
Figure imgf000184_0001
In analogy to intermediate 85, phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (150 mg,
259 μηηοΙ, intermediate 1 ), (+/-)-1 -(tetrahydro-2H-pyran-3-yl)methanamine hydrochloride (1 :1 ) (39.2 mg, 259 μηιοΙ) together in DMF (1.5ml_) and N,N-diisopropylethylamine (45 μΙ_,
260 μηηοΙ), we obtained after one single purification using a Biotage chromatography system (1 1 g snap KP-NH column, hexane / 50 - 100% ethyl acetate, then ethyl acetate / 0 - 40% ethanol) 138 mg (100 % purity, 88 % yield) of the desired title compound.
LC-MS (method 2): Rt = 1 .53 min; MS (ESIpos): m/z = 601 [M+H]+
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.15 - -0.06 (m, 9H), 0.79 - 0.88 (m, 2H), 1.14 - 1.30 (m, 1 H), 1 .40 - 1 .52 (m, 1 H), 1 .54 - 1 .79 (m, 3H), 2.96 - 3.02 (m, 2H), 3.09 (dd, 1 H), 3.30 (ddd, 1 H), 3.54 - 3.61 (m, 2H), 3.68 - 3.79 (m, 2H), 5.68 (s, 2H), 6.48 (t, 1 H), 6.57 (d, 1 H), 7.34 - 7.42 (m, 2H), 8.28 (d, 1 H), 8.36 (s, 1 H), 8.95 (s, 1 H).
Intermediate 138
(+/-)-1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl]oxy}phenyl)-3-(tetrahydrofuran-3-ylmethyl)urea
Figure imgf000184_0002
In analogy to intermediate 85, phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (150 mg, 259 μηηοΙ, intermediate 1 ), (+/-)-1 -(tetrahydrofuran-3-yl)methanamine hydrochloride (1 :1 ) (35.6 mg, 259 μηιοΙ) together in DMF (1.5 mL) and N,N-diisopropylethylamine (45 μΙ_,
260 μηηοΙ) we obtained after one single purification using a Biotage chromatography system (1 1 g snap KP-NH column, hexane / 50 - 100% ethyl acetate, then ethyl acetate / 0 - 40% ethanol) 147 mg (97 % purity, 94 % yield) of the desired title compound.
LC-MS (method 2): Rt = 1 .49 min; MS (ESIpos): m/z = 587 [M+H]+
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.14 - -0.07 (m, 9H), 0.80 - 0.86 (m, 2H), 1.51 - 1.60 (m, 1 H), 1 .88 - 1 .99 (m, 1 H), 2.34 - 2.41 (m, 1 H), 3.06 - 3.14 (m, 2H), 3.42 (dd, 1 H), 3.54 - 3.77 (m, 5H), 5.68 (s, 2H), 6.54 - 6.60 (m, 2H), 7.36 - 7.42 (m, 2H), 8.28 (d, 1 H), 8.36 (s, 1 H), 8.99 (s, 1 H).
Intermediate 139
1 -{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}-3-pyridazin-4-ylurea
Figure imgf000185_0001
To solution of phenyl {4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin- 4-yl)oxy]-3,5-difluorophenyl}carbamate (90 mg, 0.16 mmol, intermediate 44) in DMF (1 mL) was added pyridazin-4-amine (23.5 mg, 247 μηηοΙ) and this mixture was stirred at 60°C for 4 hours. The mixture was diluted with water and extracted two times with ethyl acetate. The combined organic phases were washed 3 times with halfconcentrated aqueous sodium chloride solution, dried over sodium sulfate, filtered and concentrated to dryness. The resulting residue was purified via a Biotage chromatography system (KP-Sil snap column;
dichloromethane / methanol gradient with up to 3% methanol) to obtain 46 mg (48 % yield) of he desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.12—0.07 (m, 9H); 0.79-0.86 (m, 2H); 3.50-3.56 (m, 2H); 5.61 (s, 2H); 6.47 (d, 1 H); 7.47-7.53 (m, 2H); 7.82 (dd, 1 H); 7.85 (s, 1 H); 8.19 (d, 1 H); 8.95-8.99 (m, 1 H); 9-21 -9.24 (m, 1 H); 9.74 (bs, 2H). Intermediate 140
1 -{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}-3-(6-methylpyridazin-3- l)urea
Figure imgf000186_0001
To solution of phenyl {4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin- 4-yl)oxy]-3,5-difluorophenyl}carbamate (730 mg, 1 .34 mmol, intermediate 44) in DMF (10 mL) was added 6-methylpyridazin-3-amine (219 mg, 2.01 mmol) and this mixture was stirred at 60°C for 4 hours. The mixture was diluted with water and extracted two times with ethyl acetate. The combined organic phases were washed 3 times with halfconcentrated aqueous sodium chloride solution, dried over sodium sulfate, filtered and concentrated to dryness. The resulting residue was purified via a Biotage chromatography system (KP-Sil snap column; dichloromethane / methanol gradient with up to 2% methanol) to obtain 580 mg (70 % yield) of he desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.12 - -0.06 (m, 9H); 0.80-0.86 (m, 2H); 2.25 (s, 3H); 3.50-3.56 (m, 2H); 5.81 (s, 2H); 6.47 (d, 1 H); 7.49-7.59 (m, 3H); 7.85 (s, 1 H); 7.91 (d, 1 H); 8.19 (d, 1 H); 9.92 (bs, 1 H); 10.2 (bs, 1 H).
Intermediate 141
1 -{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}-3-pyridin-3-ylurea
Figure imgf000187_0001
To solution of phenyl {4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin- 4-yl)oxy]-3,5-difluorophenyl}carbamate (1 10 mg, 0.2 mmol, intermediate 44) in DMF (1.7 mL) was added pyridin-3-amine (28.4 mg, 302 μηηοΙ) and this mixture was stirred at 60°C for 4 hours. The mixture was diluted with water and extracted two times with ethyl acetate. The combined organic phases were washed 3 times with halfconcentrated aqueous sodium chloride solution, dried over sodium sulfate, filtered and concentrated to dryness. The resulting residue was purified via a Biotage chromatography system (KP-Sil snap column;
dichloromethane / methanol gradient with up to 3% methanol) to obtain 1 1 1 mg (96 % yield) of he desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.12 - -0.06 (m, 9H); 0.80-0.86 (m, 2H); 3.50-3.56 (m, 2H); 5.81 (s, 2H); 6.47 (d, 1 H); 7.34 (ddd, 1 H); 7.45-7.52 (m, 2H); 7.85 (s, 1 H); 7.95 (ddd, 1 H); 8.18 (d, 1 H); 8.22 (dd, 1 H); 8.63 d, 1 H); 9.25 (bs, 1 H); 9.49 (bs, 1 H).
Intermediate 142
1 -{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}-3-pyridin-2-ylurea
Figure imgf000188_0001
To solution of phenyl {4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin- 4-yl)oxy]-3,5-difluorophenyl}carbamate (90 mg, 0.17 mmol, intermediate 44) in DMF (1 mL) was added pyridin-2-amine (23.3 mg, 247 μηηοΙ) and this mixture was stirred at 60°C for 4 hours. The mixture was diluted with water and extracted two times with ethyl acetate. The combined organic phases were washed 3 times with halfconcentrated aqueous sodium chloride solution, dried over sodium sulfate, filtered and concentrated to dryness. The resulting residue was purified via a Biotage chromatography system (KP-Sil snap column;
dichloromethane / methanol gradient with up to 3% methanol) to obtain 33 mg (35 % yield) of the desired title compound.
1H-NMR (400 MHz, CDCI3) δ [ppm]: -0.07 - -0.02 (m, 9H); 0.89-0.95 (m, 2H); 3.52-3.58 (m, 2H); 5.84 (s, 2H); 6.35 (d, 1 H); 6.81 (bd, 1 H); 7.00-7.05 (m, 1 H); 7.39-7.47 (m, 2H); 7.68-7.80 (m+bs, 2H); 8.14 (d, 1 H); 8.28-8.31 (m, 1 H); 12.25 (bs, 1 H).
Intermediate 143
4-(2,6-difluoro-4-nitrophenoxy)-1 H-pyrrolo[2,3-b]pyridine
Figure imgf000188_0002
A solution of 1 ,2,3-trifluoro-5-nitrobenzene (CAS No. [66684-58-0]; 3.59 g, 20.3 mmol) and 1 H- pyrrolo[2,3-b]pyridin-4-ol (CAS No. [74420-02-3]; 1 .10 eq., 2.99 g, 22.3 mmol) in DMSO (65 mL) was treated with potassium carbonate (4.00 eq, 1 1 .2 g, 81.1 mmol) and stirred at room temperature for 1 hour. The reaction mixture was diluted with ethyl acetate (500 mL) and washed with water (3 x 200 mL) and brine (150 mL), dried with sodium sulfate and concentrated in vacuo. The obtained material was purified by flash chromatography (S1O2- hexane/ ethyl acetate) to give the title compound (3.1 g, 52%).
LC-MS (method 2): Rt = 1 .13 min; MS (ESIpos): m/z = 292 [M+H]+.
1H-NMR (400 MHz, DMSO-d6) δ [ppm] = 6.35 (d, 1 H), 6.59 (d, 1 H), 7.47 (d, 1 H), 8.13 (d, 1 H), 8.37 - 8.43 (m, 2H), 1 1 .97 (br s, 1 H).
Intermediate 144
4-(2,6-difluoro-4-nitrophenoxy)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridine
Figure imgf000189_0001
An ice-cooled solution of 4-(2,6-difluoro-4-nitrophenoxy)-1 /-/-pyrrolo[2,3-b]pyridine (intermediate 143; 3.1 1 g, 10.7 mmol) in acetonitrile (100 mL) was treated with Λ/,/V-diisopropyl ethylamine (1 .80 eq, 3.35 mL, 19.2 mmol) and [2-(chloromethoxy)ethyl](trimethyl)silane (CAS No. [76513-69-4]; 1 .40 eq, 2.65 mL, 15.0 mmol), warmed to rt and stirring continued overnight. The reaction mixture was poured on ice water (150 mL) and the aqueous phase extracted with ethyl acetate (2 x 400 mL). The combined organic layers were washed with brine (150 mL), dried with sodium sulfate and concentrated in vacuo. The obtained material was purified by flash chromatography (KP-NH®-SiC>2-hexane/ ethyl acetate) to give the title compound (3.9 g, 85%).
LC-MS (method 2): Rt = 1 .58 min; MS (ESIpos): m/z = 422 [M+H]+.
1H-NMR (400 MHz, DMSO-d6) δ [ppm] = -0.1 1 (s, 9H), 0.79 - 0.83 (m, 2H), 3.50 - 3.54 (m, 2H), 5.64 (s, 2H), 6.48 (d, 1 H), 6.69 (d, 1 H), 7.66 (d, 1 H), 8.20 (d, 1 H), 8.38 - 8.44 (m, 2H). Intermediate 145
3,5-difluoro-4-[(1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]aniline
Figure imgf000190_0001
A solution of 4-(2,6-difluoro-4-nitrophenoxy)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 /-/-pyrrolo[2,3- bjpyridine (intermediate 144; 1 .73 g, 4.1 1 mmol) in ethyl acetate (32 mL) was treated with palladium on carbon (10wt%; 0.05 eq., 218 mg, 0.205 mmol) and stirred under a hydrogen atmosphere at rt for 2 h. The reaction mixture was filtrated over Celite, washed with ethyl acetate and the filtrate concentrated in vacuo to give the title compound (1 .58 g, 93%) which was not further purified.
LC-MS (method 2): Rt = 1 .42 min; MS (ESIpos): m/z = 392 [M+H]+.
1H-NMR (400 MHz, DMSO-d6) δ [ppm] = -0.10 (s, 9H), 0.78 - 0.83 (m, 2H), 3.49 - 3.53 (m, 2H), 5.61 (s, 2H), 5.80 (br s, 2H), 6.35 - 6.40 (m, 3H), 6.45 (d, 1 H), 7.57 (d, 1 H), 8.13 (d, 1 H). Intermediate 146
phenyl {3,5-difluoro-4-[(1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4- yl)oxy]phenyl}carbamate
Figure imgf000190_0002
An ice-cooled solution of 3,5-difluoro-4-[(1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 /-/-pyrrolo[2,3- b]pyridin-4-yl)oxy]aniline (intermediate 145; 1.46 g, 3.73 mmol) and pyridine (5.0 eq., 1 .5 ml_, 19 mmol) in THF (13 mL) was treated with phenyl chloroformate (CAS No. [1885-14-9]; 1.1 eq, 0.51 mL, 4.1 mmol), the mixture warmed to rt and stirring continued for 70 minutes.
The reaction mixture was diluted with ethyl acetate and washed with 1 M aqueous hydrochloric acid, aqueous sat. sodium hydrocarbonate solution and brine. The resulting organic layer was dried with sodium sulfate, concentrated in vacuo and the obtained material purified by flash chromatography (SiC>2-hexane/ ethyl acetate) to give the title compound (1 .61 g, 84 %) containing 1 -{3,5-difluoro-4-[(1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 /-/-pyrrolo[2,3-b]pyridin-4- yl)oxy]phenyl}urea.
LC-MS (method 2): Rt = 1 .59 min; MS (ESIpos): m/z = 512 [M+H]+.
Intermediate 147
1 -{3,5-difluoro-4-[(1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl}- 3-[2-(piperidin-1 -yl)ethyl]urea
Figure imgf000191_0001
To a solution of phenyl {3,5-difluoro-4-[(1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl)oxy]phenyl}carbamate (100 mg, 195 μηηοΙ, intermediate 146) in DMF (I .O mL) was added 2-(piperidin-1 -yl)ethanamine (LOO eq., 25.1 mg, 195 μη"ΐοΙ) and this mixture was stirred at 60 °C for 75 minutes. After cooling to room temperature ethylacetate and water were added to the reaction mixture and the phases were separated. The aqueous phase was extracted two times with ethylacetate, the combined organic phases were washed with brine, dried over sodium sulfate, filtered and concentrated to dryness. The resulting residue was purified by flash chromatography (dichloromethane/ methanol) to give the title compound (1 10 mg, 95%).
LC-MS (method 2): Rt = 1 .51 min; MS (ESIneg): m/z = 544 [M-H]\ Intermediate 148
N3-({3,5-difluoro^-[(H[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4- yl)oxy]phenyl}carbamoyl)-beta-alaninamide
Figure imgf000192_0001
This intermediate was prepared in analogy to intermediate 147 by reacting phenyl {3,5- difluoro-4-[(1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl}carba- mate (100 mg, 195 μη"ΐοΙ, intermediate 146), beta-alaninamide (1 .00 eq., 17.2 mg, 195 μη"ΐοΙ) and additionally N,N-diisopropylethylamine (2.0 eq., 68 μΙ_, 391 μmol) in DMF for 4 hours at 60 °C to give after flash chromatography (dichloromethane/ methanol) the title compound (65 mg, 64%).
LC-MS (method 2): Rt = 1 .25 min; MS (ESIpos): m/z = 506 [M+H]+.
Intermediate 149
1 -{3,5-difluoro-4-[(1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl}- 3-(1 H-1 ,2,3-triazol-5-ylmeth l)urea
H
Figure imgf000192_0002
This intermediate was prepared in analogy to intermediate 147 by reacting phenyl {3,5- difluoro-4-[(1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl}carba- mate (100 mg, 195 μηιοΙ, intermediate 146), 1 -(1 H-1 ,2,3-triazol-5-yl)methanamine (1 .00 eq., 19.2 mg, 195 μηιοΙ) and additionally N,N-diisopropylethylamine (2.0 eq., 68 μΙ_, 391 μηιοΙ) in DMF for 4 hours at 60 °C to give after flash chromatography (dichloromethane/ methanol) the title compound (48 mg, 48%).
LC-MS (method 2): Rt = 1 .02 min; MS (ESIpos): m/z = 516 [M+H]+. Intermediate 150
1 -{3,5-difluoro-4-[(1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl}- 3-[3-(dimethylamino) ropyl urea
Figure imgf000193_0001
This intermediate was prepared in analogy to intermediate 147 by reacting phenyl {3,5- difluoro-4-[(1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl}carba- mate (100 mg, 195 μηηοΙ, intermediate 146) and N,N-dimethylpropane-1 ,3-diamine (1 .00 eq., 20.0 mg, 195 μηηοΙ) in DMF for 2 hours at 60 °C to give after flash chromatography (dichloromethane/ methanol) the title compound (79 mg, 77%).
LC-MS (method 2): Rt = 1 .44 min; MS (ESIpos): m/z = 521 [M+H]+.
Intermediate 151
4-[({3,5-difluoro-4-[(1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4- yl)oxy]phenyl}carbamoyl)amino]butanamide
H
Figure imgf000193_0002
This intermediate was prepared in analogy to intermediate 147 by reacting phenyl {3,5- difluoro-4-[(1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl}carba- mate (100 mg, 195 μηηοΙ, intermediate 146), 4-aminobutanamide hydrochloride (1 :1 ) (1 .00 eq., 27.1 mg, 195 μη"ΐοΙ) and additionally N,N-diisopropylethylamine (2.0 eq., 68 μΙ_, 391 μηηοΙ) in DMF for 75 minutes at 60 °C to give after flash chromatography (dichloromethane/ methanol) the title compound (96 mg, 91 %).
LC-MS (method 2): Rt = 1 .26 min; MS (ESIpos): m/z = 520 [M+H]+.
Intermediate 152
1 -{3,5-difluoro-4-[(1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl}- 3-(2-methoxyethyl)urea
Figure imgf000194_0001
This intermediate was prepared in analogy to intermediate 147 by reacting phenyl {3,5- difluoro-4-[(1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl}carba- mate (100 mg, 195 μηηοΙ, intermediate 146) and 2-methoxyethanamine (1 .00 eq., 14.7 mg, 195 μηηοΙ) in DMF for 2 hours at 60 °C to give after flash chromatography (dichloromethane/ methanol) the title compound (83 mg, 86%).
LC-MS (method 2): Rt = 1 .38 min; MS (ESIpos): m/z = 492 [M+H]+.
Intermediate 153
1 -{3,5-difluoro-4-[(1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl}- 3-(pyridin-2-ylmethyl)urea
Figure imgf000194_0002
This intermediate was prepared in analogy to intermediate 147 by reacting phenyl {3,5- difluoro-4-[(1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl}carba- mate (99 mg, 194 μηηοΙ, intermediate 146) and 1 -(pyridin-2-yl)methanamine (1.00 eq.,
20.9 mg, 194 μηηοΙ) in DMF for 2 hours at 60 °C to give after flash chromatography (dichloro- methane/ methanol) the title compound (65 mg, 56%).
LC-MS (method 2): Rt = 1 .38 min; MS (ESIpos): m/z = 526 [M+H]+.
Intermediate 154
1 -{3,5-difluoro-4-[(1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl}- 3-[3-(methylsulfonyl)pro l]urea
H
Figure imgf000195_0001
This intermediate was prepared in analogy to intermediate 147 by reacting phenyl {3,5- difluoro-4-[(1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl}carba- mate (100 mg, 195 μη"ΐοΙ, intermediate 146), 3-(methylsulfonyl)propan-1 -amine hydrochloride (1 :1 ) (1.00 eq., 33.9 mg, 195 μηηοΙ) and additionally N,N-diisopropylethylamine (1.0 eq., 34 μΙ_, 195 μηηοΙ) in DMF for 2 hours at 60 °C to give after flash chromatography (dichloromethane/ methanol) the title compound (75 mg, 69%).
LC-MS (method 2): Rt = 1 .31 min; MS (ESIpos): m/z = 555 [M+H]+. Intermediate 155
1 -{3,5-difluoro-4-[(1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl}- 3-[2-(dimethylamino)ethyl urea
Figure imgf000195_0002
This intermediate was prepared in analogy to intermediate 147 by reacting phenyl {3,5- difluoro-4-[(1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl}carba- mate (100 mg, 195 μηηοΙ, intermediate 146) and N,N-dimethylethane-1 ,2-diamine (1 .00 eq., 21.5 μΙ_, 195 μηηοΙ) in DMF for 2 hours at 60 °C to give after flash chromatography (dichloro- methane/ methanol) the title compound (72 mg, 74%).
LC-MS (method 2): Rt = 1.41 min; MS (ESIneg): m/z = 504 [M-H]\
Intermediate 156
1 -{3,5-difluoro-4-[(1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl}- 3-[3-(piperidin-1 -yl)pro l]urea
Figure imgf000196_0001
This intermediate was prepared in analogy to intermediate 147 by reacting phenyl {3,5- difluoro-4-[(1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl}carba- mate (100 mg, 195 μηιοΙ, intermediate 146) and 3-(piperidin-1 -yl)propan-1 -amine (1 .00 eq., 31.1 μΙ_, 195 μηιοΙ) in DMF for 2 hours at 60 °C to give after flash chromatography (dichloro- methane/ methanol) the title compound (65 mg, 59%).
LC-MS (method 2): Rt = 1 .60 min; MS (ESIneg): m/z = 558 [M-H]\
Intermediate 157
3-bromo-4-(2,6-difluoro-4-nitrophenoxy)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridine
O
Figure imgf000196_0002
A solution of 4-(2,6-difluoro-4-nitrophenoxy)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 /-/-pyrrol o[2, 3- b]pyridine (intermediate 144; 1 .55 g, 3.68 mmol) in DMF (31 mL) was treated with 1 - bromopyrrolidine-2,5-dione (CAS No. [128-08-5]; 1.10 eq, 720 mg, 4.05 mmol) and stirred at rt overnight. The reaction mixture was diluted with water and extracted with ethyl acetate. The organic layer was washed with aqueous sat. sodium hydrocarbonate solution and brine, filtrated over a hydrophobic phase separation filter paper and concentrated in vacuo. The obtained material was purified by flash chromatography (Si02-hexane/ ethyl acetate) to give the title compound (1 .57 g, 85%).
LC-MS (method 2): Rt = 1 .61 min; MS (ESIpos): m/z = 500/502 [M+H]+ (Br isotope pattern). 1H-NMR (400 MHz, DMSO-d6) δ [ppm] = -0.09 (s, 9H), 0.79 - 0.86 (m, 2H), 3.52 - 3.56 (m, 2H), 5.62 (s, 2H), 6.67 (d, 1 H), 7.94 (s, 1 H), 8.22 (d, 1 H), 8.40 - 8.45 (m, 2H).
Intermediate 158
phenyl {4-[(3-bromo-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyljcarbamate
Figure imgf000197_0001
A solution of 3-bromo-4-(2,6-difluoro-4-nitrophenoxy)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 /-/- pyrrolo[2,3-b]pyridine (intermediate 157; 3.25 g, 6.50 mmol) in methanol (130 mL) was treated with tin(ll) chloride dihydrate (CAS No. [10025-69-1 ]; 3.00 eq, 4.40 g, 19.5 mmol) and stirred at 65 C overnight. The reaction mixture was cooled to rt and concentrated in vacuo. The residue was taken up with ethyl acetate and aqueous sat. sodium carbonate solution, filtrated over diatomite and the phases separated. The organic phase was washed with aqueous sat. sodium carbonate solution, dried with sodium sulfate and concentrated in vacuo. The obtained material was purified by flash chromatography (Si02-hexane/ ethyl acetate) to give the title compound (2.28 g, 67%).
LC-MS (method 2): Rt = 1 .53 min; MS (ESIpos): m/z = 470/472 [M+H]+ (Br isotope pattern).
1H-NMR (400 MHz, DMSO-d6) δ [ppm] = -0.09 (s, 9H), 0.80 - 0.84 (m, 2H), 3.50 - 3.54 (m, 2H), 5.59 (s, 2H), 5.82 (br s, 2H), 6.36 - 6.42 (m, 3H), 7.83 (s, 1 H), 8.16 (d, 1 H). Intermediate 159
phenyl {4-[(3-bromo-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}carbamate
Figure imgf000198_0001
An ice-cooled solution of 4-[(3-bromo-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 /-/-pyrrolo[2,3- b]pyridin-4-yl)oxy]-3,5-difluoroaniline (intermediate 158; 2.20 g, 4.68 mmol) and pyridine (5.0 eq., 1 .9 ml_, 23 mmol) in THF (25 mL) was treated with phenyl chloroformate (CAS No. [1885- 14-9]; 1.3 eq, 0.76 mL, 6.1 mmol), the mixture warmed to rt and stirring continued for 4 hours. The reaction mixture was diluted with ethyl acetate and washed with 1 M aqueous hydrochloric acid, aqueous sat. sodium hydrocarbonate solution and brine. The resulting organic layer was dried with sodium sulfate and concentrated in vacuo to give the crude title compound (3.5 g) containing 1 -{4-[(3-bromo-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 /-/-pyrrolo[2,3-b]pyridin-4-yl)oxy]- 3,5-difluorophenyl}urea which was used as is in the next steps.
LC-MS (method 2): Rt = 1 .66 min; MS (ESIpos): m/z = 590/592 [M+H]+ (Br isotope pattern).
Intermediate 160
1 -{4-[(3-bromo-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}-3-(3-methoxypropyl)urea
Figure imgf000198_0002
To a solution of phenyl {4-[(3-bromo-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl)oxy]-3,5-difluorophenyl}carbamate (225 mg, 381 μηηοΙ, intermediate 159) in DMF (4.0 mL) was added 3-methoxypropan-1 -amine (1.20 eq., 40.8 mg, 457 μηηοΙ) and this mixture was stirred at 70 °C for 18 hours. The reaction mixture was diluted with ethyl acetate and washed with water. The organic phase was separated, dried and concentrated in vacuo. The crude product (223 mg) was used in the next step without any further purification.
LC-MS (method 2): Rt = 1 .47 min; MS (ESIpos): m/z = 585/587 [M+H]+ (Br isotope pattern).
Intermediate 161
1 -{4-[(3-bromo-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}-3-[(1 -methyl-1 H-pyrazol-3-yl)methyl]urea
3
Figure imgf000199_0001
This intermediate was prepared in analogy to intermediate 160 by reacting phenyl {4-[(3- bromo-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluoro- phenyljcarbamate (225 mg, 381 μηηοΙ, intermediate 159) and 1 -(1 -methyl-1 H-pyrazol-3- yl)methanamine (1.20 eq., 50.8 mg, 457 μηιοΙ) in DMF at 70 °C for 18 hours to give after aqueous work-up the crude product (231 mg) which was used in the next step without any further purification.
LC-MS (method 2): Rt = 1 .42 min; MS (ESIpos): m/z = 607/609 [M+H]+ (Br isotope pattern). Intermediate 162
1 -{4-[(3-bromo-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}-3-(1 ,3-thiazol-2-ylmethyl)urea
Figure imgf000200_0001
This intermediate was prepared in analogy to intermediate 160 by reacting phenyl {4-[(3- bromo-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluoro- phenyljcarbamate (225 mg, 381 μmol, intermediate 159) and 1 -(1 ,3-thiazol-2-yl)methanamine (1 .20 eq., 52.2 mg, 457 μηηοΙ) in DMF at 70 °C for 18 hours to give after aqueous work-up the crude product (233 mg) which was used in the next step without any further purification. LC-MS (method 2): Rt = 1 .45 min; MS (ESIpos): m/z = 610/612 [M+H]+ (Br isotope pattern).
Intermediate 163
1 -{4-[(3-bromo-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}-3-(1 H-pyrazol-3-ylmethyl)urea
Figure imgf000200_0002
This intermediate was prepared in analogy to intermediate 160 by reacting phenyl {4-[(3- bromo-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluoro- phenyljcarbamate (225 mg, 381 μηηοΙ, intermediate 159) and 1 -(1 H-pyrazol-3-yl)methanamine (1 .20 eq., 44.4 mg, 457 μηιοΙ) in DMF at 70 °C for 18 hours to give after aqueous work-up the crude product (226 mg) which was used in the next step without any further purification.
LC-MS (method 2): Rt = 1 .38 min; MS (ESIpos): m/z = 593/595 [M+H]+ (Br isotope pattern). Intermediate 164
N3-({4-[(3-bromo-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}carbamoyl)-beta-alaninamide
Figure imgf000201_0001
This intermediate was prepared in analogy to intermediate 160 by reacting phenyl {4-[(3- bromo-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluoro- phenyljcarbamate (150 mg, 206 μηηοΙ, intermediate 159), beta-alaninamide (1 .00 eq., 18.1 mg, 206 μηιοΙ) and additionally N,N-diisopropylethylamine (2.0 eq., 72 μΙ_, 410 μηιοΙ) in DMF for 4 hours at 60 °C to give after concentration of the reaction mixture in vacuo the crude product (120 mg) which was used in the next step without any further purification.
LC-MS (method 2): Rt = 1 .36 min; MS (ESIpos): m/z = 584/586 [M+H]+ (Br isotope pattern).
Intermediate 165
1 -{4-[(3-bromo-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}-3-[2-(piperidin-1 -yl)ethyl]urea
Figure imgf000201_0002
This intermediate was prepared in analogy to intermediate 160 by reacting phenyl {4-[(3- bromo-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluoro- phenyljcarbamate (150 mg, 206 μηηοΙ, intermediate 159) and 2-(piperidin-1 -yl)ethanamine (1 .00 eq., 26.4 mg, 206 μηηοΙ) in DMF for 2 hours at 60 °C to give after concentration of the reaction mixture in vacuo the crude product (129 mg) which was used in the next step without any further purification.
LC-MS (method 2): Rt = 1 .60 min; MS (ESIpos): m/z = 624/626 [M+H]+ (Br isotope pattern).
Intermediate 166
N-{2-[({4-[(3-bromo-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}carbamo l)amino]ethyl}methanesulfonamide
Figure imgf000202_0001
This intermediate was prepared in analogy to intermediate 160 by reacting phenyl {4-[(3- bromo-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluoro- phenyljcarbamate (150 mg, 206 μηηοΙ, intermediate 159) and N-(2-aminoethyl)methane- sulfonamide (1.00 eq., 28.4 mg, 206 μηιοΙ) in DMF for 2 hours at 60 °C to give after concentration of the reaction mixture in vacuo the crude product (131 mg) which was used in the next step without any further purification.
LC-MS (method 2): Rt = 1 .40 min; MS (ESIpos): m/z = 634/636 [M+H]+ (Br isotope pattern).
Intermediate 167
1 -{4-[(3-bromo-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}-3-[3- morpholin-4-yl)propyl]urea
Figure imgf000203_0001
This intermediate was prepared in analogy to intermediate 160 by reacting phenyl {4-[(3- bromo-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluoro- phenyljcarbamate (150 mg, 206 μηηοΙ, intermediate 159) and 3-(morpholin-4-yl)propan-1 - amine (1 .00 eq., 29.7 mg, 206 μηηοΙ) in DMF for 2 hours at 60 °C to give after concentration of the reaction mixture in vacuo the crude product (132 mg) which was used in the next step without any further purification.
LC-MS (method 2): Rt = 1 .46 min; MS (ESIpos): m/z = 640/642 [M+H]+ (Br isotope pattern).
Intermediate 168
N-{2-[({4-[(3-bromo-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}carbamo l)amino ethyl}acetamide
H
Figure imgf000203_0002
This intermediate was prepared in analogy to intermediate 160 by reacting phenyl {4-[(3- bromo-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluoro- phenyljcarbamate (150 mg, 206 μηηοΙ, intermediate 159) and N-(2-aminoethyl)acetamide (1 .00 eq., 21.0 mg, 206 μηηοΙ) in DMF for 2 hours at 60 °C to give after concentration of the reaction mixture in vacuo the crude product (123 mg) which was used in the next step without any further purification.
LC-MS (method 2): Rt = 1 .39 min; MS (ESIpos): m/z = 598/600 [M+H]+ (Br isotope pattern). Intermediate 169
1 -{4-[(3-bromo-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}-3-[2-(mor holin-4- l)-2-oxoethyl]urea
Figure imgf000204_0001
This intermediate was prepared in analogy to intermediate 160 by reacting phenyl {4-[(3- bromo-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluoro- phenyljcarbamate (150 mg, 206 μηηοΙ, intermediate 159), 2-amino-1 -(morpholin-4-yl)ethanone (LOO eq., 29.7 mg, 206 μηιοΙ) and additionally N,N-diisopropylethylamine (2.0 eq., 72 μΙ_, 410 μηηοΙ) in DMF for 4 hours at 60 °C to give after concentration of the reaction mixture in vacuo the crude product (132 mg) which was used in the next step without any further purification.
LC-MS (method 2): Rt = 1 .42 min; MS (ESIpos): m/z = 640/642 [M+H]+ (Br isotope pattern). Intermediate 170
1 -{4-[(3-bromo-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}-3-(pyridin-2- lmeth l)urea
Figure imgf000204_0002
This intermediate was prepared in analogy to intermediate 160 by reacting phenyl {4-[(3- bromo-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluoro- phenyljcarbamate (150 mg, 206 μηηοΙ, intermediate 159) and 1 -(pyridin-2-yl)methanamine (1 .00 eq., 22.3 mg, 206 μιτιοΙ) in DMF for 2 hours at 60 °C to give after concentration of the reaction mixture in vacuo the crude product (125 mg) which was used in the next step without any further purification.
LC-MS (method 2): Rt = 1 .49 min; MS (ESIpos): m/z = 604/606 [M+H]+ (Br isotope pattern).
Intermediate 171
1 -{4-[(3-bromo-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}-3-[(1 ,1 -dioxidothietan-3-yl)methyl]urea
Figure imgf000205_0001
This intermediate was prepared in analogy to intermediate 160 by reacting phenyl {4-[(3- bromo-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluoro- phenyljcarbamate (150 mg, 206 μηηοΙ, intermediate 159) and 1 -(1 ,1 -dioxidothietan-3- yl)methanamine (LOO eq., 27.8 mg, 206 μηιοΙ) in DMF for 2 hours at 60 °C to give after concentration of the reaction mixture in vacuo the crude product (130 mg) which was used in the next step without any further purification.
LC-MS (method 2): Rt = 1 .43 min; MS (ESIpos): m/z = 631/633 [M+H]+ (Br isotope pattern). Intermediate 172
1 -{4-[(3-bromo-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}-3-(2-methoxyethyl)urea
Figure imgf000206_0001
This intermediate was prepared in analogy to intermediate 160 by reacting phenyl {4-[(3- bromo-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluoro- phenyljcarbamate (150 mg, 206 μmol, intermediate 159) and 2-methoxyethanamine (1 .00 eq., 15.5 mg, 206 μmol) in DMF for 2 hours at 60 °C to give after concentration of the reaction mixture in vacuo the crude product (1 18 mg) which was used in the next step without any further purification.
LC-MS (method 2): Rt = 1 .48 min; MS (ESIpos): m/z = 571/573 [M+H]+ (Br isotope pattern).
Intermediate 173
1 -{4-[(3-bromo-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}-3-(pyridin-4-ylmethyl)urea
Figure imgf000206_0002
This intermediate was prepared in analogy to intermediate 160 by reacting phenyl {4-[(3- bromo-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluoro- phenyljcarbamate (150 mg, 206 μηηοΙ, intermediate 159) and 1 -(pyridin-4-yl)methanamine (1 .00 eq., 22.3 mg, 206 μηιοΙ) in DMF for 2 hours at 60 °C to give after concentration of the reaction mixture in vacuo the crude product (124 mg) which was used in the next step without any further purification.
LC-MS (method 2): Rt = 1 .46 min; MS (ESIpos): m/z = 604/606 [M+H]+ (Br isotope pattern). Intermediate 174
N2-({4-[(3-bromo-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}carbamo l)glycinamide
H
Figure imgf000207_0001
This intermediate was prepared in analogy to intermediate 160 by reacting phenyl {4-[(3- bromo-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluoro- phenyljcarbamate (150 mg, 206 μηηοΙ, intermediate 159), glycinamide hydrochloride (1 :1 ) (I .OO eq., 22.7 mg, 206 μηηοΙ) and additionally N,N-diisopropylethylamine (2.0 eq., 72 μΙ_, 410 μηηοΙ) in DMF for 2 hours at 60 °C to give after concentration of the reaction mixture in vacuo the crude product (1 17 mg) which was used in the next step without any further purification.
LC-MS (method 2): Rt = 1 .34 min; MS (ESIpos): m/z = 570/572 [M+H]+ (Br isotope pattern). Intermediate 175
1 -{4-[(3-bromo-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}-3-[3-(piperidin-1 - l)propyl]urea
Figure imgf000207_0002
This intermediate was prepared in analogy to intermediate 160 by reacting phenyl {4-[(3- bromo-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluoro- phenyljcarbamate (150 mg, 206 μηηοΙ, intermediate 159) and 3-(piperidin-1 -yl)propan-1 -amine (1 .00 eq., 29.3 mg, 206 μιτιοΙ) in DMF for 2 hours at 60 °C to give after concentration of the reaction mixture in vacuo the crude product (131 mg) which was used in the next step without any further purification.
LC-MS (method 2): Rt = 1 .61 min; MS (ESIpos): m/z = 638/640 [M+H]+ (Br isotope pattern).
Intermediate 176
1 -{4-[(3-bromo-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}-3-(1 H-1 ,2,3-triazol-4-ylmethyl)urea
Figure imgf000208_0001
This intermediate was prepared in analogy to intermediate 160 by reacting phenyl {4-[(3- bromo-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluoro- phenyljcarbamate (150 mg, 206 μηηοΙ, intermediate 159), 1 -(1 H-1 ,2,3-triazol-4-yl)methanamine hydrochloride (1 :1 ) (1.00 eq., 27.7 mg, 206 μηηοΙ) and additionally N,N-diisopropylethylamine (2.0 eq., 72 μΙ_, 410 μηηοΙ) in DMF for 2 hours at 60 °C to give after concentration of the reaction mixture in vacuo the crude product (123 mg) which was used in the next step without any further purification.
LC-MS (method 2): Rt = 1 .14 min; MS (ESIpos): m/z = 594/596 [M+H]+ (Br isotope pattern). Intermediate 177
1 -{4-[(3-bromo-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}-3-[3- methylsulfon l)propyl]urea
Figure imgf000209_0001
This intermediate was prepared in analogy to intermediate 160 by reacting phenyl {4-[(3- bromo-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluoro- phenyljcarbamate (150 mg, 206 μηηοΙ, intermediate 159), 3-(methylsulfonyl)propan-1 -amine hydrochloride (1 :1 ) (1.00 eq., 25.7 mg, 206 μηηοΙ) and additionally N,N-diisopropylethylamine (2.0 eq., 72 μΙ_, 410 μηηοΙ) in DMF for 2 hours at 60 °C to give after concentration of the reaction mixture in vacuo the crude product (130 mg) which was used in the next step without any further purification.
LC-MS (method 2): Rt = 1 .41 min; MS (ESIpos): m/z = 633/635 [M+H]+ (Br isotope pattern). Intermediate 178
4-[({4-[(3-bromo-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}carbamoyl)amino]butanamide
Figure imgf000209_0002
This intermediate was prepared in analogy to intermediate 160 by reacting phenyl {4-[(3- bromo-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluoro- phenyljcarbamate (150 mg, 206 μηηοΙ, intermediate 159), 4-aminobutanamide hydrochloride (1 :1 ) (1.00 eq., 28.5 mg, 206 μηηοΙ) and additionally N,N-diisopropylethylamine (2.0 eq., 72 μΙ_, 410 μηηοΙ) in DMF for 2 hours at 60 °C to give after concentration of the reaction mixture in vacuo the crude product (123 mg) which was used in the next step without any further purification.
LC-MS (method 2): Rt = 1 .36 min; MS (ESIpos): m/z = 598/600 [M+H]+ (Br isotope pattern).
Intermediate 179
1 -{4-[(3-bromo-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}-3-[2-(4-methylpiperazin-1 - l)-2-oxoethyl]urea
Figure imgf000210_0001
This intermediate was prepared in analogy to intermediate 160 by reacting phenyl {4-[(3- bromo-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluoro- phenyljcarbamate (150 mg, 206 μηηοΙ, intermediate 159) and 2-amino-1 -(4-methylpiperazin-1 - yl)ethanone (LOO eq., 32.3 mg, 206 μπιοΙ) in DMF for 2 hours at 60 °C to give after concentration of the reaction mixture in vacuo the crude product (137 mg) which was used in the next step without any further purification.
LC-MS (method 2): Rt = 1 .41 min; MS (ESIpos): m/z = 653/655 [M+H]+ (Br isotope pattern).
ntermediate 180
Figure imgf000211_0001
A solution of 4-(2,6-difluoro-4-nitrophenoxy)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridine (intermediate 144; 5.00 g, 1 1.9 mmol) in DMF (100 mL) was treated with 1 - iodopyrrolidine-2,5-dione (1 .50 eq., 4.00 g, 17.8 mmol) and stirred at room temperature for 2 hours. The reaction mixture was diluted with water and extracted with ethyl acetate. The organic layer was washed with aqueous sat. sodium hydrocarbonate solution and brine, filtrated over a hydrophobic phase separation filter paper and concentrated in vacuo. The obtained material was purified by flash chromatography (Si02-hexane/ ethyl acetate) to give the title compound (6.27 g, 92%).
LC-MS (method 2): Rt = 1 .64 min; MS (ESIpos): m/z = 548 [M+H]+.
1H-NMR (400 MHz, DMSO-d6) δ [ppm] = -0.09 (s, 9H), 0.80 - 0.84 (m, 2H), 3.51 - 3.55 (m, 2H), 5.61 (s, 2H), 6.64 (d, 1 H), 7.93 (s, 1 H), 8.21 (d, 1 H), 8.40 - 8.45 (m, 2H).
Intermediate 181
4-(2,6-difluoro-4-nitrophenoxy)-3-methyl-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-
Figure imgf000211_0002
b]pyridine A solution of 4-(2,6-difluoro-4-nitrophenoxy)-3-iodo-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 /-/- pyrrolo[2,3-b]pyridine (intermediate 180; 200 mg, 0.365 mmol) in anhydrous 1 ,4-dioxane (5 mL) under argon was treated with [1 ,1 '-bis(diphenylphosphino)ferrocene]di- chloropalladium(ll), complex with dichloromethane (CAS No. [95464-05-4]; 0.05 eq., 15 mg, 18 mol) and dropwise with dimethylzinc (CAS No. [544-97-8]; 3.00 eq, 548 μΙ_ of a 2 M solution in toluene) and stirred at 100 C for 30 minutes. The reaction mixture was cooled to rt and taken up with ethyl acetate and water. The phases were separated and the aqueous phase extracted with ethyl acetate. The combined organic phases were dried with sodium sulfate and concentrated in vacuo. The obtained material was purified by flash chromatography (SiC>2-hexane/ ethyl acetate) to give the title compound along with starting material (20%) and dehalogenated starting material (20%, 1 10 mg in total).
LC-MS (method 2): Rt = 1 .65 min; MS (ESIpos): m/z = 436 [M+H]+. Intermediate 182
3,5-difluoro-4-[(3-methyl-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4- yl)oxy]aniline
Figure imgf000212_0001
A solution of 4-(2,6-difluoro-4-nitrophenoxy)-3-methyl-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 /-/- pyrrolo[2,3-b]pyridine (intermediate 181 ; 1 10 mg) in ethanol (10 mL) was treated with palladium(ll) hydroxide on carbon (20wt%; 0.05 eq., 14 mg, 13 μηιοΙ) and three drops of aqueous hydrochloric acid (4 M) and stirred under a hydrogen atmosphere at rt for 4 hours. The reaction mixture was filtrated over Celite, washed with ethanol and the filtrate concentrated in vacuo to give the title compound (90 mg) which was not further purified.
LC-MS (method 2): Rt = 1 .49 min; MS (ESIpos): m/z = 406 [M+H]+. Intermediate 183
phenyl {3,5-difluoro-4-[(3-methyl-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4- yl)oxy]phenyl}carbamate
Figure imgf000213_0001
A solution of 3,5-difluoro-4-[(3-methyl-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 /-/-pyrrolo[2,3- b]pyridin-4-yl)oxy]aniline (intermediate 182; 1 10 mg, 0.27 mmol) in ethyl acetate (2 mL) was treated with an aqueous sat. sodium hydrocarbonate solution (2 mL) and with phenyl chloroformate (CAS No. [1885-14-9]; 3.0 eq, 0.10 mL, 0.81 mmol) and the mixture stirred at rt for 2 days. As the conversion was not complete additional amounts of phenyl chloroformate (2.0 eq, 0.07 mL, 0.54 mmol and 3.0 eq, 0.10 mL, 0.81 mmol) were sequentially added and the reaction mixture stirred for another 4 days. The reaction mixture was diluted with ethyl acetate and water, the phases separated and the aqueous phase extracted with ethyl acetate (twice). The combined organic phases were washed with brine, dried with sodium sulfate and concentrated in vacuo. The obtained material was purified by flash chromatography (S1O2- hexane/ ethyl acetate) to give the title compound (60 mg) containing minor amounts of 1 -{3,5- difluoro-4-[(3-methyl-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 /-/-pyrrolo[2,3-b]pyridin-4- yl)oxy]phenyl}urea.
LC-MS (method 2): Rt = 1 .65 min; MS (ESIpos): m/z = 526 [M+H]+. Intermediate 184
1 -{3,5-difluoro-4-[(3-methyl-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4- yl)oxy]phenyl}-3-[2-(dimethylamino)ethyl]urea
Figure imgf000213_0002
To a solution of phenyl {3,5-difluoro-4-[(3-methyl-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl}carbamate (intermediate 183; 60.0 mg, 1 14 μηηοΙ) in DMF (2.0 mL) was added N,N-dimethylethane-1 ,2-diamine (1.20 eq., 12.1 mg, 137 μηιοΙ) and this mixture was stirred at 70 °C for 18 hours. The reaction mixture was diluted with ethyl acetate and washed with water and brine. The organic phase was dried and concentrated in vacuo and the crude product (59 mg) used in the next step without any further purification.
LC-MS (method 2): Rt = 1 .49 min; MS (ESIneg): m/z = 518 [M-H]\
Intermediate 185
4-(2,6-difluoro-4-nitrophenoxy)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridine-3- carbonitrile
Figure imgf000214_0001
A solution of 4-(2,6-difluoro-4-nitrophenoxy)-3-iodo-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 /-/- pyrrolo[2,3-b]pyridine (intermediate 180; 3.04 g, 5.55 mmol) in DMF (15 mL) was treated with copper(l) cyanide (CAS No. [544-92-3]; 1.30 eq., 647 mg, 7.22 mmol) and stirred at 120°C for 20 hours. The reaction mixture was taken up with ethyl acetate and water, the phases separated and the aqueous phase extracted with ethyl acetate (2x). The combined organic phases were washed with water and brine, dried with sodium sulfate and concentrated in vacuo. The obtained material was purified by flash chromatography (Si02-hexane/ ethyl acetate) to give the title compound (2.17 g, 87%).
LC-MS (method 2): Rt = 1 .50 min; MS (ESIpos): m/z = 447 [M+H]+.
1H-NMR (400 MHz, DMSO-d6) δ [ppm] = -0.10 (s, 9H), 0.82 - 0.86 (m, 2H), 3.56 - 3.60 (m, 2H), 5.70 (s, 2H), 6.87 (d, 1 H), 8.36 (d, 1 H), 8.43 - 8.48 (m, 2H), 8.73 (s, 1 H). Intermediate 186
4-(4-amino-2,6-difluorophenoxy)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridine- 3-carbonitrile
Figure imgf000215_0001
A solution of 4-(2,6-difluoro-4-nitrophenoxy)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 /-/-pyrrolo[2,3- b]pyridine-3-carbonitrile (intermediate 185; 1.05 g, 2.35 mmol) in methanol (15 mL) was treated with tin (I I ) chloride dihydrate (CAS No. [10025-69-1 ]; 3.00 eq, 1 .59 g, 7.06 mmol) and stirred at 65 °C overnight. The reaction mixture was cooled to rt and concentrated in vacuo. The residue was taken up with ethyl acetate and aqueous sat. sodium carbonate solution, filtrated over diatomite and the phases separated. The organic phase was washed with aqueous sat. sodium carbonate solution, dried with sodium sulfate and concentrated in vacuo to give the title compound (630 mg, 61 %) which was not further purified.
LC-MS (method 2): Rt = 1 .37 min; MS (ESIpos): m/z = 417 [M+H]+.
1H-NMR (400 MHz, DMSO-d6) δ [ppm] = -0.09 (s, 9H), 0.81 - 0.85 (m, 2H), 3.55 - 3.59 (m, 2H), 5.66 (s, 2H), 5.86 (br s, 2H), 6.38 - 6.44 (m, 2H), 6.57 (d, 1 H), 8.29 (d, 1 H), 8.63 (s, 1 H).
Intermediate 187
phenyl {4-[(3-cyano-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyljcarbamate
Figure imgf000215_0002
A solution of 4-(4-amino-2,6-difluorophenoxy)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 /-/- pyrrolo[2,3-b]pyridine-3-carbonitrile (intermediate 186; 390 mg, 0.936 mmol) in ethyl acetate (5 mL) was treated with an aqueous sat. sodium hydrocarbonate solution (5 mL) and with phenyl chloroformate (CAS No. [1885-14-9]; 5.0 eq, 0.59 mL, 4.7 mmol) and the mixture stirred at rt for 18 hours. The reaction mixture was diluted with ethyl acetate and water, the phases separated and the aqueous phase extracted with ethyl acetate (twice). The combined organic phases were washed with brine, dried with sodium sulfate and concentrated in vacuo. The obtained material was purified by flash chromatography (Si02-hexane/ ethyl acetate) to give the title compound (310 mg) containing 1 -{4-[(3-cyano-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}urea.
LC-MS (method 2): Rt = 1 .53 min; MS (ESIpos): m/z = 537 [M+H]+.
Intermediate 188
4-(4-amino-2,6-difluorophenoxy)-1 H-pyrrolo[2,3-b]pyridine-3-carbonitrile trifluoroacetate
Figure imgf000216_0001
A solution of 4-(4-amino-2,6-difluorophenoxy)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 /-/- pyrrolo[2,3-b]pyridine-3-carbonitrile (intermediate 186; 510 mg, 1.22 mmol) in dichloromethane (5 mL) was treated with trifluoroacetic acid (40 eq., 3.8 mL, 49 mmol) and stirred at rt overnight. The reaction mixture was concentrated in vacuo and the obtained residue stirred in cyclopentyl methyl ether for 30 min. The precipitate was filtered off and the filtrate concentrated in vacuo to give the crude title compound (350 mg) which was not further purified.
LC-MS (method 2): Rt = 0.75 min; MS (ESIpos): m/z = 287 [M-CF3COO\]+-
Intermediate 189
(+/-)-1 -{4-[(3-cyano-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}-3-(tetrahydrofuran-3-yl)urea
H
Figure imgf000217_0001
To a solution of phenyl {4-[(3-cyano-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl)oxy]-3,5-difluorophenyl}carbamate (intermediate 187; 333 mg, 621 μηηοΙ) in DMF (3.0 mL) was added (+/-)-tetrahydrofuran-3-amine (1 .20 eq, 64.9 mg, 745 μmol) and this mixture was stirred at 70 °C for 20 hours. The reaction mixture was diluted with ethyl acetate and washed with water. The organic phase was separated, dried and concentrated in vacuo. The crude product (329 mg) was used in the next step without any further purification.
LC-MS (method 2): Rt = 1 .33 min; MS (ESIpos): m/z = 530 [M+H]+.
Intermediate 190
1 -{4-[(3-cyano-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}-3-[2-(dimethylamino)ethyl]urea
H
Figure imgf000217_0002
This intermediate was prepared in analogy to intermediate 189 by reacting phenyl {4-[(3- cyano-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophe- nyljcarbamate (155 mg, 22% purity, 63.5 μηηοΙ, intermediate 187) and N,N-dimethylethane-1 ,2- diamine (1 .2 eq., 7.0 mg, 76 μηηοΙ) in DMF for 18 hours at 70 °C to give after aqueous work-up the crude product (34 mg) which was used in the next step without any further purification. LC-MS (method 2): Rt = 1 .36 min; MS (ESIpos): m/z = 531 [M+H]+. Intermediate 191
(+/-)-1 -{4-[(3-cyano-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}-3-(tetrah drofuran-2- lmethyl)urea
H
Figure imgf000218_0001
This intermediate was prepared in analogy to intermediate 189 by reacting phenyl {4-[(3- cyano-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophe- nyljcarbamate (352 mg, 656 μηηοΙ, intermediate 187) and (+/-)-1 -(tetrahydrofuran-2- yl)methanamine (1 .20 eq., 79.6 mg, 787 μηηοΙ) in DMF for 20 hours at 70 °C to give after aqueous work-up the crude product (357 mg) which was used in the next step without any further purification.
LC-MS (method 2): Rt = 1 .38 min; MS (ESIpos): m/z = 544 [M+H]+. Intermediate 192
1 -{4-[(3-cyano-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}-3-(3-methoxypropyl)urea
Figure imgf000218_0002
This intermediate was prepared in analogy to intermediate 189 by reacting phenyl {4-[(3- cyano-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophe- nyljcarbamate (319 mg, 594 μηηοΙ, intermediate 187) and 3-methoxypropan-1 -amine (1 .20 eq., 63.6 mg, 713 μηηοΙ) in DMF for 20 hours at 70 °C to give after aqueous work-up the crude product (316 mg) which was used in the next step without any further purification.
LC-MS (method 2): Rt = 1 .37 min; MS (ESIpos): m/z = 532 [M+H]+. Intermediate 193
1 -{4-[(3-cyano-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}-3-[3-(morpholin-4-yl)propyl]urea
H
Figure imgf000219_0001
This intermediate was prepared in analogy to intermediate 189 by reacting phenyl {4-[(3- cyano-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophe- nyljcarbamate (155 mg, 22% purity, 63.5 μηηοΙ, intermediate 187) and 3-(morpholin-4- yl)propan-1 -amine (1.2 eq., 1 1 mg, 76 μηηοΙ) in DMF for 18 hours at 70 °C to give after aqueous work-up the crude product (37 mg) which was used in the next step without any further purification.
LC-MS (method 2): Rt = 1 .32 min; MS (ESIpos): m/z = 587 [M+H]+.
Intermediate 194
1 -{4-[(3-cyano-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}-3-[(1 -methyl-1 H-pyrazol-3-yl)methyl]urea
Figure imgf000219_0002
This intermediate was prepared in analogy to intermediate 189 by reacting phenyl {4-[(3- cyano-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophe- nyljcarbamate (322 mg, 600 μηηοΙ, intermediate 187) and 1 -(1 -methyl-1 H-pyrazol-3- yl)methanamine (1 .20 eq., 80.0 mg, 720 μιτιοΙ) in DMF for 20 hours at 70 °C to give after aqueous work-up the crude product (332 mg) which was used in the next step without any further purification.
LC-MS (method 2): Rt = 1 .32 min; MS (ESIpos): m/z = 554 [M+H]+.
Intermediate 195
1 -{4-[(3-cyano-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}-3-(1 ,3-thiazol-2- lmeth l)urea
Figure imgf000220_0001
This intermediate was prepared in analogy to intermediate 189 by reacting phenyl {4-[(3- cyano-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophe- nyljcarbamate (350 mg, 652 μηηοΙ, intermediate 187) and 1 -(1 ,3-thiazol-2-yl)methanamine (1 .20 eq., 89.4 mg, 783 μηιοΙ) in DMF for 20 hours at 70 °C to give after aqueous work-up the crude product (363 mg) which was used in the next step without any further purification.
LC-MS (method 2): Rt = 1 .35 min; MS (ESIpos): m/z = 557 [M+H]+. Intermediate 196
1 -{4-[(3-cyano-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}-3-(pyridin-4- lmeth l)urea
Figure imgf000220_0002
This intermediate was prepared in analogy to intermediate 189 by reacting phenyl {4-[(3- cyano-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophe- nyljcarbamate (140 mg, 261 μηηοΙ, intermediate 187) and 1 -(pyridin-4-yl)methanamine (1 .20 eq., 33.9 mg, 313 μηιοΙ) in DMF for 18 hours at 70 °C to give after aqueous work-up the crude product (144 mg) which was used in the next step without any further purification.
LC-MS (method 2): Rt = 1 .31 min; MS (ESIpos): m/z = 551 [M+H]+.
Intermediate 197
1 -{4-[(3-cyano-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}-3-(2-methoxyethyl)urea
Figure imgf000221_0001
This intermediate was prepared in analogy to intermediate 189 by reacting phenyl {4-[(3- cyano-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophe- nyljcarbamate (356 mg, 663 μηηοΙ, intermediate 187) and 2-methoxyethanamine (1.20 eq., 59.8 mg, 796 μηηοΙ) in DMF for 20 hours at 70 °C to give after aqueous work-up the crude product (343 mg) which was used in the next step without any further purification.
LC-MS (method 2): Rt = 1 .34 min; MS (ESIpos): m/z = 518 [M+H]+.
Intermediate 198
1 -{4-[(3-cyano-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}-3-(1 H-pyrazol-3-ylmethyl)urea
Figure imgf000221_0002
This intermediate was prepared in analogy to intermediate 189 by reacting phenyl {4-[(3- cyano-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophe- nyljcarbamate (280 mg, 522 μηηοΙ, intermediate 187) and 1 -(1 H-pyrazol-3-yl)methanamine (1 .20 eq., 60.8 mg, 626 μηηοΙ) in DMF for 18 hours at 70 °C to give after aqueous work-up the crude product (282 mg) which was used in the next step without any further purification.
LC-MS (method 2): Rt = 1 .28 min; MS (ESIpos): m/z = 540 [M+H]+.
Intermediate 199
4-(4-bromo-2,6-difluorophenoxy)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridine- 3-carbonitrile
Figure imgf000222_0001
A solution of 4-(4-amino-2,6-difluorophenoxy)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 /-/- pyrrolo[2,3-b]pyridine-3-carbonitrile (intermediate 186; 1 .05 g, 2.52 mmol) in tribromomethane (10 mL) was treated dropwise with a solution of 3-methylbutyl nitrite (CAS No. [1 10-46-3]; 2.00 eq, 591 mg, 5.04 mmol) in tribromomethane (3 mL). The reaction mixture was heated to 100 C for 1 hour, cooled to rt and concentrated in vacuo. The obtained material was purified by flash chromatography (SiC>2-hexane/ ethyl acetate) to give the title compound (800 mg, 63%).
LC-MS (method 2): Rt = 1 .58 min; MS (ESIpos): m/z = 480/482 [M+H]+ (Br isotope pattern). 1H-NMR (400 MHz, DMSO-d6) δ [ppm] = -0.10 (s, 9H), 0.80 - 0.86 (m, 2H), 3.56 - 3.60 (m, 2H), 5.68 (s, 2H), 6.74 (d, 1 H), 7.82 - 7.86 (m, 2H), 8.31 (d, 1 H), 8.69 (s, 1 H).
Intermediate 200
(+/-)-1 -{4-[(3-bromo-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}-3-(tetrahydrofuran-3- l)urea
Figure imgf000223_0001
To a solution of phenyl {4-[(3-bromo-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl)oxy]-3,5-difluorophenyl}carbamate (225 mg, 381 μηηοΙ, intermediate 159) in DMF (4.0 mL) was added (+/-)-tetrahydrofuran-3-amine hydrochloride (1 :1 ) (56.5 mg, 457 μηηοΙ) and triethylamine (1.0 eq., 53 μΙ_, 380 μηηοΙ) and this mixture was stirred at 70 °C for 27 hours. After cooling to room temperature ethyl acetate and water were added to the reaction mixture and the phases were separated. The organic phase was dried and concentrated in vacuo. The resulting residue was purified by flash chromatography (Si02-hexane/ ethyl acetate) to give the title compound (109 mg, 44%).
LC-MS (method 2): Rt = 1 .48 min; MS (ESIpos): m/z = 583/585 [M+H]+ (Br isotope pattern). Intermediate 201
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl]oxy}phen l)-3- 6-methoxypyridazin-3-yl)urea
H
Figure imgf000223_0002
To a solution of phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}- 1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (150 mg, 259 μηηοΙ, intermediate 1 ) in DMF (700 μΙ_) was added 6-methoxypyridazin-3-amine (33.0 mg, 264 μηιοΙ, CAS No. [7252-84-8]) and the resulting reaction mixture was stirred at 90°C overnight. After cooling to room temperature ethyl acetate and brine was added. The resulting precipitate was collected from the organic layer by filtration. The white powder was dried, to obtain 82.0 mg (70 % purity, 36 % yield) of the desired title compound.
LC-MS (method 3): Rt = 1 .56 min; MS (ESIpos): m/z = 609 [M+H]+ Intermediate 202
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl]oxy}phenyl)-3-(6,7-dihydro-5H-cyclopenta[c]pyridazin-3-yl)urea
Figure imgf000224_0001
In analogy to intermediate 201 , using phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (150 mg, 259 μηηοΙ, intermediate 1 ) and 6,7-dihydro-5H-cyclopenta[c]pyridazin-3-amine (35.7 mg, 264 μηηοΙ, CAS No. [1342288-68-9]) in DMF (700 μΙ_). The resulting precipitate was collected by filtration and dried to obtain 55.5 mg (80% purity, 30 % yield) of the desired title compound.
LC-MS (method 3): Rt = 1 .57 min; MS (ESIpos): m/z = 621 [M+H]+
Intermediate 203
N-(6-bromopyridazin-3-yl)-N'-{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl^
b]pyridin-4-yl)oxy]-3,5-difluorophenyl}urea
Figure imgf000225_0001
To a solution of phenyl {4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl)oxy]-3,5-difluorophenyl}carbamate (150 mg, 275 μηηοΙ, intermediate 44) in DMF (2.1 mL) was added 6-bromopyridazin-3-amine (57.4 mg, 330 μπιοΙ, CAS No. [88497-27-2]) and the resulting mixture was stirred at 90°C over night. After cooling to room temperature ethyl acetate and water was added. After separation of the organic phase the aqueous phase was extracted with ethyl acetate. The combined organic phases were washed with brine, dried over sodium sulfate, filtered and concentrated to dryness, to obtain the crude product 130 mg (76 % yield) which was used in the next step without further purification.
LC-MS (method 3): Rt = 1 .61 min; MS (ESIpos): m/z = 625 [M+H]+
Intermediate 204
(+/-)-1 -{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}-3-(tetrahydrofuran-2-ylmethyl)urea
Figure imgf000225_0002
In analogy to intermediate 2, using phenyl {4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}carbamate (130 mg, 238 μηιοΙ, intermediate 44) and (+/-)-1 -(tetrahydrofuran-2-yl)methanamine (48.2 mg, 476 μηιοΙ, CAS No. [4795-29-3]) in DMF (4 mL). 167 mg of the crude desired product was obtained, which was used in the next step without further purification.
LC-MS (method 3): Rt = 1 .51 min; MS (ESIpos): m/z = 553 [M+H]+
Intermediate 205
1 -{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}-3-[(3S)-tetrahydrofuran-3-yl]urea
Figure imgf000226_0001
In analogy to intermediate 2, phenyl {4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}carbamate (150 mg, 275 μηιοΙ, intermediate 44), (3S)-tetrahydrofuran-3-amine (47.9 mg, 549 μπιοΙ, CAS No. [104530-79-2]) together in DMF (4 mL) were reacted to obtain a crude product which was used in the next step without further purification.
LC-MS (method 2): Rt = 1 .43 min; MS (ESIpos): m/z = 539 [M+H]+
Intermediate 206
1 -{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}-3-(2-oxaspiro[3.3]hept-6-yl)urea
H
Figure imgf000226_0002
To a solution of phenyl {4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl)oxy]-3,5-difluorophenyl}carbamate (150 mg, 275 μηηοΙ, intermediate 44), 2- oxaspiro[3.3]heptan-6-amine hydrochloride (1 :1 ) (82.2 mg, 549 μηιοΙ, CAS No. [1363381 -78- 5]) and triethylamine (77 μΙ_, 550 μmol) in DMF (4 mL) was heated to 60°C for 2 hours. The reaction mixture was cooled to room temperature, diluted with ethyl acetate and water was added. The phases were separated and the aqueous phase was extracted two times with ethyl acetate. The combined organic layers were washed with Brine, dried over Na2S04, filtered and evaporated to obtain the crude product which was used in the next step without further purification.
LC-MS (method 2): Rt = 1 .43 min; MS (ESIpos): m/z = 565 [M+H]+
Intermediate 207
1 -{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}-3-[(1 -methyl-1 H-pyrazol-3-yl)methyl]urea
Figure imgf000227_0001
In analogy to intermediate 2, phenyl {4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}carbamate (130 mg, 238 μηιοΙ, intermediate 44), and 1 -(1 -methyl-1 H-pyrazol-3-yl)methanamine (52.9 mg, 476 μπιοΙ, CAS No. [61251 1 -81 6]) in DMF (4 mL) were reacted to obtain a crude product which was used in the next step without further purification.
LC-MS (method 3): Rt = 1 .44 min; MS (ESIpos): m/z = 563 [M+H]+ Intermediate 208
1 -{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}-3-[6-(difluoromethyl)pyridazin-3-yl]urea
Figure imgf000228_0001
In analogy to intermediate 203, phenyl {4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}carbamate (150 mg, 275 μmol, intermediate 44), 6-(difluoromethyl)pyridazin-3-amine (47.8 mg, 330 μπιοΙ, CAS No. [1706450-1 1 -4]) in DMF (2.1 mL) were reacted to obtain the crude product which was used in the next step without further purification.
LC-MS (method 3): Rt = 1 .59 min; MS (ESIpos): m/z = 597 [M+H]+
Intermediate 209
(+/-)-1 -{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}-3-(tetrahydrofuran-3-yl)urea
Figure imgf000228_0002
In analogy to intermediate 2, phenyl {4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}carbamate (130 mg, 238 μηιοΙ, intermediate 44), and (+/-)-tetrahydrofuran-3-amine (41 .5 mg, 476 μπιοΙ, CAS No. [45379-55-3]) in DMF (4 mL) were reacted to obtained a crude product which was used in the next step without further purification.
LC-MS (method 3): Rt = 1 .46 min; MS (ESIpos): m/z = 539 [M+H]+ Intermediate 210
1 -{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}-3-(3-methoxypropyl)urea
Figure imgf000229_0001
In analogy to intermediate 2, phenyl {4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}carbamate (130 mg, 238 μηιοΙ, intermediate 44), and 3-methoxypropan-1 -amine (49 μΙ_, 480 μmol, CAS No. [109-85-3]), in DMF (4 mL) were reacted to obtained the crude product which was used in the next step without further purification.
LC-MS (method 3): Rt = 1 .49 min; MS (ESIpos): m/z = 541 [M+H]+
Intermediate 211
1 -{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}-3-[(3R)-tetrahydrofuran-3-yl]urea
Figure imgf000229_0002
In analogy to intermediate 2, phenyl {4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}carbamate (150 mg, 275 μηιοΙ, intermediate 45), and (3R)-tetrahydrofuran-3-amine (47.9 mg, 549 μπιοΙ, CAS No. [1 1 1769-26-7]) in DMF (4 mL) were reacted to obtained the crude product which was used in the next step without further purification.
LC-MS (method 2): Rt = 1 .43 min; MS (ESIpos): m/z = 539 [M+H]+ Intermediate 212
1 -{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}-3-(1 H-pyrazol-3-ylmethyl)urea
Figure imgf000230_0001
In analogy to intermediate 2, phenyl {4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}carbamate (150 mg, 275 μηιοΙ, intermediate 44), and 1 -(1 H-pyrazol-3-yl)methanamine (53.4 mg, 549 μπιοΙ, CAS No. [37599-58-9]), in DMF (4 mL) were reacted to obtain the crude product which was used in the next step without further purification.
LC-MS (method 2): Rt = 1 .40 min; MS (ESIpos): m/z = 549 [M+H]+
Intermediate 213
1 -{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}-3-(2,2,2-trifluoroeth l)urea
Figure imgf000230_0002
In analogy to intermediate 2, phenyl {4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}carbamate (150 mg, 275 μηιοΙ, intermediate 44), and 2,2,2-trifluoroethanamine (44 μΙ_, 550 μηιοΙ, CAS No. [753-90-2]), in DMF (4 mL) were reacted to obtain the crude product which was used in the next step without further purification. LC-MS (method 2): Rt = 1 .55 min; MS (ESIpos): m/z = 551 [M+H]+
Intermediate 214
(+/-)-N-{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}-3-[(dimeth lamino)methyl]pyrrolidine-1 -carboxamide
Figure imgf000231_0001
In analogy to intermediate 2, phenyl {4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}carbamate (150 mg, 275 μηιοΙ, intermediate 44), and (+/-)-N,N-dimethyl-1 -[-pyrrolidin-3-yl]methanamine (74.2 mg, 549 μηηοΙ, CAS No.
[99724-17-1]), in DMF (4 mL) were reacted to obtain a crude product which was used in the next step without further purification.
LC-MS (method 2): Rt = 1 .55 min; MS (ESIpos): m/z = 580 [M+H]+
Intermediate 215
1 -{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}-3-[(4-methyl-1 ,2,5-oxadiazol-3-yl)methyl]urea
Figure imgf000231_0002
In analogy to intermediate 2, phenyl {4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}carbamate (150 mg, 275 μηιοΙ, intermediate 44), and 1 -(4-methyl-1 ,2,5-oxadiazol-3-yl)methanamine (62.1 mg, 549 μηηοΙ, CAS No.
[321392-83-0]), in DMF (4.0 mL) were reacted to obtain a crude product which was used in the next step without further purification.
LC-MS (method 2): Rt = 1 .53 min; MS (ESIpos): m/z = 565 [M+H]+
Intermediate 216
1 -{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}-3-(2-fluoroethyl)urea
Figure imgf000232_0001
In analogy to intermediate 206, phenyl {4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}carbamate (150 mg, 275 μηιοΙ, intermediate 44), 2-fluoroethanamine hydrochloride (60.8 mg, 549 μπιοΙ, CAS No. [460-08-2]), and triethylamine (77 μί, 550 μηηοΙ) in DMF (4.0 mL) were reacted to obtain a crude product which was used in the next step without further purification.
LC-MS (method 2): Rt = 1 .47 min; MS (ESIpos): m/z = 515 [M+H]+
Intermediate 217
N-{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}-2-oxa-7-azaspiro[3.5]nonane-7-carboxamide
Figure imgf000232_0002
In analogy to intermediate 206, phenyl {4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}carbamate (150 mg, 275 μηιοΙ, intermediate 44), 2-oxa-7-azaspiro[3.5]nonane ethanedioate (2:1 ) (94.6 mg, 275 μηιοΙ, CAS No. [1429056- 28-9]), and triethylamine (77 μΙ_, 550 μηηοΙ) in DMF (4.0 mL) were reacted to obtain a crude product which was used in the next step without further purification.
LC-MS (method 2): Rt = 1 .50 min; MS (ESIpos): m/z = 579 [M+H]+
Intermediate 218
1 -{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}-3-(2,2-difluoroethyl)urea
Figure imgf000233_0001
In analogy to intermediate 2, phenyl {4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}carbamate (150 mg, 275 μηιοΙ, intermediate 44), and 2,2-difluoroethanamine (44.5 mg, 549 μπιοΙ, CAS No. [430-67-1 ]), in DMF (4.0 mL) were reacted to obtain a crude product which was used in the next step without further purification.
LC-MS (method 2): Rt = 1 .50 min; MS (ESIpos): m/z = 533 [M+H]+
Intermediate 219
1 -{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}-3-[(4-meth l-1 H-imidazol-2- l)methyl]urea
Figure imgf000233_0002
In analogy to intermediate 206, phenyl {4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}carbamate (150 mg, 275 μηιοΙ, intermediate 44), 1 -(4-methyl-1 H-imidazol-2-yl)methanamine dihydrochloride (106 mg, 549 μηηοΙ, CAS No.
[855250-27-0]), and triethylamine (77 μΙ_, 550 μηηοΙ) in DMF (4.0 mL) were reacted to obtain a crude product which was used in the next step without further purification.
LC-MS (method 2): Rt = 1 .42 min; MS (ESIpos): m/z = 563 [M+H]+
Intermediate 220
1 -{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}-3-(6-methoxypyridazin-3-yl)urea
Figure imgf000234_0001
In analogy to intermediate 203, phenyl {4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}carbamate (150 mg, 275 μηιοΙ, intermediate 44), and 6-methoxypyridazin-3-amine (41 .2 mg, 330 μπιοΙ, CAS No. [7252-84-8]), in DMF (2.1 mL) were reacted to obtain a crude product which was used in the next step without further purification.
LC-MS (method 3): Rt = 1 .54 min; MS (ESIpos): m/z = 578 [M+H]+
Intermediate 221
1 -{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}-3-(1 ,3,4-thiadiazol-2-yl)urea
Figure imgf000235_0001
In analogy to intermediate 203, phenyl {4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}carbamate (150 mg, 275 μηιοΙ, intermediate 44), and 1 ,3,4-thiadiazol-2-amine (55.6 mg, 549 μπιοΙ, CAS No. [4005-51 -0]), in DMF (4.0 mL) were reacted to obtain a crude product which was used in the next step without further purification.
LC-MS (method 2): Rt = 1 .01 min; MS (ESIpos): m/z = 553 [M+H]+
Intermediate 222
1 -{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}-3-(1 ,3-thiazol-2- lmethyl)urea
Figure imgf000235_0002
In analogy to intermediate 2, phenyl {4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}carbamate (150 mg, 275 μηιοΙ, intermediate 44), and 1 -(1 ,3-thiazol-2-yl)methanamine (62.7 mg, 549 μπιοΙ, CAS No. [55661 -33-1]), in DMF (4.0 mL) were reacted to obtain a crude product which was used in the next step without further purification.
LC-MS (method 2): Rt = 1 .47 min; MS (ESIpos): m/z = 566 [M+H]+ Intermediate 223
1 -{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}-3-(6-iodopyridazin-3-yl)urea
Figure imgf000236_0001
In analogy to intermediate 203, phenyl {4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}carbamate (150 mg, 275 μηιοΙ, intermediate 44), and 6-iodopyridazin-3-amine (72.9 mg, 330 μπιοΙ, CAS No. [187973-60-0]), in DMF (2.1 mL) were reacted to obtain a crude product which was used in the next step without further purification.
LC-MS (method 3): Rt = 1 .62 min; MS (ESIpos): m/z = 673 [M+H]+
Intermediate 224
1 -{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}-3-[6-(morpholin-4-yl)pyridazin-3-yl]urea
Figure imgf000236_0002
In analogy to intermediate 203, phenyl {4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}carbamate (150 mg, 275 μηιοΙ, intermediate 44), and 6-(morpholin-4-yl)pyridazin-3-amine (59.4 mg, 330 μπιοΙ, CAS No. [66346-91 -6]), in DMF (2.1 mL) were reacted to obtain a crude product which was used in the next step without further purification.
LC-MS (method 3): Rt = 1 .50 min; MS (ESIpos): m/z = 632 [M+H]+ Intermediate 225
1 -{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}-3-(5-methylpyridazin-3-yl)urea
Figure imgf000237_0001
In analogy to intermediate 203, phenyl {4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}carbamate (150 mg, 275 μmol, intermediate 44), and 5-methylpyridazin-3-amine (36.0 mg, 330 μπιοΙ, CAS No. [144294-43-9]), in DMF (2.1 mL) were reacted to obtain the crude product which was used in the next step without further purification.
LC-MS (method 3): Rt = 1 .54 min; MS (ESIpos): m/z = 561 [M+H]+
Intermediate 226
1 -{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}-3-(6-cyclopropylpyridazin-3-yl)urea
Figure imgf000237_0002
In analogy to intermediate 203, phenyl {4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}carbamate (150 mg, 275 μηιοΙ, intermediate 44), and 6-cyclopropylpyridazin-3-amine (44.6 mg, 330 μπιοΙ, CAS No. [1 159814-07-9]), in DMF (2.1 mL) were reacted to obtain a crude product which was used in the next step without further purification.
LC-MS (method 3): Rt = 1 .58 min; MS (ESIneg): m/z = 587 [M+H]+ Intermediate 227
(+/-)1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]met^
b]pyridin-4-yl]oxy}phenyl)-3-(1 -methyl-5-oxopyrrolidin-3-yl)urea
Figure imgf000238_0001
In analogy to intermediate 85, phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (150 mg, 259 μηηοΙ, intermediate 1 ), (+/-)-4-amino-1 -methylpyrrolidin-2-one hydrochloride (1 :1 ) (44.8 mg, 298 μηιοΙ) together in DMF (0.7ml_) and N,N-diisopropylethylamine (52 μΙ_, 300 μηιοΙ), we obtained after one single purification using a Biotage chromatography system (1 1 g snap KP- NH column, hexane / 50 - 100% ethyl acetate, then ethyl acetate / 0 - 50% ethanol) 1 10 mg (100 % purity, 71 % yield) of the desired title compound.
LC-MS (method 2): Rt = 1 .48 min; MS (ESIneg): m/z = 598 [M-H]"
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.12 - -0.07 (m, 9H), 0.80 - 0.86 (m, 2H), 2.17 (dd, 1 H), 2.61 (dd, 1 H), 2.73 (s, 3H), 3.19 (dd, 1 H), 3.54 - 3.60 (m, 2H), 3.64 (dd, 1 H), 4.23 - 4.31 (m, 1 H), 5.68 (s, 2H), 6.57 (d, 1 H), 6.97 (d, 1 H), 7.36 - 7.43 (m, 2H), 8.29 (d, 1 H), 8.36 (s, 1 H), 9.02 (s, 1 H).
Intermediate 228
N-(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl]oxy}phen l)-4,4-difluoropiperidine-1 -carboxamide
Figure imgf000238_0002
In analogy to intermediate 85, phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (150 mg, 259 μηιοΙ, intermediate 1 ), 4,4-difluoropiperidine (36.1 mg, 298 μηιοΙ) together in DMF (0.7ml_) and N,N-diisopropylethylamine (52 μΙ_, 300 μηηοΙ), we obtained after one single purification using a Biotage chromatography system (1 1 g snap KP-NH column, hexane / 50 - 100% ethyl acetate, then ethyl acetate / 0 - 50% ethanol) 158 mg (100 % purity, 101 % yield) of the desired title compound.
LC-MS (method 2): Rt = 1 .59 min; MS (ESIpos): m/z = 607 [M+H]+
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.1 1 - -0.07 (m, 9H), 0.80 - 0.86 (m, 2H), 1.96 - 2.08 (m, 4H), 3.54 - 3.63 (m, 6H), 5.68 (s, 2H), 6.57 (d, 1 H), 7.50 (d, 2H), 8.29 (d, 1 H), 8.37 (s, 1 H), 9.16 (s, 1 H). Intermediate 229
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl]ox phenyl)-3-[3-(propan-2-yloxy)propyl]urea
Figure imgf000239_0001
In analogy to intermediate 2, phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (150 mg, 259 μηιοΙ, intermediate 1 ), 3-(propan-2-yloxy)propan-1 -amine (41 μΙ_, 300 μηιοΙ) together in DMF (0.7 mL) we obtained the crude product, which was purified via a Biotage
chromatography system (1 1 g snap KP-NH column, hexane/ethylacetate / 50 - 100%
ethylacetate and ethylacetate/ethanol / 0 - 50% ethanol) to obtain 140 mg (78 % purity, 70 % yield) of the desired title compound.
LC-MS (method 2): Rt = 1 .59 min; MS (ESIpos): m/z = 603 [M+H]+
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.1 1 - -0.08 (m, 9H), 0.80 - 0.86 (m, 2H), 1 .09 (d, 6H), 1 .60 - 1 .68 (m, 2H), 3.12 - 3.18 (m, 2H), 3.37 - 3.41 (m, 2H), 3.48 - 3.55 (m, 1 H), 3.55 - 3.61 (m, 2H), 5.68 (s, 2H), 6.42 (t, 1 H), 6.57 (d, 1 H), 7.35 - 7.42 (m, 2H), 8.28 (d, 1 H), 8.36 (s, 1 H), 9.02 (s, 1 H). ntermediate 230
Figure imgf000240_0001
In analogy to intermediate 2, phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (150 mg, 259 μmol, intermediate 1 ), 3-methoxyazetidine (25.9 mg, 298 μηηοΙ) together in DMF (0.7 mL) we obtained the crude product, which was purified via a Biotage chromatography system (1 1 g snap KP-NH column, hexane/ethylacetate / 50 - 100% ethylacetate and ethylacetate/ethanol / 0 - 50% ethanol) to obtain 151 mg (100 % purity, 101 % yield) of the desired title compound. LC-MS (method 2): Rt = 1 .51 min; MS (ESIneg): m/z = 571 [M-H]"
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.1 1 - -0.08 (m, 9H), 0.79 - 0.87 (m, 2H), 3.23 (s, 3H), 3.54 - 3.60 (m, 2H), 3.79 (dd, 2H), 4.15 - 4.24 (m, 3H), 5.68 (s, 2H), 6.58 (d, 1 H), 7.48 - 7.54 (m, 2H), 8.29 (d, 1 H), 8.36 (s, 1 H), 8.98 (s, 1 H).
Intermediate 231
N-(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl]oxy}phenyl)-1 -oxa-6-azaspiro[3.3]heptane-6-carboxamide
Figure imgf000240_0002
In analogy to intermediate 2, phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (150 mg, 259 μηηοΙ, intermediate 1 ), 1 -oxa-6-azaspiro[3.3]heptane (29.5 mg, 298 μηηοΙ) together in DMF (0.7 mL) we obtained the crude product, which was purified via a Biotage chromatography system (1 1 g snap KP-NH column, hexane/ethylacetate / 50 - 100% ethylacetate and ethylacetate/ethanol / 0 - 50% ethanol) to obtain 67.2 mg (96 % purity, 43 % yield) of the desired title compound.
LC-MS (method 2): Rt = 1 .49 min; MS (ESIpos): m/z = 585 [M+H]+
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.12 - -0.08 (m, 9H), 0.77 - 0.90 (m, 2H), 2.84 (t, 2H), 3.54 - 3.60 (m, 2H), 4.07 (dd, 2H), 4.23 (dd, 2H), 4.42 (t, 2H), 5.68 (s, 2H), 6.57 (d, 1 H), 7.46 - 7.53 (m, 2H), 8.28 (d, 1 H), 8.36 (s, 1 H), 9.02 (s, 1 H).
Intermediate 232
N-(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl]oxy}phenyl)-2-oxa-6-azaspiro[3.5]nonane-6-carboxamide
Figure imgf000241_0001
In analogy to intermediate 2, phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (150 mg, 259 μηηοΙ, intermediate 1 ), 2-oxa-6-azaspiro[3.5]nonane (37.9 mg, 298 μηηοΙ) together in DMF (0.7 mL) we obtained the crude product, which was purified via a Biotage chromatography system (1 1 g snap KP-NH column, hexane/ethylacetate / 50 - 100% ethylacetate and ethylacetate/ethanol / 0 - 50% ethanol) to obtain 159 mg (100 % purity, 100 % yield) of the desired title compound.
LC-MS (method 2): Rt = 1 .53 min; MS (ESIpos): m/z = 613 [M+H]+
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.1 1 - -0.07 (m, 9H), 0.80 - 0.87 (m, 2H), 1.43 - 1.51 (m, 2H), 1.80 - 1 .85 (m, 2H), 3.36 - 3.41 (m, 2H), 3.55 - 3.60 (m, 2H), 3.69 (s, 2H), 4.25 - 4.31 (m, 4H), 5.68 (s, 2H), 6.58 (d, 1 H), 7.49 - 7.56 (m, 2H), 8.29 (d, 1 H), 8.37 (s, 1 H), 9.04 (s, 1 H).
Intermediate 233
1 -(3,5-difluoro-4-{[3-(trifluorom
b]pyridin-4-yl]oxy}phen l)-3-{[3-(propan-2-yl)oxetan-3-yl]methyl}urea
Figure imgf000242_0001
In analogy to intermediate 2, phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (150 mg, 259 μηηοΙ, intermediate 1 ), 1 -[3-(propan-2-yl)oxetan-3-yl]methanamine (38.5 mg, 298 μηηοΙ) together in DMF (0.7 mL) we obtained the crude product, which was purified via a Biotage chromatography system (1 1 g snap KP-NH column, hexane/ethylacetate / 50 - 100%
ethylacetate and ethylacetate/ethanol / 0 - 50% ethanol) to obtain 131 mg (100 % purity, 82 % yield) of the desired title compound.
LC-MS (method 2): Rt = 1 .57 min; MS (ESIpos): m/z = 615 [M+H]+
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.1 1 - -0.08 (m, 9H), 0.80 - 0.86 (m, 2H), 0.91 (d, 6H), 2.01 (spt, 1 H), 3.32 (d, 2H), 3.54 - 3.61 (m, 2H), 4.28 - 4.34 (m, 4H), 5.68 (s, 2H), 6.59 (d, 1 H), 6.71 - 6.78 (m, 1 H), 7.37 - 7.44 (m, 2H), 8.28 (d, 1 H), 8.36 (s, 1 H), 9.12 (s, 1 H).
Intermediate 234
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl]oxy}phenyl)-3-[3-methyl-3-(morpholin-4-yl)butyl]urea
Figure imgf000242_0002
In analogy to intermediate 2, phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (150 mg, 259 μηηοΙ, intermediate 1 ), 3-methyl-3-(morpholin-4-yl)butan-1 -amine dihydrochloride (73.0 mg, 298 μηηοΙ) together in DMF (0.7 mL) we obtained the crude product, which was purified via a Biotage chromatography system (1 1 g snap KP-NH column, hexane/ethylacetate / 50 - 100% ethylacetate and ethylacetate/ethanol / 0 - 50% ethanol) to obtain 150 mg (92 % purity, 81 % yield) of the desired title compound.
LC-MS (method 2): Rt = 1 .57 min; MS (ESIpos): m/z = 658 [M+H]+
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.1 1 - -0.08 (m, 9H), 0.79 - 0.87 (m, 2H), 0.98 (s, 6H), 1 .52 - 1 .59 (m, 2H), 2.43 - 2.48 (m, 4H), 3.13 (dt, 2H), 3.53 - 3.61 (m, 6H), 5.68 (s, 2H), 6.35 (t, 1 H), 6.57 (d, 1 H), 7.34 - 7.41 (m, 2H), 8.29 (d, 1 H), 8.36 (s, 1 H), 9.02 (s, 1 H).
Intermediate 235
1 -{4-[(3-bromo-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}-3-[(4-methyl-1 ,2,5-oxadiazol-3-yl)methyl]urea
C H ,
Br
n
Figure imgf000243_0001
3
This intermediate was prepared in analogy to intermediate 160 by reacting phenyl {4-[(3- bromo-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluoro- phenyljcarbamate (225 mg, 381 μηηοΙ, intermediate 159) and 1 -(4-methyl-1 ,2,5-oxadiazol-3- yl)methanamine (1 .20 eq., 51.7 mg, 457 μηιοΙ) in DMF at 70 °C for 18 hours to give after aqueous work-up the crude product (232 mg) which was used in the next step without any further purification.
LC-MS (method 2): Rt = 1 .49 min; MS (ESIpos): m/z = 609/61 1 [M+H]+ (Br isotope pattern).
Intermediate 236
(+/-) 1 -{4-[(3-bromo-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}-3-(tetrahydrofuran-2- lmethyl)urea
Figure imgf000244_0001
This intermediate was prepared in analogy to intermediate 160 by reacting phenyl {4-[(3- bromo-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluoro- phenyljcarbamate (225 mg, 381 μηηοΙ, intermediate 159) and (+/-) 1 -(tetrahydrofuran-2- yl)methanamine (1 .20 eq., 46.2 mg, 457 μηηοΙ) in DMF at 70 °C for 18 hours to give after aqueous work-up the crude product (228 mg) which was used in the next step without any further purification.
LC-MS (method 2): Rt = 1 .48 min; MS (ESIpos): m/z = 597/599 [M+H]+ (Br isotope pattern).
Intermediate 237
1 -{4-[(3-bromo-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}-3-pyridazin-3- lurea
Figure imgf000244_0002
This intermediate was prepared in analogy to intermediate 160 by reacting phenyl {4-[(3 bromo-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluoro- phenyljcarbamate (225 mg, 381 μηηοΙ, intermediate 159), pyridazin-3-amine (1 .20 eq. 43.5 mg, 457 μπιοΙ) and additionally triethylamine (0.50 eq., 27 μΙ_, 190 μπιοΙ) in DMF at 70 °C for 27 hours to give after aqueous work-up the crude product (225 mg) which was used in the next step without any further purification.
LC-MS (method 2): Rt = 1 .54 min; MS (ESIpos): m/z = 591/593 [M+H]+ (Br isotope pattern). Intermediate 238
1 -{4-[(3-bromo-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}-3-(6-methylpyridazin-3-yl)urea
Figure imgf000245_0001
This intermediate was prepared in analogy to intermediate 160 by reacting phenyl {4-[(3- bromo-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluoro- phenyljcarbamate (225 mg, 381 μηηοΙ, intermediate 159), 6-methylpyridazin-3-amine (1 .20 eq., 49.9 mg, 457 μηιοΙ) and additionally triethylamine (0.50 eq., 27 μΙ_, 190 μηιοΙ) in DMF at 70 °C for 27 hours to give after aqueous work-up the crude product (230 mg) which was used in the next step without any further purification.
LC-MS (method 2): Rt = 1 .47 min; MS (ESIpos): m/z = 605/607 [M+H]+ (Br isotope pattern).
Intermediate 239
1 -{4-[(3-bromo-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}-3-(1 ,3,4-thiadiazol-2-yl)urea
H H
Figure imgf000245_0002
This intermediate was prepared in analogy to intermediate 160 by reacting phenyl {4-[(3- bromo-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluoro- phenyljcarbamate (225 mg, 381 μηηοΙ, intermediate 159), 1 ,3,4-thiadiazol-2-amine (1 .20 eq., 46.2 mg, 457 μηιοΙ) and additionally triethylamine (0.50 eq., 27 μΙ_, 190 μπιοΙ) in DMF at 70 °C for 27 hours to give after aqueous work-up the crude product (227 mg) which was used in the next step without any further purification.
LC-MS (method 2): Rt = 1 .03 min; MS (ESIpos): m/z = 597/599 [M+H]+ (Br isotope pattern).
Intermediate 240
1 -{4-[(3-bromo-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}-3-[(4-methyl-1 H-imidazol-2-yl)methyl]urea
Figure imgf000246_0001
This intermediate was prepared in analogy to intermediate 160 by reacting phenyl {4-[(3- bromo-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluoro- phenyl}carbamate (225 mg, 381 μηιοΙ, intermediate 159), 1 -(4-methyl-1 H-imidazol-2- yl)methanamine (1.20 eq., 50.8 mg, 457 μηηοΙ) and additionally triethylamine (0.50 eq., 27 μΙ_, 190 μηηοΙ) in DMF at 70 °C for 27 hours to give after aqueous work-up the crude product. This was purified by flash chromatography (Si02-hexane/ ethyl acetate) to give the title compound (43 mg, 19%).
LC-MS (method 2): Rt = 1 .41 min; MS (ESIpos): m/z = 607/609 [M+H]+ (Br isotope pattern). Intermediate 241
1 -{4-[(3-cyano-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}-3-(6-methylpyridazin-3-yl)urea
Figure imgf000247_0001
This intermediate was prepared in analogy to intermediate 189 by reacting phenyl {4-[(3- cyano-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophe- nyljcarbamate (347 mg, 647 μηηοΙ, intermediate 187) and 6-methylpyridazin-3-amine (1.20 eq., 84.7 mg, 776 μηηοΙ) in DMF for 20 hours at 70 °C. The reaction mixture was filtrated and the filtrate subjected to preparative HPLC (method 4) to give the title compound (53 mg, 15%). LC-MS (method 2): Rt = 1 .38 min; MS (ESIpos): m/z = 552 [M+H]+.
Intermediate 242
1 -{4-[(3-cyano-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}-3-pyridazin-3-ylurea
Figure imgf000247_0002
This intermediate was prepared in analogy to intermediate 189 by reacting phenyl {4-[(3- cyano-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophe- nyljcarbamate (389 mg, 725 μηηοΙ, intermediate 187) and pyridazin-3-amine (1 .20 eq., 82.7 mg, 870 μmol) in DMF for 2.5 hours at 70 °C. The reaction mixture was filtrated and the filtrate subjected to preparative HPLC (method 4) to give the title compound (30 mg, 7%). LC-MS (method 2): Rt = 1 .35 min; MS (ESIpos): m/z = 538 [M+H]+. Intermediate 243
methyl 1 -[({4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin
3,5-difluorophenyl}carbamoyl)amino cyclopropanecarboxylate
H
Figure imgf000248_0001
A solution of phenyl {4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4- yl)oxy]-3,5-difluorophenyl}carbamate (1 .00 g, 1 .83 mmol, intermediate 44) and methyl 1 - aminocyclopropanecarboxylate (253 mg, 2.20 mmol, CAS No. [72784-43-1 ]) in DMF (4.9 mL) was heated to 90°C overnight. The reaction mixture was cooled, diluted with ethyl acetate and water was added. The layers were separated and the aqueous phase extracted twice with ethyl acetate. The combined organic layers were washed with Brine, dried over sodium sulfate, and evaporated in vacuo to afford the crude product. The crude product was purified by flash column chromatography (50g Si-snap colum, hexane/ethylacetate / 10% -> 60% ethylacetate) to obtain 650 mg (56 % yield) of the title compound.
LC-MS (method 2): Rt = 1 .49 min; MS (ESIpos): m/z = 567 [M+H]+
1H NMR (400 MHz, DMSO-d6) δ ppm -0.10 (s, 9 H), 0.79 - 0.85 (m, 2 H), 1 .10 - 1 .15 (m, 2 H), 1 .39 - 1 .44 (m, 2 H), 3.50 - 3.57 (m, 2 H), 3.62 (s, 3 H), 5.60 (s, 2 H), 6.44 (d, 1 H), 7.19 (s, 1 H), 7.42 (br d, 2 H), 7.83 (s, 1 H), 8.17 (d, 1 H), 9.10 (br s, 1 H)
Intermediate 244
1 -[({4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}carbamo l)amino]cyclopropanecarboxylic acid
Figure imgf000249_0001
To a solution of methyl 1 -[({4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl)oxy]-3,5-difluorophenyl}carbamoyl)amino]cyclopropanecarboxylate (600 mg, 1.06 mmol, intermediate 243) in methanol (1 .5 mL) was added lithium hydroxide (5.3 mL, 1 .0 M solution in water, 5.3 mmol) and stirred overnight. Water was added, the mixture was cooled to 0°C and 1 N hydrochloric acid was added dropwise until pH < 2. The formed precipitate was filtered and was washed with water followed by diethyl ether. The precipitate was dried to yield 500 mg (85 % yield) of the desired title compound.
LC-MS (method 2): Rt = 0.91 min; MS (ESIpos): m/z = 553 [M+H]+
1H NMR (400 MHz, DMSO-d6) δ ppm -0.09 (s, 9 H), 0.79 - 0.85 (m, 2 H), 1 .04 - 1 .09 (m, 2 H), 1 .34 - 1 .39 (m, 2 H), 3.50 - 3.56 (m, 2 H), 5.60 (s, 2 H), 6.44 (d, 1 H), 7.07 (s, 1 H), 7.42 (br d, 2 H), 7.84 (s, 1 H), 8.17 (d, 1 H), 9.05 (br s, 1 H), 12.43 (br s, 1 H)
Intermediate 245
1 -{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}-3-{1 -[(4-methylpiperazin-1 -yl)carbonyl]cyclopropyl}urea
Figure imgf000249_0002
To a solution of 1 -[({4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4- yl)oxy]-3,5-difluorophenyl}carbamoyl)amino]cyclopropanecarboxylic acid (100 mg, 181 μηιοΙ, intermediate 244) in DMF (0.7 mL) was added 1 -methylpiperazine (19.9 mg, 199 μηιοΙ), Ν,Ν- diisopropylethylamine (63 μΙ_, 360 μπιοΙ, CAS No. [109-01 -3]), 1 -(3-Dimethylaminopropyl)-3- ethylcarbodiimidhydrochloride (38.1 mg, 199 μmol) and 1 -hydroxy-1 H-benzotriazol hydrate (30.5 mg, 199 μηηοΙ). The resulting reaction mixture was stirred overnight at room temperature at which time ethyl acetate and water were added. The layers were separated and the aqueous phase was extracted twice with ethyl acetate. The combined organic layers were dried with sodium sulfate and evaporated in vacuo to yield the crude product which was used in the next step without further purification.
LC-MS (method 2): Rt = 1 .44 min; MS (ESIneg): m/z = 635 [M+H]+
Intermediate 246
1 -{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}-3-[1 -(morpholin-4- lcarbonyl)cyclopropyl]urea
Figure imgf000250_0001
In analogy to intermediate 245, 1 -[({4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}carbamoyl)amino]cyclopropanecarboxylic acid (80.0 mg, 145 μηιοΙ, intermediate 244), morpholine (14 μΙ_, 160 μηιοΙ, CAS No. [1 10-91 - 8]), N,N-diisopropylethylamine (50 μΙ_, 289 μηηοΙ), 1 -(3-Dimethylaminopropyl)-3- ethylcarbodiimide hydrochloride (30.5 mg, 159 μηηοΙ), 1 -hydroxy-1 H-benzotriazol hydrate (24.4 mg, 159 μηηοΙ) were reacted in DMF (1 .2 mL) to afford a crude product which was used in the subsequent step without further purification.
LC-MS (method 2): Rt = 1 .45 min; MS (ESIpos): m/z = 622 [M+H]+ Intermediate 247
1 -[({4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}carbamo l)amino -N,N-dimethylcyclopropanecarboxamide
H
Figure imgf000251_0001
In analogy to intermediate 245, 1 -[({4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}carbamoyl)amino]cyclopropanecarboxylic acid (80.0 mg, 145 μηιοΙ, intermediate 244), N,N-diisopropylethylamine (50 μΙ_, 290 μηιοΙ), dimethylamine (87 μΙ_, 2.0 M in THF, 170 μπιοΙ, CAS No. [124-40-3]), 1 -(3- Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (30.5 mg, 159 μηηοΙ), and 1 -hydroxy- 1 H-benzotriazol hydrate (24.4 mg, 159 μηιοΙ) were reacted in DMF (1 .2 mL) to afford a crude product which was used in the subsequent step without further purification.
LC-MS (method 2): Rt = 1 .46 min; MS (ESIpos): m/z = 581 [M+H]+
Intermediate 248
1 -{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}-3-[1 -(piperidin-1 - lcarbonyl)cyclopropyl]urea
Figure imgf000251_0002
In analogy to intermediate 245, 1 -[({4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}carbamoyl)amino]cyclopropanecarboxylic acid (80.0 mg, 145 μηιοΙ, intermediate 244), N,N-diisopropylethylamine (50 μΙ_, 290 μηιοΙ), piperidine (14 mg, 159 μηιοΙ, CAS No. [1 10-89-4]), 1 -(3-Dimethylaminopropyl)-3- ethylcarbodiimide hydrochloride (31 mg, 159 μηηοΙ), and 1 -hydroxy-1 H-benzotriazol hydrate (24 mg, 159 μηηοΙ) were reacted in DMF (1 .2 mL) to afford a crude product which was used in the subsequent step without further purification.
LC-MS (method 2): Rt = 1 .55 min; MS (ESIpos): m/z = 620 [M+H]+
Intermediate 249
(+/-) 1 -{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}-3-(1 -methoxypropan-2-yl)urea
Figure imgf000252_0001
In analogy to intermediate 2, phenyl {4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}carbamate (150 mg, 275 μηιοΙ, intermediate 44), and (+/-)-1 -methoxypropan-2-amine (58 μΙ_, 550 μπιοΙ, CAS No. [37143-54-7]) in DMF (4.0 mL) were reacted to obtain a crude product which was used in the next step without further purification.
LC-MS (method 2): Rt = 1 .53 min; MS (ESIpos): m/z = 541 [M+H]+
Intermediate 250
1 -{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}-3-[1 -(methoxymethyl)cyclopropyl]urea
Figure imgf000253_0001
In analogy to intermediate 206, phenyl {4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}carbamate (150 mg, 275 μηιοΙ intermediate 44), 1 -(methoxymethyl)cyclopropanamine hydrochloride (1 :1 ) (75.6 mg, 549 μηηοΙ, CAS No.
[1029716-05-9]), and triethylamine (77 μΙ_, 550 μπιοΙ) in DMF (4.0 mL) were reacted to obtain a crude product which was used in the next step without further purification.
LC-MS (method 2): Rt = 1 .53 min; MS (ESIpos): m/z = 553 [M+H]+
Intermediate 251
(+/-) 1 -{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}-3-(2,2-dimethyltetrahydrofuran-3-yl)urea
Figure imgf000253_0002
In analogy to intermediate 206, phenyl {4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}carbamate (150 mg, 275 μηιοΙ, intermediate 44), (+/-)-2,2-dimethyltetrahydrofuran-3-amine hydrochloride (1 :1 ) (83.3 mg, 549 μηιοΙ, CAS No. [1350473-50-5]), triethylamine (77 μΙ_, 550 μπιοΙ) in DMF (4.0 mL) were reacted to obtain crude product which was used in the next step without further purification. LC-MS (method 2): Rt = 1 .54 min; MS (ESIpos): m/z = 567 [M+H]+
Intermediate 252
(+/-) 1 -{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}-3-(5-oxaspiro[3.4]oct-7-yl)urea
Figure imgf000254_0001
In analogy to intermediate 206, phenyl {4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}carbamate (150 mg, 275 μηιοΙ, intermediate 44), (+/-)-5-oxaspiro[3.4]octan-7-amine hydrochloride (1 :1 ) (89.9 mg, 549 μηηοΙ, CAS No.
[1955557-50-2]), and triethylamine (77 μΙ_, 550 μηηοΙ) in DMF (4.0 mL) were reacted to obtain a crude product which was used in the next step without further purification.
LC-MS (method 2): Rt = 1 .57 min; MS (ESIpos): m/z = 579 [M+H]+
Intermediate 253
(+/-)1 -{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}-3-[(trans)-4-(pyrrolidin-1 -yl)tetrahydrofuran-3-yl]urea
Figure imgf000254_0002
In analogy to intermediate 2, phenyl {4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}carbamate (150 mg, 275 μηιοΙ, intermediate 44), and (+/-)-4-(trans)-(pyrrolidin-1 -yl)tetrahydrofuran-3-amine (85.8 mg, 549 μηηοΙ, CAS No.
[1212157-31 -7]), in DMF (4.0 mL) were reacted to obtain a crude product which was used in the next step without further purification.
LC-MS (method 2): Rt = 1 .50 min; MS (ESIpos): m/z = 608 [M+H]+
Intermediate 254
N2-({4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}carbamoyl)-N,N-dimeth lalaninamide
Figure imgf000255_0001
In analogy to intermediate 206, phenyl {4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}carbamate (150 mg, 275 μηιοΙ, intermediate 44), Ν,Ν-dimethylalaninamide hydrochloride (1 :1 ) (50.3 mg, 330 μπιοΙ, CAS No. [124491 -96- 9]), and triethylamine (77 μΙ_, 550 μηηοΙ) in DMF (4.0 mL) were reacted to obtain a crude product which was used in the next step without further purification.
LC-MS (method 2): Rt = 1 .47 min; MS (ESIpos): m/z = 569 [M+H]+
Intermediate 255
N2-({4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin
difluorophenyl}carbamo l)-N,N-dimethylvalinamide
Figure imgf000256_0001
In analogy to intermediate 2, phenyl {4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}carbamate (150 mg, 275 μηιοΙ, intermediate 44), and N,N-dimethylvalinamide (47.5 mg, 330 μπιοΙ, CAS No. [230643-41 -1 ]), in DMF (4.0 mL) were reacted to obtain a crude product which was used in the next step without further purification.
LC-MS (method 2): Rt = 1 .55 min; MS (ESIpos): m/z = 596 [M+H]+
Intermediate 256
(+/-) 1 -{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}-3-(3-methyltetrahydrofuran-3-yl)urea
H
Figure imgf000256_0002
In analogy to intermediate 206, phenyl {4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}carbamate (150 mg, 275 μηιοΙ, intermediate 44), (+/-)-3-methyltetrahydrofuran-3-amine hydrochloride (1 :1 ) (75.6 mg, 549 μηηοΙ, CAS No. [1423034-45-0]), and triethylamine (77 μΙ_, 550 μιτιοΙ) in DMF (4.0 mL) were reacted to obtain a crude product which was used in the next step without further purification.
LC-MS (method 2): Rt = 1 .53 min; MS (ESIpos): m/z = 553 [M+H]+ Intermediate 257
(+/-)1 -{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}-3-[7-oxabicyclo[2.2.1 ]hept-2-yl]urea - mixture of isomers
Figure imgf000257_0001
In analogy to intermediate 2, phenyl {4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}carbamate (150 mg, 275 μηιοΙ, intermediate 44), and (+/-)-7-oxabicyclo[2.2.1 ]heptan-2-amine (62.2 mg, 549 μπιοΙ, CAS No. [1314954-35- 2]) in DMF (4.0 mL) were reacted to obtain a crude product which was used in the next step without further purification.
LC-MS (method 2): Rt = 1 .50 min; MS (ESIpos): m/z = 565 [M+H]+
Intermediate 258
(+/-)-1 -{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}-3-(1 -methyl-2-oxopyrrolidin-3-yl)urea
Figure imgf000257_0002
In analogy to intermediate 2, phenyl {4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}carbamate (150 mg, 275 μηιοΙ, intermediate 44), and 3-amino-1 -methylpyrrolidin-2-one (37.6 mg, 330 μηιοΙ, CAS No. [1 19329-48-5]), in DMF (4.0 mL) were reacted to obtain a crude product which was used in the next step without further purification.
LC-MS (method 2): Rt = 1 .41 min; MS (ESIpos): m/z = 567 [M+H]+
Intermediate 259
N-(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl]oxy}phenyl)azetidine-1 -carboxamide
Figure imgf000258_0001
In analogy to intermediate 2, phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (150 mg, 259 μηηοΙ, intermediate 1 ), azetidine (17 μί, 260 μηηοΙ) together in DMF (1.3 mL) we obtained the crude product, which was purified via a Biotage chromatography system (1 1 g snap KP-NH column, hexane/ethylacetate / 50 - 100% ethylacetate and ethylacetate/ethanol / 0 - 40% ethanol) to obtain 136 mg (100 % purity, 97 % yield) of the desired title compound.
LC-MS (method 2): Rt = 1 .52 min; MS (ESIneg): m/z = 541 [M-H]"
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.13 - -0.07 (m, 9H), 0.80 - 0.86 (m, 2H), 2.21 (quin, 2H), 3.55 - 3.60 (m, 2H), 3.99 (t, 4H), 5.68 (s, 2H), 6.57 (d, 1 H), 7.49 - 7.56 (m, 2H), 8.28 (d, 1 H), 8.36 (s, 1 H), 8.86 (s, 1 H).
Intermediate 260
N-(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-py
b]pyridin-4-yl]oxy}phenyl)pyrrolidine-1 -carboxamide
Figure imgf000259_0001
In analogy to intermediate 2, phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (150 mg, 259 μηηοΙ, intermediate 1 ), pyrrolidine (22 μΙ_, 260 μηηοΙ) together in DMF (1 .3 mL) we obtained the crude product, which was purified via a Biotage chromatography system (1 1 g snap KP-NH column, hexane/ethylacetate / 50 - 100% ethylacetate and ethylacetate/ethanol / 0 - 40% ethanol) to obtain 134 mg (100 % purity, 93 % yield) of the desired title compound.
LC-MS (method 2): Rt = 1 .55 min; MS (ESIneg): m/z = 555 [M-H]"
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.14 - -0.06 (m, 9H), 0.79 - 0.86 (m, 2H), 1.83 - 1.91 (m, 4H), 3.35 - 3.42 (m, 4H), 3.54 - 3.61 (m, 2H), 5.68 (s, 2H), 6.57 (d, 1 H), 7.55 - 7.63 (m, 2H), 8.29 (d, 1 H), 8.36 (s, 1 H), 8.62 (s, 1 H).
Intermediate 261
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl]oxy}phen l)-3-[(3-fluorooxetan-3-yl)methyl]urea
Figure imgf000259_0002
In analogy to intermediate 85, phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (150 mg, 259 μηηοΙ, intermediate 1 ), 1 -(3-fluorooxetan-3-yl)methanamine (27.2 mg, 259 μηηοΙ) together in DMF (1 .5 mL) and N,N-diisopropylethylamine (45 μί, 260 μηηοΙ) we obtained the crude product, which was purified via a Biotage chromatography system (1 1 g snap KP-NH column, hexane/ethylacetate / 50 - 100% ethylacetate and ethylacetate/ethanol / 0 - 40% ethanol) to obtain 133 mg (100 % purity, 87 % yield) of the desired title compound.
LC-MS (method 2): Rt = 1 .49 min; MS (ESIpos): m/z = 591 [M+H]+
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.12 - -0.06 (m, 9H), 0.79 - 0.86 (m, 2H), 3.55 - 3.60 (m, 2H), 3.66 (dd, 2H), 4.56 - 4.66 (m, 4H), 5.68 (s, 2H), 6.58 (d, 1 H), 6.81 (t, 1 H), 7.37 - 7.43 (m, 2H), 8.28 (d, 1 H), 8.36 (s, 1 H), 9.13 (s, 1 H).
Intermediate 262
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl]oxy}phenyl)-3-(2-hydroxy-2-methylpropyl)urea
Figure imgf000260_0001
In analogy to intermediate 2, phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (150 mg, 259 μηηοΙ, intermediate 1 ), 1 -amino-2-methylpropan-2-ol (24 μΙ_, 260 μηηοΙ) together in DMF (1 .5 mL) we obtained the crude product, which was purified via a Biotage chromatography system (1 1 g snap KP-NH column, hexane/ethylacetate / 50 - 100% ethylacetate and ethylacetate/ethanol / 0 - 40% ethanol) to obtain 134 mg (100 % purity, 90 % yield) of the desired title compound.
LC-MS (method 2): Rt = 1 .47 min; MS (ESIneg): m/z = 573 [M-H]"
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.14 - -0.07 (m, 9H), 0.79 - 0.86 (m, 2H), 1 .10 (s, 6H), 3.05 (d, 2H), 3.54 - 3.60 (m, 2H), 4.58 (s, 1 H), 5.68 (s, 2H), 6.34 (t, 1 H), 6.58 (d, 1 H), 7.31 - 7.39 (m, 2H), 8.28 (d, 1 H), 8.36 (s, 1 H), 9.14 (s, 1 H).
Intermediate 263
(+/-)- 1 -(3 , 5-d if I uoro-4-{[3-(trif ^
b]pyridin-4-yl]oxy}phenyl)-3-[2-hydroxy-2-methyl-3-(morpholin-4-yl)propyl]ure
Figure imgf000261_0001
In analogy to intermediate 2, phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (150 mg, 259 μηιοΙ, intermediate 1 ), (+/-)-1 -amino-2-methyl-3-(morpholin-4-yl)propan-2-ol (51 .9 mg, 298 μηηοΙ) together in DMF (0.7 mL) we obtained the crude product, which was purified via a Biotage chromatography system (1 1 g snap KP-NH column, hexane/ethylacetate / 50 - 100% ethylacetate and ethylacetate/ethanol / 0 - 50% ethanol) to obtain 165 mg (100 % purity, 97 % yield) of the desired title compound.
LC-MS (method 2): Rt = 1 .49 min; MS (ESIpos): m/z = 660 [M+H]+
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.1 1 - -0.08 (m, 9H), 0.80 - 0.86 (m, 2H), 1 .07 (s, 3H), 2.20 - 2.29 (m, 2H), 2.45 - 2.48 (m, 2H), 3.07 - 3.20 (m, 2H), 3.54 - 3.60 (m, 6H), 4.55 (s, 1 H), 5.68 (s, 2H), 6.28 (t, 1 H), 6.58 (d, 1 H), 7.32 - 7.38 (m, 2H), 8.28 (d, 1 H), 8.36 (s, 1 H), 9.18 (s, 1 H).
Intermediate 264
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl]oxy}phenyl)-3-(3-hydroxy-3-methylbutyl)urea
Figure imgf000261_0002
In analogy to intermediate 2, phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (150 mg, 259 μηιοΙ, intermediate 1 ), 4-amino-2-methylbutan-2-ol (30.7 mg, 298 μηιοΙ) together in DMF (1 .5 mL) we obtained the crude product, which was purified via a Biotage chromatography system (1 1 g snap KP-NH column, hexane/ethylacetate / 50 - 100% ethylacetate and ethylacetate/ethanol / 0 - 50% ethanol) to obtain 1 10 mg (100 % purity, 72 % yield) of the desired title compound.
LC-MS (method 2): Rt = 1 .48 min; MS (ESIpos): m/z = 589 [M+H]+
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.13 - -0.06 (m, 9H), 0.80 - 0.86 (m, 2H), 1 .13 (s, 6H), 1 .53 - 1 .58 (m, 2H), 3.16 - 3.22 (m, 2H), 3.55 - 3.60 (m, 2H), 4.39 (s, 1 H), 5.68 (s, 2H), 6.37 (t, 1 H), 6.57 (d, 1 H), 7.35 - 7.41 (m, 2H), 8.28 (d, 1 H), 8.36 (s, 1 H), 9.09 (s, 1 H).
Intermediate 265
6-[({4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methylJ-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}carbamoyl)amino]-N-methylpyridazine-3-carboxamide
Figure imgf000262_0001
In analogy to intermediate 203, phenyl {4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}carbamate (150 mg, 275 μηιοΙ, intermediate 44), and 6-amino-N-methylpyridazine-3-carboxamide (50.2 mg, 330 μηιοΙ, CAS No. [1248423- 87-1]) in DMF (1.1 mL) were reacted to obtain a crude product which was used in the next step without further purification.
LC-MS (method 3): Rt = 1 .49 min; MS (ESIpos): m/z = 604 [M+H]+
Intermediate 266
1 -(6-tert-butylpyridazin-3-yl)-3-{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]m
b]pyridin-4-yl)oxy]-3,5-difluorophenyl}urea
Figure imgf000263_0001
In analogy to intermediate 203, phenyl {4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}carbamate (150 mg, 275 μηιοΙ, intermediate 44), and 6-tert-butylpyridazin-3-amine (49.8 mg, 330 μπιοΙ, CAS No. [82560-18-7]), in DMF (4 mL) were reacted to obtain a crude product which was used in the next step without further purification.
LC-MS (method 3): Rt = 1 .68 min; MS (ESIpos): m/z = 604 [M+H]+
Intermediate 267
6-[({4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl]-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}carbamoyl)amino]-N,N-dimethylpyridazine-3-carboxamide
Figure imgf000263_0002
In analogy to intermediate 203, phenyl {4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}carbamate (150 mg, 275 μηιοΙ, intermediate 44), and 6-amino-N,N-dimethylpyridazine-3-carboxamide (54.8 mg, 330 μηηοΙ, CAS No.
[1250216-83-1]), in DMF (4.0 mL) were reacted to obtain a crude product which was used in the next step without further purification. LC-MS (method 3): Rt = 1 .47 min; MS (ESIneg): m/z = 619 [M+H]+
Intermediate 268
1 -{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}-3-[6-(trifluoromethyl)pyridazin-3-yl]urea
Figure imgf000264_0001
In analogy to intermediate 203, phenyl {4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}carbamate (150 mg, 275 μηιοΙ, intermediate 44), and 6-(trifluoromethyl)pyridazin-3-amine (53.8 mg, 330 μηιοΙ, CAS No. [935777-24-5]), in DMF (1 .1 mL) were reacted to obtain the crude product which was used in the next step without further purification.
LC-MS (method 3): Rt = 1 .67 min; MS (ESIpos): m/z = 615 [M+H]+ Intermediate 269
1 -{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}-3-[6-(methylsulfonyl)pyridazin-3-yl]urea
Figure imgf000264_0002
In analogy to intermediate 203, phenyl {4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}carbamate (150 mg, 275 μηιοΙ, intermediate 44), and 6-(methylsulfonyl)pyridazin-3-amine (57.1 mg, 330 μηιοΙ, CAS No. [61071 -25-8]), in DMF (4.0 mL) were reacted to obtain a crude product which was used in the next step without further purification.
LC-MS (method 3): Rt = 1 .51 min; MS (ESIpos): m/z = 625 [M+H]+ Intermediate 270
(+/-)-N-(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl]ox henyl)-N'-(2-fluoro-3-methoxypropyl)urea
Figure imgf000265_0001
In analogy to intermediate 85, phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (150 mg, 259 μηηοΙ, intermediate 1 ), (+/-)-2-fluoro-3-methoxypropan-1 -amine hydrogen chloride salt (42.7 mg, 298 μηηοΙ) together in DMF (700 μΙ_) and N,N-diisopropylethylamine (52 μΙ_,
300 μηηοΙ) we obtained the crude product, which was purified via a Biotage chromatography system (1 1 g snap KP-NH column, hexane/ethylacetate / 50 - 100% ethylacetate and ethylacetate/ethanol / 0 - 50% ethanol) to obtain 107 mg (94 % purity, 65 % yield) of the desired title compound.
LC-MS (method 2): Rt = 1 .51 min; MS (ESIpos): m/z = 593 [M+H]+
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.12 - -0.06 (m, 9H), 0.79 - 0.87 (m, 2H), 3.30 (s, 3H), 3.29 - 3.60 (m, 5H), 4.61 - 4.66 (m, 1 H), 4.73 - 4.79 (m, 1 H), 5.68 (s, 2H), 6.58 (d, 1 H), 6.69 (t, 1 H), 7.35 - 7.43 (m, 2H), 8.29 (d, 1 H), 8.36 (s, 1 H), 9.18 (s, 1 H).
Intermediate 271
(+/-)-N-(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl^
b]pyridin-4-yl]ox henyl)-N'-[(4,4-dimethyloxetan-2-yl)methyl]urea
Figure imgf000266_0001
In analogy to intermediate 2, phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (150 mg, 259 μηιοΙ, intermediate 1 ), (+/-)-1 -(4,4-dimethyloxetan-2-yl)methanamine (34.3 mg, 298 μηιοΙ) together in DMF (700 μΙ_) we obtained the crude product, which was purified via a Biotage chromatography system (1 1 g snap KP-NH column, hexane/ethylacetate / 50 - 100%
ethylacetate and ethylacetate/ethanol / 0 - 50% ethanol) to obtain 1 12 mg (80 % purity, 58 % yield) of the desired title compound.
LC-MS (method 2): Rt = 1 .52 min; MS (ESIpos): m/z = 601 [M+H]+
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.1 1 - -0.07 (m, 9H), 0.79 - 0.86 (m, 2H), 1 .33 (s, 3H), 1 .38 (s, 3H), 2.14 (dd, 1 H), 2.31 (dd, 1 H), 3.27 - 3.32 (m, 2H), 3.54 - 3.60 (m, 2H), 4.50 - 4.57 (m, 1 H), 5.68 (s, 2H), 6.52 (t, 1 H), 6.58 (d, 1 H), 7.34 - 7.41 (m, 2H), 8.28 (d, 1 H), 8.36 (s, 1 H), 9.10 (s, 1 H).
Intermediate 272
(+/-)-N-(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl]ox henyl)-N'-(2-fluoro-3-methoxy-2-methylpropyl)urea
Figure imgf000266_0002
In analogy to intermediate 85, phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (150 mg, 259 μηηοΙ, intermediate 1 ), (+/-)-2-fluoro-3-methoxy-2-methylpropan-1 -amine hydrogen chloride salt(1/1 ) (46.9 mg, 298 μηιοΙ) together in DMF (700 μΙ_) and N,N-diisopropylethylamine (52 μΙ_, 300 μmol) we obtained the crude product, which was purified via a Biotage chromatography system (1 1 g snap KP-NH column, hexane/ethylacetate / 50 - 100% ethylacetate and ethylacetate/ethanol / 0 - 50% ethanol) to obtain 107 mg (100 % purity, 68 % yield) of the desired title compound.
LC-MS (method 2): Rt = 1 .55 min; MS (ESIpos): m/z = 607 [M+H]+
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.1 1 - -0.08 (m, 9H), 0.80 - 0.86 (m, 2H), 1 .26 (d, 3H), 3.32 (s, 3H), 3.34 - 3.46 (m, 4H), 3.54 - 3.61 (m, 2H), 5.68 (s, 2H), 6.58 (d, 1 H), 6.61 (t, 1 H), 7.34 - 7.42 (m, 2H), 8.28 (d, 1 H), 8.36 (s, 1 H), 9.10 (s, 1 H).
Intermediate 273
N-(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl]oxy}phenyl)-N'-{[3-(hydroxymethyl)oxetan-3-yl]methyl}urea
Figure imgf000267_0001
In analogy to intermediate 2, phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (150 mg, 259 μιτιοΙ, intermediate 1 ), [3-(aminomethyl)oxetan-3-yl]methanol (34.9 mg, 298 μηηοΙ) together in DMF (700 μΙ_) we obtained the crude product, which was purified via a Biotage
chromatography system (1 1 g snap KP-NH column, hexane/ethylacetate / 50 - 100%
ethylacetate and ethylacetate/ethanol / 0 - 50% ethanol) to obtain 66 mg (94 % purity, 39 % yield) of the desired title compound.
LC-MS (method 2): Rt = 1 .40 min; MS (ESIpos): m/z = 603 [M+H]+
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.12 - -0.07 (m, 9H), 0.80 - 0.86 (m, 2H), 3.39 (d, 2H), 3.54 - 3.62 (m, 4H), 4.30 (q, 4H), 4.98 (t, 1 H), 5.68 (s, 2H), 6.58 (d, 1 H), 6.67 (t, 1 H), 7.35 - 7.42 (m, 2H), 8.28 (d, 1 H), 8.36 (s, 1 H), 9.14 (s, 1 H). Intermediate 274
N-(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-py
b]pyridin-4-yl]oxy}phen l)-N'-[(3-hydroxyoxetan-3-yl)methyl]urea
Figure imgf000268_0001
In analogy to intermediate 2, phenyl (3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (150 mg, 259 μηηοΙ, intermediate 1 ), 3-(aminomethyl)oxetan-3-ol (30.7 mg, 298 μηηοΙ) together in DMF (700 μΙ_) we obtained the crude product, which was purified via a Biotage chromatography system (1 1 g snap KP-NH column, hexane/ethylacetate / 50 - 100% ethylacetate and ethylacetate/ethanol / 0 - 50% ethanol) to obtain 51 mg (89 % purity, 30 % yield) of the desired title compound.
LC-MS (method 2): Rt = 1 .40 min; MS (ESIpos): m/z = 589 [M+H]+
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.15 - -0.06 (m, 9H), 0.77 - 0.87 (m, 2H), 3.35 - 3.48 (m, 2H), 3.53 - 3.61 (m, 2H), 4.34 - 4.44 (m, 4H), 5.68 (s, 2H), 6.00 (s, 1 H), 6.50 - 6.63 (m, 2H), 7.37 (d, 2H), 8.28 (d, 1 H), 8.36 (s, 1 H), 9.19 (s, 1 H).
Intermediate 275
N-(2,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl]oxy}phen l)-N'-[(3-methyloxetan-3-yl)methyl]urea
Figure imgf000268_0002
In analogy to intermediate 36, in two experiments using 2,5-difluoro-4-{[3-(trifluoromethyl)-1 - {[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}aniline (50 + 250 mg, 1 10 μηηοΙ + 544 μηηοΙ, intermediate 1 ), 3-(isocyanatomethyl)-3-methyloxetane (140 μΙ_, 1 .1 mmol) (27 + 140 μΙ_, 0.21 + 1.1 mmol), in a mixture of dichloromethane (0.92 + 4.6 mL) and pyridine (0.97 + 4.8 mL), we obtained 244 mg (63% yield) of the desired title compound. LC-MS (method 3): Rt = 1 .48 min; MS (ESIpos): m/z = 587 [M+H]+
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.12 - -0.05 (m, 9H), 0.79 - 0.87 (m, 2H), 1 .24 (s, 3H), 3.33 (d, 2H) 3.53 - 3.61 (m, 2H), 4.23 (d, 2H), 4.36 (d, 2H), 5.68 (s, 2H), 6.57 (d, 1 H), 6.99 (t, 1 H), 7.53 (dd, 1 H), 8.23 - 8.30 (m, 2H), 8.35 (s, 1 H), 8.67 (s, 1 H).
Intermediate 276
4-[(2,6-difluoro-4-nitrophenyl)sulfanyl]-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridine
Figure imgf000269_0001
A mixture of 4-chloro-1 -((2-(trimethylsilyl)ethoxy)methyl)-1 H-pyrrolo[2,3-b]pyridine (12 g, commercially available or prepared according to J. Med. Chem. 2017, 4636) and 2,6-difluoro- 4-nitrobenzenethiol (8.1 1 g, commercially available) in DMF (150 mL) was stirred at room temperature under nitrogene atmosphere for 16 hours. To the reaction mixture was added 700 mL of water and the resultant mixture was extracted with threetimes with ethyl acetate. The combined organic phase was washed with water, then brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (silicagel, petrolether : ethyl acetate = 4:1 to 1 :1 ) to afford 14.5 g ) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.12 (s, 9H), 0.80 (t, 2H),. 3.50 (t, 2H), 5.62 (s, 2H), 6.42 (d, 1 H), 6.84 (d, 1 H), 7.71 (d, 1 H), 8.15 (d, 1 H), 8.26 (d, 2H). ntermediate 277
Figure imgf000270_0001
A mixture of 4-((2,6-difluoro-4-nitrophenyl)thio)-1 -((2-(trimethylsilyl)ethoxy)methyl)-1 H- pyrrolo[2,3-b]pyridine (14.5 g, 33 mmol, intermediate 276) and 1 -bromopyrrolidine-2,5-dione (CAS No. [128-08-5], 5.82 g, 33 mmol) in dichloromethane (150 mL) was stirred at room temperature for 17 hours. The reaction mixture was concentrated under reduced pressure. To the residue was added aqueous saturated sodium thiosulfate (40 mL) and aqueous saturated sodium bicarbonate (40 mL). The resultant mixture was extracted with threetimes with ethyl acetate. The combined organic phase was washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to afford (16.6 g, crude) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.09 (s, 9H), 0.82 (t, 2H), 3.53 (t, 2H), 5.61 (s, 2H), 6.55 (d, 1 H), 7.99 (s, 1 H), 8.10 (d, 1 H), 8.30 (d, 2H).
Intermediate 278
4-[(3-bromo-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)sulfanyl]-3,5- difluoroaniline
Figure imgf000270_0002
To a mixture of 3-bromo-4-((2,6-difluoro-4-nitrophenyl)thio)-1 -((2-(trimethylsilyl)ethoxy)methyl)- 1 H-pyrrolo[2,3-b]pyridine (16.6 g, crude, intermediate 277), FeC (1 .05 g, 6.47 mmol), activated carbon (2.1 g) in methanol (200 mL) was added hydrazine hydrate (6.5 g, 130 mmol) drop-wise at 50 °C. The reaction mixture was then stirred at reflux for 18 h. The reaction mixture was filtered and the filtrate was concentrated under reduced pressure. The residue was stirred in ethanol (80 mL) for 2 hours and then the mixture was filtered. The filter cake was dried under reduced pressure to afford crude product as a white solid (5.5 g), which was combined with another batch of crude product (10.6 g, from a second experiment). This combined crude product (16.1 g) was stirred in methyl t-butyl ether (15 mL) for 2 h and the resultant mixture was filtered. The filter cake was dried in vacuum, then purified by column chromatography (silicagel petrolether : ethyl acetate = 5:1 to 1 :1 ) to afford 8.06 g of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.09 (s, 9H), 0.81 (t, 2H), 3.50 (t, 2H), 5.57 (s, 2H), 6.31 (d, 1 H), 6.42 (d, 4H), 7.89 (s, 1 H), 8.06 (d, 1 H).
Intermediate 279
phenyl {4-[(3-bromo-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)sulfanyl]- 3,5-difluorophenyl}carbamate
Figure imgf000271_0001
In analogy to intermediate 1 , 4-[(3-bromo-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl)sulfanyl]-3,5-difluoroaniline (600 mg, 1.23 mmol, intermediate 278), phenyl carbonochloridate (170 μί, 1 .4 mmol) together in THF (10 mL) and pyridine (510 μί) we obtained a reaction mixture which was directly used for the next step Intermediate 280
N-{4-[(3-bromo-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)sulfanyl]-3,5- difluorophenyl}-N'-[2-(morpholin-4-yl)-2-oxoethyl]urea
Figure imgf000271_0002
To solution of phenyl {4-[(3-bromo-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyrid 4-yl)sulfanyl]-3,5-difluorophenyl}carbamate (180 mg, 297 μηηοΙ, intermediate 279) in DMF (2.0 mL) plus trimethylamine (120 μΙ_, 890 μηηοΙ) was added 2-amino-1 -(morpholin-4-yl)ethan- 1 -one (64.2 mg, 445 μηηοΙ) and this mixture was stirred at 60°C for 3 hours. After cooling to room temperature the reaction mixture was diluted with ethyl acetate. This organic phase was washed with 1 N hydrochloric acid, aqueous saturated sodium bicarbonate solution, brine and , dried via a hydrophobic filter and evaporated to dryness in vacuum.
The resulting residue was purified via a Biotage chromatography system (28 g snap KP-NH column, hexane / 0 - 100% ethyl acetate, then ethyl acetate / 0 - 70% ethanol) to obtain 189 mg (100 % purity, 97 % yield) of the desired title compound.
LC-MS (method 2): Rt = 1 .47 min; MS (ESIpos): m/z = 656 [M+H]+
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.1 1 - -0.08 (m, 9H), 0.78 - 0.85 (m, 2H), 3.40 - 3.62 (m, 10H), 4.03 (d, 2H), 5.58 (s, 2H), 6.31 (d, 1 H), 6.70 (t, 1 H), 7.37 - 7.43 (m, 2H), 7.93 (s, 1 H), 8.06 (d, 1 H), 9.75 (s, 1 H).
Intermediate 281
N-{4-[(3-bromo-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)sulfanyl]-3,5- difluorophenyl}-N'-(2-methoxyethyl)urea
Figure imgf000272_0001
In analogy to intermediate 280, phenyl {4-[(3-bromo-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)sulfanyl]-3,5-difluorophenyl}carbamate (180 mg, 297 μηιοΙ, intermediate 279), 2-methoxyethan-1 -amine (33.4 mg, 445 μηηοΙ), trimethylamine (62 μΙ_, 450 μηιοΙ) together in DMF (2.0 mL) was reacted to obtain 171 mg (100 % purity, 98 % yield) of the desired title compound.
LC-MS (method 2): Rt = 1 .53 min; MS (ESIpos): m/z = 587 [M+H]+
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.1 1 - -0.08 (m, 9H), 0.78 - 0.85 (m, 2H), 3.26 - 3.31 (m, 5H), 3.37 - 3.42 (m, 2H), 3.47 - 3.54 (m, 2H), 5.58 (s, 2H), 6.30 (d, 1 H), 6.61 (t, 1 H), 7.37 - 7.43 (m, 2H), 7.93 (s, 1 H), 8.06 (d, 1 H), 9.38 (s, 1 H). Intermediate 282
N-{4-[(3-bromo-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4
difluorophenyl}-N'-ethylurea
Figure imgf000273_0001
In analogy to intermediate 280, phenyl {4-[(3-bromo-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)sulfanyl]-3,5-difluorophenyl}carbamate (180 mg, 297 μηιοΙ, intermediate 279), ethanamine (220 μΙ_, 2.0 M in methanol, 450 μηηοΙ), trimethylamine (62 μΙ_, 450 μπιοΙ) together in DMF (2.0 mL) was reacted to obtain 163 mg (100 % purity, 99 % yield) of the desired title compound.
LC-MS (method 2): Rt = 1 .56 min; MS (ESIpos): m/z = 557 [M+H]+
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.1 1 - -0.08 (m, 9H), 0.78 - 0.85 (m, 2H), 1.07 (t, 3H), 3.13 (dt, 2H), 3.47 - 3.54 (m, 2H), 5.58 (s, 2H), 6.30 (d, 1 H), 6.54 (t, 1 H), 7.39 - 7.44 (m, 2H), 7.93 (s, 1 H), 8.06 (d, 1 H), 9.28 (s, 1 H). Intermediate 283
N-{4-[(3-bromo-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)sulfanyl]-3,5- difluorophenyl}morpholine-4-carboxamide
Figure imgf000273_0002
In analogy to intermediate 280, phenyl {4-[(3-bromo-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)sulfanyl]-3,5-difluorophenyl}carbamate (180 mg, 297 μηιοΙ, intermediate 279), morpholine (38.8 mg, 445 μηηοΙ), trimethylamine (62 μΙ_, 450 μηηοΙ) together in DMF (2.0 mL) was reacted to obtain 195 mg (crude) of the desired title compound.
LC-MS (method 2): Rt = 1 .54 min; MS (ESIpos): m/z = 599 [M+H]+
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: -0.1 1 - -0.08 (m, 9H), 0.78 - 0.85 (m, 2H), 3.44 - 3.54 (m, 6H), 3.60 - 3.66 (m, 4H), 5.58 (s, 2H), 6.30 (d, 1 H), 7.50 - 7.56 (m, 2H), 7.94 (s, 1 H), 8.07 (d, 1 H), 9.25 (s, 1 H). Intermediate 284
3-bromo-4-(2,6-difluoro-4-nitrophenoxy)-1 -(4-methylbenzene-1 -sulfonyl)-1 H-pyrrolo[2,3- b]pyridine
Figure imgf000274_0001
Step 1
To a stirred solution of 4-(2,6-difluoro-4-nitrophenoxy)-1 H-pyrrolo[2,3-b]pyridine (5.70 g, 19.6 mmol, intermediate 143) in DMF (100 mL) was added N-bromosuccinimide (3.83 g, 21 .5 mmol). The resulting mixture was stirred at room temperature for 2 hours at which time the reaction was cooled to 0°C and water was slowly added. The resulting precipitate was filtered and dried to afford 3-bromo-4-(2,6-difluoro-4-nitrophenoxy)-1 H-pyrrolo[2,3-b]pyridine (7.20 g, 99 % yield)
LC-MS (method 2): Rt = 1 .18 min; MS (ESIpos): m/z = 370 [M+H]+
1H NMR (400 MHz, DMSO-d6) δ ppm 6.55 (d, 1 H), 7.72 (d, 1 H), 8.14 (d, 1 H), 8.41 (d, 2 H), 12.34 (br s, 1 H)
Step 2
To a cooled (0°C) solution of 3-bromo-4-(2,6-difluoro-4-nitrophenoxy)-1 H-pyrrolo[2,3-b]pyridine (13.0 g, 35.1 mmol) from step 1 in DMF (200 mL) was added sodium hydride (1 .83 g, 60 % suspension in oil, 45.7 mmol) portionwise. The resulting mixture was stirred for 15 minutes at 0°C at which time p-Toluenesulfonylchloride (7.37 g, 38.6 mmol) was added and the reaction was allowed to warm slowly to room temperature overnight. The mixture was slowly poured into ice-water, and the resulting precipitate was filtered and dried to afford 15 g (81 % yield) of the desired product.
LC-MS (method 2): Rt = 1 .51 min; MS (ESIpos): m/z = 526 [M+H]+
1H NMR (400 MHz, DMSO-d6) δ ppm 2.37 (s, 3 H), 6.87 (d, 1 H), 7.46 (d, 2 H), 8.04 (d, 2 H), 8.22 (s, 1 H), 8.31 (d, 1 H), 8.42 (d, 2 H) Intermediate 285
4-{[3-bromo-1 -(4-methylbenzene-1 -sulfonyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}-3,5- difluoroaniline
Figure imgf000275_0001
To a solution of 3-bromo-4-(2,6-difluoro-4-nitrophenoxy)-1 -(4-methylbenzene-1 -sulfonyl)-1 H- pyrrolo[2,3-b]pyridine (5.20 g, 9.92 mmol, intermediate 284) in a mixture of THF: water: methanol (1 :2:1 , 200 mL), was added ammonium chloride (2.65 g, 49.6 mmol) and iron powder (2.77 g, 49.6 mmol). The resulting mixture was stirred at 80°C for 2 hours at which time the mixture was cooled and filtered over celite. The filtrate was extracted twice with ethyl acetate and the combined organic layers washed with brine, dried over sodium sulfate, and evaporated to give the crude product 4.90 g (100% yield) which was sufficiently pure for the next step without further purification.
LC-MS (method 2): Rt = 1 .39 min; MS (ESIpos): m/z = 494 [M+H]+
1H NMR (400 MHz, DMSO-d6) δ ppm 2.35 (s, 3 H), 5.85 (s, 2 H), 6.37 (d, 2 H), 6.57 (d, 1 H), 7.44 (d, 2 H), 8.02 (d, 2 H), 8.10 (s, 1 H), 8.24 (d, 1 H)
Intermediate 286
di-tert-butyl (4-{[3-bromo-1 -(4-methylbenzene-1 -sulfonyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}-3,5- difluorophenyl)-2-imidodicarbonate
H
Figure imgf000275_0002
To a solution of 4-{[3-bromo-1 -(4-methylbenzene-1 -sulfonyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}- 3,5-difluoroaniline (4.30 g, 8.70 mmol, intermediate 285) in THF (30 mL) was added di-tert- butyl dicarbonate (4.7 mL, 22 mmol) and dimethylaminopyridine (106 mg, 870 μηηοΙ). The resulting mixture was stirred at 75°C for 3 hours, at which time ethyl acetate and water were added and the layers were separated. The aqueous phase was extracted twice with ethyl acetate and the combind organic layers were washed with brine, dried over sodium sulfate, and evaporated to afford the crude product. The crude product was purified by flash column chromatography followed by crystallization from a mixture of dichloromethane and methanol to afford the title compound (1.68g, 28% yield).
LC-MS (method 2): Rt = 1 .70 min; MS (ESIpos): m/z = 696 [M+H]+
1H NMR (400 MHz, DMSO-d6) δ ppm 1 .41 (s, 18 H), 2.36 (s, 3 H), 6.46 (d, 1 H), 7.45 (d, 2 H), 7.53 (d, 2 H), 8.04 (d, 2 H), 8.19 (s, 1 H), 8.31 (d, 1 H)
Intermediate 287
N-(4-{[3-bromo-1 -(4-methylbenzene-1 -sulfonyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}-3,5- difluorophenyl)-N'-(2-methoxyethyl)urea
Figure imgf000276_0001
To a solution of 4-{[3-bromo-1 -(4-methylbenzene-1 -sulfonyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}- 3,5-difluoroaniline (4.32 g, 8.78 mmol, intermediate 285) in a 1 :1 mixture of dichloromethane and pyridine (80 mL) is added 1 -isocyanato-2-methoxyethane (4.44g, 43.9 mmol, CAS No.
[42170-95-6]). The reaction mixture is stirred at 60°C overnight upon which time the mixture is cooled to room temperature. Water and ethyl acetate were added and the phases were separated. The aqueous phase was extracted twice with ethyl acetate and the combined organic phases washed with brine, dried over sodium sulfate, filtered and evaporated to give the crude material. The crude material was purified by flash column chromatography to give the title compound (4.07g 78% yield).
LC-MS (method 2): Rt = 1 .36 min; MS (ESIpos): m/z = 595 [M+H]+
1H NMR (400 MHz, DMSO-d6) δ ppm 2.35 (s, 3 H), 3.23 - 3.28 (m, 5 H), 3.36 - 3.40 (m, 2 H), 6.46 (t, 1 H), 6.62 (d, 1 H), 7.36 (d, 2 H), 7.44 (d, 2 H), 8.03 (d, 2 H), 8.14 (s, 1 H), 8.25 (d, 1 H), 9.09 (s, 1 H) Intermediate 288
di-tert-butyl (3,5-difluoro-4-{[1 -(4-methylbenzene-1-sulfonyl)-3-(propan-2-yl)-1 H-pyrrolo[2,3- b]pyridin-4-yl]oxy}phenyl)-2-imidodicarbonate
Figure imgf000277_0001
di-tert-butyl (4-{[3-bromo-1 -(4-methylbenzene-1 -sulfonyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}-3,5- difluorophenyl)-2-imidodicarbonate (500 mg, 720 μηηοΙ, intermediate 286), tris(trimethylsilyl)silane (220μί, 720μηΊθΙ, CAS No. [1873-77-4]), 2-bromopropane (300 μΙ_, 3.2 mmol, CAS No. [75-26-3]), 2,6-dimethoxypyridine (570 μί, 4.3mmol) and lr(4',6'-dF-5-CF3- ppy)2(4,4'-dtbbpy)PF6 (16 mg, 14 μηιοΙ, CAS No. [870987-63-6]) were dissolved in the reaction vial in trifluorotoluene (1 1 mL). In a separate vial, the Ni-catalyst was prepared by dissolving Nickel (II) chloride dimethoxyethane adduct (8 mg, 36 μηιοΙ, CAS No. [29046-78-4]) and 4,4'- Di-tert-butyl-2,2'-bipyridine (10 mg, 36 μηιοΙ, CAS No. [72914-19-3]) in N,N-dimethylacetamide (4.0 mL) followed by stirring for 5 min. The catalyst solution was syringed to the sealed reaction vial and degassed by sparging with argon for 10 minutes. The MW-vial was placed in a heatblock and tempered to 40°C. The reaction mixture was pumped through the flow tubing using a peristaltic pump (Flow Setup: Loop Volume: 2mL, Tube: inner diameter: 0,2 mm wall thickness 0,2mm, 30% Peristalticpump speed ~35seconds irradiated residence time, 9h circleflow) for 9 hours at which time water and ethyl acetate were added and the layers were separated. The aqueous phase was extracted twice with ethyl acetate and the combined organic layers were washed with brine, dried over sodium sulfate, and evaporated to give the crude material. The crude material was purified by flash column chromatography to afford an inseperable mixture of the desired product di-tert-butyl (3,5-difluoro-4-{[1 -(4-methylbenzene-1 - sulfonyl)-3-(propan-2-yl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-2-imidodicarbonate and the de-brominated starting material di-tert-butyl [3,5-difluoro-4-({1 -[(4-methylphenyl)sulfonyl]-1 H- pyrrolo[2,3-b]pyridin-4-yl}oxy)phenyl]-2-imidodicarbonate (1 .69 g, 59% combined yield) LC-MS (method 2): Rt = 1 .74 min; MS (ESIpos): m/z = 659 [M+H]+ Intermediate 289
3,5-difluoro-4-{[1 -(4-methylbenzene-1 -sulfonyl)-3-(propan-2-yl)-1 H-pyrrolo[2,3-b]pyridin-4- yl]oxy}aniline— hydrogen chloride 1/1 )
Figure imgf000278_0001
di-tert-butyl (3,5-difluoro-4-{[1 -(4-methylbenzene-1 -sulfonyl)-3-(propan-2-yl)-1 H-pyrrolo[2,3- b]pyridin-4-yl]oxy}phenyl)-2-imidodicarbonate (1 .69 g, 66 % purity, 1 .70 mmol, intermediate 288) was dissolved in a 4 M solution of hydrochloric acid in dioxane (30 mL) and stirred at room temperature overnight. The solvent was subsequently evaporated to give the crude product which was used in the subsequent step without further purification.
LC-MS (method 2): Rt = 1 .45 min; MS (ESIpos): m/z = 458 [M+H]+
Intermediate 290
phenyl (3,5-difluoro-4-{[1 -(4-methylbenzene-1 -sulfonyl)-3-(propan-2-yl)-1 H-pyrrolo[2,3- b]pyridin-4-yl]oxy}phenyl)carbamate
Figure imgf000278_0002
To a stirred solution of 3,5-difluoro-4-{[1 -(4-methylbenzene-1 -sulfonyl)-3-(propan-2-yl)-1 H- pyrrolo[2,3-b]pyridin-4-yl]oxy}aniline— hydrogen chloride (1/1 ) (1 .40 g, 66 % purity, 1.87 mmol, intermediate 289) in THF (15 mL) and pyridine was added (2.0 mL, 25 mmol). The reaction mixture was cooled to 0°C and phenyl carbonochloridate (360 μΙ_, 2.9 mmol, CAS No. [1885- 14-9]) was added. The resulting mixture was stirred for 30 min at 0°C, at which time it was diluted with ethyl acetate and a 2M aqueous solution of hydrochlorid acid was added slowly. The layers were separated and the aqueous phase was extracted twice with ethyl acetate. The combined organic phases were washed with a saturated solution of sodium bicarbonate, followed by brine, dried over sodium sulfate, and evaporated to afford the crude product. The crude product was used without further purification.
LC-MS (method 3): Rt = 1 .62 min; MS (ESIpos): m/z = 579 [M+H]+ Intermediate 291
N-(3,5-difluoro-4-{[1 -(4-methylbenzene-1 -sulfonyl)-3-(propan-2-yl)-1 H-pyrrolo[2,3-b]pyridin-4- yl]oxy}phenyl)-N'-[(3-fluorooxetan-3- l)methyl]urea
Figure imgf000279_0001
In analogy to intermediate 2, phenyl (3,5-difluoro-4-{[1 -(4-methylbenzene-1 -sulfonyl)-3- (propan-2-yl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (400 mg, 66 % purity, 457 μηηοΙ, intermediate 290), and 1 -(3-fluorooxetan-3-yl)methanamine (120 mg, 1 .14 mmol, CAS No. [88331 1 -82-8]), in DMF (3.0 mL) were reacted to obtain a crude product which was used the next step without further purification.
LC-MS (method 2): Rt = 1 .40 min; MS (ESIpos): m/z = 589 [M+H]+ Intermediate 292
di-tert-butyl (3,5-difluoro-4-{[1 -(4-methylbenzene-1-sulfonyl)-3-(3,3,3-trifluoropropyl)-1 H- pyrrolo[2,3-b]pyridin-4-yl]ox phenyl)-2-imidodicarbonate
Figure imgf000280_0001
di-tert-butyl (4-{[3-bromo-1 -(4-methylbenzene-1 -sulfonyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}-3,5- difluorophenyl)-2-imidodicarbonate (200 mg, 288 μηηοΙ, intermediate 286), lr(4',6'-dF-5-CF3- ppy)2(4,4'-dtbbpy)PF6 (6.5 mg, 5.8 μηιοΙ, CAS No. [870987-63-6]), tris(trimethylsilyl)silane (89 μί, 290 μηιοΙ, CAS No. [1873-77-4]) and lithiumcarbonate (128 mg, 1 .73 mmol) were dissolved in trifluorotoluene (4.0 mL) in a MW-vial. In a separate vial, the Ni-catalyst was prepared by dissolving Nickel (II) chloride dimethoxyethane adduct (32 mg, 140 μηηοΙ, CAS No.
[29046-78-4]) and 4,4'-Di-tert-butyl-2,2'-bipyridine (39 mg, 140 μπιοΙ, CAS No. [72914-19-3]) in Ν,Ν-dimethyl acetamide (10 mL) followed by stirring for 5 min. 0.1 mL of this catalyst solution was syringed to the sealed reaction vial and argon was bubbled through the solution for another 5 min. 3-bromo-1 ,1 ,1 -trifluoropropane (180 μί, 1 .7 mmol, CAS No. [460-32-2]) was added. The MW-vial was subsequently irradiated by two 40W Kessil LED Aquarium lights (40W each, 4 cm distance) placed in a water bath to keep the temperature below 35 °C for 12 hours, at which time water and ethyl acetate were added and the layers were separated. The aqueous phase was extracted twice with ethyl acetate and the combined organic layers were washed with brine, dried over sodium sulfate, and evaporated to give the crude material, which was used without further purification.
LC-MS (method 2): Rt = 1 .68 min; MS (ESIpos): m/z = 712 [M+H]+ Intermediate 293
3,5-difluoro-4-{[1 -(4-methylbenzene-1 -sulfonyl)-3-(3,3,3-trifluoropropyl)-1 H-pyrrolo[2,3- b]pyridin-4-yl]oxy}aniline
Figure imgf000281_0001
di-tert-butyl (3,5-difluoro-4-{[1 -(4-methylbenzene-1 -sulfonyl)-3-(3,3,3-trifluoropropyl)-1 H- pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-2-imidodicarbonate (450 mg, 632 μηηοΙ, intermediate 292) was dissolved in a 4 M solution of hydrochloric acid in dioxane (9.0 mL) and stirred at room temperature overnight. The solvent was subsequently evaporated to give the crude product which was purified by preparative HPLC to afford the title compound (190 mg, 59% yield).
LC-MS (method 2): Rt = 1 .41 min; MS (ESIpos): m/z = 512 [M+H]+
1H NMR (400 MHz, DMSO-d6) δ ppm 2.35 (s, 3 H), 2.63 - 2.73 (m, 2 H), 3.01 - 3.06 (m, 2 H), 5.85 (s, 2 H), 6.38 (d, 2 H), 6.51 (d, 1 H), 7.42 (d, 2 H), 7.79 (s, 1 H), 7.97 (d, 2 H), 8.19 (d, 1 H)
Intermediate 294
phenyl (3,5-difluoro-4-{[1 -(4-methylbenzene-1 -sulfonyl)-3-(3,3,3-trifluoropropyl)-1 H-pyrrolo[2,3- b]pyridin-4-yl]oxy}phenyl)carbamate
Figure imgf000281_0002
In analogy to intermediate 290, 3,5-difluoro-4-{[1 -(4-methylbenzene-1 -sulfonyl)-3-(3,3,3- trifluoropropyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}aniline (190 mg, 371 μηηοΙ, intermediate 293) was reacted with phenyl carbonochloridate (51 μΙ_, 410 μηιοΙ, CAS No. [1885-14-9]) and pyridine (170 μΙ_, 2.1 mmol) in THF (3.0 mL) to afford the crude product which was used without further purification.
LC-MS (method 3): Rt = 1 .56 min; MS (ESIneg): m/z = 630 [M-H]"
Intermediate 295
N-(3,5-difluoro-4-{[1 -(4-methylbenzene-1 -sulfonyl)-3-(3,3,3-trifluoropropyl)-1 H-pyrrolo[2,3- b]pyridin-4-yl]oxy}phenyl -N'-[(3-fluorooxetan-3-yl)methyl]urea
Figure imgf000282_0001
In analogy to intermediate 2, phenyl (3,5-difluoro-4-{[1 -(4-methylbenzene-1 -sulfonyl)-3-(3,3,3- trifluoropropyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (230 mg, 364 μηιοΙ, intermediate 294), and 1 -(3-fluorooxetan-3-yl)methanamine (57.4 mg, 546 μηηοΙ, CAS No.
[88331 1 -82-8]), in DMF (5.0 mL) were reacted to obtain a crude product which was used in the next step without further purification.
LC-MS (method 2): Rt = 1 .38 min; MS (ESIpos): m/z = 643 [M+H]+
Intermediate 296
N-{4-[(3-bromo-1 -{[2-(trimethylsilyl)ethoxy]methylH
difluorophenyl}-N'-[(3-fluorooxetan-3- l)methyl]urea
Figure imgf000283_0001
In analogy to intermediate 2, phenyl {4-[(3-bromo-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}carbamate (22.0 g, 37.2 mmol, intermediate 159), and 1 -(3-fluorooxetan-3-yl)methanamine (6.9 mL, 74 mmol, CAS No. [88331 1 -82-8]), in DMF (200 mL) were reacted to obtain a crude product which was purified by flash column chromatography ((dichloromethane 100% to dichloromethane 85% / methanol 15%)(Snap Ultra 375g)) to obtain the title compound (15 g, 66% yield).
LC-MS (method 2): Rt = 1 .47 min; MS (ESIpos): m/z = 601 [M+H]+
1H NMR (400 MHz, DMSO-d6) δ ppm -0.09 (s, 9 H), 0.79 - 0.86 (m, 2 H), 3.50 - 3.56 (m, 2 H), 3.66 (dd, 2 H), 4.61 (ddd, 4 H), 5.60 (s, 2 H), 6.44 (d, 1 H), 6.80 (t, 1 H), 7.40 (d, 2 H), 7.86 (s, 1 H), 8.17 (d, 1 H), 9.12 (s, 1 H)
Intermediate 297
N-(3,5-difluoro-4-{[3-(3,3,3-trifluoroprop-1 -en-2-yl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-N'-[(3-fluorooxetan-3-yl)methyl]urea
O
Figure imgf000283_0002
To a stirred solution of N-{4-[(3-bromo-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-N'-[(3-fluorooxetan-3-yl)methyl]urea (1 .17 g, 1.95 mmol, intermediate 296) in degassed THF (30 mL) and water (15 mL) were added (1 ,1 - Bis(diphenylphosphino)ferrocene)-dichloropalladium(ll) (142 mg, 195 μηιοΙ, CAS No. [95464- 05-4]), (3,3,3-trifluoroprop-1 -en-2-yl)boronic acid (340 mg, 2.43 mmol, CAS No. [357274-85-2]) and potassium carbonate (806 mg, 5.84 mmol) The resulting mixture was stirred at 75°C for 5h, at which time the THF was removed evaporated, and ethyl acetate was added. The layers were separated and the aqueous phase was extracted twice with ethyl acetate. The cominbed organic layers were washed with brine, dried over sodium sulfate, and evaporated to afford the crude product. The crude material was purified by flash column chromatography to affod an inseperable mixture of the title compound and debrominated starting material 1 -{3,5-difluoro-4- [(1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl}-3-[(3- fluorooxetan-3-yl)methyl]urea (500 mg, 21 % combined yield)
LC-MS (method 2): Rt = 1 .52 min; MS (ESIpos): m/z = 618 [M+H]+
Intermediate 298
(+/-)-N-{3,5-difluoro-4-[(3-[1 ,1 ,1 -trifluoropropan-2-yl]-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4- l)oxy]phenyl}-N'-[(3-fluorooxetan-3-yl)methyl]urea
Figure imgf000284_0001
To a stirred solution of N-(3,5-difluoro-4-{[3-(3,3,3-trifluoroprop-1 -en-2-yl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-N'-[(3-fluorooxetan-3- yl)methyl]urea (1 .16 g, 50 % purity, 941 μηηοΙ, intermediate 297) in ethanol (50 mL), was added triethylamine (200 μΙ_, 1 .4 mmol) followed by palladium (10% on activated carbon, 100mg, 94.1 μηηοΙ). The flask was flushed with hydrogen and stirred under 1 atm of hydrogen for 4 hours, at which time he mixture was filtered over celite and rinsed with ethyl acetate. The filtrate was evaporated to afford the crude product which was used without further purification. LC-MS (method 2): Rt = 1 .51 min; MS (ESIpos): m/z = 619 [M+H]+ Intermediate 299
N-(3,5-difluoro-4-{[1 -(4-methylbenzene-1 -sulfonyl)-3-(propan-2-yl)-1 H-pyrrolo[2,3-b]pyridin-4- yl]oxy}phenyl)-N'-(2-methoxyethyl)urea
Figure imgf000285_0001
N-(4-{[3-bromo-1 -(4-methylbenzene-1 -sulfonyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}-3,5- difluorophenyl)-N'-(2-methoxyethyl)urea (10.0 mg, 16.8 μπΊθΙ, intermediate 287), lr(4',6'-dF-5- CF3-ppy)2(4,4'-dtbbpy)PF6 (380 g, 0.34 μπιοΙ, CAS No. [870987-63-6]), tris(trimethylsilyl)silane (5.2 μί, 17 μηιοΙ, CAS No. [1873-77-4]) and sodium carbonate (10.7 mg, 101 μηηοΙ) were dissolved in trifluorotoluene (300 μΙ_) in a MW-vial. In a separate vial, the Ni-catalyst was prepared by dissolving Nickel (II) chloride dimethoxyethane adduct (18 mg, 84 μπιοΙ, CAS No. [29046-78-4]) and 4,4'-Di-tert-butyl-2,2'-bipyridine (23 mg, 84 μπιοΙ, CAS No. [72914-19-3]) in dimethyl acetamide (10 mL) followed by stirring for 5 min. 0.1 mL of this catalyst solution was syringed to the sealed reaction vial and argon was bubbled through the solution for another 5 min. 2-bromopropane (7.1 μί, 76 μηηοΙ, CAS No. [75-26-3]) was added. The MW-vial was subsequently irradiated by two 40W Kessil LED Aquarium lights (40W each, 4 cm distance) placed in a water bath to keep the temperature below 35 °C for 12 hours, at which time water and ethyl acetate were added and the layers were separated. The aqueous phase was extracted twice with ethyl acetate and the combined organic layers were washed with brine, dried over sodium sulfate, and evaporated to give the crude material, which was used without further purification.
LC-MS (method 2): Rt = 1 .42 min; MS (ESIpos): m/z = 559 [M+H]+ Intermediate 300
N-(3,5-difluoro-4-{[1 -(4-methylbenzene-1 -sulfonyl)-3-(propan-2-yl)-1 H-pyrrolo[2,3-b]pyridin-4- yl]oxy}phenyl)-N'-[(3-methyloxetan-3- l)methyl]urea
Figure imgf000286_0001
In analogy to intermediate 2, phenyl (3,5-difluoro-4-{[1 -(4-methylbenzene-1 -sulfonyl)-3- (propan-2-yl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (250 mg, 66 % purity, 286 μηηοΙ, intermediate 290), and 1 -(3-methyloxetan-3-yl)methanamine (72.2 mg, 714 μηηοΙ, CAS No. [153209-97-3]), in DMF (2.0 mL) were reacted to obtain a crude product which was used in the next step without further purification.
LC-MS (method 2): Rt = 1 .40 min; MS (ESIpos): m/z = 585 [M+H]+
Intermediate 301
N-(3,5-difluoro-4-{[1 -(4-methylbenzene-1 -sulfonyl)-3-(propan-2-yl)-1 H-pyrrolo[2,3-b]pyridin-4- yl]oxy}phenyl)-N'-{[3-(propan-2-yl)oxetan-3-yl]methyl}urea
Figure imgf000286_0002
In analogy to intermediate 2, phenyl (3,5-difluoro-4-{[1 -(4-methylbenzene-1 -sulfonyl)-3- (propan-2-yl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (250 mg, 66 % purity, 286 μηηοΙ, intermediate 290), and 1 -[3-(propan-2-yl)oxetan-3-yl]methanamine (92.3 mg, 714 μη-ιοΙ, CAS No. [1539197-30-2]) in DMF (2.0 mL) were reacted to obtain a crude product which was used in the next step without further purification.
LC-MS (method 2): Rt = 1 .49 min; MS (ESIpos): m/z = 614 [M+H]+ Intermediate 302
N-(3,5-difluoro-4-{[1 -(4-methylbenzene-1 -sulfonyl)-3-(propan-2-yl)-1 H-pyrrolo[2,3-b]pyridin-4- yl]oxy}phenyl)morpholine-4-carboxamide
Figure imgf000287_0001
In analogy to intermediate 2, phenyl (3,5-difluoro-4-{[1 -(4-methylbenzene-1 -sulfonyl)-3- (propan-2-yl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (200 mg, 66 % purity, 229 μη-ιοΙ, intermediate 290), and morpholine (50 μΙ_, 570 μηιοΙ, CAS No. [1 10-91 -8]), in DMF (2.0 mL) were reacted to obtain a crude product which was used in the next step without further purification.
LC-MS (method 2): Rt = 1 .42 min; MS (ESIpos): m/z = 571 [M+H]+
Intermediate 303
N-(3,5-difluoro-4-{[1 -(4-methylbenzene-1 -sulfonyl)-3-(propan-2-yl)-1 H-pyrrolo[2,3-b]pyridin-4- yl]oxy}phenyl)-N'-[2-(mor holin-4-yl)-2-oxoethyl]urea
Figure imgf000287_0002
In analogy to intermediate 2, phenyl (3,5-difluoro-4-{[1 -(4-methylbenzene-1 -sulfonyl)-3- (propan-2-yl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamate (200 mg, 66 % purity, 229 μηηοΙ, intermediate 290), and 2-amino-1 -(morpholin-4-yl)ethan-1 -one (82.4 mg, 571 μηηοΙ, CAS No. [56414-96-1 ]) in DMF (2.0 mL) were reacted to obtain a crude product which was used in the next step without further purification.
LC-MS (method 2): Rt = 1 .36 min; MS (ESIpos): m/z = 629 [M+H]+ Intermediate 304
N-[3,5-difluoro-4-({1 -(4-methylbenzene-1 -sulfonyl)-3-(1 ,1 ,1 -trifluoropropan-2-yl)-1 H-pyrrolo[2,3- b]pyridin-4-yl}oxy)phenyl]-N'-(2-methoxyethyl)urea
Figure imgf000288_0001
N-(4-{[3-bromo-1 -(4-methylbenzene-1 -sulfonyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}-3,5- difluorophenyl)-N'-(2-methoxyethyl)urea (390 mg, 655 mol, intermediate 287), lr(4',6'-dF-5- CF3-ppy)2(4,4'-dtbbpy)PF6 (14.7 mg, 13.1 mol, CAS No. [870987-63-6]), tris(trimethylsilyl)silane (200 μΙ_, 650 mol, CAS No. [1873-77-4]) and sodium carbonate (278 mg, 2.62 mmol) were dissolved in 1 ,2-dimethoxyethane (14 mL) in a MW-vial. In a separate vial, the Ni-catalyst was prepared by dissolving Nickel (II) chloride dimethoxyethane adduct (7.20 mg, 32.7 mol, CAS No. [29046-78-4]) and 4,4'-Di-tert-butyl-2,2'-bipyridine (8.79 mg, 32.7 Mmol, CAS No. [72914-19-3]) in Ν,Ν-dimethyl acetamide (10 mL) followed by stirring for 5 min. The catalyst solution was syringed to the sealed reaction vial and argon was bubbled through the solution for another 5 min. 2-bromo-1 ,1 ,1 -trifluoropropane (490 μί, 2.6 mmol, CAS No. [421 -46-5]) was added. The MW-vial was subsequently irradiated by two 40W Kessil LED Aquarium lights (40W each, 4 cm distance) placed in a water bath to keep the temperature below 35 °C for 12 hours, at which time water and ethyl acetate were added and the layers were separated. The aqueous phase was extracted twice with ethyl acetate and the combined organic layers were washed with brine, dried over sodium sulfate, and evaporated to give the crude material, which was used without further purification.
LC-MS (method 2): Rt = 1 .39 min; MS (ESIpos): m/z = 613 [M+H]+ Intermediate 305
N-[4-({3-(butan-2-yl)-1 -(4-methylbenzene-1 -sulfonyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl}oxy)-3,5- difluorophenyl]-N'-(2-methoxyethyl)urea
Figure imgf000289_0001
N-(4-{[3-bromo-1 -(4-methylbenzene-1 -sulfonyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}-3,5- difluorophenyl)-N'-(2-methoxyethyl)urea (380 mg, 638 μπΊθΙ, intermediate 287), lr(4',6'-dF-5- CF3-ppy)2(4,4'-dtbbpy)PF6 (14.3 mg, 12.8 μπιοΙ, CAS No. [870987-63-6]), tris(trimethylsilyl)silane (200 μί, 640 μηιοΙ, CAS No. [1873-77-4]) and lithium carbonate (283 mg, 3.83 mmol) were dissolved in trifluorotoluene (1 1 mL) in a MW-vial. In a separate vial, the Ni-catalyst was prepared by dissolving Nickel (II) chloride dimethoxyethane adduct (700 μg, 3.2 μπιοΙ, CAS No. [29046-78-4]) and 4,4'-Di-tert-butyl-2,2'-bipyridine (860 μg, 3.2 μη-ιοΙ, CAS No. [72914-19-3]) in N,N-dimethylacetamide (3.8 mL) followed by stirring for 5 min. The catalyst catalyst solution was syringed to the sealed reaction vial and argon was bubbled through the solution for another 5 min. 2-bromobutane (310 μΙ_, 2.9 mmol, CAS No.
[78-76-2]) was added. The MW-vial was subsequently irradiated by two 40W Kessil LED Aquarium lights (40W each, 4 cm distance) placed in a water bath to keep the temperature below 35 °C for 12 hours, at which time water and ethyl acetate were added and the layers were separated. The aqueous phase was extracted twice with ethyl acetate and the combined organic layers were washed with brine, dried over sodium sulfate, and evaporated to give the crude material, which was used without further purification.
LC-MS (method 2): Rt = 1 .45 min; MS (ESIpos): m/z = 573 [M+H]+ Intermediate 306
N-[3,5-difluoro-4-({1 -(4-methylbenzene-1 -sulfonyl)-3-(3-methylbutan-2-yl)-1 H-pyrrolo[2,3- b]pyridin-4-yl}oxy)phenyl]-N'-(2-methoxyethyl)urea
Figure imgf000290_0001
N-(4-{[3-bromo-1 -(4-methylbenzene-1 -sulfonyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}-3,5- difluorophenyl)-N'-(2-methoxyethyl)urea (360 mg, 605 μηηοΙ, intermediate 287), lr(4',6'-dF-5- CF3-ppy)2(4,4'-dtbbpy)PF6 (13.6 mg, 12.1 μπιοΙ, CAS No. [870987-63-6]), tris(trimethylsilyl)silane (190 μΙ_, 600 μηιοΙ, CAS No. [1873-77-4]) and lithium carbonate (268 mg, 3.63 mmol) were dissolved in trifluorotoluene (1 1 mL) in a MW-vial. In a separate vial, the Ni-catalyst was prepared by dissolving Nickel (II) chloride dimethoxyethane adduct (6.64 mg, 30.2 μπιοΙ, CAS No. [29046-78-4]) and 4,4'-Di-tert-butyl-2,2'-bipyridine (8.1 1 mg, 30.2 μη-ιοΙ, CAS No. [72914-19-3]) in 1 ,3-Dimethyl-2-imidazolidinone (3.6 mL) followed by stirring for 5 min. The catalyst catalyst solution was syringed to the sealed reaction vial and argon was bubbled through the solution for another 5 min. 2-bromo-3-methylbutane (340 μί, 2.7 mmol CAS No. [18295-25-5]) was added. The MW-vial was subsequently irradiated by two 40W Kessil LED Aquarium lights (40W each, 4 cm distance) placed in a water bath to keep the temperature below 35 °C for 12 hours, at which time water and ethyl acetate were added and the layers were separated. The aqueous phase was extracted twice with ethyl acetate and the combined organic layers were washed with brine, dried over sodium sulfate, and evaporated to give the crude material, which was used without further purification.
LC-MS (method 2): Rt = 1 .48 min; MS (ESIpos): m/z = 587 [M+H]+ Intermediate 307
N-(3,5-difluoro-4-{[1 -(4-methylbenzene-1 -sulfonyl)-3-(pentan-3-yl)-1 H-pyrrolo[2,3-b]pyridin-4- yl]oxy}phenyl)-N'-(2-methoxyethyl)urea
Figure imgf000291_0001
N-(4-{[3-bromo-1 -(4-methylbenzene-1 -sulfonyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}-3,5- difluorophenyl)-N'-(2-methoxyethyl)urea (420 mg, 705 μηιοΙ, intermediate 287), lr(4',6'-dF-5- CF3-ppy)2(4,4'-dtbbpy)PF6 (15.8 mg, 14.1 μπιοΙ, CAS No. [870987-63-6]), tris(trimethylsilyl)silane (220 μΙ_, 710 μπιοΙ, CAS No. [1873-77-4]) and lithium carbonate (313 mg, 4.23 mmol) were dissolved in trifluorotoluene (13 mL) in a MW-vial. In a separate vial, the Ni-catalyst was prepared by dissolving Nickel (I I) chloride dimethoxyethane adduct (770 g, 3.5 mol, CAS No. [29046-78-4]) and 4,4'-Di-tert-butyl-2,2'-bipyridine (950 g, 3.5 Mmol, CAS No. [72914-19-3]) in N,N-dimethylacetamide (4.2 mL) followed by stirring for 5 min. The catalyst catalyst solution was syringed to the sealed reaction vial and argon was bubbled through the solution for another 5 min. 3-bromopentane (390 L, 3.2 mmol, CAS No.
[1809-10-5]) was added. The MW-vial was subsequently irradiated by two 40W Kessil LED Aquarium lights (40W each, 4 cm distance) placed in a water bath to keep the temperature below 35 °C for 12 hours, at which time water and ethyl acetate were added and the layers were separated. The aqueous phase was extracted twice with ethyl acetate and the combined organic layers were washed with brine, dried over sodium sulfate, and evaporated to give the crude material, which was used without further purification.
LC-MS (method 2): Rt = 1 .48 min; MS (ESIpos): m/z = 587 [M+H]+ Intermediate 308
N-(3,5-difluoro-4-{[1 -(4-methylbenzene-1 -sulfonyl)-3-(2-methylpropyl)-1 H-pyrrolo[2,3-b]pyridin- 4-yl]oxy}phenyl)-N'-(2-methoxyethyl)urea
Figure imgf000292_0001
N-(4-{[3-bromo-1 -(4-methylbenzene-1 -sulfonyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}-3,5- difluorophenyl)-N'-(2-methoxyethyl)urea (360 mg, 605 μηηοΙ, intermediate 287), lr(4',6'-dF-5- CF3-ppy)2(4,4'-dtbbpy)PF6 (13.6 mg, 12.1 mol, CAS No. [870987-63-6]), tris(trimethylsilyl)silane (190 μΙ_, 600 mol, CAS No. [1873-77-4]) and lithium carbonate (268 mg, 3.63 mmol) were dissolved in trifluorotoluene (1 1 mL) in a MW-vial. In a separate vial, the Ni-catalyst was prepared by dissolving Nickel (II) chloride dimethoxyethane adduct (6.64 mg, 30.2 mol, CAS No. [29046-78-4]) and 4,4'-Di-tert-butyl-2,2'-bipyridine (8.1 1 mg, 30.2 mol, CAS No. [72914-19-3]) in 1 ,3-Dimethyl-2-imidazolidinon (3.6 mL, 33 mmol) followed by stirring for 5 min. The catalyst catalyst solution was syringed to the sealed reaction vial and argon was bubbled through the solution for another 5 min. 1 -bromo-2-methylpropane (300 μΙ_, 2.7 mmol, CAS No. [78-77-3]) was added. The MW-vial was subsequently irradiated by two 40W Kessil LED Aquarium lights (40W each, 4 cm distance) placed in a water bath to keep the temperature below 35 °C for 12 hours, at which time water and ethyl acetate were added and the layers were separated. The aqueous phase was extracted twice with ethyl acetate and the combined organic layers were washed with brine, dried over sodium sulfate, and evaporated to give the crude material, which was used without further purification.
LC-MS (method 2): Rt = 1 .45 min; MS (ESIpos): m/z = 573 [M+H]+ Intermediate 309
N-[3,5-difluoro-4-({1 -(4-methylbenzene-1 -sulfonyl)-3-(4,4,4-trifluorobutan-2-yl)-1 H-pyrrolo[2,3- b]pyridin-4-yl}oxy)phenyl]-N'-(2-methoxyethyl)urea
Figure imgf000293_0001
N-(4-{[3-bromo-1 -(4-methylbenzene-1 -sulfonyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}-3,5- difluorophenyl)-N'-(2-methoxyethyl)urea (300 mg, 504 μηηοΙ, intermediate 287), lr(4',6'-dF-5- CF3-ppy)2(4,4'-dtbbpy)PF6 (1 1 .3 mg, 10.1 mol, CAS No. [870987-63-6]), tris(trimethylsilyl)silane (160 μΙ_, 500 mol, CAS No. [1873-77-4]) and lithium carbonate (223 mg, 3.02 mmol) were dissolved in trifluorotoluene (9.0 mL) in a MW-vial. In a separate vial, the Ni-catalyst was prepared by dissolving Nickel (II) chloride dimethoxyethane adduct (5.54 mg, 25.2 mol, CAS No. [29046-78-4]) and 4,4'-Di-tert-butyl-2,2'-bipyridine (6.76 mg, 25.2 mol, CAS No. [72914-19-3]) in N,N-dimethylacetamide (3.0 mL) followed by stirring for 5 min. The catalyst catalyst solution was syringed to the sealed reaction vial and argon was bubbled through the solution for another 5 min. 3-bromo-1 ,1 ,1 -trifluorobutane (310 μΙ_, 2.3 mmol, CAS No. [406-47-3]) was added. The MW-vial was subsequently irradiated by two 40W Kessil LED Aquarium lights (40W each, 4 cm distance) placed in a water bath to keep the temperature below 35 °C for 12 hours, at which time water and ethyl acetate were added and the layers were separated. The aqueous phase was extracted twice with ethyl acetate and the combined organic layers were washed with brine, dried over sodium sulfate, and evaporated to give the crude material, which was used without further purification.
LC-MS (method 2): Rt = 1 .42 min; MS (ESIpos): m/z = 628 [M+H]+ Intermediate 310
N-{4-[(3-bromo-1 -{[2-(trimethylsilyl)ethoxy]methy^
difluorophenyl}-2-methylazetidine-1 -carboxamide
Figure imgf000294_0001
In analogy to intermediate 206, phenyl {4-[(3-bromo-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}carbamate (150 mg, 229 μηιοΙ, intermediate 159), 2-methylazetidine— hydrogen chloride (1/1 ) (49.2 mg, 457 μπιοΙ, CAS No. [1 1521 13-37- 5]), and triethylamine (64 μΙ_, 460 μmol) in DMF (2 mL) were reacted to obtain a crude product which was used in the next step without further purification.
LC-MS (method 2): Rt = 1 .54 min; MS (ESIpos): m/z = 567 [M+H]+
Intermediate 311
N-{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}azetidine-1 -carboxamide
Figure imgf000294_0002
In analogy to intermediate 206, phenyl {4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}carbamate (500 mg, 85 % purity, 778 μηιοΙ, intermediate 44), azetidine-hydrochloride (76.5 mg, 817 μηηοΙ, CAS No. [503-29-7]) and triethylamine (120 μΙ_, 860 μηηοΙ) in DMF (6.6 ml.) were reacted to obtain a crude product which was purified by flash column chromatography to give the title compound (160 mg, 40% yield).
LC-MS (method 2): Rt = 1 .49 min; MS (ESIpos): m/z = 509 [M+H]+
1H NMR (400 MHz, DMSO-d6) δ ppm -0.09 (s, 9 H), 0.79 - 0.86 (m, 2 H), 2.16 - 2.26 (m, 2 H), 3.50 - 3.57 (m, 2 H), 3.99 (t, 4 H), 5.60 (s, 2 H), 6.43 (d, 1 H), 7.53 (d, 2 H), 7.84 (s, 1 H), 8.17 (d, 1 H), 8.86 (s, 1 H)
Intermediate 312
N-{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}-6-oxa-2-azaspiro[3.4]octane-2-carboxamide
Figure imgf000295_0001
In analogy to intermediate 2, phenyl {4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}carbamate (190 mg, 348 μηιοΙ, intermediate 44), and dimethylamine (0.17 mL, 348 μπιοΙ, 2M solution in THF, CAS - 124-40-3) in DMF (3 mL) were reacted to obtain a crude product which was used in the next step without further purification.
LC-MS (method 2): Rt = 1.49 min; MS (ESIpos): m/z = 498 [M+H]+
Intermediate 313
(+/-)-N-{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}-4,4-difluoro-3-(hydroxymethyl)piperidine-1 -carboxamide
Figure imgf000295_0002
In analogy to intermediate 2, phenyl {4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}carbamate (190 mg, 348 μηιοΙ, intermediate 44), and (+/-)-(4,4-difluoropiperidin-3-yl)methanol (105 mg, 696 μηιοΙ, CAS No. [1331823-62- 1 ]), in DMF (3 mL) were reacted to obtain a crude product which was used in the next step without further purification.
LC-MS (method 2): Rt = 1 .61 min; MS (ESIpos): m/z = 603 [M+H]+ Intermediate 314
N-{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}-N'-(1 -methox -2-meth lpropan-2-yl)urea
Figure imgf000296_0001
In analogy to intermediate 2, phenyl {4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}carbamate (150 mg, 275 μηιοΙ, intermediate 44) and 1 -methoxy-2-methylpropan-2-amine (56.7 mg, 549 μπιοΙ, CAS No. [20719-68-0]), in DMF (740 μΙ_) were reacted to obtain a crude product which was used in the next step without further purification.
LC-MS (method 2): Rt = 1 .59 min; MS (ESIpos): m/z = 555 [M+H]+
Intermediate 315
(+/-)-N-{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}-N'-1 -oxaspiro[4.4]nonan-6-ylurea - mixture of isomers
H
Figure imgf000296_0002
In analogy to intermediate 206, phenyl {4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}carbamate (150 mg, 275 μηιοΙ, intermediate 44), 1 -oxaspiro[4.4]nonan-6-amine— hydrogen chloride (1/1 ) (97.6 mg, 549 μηιοΙ, CAS No.
[951 164-20-8], mixture of isomers) and N,N-diisopropylethylamine (140 μΙ_, 820 μηηοΙ) in DMF (740 μΙ_) were reacted to obtain a crude product which was used in the next step without further purification.
LC-MS (method 2): Rt = 1 .62 min; MS (ESIpos): m/z = 594 [M+H]+
Intermediate 316
N-{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}-N'-[1 - morpholin-4- l)-1 -oxopropan-2-yl]urea
Figure imgf000297_0001
In analogy to intermediate 2, phenyl {4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}carbamate (200 mg, 366 μηιοΙ, intermediate 44), and 2-amino-1 -(morpholin-4-yl)propan-1 -one (69.5 mg, 440 μηιοΙ, CAS No. [124491 -97- 0]), in DMF (990 μΙ_) were reacted to obtain a crude product which was used without further purification.
LC-MS (method 2): Rt = 1 .47 min; MS (ESIpos): m/z = 61 1 [M+H]+
EXPERIMENTAL SECTION - EXAMPLES
The following examples describe the embodyment of the instant invention, not restricting the invention to these examples only.
Example 1
1 -(3,5-difluoro-4-{[3-(trifluoromet^
(morpholin-4-yl)propyl]urea
Figure imgf000298_0001
To a solution of 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[3-(morpholin-4-yl)propyl]urea (970 mg, 1.54 mmol, intermediate 2) in dichloromethane (21 mL) was added trifluoroacidic acid (10 ml_, 140 mmol) and this mixture was stirred for 3 hours at room temperature. The reaction mixture was carefully poured into an aqueous solution of sodium hydrogenecarbonate. This aqueous phase was extracted two times with ethyl actetate. Then the combined organic phases were washed with brine, dried over sodium sulfate and then after filtration evaporated to dryness in vacuum. The obtained crude product was purified via a Biotage chromatography system (25 g snap KP- NH column, hexane / 0 - 100% ethylacetate, then ethyl acetate / 0 - 100% methanol) to obtain 547 mg (97 % purity, 69 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 1 .60 (quin, 2H), 2.27 - 2.37 (m, 6H), 3.12 (q, 2H), 3.58 (t, 4H), 6.42 (t, 1 H), 6.46 (d, 1 H), 7.34 - 7.40 (m, 2H), 8.1 1 (s, 1 H), 8.21 (d, 1 H), 8.98 (s, 1 H), 12.63 (s, 1 H).
Example 2
1 -(3,5-difluoro-4-{[3-(trifluorometh^^
methoxyethyl)urea
Figure imgf000299_0001
In analogy to example 1 ), 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(2-methoxyethyl)urea (99.8 mg, 178 μηηοΙ, intermediate 3) was stirred with trifluoroacidic acid (1 .2 ml_, 16 mmol) in dichloromethane (2.4 ml_). The Biotage purified product was stirred in dichlormethane (5 ml_). Then the solid was isolated by filtration and dried in vacuum to yield 39 mg (97 % purity, 49 % yield) of the desired title compound.
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: 3.24 - 3.30 (m, 5H), 3.39 (t, 2H), 6.44 - 6.51 (m, 2H), 7.33 - 7.39 (m, 2H), 8.10 (s, 1 H), 8.20 (d, 1 H), 9.1 1 (s, 1 H), 12.63 (br s, 1 H).
Example 3
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[3- (methylsulfonyl)propyl]urea
Figure imgf000299_0002
In analogy to example 2), 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[3- (methylsulfonyl)propyl]urea (106 mg, 171 μηηοΙ, intermediate 4) was stirred with trifluoroacidic acid (1 .2 ml_, 15 mmol) in dichloromethane (2.3 mL) to obtain 32.6 mg (97 % purity, 38 % yield) of the desired title compound.
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: 1 .83 - 1.92 (m, 2H), 2.99 (s, 3H), 3.09 - 3.17 (m, 2H), 3.22 (q, 2H), 6.46 (d, 1 H), 6.54 (t, 1 H), 7.36 - 7.42 (m, 2H), 8.1 1 (s, 1 H), 8.21 (d, 1 H), 9.06 (s, 1 H), 12.62 (br s, 1 H). Example 4
1 -(2,2-difluoroethyl)-3-(3,5-difluoro^
yl]oxy}phenyl)urea
Figure imgf000300_0001
In analogy to example 2), 1 -(2,2-difluoroethyl)-3-(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)urea (88.5 mg, 156 μηηοΙ, intermediate 5) was stirred with trifluoroacidic acid (1 .1 mL, 14 mmol) in dichloromethane (2.1 mL) to obtain 37.6 mg (97 % purity, 54 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 3.54 (tdd, 2H), 6.07 (tt, 1 H), 6.47 (d, 1 H), 6.77 (t, 1 H), 7.36 - 7.42 (m, 2H), 8.10 - 8.13 (m, 1 H), 8.21 (d, 1 H), 9.23 (s, 1 H), 12.63 (br s, 1 H).
Example 5
N3-[(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4- yl]oxy}phenyl)carbamoyl]-beta-alaninamide
Figure imgf000300_0002
In analogy to example 2), N3-[(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamoyl]-beta- alaninamide (100 mg, 174 μηηοΙ, intermediate 6) was stirred with trifluoroacidic acid (1 .3 mL, 16 mmol) in dichloromethane (2.5 mL) to obtain 37.3 mg (93 % purity, 45 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 2.28 (t, 2H), 3.29 (q, 2H), 6.41 - 6.49 (m, 2H), 6.92 (br s, 1 H), 7.31 - 7.38 (m, 2H), 7.40 (br s, 1 H), 8.1 1 (s, 1 H), 8.21 (d, 1 H), 9.14 (s, 1 H), 12.62 (br s, 1 H). Example 6
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H^yrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-^
(py ri di n -4-y I methyl )u rea
Figure imgf000301_0001
In analogy to example 2), 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(pyridin-4- ylmethyl)urea (145 mg, 244 μηηοΙ, intermediate 7) was stirred with trifluoroacidic acid (1 .8 mL, 23 mmol) in dichloromethane (3.5 mL) to obtain 61.7 mg (95 % purity, 52 % yield) of the desired title compound.
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: 4.35 (d, 2H), 6.47 (d, 1 H), 7.04 (t, 1 H), 7.27 - 7.32 (m, 2H), 7.37 - 7.45 (m, 2H), 8.09 - 8.12 (m, 1 H), 8.21 (d, 1 H), 8.49 - 8.54 (m, 2H), 9.29 (s, 1 H), 12.63 (br s, 1 H).
Example 7
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[(1 - hy d roxy cy c I o p ro py I ) methy I ] u rea
Figure imgf000301_0002
In analogy to example 2), 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[(1 - hydroxycyclopropyl)methyl]urea (151 mg, 264 μηηοΙ, intermediate 8) was stirred with trifluoroacidic acid (1 .9 mL, 25 mmol) in dichloromethane (3.8 mL) to obtain 103 mg (95 % purity, 83 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 0.98 - 1 .05 (m, 4H), 2.08 (s, 1 H), 2.39 (qd, 2H), 6.29 - 6.33 (m, 1 H), 6.54 (d, 1 H), 7.47 - 7.53 (m, 2H), 8.15 (s, 1 H), 8.26 (d, 1 H), 10.16 (s, 1 H), 12.70 (br s, 1 H). Example 8
4-{[(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H^yrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)- carbamoyl]amino}butanamide
Figure imgf000302_0001
In analogy to example 2), 4-{[(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4- yl]oxy}phenyl)carbamoyl]amino}butanamide (1 10 mg, 187 μηηοΙ, intermediate 9) was stirred with trifluoroacidic acid (1 .3 mL, 17 mmol) in dichloromethane (2.7 mL) to obtain 45.6 mg (95 % purity, 51 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 1 .65 (quin, 2H), 2.08 (t, 3H), 3.09 (q, 2H), 6.41 - 6.50 (m, 2H), 6.77 (br s, 1 H), 7.30 (br s, 1 H), 7.35 - 7.41 (m, 2H), 8.1 1 (s, 1 H), 8.21 (d, 1 H), 9.00 (s, 1 H), 12.62 (br s, 1 H).
Example 9
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(3- methoxypropyl)urea
Figure imgf000302_0002
In analogy to example 2), 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(3- methoxypropyl)urea (88.0 mg, 153 μηηοΙ, intermediate 10) was stirred with trifluoroacidic acid (1 .1 mL, 14 mmol) in dichloromethane (2.2 mL) to obtain 38.6 mg (95 % purity, 54 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 1 .67 (quin, 2H), 3.15 (q, 2H), 3.24 (s, 3H), 3.36 (t, 2H), 6.42 (t, 1 H), 6.46 (d, 1 H), 7.34 - 7.41 (m, 2H), 8.09 - 8.12 (m, 1 H), 8.21 (d, 1 H), 9.01 (s, 1 H), 12.63 (br s, 1 H). Example 10
1 -(3,5-difluoro-4-{[3-(trifluoromet^
(morpholin-4-yl)-2-oxoethyl]urea
Figure imgf000303_0001
In analogy to example 2), 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[2-(morpholin-4-yl)-2- oxoethyl]urea (124 mg, 197 μηηοΙ, intermediate 1 1 ) was stirred with trifluoroacidic acid (1 .4 mL, 18 mmol) in dichloromethane (2.8 mL) to obtain 41.5 mg (97 % purity, 41 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 3.39 - 3.49 (m, 4H), 3.58 (dt, 4H), 4.01 (d, 2H), 6.47 (d, 1 H), 6.56 (t, 1 H), 7.33 - 7.39 (m, 2H), 8.10 - 8.12 (m, 1 H), 8.21 (d, 1 H), 9.46 (s, 1 H), 12.63 (br s, 1 H).
Example 11
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3- (py ri di n -3 -y I methyl )u rea
Figure imgf000303_0002
In analogy to example 2), 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(pyridin-3- ylmethyl)urea (99.8 mg, 168 μηηοΙ, intermediate 12) was stirred with trifluoroacidic acid (1 .2 mL, 16 mmol) in dichloromethane (2.4 mL) to obtain 86.7 mg (97 % purity, 108 % yield) of the desired title compound.
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: 4.34 (d, 2H), 6.47 (d, 1 H), 7.07 (t, 1 H), 7.35 - 7.43 (m, 3H), 7.72 (dt, 1 H), 8.1 1 (s, 1 H), 8.21 (d, 1 H), 8.46 (dd, 1 H), 8.53 (d, 1 H), 9.25 (s, 1 H), 12.62 (br s, 1 H). Example 12
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H^yrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3
(py ri di n -2 -y I methyl )u rea
Figure imgf000304_0001
In analogy to example 2), 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(pyridin-2- ylmethyl)urea (90.0 mg, 152 μηηοΙ, intermediate 13) was stirred with trifluoroacidic acid (1 .1 mL, 14 mmol) in dichloromethane (2.2 mL) to obtain 30.3 mg (93 % purity, 40 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 4.43 (d, 2H), 6.47 (d, 1 H), 7.05 (t, 1 H), 7.29 (ddd, 1 H), 7.33 - 7.44 (m, 3H), 7.79 (td, 1 H), 8.1 1 (s, 1 H), 8.21 (d, 1 H), 8.51 - 8.56 (m, 1 H), 9.38 (s, 1 H), 12.63 (br s, 1 H).
Example 13
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[2- (pyridin-4-yl)ethyl]urea
Figure imgf000304_0002
In analogy to example 2), 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[2-(pyridin-4- yl)ethyl]urea (123 mg, 202 μηηοΙ, intermediate 14) was stirred with trifluoroacidic acid (1 .4 mL, 18 mmol) in dichloromethane (2.7 mL) to obtain 42.3 mg (95 % purity, 42 % yield) of the desired title compound.
1H-NMR (500 MHz, DMSO-d6) δ [ppm]: 2.80 (t, 2H), 3.36 - 3.43 (m, 2H), 6.45 (d, 1 H), 6.50 (t, 1 H), 7.26 - 7.30 (m, 2H), 7.34 - 7.39 (m, 2H), 8.10 (s, 1 H), 8.20 (d, 1 H), 8.47 - 8.50 (m, 2H), 9.07 (s, 1 H), 12.63 (br s, 1 H). Example 14
(+/ -1 -(3,5-difluoro-4-{[3-(trifluorome
hydroxy -3 -(morpholin-4-yl)propyl]urea
Figure imgf000305_0001
In analogy to example 2), (+/-)-1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[2-hydroxy-3- (morpholin-4-yl)propyl]urea (75.5 mg, 1 17 μηηοΙ, intermediate 15) was stirred with
trifluoroacidic acid (790 μΙ_, 10 mmol) in dichloromethane (1 .6 mL) to obtain 22.6 mg (97 % purity, 36 % yield) of the desired title compound.
Ή-NMR (500 MHz, DMSO-d6) δ [ppm]: 2.28 (d, 2H), 2.37 - 2.44 (m, 4H), 2.94 - 2.99 (m, 1 H), 3.29 - 3.32 (m, 1 H), 3.57 (t, 4H), 3.66 - 3.74 (m, 1 H), 4.82 (d, 1 H), 6.37 (t, 1 H), 6.46 (d, 1 H), 7.32 - 7.38 (m, 2H), 8.1 1 (s, 1 H), 8.21 (d, 1 H), 9.13 (s, 1 H), 12.62 (br s, 1 H).
Example 15
-(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-
(tetra hy d rof u ra n -2 -y I methy I ) u rea
Figure imgf000305_0002
In analogy to example 2), (+/-)-1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(tetrahydrofuran-2- ylmethyl)urea (162 mg, 276 μηηοΙ), intermediate 16) was stirred with trifluoroacidic acid (1 .9 mL, 24 mmol) in dichloromethane (3.7 mL) to obtain 54.1 mg (97 % purity, 42 % yield) of the desired title compound.
Ή-NMR (500 MHz, DMSO-d6) δ [ppm]: 1 .48 - 1 .56 (m, 1 H), 1.77 - 1 .94 (m, 3H), 3.1 1 (ddd, 1 H), 3.24 (ddd, 1 H), 3.61 - 3.67 (m, 1 H), 3.78 (dt, 1 H), 3.87 (qd, 1 H), 6.43 - 6.48 (m, 2H), 7.33 - 7.38 (m, 2H), 8.10 (s, 1 H), 8.21 (d, 1 H), 9.07 (s, 1 H), 12.62 (br s, 1 H). Example 16
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H^yrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3- (tetrahydro-2H-pyran-4-ylmethyl)urea
Figure imgf000306_0001
In analogy to example 2), 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(tetrahydro-2H-pyran- 4-ylmethyl)urea (205 mg, 341 μmol), intermediate 17) was stirred with trifluoroacidic acid (2.3 ml_, 30 mmol) in dichloromethane (4.6 mL) to obtain 74.7 mg (95 % purity, 44 % yield) of the desired title compound.
Ή-NMR (500 MHz, DMSO-d6) δ [ppm]: 1 .18 (ddd, 2H), 1.56 (dd, 2H), 1.62 - 1 .71 (m, 1 H), 3.01 (t, 2H), 3.27 (dt, 2H), 3.85 (ddd, 2H), 6.46 (d, 1 H), 6.50 (t, 1 H), 7.35 - 7.40 (m, 2H), 8.1 1 (s, 1 H), 8.21 (d, 1 H), 8.96 (s, 1 H), 12.62 (br s, 1 H).
Example 17
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(1 H- 1 ,2,3-triazol-5-ylmethyl)urea
Figure imgf000306_0002
In analogy to example 2), 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(1 H-1 ,2,3-triazol-5- ylmethyl)urea (95.6 mg, 164 μηηοΙ), intermediate 18) was stirred with trifluoroacidic acid (1 .1 mL, 14 mmol) in dichloromethane (2.2 mL) to obtain 26.5 mg (97 % purity, 35 % yield) of the desired title compound.
1H-NMR (500 MHz, DMSO-d6) δ [ppm]: 4.37 (d, 2H), 6.46 (d, 1 H), 7.05 (t, 1 H), 7.38 - 7.44 (m, 2H), 7.61 (s, 1 H), 8.10 (s, 1 H), 8.20 (d, 1 H), 9.47 (br s, 1 H). Example 18
N2-[(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H^yrrolo[2,3-b]pyridin-4-yl]oxy}phenyl) carbamoyl]glycinamide
Figure imgf000307_0001
In analogy to example 2), N2-[(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamoyl]glycinamide (90.7 mg, 162 μmol), intermediate xx) was stirred with trifluoroacidic acid (1 .1 mL, 14 mmol) in dichloromethane (2.2 mL) to obtain 47 mg of the title compound which was further purified via preparative HPLC according to method 1 to obtain 20.1 mg (97 % purity, 28 % yield) of the desired title compound after drying.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 3.70 (d, 2H), 6.47 (d, 1 H), 6.53 (t, 1 H), 7.10 (s, 1 H), 7.33 - 7.40 (m, 2H), 7.46 (s, 1 H), 8.1 1 (s, 1 H), 8.21 (d, 1 H), 9.34 (s, 1 H), 12.34 (br s, 1 H).
Example 19
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[2- (morpholin-4-yl)ethyl]urea
Figure imgf000307_0002
To a solution of 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[2-(morpholin-4-yl)ethyl]urea (55.0 mg, 89.3 μηιοΙ, intermediate 20) in dichloromethane (4 mL) was added trifluoroacidic acid (200 μί, 2.6 mmol) and this mixture was stirred over night at room temperature. Then the reaction mixture was evaporated to dryness. After dilution of the residue with 4 mL of tetrahydrofuran, lithium hydroxide (6.42 mg, 268 μηηοΙ) in 1 mL of water was added. The reaction mixture was stirred at room temperature for 1 hour. Then the reaction mixture was evaporated to dryness and the residue was purified by preparative HPLC to obtain 1 1 mg (98 % purity, 25 % yield) of the desired title compound.
Ή-NMR (300 MHz, DMSO-d6) δ [ppm]: 2.35 - 2.46 (m, 6H), 3.19 - 3.29 (m, 2H), 3.57 - 3.66 (m, 4H), 6.32 (br t, 1 H), 6.48 (d, 1 H), 7.32 - 7.44 (m, 2H), 8.12 (s, 1 H), 8.22 (d, 1 H), 9.18 (s, 1 H), 12.63 (br s, 1 H).
Example 20
1 -(3,5-difluoro-4-{[3-(trifluoromethy^^
(piperidin-1 -yl)ethyl]urea
Figure imgf000308_0001
To a solution of 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[2-(piperidin-1 -yl)ethyl]urea (45.0 mg, 73.3 μηιοΙ, intermediate 21 ) in 1 ,4-dioxane (4 ml_) was added 12M hydrochloric acid (100 μΙ_, 12 M, 1 .2 mmol) and this mixture was stirred over night at 100°C. Then the reaction mixture was evaporated to dryness. After dilution of the residue with water, to this mixture was added an aqueous solution of sodium bicarbonate up to pH 8-9. The mixture was extracted with ethyl acetate. and the organic phase was dried over sodium sulfate, filtered and evaporated to dryness. The residue was purified via column chromatography with methanol /
dichloromethane (3:7 / v:v) to obtain 13.7 mg (95 % purity, 37 % yield) of the desired title compound.
Ή-NMR (300 MHz, DMSO-d6) δ [ppm]: 1.37 - 1.46 (m, 2H), 1.48 - 1.59 (m, 4H), 2.38 (br t, 6H), 3.22 (q, 3H), 6.29 (br t, 1 H), 6.48 (d, 1 H), 7.32 - 7.45 (m, 2H), 8.1 1 (s, 1 H), 8.22 (d, 1 H), 9.20 (s, 1 H), 12.63 (br s, 1 H).
Example 21
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H^yrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-^ (piperidin-1 -yl)propyl]urea
Figure imgf000309_0001
In analogy to example 20), 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[3-(piperidin-1 - yl)propyl]urea (43.0 mg, 68.5 μηηοΙ intermediate 22) was stirred with 12M hydrochloric acid (100 μΙ_) in 1 ,4-dioxane (4.0 mL) to obtain 12.7 mg (93 % purity, 35 % yield) of the desired title compound.
Ή-NMR (300 MHz, DMSO-d6) δ [ppm]: 1.34 - 1.44 (m, 2H), 1.45 - 1.67 (m, 6H), 2.23 - 2.36 (m, 6H), 3.12 (q, 2H), 6.46 (d, 1 H), 6.51 (br t, 1 H), 7.33 - 7.44 (m, 2H), 8.10 (s, 1 H), 8.21 (d, 1 H), 9.10 (s, 1 H), 12.60 (br s, 1 H).
Example 22
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[3- (dimethylamino)propyl]urea
C H 3
Figure imgf000309_0002
In analogy to example 20), 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[3- (dimethylamino)propyl]urea (65.0 mg, 1 1 1 μηηοΙ intermediate 23) was stirred with 12M hydrochloric acid (100 μί) in 1 ,4-dioxane (4.0 mL) to obtain 25.9 mg (97 % purity, 50 % yield) of the desired title compound.
Ή-NMR (300 MHz, DMSO-d6) δ [ppm]: 1.60 - 1.75 (m, 2H), 2.41 (s, 6H), 2.55 - 2.72 (m, 2H), 3.05 - 3.17 (m, 2H), 6.42 (br d, 1 H), 6.67 (br s, 1 H), 7.27 - 7.42 (m, 2H), 8.06 (s, 1 H), 8.17 (d, 1 H), 9.48 (br s, 1 H), 12.60 (br s, 1 H). Example 23
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H^yrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-^
(dimethylamino)ethyl]urea
Figure imgf000310_0001
In analogy to example 20), 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[2- (dimethylamino)ethyl]urea (54.0 mg, 94.1 μηηοΙ intermediate 24) was stirred with 12M hydrochloric acid (100 μΙ_) in 1 ,4-dioxane (4.0 mL) to obtain 19.3 mg (96 % purity, 44 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 2.69 - 2.90 (m, 2H), 3.36 - 3.39 (m, 2H), 6.47 (d, 1 H), 6.63 (br s, 1 H), 7.36 - 7.45 (m, 2H), 8.12 (br s, 1 H), 8.22 (d, 1 H), 9.57 (br s, 1 H), 9.99 (br s, 1 H), 12.65 (br s, 1 H).
Example 24
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H^yrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[(1 ,1 dioxidothietan-3-yl)meth l]urea
Figure imgf000310_0002
In analogy to example 2), 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[(1 ,1 -dioxidothietan-3- yl)methyl]urea (83.9 mg, 135 μηηοΙ, intermediate 25) was stirred with trifluoroacidic acid (920 μΙ_, 12 mmol) in dichloromethane (1.8 mL) to obtain 25.8 mg (97 % purity, 38 % yield) of the desired title compound.
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: 2.64 - 2.75 (m, 1 H), 3.36 (t, 2H), 3.89 - 3.97 (m, 2H), 4.19 - 4.27 (m, 2H), 6.47 (d, 1 H), 6.73 - 6.79 (m, 1 H), 7.36 - 7.43 (m, 2H), 8.1 1 (s, 1 H), 8.21 (d, 1 H), 9.19 (s, 1 H), 12.63 (br s, 1 H). Example 25
N-(2-{[(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4- yl]oxy}phenyl)carbamoyl]amino}ethyl)acetamide
Figure imgf000311_0001
In analogy to example 2),N-(2-{[(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4- yl]oxy}phenyl)carbamoyl]amino}ethyl)acetamide (69.0 mg, 1 17 μmol, intermediate 26) was stirred with tnfluoroacidic acid (800 μΙ_, 10 mmol) in dichloromethane (1.6 mL) to obtain 32.8 mg (95 % purity, 58 % yield) of the desired title compound.
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: 1 .82 (s, 3H), 3.10 - 3.19 (m, 4H), 6.41 - 6.49 (m, 2H), 7.35 - 7.42 (m, 2H), 7.96 (br s, 1 H), 8.10 (s, 1 H), 8.20 (d, 1 H), 9.12 (s, 1 H), 12.63 (br s, 1 H).
Example 26
(+/-)-1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[1 - (morpholin-4-yl)propan-2- l]urea
Figure imgf000311_0002
In analogy to example 2), (+/-)-1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[1 -(morpholin-4- yl)propan-2-yl]urea (82.0 mg, 130 μηηοΙ, intermediate 27) was stirred with tnfluoroacidic acid (880 μί, 1 1 mmol) in dichloromethane (1 .8 mL) to obtain 23.1 mg (97 % purity, 34 % yield) of the desired title compound.
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: 1 .1 1 (d, 3H), 2.21 (dd, 1 H), 2.31 - 2.45 (m, 5H), 3.57 (t, 4H), 3.78 - 3.89 (m, 1 H), 6.23 (d, 1 H), 6.46 (d, 1 H), 7.33 - 7.40 (m, 2H), 8.1 1 (s, 1 H), 8.21 (d, 1 H), 8.99 (s, 1 H), 12.63 (s, 1 H). Example 27
(+/ -1 -(3,5-difluoro-4-{[3-(trifluorom^
(morpholin-4-yl)propyl]urea
Figure imgf000312_0001
In analogy to example 2),(+/-)-1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[2-(morpholin-4- yl)propyl]urea (84.8 mg, 135 μηηοΙ, intermediate 28) was stirred with trifluoroacidic acid (910 μΙ_, 12 mmol) in dichloromethane (1.8 mL) to obtain 37.9 mg (97 % purity, 55 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 0.93 (d, 3H), 2.36 - 2.43 (m, 2H), 2.52 - 2.65 (m, 3H), 3.04 - 3.20 (m, 2H), 3.54 - 3.65 (m, 4H), 6.28 (t, 1 H), 6.46 (d, 1 H), 7.31 - 7.41 (m, 2H), 8.1 1 (s, 1 H), 8.21 (d, 1 H), 9.21 (s, 1 H), 12.63 (br s, 1 H).
Example 28
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[2- (methylsulfonyl)ethyl]urea
Figure imgf000312_0002
In analogy to example 2), 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)- ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[2-(methylsulfonyl)ethyl]urea (72.0 mg, 1 18 μηηοΙ, intermediate 29) was stirred with trifluoroacidic acid (800 μΙ_, 10 mmol) in dichloromethane (1 .6 mL) to obtain 29.7 mg (95 % purity, 50 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 3.04 (s, 3H), 3.32 (t, 2H), 3.51 - 3.60 (m, 2H), 6.46 (d, 1 H), 6.59 (t, 1 H), 7.35 - 7.42 (m, 2H), 8.1 1 (s, 1 H), 8.21 (d, 1 H), 9.31 (s, 1 H), 12.63 (br s, 1 H). Example 29
3-{[(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H^yrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)- carbamoyl]amino}propane-1 -sulfonamide
Figure imgf000313_0001
In analogy to example 2), 3-{[(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)- ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamoyl]amino}propane-1 - sulfonamide (66.1 mg, 106 μηηοΙ, intermediate 30) was stirred with trifluoroacidic acid (720 μΙ_, 9.3 mmol) in dichloromethane (1.4 mL) to obtain 8.00 mg (90 % purity, 14 % yield) of the desired title compound.
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: 1 .81 - 1.92 (m, 2H), 2.95 - 3.03 (m, 2H), 3.21 (q, 2H), 6.41 - 6.47 (m, 1 H), 6.62 (br t, 1 H), 6.82 (br s, 2H), 7.34 - 7.44 (m, 2H), 8.09 (s, 1 H), 8.16 - 8.23 (m, 1 H), 9.13 (br s, 1 H), 12.59 (br s, 1 H).
Example 30
3-(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-1 -methyl- 1 -[2-(morpholin-4-yl)ethyl]urea
Figure imgf000313_0002
In analogy to example 2), 3-(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-1 -methyl-1 -[2- (morpholin-4-yl)ethyl]urea (68.3 mg, 108 μηηοΙ, intermediate 31 ) was stirred with trifluoroacidic acid (730 μΙ_, 9.5 mmol) in dichloromethane (1 .5 mL) to obtain 10.0 mg (85 % purity, 16 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 2.40 - 2.47 (m, 6H), 2.98 (s, 3H), 3.45 (t, 2H), 3.55 (t, 4H), 6.46 (d, 1 H), 7.48 - 7.56 (m, 2H), 8.09 - 8.13 (m, 1 H), 8.22 (d, 1 H), 8.83 (s, 1 H), 12.56 (br s, 1 H). Example 31
N-(2-{[(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H^yrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)- carbamoyl]amino}ethyl)methanesulfonamide
Figure imgf000314_0001
In analogy to example 2), N-(2-{[(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4- yl]oxy}phenyl)carbamoyl]amino}ethyl)methanesulfonamide (104 mg, 167 μηηοΙ, intermediate 32) was stirred with trifluoroacidic acid (1 .1 ml_, 15 mmol) in dichloromethane (2.3 mL) to obtain 41 .6 mg (97 % purity, 49 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 2.92 (s, 3H), 3.04 (q, 2H), 3.22 (q, 1 H), 6.44 - 6.52 (m, 2H), 7.12 (t, 1 H), 7.35 - 7.41 (m, 2H), 8.1 1 (s, 1 H), 8.21 (d, 1 H), 9.18 (s, 1 H), 12.63 (br s, 1 H).
Example 32
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H^yrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3^yridin- 3-ylurea
Figure imgf000314_0002
In analogy to example 2), 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-pyridin-3-ylurea (68.2 mg, 1 18 μηηοΙ, intermediate 33) was stirred with trifluoroacidic acid (800 μΙ_, 10 mmol) in dichloromethane (1 .6 mL) to obtain 35.8 mg (97 % purity, 66 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 6.50 (d, 1 H), 7.34 (dd, 1 H), 7.44 - 7.50 (m, 2H), 7.95 (ddd, 1 H), 8.12 (s, 1 H), 8.21 - 8.25 (m, 2H), 8.63 (d, 1 H), 9.16 (br s, 1 H), 9.38 (br s, 1 H), 12.64 (br s, 1 H). Example 33
1 -(3,5-difluoro-4-{[3-(trifluoromet^
(trifluoromethyl)phenyl]urea
Figure imgf000315_0001
In analogy to example 2), 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[3- (trifluoromethyl)phenyl]urea (40.0 mg, 61 .9 μηηοΙ, intermediate 34) was stirred with trifluoroacidic acid (420 μΙ_, 5.4 mmol) in dichloromethane (1 .5 mL) to obtain 20.1 mg (97 % purity, 61 % yield) of the desired title compound.
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: 6.49 - 6.52 (m, 1 H), 7.36 (d, 1 H), 7.45 - 7.57 (m, 3H), 7.60 - 7.64 (m, 1 H), 8.01 (s, 1 H), 8.12 (s, 1 H), 8.23 (d, 1 H), 9.33 (br d, 2H), 12.64 (br s, 1 H).
Example 34
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(1 ,3,4- thiadiazol-2-yl)urea
Figure imgf000315_0002
In analogy to example 2), 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(1 ,3,4-thiadiazol-2- yl)urea (127 mg, 217 μηηοΙ), intermediate 35) was stirred with trifluoroacidic acid (1 .5 mL, 19 mmol) in dichloromethane (2.9 mL) to obtain 10.8 mg (90 % purity, 10 % yield) of the desired title compound after a final HPLC purification step.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 6.50 (d, 1 H), 7.53 - 7.63 (m, 3H), 8.12 (br s, 1 H), 8.22 (d, 1 H), 9.04 (br s, 1 H), 9.81 (br s, 1 H), 12.65 (br s, 1 H). Example 35
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H^yrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-^ fluoro-5-(trifluoromethyl) henyl]urea
Figure imgf000316_0001
In analogy to example 2), 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[2-fluoro-5- (trifluoromethyl)phenyl]urea (240 mg, 361 μηηοΙ), intermediate 36) was stirred with
trifluoroacidic acid (2.4 mL, 32 mmol) in dichloromethane (4.9 mL) to obtain 80.4 mg (97 % purity, 40 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 6.50 (d, 1 H), 7.42 - 7.57 (m, 4H), 8.13 (s, 1 H), 8.23 (d, 1 H), 8.56 (dd, 1 H), 9.1 1 (br s, 1 H), 9.63 (br s, 1 H), 12.65 (br s, 1 H).
Example 36
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H^yrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3- pyridazin-3-ylurea
Figure imgf000316_0002
In analogy to example 2), 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-pyridazin-3-ylurea (222 mg, 382 μηηοΙ, intermediate 37) was stirred with trifluoroacidic acid (3.0 mL, 39 mmol) in dichloromethane (6.0 mL) to obtain 43.9 mg (92 % purity, 23 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 6.50 (d, 1 H), 7.49 - 7.57 (m, 2H), 7.67 (dd, 1 H), 8.06 (dd, 1 H), 8.12 (d, 1 H), 8.22 (d, 1 H), 8.91 (dd, 1 H), 10.20 (br s, 1 H). Example 37
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H^yrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-^ methoxyphenyl)urea
Figure imgf000317_0001
In analogy to example 2), 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(2- methoxyphenyl)urea (170 mg, 279 μηηοΙ, intermediate 38) was stirred with trifluoroacidic acid (1 .9 mL, 25 mmol) in dichloromethane (3.8 mL) to obtain 17.6 mg (90 % purity, 12 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 3.89 (s, 3H), 6.50 (d, 1 H), 6.91 (ddd, 1 H), 6.99 (td, 1 H), 7.05 (dd, 1 H), 7.41 (d, 2H), 8.07 - 8.14 (m, 2H), 8.22 (d, 1 H), 8.37 (s, 1 H), 9.79 (s, 1 H), 12.64 (br s, 1 H).
Example 38
1 -(2,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[3- (morpholin-4-yl)propyl]urea
Figure imgf000317_0002
In analogy to example 1 ), 1 -(2,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[3-(morpholin-4- yl)propyl]urea (90.0 mg, 143 μηηοΙ, intermediate 42) was stirred with trifluoroacidic acid (2.2 mL, 28.6 mmol) in dichloromethane (4.4 mL) to obtain 72 mg (90 % purity, 91 % yield) of the desired title compound.
Ή-NMR (400MHz, DMSO-d6) δ [ppm]: 1 .60 (quin, 2H), 2.27 - 2.38 (m, 6H), 3.10 - 3.18 (m, 2H), 3.58 (t, 4H), 6.46 (d, 1 H), 6.72 (t, 1 H), 7.48 (dd, 1 H), 8.09 (s, 1 H), 8.20 (d, 1 H), 8.24 (dd, 1 H), 8.58 (s, 1 H), 12.59 (br s, 1 H). Example 39
1 -(2,5-difluoro-4-{[3-(trifluoromethyl)-1 H^yrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3
(morpholin-4-yl)ethyl]urea
Figure imgf000318_0001
In analogy to example 1 ), 1 -(2,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[2-(morpholin-4- yl)ethyl]urea (72.5 mg, 1 18 μηηοΙ, intermediate 43) was stirred with trifluoroacidic acid (1.6 mL, 21 mmol) in dichloromethane (3.2 mL) to obtain 47.6 mg (92 % purity, 77 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 2.35 - 2.44 (m, 6H), 3.24 (q, 2H), 3.60 (t, 4H), 6.46 (d, 1 H), 6.75 (t, 1 H), 7.48 (dd, 1 H), 8.09 (s, 1 H), 8.20 (d, 1 H), 8.26 (dd, 1 H), 8.78 (s, 1 H), 12.59 (br s, 1 H).
Example 40
1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[3-(piperidin-1 - yl)propyl]urea
Figure imgf000318_0002
To a solution of 1 -{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4- yl)oxy]-3,5-difluorophenyl}-3-[3-(piperidin-1 -yl)propyl]urea (1 15 mg, 0.194 mmol, intermediate 45) in dichloromethane (2.3 mL) was added trifluoroacidic acid (1 .1 mL, 15 mmol) and this mixture was stirred for 14 hours at room temperature. The reaction mixture was carefully poured into an aqueous solution of sodium bicarbonate. This aqueous phase was extracted two times with ethyl actetate. Then the combined organic phases were washed with brine, dried over sodium sulfate and then after filtration evaporated to dryness in vacuum. The obtained crude product was purified by HPLC (method 1 ) to obtain 51 mg (54 %) of the desired title compound.
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: 1 .32-1.42 (m, 2H); 1 .44-1 .53 (m, 4H); 1 .53-1.63 (m, 2H); 2.22-2.35 (m, 6H); 3.10 (q, 2H); 6.31 (d, 1 H); 6.43 (t, 1 H); 7.35-7.41 (m, 2H); 7.61 (s, 1 H); 8.09 (d, 1 H); 9.00 (s, 1 H); 12.12 (s, 1 H).
Example 41
1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[2- (dimethylamino)-ethyl]urea
Figure imgf000319_0001
According to the synthesis of example 40, 1 15 mg (0.213 mmol) 1 -{4-[(3-chloro-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[2- (dimethylamino)ethyl]urea (intermediate 46) in 2.5 mL dichloromethane and 1 .2 ml_ trifluoreacetic acid were stirred for 14 hours. After workup, the resulting residue was purified via a Biotage chromatography system (KP-Sil snap column; dichloromethane / methanol gradient with up to 3% methanol) to yield to 39 mg (42%) of the title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 2.17 (s, 6H); 2.33 (t, 2H); 3.19 (q, 2H); 6.28-6.33 (m, 2H); 7.32-7.38 (m, 2H); 7.61 (s, 1 H); 8.09 (d, 1 H); 9.19 (bs, 1 H); 12.12 (bs, 1 H).
Example 42
1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[2-(piperidin-1 - yl)ethyl]urea
Figure imgf000320_0001
According to the synthesis of example 40, 48mg (0.083 mmol) 1 -{4-[(3-chloro-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[2- (piperidin-1 -yl)ethyl]urea (intermediate 47) in 0.96 mL dichloromethane and 0.48 mL trifluoreacetic acid were stirred for 14 hours. After workup, the resulting residue was purified by HPLC (method 1 ) to yield to 20 mg (51 %) of the title compound.
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: 1 .34-1.44 (m, 2H); 1.47-1 .55 (m, 4H); 2.29-2.40 (m, 6H); 3.20 (q, 2H); 6.29 (t, 1 H); 6.31 (d, 1 H); 7.33-7.40 (m, 2H); 7.61 (s, 1 H); 8.09 (d, 1 H); 9.20 (s, 1 H); 12.12 (s, 1 H).
Example 43
1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[3-(morpholin-4- yl)propyl]urea
Figure imgf000320_0002
According to the synthesis of example 40, 100mg (0.168 mmol) 1 -{4-[(3-chloro-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[3- (morpholin-4-yl)propyl]urea (intermediate 48) in 2.0 mL dichloromethane and 0.98 mL tnfluoreacetic acid were stirred for 4 hours. After workup, the resulting residue was purified by HPLC (method 1 ) to yield to 38 mg (46%) of the title compound.
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: 1 .56-1.64 (m, 2H); 2.29-2.40 (m, 6H); 3.12 (q, 1 H); 3.57 (t, 3H); 6.31 (d, 1 H); 6.43 (t, 1 H); 7.34-7.41 (m, 2H); 7.61 (s, 1 H); 8.09 (d, 1 H); 8.99 (s, 1 H); 12.12 (s, 1 H).
Example 44
1 -{4-[(3-chloro-1 H^yrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(2-methoxy- ethyl)urea
H 3
Figure imgf000321_0001
According to the synthesis of example 40, 130mg (0.234 mmol) 1 -{4-[(3-chloro-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(2- methoxyethyl)urea (intermediate 49) in 2.9 mL dichloromethane and 1 .3 mL tnfluoreacetic acid were stirred for 6 hours. After workup, the resulting residue was purified by HPLC (method 1 ) to yield to 52 mg (53%) of the title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 3.22-3.30 (m, 5H); 3.39 (t, 2H); 6.32 (d, 1 H); 6.46 (t, 1 H); 7.34-7.39 (m, 2H); 7.61 (s, 1 H); 8.09 (d, 1 H); 9.07 (s, 1 H); 12.12 (s, 1 H).
Example 45
1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b ridin-4-yl)oxy]-3,5-difluorophenyl}-3-ethylurea
Figure imgf000322_0001
According to the synthesis of example 40, 130mg (0.262 mmol) 1 -{4-[(3-chloro-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-ethylurea (intermediate 50) in 3.0 mL dichloromethane and 1.5 mL tnfluoreacetic acid were stirred for 14 hours. After workup, the resulting residue was purified by HPLC (method 1 ) to yield to 44 mg (44 %) of the title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 1 .06 (t, 3H); 3.08-3.16 (m, 2H); 6.31 (d, 1 H); 6.39 (t, 1 H); 7.35-7.41 (m, 2H); 7.61 (s, 1 H); 8.09 (d, 1 H); 8.98 (s, 1 H); 12.12 (s, 1 H)
Example 46
1 -{4-[(3-chloro-1 H^yrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[2-(morpholin-4- yl)ethyl]urea
Figure imgf000322_0002
According to the synthesis of example 40, 42mg (0.071 mmol) 1 -{4-[(3-chloro-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[2- (morpholin-4-yl)ethyl]urea (intermediate 51 ) in 0.84 mL dichloromethane and 0.42 mL tnfluoreacetic acid were stirred for 4 hours. After workup, the resulting residue was purified by HPLC (method 1 ) to yield to 13 mg (38 %) of the title compound.
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: 2.35-2.44 (m, 6H); 3.22 (q, 2H); 3.57-3.61 (m, 4H); 6.31 (d, 1 H); 6.35-6.42 (m, 1 H); 7.34-7.41 (m, 2H); 7.61 (s, 1 H); 8.09 (d, 1 H); 9.24 (s, 1 H); 12.12 (s, 1 H). Example 47
1 -benzyl -3 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}urea
Figure imgf000323_0001
According to the synthesis of example 40, 145 mg (0.246 mmol) 1 -benzyl-3-{4-[(3-chloro-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}urea
(intermediate 52) in 3.0 mL dichloromethane and 1 .4 mL trifluoreacetic acid were stirred for 5 hours. After workup, the resulting residue was purified by HPLC (method 1 ) to yield to 40 mg (36 %) of the title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 4.31 (d, 2H); 6.32 (d, 1 H); 6.96 (t, 1 H); 7.22-7.28 (m, 1 H); 7.29-7.37 (m, 4H); 7.37-7.44 (m, 2H); 7.61 (s, 1 H); 8.09 (d, 1 H); 9.17 (s, 1 H); 12.12 (s, 1 H).
Example 48
1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(pyri
ylmethyl)urea
Figure imgf000323_0002
According to the synthesis of example 40, 1 15 mg (0.195 mmol) 1 -{4-[(3-chloro-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3- (pyrimidin-5-ylmethyl)urea (intermediate 53) in 2.4 mL dichloromethane and 1 .1 mL trifluoreacetic acid were stirred for 6 hours. After workup, the resulting residue was purified by HPLC (method 1 ) to yield to 24 mg (27 %) of the title compound.
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: 4.35 (d, 2H); 6.31 (d, 1 H); 7.07 (t, 1 H); 7.37-7.42 (m, 2H); 7.61 (s, 1 H); 8.09 (d, 1 H); 8.78 (s, 2H); 9.09 (s, 1 H); 9.28 (s, 1 H); 12.12 (s, 1 H).
Example 49
1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(pyridin-4-ylmethyl)urea
Figure imgf000324_0001
According to the synthesis of example 40, 80 mg (0.136 mmol) 1 -{4-[(3-chloro-1 -{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(pyridin-4- ylmethyl)urea (intermediate 54) in 1 .7 mL dichloromethane and 0.77 mL trifluoreacetic acid were stirred for 14 hours. After workup, the resulting residue was purified by HPLC (method 1 ) to yield to 30 mg (49 %) of the title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 4.34 (d, 2H); 6.31 (d, 1 H); 7.17 (t, 1 H); 7.29 (d, 2H); 7.38-7.45 (m, 2H); 7.60 (s, 1 H); 8.09 (d, 1 H); 8.49-8.54 (m, 2H); 9.42 (bs, 1 H); 12.12 (bs, 1 H).
Example 50
1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(2-cyanoethyl)urea
Figure imgf000324_0002
According to the synthesis of example 40, 100 mg (0.182 mmol) 1 -{4-[(3-chloro-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(2- cyanoethyl)urea (intermediate 55) in 2.2 mL dichloromethane and 1 .0 mL trifluoreacetic acid were stirred for 4 hours. After workup, the resulting residue was purified by HPLC (method 1 ) to yield to 25 mg (33 %) of the title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 2.70 (t, 2H); 3.33-3.39 (m, 2H); 6.32 (d, 1 H); 6.79 (t, 1 H); 7.38-7.43 (m, 2H); 7.61 (s, 1 H); 8.09 (d, 1 H); 9.27 (s, 1 H); 12.12 (s, 1 H).
Example 51
1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]p ridin-4-yl)oxy]-3,5-difluorophenyl}-3-(3-methylbutyl)urea
Figure imgf000325_0001
According to the synthesis of example 40, 130 mg (0.229 mmol) 1 -{4-[(3-chloro-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(3- methylbutyl)urea (intermediate 56) in 2.8 mL dichloromethane and 1 .3 mL trifluoreacetic acid were stirred for 6 hours. After workup, the resulting residue was purified by HPLC (method 1 ) to yield to 58 mg (59 %) of the title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 0.89 (d, 6H); 1 .30-1 .37 (m, 2H); 1 .55-1 .65 (m, 1 H); 3.08-3.15 (m, 2H); 6.31 (d, 1 H); 6.38 (t, 1 H); 7.35-7.40 (m, 2H); 7.61 (s, 1 H); 8.09 (d, 1 H); 8.95 (s, 1 H); 12.12 (s, 1 H).
Example 52
1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b] ridin-4-yl)oxy]-3,5-difluorophenyl}-3-(1 ,2-oxazol-3-yl)urea
Figure imgf000326_0001
According to the synthesis of example 40, 50 mg (0.089 mmol) 1 -{4-[(3-chloro-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(1 ,2- oxazol-3-yl)urea (intermediate 57) in 1 .1 mL dichloromethane and 0.5 mL trifluoreacetic acid were stirred for 6 hours. After workup, the resulting residue was purified by HPLC (method 1 ) to yield to 1 1 mg (29 %) of the title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 6.35 (d, 1 H); 6.86 (d, 1 H); 7.46-7.51 (m, 2H); 7.62 (s, 1 H); 8.1 1 (d, 1 H); 8.78 (d, 1 H); 9.32 (bs, 1 H); 9.93 (bs, 1 H); 12.14 (bs, 1 H).
Example 53
1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-pyridazin-3-ylurea
Figure imgf000326_0002
According to the synthesis of example 40, 450 mg (0.78 mmol) 1 -{4-[(3-chloro-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-pyridazin- 3-ylurea (intermediate 58) in 10 mL dichloromethane and 4.4 mL trifluoreacetic acid were stirred for 3 hours. During extractive workup, a white solid generated which was filtered off and collected. This yielded to 210 mg (63 %) of the title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 6.36 (d, 1 H); 7.49-7.54 (m, 2H); 7.62 (d, 1 H); 7.68 (dd, 1 H); 8.05 (dd, 1 H); 8.1 1 (d, 1 H); 8.92 (dd, 1 H); 9.97 (bs, 1 H); 10.09 (bs, 1 H); 12.15 (bs, 1 H). Example 54
1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}urea
Figure imgf000327_0001
According to the synthesis of example 40, 50 mg (0.1 1 mmol) 1 -{4-[(3-chloro-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}urea
(intermediate 59) in 1 .2 mL dichloromethane and 0.6 mL trifluoreacetic acid were stirred for 2 hours. After workup, the resulting residue was purified by HPLC (method 1 ) to yield to 16 mg (42 %) of the title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 6.16 (s, 2H); 6.32 (d, 1 H); 7.36-7.41 (m, 2H); 7.61 (s, 1 H); 8.09 (d, 1 H); 9.10 (s, 1 H); 12.12 (s, 1 H).
Example 55
N-{2-[({4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}carbamoyl)amino ethyl}acetamide
Figure imgf000327_0002
Phenyl {4-[(3-chloro-1 /-/-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}carbamate (200 mg, 90 % purity, 432 μηιοΙ, intermediate 60) was dissolved THF (2.0 mL) and N-{2- aminoethyl)acetamide (88.3 mg, 865 μηηοΙ) was added. The mixture was heated for 1 h to 60 °C. After cooling to room temperature dichloromethane was added and the precipitate was collected by suction filtration to yield 142 mg (93 % purity, 72 % yield) of the title compound. 1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 9.12 (s, 1 H), 8.10 (d, 1 H), 7.95 (br s, 1 H), 7.61 (s, 1 H), 7.39 (br d, 2H), 6.45 (br s, 1 H), 6.32 (d, 1 H), 3.15 (br s, 4H), 1.82 (s, 3H). Example 56
1 -{4-[(3-bromo-1 H-pyrrolo[2!3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[2- (dimethylamino)ethyl]urea
Figure imgf000328_0001
To a solution of 4-(3-Bromo-1 -((2-(trimethylsilyl)ethoxy)methyl)-1 H-pyrrolo[2,3- b]pyridin-4- yloxy)-3,5-difluorobenzenamine (100 mg, 0.175 mmol, intermediate 61 ) in 15 mL
dichloromethane stirring under ice-water bath, Then bis(trichloromethyl) carbonate, 62 mg (0.21 mmol) and triethylamine, 53 mg (0.5 mmol) were added at 0 °C. The reaction mixture was stirred at 0 °C for 10 minutes. Then N 1 ,N1-dimethylethane-1 ,2-diamine, 39 mg (0.44 mmol), dissolved in dichloromethane was added slowly. The reaction mixture was stirred at 0 °C for 30 minutes. Then the reaction was quenched by water and extracted with
dichloromethane. The organic phase was washed by a solution of sodium bicarbonate, dried over sodium sulfate, filtered and evaporated to dryness. Then the residue was dissolved in 8 mL 1 ,4-dioxane and 2 mL hydrochloric acid and stirring at 100 °C for 1.5 h. The mixture was evaporated to dryness and was purified by prep HPLC to afford 9.6 mg (12 %) of the product. 1H-NMR (300 MHz, DMSO-de): δ [ppm] 2.18 (s, 6H), 2.31 -2.36 (m, 2H), 3.18-3.21 (m, 2H), 6.30-6.33 (m, 2H), 7.33-7.37 (d, 2H), 7.63-7.64 (m, 1 H), 8.08-8.10 (d, 1 H), 9.19 (s, 1 H), 12.20 (s, 1 H). Example 57
1 -{4-[(3-bromo-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[3- (dimethylamino)propyl]urea
Figure imgf000328_0002
According to the synthesis of example 56, 100 mg (0.213 mmol) 4-[(3-bromo-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluoroaniline (intermediate 61 ), bis(trichloromethyl) carbonate (75.7 mg, 255 μηηοΙ) and N,N-dimethylpropane-1 ,3-diamine (54.3 mg, 531 μηηοΙ) were reacted to yield 19.3 mg (19 %) of the title compound.
1H-NMR (300 MHz, DMSO-d6): δ [ppm] 1 .55-1 .58 (m, 2H), 2.15 (s, 6H), 2.22-2.27 (m, 2H), 3.09-3.16 (m, 2H), 6.31 -6.34 (d, 1 H), 6.49 (m, 1 H), 7.37-7.41 (d, 2H), 7.65-7.66 (m, 1 H), 8.09- 8.1 1 (d, 1 H), 9.06 (s, 1 H), 12.22 (s, 1 H).
Example 58
1 -{4-[(3-bromo-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-butylurea
Figure imgf000329_0001
According to the synthesis of example 56, 100 mg (0.213 mmol) 4-[(3-bromo-1 -{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluoroaniline (intermediate 61 ), bis(trichloromethyl) carbonate (75.7 mg, 255 μηηοΙ) and butan-1 -amine (38.9 mg, 531 μηηοΙ) were reacted to yield 6.9 mg (7%) of the title compound.
1H-NMR (300 MHz, DMSO-d6): δ [ppm] 0.88-0.93 (t, 3H), 1 .28-1 .46 (m, 4H), 3.07-3.14 (m, 2H), 6.32-6.42 (m, 2H), 7.36-7.40 (d, 2H), 7.64-7.66 (m, 1 H), 8.09-8.1 1 (d, 1 H), 8.95 (s, 1 H), 12.22 (s, 1 H).
Example 59
1 -benzyl-3-{4-[(3-bromo-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}urea
Figure imgf000329_0002
According to the synthesis of example 56, 100 mg (0.213 mmol) 4-[(3-bromo-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluoroaniline (intermediate 61), bis(trichloromethyl) carbonate (75.7 mg, 255 μηηοΙ) and benzylamine (0.058 mL, 530 μηηοΙ) were reacted to yield 6.8 mg (7%) of the title compound.
1H-NMR(300 MHz, DMSO-d6): δ [ppm] 4.31-4.34 (d, 2H), 6.32-6.34 (d, 1H), 6.91-6.95 (m, 1H), 7.26-7.43 (m, 7H), 7.64-7.66 (m, 1H), 8.09-8.11 (d, 1H), 9.14 (s, 1H), 12.21 (s, 1H).
Example 60
1-(2,3-difluoro-4-{[3-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[3-(morpholin- 4-yl)propyl]urea
Figure imgf000330_0001
In analogy to example 1), 1-(2,3-difluoro-4-{[3-(trifluoromethyl)-1-{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[3-(morpholin-4- yl)propyl]urea (69.0 mg, 110 μηηοΙ, intermediate 70) was stirred with trifluoroacidic acid (750 μΙ_, 9.7 mmol) in dichloromethane (1.5 mL). After purification using a Biotage chromatography system we obtained 47 mg (92 % purity, 79 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 1.60 (quin, 2H), 2.26 - 2.39 (m, 6H), 3.14 (q, 2H), 3.58 (t, 4H), 6.49 (d, 1H), 6.66 (t, 1H), 7.12-7.18 (m, 1H), 8.01 (t, 1H), 8.10 (s, 1H), 8.21 (d, 1H), 8.55 (d, 1H), 12.61 (s, 1H).
Example 61
1-(2,3-difluoro-4-{[3-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[2-(morpholin- 4-yl)ethyl]urea
Figure imgf000330_0002
In analogy to example 1), 1-(2,3-difluoro-4-{[3-(trifluoromethyl)-1-{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[2-(morpholin-4- yl)ethyl]urea (62.0 mg, 101 μηηοΙ, intermediate 71) was stirred with trifluoroacidic acid (700 μί, 9.1 mmol) in dichloromethane (1 .4 mL). After purification using a Biotage chromatography system we obtained 35 mg (95 % purity, 68 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 2.40 (br t, 6H), 3.24 (q, 2H), 3.60 (t, 4H), 6.49 (d, 1 H), 6.68 (t, 1 H), 7.15 (t, 1 H), 8.02 (t, 1 H), 8.1 1 (s, 1 H), 8.21 (d, 1 H), 8.75 (d, 1 H), 12.61 (s, 1 H).
Example 62
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[2- (dimethylamino)ethyl]thiourea
Figure imgf000331_0001
In analogy to example 1 ), 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[2- (dimethylamino)ethyl]thiourea (70.0 mg, 1 19 μηηοΙ, intermediate 72) was stirred with trifluoroacidic acid (800 μΙ_, 10.4 mmol) in dichloromethane (1 .6 mL). After purification using a Biotage chromatography system we obtained 10.2 mg (95 % purity, 18 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 2.20 (s, 6H), 2.45 (t, 2H), 3.51 - 3.64 (m, 2H), 6.49 (d, 1 H), 7.57 - 7.65 (m, 2H), 8.01 (br s, 1 H), 8.13 (s, 1 H), 8.23 (d, 1 H), 10.09 (br s, 1 H), 12.65 (br s, 1 H). Example 63
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[2-(morpholin- 4-yl)ethyl]thiourea
Figure imgf000331_0002
In analogy to example 1 ), 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[2-(morpholin-4- yl)ethyl]thiourea (80.9 mg, 128 μηηοΙ, intermediate 73) was stirred with trifluoroacidic acid (870 μΙ_, 1 1 mmol) in dichloromethane (1 .7 mL). After purification using a Biotage chromatography system we obtained 26.7 mg (92 % purity, 38 % yield) of the desired title compound.
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: 2.36 - 2.46 (m, 4H), 2.52 - 2.55 (m, 2H), 3.52 - 3.68 (m, 6H), 6.50 (d, 1 H), 7.50 - 7.61 (m, 2H), 8.06 - 8.18 (m, 2H), 8.23 (d, 1 H), 10.1 1 (br s, 1 H), 12.65 (br s, 1 H). Example 64
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(2- methoxyethyl)thiourea
Figure imgf000332_0001
In analogy to example 1 ), 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(2- methoxyethyl)thiourea (45.0 mg, 78.0 μηηοΙ, intermediate 74) was stirred with trifluoroacidic acid (530 μΙ_, 6.9 mmol) in dichloromethane (1 .1 mL). After purification using a Biotage chromatography system we obtained 10.3 mg (97 % purity, 29 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 3.30 (s, 3H), 3.51 (t, 2H), 3.67 (q, 2H), 6.50 (d, 1 H), 7.53 - 7.61 (m, 2H), 8.13 (s, 1 H), 8.17 (br s, 1 H), 8.24 (d, 1 H), 9.99 (br s, 1 H), 12.66 (br s, 1 H).
Example 65
1 -(3,5-difluoro-4-{[3-(trifluorometh l)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-ethylthiourea
Figure imgf000332_0002
In analogy to example 1 ), 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-ethylthiourea (58.0 mg, 106 μηηοΙ, intermediate 75) was stirred with trifluoroacidic acid (720 μΙ_, 9.3 mmol) in dichloromethane (1 .4 ml_). After purification using a Biotage chromatography system we obtained 19.0 mg (95 % purity, 41 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 1 .14 (t, 3H), 3.45 - 3.56 (m, 2H), 6.50 (d, 1 H), 7.52 (br d, 2H), 8.07 - 8.18 (m, 2H), 8.24 (d, 1 H), 9.85 (br s, 1 H), 12.66 (br s, 1 H).
Example 66
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[3-(morpholin- 4-yl)propyl]thiourea
Figure imgf000333_0001
In analogy to example 1 ), 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[3-(morpholin-4- yl)propyl]thiourea (71 .0 mg, 1 10 μηηοΙ, intermediate 76) was stirred with trifluoroacidic acid (740 μΙ_, 9.7 mmol) in dichloromethane (1 .5 ml_). After purification using a Biotage
chromatography system we obtained 19.1 mg (95 % purity, 32 % yield) of the desired title compound.
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: 1 .72 (quin, 2H), 2.29 - 2.38 (m, 6H), 3.49 - 3.60 (m, 6H), 6.49 (d, 1 H), 7.48 - 7.56 (m, 2H), 8.13 (d, 1 H), 8.15 - 8.20 (m, 1 H), 8.24 (d, 1 H), 9.91 (br s, 1 H), 12.65 (br s, 1 H).
Example 67
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}pheny
ylmethyl)urea
Figure imgf000334_0001
To a solution of 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(oxetan-3-ylmethyl)urea (1 19 mg, 207 μηιοΙ, intermediate 77) and ethylenediamine (57 μΙ_, 850μΜ) in DMF (2.4 mL) and was added 1 N tetrabutylammonium fluoride solution in THF (830 μΜ, 830μΙ_) and this mixture was stirred at 45°C overnight. The reaction mixture was cooled to room temperature and then diluted with ethylactetat. Then this organic phase were washed with water twice, brine, dried over sodium sulfate and then after filtration evaporated to dryness in vacuum. The obtained crude product was purified via a Biotage chromatography system (1 1 g snap KP-NH column, ethyl acetate / 0 - 80% ethanol) and subsequent via HPLC to obtain 68 mg again not very pure compound. The obtained compound was solved in ethyl acetate and again extracted with water twice, brine, dried over sodium sulfate and then after filtration evaporated to dryness in vacuum. The resulting residue was purified by preparative thin layer chromatography using dichloromethane / methanol 8:2 to obtain50mg (92 % purity, 50 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 3.08 (dt, 1 H), 3.37 (t, 2H), 4.31 (t, 2H), 4.62 (dd, 2H), 6.46 (d, 1 H), 6.86 (t, 1 H), 7.35 - 7.43 (m, 2H), 8.1 1 (s, 1 H), 8.21 (d, 1 H), 9.29 (s, 1 H), 12.63 (br s, 1 H).
Example 68
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)urea
Figure imgf000334_0002
In analogy to example 1 , 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)urea (1 14 mg, 228 μηηοΙ intermediate 78) was stirred with trifluoroacetic acid (1 .0 ml_, 13 mmol) in dichloromethane (2.0 ml_). After purification using a Biotage chromatography system we obtained 51.7 mg (97 % purity, 59 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 6.15 (s, 2H), 6.46 (d, 1 H), 7.34 - 7.42 (m, 2H), 8.09 - 8.12 (m, 1 H), 8.21 (d, 1 H), 9.07 (s, 1 H), 12.62 (br s, 1 H).
Example 69
1 -(3,5-difluoro-4-{[3-(trifluorometh l)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-methylurea
Figure imgf000335_0001
In analogy to example 1 , 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-methylurea (127 mg, 246 μηηοΙ, intermediate 79) was stirred with trifluoroacetic acid (1.7 ml_, 22 mmol) in
dichloromethane (3.3 ml_). After purification using a Biotage chromatography system we obtained 27.8 mg (100 % purity, 29 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 2.65 (d, 3H), 6.29 (q, 1 H), 6.46 (d, 1 H), 7.35 - 7.42 (m, 2H), 8.1 1 (s, 1 H), 8.21 (d, 1 H), 9.07 (s, 1 H), 12.62 (br s, 1 H). Example 70
3-(3,5-difluoro-4-{[3-(trifluorometh l)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-1 ,1 -dimethylurea
Figure imgf000335_0002
In analogy to example 1 , 3-(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-1 ,1 -dimethylurea (176 mg, 332 μηηοΙ, intermediate 80) was stirred with trifluoroacetic acid (2.2 mL, 29 mmol) in dichloromethane (4.5 mL). After purification using a Biotage chromatography system we obtained 49.7 mg (100 % purity, 37 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 2.95 (s, 6H), 6.46 (d, 1 H), 7.49 - 7.57 (m, 2H), 8.1 1 (s, 1 H), 8.21 (d, 1 H), 8.76 (s, 1 H), 12.63 (br s, 1 H).
Example 71
N-(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)morpholine-4- carboxamide
Figure imgf000336_0001
In analogy to example 1 , N-(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)morpholine-4- carboxamide (171 mg, 299 μηηοΙ, intermediate 81 ) was stirred with trifluoroacetic acid (2.0 mL, 26 mmol) in dichloromethane (4.0 mL). After purification using a Biotage chromatography system we obtained 45.5 mg (97 % purity, 33 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 3.42 - 3.49 (m, 4H), 3.59 - 3.66 (m, 4H), 6.46 (d, 1 H), 7.46 - 7.54 (m, 2H), 8.1 1 (s, 1 H), 8.22 (d, 1 H), 9.00 (s, 1 H), 12.64 (br s, 1 H).
Example 72
N-(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-4- methylpiperazine-1 -carboxamide
Figure imgf000336_0002
In analogy to example 1 , N-(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-4-methylpiperazine-1 - carboxamide (248 mg, 423 μηηοΙ, intermediate 82) was stirred with trifluoroacetic acid (2.9 mL, 37 mmol) in dichloromethane (5.7 mL). After purification using a Biotage chromatography system we obtained 55.1 mg (97 % purity, 28 % yield) of the desired title compound.
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: 2.20 (s, 3H), 2.29 - 2.36 (m, 4H), 3.41 - 3.51 (m, 4H), 6.46 (d, 1 H), 7.47 - 7.53 (m, 2H), 8.1 1 (s, 1 H), 8.21 (d, 1 H), 8.98 (s, 1 H), 12.63 (br s, 1 H).
Example 73
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[2-(4- methylpiperazin-1 -yl)-2-oxoeth l]urea
Figure imgf000337_0001
In analogy to example 1 , 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[2-(4-methylpiperazin- 1 -yl)-2-oxoethyl]urea (83.5 mg, 130 μηηοΙ, intermediate 83) was stirred with trifluoroacetic acid (880 μί, 1 1 mmol) in dichloromethane (1 .8 mL). After purification using a Biotage
chromatography system we obtained 16.8 mg (97 % purity, 25 % yield) of the desired title compound.
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: 2.19 (s, 3H), 2.24 - 2.34 (m, 4H), 3.37 - 3.43 (m, 2H), 3.43 - 3.50 (m, 2H), 4.00 (d, 2H), 6.47 (d, 1 H), 6.54 (t, 1 H), 7.32 - 7.40 (m, 2H), 8.1 1 (s, 1 H), 8.21 (d, 1 H), 9.45 (s, 1 H), 12.62 (br s, 1 H).
Example 74
N-(3,5-difluoro^^[3-(trifluoromethyl)-1 H-pyrTolo[2,3-b]pyridin-4-yl]oxy}phenyl)-2- azaspiro[3.3]heptane-6-carboxamide
Figure imgf000338_0001
In analogy to example 1 , N-(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-2-oxa-6- azaspiro[3.3]heptane-6-carboxamide (71 .0 mg, 121 μηηοΙ, intermediate 84) was stirred with trifluoroacetic acid (820 μΙ_, 1 1 mmol) in dichloromethane (1.6 ml_). After purification using a Biotage chromatography system we obtained 24.6 mg (97 % purity, 43 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 4.15 (s, 4H), 4.69 (s, 4H), 6.46 (d, 1 H), 7.50 (d, 2H), 8.1 1 (s, 1 H), 8.21 (d, 1 H), 8.96 (s, 1 H), 12.63 (br s, 1 H).
Example 75
N2-[(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamoyl]-N- methylglycinamide
3
Figure imgf000338_0002
In analogy to example 1 , N2-[(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamoyl]-N- methylglycinamide (140 mg, 244 μηηοΙ, intermediate 85) was stirred with trifluoroacetic acid (1 .7 ml_, 21 mmol) in dichloromethane (3.3 ml_). After purification using a Biotage chromatography system we obtained 67.1 mg (95 % purity, 59 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 2.61 (d, 3H), 3.71 (d, 2H), 6.46 (d, 1 H), 6.58 (t, 1 H), 7.34 - 7.41 (m, 2H), 7.91 (q, 1 H), 8.09 - 8.13 (m, 1 H), 8.21 (d, 1 H), 9.33 (s, 1 H), 12.63 (br s, 1 H).
Example 76
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(1 ,2-thiazol-4- yl)urea
Figure imgf000339_0001
In analogy to example 1 , 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(1 ,2-thiazol-4-yl)urea (155 mg, 265 μηηοΙ, intermediate 86) was stirred with trifluoroacetic acid (1.8 mL, 23 mmol) in dichloromethane (3.6 mL). After purification using a Biotage chromatography system we obtained 36.5 mg (95 % purity, 29 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 6.50 (d, 1 H), 7.45 - 7.52 (m, 2H), 8.12 (s, 1 H), 8.22 (d, 1 H), 8.60 (s, 1 H), 8.73 (s, 1 H), 9.38 (s, 1 H), 9.49 (s, 1 H), 12.64 (br s, 1 H).
Example 77
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(1 -methyl-1 H- pyrazol-4-yl)urea
Figure imgf000339_0002
To a solution of 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(1 -methyl-1 H-pyrazol-4-yl)urea (158 mg, 271 μηιοΙ, intermediate 87) in dichloromethane (3.7 mL) was added trifluoroacetic acid (1.8 mL, 24 mmol) and this mixture was stirred 3h at room temperature. The reaction mixture was carefully poured into an aqueous solution of sodium hydrogencarbonate. This aqueous phase was extracted two times with ethyl actetate. Then the combined organic phases were washed with brine, dried over sodium sulfate and then after filtration evaporated to dryness in vacuum. The obtained crude product was purified via a Biotage chromatography system (1 1 g snap KP-NH column, hexane / 0 - 100% ethylacetate, then ethyl acetate / 0 - 100% methanol) and the resulting compound was purified again by preparative HPLC (according to method 1 ) to obtain 19.9 mg (97 % purity, 16 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 3.79 (s, 3H), 6.49 (d, 1 H), 7.39 (d, 1 H), 7.41 - 7.48 (m, 2H), 7.77 (s, 1 H), 8.12 (s, 1 H), 8.22 (d, 1 H), 8.65 (s, 1 H), 9.13 (s, 1 H), 12.63 (br s, 1 H).
Example 78
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(6- methylpyridin-3-yl)urea
Figure imgf000340_0001
In analogy to example 1 , 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(6-methylpyridin-3- yl)urea (146 mg, 246 μηηοΙ, intermediate 88) was stirred with trifluoroacetic acid (1 .7 mL, 22 mmol) in dichloromethane (3.3 mL). After purification using a Biotage chromatography system we obtained 61.4 mg (97 % purity, 52 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 2.41 (s, 3H), 6.50 (d, 1 H), 7.19 (d, 1 H), 7.42 - 7.50 (m, 2H), 7.82 (dd, 1 H), 8.12 (s, 1 H), 8.22 (d, 1 H), 8.49 (d, 1 H), 8.99 (s, 1 H), 9.28 (s, 1 H), 12.64 (br s, 1 H). Example 79
1 -[(1 -acetylazetidin-3-yl)methyl]-3-(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin- 4-yl]oxy}phenyl)urea
Figure imgf000341_0001
In analogy to example 1 , 1 -[(1 -acetylazetidin-3-yl)methyl]-3-(3,5-difluoro-4-{[3-(trifluoromethyl)- 1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)urea (1 18 mg, 192 μmol, intermediate 89) was stirred with trifluoroacetic acid (1.3 ml_, 17 mmol) in
dichloromethane (2.6 ml_). After purification using a Biotage chromatography system we obtained 40.0 mg (90 % purity, 39 % yield) of the desired title compound.
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: 1 .73 (s, 3H), 2.68 - 2.75 (m, 1 H), 3.28 - 3.32 (m, 2H), 3.54 (dd, 1 H), 3.80 (dd, 1 H), 3.84 (t, 1 H), 4.13 (t, 1 H), 6.47 (d, 1 H), 6.64 (t, 1 H), 7.34 - 7.44 (m, 2H), 8.1 1 (s, 1 H), 8.21 (d, 1 H), 9.05 (s, 1 H), 12.63 (br s, 1 H).
Example 80
N2-[(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamoyl]-N- (2-methoxyethyl)glycinamide
Figure imgf000341_0002
In analogy to example 1 , N2-[(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)carbamoyl]-N-(2- methoxyethyl)glycinamide (160 mg, 259 μηηοΙ, intermediate 90) was stirred with trifluoroacetic acid (1 .8 ml_, 23 mmol) in dichloromethane (3.5 ml_). After purification using a Biotage chromatography system we obtained 67.6 mg (97 % purity, 52 % yield) of the desired title compound.
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: 3.22 - 3.28 (m, 5H), 3.32 - 3.37 (m, 2H), 3.74 (d, 2H), 6.47 (d, 1H), 6.56 (t, 1H), 7.33 - 7.40 (m, 2H), 8.06 (t, 1H), 8.11 (s, 1H), 8.21 (d, 1H), 9.33 (s, 1H), 12.63 (brs, 1H).
Example 81
(+/-)-1-(3,5-difluoro-4-{[3-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[(1,1- dioxidothietan-2-yl)methyl]urea
Figure imgf000342_0001
In analogy to example 1, (+/-)-1-(3,5-difluoro-4-{[3-(trifluoromethyl)-1-{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[(1 ,1-dioxidothietan-2- yl)methyl]urea (148 mg, 239 μηηοΙ, intermediate 91 ) was stirred with trifluoroacetic acid (1.6 mL, 21 mmol) in dichloromethane (3.2 mL). After purification using a Biotage chromatography system we obtained 40.0 mg (95 % purity, 32 % yield) of the desired title compound.
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: 1.72 - 1.82 (m, 1H), 2.24 (dtd, 1H), 3.51 - 3.62 (m, 2H), 3.96 - 4.14 (m,2H), 4.56 (quin, 1H), 6.47 (d, 1H), 6.68 (t, 1H), 7.34-7.42 (m, 2H), 8.11 (s, 1 H), 8.21 (d, 1 H), 9.20 (s, 1 H), 12.63 (br s, 1 H). Example 82
1-(3,5-difluoro-4-{[3-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(2- methylpyrimidin-5-yl)urea
Figure imgf000342_0002
In analogy to example 1 , 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(2-methylpyrimidin-5- yl)urea (103 mg, 174 μηηοΙ, intermediate 92) was stirred with trifluoroacetic acid (1 .2 mL, 15 mmol) in dichloromethane (2.4 mL). After purification using a Biotage chromatography system we obtained 36.2 mg (90 % purity, 40 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 2.57 (s, 3H), 6.50 (d, 1 H), 7.44 - 7.51 (m, 2H), 8.12 (s, 1 H), 8.22 (d, 1 H), 8.80 (s, 2H), 9.17 (br s, 1 H), 9.49 (br s, 1 H), 12.65 (br s, 1 H).
Example 83
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(1 H-pyrazol-4- yl)urea
Figure imgf000343_0001
In analogy to example 1 , 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(1 H-pyrazol-4-yl)urea (150 mg, 263 μηηοΙ, intermediate 93) was stirred with trifluoroacetic acid (1.8 mL, 23 mmol) in dichloromethane (3.6 mL). After purification using a Biotage chromatography system we obtained 18.7 mg (97 % purity, 16 % yield) of the desired title compound.
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: 6.48 (d, 1 H), 7.41 - 7.52 (m, 3H), 7.76 (br s, 1 H), 8.1 1 (s, 1 H), 8.22 (d, 1 H), 8.68 (s, 1 H), 9.18 (s, 1 H), 12.56 (br s, 1 H), 12.63 (br s, 1 H).
Example 84
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[2-(1 - azaspiro[3.3]hept-6-yl)ethyl]urea
Figure imgf000343_0002
In analogy to example 77, 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[2-(1 -oxa-6- azaspiro[3.3]hept-6-yl)ethyl]urea (1 19 mg, 189 μηηοΙ, intermediate 94) was stirred with trifluoroacetic acid (1.3 ml_, 17 mmol) in dichloromethane (2.6 ml_). After purification using a Biotage chromatography system and a subsequent preparative HPLC (according to method 1 ) we obtained 21.2 mg (93 % purity, 21 % yield) of the desired title compound.
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: 2.44 (t, 2H), 2.74 (t, 2H), 3.02 - 3.09 (m, 4H), 3.50 - 3.55 (m, 2H), 4.37 (t, 2H), 6.29 (t, 1 H), 6.46 (d, 1 H), 7.31 - 7.38 (m, 2H), 8.1 1 (s, 1 H), 8.21 (d, 1 H), 9.12 (s, 1 H), 12.63 (br s, 1 H).
Example 85
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[2-(1 ,1 - dioxido-1 -thia-6-azaspiro 3.3]hept-6-yl)ethyl]urea
Figure imgf000344_0001
In analogy to example 1 , 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[2-(1 ,1 -dioxido-1 -thia- 6-azaspiro[3.3]hept-6-yl)ethyl]urea (174 mg, 257 μηηοΙ, intermediate 95) was stirred with trifluoroacetic acid (1 .7 ml_, 23 mmol) in dichloromethane (3.5 ml_). After purification using a Biotage chromatography system we obtained 29.9 mg (95 % purity, 20 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 2.20 - 2.26 (m, 2H), 3.08 (q, 2H), 3.23 - 3.28 (m, 2H), 3.78 - 3.83 (m, 2H), 3.98 - 4.04 (m, 2H), 6.32 (t, 1 H), 6.46 (d, 1 H), 7.32 - 7.39 (m, 2H), 8.1 1 (s, 1 H), 8.21 (d, 1 H), 9.14 (s, 1 H), 12.63 (br s, 1 H).
Example 86
(+/-)-1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(^ oxopyrrolidin-3-yl)urea
Figure imgf000345_0001
In analogy to example 1 , (+/-)-1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(2-oxopyrrolidin-3- yl)urea (168 mg, 287 μηηοΙ, intermediate 96) was stirred with trifluoroacetic acid (1 .9 mL, 25 mmol) in dichloromethane (3.9 mL). After purification using a Biotage chromatography system we obtained 105 mg (90 % purity, 72 % yield) of the desired title compound.
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: 1 .80 - 1 .91 (m, 1 H), 2.38 - 2.44 (m, 1 H), 3.20 (dd, 2H), 4.14 - 4.22 (m, 1 H), 6.47 (d, 1 H), 6.71 - 6.79 (m, 1 H), 7.34 - 7.42 (m, 2H), 7.90 (s, 1 H), 8.1 1 (s, 1 H), 8.19 - 8.24 (m, 1 H), 9.25 - 9.30 (m, 1 H), 12.64 (br s, 1 H).
Example 87
(+/-)-1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(1 ,1 - dioxidotetrahydrothiophen-3- l)urea
Figure imgf000345_0002
In analogy to example 1 , (+/-)-1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(1 ,1 - dioxidotetrahydrothiophen-3-yl)urea (160 mg, 258 μηηοΙ, intermediate 97) was stirred with trifluoroacetic acid (1 .7 mL, 23 mmol) in dichloromethane (3.5 mL). After purification using a Biotage chromatography system we obtained 40.7 mg (93 % purity, 30 % yield) of the desired title compound. Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: 2.1 1 (dq, 1 H), 2.37 - 2.47 (m, 1 H), 3.03 (dd, 1 H), 3.14 - 3.31 (m, 2H), 3.44 (dd, 1 H), 4.40 - 4.51 (m, 1 H), 6.46 (d, 1 H), 6.90 (d, 1 H), 7.35 - 7.43 (m, 2H), 8.1 1 (s, 1 H), 8.21 (d, 1 H), 9.14 (s, 1 H), 12.63 (br s, 1 H). Example 88
(+/-)-1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(5- oxopyrrolidin-3-yl)urea
Figure imgf000346_0001
In analogy to example 1 , (+/-)-1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(5-oxopyrrolidin-3- yl)urea (125 mg, 213 μηηοΙ, intermediate 98) was stirred with trifluoroacetic acid (1 .4 mL, 19 mmol) in dichloromethane (2.9 mL). After purification using a Biotage chromatography system we obtained 35.1 mg (97 % purity, 35 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 2.07 (dd, 1 H), 3.07 (dd, 1 H), 3.53 (dd, 1 H), 4.27 - 4.38 (m, 1 H), 6.46 (d, 1 H), 6.91 (d, 1 H), 7.34 - 7.42 (m, 2H), 7.68 (s, 1 H), 8.1 1 (s, 1 H), 8.21 (d, 1 H), 8.92 (s, 1 H), 12.63 (br s, 1 H).
Example 89
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(1 ,1 - dioxidotetrahydro-2H-thiop ran-4-yl)urea
Figure imgf000346_0002
In analogy to example 1 , 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(1 ,1 - dioxidotetrahydro-2H-thiopyran-4-yl)urea (152 mg, 239 μηηοΙ, intermediate 99) was stirred with trifluoroacetic acid (1 .6 mL, 21 mmol) in dichloromethane (3.2 mL). After purification using a Biotage chromatography system we obtained 56.1 mg (97 % purity, 45 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 1 .90 - 2.01 (m, 2H), 2.13 (br dd, 2H), 3.06 (br d, 2H), 3.24 - 3.32 (m, 2H), 3.82 - 3.94 (m, 1 H), 6.46 (d, 1 H), 6.70 (d, 1 H), 7.35 - 7.42 (m, 2H), 8.1 1 (s, 1 H), 8.21 (d, 1 H), 8.87 (s, 1 H), 12.63 (br s, 1 H).
Example 90
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(1 H-pyrazol-3- ylmethyl)urea
Figure imgf000347_0001
In analogy to example 1 , 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(1 H-pyrazol-3- ylmethyl)urea (147 mg, 252 μηηοΙ, intermediate 100) was stirred with trifluoroacetic acid (1 .7 ml_, 22 mmol) in dichloromethane (3.4 ml_). After purification using a Biotage
chromatography system we obtained 26.1 mg (90 % purity, 21 % yield) of the desired title compound.
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: 4.25 - 4.37 (m, 2H), 6.1 1 - 6.20 (m, 1 H), 6.47 (d, 1 H), 6.73 (br s, 1 H), 7.39 (br d, 2H), 7.67 (br s, 1 H), 8.1 1 (s, 1 H), 8.21 (d, 1 H), 9.10 (s, 1 H), 12.56 - 12.72 (m, 2H).
Example 91
1 - (3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(1 H-imidazol-
2- ylmethyl)urea
Figure imgf000347_0002
In analogy to example 1 , 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(1 H-imidazol-2- ylmethyl)urea (1 17 mg, 201 μηηοΙ, intermediate 101 ) was stirred with trifluoroacetic acid (1 .4 ml_, 18 mmol) in dichloromethane (2.7 ml_). After purification using a Biotage
chromatography system we obtained 41.3 mg (95 % purity, 43 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 4.32 (d, 2H), 6.46 (d, 1 H), 6.83 (t, 2H), 7.04 (br s, 1 H), 7.35 - 7.44 (m, 2H), 8.1 1 (s, 1 H), 8.21 (d, 1 H), 9.23 (s, 1 H), 1 1.85 (br s, 1 H), 12.63 (br s, 1 H). Example 92
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[(1 -methyl-1 H- pyrazol-3-yl)methyl]urea
Figure imgf000348_0001
In analogy to example 1 , 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[(1 -methyl-1 H-pyrazol- 3-yl)methyl]urea (207 mg, 347 μηηοΙ, intermediate 102) was stirred with trifluoroacetic acid (2.3 ml_, 30 mmol) in dichloromethane (4.7 ml_). After purification using a Biotage
chromatography system we obtained 62.7 mg (97 % purity, 38 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 3.33 (s, 3H), 4.24 (d, 2H), 6.13 (d, 1 H), 6.47 (d, 1 H), 6.72 (t, 1 H), 7.34 - 7.42 (m, 2H), 7.61 (d, 1 H), 8.1 1 (s, 1 H), 8.21 (d, 1 H), 9.09 (s, 1 H), 12.63 (br s, 1 H).
Example 93
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(1 ,3-thiazol-2- ylmethyl)urea
Figure imgf000349_0001
In analogy to example 1 , 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(1 ,3-thiazol-2- ylmethyl)urea (216 mg, 359 μηηοΙ, intermediate 103) was stirred with trifluoroacetic acid (2.4 ml_, 32 mmol) in dichloromethane (4.9 ml_). After purification using a Biotage
chromatography system we obtained 62.5 mg (97 % purity, 36 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 4.61 (d, 2H), 6.49 (d, 1 H), 7.25 (t, 1 H), 7.38 - 7.46 (m, 2H), 7.63 (d, 1 H), 7.74 (d, 1 H), 8.1 1 (s, 1 H), 8.21 (d, 1 H), 9.37 (s, 1 H), 12.63 (s, 1 H).
Example 94
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(pyrimidin-4- ylmethyl)urea
Figure imgf000349_0002
In analogy to example 1 , 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(pyrimidin-4- ylmethyl)urea (175 mg, 294 μηηοΙ, intermediate 104) was stirred with trifluoroacetic acid (2.0 ml_, 26 mmol) in dichloromethane (4.0 ml_). After purification using a Biotage chromatography system we obtained 35.8 mg (97 % purity, 25 % yield) of the desired title compound.
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: 4.43 (d, 2H), 6.47 (d, 1 H), 7.07 (t, 1 H), 7.36 - 7.43 (m, 2H), 7.46 (dd, 1 H), 8.1 1 (s, 1 H), 8.21 (d, 1 H), 8.76 (d, 1 H), 9.13 (d, 1 H), 9.43 (s, 1 H), 12.63 (br s, 1 H).
Example 95
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[(2- methylpyridin-4-yl)methyl]urea
Figure imgf000350_0001
In analogy to example 1 , 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[(2-methylpyridin-4- yl)methyl]urea (178 mg, 293 μηηοΙ, intermediate 105) was stirred with trifluoroacetic acid (2.0 ml_, 26 mmol) in dichloromethane (4.0 ml_). After purification using a Biotage
chromatography system we obtained 73.0 mg (95 % purity, 50 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 2.45 (s, 3H), 4.30 (d, 2H), 6.47 (d, 1 H), 7.00 (t, 1 H), 7.09 (br d, 1 H), 7.15 (s, 1 H), 7.36 - 7.45 (m, 2H), 8.1 1 (s, 1 H), 8.21 (d, 1 H), 8.37 (d, 1 H), 9.25 (s, 1 H), 12.63 (br s, 1 H).
Example 96
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}pheny
ylmethyl)urea
Figure imgf000351_0001
In analogy to example 1 , 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(pyridazin-3- ylmethyl)urea (190 mg, 320 μηηοΙ, intermediate 106) was stirred with trifluoroacetic acid (2.2 ml_, 28 mmol) in dichloromethane (4.3 ml_). After purification using a Biotage
chromatography system we obtained 50.2 mg (97 % purity, 33 % yield) of the desired title compound.
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: 4.62 (d, 2H), 6.47 (d, 1 H), 7.21 (t, 1 H), 7.36 - 7.44 (m, 2H), 7.62 - 7.72 (m, 2H), 8.1 1 (s, 1 H), 8.21 (d, 1 H), 9.15 (dd, 1 H), 9.40 (s, 1 H), 12.63 (br s, 1 H). Example 97
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[(5-methyl-1 H- imidazol-2-yl)methyl]urea
Figure imgf000351_0002
In analogy to example 1 , 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[(5-methyl-1 H- imidazol-2-yl)methyl]urea (145 mg, 243 μηηοΙ, intermediate 107) was stirred with trifluoroacetic acid (1 .6 ml_, 21 mmol) in dichloromethane (3.3 ml_). After purification using a Biotage chromatography system we obtained 70.1 mg (90 % purity, 56 % yield) of the desired title compound. 1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 2.10 (s, 3H), 4.25 (d, 2H), 6.46 (d, 1 H), 6.67 (br s, 1 H), 6.78 (t, 1H), 7.35-7.42 (m, 2H), 8.11 (s, 1H), 8.21 (d, 1H), 9.21 (s, 1H), 11.55 (br s, 1H), 12.63 (brs, 1H). Example 98
1-(3,5-difluoro-4-{[3-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-{[3- (methoxymethyl)-l ,2,4-oxadiazol-5-yl]methyl}urea
Figure imgf000352_0001
In analogy to example 1, 1-(3,5-difluoro-4-{[3-(trifluoromethyl)-1-{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-{[3-(methoxymethyl)- 1 ,2,4-oxadiazol-5-yl]methyl}urea (184 mg, 293 μηηοΙ, intermediate 108) was stirred with trifluoroacetic acid (2.0 ml_, 26 mmol) in dichloromethane (4.0 ml_). After purification using a Biotage chromatography system we obtained 47.0 mg (90 % purity, 29 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 3.34 (s, 3H), 4.53 (s, 2H), 4.62 (d, 2H), 6.48 (d, 1H), 7.17 (t, 1H), 7.36 -7.44 (m, 2H), 8.11 (s, 1H), 8.21 (d, 1H), 9.49 (s, 1H), 12.63 (brs, 1H).
Example 99
1-(3,5-difluoro-4-{[3-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[(5-methyl-4H- 1 ,2,4-triazol-3-yl)methyl]urea
Figure imgf000352_0002
In analogy to example 1 , 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[(5-methyl-4H-1 ,2,4- triazol-3-yl)methyl]urea (134 mg, 224 μηηοΙ, intermediate 109) was stirred with trifluoroacetic acid (1 .5 ml_, 20 mmol) in dichloromethane (3.0 ml_). After purification using a Biotage chromatography system we obtained 29.9 mg (90 % purity, 26 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 2.30 (s, 3H), 4.30 (br d, 2H), 6.47 (d, 1 H), 6.80 (br s, 1 H), 7.34 - 7.42 (m, 2H), 8.1 1 (s, 1 H), 8.21 (d, 1 H), 9.21 (s, 1 H), 12.63 (br s, 1 H), 13.43 (br s, 1 H).
Example 100
(+/-)-1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3- (tetrahydrofuran-3-yl)urea
Figure imgf000353_0001
In analogy to example 1 , (+/-)-1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(tetrahydrofuran-3- yl)urea (101 mg, 176 μηηοΙ, intermediate 1 10) was stirred with trifluoroacetic acid (1 .2 ml_, 16 mmol) in dichloromethane (2.4 ml_). After purification using a Biotage chromatography system we obtained 49.1 mg (85 % purity, 53 % yield) of the desired title compound.
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: 1 .68 - 1 .82 (m, 1 H), 2.07 - 2.19 (m, 1 H), 3.50 (dd, 1 H), 3.66 - 3.85 (m, 3H), 4.16 - 4.26 (m, 1 H), 6.46 (d, 1 H), 6.72 (br d, 1 H), 7.33 - 7.43 (m, 2H), 8.1 1 (s, 1 H), 8.21 (d, 1 H), 8.86 (s, 1 H), 12.63 (br s, 1 H).
Example 101
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[(3R)- tetrahydrofuran-3-yl]urea
Figure imgf000354_0001
In analogy to example 77, 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[(3R)-tetrahydrofuran- 3-yl]urea (104 mg, 182 μmol, intermediate 1 1 1 ) was stirred with trifluoroacetic acid (1.2 ml_, 16 mmol) in dichloromethane (2.5 ml_). After purification using a Biotage chromatography system and a subsequent preparative HPLC (according to method 1 ) we obtained 25.4 mg (95 % purity, 30 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 1 .70 - 1 .79 (m, 1 H), 2.13 (dq, 1 H), 3.50 (dd, 1 H), 3.67 - 3.84 (m, 3H), 4.18 - 4.25 (m, 1 H), 6.46 (d, 1 H), 6.74 (br d, 1 H), 7.34 - 7.41 (m, 2H), 8.1 1 (d, 1 H), 8.21 (d, 1 H), 8.88 (br s, 1 H), 1 1.57 - 12.46 (m, 1 H).
Example 102
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[(3S)- tetrahydrofuran-3-yl]urea
Figure imgf000354_0002
In analogy to example 1 , 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[(3S)-tetrahydrofuran- 3-yl]urea (159 mg, 278 μηηοΙ, intermediate 1 12) was stirred with trifluoroacetic acid (1 .9 ml_, 24 mmol) in dichloromethane (3.8 ml_). After purification using a Biotage chromatography system we obtained 49.4 mg (95 % purity, 38 % yield) of the desired title compound. Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: 1 .70 - 1 .79 (m, 1 H), 2.08 - 2.18 (m, 1 H), 2.13 (dq, 1 H), 3.50 (dd, 1 H), 3.67 - 3.84 (m, 3H), 4.18 - 4.25 (m, 1 H), 6.46 (d, 1 H), 6.72 (br d, 1 H), 7.34 - 7.41 (m, 2H), 8.1 1 (d, 1 H), 8.21 (d, 1 H), 8.85 (s, 1 H), 12.63 (br s, 1 H). Example 103
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-{3-[(2R,6R)- 2,6-dimethylmorpholin-4- l]propyl}urea
Figure imgf000355_0001
In analogy to example 1 , 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-{3-[(2R,6R)-2,6- dimethylmorpholin-4-yl]propyl}urea (139 mg, 212 μηηοΙ, intermediate 1 13) was stirred with trifluoroacetic acid (1 .4 mL, 19 mmol) in dichloromethane (2.9 mL). After purification using a Biotage chromatography system we obtained 54.8 mg (95 % purity, 47 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 1.04 (d, 6H), 1.51 - 1 .64 (m, 4H), 2.27 (t, 2H), 2.73 (br d, 2H), 3.12 (q, 2H), 3.50 - 3.59 (m, 2H), 6.41 (t, 1 H), 6.46 (d, 1 H), 7.34 - 7.42 (m, 2H), 8.1 1 (s, 1 H), 8.21 (d, 1 H), 8.98 (s, 1 H), 12.63 (br s, 1 H).
Example 104
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[(1 -methyl-1 H- imidazol-2-yl)methyl]urea
Figure imgf000355_0002
In analogy to example 1 , 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[(1 -methyl-1 H- imidazol-2-yl)methyl]urea (163 mg, 273 μηηοΙ, intermediate 1 14) was stirred with trifluoroacetic acid (1 .8 ml_, 24 mmol) in dichloromethane (3.7 ml_). After purification using a Biotage chromatography system we obtained 53.4 mg (90 % purity, 38 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 3.63 (s, 3H), 4.35 (d, 2H), 6.47 (d, 1 H), 6.81 (d, 1 H), 6.87 (t, 1 H), 7.10 (d, 1 H), 7.34 - 7.42 (m, 2H), 8.1 1 (s, 1 H), 8.21 (d, 1 H), 9.21 (s, 1 H), 12.63 (br s, 1 H).
Example 105
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[(4-methyl- 1 ,2,5-oxadiazol-3-yl)meth l]urea
Figure imgf000356_0001
In analogy to example 1 , 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[(4-methyl-1 ,2,5- oxadiazol-3-yl)methyl]urea (144 mg, 241 μηηοΙ, intermediate 1 15) was stirred with
trifluoroacetic acid (1 .6 ml_, 21 mmol) in dichloromethane (3.3 ml_). After purification using a Biotage chromatography system (1 1 g snap KP-NH column, hexane / 0 - 100% ethyl acetate, then ethyl acetate / 0 - 100% ethanol), we obtained 69.3 mg (93 % purity, 57 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 2.39 (s, 3H), 4.52 (d, 2H), 6.47 (d, 1 H), 7.08 (t, 1 H), 7.35 - 7.43 (m, 2H), 8.1 1 (s, 1 H), 8.21 (d, 1 H), 9.29 (s, 1 H), 12.63 (br s, 1 H). Example 106
1 -(3,5 lifluoro^^[3-(trifluoromethyl)-1 H-pyrTolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[(2- methoxypyridin-4-yl)methyl]urea
Figure imgf000357_0001
In analogy to example 1 , 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[(2-methoxypyridin-4- yl)methyl]urea (139 mg, 222 μηηοΙ, intermediate 1 16) was stirred with trifluoroacetic acid (1 .5 ml_, 20 mmol) in dichloromethane (3.0 ml_). After purification using a Biotage
chromatography system (1 1 g snap KP-NH column, hexane / 0 - 100% ethyl acetate, then ethyl acetate / 0 - 100% ethanol), we obtained 73.4 mg (90 % purity, 60 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 3.83 (s, 3H), 4.30 (d, 2H), 6.47 (d, 1 H), 6.69 (s, 1 H), 6.91 (dd, 1 H), 6.99 (t, 1 H), 7.37 - 7.43 (m, 2H), 8.08 - 8.13 (m, 2H), 8.21 (d, 1 H), 9.25 (s, 1 H), 12.63 (s, 1 H).
Example 107
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[(1 -methyl-1 H- imidazol-4-yl)methyl]urea
Figure imgf000357_0002
In analogy to example 1 , 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[(1 -methyl-1 H- imidazol-4-yl)methyl]urea (172 mg, 288 μηηοΙ, intermediate 1 17) was stirred with trifluoroacetic acid (2.0 ml_, 25 mmol) in dichloromethane (3.9 ml_). After purification using a Biotage chromatography system (1 1 g snap KP-NH column, hexane / 0 - 100% ethyl acetate, then ethyl acetate / 0 - 100% ethanol), we obtained 46.6 mg (90 % purity, 31 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 3.61 (s, 3H), 4.14 (d, 2H), 6.47 (d, 1 H), 6.61 (t, 1 H), 6.98 (s, 1 H), 7.33 - 7.40 (m, 2H), 7.52 (s, 1 H), 8.1 1 (s, 1 H), 8.21 (d, 1 H), 9.08 (s, 1 H), 12.63 (br s, 1 H).
Example 108
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-{2-[(2RS,6RS)- 2,6-dimethylmorpholin-4-yl]ethyl}urea
Figure imgf000358_0001
In analogy to example 1 , 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-{2-[(2RS,6RS)-2,6- dimethylmorpholin-4-yl]ethyl}urea (166 mg, 258 μηηοΙ, intermediate 1 18) was stirred with trifluoroacetic acid (1 .7 mL, 23 mmol) in dichloromethane (3.5 mL). After purification using a Biotage chromatography system (1 1 g snap KP-NH column, hexane / 0 - 100% ethyl acetate, then ethyl acetate / 0 - 100% ethanol), we obtained 26.2 mg (90 % purity, 18 % yield) of the desired title compound.
NMR of main isomer:
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: 1 .05 (d, 6H), 2.28 - 2.45 (m, 4H), 2.77 (br d, 2H), 3.19
- 3.26 (m, 2H), 3.52 - 3.61 (m, 2H), 6.30 (t, 1 H), 6.46 (d, 1 H), 7.32 - 7.41 (m, 2H), 8.1 1 (s, 1 H), 8.21 (d, 1 H), 9.16 (s, 1 H), 12.63 (br s, 1 H).
Example 109
1 -[(2-cyanopyridin-4-yl)methyl]-3-(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrroloP
yl]oxy}phenyl)urea
Figure imgf000359_0001
In analogy to example 77, 1 -[(2-cyanopyridin-4-yl)methyl]-3-(3,5-difluoro-4-{[3-(trifluoromethyl)- 1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)urea (1 1 1 mg, 179 μηηοΙ, intermediate 1 19) was stirred with trifluoroacetic acid (1.2 ml_, 16 mmol) in
dichloromethane (2.4 ml_). After purification using a Biotage chromatography system and a subsequent preparative HPLC (according to method 1 ) we obtained 35.6 mg (97 % purity, 39 % yield) of the desired title compound.
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: 4.41 (d, 2H), 6.46 (d, 1 H), 7.10 (t, 1 H), 7.36 - 7.43 (m, 2H), 7.65 (dd, 1 H), 7.95 (d, 1 H), 8.1 1 (s, 1 H), 8.21 (d, 1 H), 8.71 (d, 1 H), 9.38 (s, 1 H), 12.59 (br s, 1 H).
Example 110
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(pyridazin-4- ylmethyl)urea
Figure imgf000359_0002
In analogy to example 77, 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(pyridazin-4- ylmethyl)urea (49.8 mg, 83.8 μηηοΙ, intermediate 120) was stirred with trifluoroacetic acid (570 μΙ_, 7.4 mmol) in dichloromethane (1 .1 ml_). After purification using a Biotage chromatography system and a subsequent preparative HPLC (according to method 1 ) we obtained 8.10 mg (97 % purity, 20 % yield) of the desired title compound.
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: 4.38 (d, 2H), 6.46 (d, 1 H), 7.1 1 (t, 1 H), 7.35 - 7.44 (m, 2H), 7.56 (dd, 1 H), 8.1 1 (s, 1 H), 8.21 (d, 1 H), 9.15 - 9.20 (m, 2H), 9.40 (s, 1 H), 12.33 (br s, 1 H).
Example 111
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(1 ,2,4- oxadiazol-3-ylmethyl)urea
Figure imgf000360_0001
In analogy to example 1 , 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(1 ,2,4-oxadiazol-3- ylmethyl)urea (1 12 mg, 192 μηηοΙ, intermediate 121 ) was stirred with trifluoroacetic acid (1 .3 ml_, 17 mmol) in dichloromethane (2.6 ml_). After purification using a Biotage
chromatography system (1 1 g snap KP-NH column, hexane / 0 - 100% ethyl acetate, then ethyl acetate / 0 - 100% ethanol), we obtained 29.7 mg (97 % purity, 33 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 4.50 (d, 2H), 6.47 (d, 1 H), 7.06 (t, 1 H), 7.35 - 7.44 (m, 2H), 8.1 1 (s, 1 H), 8.21 (d, 1 H), 9.34 (s, 1 H), 9.57 (s, 1 H), 12.06 (br s, 1 H).
Example 112
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyTO^
ylmethyl)urea
Figure imgf000361_0001
In analogy to example 77, 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(1 ,3-oxazol-2- ylmethyl)urea (175 mg, 300 μηηοΙ), intermediate 122) was stirred with trifluoroacetic acid (2.0 ml_, 26 mmol) in dichloromethane (4.1 ml_). After purification using a Biotage
chromatography system and a subsequent preparative HPLC (according to method 1 ) we obtained 36.7 mg (97 % purity, 26 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 4.43 (d, 2H), 6.47 (d, 1 H), 7.03 (t, 1 H), 7.17 (s, 1 H), 7.36 - 7.43 (m, 2H), 8.06 (s, 1 H), 8.1 1 (s, 1 H), 8.21 (d, 1 H), 9.32 (s, 1 H), 12.60 (br s, 1 H).
Example 113
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(1 ,3-thiazol-5- ylmethyl)urea
Figure imgf000361_0002
In analogy to example 77, 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(1 ,3-thiazol-5- ylmethyl)urea (136 mg, 227 μηηοΙ, intermediate 123) was stirred with trifluoroacetic acid (1 .5 ml_, 20 mmol) in dichloromethane (3.1 ml_). After purification using a Biotage
chromatography system and a subsequent preparative HPLC (according to method 1 ) we obtained 18.9 mg (97 % purity, 17 % yield) of the desired title compound. 1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 4.53 (d, 2H), 6.48 (d, 1 H), 7.05 (t, 1 H), 7.37 - 7.43 2H), 7.79 (s, 1 H), 8.1 1 (s, 1 H), 8.21 (d, 1 H), 8.98 (d, 1 H), 9.19 (s, 1 H), 12.63 (br s, 1 H).
Example 114
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[2-(2-oxa-6 azaspiro[3.3]hept-6-yl)ethyl]urea
Figure imgf000362_0001
To a solution of 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[2-(2-oxa-6-azaspiro[3.3]hept-6-yl)ethyl]urea (1 16 mg, 185 μηιοΙ, intermediate 124) in dichloromethane (2.5 mL) was added trifluoroacetic acid
(1 .3 mL, 16 mmol) and this mixture was stirred 3h at room temperature. The reaction mixture was carefully poured into an aqueous solution of sodium hydrogencarbonate. This aqueous phase was extracted two times with ethyl actetate. Then the combined organic phases were washed with brine, dried over sodium sulfate and then after filtration evaporated to dryness in vacuum. The obtained crude product was purified by preparative HPLC (according to method 1 ) to obtain 29.8 mg (97 % purity, 31 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 2.39 - 2.46 (m, 2H), 3.04 (q, 2H), 3.29 - 3.33 (m, 4H), 4.60 (s, 4H), 6.29 (br t, 1 H), 6.46 (d, 1 H), 7.31 - 7.38 (m, 2H), 8.1 1 (s, 1 H), 8.21 (d, 1 H), 9.1 1 (s, 1 H), 12.63 (br s, 1 H).
Example 115
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[(5-methyl- 1 ,3,4-oxadiazol-2-yl)meth l]urea
Figure imgf000362_0002
In analogy to example 1 14, 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[(5-methyl-1 ,3,4- oxadiazol-2-yl)methyl]urea (1 18 mg, 197 μηηοΙ, intermediate 125) was stirred with trifluoroacetic acid (1 .3 mL, 17 mmol) in dichloromethane (2.7 mL). After purification using a preparative HPLC (according to method 1 ) we obtained 9.80 mg (97 % purity, 10 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 2.48 (s, 3H), 4.51 (d, 2H), 6.47 (d, 1 H), 7.10 (t, 1 H), 7.37 - 7.43 (m, 2H), 8.1 1 (s, 1 H), 8.21 (d, 1 H), 9.38 (s, 1 H).
Example 116
N-(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-N'-[(3- methyloxetan-3-yl)methyl]urea
Figure imgf000363_0001
In analogy to example 67, N-(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-N'-[(3-methyloxetan-3- yl)methyl]urea (124 mg, 212 μηιοΙ, intermediate 126) were reacted with 1 N tetra-N- butylammoniumfluoride in tetrahydrofurane (850 μί, 1 .0 M, 850 μηηοΙ) and ethylenediamine (58 μί, 870μΜ) in DMF (2.5 mL) to give after purification via a Biotage chromatography system, a subsequent HPLC chromatography followed by a preparative thin layer chromatography using dichloromethane / methanol (8:2) 34.3 mg (95 % purity, 34 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 1 .23 (s, 3H), 3.28 - 3.32 (m, 2H), 4.21 (d, 2H), 4.38 (d, 2H), 6.47 (d, 1 H), 6.79 (t, 1 H), 7.36 - 7.44 (m, 2H), 8.1 1 (s, 1 H), 8.21 (d, 1 H), 9.12 (s, 1 H), 12.64 (br s, 1 H). Example 117
1 -(3,5 lifluoro^^[3-(trifluoromethyl)-1 H-pyrTolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(5- methylpyridazin-3-yl)urea
Figure imgf000364_0001
In analogy to example 1 , 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(5-methylpyridazin-3- yl)urea (39.5 mg, 66.4 μηηοΙ, intermediate 127) was stirred with trifluoroacetic acid (450 μΙ_, 5.8 mmol) in dichloromethane (900 μΙ_). After purification using a Biotage chromatography system (1 1 g snap KP-NH column, hexane / 0 - 100% ethyl acetate, then ethyl acetate / 0 - 100% ethanol), we obtained 13.2 mg (92 % purity, 39 % yield) of the desired title compound. 1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 2.33 (s, 3H), 6.51 (d, 1 H), 7.51 (d, 2H), 7.86 (s, 1 H), 8.13 (s, 1 H), 8.23 (d, 1 H), 8.80 (d, 1 H), 9.91 (br s, 1 H), 10.21 (br s, 1 H), 12.65 (br s, 1 H).
Example 118
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[(2R)- tetrahydrofuran-2-ylmethyl]urea
Figure imgf000364_0002
In analogy to example 1 14, 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[(2R)-tetrahydrofuran- 2-ylmethyl]urea (171 mg, 291 μηηοΙ, intermediate 128) was stirred with trifluoroacetic acid (2.0 ml_, 26 mmol) in dichloromethane (3.9 ml_). After purification using a preparative HPLC (according to method 1 ) we obtained 24.5 mg (97 % purity, 18 % yield) of the desired title compound.
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: 1.47 - 1 .57 (m, 1 H), 1 .77 - 1.95 (m, 3H), 3.06 - 3.16 (m, 1 H), 3.20 - 3.29 (m, 1 H), 3.61 - 3.67 (m, 1 H), 3.75 - 3.82 (m, 1 H), 3.83 - 3.91 (m, 1 H), 6.40 - 6.49 (m, 2H), 7.32 - 7.40 (m, 2H), 8.1 1 (s, 1 H), 8.21 (d, 1 H), 9.04 (s, 1 H), 12.59 (br s, 1 H). Example 119
1 -(3,5 lifluoro^^[3-(trifluoromethyl)-1 H-pyrTolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[(2S)- tetrahydrofuran-2-ylmethyl]urea
Figure imgf000365_0001
In analogy to example 1 14, 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[(2S)-tetrahydrofuran- 2-ylmethyl]urea (136 mg, 232 μηηοΙ, intermediate 129) was stirred with trifluoroacetic acid (1 .6 mL, 20 mmol) in dichloromethane (3.1 mL). After purification using a preparative HPLC (according to method 1 ) we obtained 42.6 mg (97 % purity, 39 % yield) of the desired title compound.
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: 1.47 - 1 .57 (m, 1 H), 1 .77 - 1.95 (m, 3H), 3.06 - 3.16 (m, 1 H), 3.20 - 3.29 (m, 1 H), 3.61 - 3.67 (m, 1 H), 3.75 - 3.82 (m, 1 H), 3.83 - 3.91 (m, 1 H), 6.40 - 6.49 (m, 2H), 7.32 - 7.40 (m, 2H), 8.1 1 (s, 1 H), 8.21 (d, 1 H), 9.04 (s, 1 H), 12.37 (br s, 1 H). Example 120
(+/-)-1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[(5,5- dimethyltetrahydrofuran-2- l)methyl]urea
Figure imgf000365_0002
In analogy to example 1 14, (+/-)-1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[(5,5- dimethyltetrahydrofuran-2-yl)methyl]urea (177 mg, 288 μηηοΙ), intermediate 130) was stirred with trifluoroacetic acid (1.9 mL, 25 mmol) in dichloromethane (3.9 mL). After purification using a preparative HPLC (according to method 1 ) we obtained 49.8 mg (92 % purity, 33 % yield) of the desired title compound. 1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 1 .16 (s, 3H), 1.22 (s, 3H), 1.59 - 1 .74 (m, 3H), 1 .93 - 2.03 (m, 1 H), 3.03 - 3.1 1 (m, 1 H), 3.21 - 3.29 (m, 1 H), 3.92 - 4.00 (m, 1 H), 6.39 (br t, 1 H), 6.47 (d, 1 H), 7.32 - 7.39 (m, 2H), 8.1 1 (s, 1 H), 8.21 (d, 1 H), 9.12 (s, 1 H), 12.62 (br s, 1 H). Example 121
1 -(3,5-difluoro-4-{[3-(trifluoromet^
2H-pyran-4-yl)urea
Figure imgf000366_0001
In analogy to example 1 , 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(tetrahydro-2H-pyran- 4-yl)urea (132 mg, 225 μηηοΙ, intermediate 131 ) was stirred with trifluoroacetic acid (1 .5 ml_, 20 mmol) in dichloromethane (3.0 ml_). After purification using a Biotage chromatography system (1 1 g snap KP-NH column, hexane / 0 - 100% ethyl acetate, then ethyl acetate / 0 - 100% ethanol), we obtained 44.2 mg (97 % purity, 42 % yield) of the desired title compound. Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: 1 .36 - 1 .47 (m, 2H), 1.75 - 1 .83 (m, 2H), 3.38 (dt, 2H), 3.64 - 3.74 (m, 1 H), 3.83 (dt, 2H), 6.46 (d, 1 H), 6.50 (d, 1 H), 7.34 - 7.41 (m, 2H), 8.1 1 (s, 1 H), 8.21 (d, 1 H), 8.88 (s, 1 H), 12.63 (br s, 1 H).
Example 122
(+/-)-1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3- (tetrahydro-2H-pyran-2-ylmethyl)urea
Figure imgf000366_0002
In analogy to example 1 , (+/-)-1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(tetrahydro-2H-pyran- 2-ylmethyl)urea (128 mg, 213 μηηοΙ, intermediate 132) was stirred with trifluoroacetic acid (1.4 mL, 19 mmol) in dichloromethane (2.9 mL). After purification using a Biotage
chromatography system (11 g snap KP-NH column, hexane / 0 - 100% ethyl acetate, then ethyl acetate / 0 - 100% ethanol) we obtained 32.0 mg (92 % purity, 29 % yield) of the desired title compound.
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: 1.13 - 1.30 (m, 1H), 1.40 - 1.51 (m, 3H), 1.55 (br d, 1H), 1.77 (br s, 1H), 2.98 - 3.06 (m, 1H), 3.23 (ddd, 1H), 3.28 - 3.40 (m, 2H), 3.86 - 3.93 (m, 1H), 6.41 -6.49 (m, 2H), 7.32 -7.38 (m, 2H), 8.11 (s, 1H), 8.21 (d, 1H), 9.08 (s, 1H), 12.63 (br s, 1H).
Example 123
(+/-)-1-(3,5-difluoro-4-{[3-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3- (tetrahydro-2H-pyran-3-yl)urea
Figure imgf000367_0001
In analogy to example 1, (+/-)-1-(3,5-difluoro-4-{[3-(trifluoromethyl)-1-{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(tetrahydro-2H-pyran- 3-yl)urea (145 mg, 247 μηηοΙ, intermediate 133) was stirred with trifluoroacetic acid (1.7 mL, 22 mmol) in dichloromethane (3.4 mL). After purification using a Biotage chromatography system (11 g snap KP-NH column, ethyl acetate / 0 - 50% ethanol) we obtained 76.4 mg (97 % purity, 66 % yield) of the desired title compound.
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: 1.46 - 1.58 (m, 2H), 1.62 - 1.74 (m, 1H), 1.79 - 1.90 (m, 1H), 3.25 (dd, 1H), 3.42 - 3.51 (m, 1H), 3.57 - 3.67 (m, 2H), 3.72 (dd, 1H), 6.46 (d, 1H), 6.54 (d, 1H), 7.32 -7.39 (m, 2H), 8.11 (s, 1H), 8.21 (d, 1H), 8.93 (s, 1H), 12.63 (s, 1H).
Example 124
(+/-)-1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[ methyltetrahydrofuran-2-yl methyl]urea
Figure imgf000368_0001
In analogy to example 1 , (+/-)-1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[(2- methyltetrahydrofuran-2-yl)methyl]urea (150 mg, 250 μmol, intermediate 134) was stirred with trifluoroacetic acid (1 .7 ml_, 22 mmol) in dichloromethane (3.4 ml_). After purification using a Biotage chromatography system (1 1 g snap KP-NH column, ethyl acetate / 0 - 50% ethanol) we obtained 86.4 mg (97 % purity, 71 % yield) of the desired title compound.
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: 1 .12 (s, 3H), 1 .52 - 1.66 (m, 1 H), 1.72 - 1 .93 (m, 3H), 3.15 (ddd, 2H), 3.75 (td, 2H), 6.38 (t, 1 H), 6.47 (d, 1 H), 7.32 - 7.39 (m, 2H), 8.1 1 (s, 1 H), 8.21 (d, 1 H), 9.05 (s, 1 H), 12.63 (s, 1 H). Example 125
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(2-methoxy-2- methylpropyl)urea
Figure imgf000368_0002
In analogy to example 1 , 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(2-methoxy-2- methylpropyl)urea (136 mg, 231 μηηοΙ, intermediate 135) was stirred with trifluoroacetic acid (1 .6 ml_, 21 mmol) in dichloromethane (3.2 ml_). After purification using a Biotage
chromatography system (1 1 g snap KP-NH column, ethyl acetate / 0 - 50% ethanol) we obtained 84.9 mg (97 % purity, 78 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 1 .10 (s, 6H), 3.13 (s, 3H), 3.15 (d, 2H), 6.31 (t, 1 H), 6.47 (d, 1 H), 7.31 - 7.38 (m, 2H), 8.1 1 (s, 1 H), 8.21 (d, 1 H), 9.08 (s, 1 H), 12.63 (s, 1 H). Example 126
1 -(3,5-difluoro-4-{[3-(trifluorom
(morpholin-4-yl)propyl]urea
Figure imgf000369_0001
In analogy to example 1 , 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[2-methyl-2- (morpholin-4-yl)propyl]urea (144 mg, 224 μηηοΙ, intermediate 136) was stirred with
trifluoroacetic acid (1 .6 mL, 20 mmol) in dichloromethane (3.1 mL). After purification using a Biotage chromatography system (1 1 g snap KP-NH column, ethyl acetate / 0 - 50% ethanol) we obtained 89.2 mg (95 % purity, 74 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 0.97 (s, 6H), 2.44 - 2.48 (m, 4H), 3.10 (d, 2H), 3.57 - 3.65 (m, 4H), 6.16 (t, 1 H), 6.47 (d, 1 H), 7.33 - 7.39 (m, 2H), 8.1 1 (s, 1 H), 8.21 (d, 1 H), 9.27 (s, 1 H), 12.63 (s, 1 H). Example 127
(+/-)-1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3- (tetrahydro-2H-pyran-3-ylmethyl)urea
Figure imgf000369_0002
In analogy to example 1 , (+/-)-1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(tetrahydro-2H-pyran- 3-ylmethyl)urea (134 mg, 223 μηηοΙ, intermediate 137) was stirred with trifluoroacetic acid (1 .6 mL, 20 mmol) in dichloromethane (3.1 mL). After purification using a Biotage
chromatography system (1 1 g snap KP-NH column, ethyl acetate / 0 - 50% ethanol) we obtained 86.4 mg (95 % purity, 78 % yield) of the desired title compound. Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: 1.16 - 1 .31 (m, 1 H), 1 .40 - 1.52 (m, 1 H), 1.54 - 1.80 (m, 3H), 2.94 - 3.03 (m, 2H), 3.09 (dd, 1 H), 3.26 - 3.32 (m, 1 H), 3.68 - 3.79 (m, 2H), 6.44 - 6.50 (m, 2H), 7.34 - 7.41 (m, 2H), 8.1 1 (s, 1 H), 8.21 (d, 1 H), 8.93 (s, 1 H), 12.63 (s, 1 H). Example 128
(+/-)-1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3- (tetrahydrofuran-3-ylmethyl)urea
Figure imgf000370_0001
In analogy to example 1 , (+/-)-1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(tetrahydrofuran-3- ylmethyl)urea (143 mg, 244 μηηοΙ, intermediate 138) was stirred with trifluoroacetic acid (1 .7 ml_, 22 mmol) in dichloromethane (3.4 ml_). After purification using a Biotage
chromatography system (1 1 g snap KP-NH column, ethyl acetate / 0 - 50% ethanol) we obtained 84.4 mg (95 % purity, 72 % yield) of the desired title compound.
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: 1 .55 (td, 1 H), 1 .87 - 1 .98 (m, 1 H), 2.34 - 2.46 (m, 1 H), 3.05 - 3.15 (m, 2H), 3.42 (dd, 1 H), 3.62 (q, 1 H), 3.66 - 3.77 (m, 2H), 6.47 (d, 1 H), 6.56 (t, 1 H), 7.33 - 7.43 (m, 2H), 8.1 1 (s, 1 H), 8.21 (d, 1 H), 8.97 (s, 1 H), 12.63 (br s, 1 H).
Example 129
1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-pyridazin-4-ylurea
Figure imgf000370_0002
To 1 -{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}-3-pyridazin-4-ylurea (43.0 mg, 100 % purity, 78.6 μηηοΙ, intermediate 139) in dichloromethane (900 μΙ_) was added trifluoroacetic acid (420 μΙ_, 5.5 mmol) and this mixture was stirred over night at room temperature. The reaction mixture was carefully poured into an aqueous solution of sodium hydrogencarbonate. This aqueous phase was extracted two times with ethyl actetate. Then the combined organic phases were washed with brine and then evaporated to dryness in vacuum. The obtained crude product was purified by preparative HPLC (according to method 2) to obtain 6.00 mg (95 % purity, 17 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 6.36 (d, 1 H), 7.47 - 7.53 (m, 2H), 7.63 (s, 1 H), 7.82 (dd, 1 H), 8.1 1 (d, 1 H), 8.96 (d, 1 H), 9.23 (d, 1 H), 9.92 (br s, 2H), 12.14 (br s, 1 H).
Example 130
1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(6-methylpyrid yl)urea
Figure imgf000371_0001
To 1 -{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}-3-(6-methylpyridazin-3-yl)urea (580 mg, 1 .03 mmol, intermediate 140) in dichloromethane (40 mL) was added trifluoroacetic acid (5.6 ml_, 72 mmol) and this mixture was stirred over night at room temperature. The reaction mixture was carefully poured into an aqueous solution of sodium hydrogencarbonate. This aqueous phase was extracted two times with ethyl actetate. Then the combined organic phases were washed with brine and then evaporated to dryness in vacuum. The obtained crude product was purified via a Biotage chromatography system (KP-NH snap column; dichloromethane / methanol gradient with up to 100% methanol) to obtain 90 mg (19 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 2.55 (s, 3H); 6.36 (d, 1 H); 7.48-7.58 (m, 3H); 7.63 (d, 1 H); 7.92 (d, 1 H); 8.1 1 (d, 1 H); 9.93 (bs, 1 H); 10.2 (bs, 1 H); 12.15 (bs, 1 H). Example 131
1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]p ridin-4- l)oxy]-3,5-difluorophenyl}-3-pyridin-3-ylurea
Figure imgf000372_0001
To 1 -{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}-3-pyridin-3-ylurea (105 mg, 192 μηηοΙ, intermediate 141 ) in dichloromethane (2 mL) was added trifluoroacetic acid (1 ml_, 13 mmol) and this mixture was stirred over night at room temperature. The reaction mixture was carefully poured into an aqueous solution of sodium hydrogencarbonate. This aqueous phase was extracted two times with ethyl actetate. Then the combined organic phases were washed with brine and then evaporated to dryness in vacuum. The obtained crude product was purified by preparative HPLC (according to method 2) to obtain 23 mg (27 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 6.35 (d, 1 H); 7.34 (ddd, 1 H); 7.45-7.50 (m, 2H); 7.62 (d, 1 H); 7.93-7.98 (m, 1 H); 8.1 1 (d, 1 H); 8.22 (dd, 1 H); 8.63 (d, 1 H); 9.19 (bs, 1 H); 9.42 (bs, 1 H); 12.14 (bs, 1 H).
Example 132
1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]p ridin-4- l)oxy]-3,5-difluorophenyl}-3-pyridin-2-ylurea
Figure imgf000372_0002
To 1 -{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}-3-pyridin-2-ylurea (30.0 mg, 54.9 μηηοΙ, intermediate 142) in dichloromethane (0.6 mL) was added trifluoroacetic acid (0.3 mL, 3.8 mmol) and this mixture was stirred over night at room temperature. The reaction mixture was carefully poured into an aqueous solution of sodium hydrogencarbonate. This aqueous phase was extracted two times with ethyl actetate. Then the combined organic phases were washed with brine and then evaporated to dryness in vacuum. The obtained crude product was purified by preparative HPLC (according to method 3) to obtain 4 mg (17 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 6.36 (d, 1 H); 7.03-7.08 (m, 1 H); 7.47 (d, 1 H); 7.58- 7.64 (m, 3H); 7.75-7.82 (m, 1 H); 8.1 1 (d, 1 H); 8.30-8.34 (m, 1 H); 9.77 (bs, 1 H); 1 1 .18 (bs, 1 H); 12.14 (bs, 1 H).
Example 133
1 -[3,5-difluoro-4-(1 H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-3-[2-(piperidin-1 -yl)ethyl]urea
Figure imgf000373_0001
To a 1 -{3,5-difluoro-4-[(1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4- yl)oxy]phenyl}-3-[2-(piperidin-1 -yl)ethyl]urea (1 10 mg, 202 μηηοΙ, intermediate 147) in dichloromethane (300 μΙ_) was added trifluoroacetic acid (20.0 eq., 310 μΙ_) and this mixture was stirred overnight at room temperature. The reaction mixture was evaporated to dryness in vacuo to give a mixture of the title compound and 1 -(3,5-difluoro-4-{[1 -(hydroxymethyl)-1 H- pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[2-(piperidin-1 -yl)ethyl]urea. To this crude material THF (500 μΙ_) and aqueous sodium hydroxide (400 μΙ_, 2.0 M, 790 μηιοΙ) were added and the mixture stirred at 50 °C overnight. The reaction mixture was evaporated to dryness in vacuo and the residue subjected to preparative HPLC (method 4) to give the title compound (10 mg, 9%).
LC-MS (method 2): Rt = 1 .09 min; MS (ESIpos): m/z = 416 [M+H]+.
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: 1.39 - 1 .42 (m, 2H), 1.49 - 1.54 (m, 4H), 2.32 - 2.37 (m, 6H), 3.20 (q, 2H), 6.28 - 6.30 (m, 2H), 6.40 (d, 1 H), 7.32 - 7.38 (m, 2H), 7.40 (dd, 1 H), 8.08 (d, 1 H), 9.21 (bs, 1 H), 1 1.82 (bs, 1 H). Example 134
N3-{[3,5-difluoro-4-(1 H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]carbamoyl}-beta-alaninamide
Figure imgf000374_0001
In analogy to example 133 N3-({3,5-difluoro-4-[(1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl}carbamoyl)-beta-alaninamide (65.0 mg, 129 μηιοΙ, intermediate 148) was treated with trifluoroacetic acid (198 μΙ_) in dichloromethane and subsequently with aqueous sodium hydroxide (260 μΙ_, 2.0 M, 520 μηηοΙ) in THF to give after preparative HPLC (method 4) the title compound (1.7 mg, 2%).
LC-MS (method 2): Rt = 0.77 min; MS (ESIpos): m/z = 376 [M+H]+.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 2.28 (t, 2H), 3.29 (q, 2H), 6.17 - 6.45 (m, 3H), 6.92 (bs, 1 H), 7.31 - 7.41 (m, 4H), 7.97 - 8.08 (m, 1 H), 9.1 1 - 9.13 (m, 1 H), 1 1.47 - 1 1 .82 (m, 1 H).
Example 135
1 -[3,5-difluoro-4-(1 H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-3-(1 H-1 ,2,3-triazol-5-ylmethyl)urea
Figure imgf000374_0002
In analogy to example 133 1 -{3,5-difluoro-4-[(1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl}-3-(1 H-1 ,2,3-triazol-5-ylmethyl)urea (48.0 mg, 93 μηηοΙ, intermediate 149) was treated with trifluoroacetic acid (143 μΙ_) in dichloromethane and subsequently with aqueous sodium hydroxide (190 μΙ_, 2.0 M, 370 μηηοΙ) in THF to give after preparative HPLC (method 4) the title compound (6.5 mg, 12%).
LC-MS (method 2): Rt = 0.59 min; MS (ESIpos): m/z = 386 [M+H]+.
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: 4.38 - 4.44 (m, 3H), 6.17 - 6.40 (m, 1 H), 6.86 - 6.90 (m, 1 H), 7.06 - 7.41 (m, 3H), 7.72 (bs, 1 H), 7.97 - 8.08 (m, 1 H), 9.1 1 - 9.13 (m, 1 H), 1 1 .48 - 1 1.83 (m, 1 H), 14.85 (bs, 1 H). Example 136
1 -[3,5-difluoro-4-(1 H-pyrrolo 2,3-b]pyridin-4-yloxy)phenyl]-3-[3-(dimethylamino)propyl]urea
Figure imgf000375_0001
In analogy to example 133 1 -{3,5-difluoro-4-[(1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl}-3-[3-(dimethylamino)propyl]urea (51.0 mg, 131 μηιοΙ, intermediate 150) was treated with trifluoroacetic acid (1 mL) in dichloromethane and subsequently with aqueous sodium hydroxide (200 μΙ_, 2.0 M, 390 μηηοΙ) in THF to give after preparative HPLC (method 4) the title compound (15 mg, 29%).
LC-MS (method 2): Rt = 0.96 min; MS (ESIpos): m/z = 390 [M+H]+.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 1.56 (quint, 2H), 2.13 (s, 6H), 2.23 (t, 2H), 3.12 (q, 2H), 6.29 (d, 1 H), 6.39 (d, 1 H), 6.60 (t, 1 H), 7.34 - 7.40 (m, 3H), 8.07 (d, 1 H), 9.17 (bs, 1 H), 1 1.82 (bs, 1 H).
Example 137
4-({[3,5-difluoro-4-(1 H-p rrolo[2,3-b]pyridin-4-yloxy)phenyl]carbamoyl}amino)butanamide
Figure imgf000375_0002
In analogy to example 133 4-[({3,5-difluoro-4-[(1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl}carbamoyl)amino]butanamide (96.0 mg, 185 μηιοΙ, intermediate 151 ) was treated with trifluoroacetic acid (285 μΙ_) in dichloromethane and subsequently with aqueous sodium hydroxide (370 μΙ_, 2.0 M, 740 μηηοΙ) in THF to give after preparative HPLC (method 4) the title compound (1.2 mg, 1 %).
LC-MS (method 2): Rt = 0.79 min; MS (ESIpos): m/z = 390 [M+H]+.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 1.65 (quint, 2H), 2.08 (t, 2H), 3.09 (q, 2H), 4.44 (s, 1 H), 6.17 - 6.28 (m, 1 H), 6.39 - 6.46 (m, 1 H), 6.77 (bs, 1 H), 7.07. (d, 1 H), 7.31 - 7.41 (m, 3H), 7.97 - 8.08 (m, 1 H), 8.98 - 9.00 (m, 1 H), 1 1.48 - 1 1.82 (m, 1 H). Example 138
1 -[3,5-difluoro-4-(1 H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-3-(2-methoxyethyl)urea
Figure imgf000376_0001
In analogy to example 133 1 -{3,5-difluoro-4-[(1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl}-3-(2-methoxyethyl)urea (68.0 mg, 138 μηιοΙ, intermediate 152) was treated with trifluoroacetic acid (213 μΙ_) in dichloromethane and subsequently with aqueous sodium hydroxide (280 μΙ_, 2.0 M, 560 μηηοΙ) in THF to give after preparative HPLC (method 4) the title compound (1.7 mg, 2%).
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: 3.24 - 3.31 (m, 7H), 6.28 - 6.29 (m, 1 H), 6.40 (d, 1 H), 6.51 (t, 1 H), 7.32 - 7.40 (m, 3H), 8.07 (d, 1 H), 9.13 (bs, 1 H), 1 1 .82 (bs, 1 H).
Example 139
1 -[3,5-difluoro-4-(1 H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-3-(pyridin-2-ylmethyl)urea
Figure imgf000376_0002
In analogy to example 133 1 -{3,5-difluoro-4-[(1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl}-3-(pyridin-2-ylmethyl)urea (65.0 mg, 124 μηιοΙ, intermediate 153) was treated with trifluoroacetic acid (190 μΙ_) in dichloromethane and subsequently with aqueous sodium hydroxide (250 μΙ_, 2.0 M, 490 μηηοΙ) in THF to give after preparative HPLC (method 4) the title compound (1.1 mg, 2%).
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 4.43 (d, 2H), 6.28 - 6.30 (m, 1 H), 6.40 (d, 1 H), 7.22 (t, 1 H), 7.28 (ddd, 1 H), 7.35 - 7.42 (m, 4H), 7.79 (dt, 1 H), 8.07 (d, 1 H), 8.52 - 8. 54 (m, 1 H), 9.53 (bs, 1 H), 1 1 .82 (bs, 1 H). Example 140
1 -[3,5-difluoro-4-(1 H-pyrrolo[2,3-b]p ridin-4-yloxy)phenyl]-3-[3-(methylsulfonyl)propyl]urea
Figure imgf000377_0001
In analogy to example 133 1 -{3,5-difluoro-4-[(1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl}-3-[3-(methylsulfonyl)propyl]urea (73.0 mg, 132 μηιοΙ, intermediate 154) was treated with trifluoroacetic acid (250 μΙ_) in dichloromethane and subsequently with aqueous sodium hydroxide (260 μΙ_, 2.0 M, 520 μηηοΙ) in THF to give after preparative HPLC (method 4) the title compound (25 mg, 33%).
LC-MS (method 2): Rt = 0.84 min; MS (ESIpos): m/z = 425 [M+H]+.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 1.83 - 1 .91 (m, 2H), 2.99 (s, 3H), 3.1 1 - 3.15 (m, 2H), 3.22 (q, 2H), 6.28 - 6.29 (m, 1 H), 6.39 (d, 1 H), 6.54 (t, 1 H), 7.35 - 7.41 (m, 3H), 8.08 (d, 1 H), 9.05 (s, 1 H), 1 1.83 (bs, 1 H).
Example 141
1 -[3,5-difluoro-4-(1 H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-3-[2-(dimethylamino)ethyl]urea
Figure imgf000377_0002
In analogy to example 133 1 -{3,5-difluoro-4-[(1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl}-3-[2-(dimethylamino)ethyl]urea (56.0 mg, 1 1 1 μηιοΙ, intermediate 155) was treated with trifluoroacetic acid (170 μΙ_) in dichloromethane and subsequently with aqueous sodium hydroxide (200 μΙ_, 2.0 M, 400 μηηοΙ) in THF to give after preparative HPLC (method 4) the title compound (5 mg, 10%).
LC-MS (method 2): Rt = 0.92 min; MS (ESIpos): m/z = 376 [M+H]+.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 2.17 (s, 6H), 2.33 (t, 2H), 3.19 (q, 2H), 6.29 (d, 1 H), 6.40 (d, 1 H), 6.46 (t, 1 H), 7.32 - 7.38 (m, 2H), 7.40 (d, 1 H), 8.07 (d, 1 H), 9.33 (bs, 1 H), 1 1 .82 (bs, 1 H). Example 142
1 -[3,5-difluoro-4-(1 H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-3-[3-(piperidin-1 -yl)propyl]urea
Figure imgf000378_0001
In analogy to example 133 1 -{3,5-difluoro-4-[(1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl}-3-[3-(piperidin-1 -yl)propyl]urea (64.0 mg, 1 14 μηιοΙ, intermediate 156) was treated with trifluoroacetic acid (176 μΙ_) in dichloromethane and subsequently with aqueous sodium hydroxide (220 μΙ_, 2.0 M, 450 μηηοΙ) in THF to give after preparative HPLC (method 4) the title compound (13 mg, 19%).
LC-MS (method 2): Rt = 1 .12 min; MS (ESIpos): m/z = 430 [M+H]+.
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: 1 .36 - 1 .40 (m, 2H), 1.47 - 1 .52 (m, 4H), 1.59 (quint, 2H), 2.25 - 2.33 (m, 6H), 3.1 1 (q, 2H), 6.28 - 6.29 (m, 1 H), 6.39 (d, 1 H), 6.43 (t, 1 H), 7.33 - 7.38 (m, 2H), 7.40 (dd, 1 H), 8.08 (d, 1 H), 8.99 (bs, 1 H), 1 1 .82 (bs, 1 H).
Example 143
1 -{4-[(3-bromo-1 H-pyrrolo 2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(3-methoxypropyl)urea
Figure imgf000378_0002
A mixture of crude 1 -{4-[(3-bromo-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin- 4-yl)oxy]-3,5-difluorophenyl}-3-(3-methoxypropyl)urea (223 mg, 381 μηιοΙ, intermediate 160) in dichloromethane (2 mL) was treated with trifluoroacetic acid (20 eq., 590 μΙ_, 7.6 mmol) and this mixture was stirred overnight at room temperature. The reaction mixture was concentrated in vacuo and the residue subjected to preparative HPLC (method 4) to give the title compound (76.5 mg, 43%).
LC-MS (method 2): Rt = 1 .00 min; MS (ESIpos): m/z = 455/457 [M+H]+ (Br isotope pattern). 1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 1 .64 - 1 .71 (m, 2H), 3.15 (q, 2H), 3.25 (s, 3H), 3.36 (t, 2H), 6.32 (d, 1 H), 6.41 (t, 1 H), 7.35 - 7.40 (m, 2H), 7.64 (d, 1 H), 8.10 (d, 1 H), 9.00 (bs, 1 H), 12.20 (bs, 1 H). Example 144
1 -{4-[(3-bromo-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[(1 -methyl-1 H-pyrazol- 3-yl)methyl]urea
Figure imgf000379_0001
In analogy to example 143 crude 1 -{4-[(3-bromo-1-{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[(1 -methyl-1 H-pyrazol-3-yl)methyl]urea (231 mg, 380 μηηοΙ, intermediate 161 ) was reacted with trifluoroacetic acid (20 eq., 590 μΙ_, 7.6 mmol) in dichloromethane to give after preparative HPLC (method 4) the title compound (29 mg, 15%).
LC-MS (method 2): Rt = 0.95 min; MS (ESIpos): m/z = 477/479 [M+H]+ (Br isotope pattern).
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 3.80 (s, 3H), 4.24 (d, 2H), 6.13 (d, 1 H), 6.33 (d, 1 H), 6.71 (t, 1 H), 7.35 - 7.41 (m, 2H), 7.61 (d, 1 H), 7.64 (d, 1 H), 8.10 (d, 1 H), 9.08 (bs, 1 H), 12.21 (bs, 1 H). Example 145
1 -{4-[(3-bromo-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(1 ,3-thiazol-2- ylmethyl)urea
Figure imgf000379_0002
In analogy to example 143 crude 1 -{4-[(3-bromo-1-{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(1 ,3-thiazol-2-ylmethyl)urea (232 mg,
380 μηηοΙ, intermediate 162) was reacted with trifluoroacetic acid (20 eq., 590 μΙ_, 7.6 mmol) in dichloromethane to give after preparative HPLC (method 4) the title compound (63 mg, 33%).
LC-MS (method 2): Rt = 0.99 min; MS (ESIpos): m/z = 480/482 [M+H]+ (Br isotope pattern).
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 4.61 (d, 2H), 6.34 (d, 1 H), 7.26 (t, 1 H), 7.39 - 7.45 (m, 2H), 7.63 - 7.64 (m, 2H), 7.74 (d, 1 H), 8.10 (d, 1 H), 9.38 (bs, 1 H), 12.20 (bs, 1 H). Example 146
1 -{4-[(3-bromo-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(1 H-pyrazol-3- ylmethyl)urea
Figure imgf000380_0001
In analogy to example 143 crude 1 -{4-[(3-bromo-1-{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(1 H-pyrazol-3-ylmethyl)urea (226 mg, 381 μηηοΙ, intermediate 163) was reacted with trifluoroacetic acid (20 eq., 590 μΙ_, 7.6 mmol) in dichloromethane to give after preparative HPLC (method 4) the title compound (8 mg, 4%). LC-MS (method 2): Rt = 0.91 min; MS (ESIpos): m/z = 463/465 [M+H]+ (Br isotope pattern). 1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 4.30 (d, 2H), 6.17 (d, 1 H), 6.33 (d, 1 H), 6.72 - 6.75 (m, 1 H), 7.36 - 7.42 (m, 2H), 7.64 (d, 1 H), 7.74 (d, 1 H), 8.10 (d, 1 H), 9.09 (bs, 1 H), 12.20 (bs, 1 H), 12.65 (bs, 1 H).
Example 147
N3-({4-[(3-bromo-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}carbamoyl)-beta- alaninamide
Figure imgf000380_0002
In analogy to example 143 crude N3-({4-[(3-bromo-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}carbamoyl)-beta-alaninamide (120 mg, 206 μηηοΙ, intermediate 164) was reacted with trifluoroacetic acid (20 eq., 320 μί, 4.1 mmol) in dichloromethane to give after preparative HPLC (method 4) the title compound (22 mg, 21 %). LC-MS (method 2): Rt = 0.86 min; MS (ESIpos): m/z = 454/456 [M+H]+ (Br isotope pattern). 1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 2.28 (t, 2H), 3.29 (q, 2H), 6.32 (d, 1 H), 6.44 (t, 1 H), 6.92 (bs, 1 H), 7.33 - 7.40 (m, 3H), 7.64 (d, 1 H), 8.10 (d, 1 H), 9.15 (bs, 1 H), 12.20 (bs, 1 H). Example 148
1 -{4-[(3-bromo-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[2-(piperidin-1 - yl)ethyl]urea
Figure imgf000381_0001
In analogy to example 143 crude 1 -{4-[(3-bromo-1-{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[2-(piperidin-1 -yl)ethyl]urea (129 mg, 206 μmol, intermediate 165) was reacted with trifluoroacetic acid (20 eq., 320 μΙ_, 4.1 mmol) in dichloromethane to give after preparative HPLC (method 4) the title compound (33 mg, 31 %). LC-MS (method 2): Rt = 1 .17 min; MS (ESIpos): m/z = 494/496 [M+H]+ (Br isotope pattern). Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: 1.36 - 1 .40 (m, 2H), 1.49 - 1.54 (m, 4H), 2.32 - 2.37 (m, 6H), 3.20 (q, 2H), 6.28 (t, 1 H), 6.32 (d, 1 H), 7.33 - 7.39 (m, 2H), 7.64 (d, 1 H), 8.10 (d, 1 H), 9.20 (bs, 1 H), 12.20 (bs, 1 H).
Example 149
N-{2-[({4-[(3-bromo-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}carbamo l)amino]ethyl}methanesulfonamide
Figure imgf000381_0002
In analogy to example 143 crude N-{2-[({4-[(3-bromo-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}carbamoyl)amino]ethyl}methanesulfonamide (131 mg, 206 μηηοΙ, intermediate 166) was reacted with trifluoroacetic acid (20 eq., 320 μί, 4.1 mmol) in dichloromethane to give after preparative HPLC (method 4) the title compound (19 mg, 18%).
LC-MS (method 2): Rt = 0.93 min; MS (ESIpos): m/z = 504/506 [M+H]+ (Br isotope pattern). 1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 2.92 (s, 3H), 3.02 - 3.06 (m, 2H), 3.22 (q, 2H), 6.32 (d, 1 H), 6.53 - 6.55 (m, 1 H), 7.12 (t, 1 H), 7.36 - 7.41 (m, 2H), 7.64 (s, 1 H), 8.10 (d, 1 H), 9.22 (bs, 1 H), 12.20 (bs, 1 H). Example 150
1 -{4-[(3-bromo-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[3-(morpho
yl)propyl]urea
Figure imgf000382_0001
In analogy to example 143 crude 1 -{4-[(3-bromo-1-{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[3-(morpholin-4-yl)propyl]urea (132 mg, 206 μηηοΙ, intermediate 167) was reacted with trifluoroacetic acid (20 eq., 320 μΙ_, 4.1 mmol) in dichloromethane to give after preparative HPLC (method 4) the title compound (18 mg, 17%). LC-MS (method 2): Rt = 0.99 min; MS (ESIpos): m/z = 510/51 1 [M+H]+ (Br isotope pattern). 1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 1.60 (quint, 2H), 2.28 - 2.34 (m, 6H), 3.12 (q, 2H), 3.56 - 3.59 (m, 4H), 6.32 (d, 1 H), 6.45 (t, 1 H), 7.35 - 7.41 (m, 2H), 7.64 (s, 1 H), 8.10 (d, 1 H), 9.01 (bs, 1 H), 12.20 (bs, 1 H).
Example 151
N-{2-[({4-[(3-bromo-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}carbamo l)amino]ethyl}acetamide
Figure imgf000382_0002
In analogy to example 143 crude N-{2-[({4-[(3-bromo-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}carbamoyl)amino]ethyl}acetamide (123 mg, 206 μηηοΙ, intermediate 168) was reacted with trifluoroacetic acid (20 eq., 320 μί, 4.1 mmol) in dichloromethane to give after preparative HPLC (method 4) the title compound (10 mg, 10%). LC-MS (method 2): Rt = 0.89 min; MS (ESIpos): m/z = 468/470 [M+H]+ (Br isotope pattern). 1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 1 .82 (s, 3H), 3.13 - 3.15 (m, 4H), 6.32 (d, 1 H), 6.44 - 6.46 (m, 1 H), 7.36 - 7.42 (m, 2H), 7.64 (d, 1 H), 7.96 - 7.97 (m, 1 H), 8.10 (d, 1 H), 9.13 (bs, 1 H), 12.20 (bs, 1 H). Example 152
1 -{4-[(3-bromo-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[2-(morpho
oxoethyl]urea
Figure imgf000383_0001
In analogy to example 143 crude 1 -{4-[(3-bromo-1-{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[2-(morpholin-4-yl)-2-oxoethyl]urea
(132 mg, 206 μηηοΙ, intermediate 169) was reacted with trifluoroacetic acid (20 eq., 320 μΙ_, 4.1 mmol) in dichloromethane to give after preparative HPLC (method 4) the title compound (33 mg, 30%).
LC-MS (method 2): Rt = 0.94 min; MS (ESIpos): m/z = 510/512 [M+H]+ (Br isotope pattern).
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: 3.41 - 3.43 (m, 2H), 3.46 - 3.48 (m, 2H), 3.56 - 3.61 (m, 4H), 4.01 (d, 2H), 6.33 (d, 1 H), 6.57 (t, 1 H), 7.34 - 7.39 (m, 2H), 7.64 (d, 1 H), 8.09 (d, 1 H), 9.47 (bs, 1 H), 12.20 (bs, 1 H). Example 153
1 -{4-[(3-bromo-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(pyridin-2-ylmethyl)urea
Figure imgf000383_0002
In analogy to example 143 crude 1 -{4-[(3-bromo-1-{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(pyridin-2-ylmethyl)urea (125 mg,
206 μηηοΙ, intermediate 170) was reacted with trifluoroacetic acid (20 eq., 320 μΙ_, 4.1 mmol) in dichloromethane to give after preparative HPLC (method 4) the title compound (16 mg, 15%). LC-MS (method 2): Rt = 1 .02 min; MS (ESIpos): m/z = 474/476 [M+H]+ (Br isotope pattern). 1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 4.43 (d, 2H), 6.33 (d, 1 H), 7.06 (t, 1 H), 7.29 (ddd, 1 H), 7.35 - 7.43 (m, 3H), 7.64 (s, 1 H), 7.79 (dt, 1 H), 8.10 (d, 1 H), 8.54 (ddd, 1 H), 9.38 (bs, 1 H), 12.20 (bs, 1 H). Example 154
1 -{4-[(3-bromo-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[(1 ,1 -dioxid
yl)methyl]urea
Figure imgf000384_0001
In analogy to example 143 crude 1 -{4-[(3-bromo-1-{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[(1 ,1 -dioxidothietan-3-yl)methyl]urea (130 mg, 206 μηηοΙ, intermediate 171 ) was reacted with trifluoroacetic acid (20 eq., 320 μΙ_, 4.1 mmol) in dichloromethane to give after preparative HPLC (method 4) the title compound (35 mg, 33%).
LC-MS (method 2): Rt = 0.95 min; MS (ESIpos): m/z = 501/503 [M+H]+ (Br isotope pattern).
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 2.65 - 2.73 (m, 1 H), 3.36 - 3.38 (m, 2H), 3.90 - 3.95 (m, 2H), 4.20 - 4.26 (m, 2H), 6.32 (d, 1 H), 6.78 - 6.84 (m, 1 H), 7.37 - 7.43 (m, 2H), 7.64 (s, 1 H), 8.10 (d, 1 H), 9.24 - 9.25 (m, 1 H), 12.20 (bs, 1 H). Example 155
1 -{4-[(3-bromo-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(2-methoxyethyl)urea
Figure imgf000384_0002
In analogy to example 143 crude 1 -{4-[(3-bromo-1-{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(2-methoxyethyl)urea (1 18 mg, 206 μηιοΙ, intermediate 172) was reacted with trifluoroacetic acid (20 eq., 320 μΙ_, 4.1 mmol) in
dichloromethane to give after preparative HPLC (method 4) the title compound (42 mg, 45%). LC-MS (method 2): Rt = 1 .00 min; MS (ESIpos): m/z = 441/443 [M+H]+ (Br isotope pattern). 1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 3.25 - 3.29 (m, 5H), 3.38 - 3.40 (m, 2H), 6.32 (d, 1 H), 6.48 (t, 1 H), 7.33 - 7.39 (m, 2H), 7.64 (s, 1 H), 8.10 (d, 1 H), 9.10 (bs, 1 H), 12.20 (bs, 1 H). Example 156
1 -{4-[(3-bromo-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(pyridin-4-ylmethy
Figure imgf000385_0001
In analogy to example 143 crude 1 -{4-[(3-bromo-1-{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(pyridin-4-ylmethyl)urea (124 mg,
206 μηηοΙ, intermediate 173) was reacted with trifluoroacetic acid (20 eq., 320 μΙ_, 4.1 mmol) in dichloromethane to give after preparative HPLC (method 4) the title compound (20 mg, 18%). LC-MS (method 2): Rt = 0.98 min; MS (ESIpos): m/z = 474/476 [M+H]+ (Br isotope pattern). Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: 4.35 (d, 2H), 6.32 (d, 1 H), 7.07 - 7.1 1 (m, 1 H), 7.29 - 7.30 (m, 2H), 7.38 - 7.44 (m, 2H), 7.64 (bs, 1 H), 8.10 (d, 1 H), 8.51 - 8.52 (m, 2H), 9.34 (bs, 1 H), 12.20 (bs, 1 H).
Example 157
N2-({4-[(3-bromo-1 H-pyrrolo 2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}carbamoyl)glycinamide
Figure imgf000385_0002
In analogy to example 143 crude N2-({4-[(3-bromo-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}carbamoyl)glycinamide (1 17 mg, 206 μηιοΙ, intermediate 174) was reacted with trifluoroacetic acid (20 eq., 320 μΙ_, 4.1 mmol) in
dichloromethane to give after preparative HPLC (method 4) the title compound (22 mg, 22%). LC-MS (method 2): Rt = 0.85 min; MS (ESIpos): m/z = 440/442 [M+H]+ (Br isotope pattern). 1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 3.71 (d, 2H), 6.32 (d, 1 H), 6.54 (t, 1 H), 7.10 (bs, 1 H), 7.34 - 7.39 (m, 2H), 7.45 (bs, 1 H), 7.64 (d, 1 H), 8.10 (d, 1 H), 9.34 (bs, 1 H), 12.20 (bs, 1 H). Example 158
1 -{4-[(3-bromo-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[3-(piperidin-1 - yl)propyl]urea
Figure imgf000386_0001
In analogy to example 143 crude 1 -{4-[(3-bromo-1-{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[3-(piperidin-1 -yl)propyl]urea (131 mg, 206 μηηοΙ, intermediate 175) was reacted with trifluoroacetic acid (20 eq., 320 μΙ_, 4.1 mmol) in dichloromethane to give after preparative HPLC (method 4) the title compound (27 mg, 23%). LC-MS (method 2): Rt = 1 .20 min; MS (ESIpos): m/z = 508/510 [M+H]+ (Br isotope pattern). Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: 1 .34 - 1 .40 (m, 2H), 1.46 - 1 .50 (m, 4H), 1.58 (quint, 2H), 2.23 - 2.30 (m, 6H), 3.1 1 (q, 2H), 6.32 (d, 1 H), 6.46 (t, 1 H), 7.35 - 7.41 (m, 2H), 7.64 (s, 1 H), 8.10 (d, 1 H), 9.03 (bs, 1 H), 12.20 (bs, 1 H).
Example 159
1 -{4-[(3-bromo-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(1 H-1 ,2,3-triazol-4- ylmethyl)urea
Figure imgf000386_0002
In analogy to example 143 crude 1 -{4-[(3-bromo-1-{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(1 H-1 ,2,3-triazol-4-ylmethyl)urea (123 mg, 206 μηηοΙ, intermediate 176) was reacted with trifluoroacetic acid (20 eq., 320 μί, 4.1 mmol) in dichloromethane to give after preparative HPLC (method 4) the title compound (16 mg, 15%). LC-MS (method 2): Rt = 0.70 min; MS (ESIpos): m/z = 464/466 [M+H]+ (Br isotope pattern). 1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 4.37 (d, 2H), 6.32 (d, 1 H), 6.90 (t, 1 H), 7.37 - 7.42 (m, 2H), 7.64 (d, 1 H), 7.73 (bs, 1 H), 8.10 (d, 1 H), 9.15 (bs, 1 H), 12.20 (bs, 1 H), 14.86 (bs, 1 H). Example 160
1 -{4-[(3-bromo-1 H-pyrrolo[2!3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[3- (methylsulfonyl)propyl]urea
Figure imgf000387_0001
In analogy to example 143 crude 1 -{4-[(3-bromo-1-{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[3-(methylsulfonyl)propyl]urea (130 mg, 206 μηηοΙ, intermediate 177) was reacted with trifluoroacetic acid (20 eq., 320 μΙ_, 4.1 mmol) in dichloromethane to give after preparative HPLC (method 4) the title compound (9 mg, 9%). LC-MS (method 2): Rt = 0.93 min; MS (ESIpos): m/z = 503/505 [M+H]+ (Br isotope pattern). 1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 1.83 - 1 .91 (m, 2H), 2.99 (s, 3H), 3.1 1 - 3.15 (m, 2H), 3.22 (q, 2H), 6.32 (d, 1 H), 6.58 (t, 1 H), 7.36 - 7.42 (m, 2H), 7.64 (d, 1 H), 8.10 (d, 1 H), 9.10 (bs, 1 H), 12.20 (bs, 1 H).
Example 161
4-[({4-[(3-bromo-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}carbamo l)amino]butanamide
Figure imgf000387_0002
In analogy to example 143 crude 4-[({4-[(3-bromo-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}carbamoyl)amino]butanamide (123 mg, 206 μηηοΙ, intermediate 178) was reacted with trifluoroacetic acid (20 eq., 320 μί, 4.1 mmol) in dichloromethane to give after preparative HPLC (2 consecutive separations, methods 2 and 4) the title compound (13 mg, 10%).
LC-MS (method 2): Rt = 0.93 min; MS (ESIpos): m/z = 468/470 [M+H]+ (Br isotope pattern). 1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 1 .61 - 1 .69 (m, 2H), 2.08 (t, 2H), 3.09 (q, 2H), 6.32 (d, 1 H), 6.49 (bs, 1 H), 6.77 (bs, 1 H), 7.31 (bs, 1 H), 7.36 - 7.41 (m, 2H), 7.64 (s, 1 H), 8.10 (d, 1 H), 9.05 (bs, 1 H), 12.20 (bs, 1 H). Example 162
1 -{4-[(3-bromo-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[2-(4-methy
yl)-2-oxoethyl]urea
Figure imgf000388_0001
In analogy to example 143 crude 1 -{4-[(3-bromo-1-{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[2-(4-methylpiperazin-1 -yl)-2-oxoethyl]urea (137 mg, 206 μηηοΙ, intermediate 179) was reacted with trifluoroacetic acid (20 eq., 320 μΙ_, 4.1 mmol) in dichloromethane to give after preparative HPLC (2 consecutive separations, methods 2 and 4) the title compound (10 mg, 7%).
LC-MS (method 2): Rt = 1 .00 min; MS (ESIpos): m/z = 523/525 [M+H]+ (Br isotope pattern).
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: 2.19 (s, 3H), 2.25 - 2.28 (m, 2H), 2.31 - 2.33 (m, 2H), 3.38 - 3.41 (m, 2H), 3.45 - 3.48 (m, 2H), 4.00 (d, 2H), 6.33 (d, 1 H), 6.56 (t, 1 H), 7.34 - 7.39 (m, 2H), 7.64 (s, 1 H), 8.09 (d, 1 H), 9.47 (bs, 1 H), 12.20 (bs, 1 H). Example 163
1 -{3,5-difluoro-4-[(3-methyl-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl}-3-[2- (dimethylamino)ethyl]urea
Figure imgf000388_0002
In analogy to example 143 crude 1 -{3,5-difluoro-4-[(3-methyl-1 -{[2-(trimethylsilyl)ethoxy]me- thyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl}-3-[2-(dimethylamino)ethyl]urea (59 mg,
1 14 μηηοΙ, intermediate 184) was reacted with trifluoroacetic acid (40 eq., 350 μΙ_, 4.6 mmol) in dichloromethane to give after preparative HPLC (method 4) the title compound (6 mg, 1 1 %).
LC-MS (method 2): Rt = 1 .10 min; MS (ESIpos): m/z = 390 [M+H]+.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 2.17 (s, 6H), 2.32 - 2.35 (m, 2H), 2.43 (s, 3H), 3.19 (q, 2H), 6.17 (d, 1 H), 6.29 (t, 1 H), 7.15 - 7.16 (m, 1 H), 7.31 - 7.37 (m, 2H), 7.98 (d, 1 H), 9.16 (bs, 1 H), 1 1.43 (bs, 1 H). Example 164
(+/-)-1 -{4-[(3-cyano-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(tetr^
yl)urea
Figure imgf000389_0001
In analogy to example 143 crude (+/-)-1 -{4-[(3-cyano-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(tetrahydrofuran-3-yl)urea (329 mg, 621 μηηοΙ, intermediate 189) was reacted with trifluoroacetic acid (40 eq., 1.9 ml_, 25 mmol) in dichloromethane to give after preparative HPLC (2 consecutive separations, methods 2 and 4) the title compound (40 mg, 16%).
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: 1.72 - 1 .77 (m, 1 H), 2.07 - 2.18 (m, 1 H), 3.51 (dd, 1 H), 3.68 - 3.83 (m, 3H), 4.18 - 4.25 (m, 1 H), 6.52 (d, 1 H), 6.72 (d, 1 H), 7.37 - 7.43 (m, 2H), 8.23 (d, 1 H), 8.45 (s, 1 H), 8.87 (s, 1 H), 12.99 (bs, 1 H).
Example 165
1 -{4-[(3-cyano-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[2- (dimethylamino)ethyl]urea
Figure imgf000389_0002
In analogy to example 143 crude 1 -{4-[(3-cyano-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[2-(dimethylamino)ethyl]urea (34 mg, 63 μηηοΙ, intermediate 190) was reacted with trifluoroacetic acid (20 eq., 98 μΙ_, 1.3 mmol) in dichloromethane to give after preparative HPLC (method 4) the title compound (22 mg, 78%). LC-MS (method 2): Rt = 0.80 min; MS (ESIneg): m/z = 401 [M+H]+.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 2.20 (s, 6H), 2.37 (t, 2H), 3.21 (q, 2H), 6.33 (t, 1 H), 6.52 (d, 1 H), 7.35 - 7.40 (m, 2H), 8.23 (d, 1 H), 8.44 (s, 1 H), 9.22 (bs, 1 H), 12.97 (bs, 1 H). Example 166
(+/-)-1 -{4-[(3-cyano-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(tetra
ylmethyl)urea
Figure imgf000390_0001
In analogy to example 143 crude (+/-)-1 -{4-[(3-cyano-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(tetrahydrofuran-2-ylmethyl)urea (357 mg, 656 μηηοΙ, intermediate 191 ) was reacted with trifluoroacetic acid (40 eq., 2.0 ml_, 26 mmol) in dichloromethane to give after preparative HPLC (2 consecutive separations, methods 2 and 4) the title compound (27 mg, 9%).
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: 1.48 - 1 .56 (m, 1 H), 1.77 - 1.94 (m, 3H), 3.08 - 3.14 (m, 1 H), 3.22 - 3.28 (m, 1 H), 3.61 - 3.68 (m, 1 H), 3.76 - 3.81 (m, 1 H), 3.84 - 3.91 (m, 1 H), 6.44 (t, 1 H), 6.52 (d, 1 H), 7.35 - 7.41 (m, 2H), 8.23 (d, 1 H), 8.44 (s, 1 H), 9.06 (s, 1 H), 12.98 (bs, 1 H). Example 167
1 -{4-[(3-cyano-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(3-methoxypropyl)urea
Figure imgf000390_0002
In analogy to example 143 crude 1 -{4-[(3-cyano-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(3-methoxypropyl)urea (316 mg, 594 μηιοΙ, intermediate 192) was reacted with trifluoroacetic acid (40 eq., 1.8 mL, 24 mmol) in
dichloromethane to give after preparative HPLC (2 consecutive separations, methods 2 and 4) the title compound (23 mg, 10%).
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 1.68 (quint, 2H), 3.15 (q, 2H), 3.24 (s, 3H), 3.37 (t, 2H), 6.42 (t, 1 H), 6.52 (d, 1 H), 7.37 - 7.43 (m, 2H), 8.23 (d, 1 H), 8.44 (s, 1 H), 9.02 (bs, 1 H), 12.98 (bs, 1 H). Example 168
1 -{4-[(3-cyano-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[3-(morph
yl)propyl]urea
Figure imgf000391_0001
In analogy to example 143 crude 1 -{4-[(3-cyano-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[3-(morpholin-4-yl)propyl]urea (37 mg, 64 μmol, intermediate 193) was reacted with trifluoroacetic acid (20 eq., 98 μΙ_, 1.3 mmol) in dichloromethane to give after preparative HPLC (method 4) the title compound (17 mg, 54%). LC-MS (method 2): Rt = 0.78 min; MS (ESIpos): m/z = 457 [M+H]+.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 1.63 (bs, 2H), 2.35 (bs, 4H), 3.14 (q, 2H), 3.59 (bs, 4H), 6.44 (bs, 1 H), 6.51 (d, 1 H), 7.37 - 7.43 (m, 2H), 8.23 (d, 1 H), 8.45 (s, 1 H), 9.02 (bs, 1 H), 12.99 (bs, 1 H).
Example 169
1 -{4-[(3-cyano-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[(1 -methyl-1 H-pyrazol-3- yl)methyl]urea
Figure imgf000391_0002
In analogy to example 143 crude 1 -{4-[(3-cyano-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[(1 -methyl-1 H-pyrazol-3-yl)methyl]urea (332 mg, 600 μηηοΙ, intermediate 194) was reacted with trifluoroacetic acid (40 eq., 1.8 ml_, 24 mmol) in dichloromethane to give after preparative HPLC (method 4) the title compound (63 mg, 20%).
LC-MS (method 2): Rt = 0.75 min; MS (ESIpos): m/z = 424 [M+H]+.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 3.80 (s, 3H), 4.24 (d, 2H), 6.14 (d, 1 H), 6.52 (d, 1 H), 6.73 (t, 1 H), 7.38 - 7.43 (m, 2H), 7.61 (d, 1 H), 8.23 (d, 1 H), 8.44 (s, 1 H), 9.10 (bs, 1 H), 12.98 (bs, 1 H). Example 170
1 -{4-[(3-cyano-1 H-pyrrolo[2!3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(1 ,3-thiazol-2- ylmethyl)urea
Figure imgf000392_0001
In analogy to example 143 crude 1 -{4-[(3-cyano-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(1 ,3-thiazol-2-ylmethyl)urea (363 mg, 652 μηηοΙ, intermediate 195) was reacted with trifluoroacetic acid (40 eq., 2.0 mL, 26 mmol) in dichloromethane to give after preparative HPLC (method 4) the title compound (38 mg, 12%). LC-MS (method 2): Rt = 0.77 min; MS (ESIpos): m/z = 427 [M+H]+.
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: 4.61 (d, 2H), 6.54 (d, 1 H), 7.26 (t, 1 H), 7.43 - 7.45 (m, 2H), 7.64 (d, 1 H), 7.75 (d, 1 H), 8.23 (d, 1 H), 8.45 (s, 1 H), 9.40 (bs, 1 H), 12.99 (bs, 1 H).
Example 171
1 -{4-[(3-cyano-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(pyridin-4-ylmethyl)urea
Figure imgf000392_0002
In analogy to example 143 crude 1 -{4-[(3-cyano-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(pyridin-4-ylmethyl)urea (144 mg,
261 μηηοΙ, intermediate 196) was reacted with trifluoroacetic acid (40 eq., 800 μί, 10 mmol) in dichloromethane to give after preparative HPLC (method 4) the title compound (59 mg, 54%). LC-MS (method 2): Rt = 0.74 min; MS (ESIpos): m/z = 421 [M+H]+.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 4.35 (d, 2H), 6.52 (d, 1 H), 7.04 (t, 1 H), 7.29 - 7.31 (m, 2H), 7.40 - 7.45 (m, 2H), 8.23 (d, 1 H), 8.44 (d, 1 H), 8.51 - 8.52 (m, 2H), 9.30 (bs, 1 H), 12.99 (bs, 1 H). Example 172
1 -{4-[(3-cyano-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(2-methoxyethyl)urea
Figure imgf000393_0001
In analogy to example 143 crude 1 -{4-[(3-cyano-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(2-methoxyethyl)urea (343 mg, 663 μηιοΙ, intermediate 197) was reacted with trifluoroacetic acid (40 eq., 2.0 ml_, 27 mmol) in
dichloromethane to give after preparative HPLC (method 4) the title compound (72 mg, 27%). LC-MS (method 2): Rt = 0.75 min; MS (ESIpos): m/z = 388 [M+H]+.
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: 3.25 - 3.29 (m, 5H), 3.38 - 3.41 (m, 2H), 6.45 (t, 1 H), 6.52 (d, 1 H), 7.36 - 7.41 (m, 2H), 8.23 (d, 1 H), 8.44 (s, 1 H), 9.08 (bs, 1 H), 12.98 (bs, 1 H).
Example 173
1 -{4-[(3-cyano-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(1 H-pyrazol-3- ylmethyl)urea
Figure imgf000393_0002
In analogy to example 143 crude 1 -{4-[(3-cyano-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(1 H-pyrazol-3-ylmethyl)urea (282 mg, 522 μηηοΙ, intermediate 198) was reacted with trifluoroacetic acid (40 eq., 1.6 mL, 21 mmol) in dichloromethane to give after preparative HPLC (method 4) the title compound (69 mg, 29%). LC-MS (method 2): Rt = 0.71 min; MS (ESIpos): m/z = 410 [M+H]+.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 4.30 (d, 2H), 6.17 (s, 1 H), 6.52 (d, 1 H), 6.76 (bs, 1 H), 7.40 - 7.42 (m, 2H), 7.63 (bs, 1 H), 8.23 (d, 1 H), 8.44 (s, 1 H), 9.1 1 (s, 1 H), 12.64 (bs, 1 H), 12.99 (bs, 1 H). Example 174
(+/-)-1 -{4-[(3-bromo-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(tetra
yl)urea
Figure imgf000394_0001
A solution of (+/-)-1 -{4-[(3-bromo-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4- yl)oxy]-3,5-difluorophenyl}-3-(tetrahydrofuran-3-yl)urea (100 mg, 171 μιηοΙ, intermediate 200) in dichloromethane (2 mL) was treated with trifluoroacetic acid (20 eq., 260 μΙ_, 3.4 mmol) and stirred at room temperature overnight. The reaction mixture was evaporated in vacuo to give (+/-)-1 -(4-{[3-bromo-1 -(hydroxymethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}-3,5-difluorophenyl)-3- (tetrahydrofuran-3-yl)urea trifluoroacetate (1 :1 ). A part of this crude intermediate (55 mg) was dissolved in THF (1.0 mL), aqueous sodium hydroxide (5.0 eq., 280 μί, 2.0 M, 570 μηιοΙ) was added and the mixture stirred at 60 °C for 24 hours. The reaction mixture was evaporated in vacuo and the obtained residue subjected to preparative HPLC (method 4) to give the title compound (9 mg).
LC-MS (method 2): Rt =0.96 min; MS (ESIpos): m/z = 453/455 [M+H]+ (Br isotope pattern).
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: 1.71 - 1 .78 (m, 1 H), 2.09 - 2.18 (m, 1 H), 3.51 (dd, 1 H), 3.68 - 3.83 (m, 3H), 4.18 - 4.25 (m, 1 H), 6.52 (d, 1 H), 6.72 (d, 1 H), 7.35 - 7.40 (m, 2H), 7.64 (s, 1 H), 8.10 (d, 1 H), 8.86 (bs, 1 H), 12.20 (bs, 1 H). Example 175
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(6- methoxypyridazin-3-yl)urea
Figure imgf000394_0002
In analogy to example 1 , 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(6-methoxypyridazin- 3-yl)urea (85.0 mg, 139 μηηοΙ, intermediate 201 ) was stirred with trifluoroacetic acid (320 μί, 4.2 mmol) in dichloromethane (450 μΙ_) to afford after preperative HPLC purification the title compound (8 mg, 1 1 % yield).
LC-MS (method 2): Rt = 1 .1 1 min; MS (ESIpos): m/z = 481 [M+H]+
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 3.98 (s, 3 H), 6.49 (d, 1 H), 7.28 (d, 1 H), 7.53 (d, 2 H), 7.97 (d, 1 H), 8.1 1 (d, 1 H), 8.22 (d, 1 H).
Example 176
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(6,7-dihydro- 5H-cyclopenta[c]pyridazin-3-yl)urea
Figure imgf000395_0001
In analogy to example 1 , 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(6,7-dihydro-5H- cyclopenta[c]pyridazin-3-yl)urea (55.0 mg, 88.6 μηηοΙ, intermediate 202) was stirred with trifluoroacetic acid (200 μΙ_, 2.7 mmol) in dichloromethane (290 μΙ_) to afford after preperative HPLC purification the title compound (5 mg, 1 1 % yield).
LC-MS (method 2): Rt = 1 .14 min; MS (ESIpos): m/z = 491 [M+H]+
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 2.03 - 2.13 (m, 2 H), 2.95 (t, 2 H), 3.01 (t, 2 H), 6.51 (d, 1 H), 7.51 (d, 3 H), 7.79 (s, 1 H), 8.13 (s, 1 H), 8.23 (d, 1 H), 9.87 (br s, 1 H), 10.43 (br s, 1 H).
Example 177
1 -(6-bromopyridazin-3-yl)-3-{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}urea
H H
Figure imgf000395_0002
In analogy to example 1 , 1 -(6-bromopyridazin-3-yl)-3-{4-[(3-chloro-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}urea
(120 mg, 192 μηηοΙ, intermediate 203) was stirred with trifluoroacetic acid (740 μΙ_, 9.6 mmol) in dichloromethane (1 .2 mL) to afford after preperative HPLC purification the title compound (1 mg, 1 % yield).
LC-MS (method 3): Rt = 1 .16 min; MS (ESIpos): m/z = 495 [M+H]+
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 6.36 (d, 1 H), 7.51 (br d, 2 H), 7.63 (s, 1 H), 7.96 (d, 1 H), 8.06 - 8.13 (m, 2 H), 9.89 (br s, 1 H), 12.15 (br s, 1 H). Example 178
(+/-)-1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(tetrahydrofuran-2- ylmethyl)urea
Figure imgf000396_0001
To a solution of (+/-)-1 -{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[tetrahydrofuran-2-ylmethyl]urea (130 mg, 235 μηηοΙ, intermediate 204) in dichloromethane (5.0 mL) was added trifluoroacetic acid (1 .0 mL,
13 mmol). The resulting mixture was stirred overnight at room temperature, at which time the mixture was slowly basified with a 1 M aqueous solution of sodium hydroxide. The basified mixture was stirred for 5 minutes at room temperature, at which time ethyl acetate was added and the layers were separated. The aqueous phase was extracted twice with ethyl acetate, and the combined organic layers were washed with brine, dried over sodium sulfate, and evaporated to afford the crude urea. The crude product was purified by preperative HPLC to afford the title compound (33 mg, 33 % yield).
LC-MS (method 2): Rt = 1 .04 min; MS (ESIpos): m/z = 423 [M+H]+
1H NMR (400 MHz, DMSO-d6) δ ppm 1 .47 - 1 .57 (m, 1 H), 1 .77 - 1 .95 (m, 3 H), 3.07 - 3.15 (m, 1 H), 3.21 - 3.28 (m, 1 H), 3.61 - 3.68 (m, 1 H), 3.74 - 3.82 (m, 1 H), 3.84 - 3.91 (m, 1 H), 6.32 (d, 1 H), 6.44 (t, 1 H), 7.36 (d, 2 H), 7.61 (s, 1 H), 8.10 (d, 1 H), 9.05 (s, 1 H), 12.12 (br d, 1 H) Example 179
1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy
yl]urea
Figure imgf000397_0001
In analogy to example 178, 1 -{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[(3S)-tetrahydrofuran-3-yl]urea (145 mg, 269 μmol, intermediate 205) was stirred with trifluoroacetic acid (1 .0 mL, 13 mmol) in dichloromethane (5.0 mL) to afford after preperative HPLC purification the title compound (33 mg, 30 % yield). LC-MS (method 2): Rt = 1.04 min; MS (ESIpos): m/z = 409 [M+H]+
1H N MR (400 MHz, DMSO-d6) δ ppm 1 .70 - 1 .79 (m, 1 H), 2.13 (dq, 1 H), 3.50 (dd, 1 H), 3.67 - 3.84 (m, 3 H), 4.18 - 4.26 (m, 1 H), 6.32 (d, 1 H), 6.71 (d, 1 H), 7.37 (d, 2 H), 7.61 (s, 1 H), 8.10 (d, 1 H), 8.85 (s, 1 H), 12.12 (br s, 1 H)
Example 180
1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[(1 -methyl-1 H-pyrazol-3- yl)methyl]urea
Figure imgf000397_0002
To a solution of 1 -{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4- yl)oxy]-3,5-difluorophenyl}-3-[(1 -methyl-1 H-pyrazol-3-yl)methyl]urea (130 mg, 231 μηηοΙ, intermediate 207) in dichloromethane (5.0 mL) was added trifluoroacetic acid (1 .0 mL, 13 mmol). The reaction mixture was stirred at room temperature overnight at which time the mixture was basified with a 1 M aqueous solution of sodium hydroxide. The resulting precipitate was collected by filtration and dried to yield the title compound (19 mg, 19 % yield)
LC-MS (method 2): Rt = 0.98 min; MS (ESIpos): m/z = 433 [M+H]+
1H NMR (400 MHz, DMSO-d6) δ ppm 3.79 (s, 3 H), 4.24 (d, 2 H), 6.13 (d, 1 H), 6.32 (d, 1 H), 6.72 (br t, 1 H), 7.38 (d, 2 H), 7.61 (s, 2 H), 8.10 (d, 1 H), 9.09 (s, 1 H), 12.12 (br s, 1 H) Example 181
1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(2-oxaspiro[3.3]hept-^ yl)urea
Figure imgf000398_0001
A solution of 1 -{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4- yl)oxy]-3,5-difluorophenyl}-3-(2-oxaspiro[3.3]hept-6-yl)urea (150 mg, 265 μηιοΙ, intermediate 206) in DMF (2.0 mL) was treated with ceasium fluoride (80.6 mg, 531 μηηοΙ) and stirred at 90°C overnight. An additional charge of ceasium fluoride (80.6 mg, 531 μηηοΙ) was added and stirred at 100°C overnight. Water and ethyl acetate were added and the layers were separated. The aqueous phase was extracted twice with ethyl acetate, and the combined organic layers were washed with brine, dried over sodium sulfate, filtered and evaporated to afford the crude product. The crude product was purified by preparativeHPLC (method 7), to obtain 5 mg (4 % yield) of the title compound.
LC-MS (method 2): Rt = 1 .00 min; MS (ESIpos): m/z = 435 [M+H]+
1H NMR (400 MHz, DMSO-d6) δ ppm 2.03 - 2.12 (m, 2 H), 2.53 - 2.57 (m, 2 H), 3.94 (sxt, 1 H), 4.49 (s, 2 H), 4.60 (s, 2 H), 6.31 (d, 1 H), 6.73 (d, 1 H), 7.36 (d, 2 H), 7.61 (d, 1 H), 8.09 (d, 1 H), 9.03 (s, 1 H), 12.13 (br s, 1 H)
Example 182
1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[6- (difluoromethyl)pyridazin-3-yl]urea
Figure imgf000398_0002
In analogy to example 178, 1 -{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[6-(difluoromethyl)pyridazin-3-yl]urea (120 mg, 201 μηηοΙ, intermediate 208) was stirred with trifluoroacetic acid (770 μΙ_, 10 mmol) in dichloromethane (1 .3 ml.) to afford after preperative HPLC purification the title compound (10 mg, 10 % yield).
LC-MS (method 2): Rt = 1 .14 min; MS (ESIneg): m/z = 467 [M+H]+
1H NMR (400 MHz, DMSO-d6) δ ppm 6.37 (d, 1 H), 7.19 (t, 1 H), 7.53 (d, 2 H), 7.63 (s, 1 8.01 (d, 1 H), 8.1 1 (d, 1 H), 8.30 (d, 1 H).
Example 183
(+/-)-1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(tetrahydrofuran-3- yl)urea
Figure imgf000399_0001
In analogy to example 178, (+/-)-1 -{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[tetrahydrofuran-3-yl]urea (125 mg, 232 μηηοΙ, intermediate 209) was stirred with trifluoroacetic acid (1 .0 ml_, 13 mmol) in dichloromethane (5.0 mL) to afford after preperative HPLC purification the title compound (19 mg, 20 % yield).
LC-MS (method 2): Rt = 0.98 min; MS (ESIpos): m/z = 409 [M+H]+
1H NMR (400 MHz, DMSO-d6) δ ppm 1 .70 - 1 .79 (m, 1 H), 2.13 (dq, 1 H), 3.50 (dd, 1 H), 3.66 - 3.84 (m, 3 H), 4.17 - 4.26 (m, 1 H), 6.32 (d, 1 H), 6.71 (d, 1 H), 7.37 (d, 2 H), 7.61 (d, 1 H), 8.10 (d, 1 H), 8.84 (s, 1 H), 12.13 (br s, 1 H)
Example 184
1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(3-methoxypropyl)urea
Figure imgf000399_0002
In analogy to example 178, 1 -{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(3-methoxypropyl)urea (125 mg, 231 μηιοΙ, intermediate 210) was stirred with trifluoroacetic acid (1 .0 mL, 13 mmol) in dichloromethane (5.0 mL) to afford after preperative HPLC purification the title compound (35 mg, 37 % yield). LC-MS (method 2): Rt = 1 .02 min; MS (ESIpos): m/z = 41 1 [M+H]+
1H NMR (400 MHz, DMSO-d6) δ ppm 1 .67 (quin, 2 H), 3.1 1 - 3.18 (m, 2 H), 3.24 (s, 3 H), 3.36 (t, 2 H), 6.32 (d, 1 H), 6.41 (t, 1 H), 7.38 (d, 2 H), 7.61 (s, 1 H), 8.10 (d, 1 H), 9.00 (s, 1 H), 12.12 (s, 1 H)
Example 185
1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[(3R)-tetrahydrofuran-3- yl]urea
Figure imgf000400_0001
In analogy to example 178, 1 -{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[(3R)-tetrahydrofuran-3-yl]urea (145 mg, 269 μηιοΙ, intermediate 21 1 ) was stirred with trifluoroacetic acid (1 .0 mL, 13 mmol) in dichloromethane (5.0 mL) to afford after preperative HPLC purification the title compound (43 mg, 39 % yield). LC-MS (method 2): Rt = 1.03 min; MS (ESIpos): m/z = 409 [M+H]+
1H NMR (400 MHz, DMSO-d6) δ ppm 1 .70 - 1 .79 (m, 1 H), 2.13 (dq, 1 H), 3.50 (dd, 1 H), 3.66 - 3.84 (m, 3 H), 4.17 - 4.26 (m, 1 H), 6.32 (d, 1 H), 6.71 (d, 1 H), 7.37 (d, 2 H), 7.61 (d, 1 H), 8.10 (d, 1 H), 8.84 (s, 1 H), 12.13 (br s, 1 H)
Example 186
1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(1 H-pyrazol-3- ylmethyl)urea
H
Figure imgf000400_0002
In analogy to example 178, 1 -{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(1 H-pyrazol-3-ylmethyl)urea (150 mg, 273 μηιοΙ, intermediate 212) was stirred with trifluoroacetic acid (1 .0 ml_, 13 mmol) in dichloromethane (5.0 mL) to afford after preperative HPLC purification the title compound (4 mg, 3 % yield). LC-MS (method 2): Rt = 0.95 min; MS (ESIpos): m/z = 419 [M+H]+
1H NMR (400 MHz, DMSO-d6) δ ppm 4.29 (br d, 2 H), 6.17 (s, 1 H), 6.32 (d, 1 H), 6.75 (br s, 1 H), 7.39 (d, 2 H), 7.61 (s, 1 H), 7.65 (br s, 1 H), 8.10 (d, 1 H), 9.10 (s, 1 H), 12.12 (br s, 1 H), 12.65 (br s, 1 H) Example 187
1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b ridin-4-yl)oxy]-3,5-difluorophenyl}-3-(2,2,2-trifluoroethyl)urea
Figure imgf000401_0001
In analogy to example 178, 1 -{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(2,2,2-trifluoroethyl)urea (150 mg, 272 μηηοΙ, intermediate 213) was stirred with trifluoroacetic acid (1 .0 mL, 13 mmol) in dichloromethane (5.0 mL) to afford after preperative HPLC purification the title compound (27 mg, 23 % yield). LC-MS (method 2): Rt = 1 .14 min; MS (ESIpos): m/z = 421 [M+H]+
1H NMR (400 MHz, DMSO-d6) δ ppm 3.94 (qd, 2 H), 6.33 (d, 1 H), 7.05 (t, 1 H), 7.41 (d, 2 H), 7.62 (s, 1 H), 8.10 (d, 1 H), 9.30 (s, 1 H), 12.13 (br s, 1 H)
Example 188
(+/-)-N-{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3- [(dimethylamino)methyl]pyrrolidine-1 -carboxamide
Figure imgf000401_0002
In analogy to example 178, (+/-)-N-{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[(dimethylamino)methyl]pyrrolidine-1 - carboxamide (155 mg, 267 μηηοΙ, intermediate 214) was stirred with trifluoroacetic acid
(1 .0 ml_, 13 mmol) in dichloromethane (5.0 mL) to afford after preperative HPLC purification the title compound (56 mg, 46 % yield).
LC-MS (method 2): Rt = 1 .1 1 min; MS (ESIpos): m/z = 450 [M+H]+
1H NMR (400 MHz, DMSO-d6) δ ppm 1 .57 (dq, 1 H), 1 .93 - 2.02 (m, 1 H), 2.16 (s, 6 H), 2.18 - 2.29 (m, 2 H), 2.39 - 2.47 (m, 1 H), 3.09 (dd, 1 H), 3.30 - 3.38 (m, 1 H), 3.49 (dq, 1 H), 3.57 (dd, 1 H), 6.31 (d, 1 H), 7.57 - 7.63 (m, 3 H), 8.10 (d, 1 H), 8.63 (s, 1 H), 12.12 (br s, 1 H)
Example 189
1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[(4-methyl-1 ,2,5- oxadiazol-3-yl)methyl]urea
Figure imgf000402_0001
In analogy to example 178, 1 -{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[(4-methyl-1 ,2,5-oxadiazol-3-yl)methyl]urea (150 mg, 265 μηηοΙ, intermediate 215) was stirred with trifluoroacetic acid (1 .0 mL, 13 mmol) in dichloromethane (5.0 mL) to afford after preperative HPLC purification the title compound (41 mg, 35 % yield).
LC-MS (method 2): Rt = 1 .1 1 min; MS (ESIpos): m/z = 435 [M+H]+
1H NMR (400 MHz, DMSO-d6) δ ppm 2.40 (s, 3 H), 4.52 (d, 2 H), 6.32 (d, 1 H), 7.08 (t, 1 H), 7.39 (d, 2 H), 7.61 (d, 1 H), 8.09 (d, 1 H), 9.29 (s, 1 H), 12.13 (br s, 1 H)
Example 190
1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(2-fluoroethyl)urea
Figure imgf000402_0002
In analogy to example 178, 1 -{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(2-fluoroethyl)urea (140 mg, 272 μηηοΙ, intermediate 216) was stirred with trifluoroacetic acid (1.0 ml_, 13 mmol) in dichloromethane (5.0 mL) to afford after preperative HPLC purification the title compound (39 mg, 37 % yield).
LC-MS (method 2): Rt = 1 .01 min; MS (ESIpos): m/z = 385 [M+H]+
1H NMR (400 MHz, DMSO-d6) δ ppm 3.41 (dq, 2 H), 4.47 (dt, 2 H), 6.32 (d, 1 H), 6.66 (t, 1 H), 7.39 (d, 2 H), 7.61 (s, 1 H), 8.10 (d, 1 H), 9.12 (s, 1 H), 12.13 (br s, 1 H)
Example 191
N-{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-2-oxa-7- azaspiro[3.5]nonane-7-carboxamide
Figure imgf000403_0001
In analogy to example 178, N-{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-2-oxa-7-azaspiro[3.5]nonane-7-carboxamide (155 mg, 268 μηηοΙ, intermediate 217) was stirred with trifluoroacetic acid (1 .0 mL, 13 mmol) in dichloromethane (5.0 mL) to afford after preperative HPLC purification the title compound (40 mg, 30 % yield).
LC-MS (method 2): Rt = 1 .03 min; MS (ESIpos): m/z = 449 [M+H]+
1H NMR (400 MHz, DMSO-d6) δ ppm 1 .77 - 1 .82 (m, 4 H), 3.37 - 3.41 (m, 4 H), 4.34 (s, 4 H), 6.31 (d, 1 H), 7.50 (d, 2 H), 7.61 (s, 1 H), 8.10 (d, 1 H), 8.97 (s, 1 H), 12.12 (br s, 1 H) Example 192
1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b ridin-4-yl)oxy]-3,5-difluorophenyl}-3-(2,2-difluoroethyl)urea
Figure imgf000403_0002
In analogy to example 1 , 1 -{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(2,2-difluoroethyl)urea (140 mg, 263 μηιοΙ, intermediate 218) was stirred with trifluoroacetic acid (1 .0 ml_, 13 mmol) in dichloromethane (5.0 mL) to afford after preperative HPLC purification the title compound (47 mg, 44 % yield). LC-MS (method 2): Rt = 1 .05 min; MS (ESIpos): m/z = 403 [M+H]+
1H NMR (400 MHz, DMSO-d6) δ ppm 3.54 (tdd, 2 H), 6.07 (tt, 1 H), 6.33 (d, 1 H), 6.77 (t, 1 H), 7.40 (d, 2 H), 7.61 (s, 1 H), 8.10 (d, 1 H), 9.23 (s, 1 H), 12.13 (br s, 1 H)
Example 193
1 - {4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[(4-methyl-1 H-imidazol-
2- yl)methyl]urea
Figure imgf000404_0001
In analogy to example 178, 1 -{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[(4-methyl-1 H-imidazol-2-yl)methyl]urea (150 mg, 266 μηηοΙ, intermediate 219) was stirred with trifluoroacetic acid (1 .0 mL, 13 mmol) in dichloromethane (5.0 mL) to afford after preperative HPLC purification the title compound (45 mg, 37 % yield).
LC-MS (method 2): Rt = 0.99 min; MS (ESIpos): m/z = 433 [M+H]+
1H NMR (400 MHz, DMSO-d6) δ ppm 2.10 (s, 3 H), 4.25 (d, 2 H), 6.32 (d, 1 H), 6.64 (br s, 1 H), 6.79 (t, 1 H), 7.39 (d, 2 H), 7.61 (s, 1 H), 8.10 (d, 1 H), 9.22 (s, 1 H), 1 1 .57 (br s, 1 H), 12.13 (br s, 1 H)
Example 194
1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(6-methoxypyridazin-3- yl)urea
H H
Figure imgf000404_0002
In analogy to example 178, 1 -{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(6-methoxypyridazin-3-yl)urea (120 mg, 208 μηιοΙ, intermediate 220) was stirred with trifluoroacetic acid (800 μΙ_, 10 mmol) in dichloromethane (1 .3 mL) to afford after preperative HPLC purification the title compound (1 1 mg, 12 % yield). LC-MS (method 2): Rt = 1 .1 1 min; MS (ESIpos): m/z = 447 [M+H]+
1H NMR (400 MHz, DMSO-d6) δ ppm 3.97 (s, 3 H), 6.36 (d, 1 H), 7.27 (d, 1 H), 7.51 (d, 2 H), 7.60 (s, 1 H), 7.94 (d, 1 H), 8.1 1 (d, 1 H)
Example 195
1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(1 ,3,4-thiadiazol-2- yl)urea
Figure imgf000405_0001
In analogy to example 178, 1 -{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(1 ,3,4-thiadiazol-2-yl)urea (150 mg, 271 μηηοΙ, intermediate 221 ) was stirred with trifluoroacetic acid (1 .0 mL, 13 mmol) in dichloromethane (5.0 mL) to afford after preperative HPLC purification the title compound (5 mg, 4 % yield over two steps).
LC-MS (method 2): Rt = 0.70 min; MS (ESIpos): m/z = 423 [M+H]+
1H NMR (400 MHz, DMSO-d6) δ ppm 6.35 (d, 1 H), 7.55 (br d, 2 H), 7.63 (d, 1 H), 8.1 1 (d, 1 H), 9.05 (br s, 1 H), 9.65 (br s, 1 H), 12.15 (br s, 1 H)
Example 196
1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(1 ,3-thiazol-2- ylmethyl)urea
Figure imgf000405_0002
In analogy to example 178, 1 -{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(1 ,3-thiazol-2-ylmethyl)urea (150 mg, 265 μηιοΙ, intermediate 222) was stirred with trifluoroacetic acid (1 .0 ml_, 13 mmol) in dichloromethane (5.0 mL) to afford after preperative HPLC purification the title compound (60 mg, 51 % yield over two steps).
LC-MS (method 2): Rt = 1 .02 min; MS (ESIpos): m/z = 436 [M+H]+
1H NMR (400 MHz, DMSO-d6) δ ppm 4.61 (d, 2 H), 6.34 (d, 1 H), 7.26 (t, 1 H), 7.42 (d, 2 H), 7.61 (s, 1 H), 7.63 (d, 1 H), 7.74 (d, 1 H), 8.09 (d, 1 H), 9.39 (s, 1 H), 12.13 (br s, 1 H)
Example 197
1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(6-iodopyrid
yl)urea
Figure imgf000406_0001
In analogy to example 178, 1 -{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(6-iodopyridazin-3-yl)urea (120 mg, 178 μηιοΙ, intermediate 223) was stirred with trifluoroacetic acid (690 μΙ_, 8.9 mmol) in dichloromethane (1 .1 mL) to afford after preperative HPLC purification the title compound (4 mg, 4 % yield). LC-MS (method 2): Rt = 1 .15 min; MS (ESIpos): m/z = 541 [M]+
1H NMR (400 MHz, DMSO-d6) δ ppm 6.32 (d, 1 H), 6.38 (d, 1 H), 6.99 (d, 1 H), 7.1 1 (d, 2 H), 7.61 (s, 1 H), 8.10 (d, 1 H)
Example 198
1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[6-(morpholin-4- yl)pyridazin-3-yl]urea
Figure imgf000406_0002
In analogy to example 178, 1 -{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[6-(morpholin-4-yl)pyridazin-3-yl]urea (120 mg, 190 μηιοΙ, intermediate 224) was stirred with trifluoroacetic acid (730 μΙ_, 9.5 mmol) in dichloromethane (1 .2 mL) to afford after preperative HPLC purification the title compound (31 mg, 32 % yield).
LC-MS (method 2): Rt = 1 .06 min; MS (ESIpos): m/z = 502 [M+H]+
1H NMR (400 MHz, DMSO-d6) δ ppm 3.43 - 3.48 (m, 4 H), 3.71 - 3.76 (m, 4 H), 6.36 (d, 1 H), 7.43 (d, 1 H), 7.50 (d, 2 H), 7.63 (s, 1 H), 7.79 (d, 1 H), 8.1 1 (d, 1 H), 9.62 (s, 1 H), 10.15 (br s, 1 H), 12.14 (br s, 1 H)
Example 199
1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(5-methylpyrid yl)urea
Figure imgf000407_0001
In analogy to example 178, 1 -{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(5-methylpyridazin-3-yl)urea (80.0 mg, 143 μηιοΙ, intermediate 225) was stirred with trifluoroacetic acid (550 μΙ_, 7.1 mmol) in dichloromethane (920 μΙ_) to afford after preperative HPLC purification the title compound (1 1 mg, 17 % yield). LC-MS (method 2): Rt = 1 .07 min; MS (ESIpos): m/z = 431 [M+H]+
1H NMR (400 MHz, DMSO-d6) δ ppm 2.33 (s, 3 H), 6.37 (d, 1 H), 7.52 (d, 2 H), 7.63 (s, 1 H), 7.86 (s, 1 H), 8.1 1 (d, 1 H), 8.80 (d, 1 H), 9.92 (br s, 1 H), 10.22 (br s, 1 H), 12.15 (br s, 1 H)
Example 200
1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(6-cyclopropylpyridazin- 3-yl)urea
Figure imgf000407_0002
In analogy to example 178, 1 -{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(6-cyclopropylpyridazin-3-yl)urea (120 mg, 204 μηιοΙ, intermediate 226) was stirred with trifluoroacetic acid (790 μΙ_, 10 mmol) in dichloromethane (1 .3 mL) to afford after preperative HPLC purification the title compound (25 mg, 26 % yield). LC-MS (method 2): Rt = 1 .16 min; MS (ESIpos): m/z = 457 [M+H]+
1H NMR (400 MHz, DMSO-d6) δ ppm 0.95 - 1 .00 (m, 2 H), 1 .04 (dt, 2 H), 2.17 - 2.24 (m, 1 H), 6.36 (d, 1 H), 7.50 (m, 3 H), 7.63 (s, 1 H), 7.89 (d, 1 H), 8.1 1 (d, 1 H), 9.92 (br s, 1 H), 10.21 (br s, 1 H), 12.14 (br s, 1 H)
Example 201
(+/-)-1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(1 -methyl- 5-oxopyrrolidin-3-yl)urea
Figure imgf000408_0001
In analogy to example 1 , (+/-)-1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(1 -methyl-5- oxopyrrolidin-3-yl)urea (1 10 mg, 183 μηηοΙ, intermediate 227) was stirred with trifluoroacetic acid (0.9 mL, 12 mmol) in dichloromethane (1.8 mL). After purification using a Biotage chromatography system we obtained 65.6 mg (95 % purity, 72 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 2.17 (dd, 1 H), 2.61 (dd, 1 H), 2.73 (s, 3H), 3.19 (dd, 1 H), 3.64 (dd, 1 H), 4.22 - 4.32 (m, 1 H), 6.46 (d, 1 H), 6.96 (d, 1 H), 7.35 - 7.42 (m, 2H), 8.1 1 (s, 1 H), 8.21 (d, 1 H), 9.00 (s, 1 H), 12.63 (s, 1 H).
Example 202
N-(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-4,4- difluoropiperidine-1 -carboxamide
Figure imgf000408_0002
In analogy to example 1 , N-(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-4,4-difluoropiperidine-1 - carboxamide (158 mg, 260 μηηοΙ, intermediate 228) was stirred with trifluoroacetic acid
(0.9 ml_, 12 mmol) in dichloromethane (1 .8 ml_). After purification using a Biotage
chromatography system we obtained 72.9 mg (95 % purity, 56 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 1 .95 - 2.08 (m, 4H), 3.55 - 3.64 (m, 4H), 6.46 (d, 1 H), 7.45 - 7.53 (m, 2H), 8.1 1 (s, 1 H), 8.22 (d, 1 H), 9.15 (s, 1 H), 12.64 (br s, 1 H). Example 203
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[3-(propan-2- yloxy)propyl]urea
Figure imgf000409_0001
In analogy to example 1 , 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[3-(propan-2- yloxy)propyl]urea (140 mg, 233 μηηοΙ, intermediate 229) was stirred with trifluoroacetic acid (0.9 ml_, 12 mmol) in dichloromethane (1.8 ml_). After purification using a Biotage
chromatography system we obtained 69.9 mg (95 % purity, 60 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 1 .09 (d, 6H), 1 .64 (quin, 2H), 3.15 (q, 2H), 3.39 (t, 2H), 3.52 (spt, 1 H), 6.41 (t, 1 H), 6.46 (d, 1 H), 7.34 - 7.42 (m, 2H), 8.1 1 (s, 1 H), 8.21 (d, 1 H), 9.01 (s, 1 H), 12.63 (br s, 1 H).
Example 204
N-(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3- methoxyazetidine-1 -carboxamide
O
Figure imgf000409_0002
In analogy to example 1 , N-(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-methoxyazetidine-1 - carboxamide (151 mg, 264 μηηοΙ, intermediate 230) was stirred with trifluoroacetic acid
(0.9 ml_, 12 mmol) in dichloromethane (1 .8 ml_). After purification using a Biotage
chromatography system we obtained 70.3 mg (95 % purity, 57 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 3.33 (s, 3H), 3.79 (dd, 2H), 4.14 - 4.24 (m, 3H), 6.46 (d, 1 H), 7.46 - 7.54 (m, 2H), 8.1 1 (s, 1 H), 8.21 (d, 1 H), 8.97 (s, 1 H), 12.63 (br s, 1 H).
Example 205
N-(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-1 - azaspiro[3.3]heptane-6-carboxamide
Figure imgf000410_0001
In analogy to example 1 , N-(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-1 -oxa-6- azaspiro[3.3]heptane-6-carboxamide (67.2 mg, 1 15 μηηοΙ, intermediate 231 ) was stirred with trifluoroacetic acid (0.9 ml_, 12 mmol) in dichloromethane (1 .8 ml_). After purification using a Biotage chromatography system we obtained 31.5 mg (90 % purity, 54 % yield) of the desired title compound.
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: 2.84 (t, 2H), 4.07 (dd, 2H), 4.23 (dd, 2H), 4.38 - 4.46 (m, 2H), 6.46 (d, 1 H), 7.45 - 7.53 (m, 2H), 8.1 1 (s, 1 H), 8.21 (d, 1 H), 9.00 (s, 1 H), 12.63 (br s, 1 H).
Example 206
N-(3,5-difluoro^^[3-(trifluoromethyl)-1 H-pyrTolo[2,3-b]pyridin-4-yl]oxy}phenyl)-2- azaspiro[3.5]nonane-6-carboxamide
Figure imgf000411_0001
In analogy to example 1 , N-(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-2-oxa-6- azaspiro[3.5]nonane-6-carboxamide (159 mg, 260 μmol, intermediate 232) was stirred with trifluoroacetic acid (0.9 ml_, 12 mmol) in dichloromethane (1 .8 ml_). After purification using a Biotage chromatography system we obtained 70.2 mg (90 % purity, 50 % yield) of the desired title compound.
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: 1.41 - 1 .52 (m, 2H), 1 .77 - 1.87 (m, 2H), 3.35 - 3.41 (m, 2H), 3.69 (s, 2H), 4.24 - 4.31 (m, 4H), 6.47 (d, 1 H), 7.48 - 7.55 (m, 2H), 8.1 1 (s, 1 H), 8.21 (d, 1 H), 9.02 (s, 1 H), 12.63 (br s, 1 H). Example 207
N-(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-N'-{[3-(propan-2- yl)oxetan-3-yl]methyl}urea
Figure imgf000411_0002
In two independent experiments to a solution of N-(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-N'-{[3-(propan-2- yl)oxetan-3-yl]methyl}urea (200 mg, 325 mol) (50 + 200 mg, 81 mol + 325 mol,
intermediate 233) and ethylenediamine (22 + 89 μΙ_, 334 + 1300μηΊθΙ) in DMF (1.0 + 4.0 mL) was added a solution of 1 N tetrabutylammoniume fluoride in THF (325 + 1300μΙ_, 325 + 1300μη"ΐοΙ) and this mixture was stirred at 45°C overnight. After cooling to room temperature the two mixtures were combined and poured into water and extracted two times with ethyl acetate. The combined organic phase was washed with brine, filtrated over a hydrophobic phase separation filter paper and concentrated in vacuo. The obtained residue was purified via a Biotage chromatography system (1 1 g snap KP-NH column, ethyl acetate / 0 - 80% ethanol) to obtain a crude product, which was solved in ethyl acetate, washed two times with water, filtrated over a hydrophobic phase separation filter paper and concentrated in vacuo. The resulting residue was then purified via HPLC to obtain 59 mg (97 % purity, 30 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 0.91 (d, 6H), 2.01 (quin, 1 H), 3.32 (d, 2H), 4.28 - 4.34 (m, 4H), 6.48 (d, 1 H), 6.71 (t, 1 H), 7.36 - 7.43 (m, 2H), 8.1 1 (s, 1 H), 8.21 (d, 1 H), 9.08 (s, 1 H), 12.62 (br s, 1 H).
Example 208
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[3-methyl-3- (morpholin-4-yl)butyl]urea
Figure imgf000412_0001
In analogy to example 1 , 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[3-methyl-3- (morpholin-4-yl)butyl]urea (150 mg, 228 μηηοΙ, intermediate 234) was stirred with trifluoroacetic acid (0.9 ml_, 12 mmol) in dichloromethane (1.8 ml_). After purification using a Biotage chromatography system we obtained 92.7 mg (95 % purity, 73 % yield) of the desired title compound.
LC-MS (method 2): Rt = 1 .16 min; MS (ESIpos): m/z = 528 [M+H]+
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: 0.98 (s, 6H), 1 .52 - 1.59 (m, 2H), 2.43 - 2.48 (m, 4H), 3.13 (dt, 2H), 3.53 - 3.62 (m, 4H), 6.38 (t, 1 H), 6.46 (d, 1 H), 7.33 - 7.41 (m, 2H), 8.1 1 (s, 1 H), 8.21 (d, 1 H), 9.05 (s, 1 H), 12.63 (br s, 1 H). Example 209
1 -{4-[(3-bromo-1 H-pyrrolo[2!3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[(4-methyl-1 ,2,5- oxadiazol-3-yl)methyl]urea
Figure imgf000413_0001
In analogy to example 143, crude 1 -{4-[(3-bromo-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[(4-methyl-1 ,2,5-oxadiazol-3-yl)methyl]urea (232 mg, 381 μηηοΙ, intermediate 235) was reacted with trifluoroacetic acid (40 eq., 1.2 ml_, 15 mmol) in dichloromethane for 2 days to give after preparative HPLC (method 4) the title compound (83 mg, 43%).
LC-MS (method 2): Rt = 1 .04 min; MS (ESIpos): m/z = 479/481 [M+H]+ (Br isotope pattern).
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 2.39 (s, 3H), 4.52 (d, 2H), 6.33 (d, 1 H), 7.10 (t, 1 H), 7.37 - 7.42 (m, 2H), 7.64 (d, 1 H), 8.09 (d, 1 H), 9.30 (bs, 1 H), 12.20 (bs, 1 H).
Example 210
(+/-) 1 -{4-[(3-bromo-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(tetrahydrofuran-2- ylmethyl)urea
Figure imgf000413_0002
In analogy to example 143, crude (+/-) 1 -{4-[(3-bromo-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(tetrahydrofuran-2-ylmethyl)urea (228 mg, 381 μηηοΙ, intermediate 236) was reacted with trifluoroacetic acid (40 eq., 1.2 ml_, 15 mmol) in dichloromethane for 2 days to give after preparative HPLC (method 4) the title compound (59 mg, 32%).
LC-MS (method 2): Rt = 1 .02 min; MS (ESIpos): m/z = 467/469 [M+H]+ (Br isotope pattern). Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: 1.48 - 1 .56 (m, 1 H), 1.78 - 1.92 (m, 3H), 3.08 - 3.14 (m, 1 H), 3.21 - 3.28 (m, 1 H), 3.61 - 3.67 (m, 1 H), 3.76 - 3.81 (m, 1 H), 3.84 - 3.90 (m, 1 H), 6.32 (d, 1 H), 6.45 (t, 1 H), 7.33 - 7.39 (m, 2H), 7.64 (s, 1 H), 8.10 (d, 1 H), 9.06 (bs, 1 H), 12.20 (bs, 1 H). Example 211
1 -{4-[(3-bromo-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-pyridazin-3-ylurea
Figure imgf000414_0001
In analogy to example 143 crude 1 -{4-[(3-bromo-1-{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-pyridazin-3-ylurea (225 mg, 380 μηιοΙ, intermediate 237) was reacted with trifluoroacetic acid (40 eq., 1.2 ml_, 15 mmol) in
dichloromethane for 2 days to give after preparative HPLC (method 4) the title compound (0.3 mg, 0.2%).
LC-MS (method 2): Rt = 0.99 min; MS (ESIpos): m/z = 461/463 [M+H]+ (Br isotope pattern). Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: 6.37 (d, 1 H), 7.49 - 7.54 (m, 2H), 7.66 - 7.70 (m, 2H), 8.05 (dd, 1 H), 8.1 1 (d, 1 H), 8.93 (dd, 1 H), 9.97 (bs, 1 H), 10.10 (bs, 1 H), 12.23 (bs, 1 H).
Example 212
1 -{4-[(3-bromo-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(6-methylpyridazin-3- yl)urea
Figure imgf000414_0002
In analogy to example 143 crude 1 -{4-[(3-bromo-1-{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(6-methylpyridazin-3-yl)urea (230 mg, 380 μηηοΙ, intermediate 238) was reacted with trifluoroacetic acid (40 eq., 1.2 ml_, 15 mmol) in dichloromethane for 2 days to give after preparative HPLC (method 4) the title compound (0.1 mg, 0.1 %).
LC-MS (method 2): Rt = 1 .06 min; MS (ESIpos): m/z = 475/477 [M+H]+ (Br isotope pattern). 1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 2.55 (s, 3H), 6.36 (d, 1 H), 7.48 - 7.54 (m, 2H), 7.57 (d, 1 H), 7.66 (d, 1 H), 7.92 (d, 1 H), 8.1 1 (d, 1 H), 9.90 (bs, 1 H), 10.18 (bs, 1 H), 12.23 (bs, 1 H). Example 213
1 -{4-[(3-bromo-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3!5-difluorophenyl}-3-(1 !3,4-thiadiazol-2^ yl)urea
Figure imgf000415_0001
In analogy to example 143 crude 1 -{4-[(3-bromo-1-{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(1 ,3,4-thiadiazol-2-yl)urea (227 mg, 380 μmol, intermediate 239) was reacted with trifluoroacetic acid (40 eq., 1.2 ml_, 15 mmol) in dichloromethane for 2 days to give after preparative HPLC (method 4) the title compound (7 mg, 4%).
LC-MS (method 2): Rt = 0.63 min; MS (ESIpos): m/z = 467/469 [M+H]+ (Br isotope pattern).
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 6.35 (d, 1 H), 7.54 - 7.56 (m, 2H), 7.66 (d, 1 H), 8.1 1 (d, 1 H), 9.04 (bs, 1 H), 9.64 (bs, 1 H), 1 1 .53 (bs, 1 H), 12.23 (bs, 1 H).
Example 214
1 -{4-[(3-bromo-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[(4-methyl-1 H-imidazol- 2-yl)methyl]urea
Figure imgf000415_0002
In analogy to example 143 1 -{4-[(3-bromo-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[(4-methyl-1 H-imidazol-2-yl)methyl]urea (43 mg, 71 μηηοΙ, intermediate 240) was reacted with trifluoroacetic acid (40 eq., 220 μΙ_, 2.8 mmol) in dichloromethane for 2 days to give after preparative HPLC (method 4) the title compound (6 mg, 16%).
LC-MS (method 2): Rt = 0.93 min; MS (ESIpos): m/z = 477/479 [M+H]+ (Br isotope pattern). 1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 2.10 (s, 3H), 4.25 (d, 2H), 6.32 (d, 1 H), 6.62 (bs, 1 H), 6.79 (t, 1 H), 7.36 - 7.42 (m, 2H), 7.64 (d, 1 H), 8.10 (d, 1 H), 9.23 (bs, 1 H), 1 1.59 (bs, 1 H), 12.21 (bs, 1 H). Example 215
1 -{4-[(3-cyano-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(6-methylpyridazin-3- yl)urea
Figure imgf000416_0001
In analogy to example 143 1 -{4-[(3-cyano-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(6-methylpyridazin-3-yl)urea (53 mg, 95 μηιοΙ, intermediate 241 ) was reacted with trifluoroacetic acid (40 eq., 290 μΙ_, 3.8 mmol) in
dichloromethane to give after preparative HPLC (method 4) the title compound (1.4 mg, 3%). LC-MS (method 2): Rt = 0.82 min; MS (ESIpos): m/z = 422 [M+H]+.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 2.55 (s, 3H), 6.56 (d, 1 H), 7.50 - 7.58 (m, 3H), 7.92 (d, 1 H), 8.25 (d, 1 H), 8.46 (s, 1 H), 9.95 (bs, 1 H), 10.23 (bs, 1 H), 12.95 (bs, 1 H).
Example 216
1 -{4-[(3-cyano-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-pyridazin-3-ylurea
Figure imgf000416_0002
In analogy to example 143 1 -{4-[(3-cyano-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-pyridazin-3-ylurea (28 mg, 52 μηηοΙ, intermediate 242) was reacted with trifluoroacetic acid (40 eq., 160 μΙ_, 2.1 mmol) in dichloromethane to give after preparative HPLC (method 4) the title compound (0.8 mg, 3%).
LC-MS (method 2): Rt = 0.78 min; MS (ESIpos): m/z = 408 [M+H]+.
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: 6.35 - 6.57 (m, 1 H), 7.50 - 7.57 (m, 2H), 7.66 - 7.70 (m, 1 H), 7.91 - 8.07 (m, 1 H), 8.10 - 8.25 (m, 1 H), 8.46 (s, 1 H), 8.93 (dd, 1 H), 9.93 - 10.03 (m, 1 H), 10.16 - 10.21 (m, 1 H), 12.23 - 12.96 (m, 1 H). Example 217
1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-{1 -[(4-methylpiperazin- 1 -yl)carbonyl]cyclopropyl}urea
Figure imgf000417_0001
In analogy to example 178, 1 -{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-{1 -[(4-methylpiperazin-1 -yl)carbonyl]cyclopropyl}urea (80.0 mg, 126 μmol, intermediate 245) was stirred with trifluoroacetic acid (490 μΙ_, 6.3 mmol) in dichloromethane (810 μΙ_, 13 mmol) to afford after preperative HPLC purification the title compound (21 mg, 33 % yield).
LC-MS (method 2): Rt = 0.99 min; MS (ESIneg): m/z = 503 [M-H]"
1H NMR (400 MHz, DMSO-d6) δ ppm 0.93 - 0.97 (m, 2 H), 1 .17 - 1 .21 (m, 2 H), 2.16 (s, 3 H), 2.26 (br t, 4 H), 3.54 (br s, 4 H), 6.32 (d, 1 H), 7.38 (d, 3 H), 7.61 (d, 1 H), 8.09 (d, 1 H), 8.88 (s, 1 H), 12.13 (br s, 1 H) Example 218
1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[1 -(morpholin-4- ylcarbonyl)cyclopropyl]urea
Figure imgf000417_0002
In analogy to example 178, 1 -{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[1 -(morpholin-4-ylcarbonyl)cyclopropyl]urea (100 mg, 161 μιτιοΙ, intermediate 246) was stirred with trifluoroacetic acid (620 μΙ_, 8.0 mmol) in dichloromethane (1 .0 ml_, 16 mmol) to afford after preperative HPLC purification the title compound (4 mg, 5 % yield).
LC-MS (method 2): Rt = 0.98 min; MS (ESIneg): m/z = 492 [M+H]+
1H NMR (400 MHz, DMSO-d6) δ ppm 0.92 (br s, 2 H), 1 .16 - 1.21 (m, 2 H), 3.54 (br s, 8 H), 6.32 (d, 1 H), 7.40 (br d, 2 H), 7.60 (s, 1 H), 8.09 (d, 1 H), 8.26 (br s, 1 H), 9.86 (br s, 1 H), 12.04 (br s, 1 H) Example 219
1 -[({4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}carbamoyl)ami dimethylcyclopropanecarboxamide
Figure imgf000418_0001
In analogy to example 178, 1 -[({4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl)oxy]-3,5-difluorophenyl}carbamoyl)amino]-N,N- dimethylcyclopropanecarboxamide (80.0 mg, 138 μηηοΙ, intermediate 247) was stirred with trifluoroacetic acid (530 μΙ_, 6.9 mmol) in dichloromethane (890 μΙ_, 14 mmol) to afford after preperative HPLC purification the title compound (17 mg, 27 % yield).
LC-MS (method 2): Rt = 1 .00 min; MS (ESIpos): m/z = 450 [M+H]+
1H NMR (400 MHz, DMSO-d6) δ ppm 0.90 - 0.97 (m, 2 H), 1.17 - 1 .24 (m, 2 H), 2.96 (br s, 6 H), 6.32 (d, 1 H), 7.39 (d, 2 H), 7.58 - 7.65 (m, 2 H), 8.09 (d, 1 H), 9.19 (br s, 1 H)
Example 220
1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[1 -(piperidin-1 - ylcarbonyl)cyclopropyl]urea
Figure imgf000418_0002
In analogy to example 178, 1 -{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[1 -(piperidin-1 -ylcarbonyl)cyclopropyl]urea (80.0 mg, 129 μηηοΙ, intermediate 248) was stirred with trifluoroacetic acid (500 μΙ_, 6.4 mmol) in dichloromethane (830 μΙ_, 13 mmol) to afford after preperative HPLC purification the title compound (27 mg, 42 % yield).
LC-MS (method 2): Rt = 1 .12 min; MS (ESIpos): m/z = 490 [M+H]+
1H NMR (400 MHz, DMSO-d6) δ ppm 0.90 - 0.94 (m, 2 H), 1.17 (br d, 2 H), 1 .44 (br s, 4 H), 1 .57 (br d, 2 H), 3.50 (br s, 4 H), 6.32 (d, 1 H), 7.39 (d, 2 H), 7.60 (s, 1 H), 7.87 (br s, 1 H), 8.09 (d, 1 H), 9.39 (br s, 1 H), 12.1 1 (br s, 1 H) Example 221
(+/-)1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(1 -methoxypropan- 2-yl)urea
Figure imgf000419_0001
In analogy to example 178, (+/-) 1 -{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[-1 -methoxypropan-2-yl]urea (145 mg, 268 μηηοΙ, intermediate 249) was stirred with trifluoroacetic acid (1 .0 ml_, 13 mmol) in dichloromethane (5.0 mL) to afford after preperative HPLC purification the title compound (42 mg, 38 % yield).
LC-MS (method 2): Rt = 1 .07 min; MS (ESIpos): m/z = 41 1 [M+H]+
1H NMR (400 MHz, DMSO-d6) δ ppm 1 .10 (d, 3 H), 3.25 - 3.31 (m, 4 H), 3.34 - 3.36 (m, 1 H), 3.81 - 3.92 (m, 1 H), 6.30 - 6.36 (m, 2 H), 7.35 (d, 2 H), 7.61 (d, 1 H), 8.10 (d, 1 H), 8.95 (s, 1 H), 12.12 (br s, 1 H) Example 222
1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[1■
(methoxymethyl)cyclopropyl]urea
Figure imgf000419_0002
In analogy to example 178, 1 -{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[1 -(methoxymethyl)cyclopropyl]urea (150 mg,
271 μηηοΙ, intermediate 250) was stirred with trifluoroacetic acid (1 .0 mL, 13 mmol) in dichloromethane (4.0 mL, 62 mmol) to afford after preperative HPLC purification the title compound (37 mg, 32 % yield).
LC-MS (method 2): Rt = 1 .07 min; MS (ESIpos): m/z = 423 [M+H]+
1H NMR (400 MHz, DMSO-d6) δ ppm 0.72 (s, 4 H), 3.28 (s, 3 H), 3.37 (s, 2 H), 6.32 (d, 1 H), 6.81 (s, 1 H), 7.37 (d, 2 H), 7.61 (d, 1 H), 8.10 (d, 1 H), 8.82 (s, 1 H), 12.12 (br s, 1 H) Example 223
(+/-) 1 -{4-[(3-chloro-1 H-pyrrolo[2!3-b]pyridin-4-yl)oxy]-3!5-difluorophenyl}-3-(2,2- dimethyltetrahydrofuran-3-yl)urea
Figure imgf000420_0001
In analogy to example 178, (+/-)1 -{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[(3S)-2,2-dimethyltetrahydrofuran-3-yl]urea (150 mg, 264 μηηοΙ, intermediate 251 ) was stirred with trifluoroacetic acid (1 .0 mL, 13 mmol) in dichloromethane (4.0 mL, 62 mmol) to afford after preperative HPLC purification the title compound (33 mg, 28 % yield).
LC-MS (method 2): Rt = 1 .08 min; MS (ESIpos): m/z = 437 [M+H]+
1H NMR (400 MHz, DMSO-d6) δ ppm 1.07 (s, 3 H), 1 .17 (s, 3 H), 1 .70 - 1 .79 (m, 1 H), 2.25 - 2.35 (m, 1 H), 3.67 - 3.81 (m, 2 H), 3.93 - 4.01 (m, 1 H), 6.32 (d, 1 H), 6.54 (d, 1 H), 7.37 (d, 2 H), 7.61 (s, 1 H), 8.10 (d, 1 H), 8.87 (s, 1 H), 12.12 (br s, 1 H)
Example 224
(+/-) 1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(5-oxaspi
7-yl)urea
Figure imgf000420_0002
In analogy to example 178, (+/-) 1 -{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[(7R)-5-oxaspiro[3.4]oct-7-yl]urea (150 mg, 259 μηηοΙ, intermediate 252) was stirred with trifluoroacetic acid (1 .0 mL, 13 mmol) in dichloromethane (4.0 mL, 62 mmol) to afford after preperative HPLC purification the title compound (39 mg, 33 % yield).
LC-MS (method 2): Rt = 1 .14 min; MS (ESIpos): m/z = 449 [M+H]+
1H NMR (400 MHz, DMSO-d6) δ ppm 1 .45 - 1 .58 (m, 1 H), 1 .58 - 1 .68 (m, 1 H), 1 .90 (dd, 1 H), 1 .98 (ddt, 1 H), 2.05 - 2.21 (m, 3 H), 2.25 (dd, 1 H), 3.48 (dd, 1 H), 3.86 (dd, 1 H), 4.17 - 4.26 (m, 1 H), 6.32 (d, 1 H), 6.63 (d, 1 H), 7.37 (d, 2 H), 7.61 (d, 1 H), 8.10 (d, 1 H), 8.90 (s, 1 H), 12.12 (br s, 1 H) Example 225
(+/-) 1 -{4-[(3-chloro-1 H-pyrrolo[2!3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[(trans)-4- (pyrrolidin-1 -yl)tetrahydrofuran-3- l]urea
Figure imgf000421_0001
In analogy to example 178, (+/-) 1 -{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[(trans)-4-(pyrrolidin-1 -yl)tetrahydrofuran-3- yl]urea (160 mg, 263 μηηοΙ, intermediate 253) was stirred with trifluoroacetic acid (1 .0 mL, 13 mmol) in dichloromethane (4.0 mL, 62 mmol) to afford after preperative HPLC purification the title compound (35 mg, 28 % yield).
LC-MS (method 2): Rt = 1 .04 min; MS (ESIpos): m/z = 478 [M+H]+
1H NMR (400 MHz, DMSO-d6) δ ppm 1.67 (br s, 5 H), 2.66 - 2.72 (m, 1 H), 3.51 (dd, 1 H), 3.60 (dd, 1 H), 3.89 (td, 2 H), 4.14 - 4.22 (m, 1 H), 6.31 (d, 1 H), 6.96 (br d, 1 H), 7.39 (d, 2 H), 7.61 (s, 1 H), 8.09 (d, 1 H), 9.08 (br s, 1 H), 12.10 (br s, 1 H) Example 226
N2-({4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}carbamoyl)-N,N- dimethylalaninamide
Figure imgf000421_0002
In analogy to example 178, N2-({4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}carbamoyl)-N,N-dimethylalaninamide (60.0 mg, 106 μηηοΙ, intermediate 254) was stirred with trifluoroacetic acid (410 μί, 5.3 mmol) in dichloromethane (680 μί, 1 1 mmol) to afford after preperative HPLC purification the title compound (20 mg, 39 % yield).
LC-MS (method 2): Rt = 1 .01 min; MS (ESIpos): m/z = 438 [M+H]+
1H NMR (400 MHz, DMSO-d6) δ ppm 1 .21 (d, 3 H), 2.86 (s, 3 H), 3.05 (s, 3 H), 4.68 (quin, 1 H), 6.32 (d, 1 H), 6.72 (d, 1 H), 7.34 (d, 2 H), 7.61 (s, 1 H), 8.09 (d, 1 H), 9.29 (s, 1 H), 12.12 (br s, 1 H) Example 227
N2-({4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}carbamo
dimethylvalinamide
Figure imgf000422_0001
In analogy to example 178, N2-({4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}carbamoyl)-N,N-dimethylvalinamide (60.0 mg, 101 μηηοΙ, intermediate 255) was stirred with trifluoroacetic acid (390 μΙ_, 5.0 mmol) in dichloromethane (650 μΙ_, 10 mmol) to afford after preperative HPLC purification the title compound (30 mg, 59 % yield).
LC-MS (method 2): Rt = 1 .12 min; MS (ESIpos): m/z = 466 [M+H]+
1H NMR (400 MHz, DMSO-d6) δ ppm 0.86 (d, 3 H), 0.90 (d, 3 H), 2.86 (s, 3 H), 3.08 (s, 3 H), 4.57 (dd, 1 H), 6.32 (d, 1 H), 6.61 (d, 1 H), 7.34 (d, 2 H), 7.61 (s, 1 H), 8.09 (d, 1 H), 9.22 (s, 1 H), 12.12 (br s, 1 H) Example 228
(+/-)1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(3- methyltetrahydrofuran-3-yl)urea
Figure imgf000422_0002
In analogy to example 178, (+/-)-1 -{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[3-methyltetrahydrofuran-3-yl]urea
(150 mg, 271 μηηοΙ, intermediate 256) was stirred with trifluoroacetic acid (1 .0 mL, 13 mmol) in dichloromethane (4.0 mL, 62 mmol) to afford after preperative HPLC purification the title compound (15 mg, 13 % yield).
LC-MS (method 2): Rt = 1 .07 min; MS (ESIpos): m/z = 423 [M+H]+
1H NMR (400 MHz, DMSO-d6) δ ppm 1 .43 (s, 3 H), 1 .86 (dt, 1 H), 2.17 (dt, 1 H), 3.53 (d, 1 H), 3.78 - 3.85 (m, 3 H), 6.32 (d, 1 H), 6.63 (s, 1 H), 7.35 (d, 2 H), 7.61 (d, 1 H), 8.10 (d, 1 H), 8.83 (s, 1 H), 12.12 (br s, 1 H) Example 229
(+/-)1 -{4-[(3-chloro-1 H-pyrrolo[2!3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[7- oxabicyclo[2.2.1 ]hept-2-yl]urea - mixture of isomers
Figure imgf000423_0001
In analogy to example 178, (+/-)1 -{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[7-oxabicyclo[2.2.1 ]hept-2-yl]urea (150 mg, 265 μηηοΙ, intermediate 257, mixture of isomers) was stirred with trifluoroacetic acid (1 .0 mL, 13 mmol) in dichloromethane (4.0 mL, 62 mmol) to afford after preperative HPLC purification the title compound (12 mg, 10 % yield).
LC-MS (method 2): Rt = 1 .07 min; MS (ESIpos): m/z = 435 [M+H]+
1H NMR (400 MHz, DMSO-d6) δ ppm 1.30 - 1 .60 (m, 5 H), 1 .93 (dd, 1 H), 3.76 (td, 1 H), 4.26 (d, 1 H), 4.53 - 4.58 (m, 1 H), 6.32 (d, 1 H), 6.48 (d, 1 H), 7.35 (d, 2 H), 7.61 (s, 1 H), 8.10 (d, 1 H), 8.85 (s, 1 H), 12.12 (br s, 1 H) Example 230
(+/-)-1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(1 -methyl-2- oxopyrrolidin-3-yl)urea
Figure imgf000423_0002
In analogy to example 178, (+/-)-1 -{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(1 -methyl-2-oxopyrrolidin-3-yl)urea
(60.0 mg, 106 μηηοΙ, intermediate 258) was stirred with trifluoroacetic acid (410 μί, 5.3 mmol) in dichloromethane (680 μί, 1 1 mmol) to afford after preperative HPLC purification the title compound (1 1 mg, 22 % yield).
LC-MS (method 2): Rt = 0.96 min; MS (ESIpos): m/z = 436 [M+H]+
1H NMR (400 MHz, DMSO-d6) δ ppm 1 .83 (dq, 1 H), 2.38 (dddd, 1 H), 2.77 (s, 3 H), 3.27 - 3.32 (m, 2 H), 4.20 - 4.27 (m, 1 H), 6.32 (d, 1 H), 6.75 (d, 1 H), 7.38 (d, 2 H), 7.61 (s, 1 H), 8.10 (d, 1 H), 9.21 (s, 1 H), 12.12 (br s, 1 H) Example 231
N-(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)azetidine-1 - carboxamide
Figure imgf000424_0001
In analogy to example 1 , N-(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)azetidine-1 -carboxamide (132 mg, 243 μηηοΙ, intermediate 259) was stirred with trifluoroacetic acid (1 .7 mL, 22 mmol) in dichloromethane (3.4 mL). After purification using a Biotage chromatography system (1 1 g snap KP-NH column, ethyl acetate / 0 - 50% ethanol) we obtained 82.3 mg (97 % purity, 80 % yield) of the desired title compound.
LC-MS (method 2): Rt = 1 .08 min; MS (ESIpos): m/z = 413 [M+H]+
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: 2.17 - 2.25 (m, 2H), 3.96 - 4.01 (m, 4H), 6.46 (d, 1 H), 7.47 - 7.57 (m, 2H), 8.1 1 (s, 1 H), 8.21 (d, 1 H), 8.85 (s, 1 H), 12.63 (br s, 1 H). Example 232
N-(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)pyrrolidine-1 - carboxamide
Figure imgf000424_0002
In analogy to example 1 , N-(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)pyrrolidine-1 - carboxamide (130 mg, 234 μηηοΙ, intermediate 260) was stirred with trifluoroacetic acid
(1 .6 mL, 21 mmol) in dichloromethane (3.2 mL). After purification using a Biotage
chromatography system we obtained 66.2 mg (97 % purity, 64 % yield) of the desired title compound.
LC-MS (method 2): Rt = 1 .13 min; MS (ESIpos): m/z = 427 [M+H]+
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: 1 .82 - 1 .92 (m, 4H), 3.35 - 3.42 (m, 4H), 6.46 (d, 1 H), 7.54 - 7.61 (m, 2H), 8.1 1 (s, 1 H), 8.22 (d, 1 H), 8.61 (s, 1 H), 12.63 (s, 1 H). Example 233
N-iS.S-difluoro^^p-itrifluoromethylJ-I H-pyrTolop.S-blpyridin^-ylloxylphenylJ-N'-IiS- fluorooxetan-3-yl)methyl]urea
Figure imgf000425_0001
In analogy to intermediate 67, in two experiments using N-(3,5-difluoro-4-{[3-(trifluoromethyl)- 1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-N'-[(3- fluorooxetan-3-yl)methyl]urea (50 + 268 mg, 85 + 454 μηηοΙ, intermediate 261 ) were reacted with 1 N tetra-N-butylammoniumfluoride in tetrahydrofurane (0.34 + 1 .8 ml_, 1.0 M, 0.34 + 1 .8 mmol) and ethylenediamine (0.9 + 120 μΙ_, 0.35 + 1 .9 mmol) in DMF (1.0 + 5.4 mL) to give after purification via a Biotage chromatography system, a subsequent HPLC chromatography followed by a preparative thin layer chromatography using dichloromethane / methanol (8:2) 1 10 mg (95 % purity, 43 % yield) of the desired title compound.
LC-MS (method 2): Rt = 1 .02 min; MS (ESIpos): m/z = 461 [M+H]+
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 3.66 (dd, 2H), 4.55 - 4.67 (m, 4H), 6.47 (d, 1 H), 6.89 (t, 1 H), 7.36 - 7.42 (m, 2H), 8.1 1 (s, 1 H), 8.21 (d, 1 H), 9.22 (s, 1 H), 12.63 (br s, 1 H).
Example 234
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(2-hydroxy-2- methylpropyl)urea
Figure imgf000425_0002
In analogy to example 77, 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(2-hydroxy-2- methylpropyl)urea (130 mg, 226 μηηοΙ, intermediate 262) was stirred with trifluoroacetic acid (1 .6 mL, 20 mmol) in dichloromethane (3.1 mL). After purification using a Biotage chromatography system and a subsequent preparative HPLC we obtained 18.4 mg (90 % purity, 16 % yield) of the desired title compound.
LC-MS (method 2): Rt = 1 .02 min; MS (ESIpos): m/z = 445 [M+H]+
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 1 .10 (s, 6H), 3.05 (d, 2H), 4.58 (s, 1 H), 6.34 (t, 1 H), 6.47 (d, 1 H), 7.31 - 7.40 (m, 2H), 8.1 1 (s, 1 H), 8.21 (d, 1 H), 9.14 (s, 1 H), 12.63 (br s, 1 H).
Example 235
(+/-)-1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[2- hydroxy-2-methyl-3-(morpholin-4-yl)propyl]urea
Figure imgf000426_0001
In analogy to example 1 14, (+/-)-1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[2-hydroxy-2-methyl- 3-(morpholin-4-yl)propyl]urea (230 mg, 348 μηηοΙ, intermediate 270) was stirred with
trifluoroacetic acid (1 .6 ml_, 21 mmol) in dichloromethane (3.2 ml_). After purification using a preparative HPLC (according to method 1 ), we obtained 55.8 mg (97 % purity, 29 % yield) of the desired title compound.
LC-MS (method 2): Rt = 1 .05 min; MS (ESIpos): m/z = 530 [M+H]+
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: 1 .07 (s, 3H), 2.08 - 2.09 (m, 2H), 2.20 - 2.29 (m, 2H), 3.07 - 3.20 (m, 2H), 3.53 - 3.60 (m, 4H), 4.55 (s, 1 H), 6.27 (t, 1 H), 6.47 (d, 1 H), 7.31 - 7.38 (m, 2H), 8.1 1 (s, 1 H), 8.21 (d, 1 H), 9.16 (s, 1 H), 12.63 (br s, 1 H).
Example 236
1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(3-hydroxy-3- methylbutyl)urea
Figure imgf000426_0002
In analogy to example 77, 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(3-hydroxy-3- methylbutyl)urea (1 10 mg, 187 μηηοΙ, intermediate 264) was stirred with trifluoroacetic acid (0.9 ml_, 12 mmol) in dichloromethane (1.8 ml_). After purification using a Biotage
chromatography system (1 1 g snap KP-NH column, hexane / 0 - 100% ethylacetate, then ethyl acetate / 0 - 80% ethanol) followed by a preparative HPLC (according to method 1 ) we obtained 24.0 mg (95 % purity, 27 % yield) of the desired title compound.
LC-MS (method 2): Rt = 1 .04 min; MS (ESIpos): m/z = 459 [M+H]+
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: 1 .13 (s, 6H), 1 .52 - 1.59 (m, 2H), 3.16 - 3.23 (m, 2H), 4.39 (s, 1 H), 6.35 (t, 1 H), 6.46 (d, 1 H), 7.34 - 7.41 (m, 2H), 8.1 1 (s, 1 H), 8.21 (d, 1 H), 9.07 (s, 1 H), 12.62 (br s, 1 H).
Example 237
6-[({4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}carbamoyl)amino]-N- methylpyridazine-3-carboxamide
Figure imgf000427_0001
In analogy example 178, 6-[({4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl)oxy]-3,5-difluorophenyl}carbamoyl)amino]-N-methylpyridazine-3-carboxamide
(100 mg, 166 μηηοΙ, intermediate 265) was stirred with trifluoroacetic acid (640 μΙ_, 8.3 mmol) in dichloromethane (1 .1 ml_, 17 mmol) to afford after preperative HPLC purification the title compound (5 mg, 6 % yield).
LC-MS (method 2): Rt = 1 .01 min; MS (ESIpos): m/z = 474 [M+H]+
1H NMR (400 MHz, DMSO-d6) δ ppm 2.85 (d, 3 H), 6.37 (d, 1 H), 7.50 (d, 2 H), 7.63 (d, 1 H), 8.1 1 (d, 1 H), 8.18 (d, 1 H), 8.25 - 8.31 (m, 1 H), 9.05 (q, 1 H), 9.93 (s, 1 H), 10.30 (s, 1 H), 12.15 (br d, 1 H) Example 238
1 -(6-tert-butylpyridazin-3-yl)-3-{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}urea
Figure imgf000428_0001
In analogy to example 178, 1 -(6-tert-butylpyridazin-3-yl)-3-{4-[(3-chloro-1 -{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}urea
(100 mg, 166 μηηοΙ, intermediate 266) was stirred with trifluoroacetic acid (640 μΙ_, 8.3 mmol) in dichloromethane (1 .1 ml_, 17 mmol) to afford after preperative HPLC purification the title compound (5 mg, 6 % yield).
LC-MS (method 2): Rt = 1 .28 min; MS (ESIpos): m/z = 473 [M+H]+
1H NMR (400 MHz, DMSO-d6) δ ppm 1 .36 (s, 9 H), 6.36 (d, 1 H), 7.52 (d, 2 H), 7.62 (d, 1 H), 7.81 (d, 1 H), 7.94 (d, 1 H), 8.1 1 (d, 1 H), 9.89 (s, 1 H), 10.21 (s, 1 H), 12.15 (br s, 1 H)
Example 239
6-[({4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}carbamoyl)amino]-N,N- dimethylpyridazine-3-carboxamide
Figure imgf000428_0002
In analogy to example 178, 6-[({4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl)oxy]-3,5-difluorophenyl}carbamoyl)amino]-N,N-dimethylpyridazine-3- carboxamide (100 mg, 162 μηηοΙ, intermediate 267) was stirred with trifluoroacetic acid (620 μΙ_, 8.1 mmol) in dichloromethane (1 .0 ml_, 16 mmol) to afford after preperative HPLC purification the title compound (3 mg, 4 % yield).
LC-MS (method 2): Rt = 1 .00 min; MS (ESIpos): m/z = 488 [M+H]+
1H NMR (400 MHz, DMSO-d6) δ ppm 3.04 (s, 3 H), 3.05 (s, 3 H), 6.37 (d, 1 H), 7.52 (d, 2 H), 7.63 (d, 1 H), 7.85 (d, 1 H), 8.1 1 (d, 1 H), 8.19 (d, 1 H), 10.07 (s, 1 H), 10.21 (s, 1 H), 12.15 (br d, 1 H) Example 240
1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[6- (trifluoromethyl)pyridazin-3-yl]urea
Figure imgf000429_0001
In analogy to example 178, 1 -{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[6-(trifluoromethyl)pyridazin-3-yl]urea (20.0 mg, 32.5 μηηοΙ, intermediate 268) was stirred with trifluoroacetic acid (130 μΙ_, 1 .6 mmol) in dichloromethane (210 μΙ_, 3.3 mmol) to afford after preperative HPLC purification the title compound 1.60 mg (98 % purity, 10 % yield).
LC-MS (method 2): Rt = 1 .21 min; MS (ESIpos): m/z = 485 [M+H]+
1H NMR (400 MHz, DMSO-d6) δ ppm 6.37 (d, 1 H), 7.53 (d, 2 H), 7.63 (s, 1 H), 8.1 1 (d, 1 H), 8.20 (d, 1 H), 8.37 (d, 1 H), 9.91 (br d, 1 H), 10.53 (br s, 1 H), 12.15 (br s, 1 H)
Example 241
1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[6- (methylsulfonyl)pyridazin-3-yl]urea
Figure imgf000429_0002
In analogy to example 179, 1 -{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[6-(methylsulfonyl)pyridazin-3-yl]urea (90.0 mg, 144 μηηοΙ, intermediate 269) was stirred with trifluoroacetic acid (550 μΙ_, 7.2 mmol) in dichloromethane (930 μΙ_, 14 mmol) to afford after preperative HPLC purification the title compound (1 .2 mg, 2 % yield).
LC-MS (method 2): Rt = 0.99 min; MS (ESIpos): m/z = 495 [M+H]+
1H NMR (400 MHz, DMSO-d6) δ ppm 3.36 (s, 3 H), 6.36 (d, 1 H), 7.57 (d, 2 H), 7.62 (s, 1 H), 7.98 - 8.06 (m, 1 H), 8.1 1 (d, 1 H), 8.35 (d, 1 H) Example 242
(+/-)-N-(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-N^ fluoro-3-methoxypropyl urea
Figure imgf000430_0001
In analogy to example 1 , (+/-)-N-(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-N'-(2-fluoro-3- methoxypropyl)urea (107 mg, 181 μmol, intermediate 270) was reacted with trifluoroacetic acid (900 μί, 12 mmol) in dichloromethane (1.8 mL) to obtain 62.0 mg (95 % purity, 71 % yield) of the desired title compound.
LC-MS (method 2): Rt = 1 .07 min; MS (ESIpos): m/z = 463 [M+H]+
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 3.30 (s, 3H), 3.31 - 3.60 (m, 4H), 4.59 - 4.79 (m, 1 H), 6.47 (d, 1 H), 6.66 (t, 1 H), 7.34 - 7.42 (m, 2H), 8.09 - 8.13 (m, 1 H), 8.21 (d, 1 H), 9.14 (s, 1 H), 12.63 (br s, 1 H). Example 243
(+/-)-N-(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-N'-[(4,4- dimethyloxetan-2-yl)methyl]urea
Figure imgf000430_0002
In analogy to example 67, (+/-)-N-(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-N'-[(4,4-dimethyloxetan- 2-yl)methyl]urea (1 12 mg, 186 μηηοΙ, intermediate 271 ) was reacted with tetra-N- butylammonium fluoride in THF (750 μΙ_, 1.0 M, 750 μηηοΙ) and ethylene diamine (51 μΙ_, 760 μηιοΙ) in DMF (2.2 mL) to obtain 37.1 mg (92 % purity, 39 % yield) of the desired title compound.
LC-MS (method 2): Rt = 1 .1 1 min; MS (ESIpos): m/z = 471 [M+H]+ 1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 1.33 (s, 3H), 1.38 (s, 3H), 2.14 (dd, 1 H), 2.27 - 2.34 (m, 1 H), 3.29 (t, 2H), 4.49 - 4.57 (m, 1 H), 6.47 (d, 1 H), 6.57 (br t, 1 H), 7.33 - 7.41 (m, 2H), 8.1 1 (s, 1 H), 8.21 (d, 1 H), 9.15 (s, 1 H), 12.62 (br s, 1 H). Example 244
(+/-)-N-(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-N'-(2- fluoro-3-methoxy-2-meth lpropyl)urea
Figure imgf000431_0001
In analogy to example 1 , (+/-)-N-(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-N'-(2-fluoro-3-methoxy- 2-methylpropyl)urea (107 mg, 176 μηηοΙ, intermediate 272) was reacted with TFA (900 μΙ_, 12 mmol) in dichloromethane (1.8 mL) to obtain 60.6 mg (95 % purity, 69 % yield) of the desired title compound.
LC-MS (method 2): Rt = 1 .1 1 min; MS (ESIpos): m/z = 477 [M+H]+
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 1 .26 (d, 3H), 3.32 (s, 3H), 3.34 - 3.47 (m, 4H), 6.47 (d, 1 H), 6.57 (t, 1 H), 7.34 - 7.41 (m, 2H), 8.1 1 (s, 1 H), 8.21 (d, 1 H), 9.05 (s, 1 H), 12.63 (s, 1 H).
Example 245
N-(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-N'-{[3- (hydroxymethyl)oxetan-3-yl]methyl}urea
Figure imgf000431_0002
In analogy to example 67, N-(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-N'-{[3- (hydroxymethyl)oxetan-3-yl]methyl}urea (65.5 mg, 109 μηηοΙ, intermediate 273) was reacted with (430 μΙ_, 1.0 M, 430 μηιοΙ) and ethylene diamine (30 μΙ_, 450 μηιοΙ) in DMF (1.3 mL) to obtain 1 1.1 mg (95 % purity, 21 % yield) of the desired title compound.
LC-MS (method 2): Rt = 0.94 min; MS (ESIpos): m/z = 473 [M+H]+
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: 3.36 - 3.41 (m, 2H), 3.59 (d, 2H), 4.26 - 4.34 (m, 4H), 4.98 (t, 1 H), 6.47 (d, 1 H), 6.99 (br s, 1 H), 7.36 - 7.43 (m, 2H), 8.1 1 (s, 1 H), 8.21 (d, 1 H), 9.48 (br s, 1 H), 12.63 (br s, 1 H).
Example 246
N-(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-N'-[(3- hydroxyoxetan-3-yl)methyl]urea
Figure imgf000432_0001
In analogy to example 67, N-(3,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2-
(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-N'-[(3-hydroxyoxetan-3- yl)methyl]urea (50.9 mg, 86.5 μηηοΙ, intermediate 274) was reacted with (350 μί, 1.0 M, 350 μηιοΙ) and ethylene diamine (24 μΙ_, 350 μηιοΙ) in DMF (1 .0 mL) to obtain 8.4 mg (90 % purity, 19 % yield) of the desired title compound.
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 3.42 (d, 2H), 4.36 - 4.42 (m, 4H), 6.00 (s, 1 H), 6.47 (d, 1 H), 6.74 (t, 1 H), 7.34 - 7.41 (m, 2H), 8.09 - 8.12 (m, 1 H), 8.21 (d, 1 H), 9.36 (s, 1 H), 12.63 (br s, 1 H).
Example 247
N-(2,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-N'-[(3- methyloxetan-3-yl)methyl]urea
Figure imgf000432_0002
In analogy to intermediate 67, N-(2,5-difluoro-4-{[3-(trifluoromethyl)-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-N'-[(3-methyloxetan-3- yl)methyl]urea (120 mg, 205 μηιοΙ, intermediate 275) was reacted with 1 N tetra-N- butylammoniumfluoride in tetrahydrofurane (820 μΙ_, 1.0 M, 820 μηηοΙ) and ethylenediamine (56 μΙ_, 840 μmol) in DMF (2.5 mL) to give after purification via a Biotage chromatography system and a subsequent HPLC chromatography 41.2 mg (95 % purity, 42 % yield) of the desired title compound.
LC-MS (method 2): Rt = 1 .04 min; MS (ESIneg): m/z = 455 [M-H]"
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 1 .24 (s, 3H), 3.33 (d, 2H), 4.23 (d, 2H), 4.36 (d, 2H), 6.47 (d, 1 H), 6.98 (t, 1 H), 7.50 (dd, 1 H), 8.10 (s, 1 H), 8.20 (d, 1 H), 8.26 (dd, 1 H), 8.65 (s, 1 H), 12.58 (br s, 1 H).
Example 248
N-{4-[(3-bromo-1 H-pyrrolo[2,3-b]pyridin-4-yl)sulfanyl]-3,5-difluorophenyl}-N'-[2-(morpholin yl)-2-oxoethyl]urea
Figure imgf000433_0001
In analogy to example 1 , N-{4-[(3-bromo-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl)sulfanyl]-3,5-difluorophenyl}-N'-[2-(morpholin-4-yl)-2-oxoethyl]urea (180 mg, 274 μηηοΙ, intermediate 280) was reacted with TFA (1 .9 mL, 24 mmol) in dichloromethane (5.0 mL) to obtain 146 mg (90 % purity, 91 % yield) of the desired title compound.
LC-MS (method 3): Rt = 1 .02 min; MS (ESIneg): m/z = 524 [M-H]"
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 3.39 - 3.49 (m, 4H), 3.59 (dt, 4H), 4.03 (d, 2H), 6.22 (d, 1 H), 6.69 (t, 1 H), 7.37 - 7.42 (m, 2H), 7.71 (s, 1 H), 7.99 (d, 1 H), 9.73 (s, 1 H), 12.21 (br s, 1 H). Example 249
N-{4-[(3-bromo-1 H-pyrrolo[2!3-b]pyridin-4-yl)sulfanyl]-3,5-difluorophenyl}-N'-(2- methoxyethyl)urea
Figure imgf000434_0001
In analogy to example 1 , N-{4-[(3-bromo-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl)sulfanyl]-3,5-difluorophenyl}-N'-(2-methoxyethyl)urea (160 mg, 272 μηηοΙ) intermediate 281 ) was reacted with TFA (1 .8 mL, 24 mmol) in dichloromethane (5.0 mL) to obtain 100 mg (92 % purity, 74 % yield) of the desired title compound.
LC-MS (method 3): Rt = 1 .08 min; MS (ESIpos): m/z = 457 [M+H]+
Ή-NMR (400 MHz, DMSO-d6) δ [ppm]: 3.25 - 3.31 (m, 5H), 3.37 - 3.43 (m, 2H), 6.21 (d, 1 H), 6.57 (t, 1 H), 7.36 - 7.42 (m, 2H), 7.71 (s, 1 H), 8.00 (d, 1 H), 9.33 (s, 1 H), 12.21 (s, 1 H).
Example 250
N-{4-[(3-bromo-1 H-pyrrolo[2,3-b]p ridin-4-yl)sulfanyl]-3,5-difluorophenyl}-N'-ethylurea
Figure imgf000434_0002
In analogy to example 77, N-{4-[(3-bromo-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl)sulfanyl]-3,5-difluorophenyl}-N'-ethylurea (160 mg, 287 μηηοΙ, intermediate 282) was reacted with TFA (1 .9 mL, 24 mmol) in dichloromethane (5.0 mL) to obtain 35 mg (97 % purity, 28 % yield) of the desired title compound.
LC-MS (method 3): Rt = 1 .1 1 min; MS (ESIpos): m/z = 427 [M+H]+
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 1.07 (t, 3H), 3.13 (dt, 2H), 6.21 (d, 1 H), 6.53 (t, 1 H), 7.38 - 7.44 (m, 2H), 7.71 (s, 1 H), 8.00 (d, 1 H), 9.28 (s, 1 H), 12.20 (br s, 1 H). Example 251
N-{4-[(3-bromo-1 H-pyrrolo[2,3-b]pyridin-4-yl)sulfanyl]-3,5-difluorophenyl}morpholine-4- carboxamide
Figure imgf000435_0001
In analogy to example 77, N-{4-[(3-bromo-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl)sulfanyl]-3,5-difluorophenyl}morpholine-4-carboxamide (185 mg, 309 μηηοΙ, intermediate 283) was reacted with TFA (2.1 mL, 27 mmol) in dichloromethane (5.0 mL) to obtain 66 mg (97 % purity, 44 % yield) of the desired title compound.
LC-MS (method 3): Rt = 1 .10 min; MS (ESIpos): m/z = 469 [M+H]+
1H-NMR (400 MHz, DMSO-d6) δ [ppm]: 3.44 - 3.50 (m, 4H), 3.60 - 3.66 (m, 4H), 6.20 (d, 1 H), 7.49 - 7.55 (m, 2H), 7.71 (s, 1 H), 8.00 (d, 1 H), 9.25 (br s, 1 H), 12.21 (br s, 1 H).
Example 252
N-(3,5-difluoro-4-{[3-(propan-2-yl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-N'-[(3-fluorooxetan- 3-yl)methyl]urea
Figure imgf000435_0002
To a solution of N-(3,5-difluoro-4-{[1 -(4-methylbenzene-1 -sulfonyl)-3-(propan-2-yl)-1 H- pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-N'-[(3-fluorooxetan-3-yl)methyl]urea (250 mg, 425 μηιοΙ, intermediate 291 ) in methanol (7.0 mL) was added sodium hydroxide (34 mg, 849 μηηοΙ). The resulting mixture was stirred at room temperature overnight, at which time water and ethyl acetate were added and the layers were separated. The aqueous phase was extracted twice with ethyl acetate, and the combined organic layers were washed with brine, dried over sodium sulfate and evaporated to give the crude product. The crude product was purified by preperative HPLC to afford the title compound (5 mg, 3% yield).
LC-MS (method 2): Rt = 1 .1 1 min; MS (ESIpos): m/z = 436 [M+H]+ 1H NMR (400 MHz, DMSO-d6) δ ppm 1 .32 (d, 6 H), 3.29 - 3.36 (m, 1 H), 3.65 (dd, 2 H), 4.56 - 4.66 (m, 4 H), 6.19 (d, 1 H), 7.01 (br s, 1 H), 7.15 (s, 1 H), 7.39 (d, 2 H), 7.99 (d, 1 H), 9.34 (br s, 1 H), 1 1 .46 (br s, 1 H) Example 253
N-(3,5-difluoro-4-{[3-(3,3,3-trifluoropropyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-N'-[(3- fluorooxetan-3-yl)methyl]urea
Figure imgf000436_0001
In analogy to example 252, N-(3,5-difluoro-4-{[1 -(4-methylbenzene-1 -sulfonyl)-3-(3,3,3- trifluoropropyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-N'-[(3-fluorooxetan-3-yl)methyl]urea (230 mg, 358 μηηοΙ, intermediate 295) was reacted with sodium hydroxide (28.6 mg, 716 μηηοΙ) in methanol (5.0 mL), to afford after preperative HPLC purification the title compound (13 mg, 7 % yield).
LC-MS (method 2): Rt = 1 .10 min; MS (ESIpos): m/z = 489 [M+H]+
1H NMR (400 MHz, DMSO-d6) δ ppm 2.59 - 2.73 (m, 2 H), 3.03 - 3.09 (m, 2 H), 3.66 (dd, 2 H), 4.61 (ddd, 4 H), 6.24 (d, 1 H), 6.79 (t, 1 H), 7.32 (d, 1 H), 7.39 (d, 2 H), 8.03 (d, 1 H), 9.10 (s, 1 H), 1 1.62 (d, 1 H)
Example 254
(+/-)-N-[3,5-difluoro-4-({3-[1 ,1 ,1 -trifluoropropan-2-yl]-1 H-pyrrolo[2,3-b]pyridin-4-yl}oxy)phenyl]- N'-[(3-fluorooxetan-3-yl)meth l]urea
Figure imgf000436_0002
To a solution of (+/-)-N-{3,5-difluoro-4-[(3-[1 ,1 ,1 -trifluoropropan-2-yl]-1 -{[2- (trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl}-N'-[(3-fluorooxetan-3- yl)methyl]urea (600 mg, 50 % purity, 485 μηηοΙ, intermediate 298) in DMF (15 mL) was added tetra-n-butylammoniumfluoride (1 .0 M solution in THF, 1 .9 mL, 1.9 mmol) and ethylenediamine (130 μΙ_, 2.0 mmol). The resulting mixture was stirred at 60°C overnight, at which time an additional amount of tetra-n-butylammoniumfluoride (1.0 M solution in THF, 0.8 mL, 0.8 mmol) and ethylenediamine (65 μί, 1 .0 mmol) were added. The mixture was subsequently stirred for an additional 24 hours at 60°C, at which time the reaction was cooled to room temperature, water and ethyl acetate were added, and the layers were separated. The aqueous phase was extracted twice with ethyl acetate, and the combined organic layers were washed with brine, dried over sodium sulfate, and evaporated to give the crude urea. The crude product was purified by preperative HPLC to afford the title compound (60 mg, 25% yield).
LC-MS (method 2): Rt = 1 .1 1 min; MS (ESIpos): m/z = 489 [M+H]+
1H NMR (400 MHz, DMSO-d6) δ ppm 1.55 (d, 3 H), 3.66 (dd, 2 H), 4.14 - 4.28 (m, 1 H), 4.61 (ddd, 4 H), 6.28 (d, 1 H), 6.80 (t, 1 H), 7.38 (d, 2 H), 7.53 (d, 1 H), 8.06 (d, 1 H), 9.10 (s, 1 H), 1 1.95 (d, 1 H) Example 255
N-(3,5-difluoro-4-{[3-(propan-2-yl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-N'-(2- methoxyethyl)urea
Figure imgf000437_0001
In analogy to example 252, N-(3,5-difluoro-4-{[1 -(4-methylbenzene-1 -sulfonyl)-3-(propan-2-yl)- 1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-N'-(2-methoxyethyl)urea (195 mg, 349 μηηοΙ, intermediate 299) was reacted with sodium hydroxide (27.9 mg, 698 μηηοΙ) in methanol (5.0 mL), to afford after preperative HPLC purification the title compound (17 mg, 1 1 % yield). LC-MS (method 2): Rt = 1 .12 min; MS (ESIpos): m/z = 406 [M+H]+
1H NMR (400 MHz, DMSO-d6) δ ppm 1 .32 (d, 6 H), 3.24 - 3.29 (m, 5 H), 3.39 (t, 2 H), 6.18 (d, 1 H), 6.48 (br t, 1 H), 7.15 (d, 1 H), 7.36 (d, 2 H), 7.99 (d, 1 H), 9.09 (s, 1 H), 1 1 .46 (br d, 1 H) Example 256
N-iS.S-difluoro^-tP-ipropan^-ylJ-I H-pyrTolop.S-blpyridin^-ylloxylphenylJ-N'-IiS- methyloxetan-3-yl)methyl]urea
Figure imgf000438_0001
In analogy to example 252, N-(3,5-difluoro-4-{[1 -(4-methylbenzene-1 -sulfonyl)-3-(propan-2-yl)-
1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-N'-[(3-methyloxetan-3-yl)methyl]urea (160 mg, 274 μηηοΙ, intermediate 300) was reacted with sodium hydroxide (32.8 mg, 821 μηηοΙ) in methanol (6.0 mL), to afford after preperative HPLC purification the title compound (6 mg, 5 % yield).
LC-MS (method 2): Rt = 1 .12 min; MS (ESIpos): m/z = 432 [M+H]+
1H NMR (400 MHz, DMSO-d6) δ ppm 1 .23 (s, 3 H), 1 .32 (d, 6 H), 3.27 - 3.31 (m, 3 H), 4.19 (d,
2 H), 4.39 (d, 2 H), 6.19 (d, 1 H), 7.14 (s, 1 H), 7.41 (d, 2 H), 7.49 (br s, 1 H), 7.98 (d, 1 H), 9.88 (br s, 1 H), 1 1 .46 (br s, 1 H) Example 257
N-(3,5-difluoro-4-{[3-(propan-2-yl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-N'-{[3-(propan-2- yl)oxetan-3-yl]methyl}urea
Figure imgf000438_0002
In analogy to example 252, N-(3,5-difluoro-4-{[1 -(4-methylbenzene-1 -sulfonyl)-3-(propan-2-yl)- 1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-N'-{[3-(propan-2-yl)oxetan-3-yl]methyl}urea (160 mg, 261 μηηοΙ, intermediate 301 ) was reacted with sodium hydroxide (31.3 mg, 783 μηηοΙ) in methanol (6.0 mL), to afford after preperative HPLC purification the title compound (10 mg, 8 % yield).
LC-MS (method 2): Rt = 1 .23 min; MS (ESIpos): m/z = 460 [M+H]+ 1H NMR (400 MHz, DMSO-d6) δ ppm 0.91 (d, 6 H), 1 .32 (d, 6 H), 2.01 (quin, 1 H), 3.27 - 3.32 (m, 2 H), 4.30 (d, 2 H), 4.33 (d, 2 H), 6.19 (d, 1 H), 6.89 (br s, 1 H), 7.15 (s, 1 H), 7.40 (d, 2 H), 7.99 (d, 1 H), 9.27 (br s, 1 H), 1 1.46 (br s, 1 H) Example 258
N-(3,5-difluoro-4-{[3-(propan-2-yl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)morpholine-4- carboxamide
Figure imgf000439_0001
In analogy to example 252, N-(3,5-difluoro-4-{[1 -(4-methylbenzene-1 -sulfonyl)-3-(propan-2-yl)- 1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)morpholine-4-carboxamide (130 mg, 228 μηηοΙ, intermediate 302) was reacted with sodium hydroxide (27.3 mg, 683 μηηοΙ) in methanol (6.0 ml_), to afford after preperative HPLC purification the title compound (35 mg, 33 % yield). LC-MS (method 2): Rt = 1 .13 min; MS (ESIpos): m/z = 418 [M+H]+
1H NMR (400 MHz, DMSO-d6) δ ppm 1 .32 (d, 6 H), 3.27 - 3.32 (m, 1 H), 3.44 - 3.47 (m, 4 H), 3.60 - 3.64 (m, 4 H), 6.18 (d, 1 H), 7.15 (s, 1 H), 7.48 (d, 2 H), 7.99 (d, 1 H), 9.00 (br s, 1 H), 1 1.46 (br s, 1 H)
Example 259
N-(3,5-difluoro-4-{[3-(propan-2-yl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-N'-[2-(morpholin-4- yl)-2-oxoethyl]urea
Figure imgf000439_0002
In analogy to example 252, N-(3,5-difluoro-4-{[1 -(4-methylbenzene-1 -sulfonyl)-3-(propan-2-yl)- 1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-N'-[2-(morpholin-4-yl)-2-oxoethyl]urea (140 mg, 223 μηηοΙ, intermediate 303) was reacted with sodium hydroxide (27 mg, 669 μηηοΙ) in methanol (6.0 mL), to afford after preperative HPLC purification the title compound (16 mg, 14 % yield).
LC-MS (method 2): Rt = 1 .05 min; MS (ESIpos): m/z = 474 [M+H]+
1H NMR (400 MHz, DMSO-d6) δ ppm 1 .32 (d, 6 H), 3.44 (dt, 4 H), 3.58 (dt, 4 H), 4.00 (s, 2 H), 6.19 (d, 1 H), 6.66 (br s, 1 H), 7.15 (s, 1 H), 7.36 (d, 2 H), 7.99 (d, 1 H), 9.55 (br s, 1 H), 1 1 .46 (br s, 1 H)
Example 260
(+/-)-N-[3,5-difluoro-4-({3-[1 ,1 ,1 -trifluoropropan-2-yl]-1 H-pyrrolo[2,3-b]pyridin-4-yl}oxy)phenyl]- N'-(2-methoxyethyl)urea
Figure imgf000440_0001
In analogy to example 252, (+/-)-N-[3,5-difluoro-4-({1 -(4-methylbenzene-1 -sulfonyl)-3-[1 ,1 ,1 - trifluoropropan-2-yl]-1 H-pyrrolo[2,3-b]pyridin-4-yl}oxy)phenyl]-N'-(2-methoxyethyl)urea
(400 mg, 653 μηηοΙ, intermediate 304) was reacted with sodium hydroxide (52.2 mg, 1 .31 mmol) in methanol (8.0 mL), to afford after preperative HPLC purification the title compound (60 mg, 19 % yield over 2 steps).
LC-MS (method 2): Rt = 1 .1 1 min; MS (ESIpos): m/z = 459 [M+H]+
1H NMR (400 MHz, DMSO-d6) δ ppm 1 .54 (d, 3 H), 3.26 (m, 2 H), 3.28 (s, 3 H), 3.38 (t, 2 H), 4.14 - 4.29 (m, 1 H), 6.26 (d, 1 H), 6.77 (br s, 1 H), 7.37 (d, 2 H), 7.52 (s, 1 H), 8.05 (d, 1 H), 9.40 (br s, 1 H), 1 1 .95 (br s, 1 H)
Example 261
(+/-)-N-[4-({3-(butan-2-yl)-1 H-pyrrolo[2,3-b]pyridin-4-yl}oxy)-3,5-difluorophenyl]-N'-(2- methoxyethyl)urea
Figure imgf000440_0002
In analogy to example 252, (+/-)-N-[4-({3-butan-2-yl]-1 -(4-methylbenzene-1 -sulfonyl)-1 H- pyrrolo[2,3-b]pyridin-4-yl}oxy)-3,5-difluorophenyl]-N'-(2-methoxyethyl)urea (360 mg, 629 μηιοΙ, intermediate 305) was reacted with sodium hydroxide (50.3 mg, 1.26 mmol) in methanol (7.8 mL), to afford after preperative HPLC purification the title compound (49 mg, 18 % yield over two steps).
LC-MS (method 2): Rt = 1 .17 min; MS (ESIpos): m/z = 419 [M+H]+
1H NMR (400 MHz, DMSO-d6) δ ppm 0.86 (t, 3 H), 1 .29 (d, 3 H), 1.53 - 1 .65 (m, 1 H), 1 .75 - 1 .86 (m, 1 H), 3.1 1 (sxt, 1 H), 3.24 - 3.29 (m, 5 H), 3.39 (t, 2 H), 6.18 (d, 1 H), 6.44 (t, 1 H), 7.15 (d, 1 H), 7.35 (d, 2 H), 7.98 (d, 1 H), 9.05 (s, 1 H), 1 1.48 (d, 1 H)
Example 262
(+/-)-N-[3,5-difluoro-4-({3-(3-methylbutan-2-yl)-1 H-pyrrolo[2,3-b]pyridin-4-yl}oxy)phenyl]-N'-(2- methoxyethyl)urea
Figure imgf000441_0001
In analogy to example 252, (+/-)-N-[3,5-difluoro-4-({1 -(4-methylbenzene-1 -sulfonyl)-3-[3- methylbutan-2-yl]-1 H-pyrrolo[2,3-b]pyridin-4-yl}oxy)phenyl]-N'-(2-methoxyethyl)urea (350 mg, 597 μηηοΙ, intermediate 306) was reacted with sodium hydroxide (47.7 mg, 1 .19 mmol) in methanol (8.0 mL), to afford after preperative HPLC purification the title compound (17 mg, 6 % yield over two steps).
LC-MS (method 2): Rt = 1 .22 min; MS (ESIpos): m/z = 433 [M+H]+
1H NMR (400 MHz, DMSO-d6) δ ppm 0.83 (d, 1 H), 0.86 (d, 1 H), 1 .24 (d, 3 H), 2.03 (dq, 1 H), 3.01 - 3.14 (m, 1 H), 3.24 - 3.29 (m, 5 H), 3.37 - 3.41 (m, 2 H), 6.17 (d, 1 H), 6.43 (t, 1 H), 7.16 (d, 1 H), 7.35 (d, 2 H), 7.98 (d, 1 H), 9.04 (s, 1 H), 1 1 .49 (s, 1 H)
Example 263
N-(3,5-difluoro-4-{[3-(pentan-3-yl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-N'-(2- methoxyethyl)urea
H H
Figure imgf000441_0002
In analogy to example 252, N-(3,5-difluoro-4-{[1 -(4-methylbenzene-1 -sulfonyl)-3-(pentan-3-yl)- 1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-N'-(2-methoxyethyl)urea (410 mg, 699 μηηοΙ, intermediate 307) was reacted with sodium hydroxide (55.9 mg, 1.40 mmol) in methanol (8.0 mL), to afford after preperative HPLC purification the title compound (34 mg, 13 % yield over two steps).
LC-MS (method 2): Rt = 1 .23 min; MS (ESIpos): m/z = 433 [M+H]+
1H NMR (400 MHz, DMSO-d6) δ ppm 0.80 (t, 6 H), 1 .66 - 1 .76 (m, 4 H), 2.93 (quin, 1 H), 3.24 - 3.30 (m, 5 H), 3.37 - 3.41 (m, 2 H), 6.17 (d, 1 H), 6.43 (t, 1 H), 7.16 (d, 1 H), 7.35 (d, 2 H), 7.98 (d, 1 H), 9.03 (s, 1 H), 1 1 .50 (d, 1 H)
Example 264
N-(3,5-difluoro-4-{[3-(2-methylpropyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-N'-(2- methoxyethyl)urea
Figure imgf000442_0001
In analogy to example 252, N-(3,5-difluoro-4-{[1 -(4-methylbenzene-1 -sulfonyl)-3-(2- methylpropyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-N'-(2-methoxyethyl)urea (340 mg, 594 μηηοΙ, intermediate 308) was reacted with sodium hydroxide (47.5 mg, 1 .19 mmol) in methanol (8.0 mL), to afford after preperative HPLC purification the title compound (60 mg, 24 % yield over two steps).
LC-MS (method 2): Rt = 1 .17 min; MS (ESIpos): m/z = 419 [M+H]+
1H NMR (400 MHz, DMSO-d6) δ ppm 0.89 (d, 6 H), 1 .98 (dquin, 1 H), 2.65 - 2.69 (m, 2 H), 3.23 - 3.30 (m, 5 H), 3.37 - 3.41 (m, 2 H), 6.17 (d, 1 H), 6.43 (t, 1 H), 7.15 (d, 1 H), 7.35 (d, 2 H), 7.98 (d, 1 H), 9.04 (s, 1 H), 1 1.49 (s, 1 H)
Example 265
(+/-)-N-[3,5-difluoro-4-({3-[4!4!4-trifluorobutan-2-yl]-1 H-pyrrolo[2,3-b]pyridin-4-yl}oxy)phenyl]- (2-methoxyethyl)urea
Figure imgf000443_0001
In analogy to example 252, (+/-)-N-[3,5-difluoro-4-({1 -(4-methylbenzene-1 -sulfonyl)-3-[4,4,4- trifluorobutan-2-yl]-1 H-pyrrolo[2,3-b]pyridin-4-yl}oxy)phenyl]-N'-(2-methoxyethyl)urea (662 mg, 50 % purity, 528 μηηοΙ, intermediate 309) was reacted with sodium hydroxide (42.3 mg, 1 .06 mmol) in methanol (10 ml_), to afford after preperative HPLC purification the title compound (97 mg, 38 % yield).
LC-MS (method 2): Rt = 1 .15 min; MS (ESIpos): m/z = 474 [M+H]+
1H NMR (400 MHz, DMSO-d6) δ ppm 1 .42 (d, 3 H), 2.54 - 2.63 (m, 1 H), 2.74 - 2.91 (m, 1 H), 3.23 - 3.30 (m, 5 H), 3.36 - 3.41 (m, 2 H), 3.55 (sxt, 1 H), 6.23 (d, 1 H), 6.45 (t, 1 H), 7.32 (d, 1 H), 7.36 (d, 2 H), 8.02 (d, 1 H), 9.06 (s, 1 H), 1 1 .61 (s, 1 H) Example 266
N-{4-[(3-bromo-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-2-methylazetidine-1 - carboxamide
Figure imgf000443_0002
In analogy to example 178, N-{4-[(3-bromo-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-2-methylazetidine-1 -carboxamide (125 mg, 220 μηηοΙ, intermediate 310) was stirred with trifluoroacetic acid (760 μΙ_, 9.9 mmol) in dichloromethane (10 mL) to afford after preperative HPLC purification the title compound (48 mg, 50 % yield). LC-MS (method 2): Rt = 1 .10 min; MS (ESIpos): m/z = 437 [M+H]+
1H NMR (400 MHz, DMSO-d6) δ ppm 1 .36 (d, 3 H), 1 .74 - 1.86 (m, 1 H), 2.35 - 2.42 (m, 1 H), 3.85 - 3.93 (m, 1 H), 3.99 (td, 1 H), 4.34 - 4.44 (m, 1 H), 6.31 (d, 1 H), 7.53 (d, 2 H), 7.64 (s, 1 H), 8.09 (d, 1 H), 8.70 (s, 1 H), 12.20 (br s, 1 H) Example 267
N-{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}azetidine-1 -carboxamide
Figure imgf000444_0001
In analogy to example 178, N-{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl)oxy]-3,5-difluorophenyl}azetidine-1 -carboxamide (80.0 mg, 157 μηιοΙ,
intermediate 31 1 ) was stirred with trifluoroacetic acid (520 μΙ_, 6.8 mmol) in dichloromethane (5.1 mL) to afford after preperative HPLC purification the title compound (48 mg, 79 % yield). LC-MS (method 3): Rt = 1 .01 min; MS (ESIpos): m/z = 379 [M+H]+
1H NMR (400 MHz, DMSO-d6) δ ppm 2.15 - 2.26 (m, 2 H), 3.99 (t, 4 H), 6.32 (d, 1 H), 7.52 (d, 2 H), 7.61 (s, 1 H), 8.10 (d, 1 H), 8.85 (s, 1 H), 12.12 (br s, 1 H)
Example 268
N'-{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-N,N-dimethylurea
Figure imgf000444_0002
In analogy to example 178, N-{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-6-oxa-2-azaspiro[3.4]octane-2-carboxamide (260 mg, 460 μηηοΙ, intermediate 312) was stirred with tirfluoroacetic acid (1 .6 mL, 21 mmol) in dichloromethane (4.0 mL) to afford after preperative HPLC purification the title compound (3 mg, 2 % yield).
1H NMR (400 MHz, DMSO-d6) δ ppm 2.95 (s, 6 H), 6.32 (d, 1 H), 7.53 (d, 2 H), 7.61 (s, 1 H), 8.10 (d, 1 H), 8.76 (s, 1 H), 12.13 (br s, 1 H) Example 269
(+/-)-N-{4-[(3-chloro-1 H-pyrrolo[2!3-b]pyridin-4-yl)oxy]-3!5-difluorophenyl}-4,4-difluoro-3- (hydroxymethyl)piperidine-l -carboxamide
Figure imgf000445_0001
In analogy to example 178, (+/-)-N-{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-4,4-difluoro-3-(hydroxymethyl)piperidine-1 - carboxamide (210 mg, 348 μηηοΙ, intermediate 313) was stirred with trifluoroacetic acid (1 .2 mL, 16 mmol) in dichloromethane (2.0 mL) to afford after preperative HPLC purification the title compound (80 mg, 44 % yield).
LC-MS (method 2): Rt = 1 .05 min; MS (ESIpos): m/z = 473 [M+H]+
1H NMR (400 MHz, DMSO-d6) δ ppm 1 .89 - 2.19 (m, 3 H), 3.05 (dd, 1 H), 3.19 - 3.29 (m, 1 H), 3.34 - 3.41 (m, 1 H), 3.77 (dt, 1 H), 3.96 (br d, 1 H), 4.17 (br d, 1 H), 4.87 (dd, 1 H), 6.32 (d, 1 H), 7.49 (d, 2 H), 7.62 (d, 1 H), 8.10 (d, 1 H), 9.17 (s, 1 H), 12.13 (br s, 1 H) Example 270
N-{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-N'-(1 -methoxy-2- methylpropan-2-yl)urea
Figure imgf000445_0002
In analogy to example 178, N-{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H-pyrrolo[2,3- b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-N'-(1 -methoxy-2-methylpropan-2-yl)urea (120 mg, 216 μηηοΙ, intermediate 314) was stirred with trifluoroacetic acid (830 μί, 1 1 mmol) in dichloromethane (1 .4 mL) to afford after preperative HPLC purification the title compound (30 mg, 32 % yield).
LC-MS (method 2): Rt = 1 .16 min; MS (ESIpos): m/z = 425 [M+H]+
1H NMR (400 MHz, DMSO-d6) δ ppm 1.27 (s, 6 H), 3.31 (s, 3 H), 3.35 (s, 2 H), 6.15 (s, 1 H), 6.32 (d, 1 H), 7.31 (d, 2 H), 7.61 (s, 1 H), 8.09 (d, 1 H), 8.95 (s, 1 H), 1 1 .89 - 12.36 (m, 1 H) Example 271
(+/-)-N-{4-[(3-chloro-1 H-pyrrolo[2!3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-N'-1 - oxaspiro[4.4]nonan-6-ylurea - mixture of isomers
Figure imgf000446_0001
In analogy to example 178, (+/-)-N-{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-N'-1 -oxaspiro[4.4]nonan-6-ylurea (120 mg, 202 μηηοΙ, intermediate 315) was stirred with trifluoroacetic acid (780 μΙ_, 10 mmol) in dichloromethane (1 .3 mL) to afford after preperative HPLC purification the title compound (30 mg, 31 % yield).
LC-MS (method 2): Rt = 1 .20 min; MS (ESIpos): m/z = 463 [M+H]+
1H NMR (400 MHz, DMSO-d6) δ ppm 1 .38 - 2.00 (m, 10 H), 3.73 - 3.90 (m, 3 H), 6.17 (d, 1 H), 6.32 (d, 1 H), 7.34 (d, 2 H), 7.61 (d, 1 H), 8.10 (d, 1 H), 9.17 (s, 1 H), 12.12 (br d, 1 H)
Example 272
(+/-)-N-{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-N'-[1 -(morpholin-4- yl)-1 -oxopropan-2-yl]urea
Figure imgf000446_0002
In analogy to example 178, (+/-)-N-{4-[(3-chloro-1 -{[2-(trimethylsilyl)ethoxy]methyl}-1 H- pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-N'-[1 -(morpholin-4-yl)-1 -oxopropan-2-yl]urea (60.0 mg, 98.3 μηηοΙ, intermediate 316) was stirred with trifluoroacetic acid (380 μΙ_, 4.9 mmol) in dichloromethane (630 μΙ_) to afford after preperative HPLC purification the title compound (8 mg, 16 % yield).
LC-MS (method 2): Rt = 1 .02 min; MS (ESIpos): m/z = 480 [M+H]+
1H NMR (400 MHz, DMSO-d6) δ ppm 1 .22 (d, 3 H), 3.43 - 3.68 (m, 8 H), 4.70 (quin, 1 H), 6.32 (d, 1 H), 6.75 (d, 1 H), 7.35 (d, 2 H), 7.61 (d, 1 H), 8.09 (d, 1 H), 9.27 (s, 1 H), 12.13 (br s, 1 H) EXPERIMENTAL SECTION BIOLOGICAL ASSAYS
Biological in vitro assays
The in vitro activity of the compounds of the present invention can be demonstrated in the following assays:
The example testing experiments described herein serve to illustrate the present invention and the invention is not limited to the examples given.
Biological Evaluation
In order that this invention may be better understood, the following examples are set forth. These examples are for the purpose of illustration only, and are not to be construed as limiting the scope of the invention in any manner. All publications mentioned herein are incorporated by reference in their entirety.
Demonstration of the activity of the compounds of the present invention may be accomplished through in vitro and in vivo assays that are well known in the art. For example, to demonstrate the efficacy of a pharmaceutical agent to inhibit and be selective against e.g. TBK1 the following assays may be used.
Binding competition assay The ability of the compounds of the present invention to inhibit the binding of an Alexa647- labelled ATP-competitive kinase inhibitor to a Glutathione-S-transferase- (GST-) fusion protein was quantified employing the TR-FRET-based binding competition assay as described in the following paragraphs. A recombinant fusion protein of N-terminal GST and full-length human , expressed by baculovirus infected SF9 insect cells and purified by Glutathione Sepharose affinity
chromatography, was used as GST- fusion protein. Tracer 222 from Invitrogen (catalogue no. PR9198A) was used as Alexa647-labelled ATP-competitive kinase inhibitor.
For the assay 50 nl of a 10Ofold concentrated solution of the test compound in DMSO was pipetted into either a black low volume 384well microtiter plate or a black 1536well microtiter plate (both Greiner Bio-One, Frickenhausen, Germany), 3 μΙ_ solution of Tracer 222 (25 nM => final concentration in 5 μΙ_ assay volume is 15 nM) in aqueous assay buffer [25 mM Tris/HCI pH 7.5, 10 mM MgC , 5 mM β-glycerolphosphate, 2.5 mM dithiothreitol, 0.5 mM ethylene glycol-bis(2-aminoethylether)-/V,/V,/V',/V'-tetraacetic acid [EGTA], 0.5 mM sodium ortho- vanadate, 0.01 % (w/v) bovine serum albumin [BSA], 0.005% (w/v) Pluronic F-127 (Sigma)] were added. Then the binding competition was started by the addition of 2 μΙ_ of a solution of the GST- fusion protein (2.5 nM => final cone, in the 5 μΙ_ assay volume is 1 nM) and of Anti- GST-Tb (1 .25 nM => final cone, in the 5 μΙ_ assay volume is 0.5 nM), a Lumi4®-Tb Cryptate- conjugated anti-GST-antibody from Cisbio Bioassays (France), in assay buffer. The resulting mixture was incubated 30 min at 22°C to allow the formation of a complex between the Tracer 222, the fusion protein and Anti-GST-Tb. Subsequently the amount of this complex was evaluated by measurement of the resonance energy transfer from the Tb- cryptate to the Tracer 222. Therefore, the fluorescence emissions at 620 nm and 665 nm after excitation at 350 nm were measured in a TR-FRET reader, e.g. a Pherastar (BMG
Labtechnologies, Offenburg, Germany) or a Viewlux (Perkin-Elmer). The ratio of the emissions at 665 nm and at 622 nm was taken as the measure for the amount of the complex. The data were normalised (assay reaction without inhibitor = 0 % inhibition, all other assay components but GST- fusion protein = 100 % inhibition). Usually the test compounds were tested on the same microtiterplate in 1 1 different concentrations in the range of 20 μΜ to 0.07 nM (20 μΜ, 5.7 μΜ, 1.6 μΜ, 0.47 μΜ, 0.13 μΜ, 38 ηΜ, 1 1 ηΜ, 3.1 ηΜ, 0.9 ηΜ, 0.25 nM and 0.07 nM, the dilution series prepared separately before the assay on the level of the 10Ofold concentrated solutions in DMSO by serial dilutions, exact concentrations may vary depending pipettors used) in duplicate values for each concentration and IC50 values were calculated using Genedata Screener™ software.
Table 1 : Measured I C50 values of compounds regarding inhibition
Example IC50 [nM] Example IC50 [nM] Example IC50 [nM]
1 6.9 24 2.7 47 13.2
2 10.6 25 7.0 48 13.3
3 8.8 26 8.8 49 13.5
4 15.2 27 9.6 50 16.4
5 6.7 28 7.2 51 21.1
6 8.7 29 5.4 52 32.9
7 166.0 30 8.1 53 16.3
8 7.5 31 99.1 54 34.8
9 13.0 32 6.8 55 22.0
10 10.5 33 13.7 56 334.0
1 1 15.1 34 61.1 57 3.3
12 7.5 35 14.2 58 5.7
13 21.3 36 201 .0 59 42.5
14 6.5 37 15.1 60 69.2
15 13.3 38 222.0 61 26.7
16 14.6 39 29.4 62 36.9
17 10.1 40 27.9 63 7.4
18 6.0 41 5.3 64 23.3
19 12.8 42 5.0 65 51.8
20 4.7 43 5.2 66 65.3
21 7.7 44 9.9 67 28.8
22 5.4 45 9.4 68 12,2
23 3.0 46 10.0 69 13,4 Example ICso [nM] Example ICso [nM] Example ICso [nM]
70 103 115 8,12 160 6,86
71 78,7 116 13,9 161 10,9
72 34,9 117 25,5 162 13,4
73 9,77 118 45,8 163 11,1
74 62,6 119 24,6 164 22,7
75 6,13 120 42,4 165 8,17
76 28,3 121 20,1 166 22
77 24,4 122 44,7 167 29,3
78 15,6 123 22,6 168 19,1
79 10,3 124 21,8 169 17
80 5,38 125 59,4 170 30,1
81 7,04 126 9,12 171 10,8
82 6,26 127 22 172 33,8
83 13 128 37,2 173 13,8
84 3,77 129 25,3 174 21,6
85 7,67 130 43,1 175 49,1
86 19,8 131 19,9 177 16,7
87 6,04 132 72,2 178 17,3
88 5,91 133 54,6 179 57,8
89 6,23 134 107 180 19,1
90 9,34 135 210 181 66,3
91 8,69 136 64,3 182 42,4
92 12,4 137 106 183 38,1
93 12,1 138 210 184 6,85
94 6,01 139 151 185 51,2
95 18,8 140 138 186 31,8
96 6,92 141 59,7 187 81,5
97 7,35 142 58,6 188 181
98 14,2 143 34,2 189 55,9
99 10 144 31,7 190 36,3
100 14 145 30,5 191 215
101 21,3 146 17,7 192 33,2
102 14,1 147 6,1 193 21,9
103 10,8 148 3,09 194 61,7
104 9,14 149 7,52 195 22,9
105 24 150 6,06 196 28,3
106 23,2 151 8,06 197 149
107 13,5 152 14,9 198 37,2
108 17,1 153 11,1 199 33,8
109 16,4 154 12,1 200 149
110 11 155 15,2 201 7,49
111 11,7 156 7,98 202 226
112 13 157 5,59 203 31,9
113 13,1 158 4,16 204 110
114 8,18 159 9,28 205 124 Example ICso [nM] Example ICso [nM] Example ICso [nM]
206 107 251 49,5
207 17,9 252 11,7
208 9,94 253 73,1
209 23,8 254 20,9
210 22,1 255 11,4
211 11,6 256 11,4
212 20,4 257 20,8
213 10,1 258 45
214 7,45 259 7,3
215 18,9 260 16,2
216 17,8 261 22,7
217 6,47 262 38,7
218 16,1 263 45,6
219 16,2 264 29,1
220 14,3 265 61,7
221 38,5 266 86,9
222 59,4 267 266
223 49,2 268 282
224 44,2 269 225
225 11,4 270 112
226 74,4 271 117
227 138 272 229
228 45,3
229 35,4
230 34,2
231 128
232 140
233 16,5
234 15,3
235 13
236 14,2
237 30,3
238 69,1
239 19
240 62,4
241 20,5
242 24,4
243 26,2
244 25,6
245 11,2
246 11,9
247 41,1
248 205
249 60,8
250 80,7 TBK1 high ATP kinase assay
TBK1 -inhibitory activity of compounds of the present invention at a high ATP concentration after preincubation of enzyme and test compounds was quantified employing the TR-FRET- based TBK1 assay as described in the following paragraphs.
Recombinant full-length N-terminally His-tagged human TBK1 , expressed in insect cells and purified by Ni-NTA affinity chromatography, was purchased from Life Technologies (Cat. No PR5618B) and used as enzyme. As substrate for the kinase reaction biotinylated peptide biotin-Ahx-GDEDFSSFAEPG (C-terminus in amide form) was used which can be purchased e.g. form the company Biosyntan (Berlin-Buch, Germany).
For the assay 50 nl of a 10Ofold concentrated solution of the test compound in DMSO was pipetted into either a black low volume 384well microtiter plate or a black 1536well microtiter plate (both Greiner Bio-One, Frickenhausen, Germany), 2 μΙ_ of a solution of TBK1 in aqueous assay buffer [50 mM HEPES pH 7.0, 10 mM MgCI2, 1 .0 mM dithiothreitol, 0.05 % (w/v) bovine serum albumine, 0.01 % (v/v) Nonidet-P40 (Sigma), protease inhibitor mixture ("Complete w/o EDTA" from Roche, 1 tablet per 5 mL)] were added and the mixture was incubated for 15 min at 22°C to allow pre-binding of the test compounds to the enzyme before the start of the kinase reaction. Then the kinase reaction was started by the addition of 3 μΙ_ of a solution of adenosine-tri-phosphate (ATP, 1 .67 mM => final cone, in the 5 μΙ_ assay volume is 1 mM) and substrate (1 .67 μΜ => final cone, in the 5 μΙ_ assay volume is 1 μΜ) in assay buffer and the resulting mixture was incubated for a reaction time of 30 min at 22°C. The concentration of TBK1 was adjusted depending of the activity of the enzyme lot and was chosen appropriate to have the assay in the linear range, typical concentrations were in the range of 0.002- 0.004 μg mL. The reaction was stopped by the addition of 3 μΙ_ of a solution of TR-FRET detection reagents (0.33 μΜ streptavidine-XL665 [Cisbio Bioassays, Codolet, France], 2.5 nM anti-phosho-Serine antibody [Merck Millipore, "STK antibody", cat. # 35-002] and 1.25 nM LANCE EU-W1024 labeled anti-mouse IgG antibody [Perkin-Elmer, product no. AD0077]) in an aqueous EDTA-solution (167 mM EDTA, 0.13 % (w/v) bovine serum albumin in 100 mM HEPES/NaOH pH 7.5).
The resulting mixture was incubated 1 h at 22°C to allow the formation of complex between the phosphorylated biotinylated peptide and the detection reagents. Subsequently the amount of phosphorylated substrate was evaluated by measurement of the resonance energy transfer from the Eu-chelate to the streptavidine-XL. Therefore, the fluorescence emissions at 620 nm and 665 nm after excitation at 350 nm was measured in a TR-FRET reader, e.g. a Pherastar (BMG Labtechnologies, Offenburg, Germany) or a Viewlux (Perkin-Elmer). The ratio of the emissions at 665 nm and at 622 nm was taken as the measure for the amount of phosphorylated substrate. The data were normalised (enzyme reaction without inhibitor = 0 % inhibition, all other assay components but no enzyme = 100 % inhibition). Usually the test compounds were tested on the same microtiterplate in 1 1 different concentrations in the range of 20 μΜ to 0.07 nM (20 μΜ, 5.7 μΜ, 1.6 μΜ, 0.47 μΜ, 0.13 μΜ, 38 ηΜ, 1 1 ηΜ, 3.1 ηΜ,
0.9 ηΜ, 0.25 nM and 0.07 nM, the dilution series prepared separately before the assay on the level of the 10Ofold concentrated solutions in DMSO by serial dilutions, exact concentrations may vary depending pipettors used) in duplicate values for each concentration and IC50 values were calculated using Genedata Screener™ software.
Table 2: Measured I C50 values of compounds regarding TBK1 inhibition as selectivity assay
Example IC50 [nM] Example IC50 [nM] Example IC50 [nM]
1 >20 33 >20 66 >20
2 >20 34 >20 67 >20
3 >20 35 >20 67 >20
4 >20 36 >20 68 >20
5 >20 37 >20 69 >20
6 >20 38 >20 70 >20
7 >20 39 >20 71 >20
8 >20 40 >20 72 >20
9 >20 41 >20 73 >20
10 >20 42 >20 74 >20
1 1 >20 43 >20 75 >20
12 >20 44 >20 76 >20
13 >20 45 >20 77 >20
14 >20 46 >20 78 >20
15 >20 47 >20 79 >20
16 >20 48 16 80 >20
17 >20 49 >20 81 >20
18 >20 50 >20 82 >20
19 >20 51 >20 83 >20
20 >20 52 14 84 >20
21 >20 53 >20 85 >20
22 >20 54 >20 86 >20
23 >20 55 >20 87 >20
24 >20 57 >20 88 >20
25 >20 58 >20 89 >20
26 >20 59 >20 90 >20
27 >20 60 >20 91 >20
28 >20 61 >20 92 >20
29 >20 62 >20 93 >20
30 >20 63 >20 94 >20
31 >20 64 >20 95 >20
32 >20 65 >20 96 >20 Example ICso [nM] Example ICso [nM] Example ICso [nM]
97 >20 142 >20 187 >20
98 >20 143 >20 188 >20
99 >20 144 >20 189 >20
100 >20 145 >20 190 >20
101 >20 146 >20 191 >20
102 >20 147 >20 192 >20
103 >20 148 >20 194 >20
104 >20 149 >20 195 >20
105 >20 150 >20 196 >20
106 >20 151 >20 197 >20
107 >20 152 >20 198 >20
108 >20 153 >20 199 >20
109 >20 154 >20 200 >20
1 10 >20 155 >20 201 >20
1 1 1 >20 156 >20 202 >20
1 12 >20 157 >20 203 >20
1 13 >20 158 >20 204 >20
1 14 >20 159 >20 205 >20
1 15 >20 160 >20 206 >20
1 16 >20 161 >20 207 >20
1 17 >20 162 >20 208 >20
1 18 >20 163 >20 209 >20
1 19 >20 164 >20 210 >20
120 >20 165 >20 21 1 >20
121 >20 166 >20 212 >20
122 >20 167 >20 213 >20
123 >20 168 >20 214 >20
124 >20 169 >20 215 >20
125 >20 170 >20 216 >20
126 >20 171 >20 217 >20
127 >20 172 >20 218 >20
128 >20 173 >20 219 >20
129 >20 174 >20 220 >20
130 >20 175 >20 221 >20
131 >20 176 >20 222 >20
132 >20 177 >20 223 >20
133 >20 178 >20 224 >20
134 >20 179 >20 225 >20
135 >20 180 >20 226 >20
136 >20 181 >20 227 >20
137 >20 182 >20 228 >20
138 >20 183 >20 229 >20
139 >20 184 >20 230 >20
140 >20 185 >20 231 >20
141 >20 186 >20 232 >20 Example ICso [nM] Example ICso [nM] Example ICso [nM]
233 >20
234 >20
235 >20
236 >20
237 >20
238 >20
239 >20
240 >20
241 >20
242 >20
243 >20
244 >20
245 >20
246 >20
247 >20
248 >20
249 >20
250 >20
251 >20
252 >20
253 >20
254 >20
255 >20
256 >20
257 >20
258 >20
259 >20
260 >20
261 >20
262 >20
263 >20
264 >20
265 >20
266 >20
267 >20
268 >20
269 >20
270 >20
271 >20
272 >20 Phosphorylation assay in human cell line
Phosphorylation assays were carried out in Jurkat E6.1 cells from American Type Culture Collection (ATCC) stably overexpressing human FLAG-tagged SLP-76 (proprietary). Cultured cells were kept in RPMI 1640 medium supplemented with 1 % FCS at a cell density of 2x 10e6/ml_ 24h prior compound testing. Starved cells were simultaneously treated with 350 ng/mL a-CD3 antibody (clone OKT3. ebioscience #16-0037-85. plate-bound) and test compound for 30 min at 37 °C. Applied compounds were tested at either fixed concentration of 10 μη"ΐοΙ/Ι_ and 20 μη"ΐοΙ/Ι_ or in a 8 point dose response titration of increase compound concentration with 10 nmol/L. 50 nmol/L. 100 nmol/L. 500 nmol/L. 1 μη-ιοΙ/Ι_. 5 μη-ιοΙ/Ι_. 10 μη"ΐοΙ/Ι_ and 20 μη"ΐοΙ/Ι_ in triplicates. The cells were washed once in phosphate-buffered saline (pH 7.4). Cells were lysed using a lysis buffer containing 50 mmol/L Tris-CI (pH 7.5). 150 mM NaCI. 2 mM EDTA. 1 % Triton-X 100. 0.5 % Na-DOC. 0.1 % SDS. 1/10 complete mini protease inhibitor cocktail (Roche #1 1836170001 ) and 1/10 PhosSTOP phosphatase inhibitor cocktail (Roche #04906837001 ). A total of 1 .25 μg cell lysate was analyzed by capillary electrophoresis using the Peggy Sue™ System (proteinsimple® San Jose. CA USA) with a 12-230kDa size- based master kit with split buffer / a-rabbit-HRP #PS-MK18 / a-mouse-HRP #PS-MK19 according to manufacture's protocol. Probe antibodies used were a rabbit monoclonal antibody supernatant raised against human phospho-Ser376-SLP-76 peptide (proprietary) and for mormalization an a-alpha-Tubulin. mouse monoclonal antibody (Sigma #T9026). As control for maximal effect (max control, which represent the maximally possible inhibition of pSer376- SLP-76 by a test compound) cells with no a-CD3 (clone OKT3. ebioscience #16-0037-85. plate-bound) and no test compound treatment were used. Cells with a-CD3 treatment only were used as negative control (min control, which represent the minimally possible inhibition of pSer376-SLP-76 by a test compound)
AUC values of each respective test sample were normalized using the AUC of housekeeping gene alpha-Tubulin and AUC of pSer376-SLP-76 of the min control. The percentage of the amount of pSer-SLP-76 in the treatment samples was calculated using the max control and min control values of the respective Peggy Sue™ run.
Table 3: Measured I C50 values / % amount of pSer376-SLP-76 of compound
Figure imgf000456_0001
Stimulation of IFNg production from human primary peripheral blood mononuclear cells (PBMCs)
The effect of the compound in the activation of human T cells was tested by measuring the production of the proinflammatory cytokine IFNg in vitro. Fresh human PBMCs were isolated and activated in vitro with coated a-CD3 (clone OKT3. ebioscience #16-0037-85. plate-bound). Concentration of a-CD3 was titrated in order to obtain a sub-optimal activation of PBMCs (1 x106 PBMCs/mL). Cells were activated for 22 hours with the compounds and the supernatant of the culture was isolated and tested for IFNg concentration. Applied compounds were tested at either fixed concentration of 200 nmol/L or in a 8 point dose response titration of increase compound concentration from 10 nmol/L to 5 μη"ΐοΙ/Ι_ in triplicates. IFNg concentration was determined by ELISA (Opt EIA human IFNg ELISA BD #555142). Plate was coated with a- IFNg overnight. The plates were washed 3 times and the supernatant from the PBMCs culture was added to the wells and incubated for 2 hours. Plates were washed and detection antibody and the SAv-HRP was added for 1 h. Plates were washed and the substrate was added until the standard turns blue. The reaction is stopped by adding 50 μΙ_ 2N H2S04. Absorbance was measured with a TECAN Reader at 450 to 570 nm. Concentration of IFNg was calculated from the absorbance using standards of known concentration.
Table 3: Human primary peripheral blood mononuclear cells: efficacy of selected example in IFNg production
Max. IFNg increase in % IFNg
Example over control (a-CD3 alone) EC50 nM
1 189 23

Claims

Claims
1. A compounds of formula (I)
Figure imgf000457_0001
in which
X represents a nitrogen, a sulphur or an oxygene atom,
Y represents a sulphur or an oxygene atom,
R1 represents hydrogen, halogen, Ci-C6-alkyl, halo-Ci-C6-alkyl or cyano,
R2 represents fluorine or chlorine,
R3 represents hydrogen or Ci-C6-alkyl,
R4 represents hydrogen or represents Ci-C6-alkyl-, which may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of halogen, cyano, hydroxy, Ci-C3-alkoxy-, -N H2, -N H-(Ci-C6-alkyl), -N(Ci-C6-alkyl)2, -N H-(Ci-C6-alkyl)-Ci-C6-alkoxy, Ci-C6-alkyl-, Ci-C6-alkoxy-, -S(=0)2N H2, -C(=0)-R9, -C(=0)-N H-Rx, -C(=0)-N R5R6, -N H-C(=0)-R9,
-N H-S(=0)2-R9, -S(=0)2-R9, -S(=0)(=N Ry)-Rx, -S(=0)-Rx,
C3-Cio-cycloalkyl- which itself may optionally be mono- or polysubstituted by dentical or different substituents from the group consisting of of halogen, cyano, nitro, hydroxy, amino, oxo, carboxy, Ci-C6-alkyl-, Ci-C6-alkoxy-, Ci-C6-alkoxy- Ci-C6-alkyl-, hydroxy-Ci-C6-alkyl-, Ci-C6-alkylamino-, Ci-C6-alkylcarbonylamino- , amino-Ci-C6-alkyl-, Ci-C6-alkylamino-Ci-C6-alkyl-, halo-Ci-C6-alkyl-, halo-Ci-C6-alkoxy-, C3-Cio-cycloalkyl-, phenyl-, halophenyl-, phenyl-Ci-C6-alkyl-, phenoxy-, pyridinyl-, -C(=0)-N R5R6, -N H-C(=0)-R8, -C(=0)-R7, -S(=0)2-N R5R6, -S(=0)-R8, -S(=0)(=N R5)-R6, -S(=0)2-R8, -N H-S(=0)2-R8, or a monocyclic heterocyclyl radical having 3 to 8 ring atoms, monocyclic heteroaryl- having 5 or 6 ring atoms which itself may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of halogen, amino, hydroxy, cyano, nitro, carboxy, Ci-C6-alkyl-, Ci-C6-alkoxy-, C1-C6- alkoxy-Ci-C6-alkyl-, hydroxy-Ci-C6-alkyl-,
Ci-C6-alkylamino-, amino-Ci-C6-alkyl-, Ci-C6-alkylamino-Ci-C6-alkyl, halo-Ci-C6- alkyl-, halo-Ci-C6-alkoxy-, C3-Cio-cycloalkyl and a monocyclic heterocyclyl radical having 3 to 8 ring atoms, monocyclic heterocyclyl- having 3 to 8 ring atoms which itself may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of halogen, amino, hydroxy, cyano, oxo, carboxy, Ci-C6-alkyl-, -carboxy-Ci-C6-alkyl-, Ci-C6-alkoxy-, Ci-C6-alkoxy-Ci-C6-alkyl-,
Ci-C6-alkylamino-, amino-Ci-C6-alkyl-, Ci-C6-alkylamino-Ci-C6-alkyl-, hydroxy-Ci-C6-alkyl-, halo-Ci-C6-alkyl-, halo-Ci-C6-alkoxy-, C3-Cio-cycloalkyl- and a monocyclic heterocyclyl radical having 3 to 8 ring atoms, phenyl- which itself may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of halogen, amino, hydroxy, cyano, nitro, carboxy, Ci-C6-alkyl-, Ci-C6-alkoxy-, Ci-C6-alkoxy-Ci-C6-alkyl-, Ci-C6-alkyl-amino-, amino-Ci-C6-alkyl-, Ci-C6-alkylaminocarbonyl-, Ci-C6-alkyl- aminosulphonyl-, Ci-C6-alkylamino-Ci-C6-alkyl-, hydroxy-Ci-C6-alkyl-, halo-Ci-C6-alkyl-, halo-Ci-C6-alkoxy-, C3-Cio-cycloalkyl- and a monocyclic heterocyclyl radical having 3 to 8 ring atoms, spirocycloalkyl, 5 to 12 membered heterospirocycloalkyl, bicycloalkyl-, heterobicycloalkyl-, bridged cycloalkyl or a bridged heterocycloalkyl, naphthyl or bicyclic heteroaryl, or partially saturated bicyclic aryl- or heteroaryl,
each of which mentioned supra may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of halogen, cyano, nitro, hydroxy, amino, oxo, carboxy, Ci-C6-alkyl-, Ci-C6-alkoxy-, Ci-C6-alkoxy- Ci-C6-alkyl-, hydroxy-Ci-C6-alkyl-, Ci-C6-alkylamino-, Ci-C6-alkylcarbonylamino- , amino-Ci-C6-alkyl-, Ci-C6-alkylamino-Ci-C6-alkyl-, halo-Ci-C6-alkyl-, halo-Ci-C6-alkoxy-, C3-Cio-cycloalkyl-, phenyl-, halophenyl-, phenyl-Ci-C6-alkyl-, phenoxy-, pyridinyl-, -C(=0)-N R5R6, -N H-C(=0)-R8, -C(=0)-R7, -S(=0)2-N R5R6, -S(=0)-R8, -S(=0)(=N R5)-R6, -S(=0)2-R8, -N H-S(=0)2-R8, or a monocyclic heterocyclyl radical having 3 to 8 ring atoms,
or
represents C3-Cio-cycloalkyl- which may optionally be mono- or polysubstituted by dentical or different substituents from the group consisting of of of halogen, cyano, nitro, hydroxy, amino, oxo, carboxy, Ci-C6-alkyl-, Ci-C6-alkoxy-,
Ci-C6-alkoxy-Ci-C6-alkyl-, hydroxy-Ci-C6-alkyl-, Ci-C6-alkylamino-,
Ci-C6-alkylcarbonylamino-, amino-Ci-C6-alkyl-, Ci-C6-alkylamino-Ci-C6-alkyl-, halo-Ci-C6-alkyl-, halo-Ci-C6-alkoxy-, C3-Cio-cycloalkyl-, phenyl-, halophenyl-, phenyl-d-Ce-alkyl-, phenoxy-, pyridinyl-, -C(=0)-NR5R6, -NH-C(=0)-R8, -C(=0)-R7, -S(=0)2-NR5R6, -S(=0)-R8, -S(=0)(=NR5)-R6, -S(=0)2-R8,
-NH-S(=0)2-R8, or a monocyclic heterocyclyl radical having 3 to 8 ring atoms, or
represents monocyclic heteroaryl- having 5 or 6 ring atoms which may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of of halogen, cyano, nitro, hydroxy, amino, carboxy, Ci-C6-alkyl-, Ci-C6-alkoxy-, Ci-C6-alkoxy-Ci-C6-alkyl-, hydroxy-Ci-C6-alkyl-,
Ci-C6-alkylamino-, Ci-C6-alkylcarbonylamino-, amino-Ci-C6-alkyl-, C1-C6- alkylamino-Ci-C6-alkyl-, halo-Ci-C6-alkyl-, halo-Ci-C6-alkoxy-, C3-Cio-cycloalkyl-, phenyl-, halophenyl-, phenyl-Ci-C6-alkyl-, phenoxy-, pyridinyl-, -C(=0)-NR5R6, -NH-C(=0)-R8, -C(=0)-R7, -S(=0)2-NR5R6, -S(=0)-R8,
-S(=0)(=NR5)-R6, -S(=0)2-R8, -NH-S(=0)2-R8, or a monocyclic heterocyclyl radical having 3 to 8 ring atoms,
or
represents monocyclic heterocyclyl- having 3 to 8 ring atoms which may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of of halogen, cyano, nitro, hydroxy, amino, oxo, carboxy, Ci-C6-alkyl-, Ci-C6-alkoxy-, Ci-C6-alkoxy-Ci-C6-alkyl-, hydroxy-Ci-C6-alkyl-, Ci-C6-alkylamino-, Ci-C6-alkylcarbonylamino-, amino-Ci-C6-alkyl-,
Ci-C6-alkylamino-Ci-C6-alkyl-, halo-Ci-C6-alkyl-, halo-Ci-C6-alkoxy-, C3-C10- cycloalkyl-, phenyl-, halophenyl-, phenyl-Ci-C6-alkyl-, phenoxy-, pyridinyl-,
-C(=0)-NR5R6, -NH-C(=0)-R8, -C(=0)-R7, -S(=0)2-NR5R6, -S(=0)-R8,
-S(=0)(=NR5)-R6, -S(=0)2-R8, -NH-S(=0)2-R8, or a monocyclic heterocyclyl radical having 3 to 8 ring atoms,
or
represents phenyl- which may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of of halogen, cyano, nitro, hydroxy, amino, carboxy, Ci-C6-alkyl-, Ci-C6-alkoxy-, Ci-C6-alkoxy-Ci-C6- alkyl-, hydroxy-Ci-C6-alkyl-, Ci-C6-alkylamino-, Ci-C6-alkylcarbonylamino-, amino-Ci-C6-alkyl-, Ci-C6-alkylamino-Ci-C6-alkyl-, halo-Ci-C6-alkyl-, halo-Ci-C6- alkoxy-, C3-Cio-cycloalkyl-, phenyl-, halophenyl-, phenyl-Ci-C6-alkyl-, phenoxy-, pyridinyl-, -C(=0)-NR5R6, -NH-C(=0)-R8, -C(=0)-R7, -S(=0)2-NR5R6, -S(=0)-R8, -S(=0)(=NR5)-R6, -S(=0)2-R8, -NH-S(=0)2-R8, or a monocyclic heterocyclyl radical having 3 to 8 ring atoms,
or
represents a spirocycloalkyl radical, a 5 to 12 membered heterospirocycloalkyl radical, a bicycloalkyl, a heterobicycloalkyl radical, a bridged cycloalkyl radical or a bridged heterocycloalkyi radical, a naphthyl radical or a bicyclic heteroaryl radical, or a partially saturated bicyclic aryl- or heteroaryl radical, where the radicals mentioned may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of of halogen, cyano, nitro, hydroxy, amino, oxo, carboxy, Ci-C6-alkyl-, Ci-C6-alkoxy-, Ci-C6-alkoxy-Ci-C6- alkyl-, hydroxy-Ci-C6-alkyl-, Ci-C6-alkylamino-, Ci-C6-alkylcarbonylamino-, amino-Ci-C6-alkyl-, Ci-C6-alkylamino-Ci-C6-alkyl-, halo-Ci-C6-alkyl-, halo-Ci-C6- alkoxy-, C3-Cio-cycloalkyl-, phenyl-, halophenyl-, phenyl-Ci-C6-alkyl-, phenoxy-, pyridinyl-, -C(=0)-NR5R6, -NH-C(=0)-R8, -C(=0)-R7, -S(=0)2-NR5R6,
-S(=0)-R8, -S(=0)(=NR5)-R6, -S(=0)2-R8, -NH-S(=0)2-R8, or a monocyclic heterocyclyl radical having 3 to 8 ring atoms,
or
R3 and R4 together with the nitrogen atom form a 4 to 10 membered heterocycloalkyi or a
5 to 12 membered heterospirocycloalkyl, which may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of of halogen, cyano, nitro, hydroxy, amino, oxo, carboxy, Ci-C6-alkyl-, Ci-C6-alkoxy-, Ci-C6-alkoxy-Ci-C6-alkyl-, hydroxy-Ci-C6-alkyl-,
Ci-C6-alkylamino-, Ci-C6-alkylcarbonylamino-, amino-Ci-C6-alkyl-, C1-C6- alkylamino-Ci-C6-alkyl-, halo-Ci-C6-alkyl-, halo-Ci-C6-alkoxy-, C3-Cio-cycloalkyl-, phenyl-, halophenyl-, phenyl-Ci-C6-alkyl-, phenoxy-, pyridinyl-, -C(=0)-NR5R6,
-NH-C(=0)-R8, -C(=0)-R7, -S(=0)2-NR5R6, -S(=0)-R8,
-S(=0)(=NR5)-R6, -S(=0)2-R8, -NH-S(=0)2-R8, or a monocyclic heterocyclyl radical having 3 to 8 ring atoms,
R5 and R6 independently of one another represent hydrogen, Ci-C3-alkyl-, cyclopropyl- or di-Ci-C3-alkylamino-Ci-C3-alkyl-, or
R5 and R6 together with the nitrogen atom form a monocyclic heterocyclyl- having 3 to 8 ring atoms which itself may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of halogen, amino, hydroxy, cyano, oxo, Ci-C6-alkyl-, Ci-C6-alkoxy-, Ci-C6-alkylamino-, halo-Ci-C6-alkyl-, halo-Ci-C6-alkoxy-,
R7 represents hydroxy, Ci-C6-alkyl-, Ci-C6-alkoxy-, halo-Ci-C3-alkyl-, hydroxy-Ci-
C3-alkyl-, Ci-C3-alkoxy-Ci-C3-alkyl-, Cs-Cs-cycloalkyl-, phenyl-, monocyclic heterocyclyl- having 3 to 8 ring atoms or monocyclic heteroaryl- having 5 or 6 ring atoms where phenyl-, heteroaryl- and heterocyclyl- may optionally be mono- or disubstituted by halogen, Ci-C3-alkoxy- or Ci-C3-alkyl-, R8 represents Ci-C6-alkyl-,
R9 represents Ci-Ce-alkyI-, -NH2, -NH-Ci-C6-alkyl, -N(Ci-C6-alkyl)2, or Ci-C6-alkoxy- Ci-Ce-alkyI-,
or
represents monocyclic heterocyclyl- having 3 to 8 ring atoms which itself may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of of halogen, cyano, nitro, hydroxy, amino, oxo, carboxy, Ci-Ce-alkyI-, d-Ce-alkoxy-, Ci-Ce-alkoxy-Ci-Ce-alkyl-, hydroxy-d-Ce-alkyl-,
Ci-C6-alkylamino-, Ci-C6-alkylcarbonylamino-, amino-Ci-C6-alkyl-, C1-C6- alkylamino-Ci-C6-alkyl-, halo-Ci-C6-alkyl-, halo-Ci-C6-alkoxy-, C3-Cio-cycloalkyl-, phenyl-, halophenyl-, phenyl-Ci-C6-alkyl-, phenoxy-, pyridinyl-, -C(=0)-NR5R6, -NH-C(=0)-R8, -C(=0)-R7, -S(=0)2-NR5R6, -S(=0)-R8,
-S(=0)(=NR5)-R6, -S(=0)2-R8, -NH-S(=0)2-R8, or a monocyclic heterocyclyl radical having 3 to 8 ring atoms,
Rx represents Ci-C6-alkyl- or Ci-C6-alkoxy-Ci-C6-alkyl-,
Ry represents hydrogen, halo-Ci-C6-alkyl, Ci-C6-alkyl, Ci-C6-alkyl substituted with
C3-C6-cycloalkyl,
and their polymorphs, enantiomers, diastereomers, racemates, tautomers, solvates, physiologically acceptable salts and solvates of these salts.
2. Compounds of formula (I), according to claim 1 , in which
X represents an oxygene atom,
Y represents a sulphur or an oxygene atom,
R1 represents hydrogen, halogen, Ci-C6-alkyl, halo-Ci-C6-alkyl and cyano,
R2 represents fluorine,
R3 represents hydrogen or Ci-C6-alkyl,
R4 represents hydrogen or represents Ci-C6-alkyl-, which may optionally be mono- or disubstituted by identical or different substituents from the group consisting of halogen, cyano, hydroxy, Ci-C3-alkoxy-, -NH2, -NH- (d-Ce-alkyl), -N(Ci-C6-alkyl)2, -NH-(Ci-C6-alkyl)-Ci-C6-alkoxy, Ci-C6- alkyl-, Ci-Ce-alkoxy-, -S(=0)2NH2, -C(=0)-R9, -C(=0)-NH-Rx, -NH-C(=0)- R9, -NH-S(=0)2-R9, -S(=0)2-R9, -S(=0)(=NRy)-Rx, -S(=0)-Rx, C3-C10- cycloalkyl-,
monocyclic heteroaryl- having 5 or 6 ring atoms which itself may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of halogen, cyano, nitro, hydroxy, amino, carboxy, Ci-C6-alkyl-, Ci-C6-alkoxy-, Ci-C6-alkoxy-Ci-C6-alkyl-, hydroxy-Ci-C6-alkyl-, Ci-C6-alkylamino-, Ci-C6-alkylcarbonylamino-, amino-Ci-C6-alkyl-, Ci-C6-alkylamino-Ci-C6-alkyl-, halo-Ci-C6-alkyl-, halo-Ci-C6-alkoxy-, C3-Cio-cycloalkyl-, phenyl-, halophenyl-, phenyl-Ci- Ce-alkyl-, phenoxy-, pyridinyl-, -C(=0)-N R5R6, -N H-C(=0)-R8, -C(=0)- R7, -S(=0)2-N R5R6, -S(=0)-R8, -S(=0)(=N R5)-R6, -S(=0)2-R8, -N H- S(=0)2-R8, or a monocyclic heterocyclyl radical having 3 to 8 ring atoms, monocyclic heterocyclyl- having 4 to 8 ring atoms which itself may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of halogen, cyano, nitro, hydroxy, amino, oxo, carboxy, Ci-C6-alkyl-, Ci-C6-alkoxy-, Ci-C6-alkoxy-Ci-C6- alkyl-, hydroxy-Ci-C6-alkyl-, Ci-C6-alkylamino-, C1-C6- alkylcarbonylamino-, amino-Ci-C6-alkyl-, Ci-C6-alkylamino-Ci-C6-alkyl-, halo-Ci-C6-alkyl-, halo-Ci-C6-alkoxy-, C3-Cio-cycloalkyl-, phenyl-, halophenyl-, phenyl-Ci-C6-alkyl-, phenoxy-, pyridinyl-, -C(=0)-N R5R6, - N H-C(=0)-R8, -C(=0)-R7, -S(=0)2-N R5R6, -S(=0)-R8, -S(=0)(=N R5)- R6, -S(=0)2-R8, -N H-S(=0)2-R8, or a monocyclic heterocyclyl radical having 3 to 8 ring atoms, phenyl- which itself may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of halogen, cyano, nitro, hydroxy, amino, carboxy, Ci-C6-alkyl-, Ci-C6-alkoxy-, C1-C6- alkoxy-Ci-C6-alkyl-, hydroxy-Ci-C6-alkyl-, Ci-C6-alkylamino-, C1-C6- alkylcarbonylamino-, amino-Ci-C6-alkyl-, Ci-C6-alkylamino-Ci-C6-alkyl-, halo-Ci-C6-alkyl-, halo-Ci-C6-alkoxy-, C3-Cio-cycloalkyl-, phenyl-, halophenyl-, phenyl-Ci-C6-alkyl-, phenoxy-, pyridinyl-, -C(=0)-N R5R6, - N H-C(=0)-R8, -C(=0)-R7, -S(=0)2-N R5R6, -S(=0)-R8, -S(=0)(=N R5)- R6, -S(=0)2-R8, -N H-S(=0)2-R8, or a monocyclic heterocyclyl radical having 3 to 8 ring atoms, spirocycloalkyl-, heterospirocycloalkyl-, bicycloalkyl-, heterobicycloalkyl-, bridged cycloalkyl or a bridged heterocycloalkyl, naphthyl or bicyclic heteroaryl, or partially saturated bicyclic aryl- or heteroaryl, each of which mentioned may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of halogen, cyano, nitro, hydroxy, amino, oxo, carboxy, Ci-C6-alkyl-, Ci-C6-alkoxy-, Ci-C6-alkoxy- Ci-C6-alkyl-, hydroxy-Ci-C6-alkyl-, Ci-C6-alkylamino-, C1-C6- alkylcarbonylamino-, amino-Ci-C6-alkyl-, Ci-C6-alkylamino-Ci-C6-alkyl-, halo-Ci-C6-alkyl-, halo-Ci-C6-alkoxy-, C3-Cio-cycloalkyl-, phenyl-, halophenyl-, phenyl-Ci-C6-alkyl-, phenoxy-, pyridinyl-, -C(=0)-N R5R6, - N H-C(=0)-R8, -C(=0)-R7, -S(=0)2-N R5R6, -S(=0)-R8, -S(=0)(=N R5)- R6, -S(=0)2-R8, -N H-S(=0)2-R8, or a monocyclic heterocyclyl radical having 3 to 8 ring atoms, represents monocyclic heterocyclyl- having 3 to 8 ring atoms which may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of halogen, cyano, nitro, hydroxy, amino, oxo, carboxy, Ci-C6-alkyl-, Ci-C6-alkoxy-, Ci-C6-alkoxy-Ci-C6- alkyl-, hydroxy-Ci-C6-alkyl-, Ci-C6-alkylamino-, C1-C6- alkylcarbonylamino-, amino-Ci-C6-alkyl-, Ci-C6-alkylamino-Ci-C6-alkyl-, halo-Ci-C6-alkyl-, halo-Ci-C6-alkoxy-, C3-Cio-cycloalkyl-, phenyl-, halophenyl-, phenyl-Ci-C6-alkyl-, phenoxy-, pyridinyl-, -C(=0)-N R5R6, - N H-C(=0)-R8, -C(=0)-R7, -S(=0)2-N R5R6, -S(=0)-R8, -S(=0)(=N R5)- R6, -S(=0)2-R8, -N H-S(=0)2-R8, or a monocyclic heterocyclyl radical having 3 to 8 ring atoms,
or
represents phenyl- which may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of halogen, cyano, nitro, hydroxy, amino, carboxy, Ci-C6-alkyl-, Ci-C6-alkoxy-, C1-C6- alkoxy-Ci-C6-alkyl-, hydroxy-Ci-C6-alkyl-, Ci-C6-alkylamino-, C1-C6- alkylcarbonylamino-, amino-Ci-C6-alkyl-, Ci-C6-alkylamino-Ci-C6-alkyl-, halo-Ci-C6-alkyl-, halo-Ci-C6-alkoxy-, C3-Cio-cycloalkyl-, phenyl-, halophenyl-, phenyl-Ci-C6-alkyl-, phenoxy-, pyridinyl-, -C(=0)-N R5R6, - N H-C(=0)-R8, -C(=0)-R7, -S(=0)2-N R5R6, -S(=0)-R8, -S(=0)(=N R5)- R6, -S(=0)2-R8, -N H-S(=0)2-R8, or a monocyclic heterocyclyl radical having 3 to 8 ring atoms, together with the nitrogen atom form a 4 to 10 membered
heterocycloalkyl ring, which may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of halogen, cyano, nitro, hydroxy, amino, oxo, carboxy, Ci-C6-alkyl-, Ci-C6-alkoxy-, Ci-C6-alkoxy-Ci-C6-alkyl-, hydroxy-Ci-C6-alkyl-, C1-C6- alkylamino-, Ci-C6-alkylcarbonylamino-, amino-Ci-C6-alkyl-, C1-C6- alkylamino-Ci-C6-alkyl-, halo-Ci-C6-alkyl-, halo-Ci-C6-alkoxy-, C3-C10- cycloalkyl-, phenyl-, halophenyl-, phenyl-Ci-C6-alkyl-, phenoxy-, pyridinyh -C(=0)-NR5R6, -NH-C(=0)-R8, -C(=0)-R7, -S(=0)2-NR5R6, - S(=0)-R8, -S(=0)(=NR5)-R6, -S(=0)2-R8, -NH-S(=0)2-R8, or a monocyclic heterocyclyl radical having 3 to 8 ring atoms,
or
together with the nitrogen atom form a heterospirocycloalkyl or heterobicycloalkyl group, each of which mentioned may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of halogen, cyano, nitro, hydroxy, amino, oxo, carboxy, Ci-C6-alkyl-, Ci-C6-alkoxy-, Ci-C6-alkoxy-Ci-C6-alkyl-, hydroxy-Ci-C6- alkyl-, Ci-C6-alkylamino-, Ci-C6-alkylcarbonylamino-, amino-Ci-C6-alkyl-,
Ci-C6-alkylamino-Ci-C6-alkyl-, halo-Ci-C6-alkyl-, halo-Ci-C6-alkoxy-, C3- Cio-cycloalkyl-, phenyl-, halophenyl-, phenyl-Ci-C6-alkyl-, phenoxy-, pyridinyh -C(=0)-NR5R6, -NH-C(=0)-R8, -C(=0)-R7, -S(=0)2-NR5R6, - S(=0)-R8, -S(=0)(=NR5)-R6, -S(=0)2-R8, -NH-S(=0)2-R8, or a monocyclic heterocyclyl radical having 3 to 8 ring atoms,
R5 and R6 independently of one another represent hydrogen, Ci-C3-alkyl-,
cyclopropyl- or di-Ci-C3-alkylamino-Ci-C3-alkyl-,
R7 represents hydroxy, Ci-C6-alkyl-, Ci-C6-alkoxy-, halo-Ci-C3-alkyl-,
hydroxy-Ci-C3-alkyl-, Ci-C3-alkoxy-Ci-C3-alkyl-, Cs-Cs-cycloalkyl-, phenyl-, monocyclic heterocyclyl- having 3 to 8 ring atoms or monocyclic heteroaryl- having 5 or 6 ring atoms where phenyl-, heteroaryl- and heterocyclyl- may optionally be mono- or disubstituted by halogen, Ci- C3-alkoxy- or Ci-C3-alkyl-,
R8 represents Ci-C6-alkyl-,
R9 represents Ci-C6-alkyl-, -NH2, -NH-Ci-C6-alkyl, -N(Ci-C6-alkyl)2, Ci-C6- alkoxy-Ci-C6-alkyl-,
or
represents monocyclic heterocyclyl- having 3 to 8 ring atoms which itself may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of halogen, cyano, nitro, hydroxy, amino, oxo, carboxy, Ci-C6-alkyl-, Ci-C6-alkoxy-, Ci-C6-alkoxy-Ci-C6- alkyl-, hydroxy-Ci-C6-alkyl-, Ci-C6-alkylamino-, C1-C6- alkylcarbonylamino-, amino-Ci-C6-alkyl-, Ci-C6-alkylamino-Ci-C6-alkyl-, halo-Ci-C6-alkyl-, halo-Ci-C6-alkoxy-, C3-Cio-cycloalkyl-, phenyl-, halophenyl-, phenyl-Ci-C6-alkyl-, phenoxy-, pyridinyl-, -C(=0)-NR5R6, -
NH-C(=0)-R8, -C(=0)-R7, -S(=0)2-NR5R6, -S(=0)-R8, -S(=0)(=NR5)- R6, -S(=0)2-R8, -NH-S(=0)2-R8, or a monocyclic heterocyclyl radical having 3 to 8 ring atoms, Rx represents Ci-C6-alkyl- or Ci-C6-alkoxy-Ci-C6-alkyl-,
Ry represents hydrogen, halo-Ci-C6-alkyl, Ci-C6-alkyl, Ci-C6-alkyl
substituted with C3-C6-cycloalkyl,
and their polymorphs, enantiomers, diastereomers, racemates, tautomers, solvates, physiologically acceptable salts and solvates of these salts.
Compounds of formula (I), according to claim 1 or 2, in which
represents a sulphur or an oxygene atom,
represents a sulphur or an oxygene atom,
represents hydrogen, halogen, Ci-C6-alkyl, halo-Ci-C6-alkyl or cyano, represents fluorine,
represents hydrogen or Ci-C6-alkyl,
represents hydrogen or represents Ci-C6-alkyl-, which may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of
halogen, cyano, hydroxy, Ci-C3-alkoxy-, -N(Ci-C6-alkyl)2, -C(=0)-R9,
-C(=0)-NH-Rx, -C(=0)-NR5R6, -NH-C(=0)-R9, -NH-S(=0)2-R9 or -S(=0)2-R9, or a C3-Cio-cycloalkyl- which itself may optionally substituted by hydroxy, or a monocyclic heteroaryl- having 5 or 6 ring atoms which itself may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of cyano, Ci-C6-alkyl-, Ci-C6-alkoxy- or
Ci -Ce-a I koxy-Ci -C6-a I ky I-, or a monocyclic heterocyclyl- having 3 to 8 ring atoms which itself may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of halogen, hydroxyl, carboxy, Ci-C6-alkyl- or
hydroxy-Ci-C6-alkyl-, or a phenyl, 5 to 12 membered heterospirocycloalkyl or partially saturated bicyclic heteroaryl, each of which mentioned supra may optionally be substituted by -C(=0)-NR5R6, or
represents a C3-Cio-cycloalkyl- which may optionally substituted by
-C(=0)-NR5R6 or Ci-C6-alkoxy-Ci-C6-alkyl- or represents a monocyclic heteroaryl- having 5 or 6 ring atoms which may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of halogen, Ci-C6-alkyl-, halo-Ci-C6-alkyl-, C3-Cio-cycloalkyl-,-C(=0)-NR5R6, -S(=0)2-R8 or a monocyclic heterocyclyl radical having 3 to 8 ring atoms,
or
represents a monocyclic heterocyclyl- having 3 to 8 ring atoms which may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of halogen, oxo, Ci-C6-alkylamino-Ci-C6-alkyl or monocyclic heterocyclyl radical having 3 to 8 ring atoms
or
represents a phenyl- which may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of halogen,
Ci-C6-alkoxy- or halo-Ci-C6-alkyl-,
or
represents a 5 to 12 membered heterospirocycloalkyl radical, or a bridged heterocycloalkyl radical,
or
R3 and R4 together with the nitrogen atom form a 4 to 10 membered heterocycloalkyl or a
5 to 12 membered heterospirocycloalkyl, which may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of halogen, Ci-C6-alkyl-, Ci-C6-alkoxy- or hydroxy-Ci-C6-alkyl-,
R5 and R6 independently of one another represent hydrogen or Ci-C3-alkyl-,
R5 and R6 together with the nitrogen atom form a monocyclic heterocyclyl- having 3 to 8 ring atoms which itself may optionally be substituted by Ci-C6-alkyl-,
R8 represents Ci-C6-alkyl-,
R9 represents d-Ce-alkyl- or -NH2,
Rx represents Ci-C6-alkoxy-Ci-C6-alkyl-,
and their polymorphs, enantiomers, diastereomers, racemates, tautomers, solvates, physiologically acceptable salts and solvates of these salts.
4. Compounds of formula (I), according to any one of claim 1 to 3, in which
X represents a sulphur or an oxygene atom,
Y represents a sulphur or an oxygene atom,
R1 represents hydrogen, halogen, Ci-C6-alkyl, halo-Ci-C6-alkyl or cyano,
R2 represents fluorine,
R3 represents hydrogen or Ci-C3-alkyl, R4 represents hydrogen or represents Ci-C6-alkyl-, which may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of
halogen, cyano, hydroxy, Ci-C3-alkoxy-, -N(Ci-C3-alkyl)2,
-C(=0)-R9, -C(=0)-NH-Rx, -C(=0)-NR5R6, -NH-C(=0)-R9, -NH-S(=0)2-R9,
-S(=0)2-R9, or a C3-C7-cycloalkyl- which itself may optionally substituted by hydroxy, or a monocyclic heteroaryl- having 5 or 6 ring atoms which itself may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of cyano, Ci-C6-alkyl-, Ci-C6-alkoxy- or
Ci -Ce-a I koxy-Ci -C6-a I ky I-, or a monocyclic heterocyclyl- having 4 to 6 ring atoms which itself may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of halogen, hydroxyl, carboxy, Ci-C6-alkyl- or hydroxy-Ci- Ce-alkyl-, or a phenyl, 7 to 9 membered heterospirocycloalkyi or partially saturated bicyclic heteroaryl, each of which mentioned supra may optionally be substituted by -C(=0)-NR5R6, or
R4 represents a C3-C7-cycloalkyl- which may optionally substituted by
-C(=0)-NR5R6 or Ci-C6-alkoxy-Ci-C6-alkyl- or
represents a monocyclic heteroaryl- having 5 or 6 ring atoms which may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of halogen, Ci-C3-alkyl-, halo-Ci-C3-alkyl-,
C3-C7-cycloalkyl-, -C(=0)-NR5R6, -S(=0)2-R8 or a monocyclic heterocyclyl radical having 4 to 6 ring atoms,
or
represents a monocyclic heterocyclyl- having 4 to 6 ring atoms which may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of halogen, oxo, Ci-C3-alkylamino-Ci-C3-alkyl or monocyclic heterocyclyl radical having 4 to 6 ring atoms
or represents a phenyl- which may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of halogen,
Ci-C3-alkoxy- or halo-Ci-C3-alkyl-,
or
represents a 7 to 9 membered heterospirocycloalkyl radical, or a bridged heterocycloalkyi radical,
or
R3 and R4 together with the nitrogen atom form a 4 to 6 membered heterocycloalkyi or a
7 to 9 membered heterospirocycloalkyl, which may optionally be mono- or polysubstituted by identical or different substituents from the group consisting of halogen, Ci-C3-alkyl-, Ci-C3-alkoxy-, hydroxy-Ci-C3-alkyl-,
R5 and R6 independently of one another represent hydrogen or Ci-C3-alkyl-,
R5 and R6 together with the nitrogen atom form a monocyclic heterocyclyl- having 4 to 6 ring atoms which itself may optionally be substituted by Ci-C3-alkyl-,
R8 represents Ci-C3-alkyl-,
R9 represents Ci-C3-alkyl- or -NH2,
Rx represents Ci-C3-alkoxy-Ci-C3-alkyl-,
and their polymorphs, enantiomers, diastereomers, racemates, tautomers, solvates, physiologically acceptable salts and solvates of these salts.
5. Compounds of formula (I), according to any one of claims 1 to 4, in which
X represents an oxygene atom,
Y represents a sulphur or an oxygene atom,
R1 represents hydrogen, chlorine, bromine, methyl-, trifluoromethyl and cyano,
R2 represents fluorine,
R3 represents hydrogen or methyl,
R4 represents hydrogen, Ci-C6-alkyl-, which may optionally be mono- or disubstituted by identical or different substituents from the group consisting of halogen, cyano, hydroxy, Ci-C3-alkoxy-, -NH2, -NH-(Ci-C6- alkyl), -N(Ci-C6-alkyl)2, -NH-(Ci-C6-alkyl)-Ci-C6-alkoxy, Ci-C6-alkyl-, Ci- Ce-alkoxy-, -S(=0)2NH2, -C(=0)-R9, -C(=0)-NH-R9, -NH-C(=0)-Rx, -NH- S(=0)2-R9, -S(=0)2-R9, WO 2018/228920 PCT/EP2018/065036
Figure imgf000469_0001
Figure imgf000469_0002
or
R4 represents
Figure imgf000470_0001
or
R3 and R4 together with the nitrogen atom form the group
Figure imgf000470_0002
*' ' and
R9 represents methyl, -NH2 or -CH2-CH2-O-CH3 or
Figure imgf000470_0003
Rx represents methyl or -CH2-CH2-O-CH3,
represents hydrogen, methyl, methoxy and cyano
represents hydrogen and trifluoromethyl,
represents hydrogen, fluorine and methoxy,
represents hydrogen and methyl,
represents hydrogen and -CH2-O-CH3,
where "*" denotes the point of attachment to the remainder of the molecule, and their polymorphs, enantiomers, diastereomers, racemates, tautomers, solvates, physiologically acceptable salts and solvates of these salts. 6. Compounds of formula (I), according to any one of claims 1 to 5, in which
X represents an oxygene atom,
Y represents an oxygene atom,
R1 represents hydrogen, chlorine, bromine, methyl-, trifluoromethyl and cyano,
R2 represents fluorine,
R3 represents hydrogen or methyl,
R4 represents hydrogen, Ci-C6-alkyl-, which may optionally be mono- or disubstituted by identical or different substituents from the group consisting of halogen, cyano, hydroxy, Ci-C3-alkoxy-, -NH2, -NH-(Ci-C alkyl), -N(Ci-C6-alkyl)2, -NH-(Ci-C6-alkyl)-Ci-C6-alkoxy, Ci-C6-alkyl-, Ci Ce-alkoxy-, -S(=0)2NH2, -C(=0)-R9, -C(=0)-NH-Rx, -NH-C(=0)-R9, -NH S(=0)2-R9, -S(=0)2-R9,
WO 2018/228920 PCT/EP2018/065036
Figure imgf000472_0001
Figure imgf000472_0002
Figure imgf000472_0003
or
R3 and R4 together with the nitrogen atom form the group
Figure imgf000473_0001
and represents methyl, -IMH2 or -CH2-CH2-0-CH3 or
Figure imgf000473_0002
Rx represents methyl or -CH2-CH2-0-CH3,
R10 represents hydrogen, methyl, methoxy and cyano
R11 represents hydrogen and trifluoromethyl,
R12 represents hydrogen, fluorine and methoxy,
R13 represents hydrogen and methyl,
R14 represents hydrogen and -CH2-O-CH3,
where "*" denotes the point of attachment to the remainder of the molecule, and their polymorphs, enantiomers, diastereomers, racemates, tautomers, solvates, physiologically acceptable salts and solvates of these salts.
7. Compounds of formula (I), according to any one of claims 1 to 6, in which
X represents an oxygene atom,
Y represents an oxygene atom,
R1 represents chlorine, bromine, cyano and trifluoromethyl,
R2 represents fluorine,
R3 represents hydrogen,
R4 represents hydrogen, Ci-C6-alkyl-, which may optionally be mono- or disubstituted by identical or different substituents from the group consisting of halogen, cyano, hydroxy, Ci-C3-alkoxy-, -IMH2, -NH-(Ci-C6- alkyl), -N(Ci-C6-alkyl)2, -NH-(Ci-C6-alkyl)-Ci-C6-alkoxy, Ci-C6-alkyl-, Ci- Ce-alkoxy-, -S(=0)2NH2, -C(=0)-R9, -C(=0)-NH-Rx, -NH-C(=0)-R9, -NH- S(=0)2-R9, -S(=0)2-R9, or H
Figure imgf000474_0001
Figure imgf000474_0002
or
R4 represents
Figure imgf000474_0003
R9 represents methyl, -Nh or -CH2-CH2-0-CH3 or
Figure imgf000474_0004
Rx represents methyl or -CH2-CH2-O-CH3,
R10 represents hydrogen,
R13 represents hydrogen,
where "*" denotes the point of attachment to the remainder of the molecule, and their polymorphs, enantiomers, diastereomers, racemates, tautomers, solvates, physiologically acceptable salts and solvates of these salts. 8. Compounds of formula (I), according to any of the former claims as follows:
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[3-
(morpholin-4-yl)propyl]urea;
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(2- methoxyethyl)urea;
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[3-
(methylsulfonyl)propyl]urea;
- 1 -(2,2-difluoroethyl)-3-(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4- yl]oxy}phenyl)urea;
- N3-[(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4- yl]oxy}phenyl)carbamoyl]-beta-alaninamide;
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-
(pyridin-4-ylmethyl)urea;
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[(1 - hydroxycyclopropyl)methyl]urea;
- 4-{[(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4- yl]oxy}phenyl)carbamoyl]amino}butanamide;
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(3- methoxypropyl)urea;
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[2- (morpholin-4-yl)-2-oxoethyl]urea;
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-
(pyridin-3-ylmethyl)urea;
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3- (pyridin-2-ylmethyl)urea;
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[2-
(pyridin-4-yl)ethyl]urea;
- (+/-)-1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[2- hydroxy-3-(morpholin-4-yl)propyl]urea;
- (+/-)-1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3- (tetrahydrofuran-2-ylmethyl)urea;
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-
(tetrahydro-2H-pyran-4-ylmethyl)urea;
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(1 H- 1 ,2,3-triazol-5-ylmethyl)urea; - N2-[(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrTolo[2,3-b]pyridin-4- yl]oxy}phenyl)carbamoyl]glycinamide;
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[2-
(morpholin-4-yl)ethyl]urea;
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[2- (piperidin-1 -yl)ethyl]urea;
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[3-
(piperidin-1 -yl)propyl]urea;
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[3- (dimethylamino)propyl]urea;
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[2-
(dimethylamino)ethyl]urea;
- l -iS.S-difluoro^-i^-itrifluoromethy -I H-pyrrolop.S-^pyridin^-y oxyJpheny -S-til .l - dioxidothietan-3-yl)methyl]urea;
- N-(2-{[(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4- yl]oxy}phenyl)carbamoyl]amino}ethyl)acetamide;
- (+/-)-1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[1 -
(morpholin-4-yl)propan-2-yl]urea;
- (+/-)-1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[2- (morpholin-4-yl)propyl]urea;
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[2-
(methylsulfonyl)ethyl]urea;
- 3-{[(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4- yl]oxy}phenyl)carbamoyl]amino}propane-1 -sulfonamide;
- 3-(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-1 -methyl- 1 -[2-(morpholin-4-yl)ethyl]urea;
- N-(2-{[(3!5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4- yl]oxy}phenyl)carbamoyl]amino}ethyl)methanesulfonamide;
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-pyridin- 3-ylurea;
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[3-
(trifluoromethyl)phenyl]urea;
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(1 ,3,4- thiadiazol-2-yl)urea; - 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[2- fluoro-5-(trifluoromethyl)phenyl]urea;
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3- pyridazin-3-ylurea;
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(2- methoxyphenyl)urea;
- 1 -(2,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[3-
(morpholin-4-yl)propyl]urea;
- 1 -(2,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[2- (morpholin-4-yl)ethyl]urea;
- 1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[3-(piperidin-1 - yl)propyl]urea;
- 1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[2-
(dimethylamino)ethyl]urea;
- 1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[2-(piperidin-1 - yl)ethyl]urea;
- 1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[3-(morpholin-4- yl)propyl]urea;
- 1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(2- methoxyethyl)urea;
- 1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-ethylurea;
- 1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[2-(morpholin-4- yl)ethyl]urea;
- 1 -benzyl-3-{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}urea - 1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(pyrimidin-5- ylmethyl)urea;
- 1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(pyridin-4- ylmethyl)urea;
- 1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(2- cyanoethyl)urea;
- 1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(3- methylbutyl)urea;
- 1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(1 ,2-oxazol-3- yl)urea; - 1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-pyridazin-3- ylurea;
- 1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}urea;
- N-{2-[({4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}carbamoyl)- amino]ethyl}acetamide;
- 1 -{4-[(3-bromo-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[2-
(dimethylamino)ethyl]urea;
- 1 -{4-[(3-bromo-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[3-
(dimethylamino)propyl]urea;
- 1 -{4-[(3-bromo-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-butylurea;
- 1 -benzyl-3-{4-[(3-bromo-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}urea;
- 1 -(2,3-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[3-
(morpholin-4-yl)propyl]urea;
- 1 -(2,3-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[2- (morpholin-4-yl)ethyl]urea;
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[2-
(dimethylamino)ethyl]thiourea;
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[2-
(morpholin-4-yl)ethyl]thiourea;
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(2- methoxyethyl)thiourea;
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3- ethylthiourea and
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[3- (morpholin-4-yl)propyl]thiourea,
l -iS.S-difluoro^-i^-itrifluoromethy -I H-pyrroloP.S-blpyridin^-y oxyJpheny -S- (oxetan-3-ylmethyl)urea
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)urea
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3- methylurea
- 3-(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-1 ,1 - dimethylurea
- N-(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4- yl]oxy}phenyl)morpholine-4-carboxamide - N-iS.S-difluoro^-i^-itrifluoromethy -I H-pyrroloP.S-blpyridin^-y oxyJphenylH- methylpiperazine-1 -carboxamide
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[2-(4- methylpiperazin-1 -yl)-2-oxoethyl]urea
- N-iS.S-difluoro^-i^-itrifluoromethy -I H-pyrroloP.S-blpyridin^-y oxyJphenyl^-oxa-e- azaspiro[3.3]heptane-6-carboxamide
- N2-[(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4- yl]oxy}phenyl)carbamoyl]-N-methylglycinamide
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(1 ,2- thiazol-4-yl)urea
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(1 - methyl-1 H-pyrazol-4-yl)urea
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(6- methylpyridin-3-yl)urea
- 1 -[(1 -acetylazetidin-3-yl)methyl]-3-(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3- b]pyridin-4-yl]oxy}phenyl)urea
- N2-[(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4- yl]oxy}phenyl)carbamoyl]-N-(2-methoxyethyl)glycinamide
- (+/-)-1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3- [(1 ,1 -dioxidothietan-2-yl)methyl]urea
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(2- methylpyrimidin-5-yl)urea
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(1 H- pyrazol-4-yl)urea
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[2-(1 - oxa-6-azaspiro[3.3]hept-6-yl)ethyl]urea
- l -iS.S-difluoro^-i^-itrifluoromethy -I H-pyrrolop.S-^pyridin^-y oxyJpheny -S-p-il .l - dioxido-1 -thia-6-azaspiro[3.3]hept-6-yl)ethyl]urea
- (+/-)-1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(2- oxopyrrolidin-3-yl)urea
- (+/-)-1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3- (1 ,1 -dioxidotetrahydrothiophen-3-yl)urea
- (+/-)-1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(5- oxopyrrolidin-3-yl)urea - 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(1 ,1 - dioxidotetrahydro-2H-thiopyran-4-yl)urea
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(1 H- pyrazol-3-ylmethyl)urea
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(1 H- imidazol-2-ylmethyl)urea
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[(1 - methyl-1 H-pyrazol-3-yl)methyl]urea
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(1 ,3- thiazol-2-ylmethyl)urea
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3- (pyrimidin-4-ylmethyl)urea
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[(2- methylpyridin-4-yl)methyl]urea
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3- (pyridazin-3-ylmethyl)urea
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[(5- methyl-1 H-imidazol-2-yl)methyl]urea
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-{[3- (methoxymethyl)-l ,2,4-oxadiazol-5-yl]methyl}urea
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[(5- methyl-4H-1 ,2,4-triazol-3-yl)methyl]urea
- (+/-)-1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3- (tetrahydrofuran-3-yl)urea
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[(3R)- tetrahydrofuran-3-yl]urea
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[(3S)- tetrahydrofuran-3-yl]urea
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-{3- [(2R!6R)-2,6-dimethylmorpholin-4-yl]propyl}urea
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[(1 - methyl-1 H-imidazol-2-yl)methyl]urea
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[(4- methyl-1 ,2,5-oxadiazol-3-yl)methyl]urea - 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[(2- methoxypyridin-4-yl)methyl]urea
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[(1 - methyl-1 H-imidazol-4-yl)methyl]urea
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-{2- [(2RS!6RS)-2,6-dimethylmorpholin-4-yl]ethyl}urea
- 1 -[(2-cyanopyridin-4-yl)methyl]-3-(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3- b]pyridin-4-yl]oxy}phenyl)urea
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3- (pyridazin-4-ylmethyl)urea
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(1 ,2,4- oxadiazol-3-ylmethyl)urea
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(1 ,3- oxazol-2-ylmethyl)urea
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(1 ,3- thiazol-5-ylmethyl)urea
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[2-(2- oxa-6-azaspiro[3.3]hept-6-yl)ethyl]urea
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[(5- methyl-1 ,3,4-oxadiazol-2-yl)methyl]urea
- N-(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-N'-[(3- methyloxetan-3-yl)methyl]urea
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(5- methylpyridazin-3-yl)urea
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[(2R)- tetrahydrofuran-2-ylmethyl]urea
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[(2S)- tetrahydrofuran-2-ylmethyl]urea
- (+/-)-1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3- [(5,5-dimethyltetrahydrofuran-2-yl)methyl]urea
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3- (tetrahydro-2H-pyran-4-yl)urea
- (+/-)-1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3- (tetrahydro-2H-pyran-2-ylmethyl)urea - (+/-)-1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3- (tetrahydro-2H-pyran-3-yl)urea
- (+/-)-1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3- [(2-methyltetrahydrofuran-2-yl)methyl]urea
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(2- methoxy-2-methylpropyl)urea
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[2- methyl-2-(morpholin-4-yl)propyl]urea
- (+/-)-1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3- (tetrahydro-2H-pyran-3-ylmethyl)urea
- (+/-)-1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3- (tetrahydrofuran-3-ylmethyl)urea
- 1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-pyridazin-4- ylurea
- 1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(6- methylpyridazin-3-yl)urea
- 1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-pyridin-3-ylurea
- 1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-pyridin-2-ylurea
- 1 -[3,5-difluoro-4-(1 H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-3-[2-(piperidin-1 -yl)ethyl]urea - N3-{[3,5-difluoro-4-(1 H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]carbamoyl}-beta- alaninamide
- 1 -[3,5-difluoro-4-(1 H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-3-(1 H-1 ,2,3-triazol-5- ylmethyl)urea
- 1 -[3,5-difluoro-4-(1 H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-3-[3- (dimethylamino)propyl]urea
- 4-({[3,5-difluoro-4-(1 H-pyrrolo[2,3-b]pyridin-4- yloxy)phenyl]carbamoyl}amino)butanamide
- 1 -[3,5-difluoro-4-(1 H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-3-(2-methoxyethyl)urea
- 1 -[3,5-difluoro-4-(1 H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-3-(pyridin-2-ylmethyl)urea - 1 -[3,5-difluoro-4-(1 H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-3-[3- (methylsulfonyl)propyl]urea
- 1 -[3,5-difluoro-4-(1 H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-3-[2- (dimethylamino)ethyl]urea
- 1 -[3,5-difluoro-4-(1 H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-3-[3-(piperidin-1 - yl)propyl]urea - 1 -{4-[(3-bromo-1 H-pyrrolo[2!3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(3- methoxypropyl)urea
- 1 -{4-[(3-bromo-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[(1 -methyl-1 H- pyrazol-3-yl)methyl]urea
- 1 -{4-[(3-bromo-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(1 ,3-thiazol-2- ylmethyl)urea
- 1 -{4-[(3-bromo-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(1 H-pyrazol-3- ylmethyl)urea
- N3-({4-[(3-bromo-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}carbamoyl)-beta- alaninamide
- 1 -{4-[(3-bromo-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[2-(piperidin-1 - yl)ethyl]urea
- N-{2-[({4-[(3-bromo-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}carbamoyl)amino]ethyl}methanesulfonamide
- 1 -{4-[(3-bromo-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[3-(morpholin-4- yl)propyl]urea
- N-{2-[({4-[(3-bromo-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}carbamoyl)amino]ethyl}acetamide
- 1 -{4-[(3-bromo-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[2-(morpholin-4- yl)-2-oxoethyl]urea
- 1 -{4-[(3-bromo-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(pyridin-2- ylmethyl)urea
- 1 -{4-[(3-bromo-1 H-pyrrolo[2!3-b]pyridin-4-yl)oxy]-3!5-difluorophenyl}-3-[(1 ,1 - dioxidothietan-3-yl)methyl]urea
- 1 -{4-[(3-bromo-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(2- methoxyethyl)urea
- 1 -{4-[(3-bromo-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(pyridin-4- ylmethyl)urea
- N2-({4-[(3-bromo-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}carbamoyl)glycinamide
- 1 -{4-[(3-bromo-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[3-(piperidin-1 - yl)propyl]urea
- 1 -{4-[(3-bromo-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(1 H-1 ,2,3-triazol- 4-ylmethyl)urea - 1 -{4-[(3-bromo-1 H-pyrrolo[2!3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[3- (methylsulfonyl)propyl]urea
- 4-[({4-[(3-bromo-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}carbamoyl)amino]butanamide
- 1 -{4-[(3-bromo-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[2-(4- methylpiperazin-1 -yl)-2-oxoethyl]urea
- 1 -{3,5-difluoro-4-[(3-methyl-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]phenyl}-3-[2- (dimethylamino)ethyl]urea
- (+/-)- 1 -{4-[(3-cyano-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3- (tetrahydrofuran-3-yl)urea
- 1 -{4-[(3-cyano-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[2- (dimethylamino)ethyl]urea
- (+/-)- 1 -{4-[(3-cyano-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3- (tetrahydrofuran-2-ylmethyl)urea
- 1 -{4-[(3-cyano-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(3- methoxypropyl)urea
- 1 -{4-[(3-cyano-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[3-(morpholin-4- yl)propyl]urea
- 1 -{4-[(3-cyano-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[(1 -methyl-1 H- pyrazol-3-yl)methyl]urea
- 1 -{4-[(3-cyano-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(1 ,3-thiazol-2- ylmethyl)urea
- 1 -{4-[(3-cyano-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(pyridin-4- ylmethyl)urea
- 1 -{4-[(3-cyano-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(2- methoxyethyl)urea
- 1 -{4-[(3-cyano-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(1 H-pyrazol-3- ylmethyl)urea
- (+/-)- 1 -{4-[(3-bromo-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3- (tetrahydrofuran-3-yl)urea
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(6- methoxypyridazin-3-yl)urea
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(6,7- dihydro-5H-cyclopenta[c]pyridazin-3-yl)urea - 1 -(6-bromopyridazin-3-yl)-3-{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}urea
- (+/-)-1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3- (tetrahydrofuran-2-ylmethyl)urea
- 1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[(3S)- tetrahydrofuran-3-yl]urea
- 1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[(1 -methyl-1 H- pyrazol-3-yl)methyl]urea
- 1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(2- oxaspiro[3.3]hept-6-yl)urea
- 1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[6- (difluoromethyl)pyridazin-3-yl]urea
- (+/-)-1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3- (tetrahydrofuran-3-yl)urea
- 1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(3- methoxypropyl)urea
- 1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[(3R)- tetrahydrofuran-3-yl]urea
- 1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(1 H-pyrazol-3- ylmethyl)urea
- 1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3!5-difluorophenyl}-3-(2!2,2- trifluoroethyl)urea
- (+/-)-N-{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3- [(dimethylamino)methyl]pyrrolidine-1 -carboxamide
- 1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[(4-methyl-1 ,2,5- oxadiazol-3-yl)methyl]urea
- 1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(2- fluoroethyl)urea
- N-{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-2-oxa-7- azaspiro[3.5]nonane-7-carboxamide
- 1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(2,2- difluoroethyl)urea
- 1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[(4-methyl-1 H- imidazol-2-yl)methyl]urea - 1 -{4-[(3-chloro-1 H-pyrrolo[2!3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(6- methoxypyridazin-3-yl)urea
- 1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(1 ,3,4-thiadiazol-
2- yl)urea
- 1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(1 ,3-thiazol-2- ylmethyl)urea
- 1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(6-iodopyridazin-
3- yl)urea
- 1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[6-(morpholin-4- yl)pyridazin-3-yl]urea
- 1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(5- methylpyridazin-3-yl)urea
- 1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(6- cyclopropylpyridazin-3-yl)urea
- (+/-)-1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(1 - methyl-5-oxopyrrolidin-3-yl)urea
- N-iS.S-difluoro^-i^-itrifluoromethy -I H-pyrroloP.S-blpyridin^-y oxyJphenylH^- difluoropiperidine-1 -carboxamide
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[3- (propan-2-yloxy)propyl]urea
- N-(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3- methoxyazetidine-1 -carboxamide
- N-(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-1 -oxa-6- azaspiro[3.3]heptane-6-carboxamide
- N-(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-2-oxa-6- azaspiro[3.5]nonane-6-carboxamide
- N-iS.S-difluoro^-i^-itrifluoromethy -I H-pyrrolop.S-^pyridin^-y oxyJpheny -N'-i^- (propan-2-yl)oxetan-3-yl]methyl}urea
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[3- methyl-3-(morpholin-4-yl)butyl]urea
- 1 -{4-[(3-bromo-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[(4-methyl-1 ,2,5- oxadiazol-3-yl)methyl]urea
- (+/-) 1 -{4-[(3-bromo-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3- (tetrahydrofuran-2-ylmethyl)urea - 1 -{4-[(3-bromo-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-pyridazin-3- ylurea
- 1 -{4-[(3-bromo-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(6- methylpyridazin-3-yl)urea
- 1 -{4-[(3-bromo-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(1 ,3,4-thiadiazol- 2-yl)urea
- 1 -{4-[(3-bromo-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[(4-methyl-1 H- imidazol-2-yl)methyl]urea
- 1 -{4-[(3-cyano-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(6- methylpyridazin-3-yl)urea
- 1 -{4-[(3-cyano-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-pyridazin-3- ylurea
- 1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-{1 -[(4- methylpiperazin-1 -yl)carbonyl]cyclopropyl}urea
- 1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[1 -(morpholin-4- ylcarbonyl)cyclopropyl]urea
- 1 -[({4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}carbamoyl)amino]-N,N-dimethylcyclopropanecarboxamide
- 1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[1 -(piperidin-1 - ylcarbonyl)cyclopropyl]urea
- (+/-)1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(1 - methoxypropan-2-yl)urea
- 1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[1 - (methoxymethyl)cyclopropyl]urea
- (+/-) 1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3!5-difluorophenyl}-3-(2,2- dimethyltetrahydrofuran-3-yl)urea
- (+/-) 1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(5- oxaspiro[3.4]oct-7-yl)urea
- (+/-) 1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[(trans)-4- (pyrrolidin-1 -yl)tetrahydrofuran-3-yl]urea
- N2-({4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}carbamoyl)-N,N- dimethylalaninamide
- N2-({4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}carbamoyl)-N,N- dimethylvalinamide - (+/-)1 -{4-[(3-chloro-1 H-pyrrolo[2!3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(3- methyltetrahydrofuran-3-yl)urea
- (+/-)1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[7- oxabicyclo[2.2.1 ]hept-2-yl]urea - mixture of isomers
- (+/-)-1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-(1 -methyl-2- oxopyrrolidin-3-yl)urea
- N-(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)azetidine- 1 -carboxamide
- N-(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4- yl]oxy}phenyl)pyrrolidine-1 -carboxamide
- N-(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-N'-[(3- fluorooxetan-3-yl)methyl]urea
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(2- hydroxy-2-methylpropyl)urea
- (+/-)-1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-[2- hydroxy-2-methyl-3-(morpholin-4-yl)propyl]urea
- 1 -(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-3-(3- hydroxy-3-methylbutyl)urea
- 6-[({4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}carbamoyl)amino]-N-methylpyridazine-3-carboxamide
- 1 -(6-tert-butylpyridazin-3-yl)-3-{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}urea
- 6-[({4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5- difluorophenyl}carbamoyl)amino]-N,N-dimethylpyridazine-3-carboxamide
- 1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[6- (trifluoromethyl)pyridazin-3-yl]urea
- 1 -{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-3-[6- (methylsulfonyl)pyridazin-3-yl]urea
- (+/-)-N-(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-N'- (2-fluoro-3-methoxypropyl)urea
- (+/-)-N-(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-N'- [(4,4-dimethyloxetan-2-yl)methyl]urea
- (+/-)-N-(3,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-N'- (2-fluoro-3-methoxy-2-methylpropyl)urea - N-iS.S-difluoro^^p-itrifluoromethylJ-I H-pyrTolop.S-blpyridin^-ylloxylphenylJ-N'-tP- (hydroxymethyl)oxetan-3-yl]methyl}urea
- N-iS.S-difluoro^^p-itrifluoromethylJ-I H-pyrTolop.S-blpyridin^-ylloxylphenylJ-N'-IiS- hydroxyoxetan-3-yl)methyl]urea
- N-(2,5-difluoro-4-{[3-(trifluoromethyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-N'-[(3- methyloxetan-3-yl)methyl]urea
- N^-KS-bromo-I H-pyrrolop.S-blpyridin^-y sulfanyll-S.S-difluorophenylJ-N'-p- (morpholin-4-yl)-2-oxoethyl]urea
- N-{4-[(3-bromo-1 H-pyrrolo[2!3-b]pyridin-4-yl)sulfanyl]-3,5-difluorophenyl}-N'-(2- methoxyethyl)urea
- N-{4-[(3-bromo-1 H-pyrrolo[2,3-b]pyridin-4-yl)sulfanyl]-3,5-difluorophenyl}-N'-ethylurea
- N-{4-[(3-bromo-1 H-pyrrolo[2,3-b]pyridin-4-yl)sulfanyl]-3,5-difluorophenyl}morpholine-4- carboxamide
- N-(3,5-difluoro-4-{[3-(propan-2-yl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-N'-[(3- fluorooxetan-3-yl)methyl]urea
- N-iS^-difluoro^p-iS^^-trifluoropropylJ-I H^yrrolop^-blpyridin^-ylloxylphenylJ-N'- [(3-fluorooxetan-3-yl)methyl]urea
- (+/-)-N-[3,5-difluoro-4-({3-[1 !1 !1 -trifluoropropan-2-yl]-1 H-pyrrolo[2,3-b]pyridin-4- yl}oxy)phenyl]-N'-[(3-fluorooxetan-3-yl)methyl]urea
- N-(3,5-difluoro-4-{[3-(propan-2-yl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-N'-(2- methoxyethyl)urea
- N-(3,5-difluoro-4-{[3-(propan-2-yl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-N'-[(3- methyloxetan-3-yl)methyl]urea
- N-(3,5-difluoro-4-{[3-(propan-2-yl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-N'-{[3- (propan-2-yl)oxetan-3-yl]methyl}urea
- N-(3,5-difluoro-4-{[3-(propan-2-yl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)morpholine- 4-carboxamide
- N-(3,5-difluoro-4-{[3-(propan-2-yl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-N'-[2- (morpholin-4-yl)-2-oxoethyl]urea
- (+/-)-N-[3,5-difluoro-4-({3-[1 !1 !1 -trifluoropropan-2-yl]-1 H-pyrrolo[2,3-b]pyridin-4- yl}oxy)phenyl]-N'-(2-methoxyethyl)urea
- (+/-)-N-[4-({3-(butan-2-yl)-1 H-pyrrolo[2!3-b]pyridin-4-yl}oxy)-3,5-difluorophenyl]-N'-(2- methoxyethyl)urea
- (+/-)-N-[3!5-difluoro-4-({3-(3-methylbutan-2-yl)-1 H-pyrrolo[2,3-b]pyridin-4- yl}oxy)phenyl]-N'-(2-methoxyethyl)urea - N-(3!5-difluoro-4-{[3-(pentan-3-yl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-N'-(2- methoxyethyl)urea
- N-(3,5-difluoro-4-{[3-(2-methylpropyl)-1 H-pyrrolo[2,3-b]pyridin-4-yl]oxy}phenyl)-N'-(2- methoxyethyl)urea
- (+/-)-N-[3!5-difluoro-4-({3-[4!4,4-trifluorobutan-2-yl]-1 H-pyrrolo[2,3-b]pyridin-4- yl}oxy)phenyl]-N'-(2-methoxyethyl)urea
- N-{4-[(3-bromo-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-2-methylazetidine- 1 -carboxamide
- N-{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}azetidine-1 - carboxamide
- N'-{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-N,N-dimethylurea
- (+/-)-N-{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3!5-difluorophenyl}-4,4-difluoro- 3-(hydroxymethyl)piperidine-1 -carboxamide
- N-{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-N'-(1 -methoxy-2- methylpropan-2-yl)urea
- (+/-)-N-{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-N'-1 - oxaspiro[4.4]nonan-6-ylurea - mixture of isomers
- (+/-)-N-{4-[(3-chloro-1 H-pyrrolo[2,3-b]pyridin-4-yl)oxy]-3,5-difluorophenyl}-N'-[1 - (morpholin-4-yl)-1 -oxopropan-2-yl]urea
and their polymorphs, enantiomers, diastereomers, racemates, tautomers, solvates, physiologically acceptable salts and solvates of these salts.
A compound of general formula (I) according to any one of claims 1 to 8 for use in the treatment or prophylaxis of a disease.
A pharmaceutical composition comprising a compound of general formula (I) according to any one of claims 1 to 8 and one or more pharmaceutically acceptable excipients.
A pharmaceutical combination comprising:
• one or more first active ingredients, in particular compounds of general formula (I) according to any one of claims 1 to 8, and
• one or more pharmaceutical active anti cancer compounds or
• one or more pharmaceutical active immune checkpoint inhibitors. 12. A pharmaceutical combination according to claim 1 1 , characterized in that the pharmaceutical active immune checkpoint inhibitor is an antibody.
13. Use of a compound of general formula (I) according to any one of claims 1 to 8 for the treatment or prophylaxis of a disease.
14. Use of a compound of general formula (I) according to any one of claims 1 to 8 for the preparation of a medicament for the treatment or prophylaxis of a disease. 15. Use according to claim 13 or 14, wherein the disease is cancer or conditions with
dysregulated immune responses or other disorders associated with aberrant MAP4K1 signaling, such as liquid and solid tumours, for example. 16. Use according to claim 13 or 14, wherein the diseases, respectively the disorders are benign hyperplasias, atherosclerotic disorders, sepsis, autoimmune disorders, vascular disorders, viral infections, neurodegenerative disorders, in inflammatory disorders, and male fertility control.
PCT/EP2018/065036 2017-06-13 2018-06-07 Substituted pyrrolopyridine-derivatives WO2018228920A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA3066859A CA3066859A1 (en) 2017-06-13 2018-06-07 Substituted pyrrolopyridine-derivatives
EP18728901.2A EP3638669A1 (en) 2017-06-13 2018-06-07 Substituted pyrrolopyridine-derivatives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17175861 2017-06-13
EP17175861.8 2017-06-13

Publications (1)

Publication Number Publication Date
WO2018228920A1 true WO2018228920A1 (en) 2018-12-20

Family

ID=59055146

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2018/065036 WO2018228920A1 (en) 2017-06-13 2018-06-07 Substituted pyrrolopyridine-derivatives

Country Status (3)

Country Link
EP (1) EP3638669A1 (en)
CA (1) CA3066859A1 (en)
WO (1) WO2018228920A1 (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020193511A1 (en) 2019-03-26 2020-10-01 Janssen Pharmaceutica Nv Hpk1 inhibitors
WO2020193512A1 (en) 2019-03-26 2020-10-01 Janssen Pharmaceutica Nv Bicyclic hpk1 inhibitors
US11071730B2 (en) 2018-10-31 2021-07-27 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds
US11203591B2 (en) 2018-10-31 2021-12-21 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds
WO2021226547A3 (en) * 2020-05-08 2021-12-30 Halia Therapeutics, Inc. Targeted nek7 inhibition for modulation of the nlrp3 inflammasome
WO2022159835A1 (en) * 2021-01-25 2022-07-28 Halia Therapeutics, Inc. Nek7 inhibitors
US11453681B2 (en) 2019-05-23 2022-09-27 Gilead Sciences, Inc. Substituted eneoxindoles and uses thereof
WO2022226182A1 (en) * 2021-04-22 2022-10-27 Halia Therapeutics, Inc. Nek7 inhibitors
WO2022268520A1 (en) * 2021-06-21 2022-12-29 Bayer Aktiengesellschaft Use of substituted pyrrolidinones or their salts for increasing stress tolerance of plants
WO2023001794A1 (en) 2021-07-20 2023-01-26 Astrazeneca Ab Substituted pyrazine-2-carboxamides as hpk1 inhibitors for the treatment of cancer

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005058891A1 (en) 2003-12-09 2005-06-30 Bayer Healthcare Ag Pyrrolopyridine-substituted benzol derivatives for treating cardiovascular diseases
WO2006014325A2 (en) 2004-07-02 2006-02-09 Exelixis, Inc. C-met modulators and method of use
US20060211695A1 (en) * 2004-06-28 2006-09-21 Borzilleri Robert M Fused heterocyclic kinase inhibitors
US20070238726A1 (en) 2006-03-07 2007-10-11 Blake James F Heterobicyclic pyrazole compounds and methods of use
EP1921078A1 (en) * 2005-08-05 2008-05-14 Chugai Seiyaku Kabushiki Kaisha Multikinase inhibitor
WO2015089479A1 (en) 2013-12-13 2015-06-18 Dana-Farber Cancer Institute, Inc. Methods to treat lymphoplasmacytic lymphoma
WO2016195776A1 (en) 2015-06-04 2016-12-08 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with mll proteins
WO2016205942A1 (en) 2015-06-25 2016-12-29 University Health Network Hpk1 inhibitors and methods of using same
WO2018049200A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
WO2018049214A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
WO2018049191A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridone derivatives as hpk1 modulators and uses thereof for the treatment of cancer
WO2018049152A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyrimidine derivatives as hpk1 modulators and uses thereof for the treatment of cancer

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005058891A1 (en) 2003-12-09 2005-06-30 Bayer Healthcare Ag Pyrrolopyridine-substituted benzol derivatives for treating cardiovascular diseases
US20060211695A1 (en) * 2004-06-28 2006-09-21 Borzilleri Robert M Fused heterocyclic kinase inhibitors
WO2006014325A2 (en) 2004-07-02 2006-02-09 Exelixis, Inc. C-met modulators and method of use
EP1921078A1 (en) * 2005-08-05 2008-05-14 Chugai Seiyaku Kabushiki Kaisha Multikinase inhibitor
US20070238726A1 (en) 2006-03-07 2007-10-11 Blake James F Heterobicyclic pyrazole compounds and methods of use
WO2015089479A1 (en) 2013-12-13 2015-06-18 Dana-Farber Cancer Institute, Inc. Methods to treat lymphoplasmacytic lymphoma
WO2016195776A1 (en) 2015-06-04 2016-12-08 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with mll proteins
WO2016205942A1 (en) 2015-06-25 2016-12-29 University Health Network Hpk1 inhibitors and methods of using same
WO2018049200A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
WO2018049214A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
WO2018049191A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridone derivatives as hpk1 modulators and uses thereof for the treatment of cancer
WO2018049152A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyrimidine derivatives as hpk1 modulators and uses thereof for the treatment of cancer

Non-Patent Citations (34)

* Cited by examiner, † Cited by third party
Title
"March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure"
"Metal-Catalyzed Cross-Coupling Reactions", WILEY-VCH
ALZABIN ET AL., CANCER IMMUNOL IMMUNOTHER., vol. 59, no. 3, March 2010 (2010-03-01), pages 419 - 29
ALZABIN ET AL., J IMMUNOL., vol. 182, no. 10, 15 May 2009 (2009-05-15), pages 6187 - 94
ANGEW. CHEM. INT. ED., vol. 50, 2011, pages 1896 - 1900
BAIRD DD ET AL.: "High cumulative incidence of uterine leiomyoma in black and white women: Ultrasound evidence", AM J OBSTET GYNECOL., vol. 188, no. 1, January 2003 (2003-01-01), pages 100 - 7
BOOMER ET AL., J CELL BIOCHEM., vol. 95, no. 1, 1 May 2005 (2005-05-01), pages 34 - 44
CATAL. LETT., 2016, pages 820 - 840
CHEM. SOC. REV., vol. 40, 2011, pages 5049 - 5067
CHEMMEDCHEM, vol. 3, 2008, pages 1893
DAVID M ET AL.: "Myoma-associated pain frequency and intensity: a retrospective evaluation of 1548 myoma patients", EUR J OBSTET GYNECOL REPROD BIOL., vol. 199, April 2016 (2016-04-01), pages 137 - 40, XP029449331, DOI: doi:10.1016/j.ejogrb.2016.02.026
DI BARTOLO ET AL., J EXP MED., vol. 204, no. 3, 19 March 2007 (2007-03-19), pages 681 - 91
DOWNES E ET AL.: "The burden of uterine fibroids in five European countries", EUR J OBSTET GYNECOL REPROD BIOL., vol. 152, no. 1, September 2010 (2010-09-01), pages 96 - 102
FRASER IS ET AL.: "The FIGO Recommendations on Terminologies and Definitions for Normal and Abnormal Uterine Bleeding", SEMIN REPROD MED, vol. 29, no. 5, 2011, pages 383 - 390
HU ET AL., GENES DEV., vol. 10, no. 18, 15 September 1996 (1996-09-15), pages 2251 - 64
J. AM. CHEM. SOC., vol. 138, 2016, pages 8084 - 8087
J. MED. CHEM., 2017, pages 4636
KAWAGUCHI K ET AL.: "Immunohistochemical analysis of oestrogen receptors, progesterone receptors and Ki-67 in leiomyoma and myometrium during the menstrual cycle and pregnancy", VIRCHOWS ARCH A PATHOL ANAT HISTOPATHOL., vol. 419, no. 4, 1991, pages 309 - 15
KEIR M E ET AL., ANNU. REV. IMMUNOL., vol. 26, 2008, pages 677
LASSERRE ET AL., J CELL BIOL., vol. 195, no. 5, 28 November 2011 (2011-11-28), pages 839 - 53
LING ET AL., J BIOL CHEM., vol. 276, no. 22, 1 June 2001 (2001-06-01)
LIOU ET AL., IMMUNITY, vol. 12, no. 4, April 2000 (2000-04-01), pages 399 - 408
LIU NA ET AL: "Design, synthesis and biological evaluation of 1H-pyrrolo[2,3-b]pyridine and 1H-pyrazolo[3,4-b]pyridine derivatives as c-Met inhibitors", BIOORGANIC CHEMISTRY, ACADEMIC PRESS INC., NEW YORK, NY, US, vol. 65, 2 March 2016 (2016-03-02), pages 146 - 158, XP029445736, ISSN: 0045-2068, DOI: 10.1016/J.BIOORG.2016.02.009 *
ORG. LETT., vol. 18, 2016, pages 4012
ORG. PROCESS RES. DEV., 2010, pages 168 - 173
PURE APPL CHEM, vol. 45, 1976, pages 11 - 30
S. M. BERGE ET AL.: "Pharmaceutical Salts", J. PHARM. SCI., vol. 66, 1977, pages 1 - 19, XP002675560, DOI: doi:10.1002/jps.2600660104
SAUER ET AL., J BIOL CHEM., vol. 276, no. 48, 30 November 2001 (2001-11-30), pages 45207 - 16
SAWASDIKOSOL ET AL., J BIOL CHEM., vol. 282, no. 48, 30 November 2007 (2007-11-30), pages 34693 - 9
SHUI ET AL., NAT IMMUNOL., vol. 8, no. 1, January 2007 (2007-01-01), pages 84 - 91
SYNTHESIS, 2007, pages 251 - 258
T.W. GREENE; P.G.M. WUTS: "Protective Groups in Organic Synthesis", 2006, WILEY
TSUJI ET AL., J EXP MED., vol. 194, no. 4, 20 August 2001 (2001-08-20), pages 529 - 39
YANG JH ET AL.: "Impact of submucous myoma on the severity of anemia", FERTIL STERIL., vol. 95, no. 5, April 2011 (2011-04-01), pages 1769 - 72

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11071730B2 (en) 2018-10-31 2021-07-27 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds
US11203591B2 (en) 2018-10-31 2021-12-21 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds
US11897878B2 (en) 2018-10-31 2024-02-13 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds
US11925631B2 (en) 2018-10-31 2024-03-12 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds
WO2020193511A1 (en) 2019-03-26 2020-10-01 Janssen Pharmaceutica Nv Hpk1 inhibitors
WO2020193512A1 (en) 2019-03-26 2020-10-01 Janssen Pharmaceutica Nv Bicyclic hpk1 inhibitors
US11453681B2 (en) 2019-05-23 2022-09-27 Gilead Sciences, Inc. Substituted eneoxindoles and uses thereof
WO2021226547A3 (en) * 2020-05-08 2021-12-30 Halia Therapeutics, Inc. Targeted nek7 inhibition for modulation of the nlrp3 inflammasome
WO2022159835A1 (en) * 2021-01-25 2022-07-28 Halia Therapeutics, Inc. Nek7 inhibitors
WO2022226182A1 (en) * 2021-04-22 2022-10-27 Halia Therapeutics, Inc. Nek7 inhibitors
WO2022268520A1 (en) * 2021-06-21 2022-12-29 Bayer Aktiengesellschaft Use of substituted pyrrolidinones or their salts for increasing stress tolerance of plants
WO2023001794A1 (en) 2021-07-20 2023-01-26 Astrazeneca Ab Substituted pyrazine-2-carboxamides as hpk1 inhibitors for the treatment of cancer

Also Published As

Publication number Publication date
EP3638669A1 (en) 2020-04-22
CA3066859A1 (en) 2018-12-20

Similar Documents

Publication Publication Date Title
WO2018228920A1 (en) Substituted pyrrolopyridine-derivatives
US11795164B2 (en) 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer
US11427578B1 (en) Substituted pyrrolopyridine-derivatives
EP3638670B1 (en) Substituted pyrrolopyridine-derivatives as map4k1 modulators for the treatment of cancer diseases
US11591311B2 (en) 3-oxo-6-heteroaryl-2-phenyl-2,3-dihydropyridazine-4-carboxamides
WO2018228925A1 (en) Substituted pyrrolopyridine-derivatives
CA3082856A1 (en) Sulphur substituted 3-oxo-2,3-dihydropyridazine-4-carboxamides
WO2019101641A1 (en) 2-hetarylpyrimidine-4-carboxamides as aryl hydrocarbon receptor anatgonists
US20220047603A1 (en) Substituted pyrrolopyridine-derivatives
CA3082858A1 (en) 2-phenylpyrimidine-4-carboxamides as ahr inhibitors
WO2021074279A1 (en) Spiro-fused tricyclic map4k1 inhibitors
US20230113037A1 (en) [1,2,4]triazolo[1,5-c]quinazolin-5-amines
WO2021249913A1 (en) 2&#39;-(quinolin-3-yl)-5&#39;,6&#39;-dihydrospiro[azetidine-3,4&#39;-pyrrolo[1,2-b]pyrazole]-1-carboxylate derivatives and related compounds as map4k1 (hpk1) inhibitors for the treatment of cancer
EP3700907A1 (en) Novel pyrazolo-pyrrolo-pyrimidine-dione derivatives as p2x3 inhibitors
WO2017102091A1 (en) Heteroarylbenzimidazole compounds
EP4288437A1 (en) Map4k1 inhibitors
WO2022029063A1 (en) Pyrido[1,2,4]triazolo[1,5-c]pyrimidin-5-amines

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18728901

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3066859

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018728901

Country of ref document: EP

Effective date: 20200113